DB00001	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00001	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy.
DB00004	DB06372	decreases effects of toxoids by pharmacodynamic antagonism.
DB00004	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00005	DB01281	Avoid combination because of increased adverse effects of Abatacept.
DB00005	DB00026	Avoid combination due to increased adverse effects of anakinra and increased risk of infections.
DB00005	DB08879	Avoid combination because of enhanced adverse effects of belimumab.
DB00005	DB08879	Avoid combination due to enhanced toxic effects of belimumab.
DB00005	DB06168	Combination should be avoided because Etanercept increase the toxic effects of canakinumab including neutropenia.
DB00005	DB08904	Avoid combination as certolizumab pegol toxic effects would be enhanced.
DB00005	DB00531	Avoid combination due to enhanced adverse effects of cyclophosphasmide and increased risk of solid cancer development.
DB00005	DB06643	Monitor therapy as there may be an enhanced immunosuppressive effect.
DB00005	DB00065	Avoid combination because etanercept may increase immunosuppressive effects of infliximab.
DB00005	DB01097	Consider modifying therapy due to enhanced adverse effects of leflunomide including hematologic toxicity.
DB00005	DB00108	Avoid combination due to enhanced adverse effects of natalizumab and increased risk of infections.
DB00005	DB00337	Avoid combination due to enhanced immunosuppressive effects.
DB00005	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00005	DB01656	Due to enhanced immunosuppressive effects, therapy modification should be considered.
DB00005	DB06688	Monitor therapy because of reduced therapeutic effect of sipuleucel-T.
DB00005	DB00864	Avoid combination due to enhanced immunosuppressive effects
DB00005	DB06273	Avoid combination due to enhanced immunosuppressive effects.
DB00005	DB08895	Etanercept increases the risk of added immunosuppression. It is recommended to avoid concurrent therapy.
DB00005	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00006	DB01609	Anticoagulants increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity.
DB00006	DB00441	Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity.
DB00006	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00006	DB06228	Anticoagulants may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding.
DB00006	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant therapy.
DB00008	DB01223	Interferon increases the effect and toxicity of theophylline
DB00008	DB00651	Interferon increases the effect and toxicity of theophylline
DB00008	DB06414	Etravirine (a CYP2C9 substrate), when used concomitantly with peginterferon alfa-2a, may experience a decrease in serum concentration. It is recommended to monitor effectiveness of etravirine therapy.
DB00008	DB01303	Interferon increases the effect and toxicity of theophylline
DB00008	DB01265	Co-administration of Peginterferon alpha-2a and Telbivudine may increase the risk of serious peripheral neuropathy.
DB00008	DB00277	Interferon increases the effect and toxicity of theophylline
DB00009	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00009	DB00727	IV nitroglycerin may decrease the effect of alteplase.
DB00009	DB00208	Increased bleeding risk. Monitor for signs of bleeding.
DB00011	DB01223	Interferon increases the effect and toxicity of theophylline
DB00011	DB00651	Interferon increases the effect and toxicity of theophylline
DB00011	DB01303	Interferon increases the effect and toxicity of theophylline
DB00011	DB00277	Interferon increases the effect and toxicity of theophylline
DB00013	DB06692	Aprotonin may antagonize the effect of Urokinase. Monitor for decreased effects of Urokinase.
DB00013	DB00055	Increased risk of bleeding.
DB00013	DB01381	Increased risk of bleeding.
DB00013	DB01404	Increased risk of bleeding.
DB00015	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00015	DB00208	Increased bleeding risk. Monitor for signs of bleeding.
DB00017	DB01356	Monitor therapy because calcitonin may reduce the serum concentration of lithium.
DB00021	DB00771	Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.
DB00021	DB01409	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00021	DB01036	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00021	DB00376	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00798	DB00695	Increased ototoxicity
DB00021	DB00662	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00021	DB00209	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00022	DB01223	Interferon increases the effect and toxicity of theophylline
DB00022	DB00651	Interferon increases the effect and toxicity of theophylline
DB00022	DB01303	Interferon increases the effect and toxicity of theophylline
DB00022	DB00277	Interferon increases the effect and toxicity of theophylline
DB00023	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00026	DB01281	Avoid combination due to enhanced adverse effects of abatacept
DB00026	DB06168	results in increased immunosuppressive effects; increases the risk of infection.
DB00026	DB08904	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB00026	DB00005	Avoid combination due to increased adverse effects of anakinra and increased risk of infections.
DB00026	DB06674	Avoid combination with anakinra due to the increased chance of serious infection.
DB00026	DB00065	Combination may enhance the toxic effect of Anakinra and should be avoided otherwise there may be an increased risk of infection
DB00026	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00026	DB01041	Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided.
DB00026	DB08895	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB00026	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00030	DB06655	Coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed.
DB00031	DB06692	Aprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase.
DB00031	DB00055	Increased risk of bleeding.
DB00031	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00031	DB01404	Increased risk of bleeding.
DB00031	DB00208	Increased bleeding risk. Monitor for signs of bleeding.
DB00034	DB01223	Interferon increases the effect and toxicity of theophylline
DB00034	DB00651	Interferon increases the effect and toxicity of theophylline
DB00034	DB01303	Interferon increases the effect and toxicity of theophylline
DB00034	DB00277	Interferon increases the effect and toxicity of theophylline
DB00035	DB01551	Opioids may enhance the adverse effects and toxicity of desmopressin. It is recommended to monitor therapy.
DB00038	DB01551	May increase the serum levels of opioid analgesics. It is recommended to monitor therapy for the signs and symptoms of respiratory depression and enhanced sedation.
DB00039	DB06769	Increases toxicity of bendamustine. Should not be administered within a 24 hour time period of antineoplastic agent administration.
DB00039	DB06813	Increases the toxicity of pralatrexate. Avoid concomitant therapy or do not use palifermin within 24 hours after administration of pralatrexate.
DB00040	DB00328	Monitor therapy due to diminished therapeutic effect of glucagon.
DB00040	DB00682	Monitor therapy due to enhanced anticoagulant effects.
DB00041	DB01013	Corticosteroids such as clobetasol may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
DB00041	DB00838	Corticosteroids such as clocortolone may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
DB00041	DB00363	Avoid combination due to enhanced adverse effects of clozapine, especially the risk of agranulocytosis.
DB00041	DB01285	Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
DB00041	DB00476	Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
DB00043	DB08879	Avoid combination due to enhanced toxic effects of monoclonal antibodies.
DB00043	DB06643	Monitor therapy due to increased risk of infections consequent to increased adverse effects of immunosuppressants.
DB00043	DB01097	Consider modifying therapy due to increased adverse effects of leflunomide including hematological toxicity.
DB00043	DB00108	Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
DB00043	DB00337	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB00043	DB01656	Consider therapy modification due to enhanced immunosuppressive effects.
DB00043	DB06688	Monitor therapy due to diminished therapeutic effect of sipuleucel-t.
DB00043	DB00864	Avoid combination due to enhanced adverse toxic effects.
DB00043	DB08895	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB00043	DB00072	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB00046	DB01193	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB00046	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00046	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00046	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB00046	DB00647	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00280	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00584	Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00668	Concomitant therapy with sympathomimetic agents may reduce the blood-glucose-lowering effect of insulin lispro.
DB00046	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00046	DB01039	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00472	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00999	Concomitant therapy with diuretics may reduce the blood-glucose-lowering effect of insulin lispro.
DB00046	DB00678	Concomitant therapy with angiotensin II receptor blockers may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00104	Concomitant therapy with somatostatin analogs may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00806	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB01278	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00046	DB00635	Concomitant therapy with corticosteriods may reduce the blood-glucose-lowering effect of insulin lispro.
DB00046	DB00178	Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00047	DB01193	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB00047	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00047	DB00195	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00047	DB01295	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB00047	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00047	DB00521	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00047	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB00047	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00047	DB00598	The beta-blocker, labetolol, may decrease symptoms of hypoglycemia.
DB00047	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00047	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB00047	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB00047	DB01359	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB00047	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00047	DB01297	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB00047	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00047	DB00052	Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars.
DB00047	DB00489	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00047	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00048	DB00063	Monitor therapy due to increased adverse effects of collagenase including risk of injection site bruising or bleeding.
DB00051	DB06168	Increases immunosuppressive effects and risk of infection.
DB00051	DB00065	Both bind to TNF alfa and thus combination results in enhanced immunosuppressive effect. It is recommended that simultaneous use of both agents be avoided.
DB00051	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00051	DB08895	Adalimumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy.
DB00051	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00052	DB00284	Somatropin may antagonize the hypoglycemic effect of acarbose. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00672	Somatropin may antagonize the hypoglycemic effect of chlorpropamide. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01276	Somatropin may antagonize the hypoglycemic effect of exenatide. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01120	Somatropin may antagonize the hypoglycemic effect of gliclazide. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00222	Somatropin may antagonize the hypoglycemic effect of glimepiride. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01067	Somatropin may antagonize the hypoglycemic effect of glipizide. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01016	Somatropin may antagonize the hypoglycemic effect of glibenclamide. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01306	Somatropin may antagonize the hypoglycemic effect of insulin aspart. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01307	Somatropin may antagonize the hypoglycemic effect of insulin detemir. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00047	Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01309	Somatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB06655	Somatropin may antagonize the hypoglycemic effect of liraglutide. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00331	Somatropin may antagonize the hypoglycemic effect of metformin. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00491	Somatropin may antagonize the hypoglycemic effect of miglitol. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00731	Somatropin may antagonize the hypoglycemic effect of nateglinide. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01132	Somatropin may antagonize the hypoglycemic effect of pioglitazone. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00412	Somatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB06335	Somatropin may antagonize the hypoglycemic effect of saxagliptin. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB01261	Somatropin may antagonize the hypoglycemic effect of sitagliptin. Monitor for changes in fasting and postprandial blood sugars.
DB00052	DB00839	Somatropin may antagonize the hypoglycemic effect of Tolazamide. Dose adjustments of Tolazamide may be required.
DB00052	DB01124	Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required.
DB00054	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00054	DB00775	Additive effects. Concomitant use is contraindicated.
DB00054	DB00072	Abciximab may increase the risk of a hypersensitivy reaction to Trastuzumab.
DB00054	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy.
DB00055	DB00758	Antiplatelet agents such as clopidogrel may enhance the adverse/toxic effect of Drotrecogin Alfa. Bleeding may occur. Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.
DB00055	DB06779	Low molecular weight heparin (LMWH) such as dalteparin may enhance the adverse/toxic effect of drotrecogin alfa. Bleeding may occur.
DB00055	DB01225	Combination should be used with caution after weighing advantages and disadvantages. Low molecular weight heparins such as enoxaparin may increase the adverse effects of drotrecogin. Monitor for bleeding if used concomitantly.
DB00055	DB00569	Drotrecogin alfa may increase the adverse effects of fondaparinux, resulting in excessive bleeding. Concomitant use should be avoided.
DB00055	DB01109	The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin.
DB00055	DB01009	The antiplatelet effect of ketoprofen may increase the bleed risk associated with drotrecogin alfa. Consider spacing use of the two agents by at least 7 days. Increase monitoring for signs and symptoms of bleeding during concomitant therapy.
DB00055	DB08813	The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin.
DB00055	DB00031	Increased risk of bleeding.
DB00055	DB06822	Low molecular weight heparins (LMWHs) such as tinzaparin may enhance the adverse/toxic effects of drotrecogin alfa. Bleeding may occur. The potential benefits of drotrecogin alfa should be weighed against the increased risk of bleeding in patients on therapeutic doses of LMWHs.
DB00055	DB00500	Increased risk of bleeding. Monitor for increased bleeding during concomitant therapy.
DB00055	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Drotrecogin alfa. Monitor for increased bleeding during concomitant thearpy.
DB00055	DB00013	Increased risk of bleeding.
DB00055	DB06684	Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.
DB00055	DB00682	Increased risk of bleeding.
DB00056	DB08879	Avoid combination due to enhanced adverse effects of belimumab.
DB00056	DB00363	Avoid combination due to adverse effects of clozapine including the risk of agranulocytosis.
DB00056	DB06643	Monitor therapy due to enhanced adverse effects of immunosuppressants including the risk of infections.
DB00056	DB01097	Consider modifying therapy due to adverse effects of leflunomide including the risk of hematologic toxicity.
DB00056	DB00108	Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
DB00056	DB00337	Avoid combination due to toxic effects of immunosuppressants.
DB00056	DB01656	Consider therapy modification due to enhanced immunosuppressive effect.
DB00056	DB06688	Monitor therapy due to reduced therapeutic effect of sipuleucel-t.
DB00056	DB00864	Avoid combination of adverse effects of immunosuppressants.
DB00056	DB08895	Avoid combination due to enhancement of immunosuppressants.
DB00056	DB00072	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB00059	DB06643	Monitor therapy due to increased immunosuppressive effect and risk of infections.
DB00059	DB01097	Immunosuppressants can increase toxic effects of leflunomide such as hematologic toxicity.
DB00059	DB00108	Avoid combination because of increased immunosuppressants and risk of infections.
DB00059	DB00337	Avoid combination because pimecrolimus enhances the adverse effects of immunosuppressants.
DB00059	DB01656	Consider therapy modification because pegaspargase enhances the immunosuppressive effect of roflumilast.
DB00059	DB06688	Monitor therapy because pegaspargase may diminish therapeutic effect of sipuleucel-T.
DB00059	DB00864	Tacrolimus enhances adverse effects of pegaspargase therefore the combination should be avoided.
DB00059	DB08895	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB00059	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00061	DB00552	Avoid combination due to decreased effect of both drugs
DB00063	DB06605	Monitor therapy due to potential risk of bleeding.
DB00063	DB00048	Monitor therapy due to increased adverse effects of collagenase including risk of injection site bruising or bleeding.
DB00063	DB06695	Monitor therapy due to increased bleeding.
DB00063	DB01254	Monitor therapy due to enhanced anticoagulant effect.
DB00063	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00063	DB01296	Monitor therapy due to enhanced antiplatelet effect.
DB00063	DB00078	Monitor therapy due to enhanced adverse effects, ie bleeding of ibritumomab.
DB00063	DB08935	Monitor therapy due to increased risk of bleeding events.
DB00063	DB00686	Pentosan can potentiate adverse effects of antiplatelet agents and thus increase bleeding risk. Combination must be used with caution.
DB00063	DB00806	Monitor therapy due to enhanced antiplatelet effect.
DB00063	DB06228	Consider modifying therapy due to enhanced anticoagulant effect.
DB00063	DB00932	Monitor therapy due to increased antiplatelet effect.
DB00063	DB00775	Additive effects. Concomitant use is contraindicated.
DB00063	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Eptifibatide. Monitor for increased bleeding during concomitant thearpy.
DB00065	DB01281	The combination shoould be avoided as there have been reports of increased risk of serious infections.
DB00065	DB00051	Both bind to TNF alfa and thus combination results in enhanced immunosuppressive effect. It is recommended that simultaneous use of both agents be avoided.
DB00065	DB00026	Combination may enhance the toxic effect of Anakinra and should be avoided otherwise there may be an increased risk of infection
DB00065	DB06168	Avoid combination due to increased risk of infection as anti-TNF agents enhance adverse effects of Canakinumab.
DB00065	DB08904	Avoid combination because anti-TNF agents increase adverse effects of certolizumab pegol
DB00065	DB06643	Therapy should be monitored when combination is initiated as there may be an increase in serious infections.
DB00065	DB00005	Avoid combination because etanercept may increase immunosuppressive effects of infliximab.
DB00065	DB06674	Avoid combination with infliximab due to the potential increased immunosuppression of infliximab.
DB00065	DB01097	Therapy modification should be considered in order to reduce the risk of hematologic toxicities.
DB00065	DB00108	Increase adverse effects of natalizumab. Avoid combination
DB00065	DB00337	Pimecrolimus enhances the adverse effects of immune suppressants thus the combination should be avoided.
DB00065	DB06372	Anti-TNF alfa agents enhance adverse effects of rilonacept thus combination should be avoided.
DB00065	DB01656	Roflumilast enhances the adverse effects of immune suppressants thus a therapy modification should be considered.
DB00065	DB06688	Monitoring is required because immunosuppressants can decrease the therapeutic effect of Sipuleucel-T.
DB00065	DB00864	Avoid combination because of risk of enhance adverse effects of immunosuppressants
DB00065	DB06273	Avoid combination because enhanced immunosuppression by anti-TNF agents.
DB00065	DB08895	Avoid combination with infliximab and other anti-TNF drugs due to the potential enhancement of tofacitinib related adverse effects.
DB00065	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00068	DB00495	The interferon increases the effect and toxicity of zidovudine
DB00070	DB00988	Consider modifying therapy due to enhanced adverse effects of dopamine.
DB00070	DB00388	Avoid combination because hyaluronidase can potentiate the vasoconstrictive effect of phenylephrine.
DB00072	DB01281	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00054	Abciximab may increase the risk of a hypersensitivy reaction to Trastuzumab.
DB00072	DB00051	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00087	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00488	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00276	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00026	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00098	Monitor therapy due to enhanced neutropenic effect
DB00072	DB00023	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00928	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00993	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00074	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB06681	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB00072	DB00443	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00290	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01008	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01101	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00958	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00262	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00291	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00515	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00242	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00631	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01285	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01380	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00531	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00091	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00987	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00851	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00111	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00970	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00694	Trastuzumab may increase the cardiotoxicity of Daunorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00004	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01234	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01248	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00997	Trastuzumab may increase the cardiotoxicity of Doxorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00095	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00445	Trastuzumab may increase the cardiotoxicity of Epirubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00530	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01196	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00005	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00773	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00322	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01073	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00687	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00544	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00317	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00441	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00056	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB00072	DB05259	Monitor therapy due to enhanced neutropenic effects of immunosuppressants.
DB00072	DB00741	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01005	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00078	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00078	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB00072	DB01177	Trastuzumab may increase the cardiotoxicity of Idarubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01181	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00619	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00065	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00762	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00480	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01206	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00888	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01042	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01033	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00563	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00959	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00305	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01204	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00075	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00688	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01024	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00108	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01280	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB04868	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB08935	Monitor therapy due to enhanced neutropenic effect of immunosuppressants
DB00072	DB00043	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB00072	DB00526	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01229	Trastuzumab may increase the risk of neutropenia and anemia. Concomitant therapy may also increase Trastuzumab serum concentration and decrease Paclitaxel serum concentrations. Monitor closely for adverse events and therapeutic response.
DB00072	DB00059	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00552	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00860	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00635	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01168	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB06372	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00073	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00877	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00398	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00428	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01268	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00864	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00853	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB06287	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00444	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB01041	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB04572	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00352	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB08895	Trastuzumab, when used in combination with tofacitinib, may increase tofacitinib adverse effects, ie. neutropenic effects. It is recommended to monitor therapy.
DB00072	DB01030	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00081	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00755	Increased risk of leukopenia and anemia due to synergistic effects. Monitor for signs and symptoms of adverse events during concomitant therapy.
DB00072	DB00620	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00385	Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00570	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00541	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00072	DB00361	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00073	DB01281	Avoid combination due to enhanced adverse effects of abatacept.
DB00073	DB09026	Consider therapy modification due to enhanced hypotensive effect of rituximab.
DB00073	DB08822	Azilsartan medoxomil used in combination with rituximab may lead to hypotension.
DB00073	DB00195	Antihypertensives like betaxolol may enhance the hypotensive effect of rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion.
DB00073	DB08904	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB00073	DB00880	Antihypertensives such as chlorothiazide may enhance the hypotensive effect of Rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion.
DB00073	DB00966	Telmisartan may increase the hypotensive effect of Rituximab. Telmisartan should be withheld prior to and throughout Rituximab administration.
DB00073	DB01162	Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab.
DB00073	DB08895	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB00073	DB00839	Additive hypotensive effects may occur. Consider withholding Tolazamide for 12 hours prior to administration of Rituximab.
DB00073	DB00214	Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Torasemide for 12 hours prior to administration of Rituximab.
DB00073	DB00519	Trandolapril may incresae the hypotensive effect of Rituximab.
DB00073	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00073	DB01021	Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Trichlormethiazide for 12 hours prior to administration of Rituximab.
DB00073	DB00177	Additive hypotensive effects may occur. Increased risk of hypotension. Consider withholding Valsartan for 12 hours prior to administration of Rituximab.
DB00073	DB00661	Verapamil may increase the hypotensive effects of Rituximab. Consider withholding Verapamil therapy for 12 hours prior to Rituximab infusion.
DB00074	DB06168	results in increased immunosuppressive effects; increases the risk of infection.
DB00074	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00074	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00075	DB00091	Muromonab increases the levels of cyclosporine
DB00075	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00075	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00076	DB08810	Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.
DB00078	DB08879	Avoid combination due to enhanced adverse effects of belimumab.
DB00078	DB00363	Avoid combination due to enhanced adverse effects of clozapine, including agranulocytosis.
DB00078	DB06643	Monitor therapy for enhanced immunosuppressive effects and increased risk of infections.
DB00078	DB00063	Monitor therapy due to enhanced adverse effects, ie bleeding of ibritumomab.
DB00078	DB01097	May need to modify therapy to avoid adverse effects of leflunomide such as hematologic toxicity.
DB00078	DB00108	Avoid combination due to increased adverse effects of natalizumab and increased risk of infections.
DB00078	DB00337	Avoid combination due to increased immunosuppressive effects.
DB00078	DB01656	Consider modifying therapy due to enhanced immunosuppressive effect.
DB00078	DB06688	Monitor therapy due to diminished therapeutic effect of sipuleucel-t.
DB00078	DB00864	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB00078	DB08895	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB00078	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00078	DB00072	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB00081	DB00108	The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00081	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00082	DB01551	Opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy.
DB00082	DB01276	Monitor therapy due to enhanced hypoglycemic effect.
DB00082	DB01306	Monitor therapy due to enhanced hypoglycemic effect.
DB00085	DB01592	If pancrelipase and iron salts are used in combination then monitor therapy. Pancrelipase may decrease the absorption of iron salts except for ferumoxytol, iron dextran complex, and iron sucrose.
DB00086	DB00208	Increased bleeding risk. Monitor for signs of bleeding.
DB00087	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00089	DB06719	Avoid combination because luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide.
DB00091	DB00819	Acetazolamide may increase the effect and toxicity of cyclosporine.
DB00091	DB09026	Avoid combination because cyclosporine increases aliskiren serum concentration.
DB00091	DB00437	Allopurinol increases the effect and toxicity of cyclosporine
DB00091	DB01118	Amiodarone may increase the therapeutic and adverse effects of cyclosporine.
DB00091	DB01351	The barbiturate, amobarbital, increases the effect of cyclosporine.
DB00091	DB00681	Monitor for nephrotoxicity
DB00091	DB00701	The protease inhibitor, amprenavir, may increase the effect of cyclosporine.
DB00091	DB01352	The barbiturate, aprobarbital, increases the effect of cyclosporine.
DB00091	DB01072	Atazanavir may increase the therapeutic and adverse effects of cyclosporine.
DB00091	DB01076	Possible myopathy and rhabdomyolysis
DB00091	DB00207	The macrolide, azithromycin, may increase the effect of cyclosporine.
DB00091	DB01393	Cyclosporine may enhance the nephrotoxic effect of fibric acid derivatives like bezafibrate. Fibric acid derivatives may decrease the serum concentration of cyclosporine. Extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary.
DB00091	DB00559	Cyclosporine may increase the effect and toxicity of bosentan.
DB00091	DB01156	Bupropion may decrease the therapeutic effect of cyclosporine.
DB00091	DB00237	The barbiturate, butabarbital, increases the effect of cyclosporine.
DB00091	DB00241	The barbiturate, butalbital, increases the effect of cyclosporine.
DB00091	DB01353	The barbiturate, butethal, increases the effect of cyclosporine.
DB00091	DB00564	Carbamazepine may decrease the therapeutic effect of cyclosporine.
DB00091	DB01136	Carvedilol may increase the therapeutic and adverse effects of cyclosporine.
DB00091	DB00520	Cyclosporine increases the effect and toxicity of caspofungin
DB00091	DB00439	Possible myopathy and rhabdomyolysis
DB00091	DB00446	Chloramphenicol may increase the effect of cyclosporine.
DB00091	DB00608	Chloroquine may increase the therapeutic and adverse effects of cyclosporine.
DB00091	DB01597	Imipenem increases the effect and toxicity of cyclosporine
DB00091	DB00537	Ciprofloxacin may increase the effect and toxicity of cyclosporine.
DB00091	DB01211	The macrolide, clarithromycin, may increase the effect of cyclosporine.
DB00091	DB01190	Clindamycin may decrease the therapeutic effect of cyclosporine.
DB00091	DB01394	Increased toxicity of both drugs
DB00091	DB01406	The androgen, danazol, may increase the effect and toxicity of cyclosporine.
DB00091	DB00586	Monitor for nephrotoxicity
DB00091	DB00390	Cyclosporine may increase the effect of digoxin.
DB00091	DB01341	The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine.
DB00091	DB00343	Diltiazem may increase the effect and toxicity of cyclosporine.
DB00091	DB04855	Cyclosporine is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB00091	DB00625	Efavirenz decreases the levels of cyclosporine
DB00091	DB00199	The macrolide, erythromycin, may increase the effect of cyclosporine.
DB00091	DB00977	The contraceptive increases the effect and toxicity of cyclosporine
DB00091	DB00754	The hydantoin decreases the effect of cyclosporine
DB00091	DB00749	Monitor for nephrotoxicity
DB00091	DB00773	Cyclosporine may increase the therapeutic and adverse effects of etoposide.
DB00091	DB00973	Cyclosporine may increase the therapeutic and adverse effects of ezetimibe.
DB00091	DB00573	Monitor for nephrotoxicity
DB00091	DB08874	Cyclosporin is an inhibitor of p-glycoprotein and concomitant therapy will result in a increase in Cmax and AUC of fidaxomicin and its metabolite.
DB00091	DB00196	Fluconazole may increase the therapeutic and adverse effects of the cyclosporine.
DB00091	DB00472	The antidepressant increases the effect and toxicity of cyclosporine
DB00091	DB00712	Monitor for nephrotoxicity
DB00091	DB01095	Possible myopathy and rhabdomyolysis
DB00091	DB01319	The protease inhibitor, fosamprenavir, may increase the effect of cyclosporine.
DB00091	DB00529	Monitor for nephrotoxicity
DB00091	DB01320	The hydantoin decreases the effect of cyclosporine
DB00091	DB00222	The sulfonylurea, glimepiride, may increase the effect of cyclosporine.
DB00091	DB01067	The sulfonylurea, glipizide, may increase the effect of cyclosporine.
DB00091	DB01016	The sulfonylurea, glibenclamide, may increase the effect of cyclosporine.
DB00091	DB00400	Griseofulvin decreases the effect of cyclosporine
DB00091	DB01354	The barbiturate, heptabarbital, increases the effect of cyclosporine.
DB00091	DB01355	The barbiturate, hexobarbital, increases the effect of cyclosporine.
DB00091	DB01050	Monitor for nephrotoxicity
DB00091	DB00619	Imatinib increases the effect and toxicity of cyclosporine
DB00091	DB01598	Imipenem increases the effect and toxicity of cyclosporine
DB00091	DB00224	The protease inhibitor, indinavir, may increase the effect of cyclosporine.
DB00091	DB00328	Monitor for nephrotoxicity
DB00091	DB01167	Itraconazole may increase the effect of cyclosporine.
DB00091	DB01321	The macrolide, josamycin, may increase the effect of cyclosporine.
DB00091	DB01026	Ketoconazole may increase the effect of cyclosporine.
DB00091	DB01009	The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine.
DB00091	DB00227	Possible myopathy and rhabdomyolysis
DB00091	DB00939	Monitor for nephrotoxicity
DB00091	DB00784	Monitor for nephrotoxicity
DB00091	DB01042	Melphalan increases toxicity of cyclosporine
DB00091	DB00532	The hydantoin decreases the effect of cyclosporine
DB00091	DB01357	The contraceptive increases the effect and toxicity of cyclosporine
DB00091	DB00474	The barbiturate, methohexital, increases the effect of cyclosporine.
DB00091	DB00563	Cyclosporine may increase the effect and toxicity of methotrexate.
DB00091	DB00422	Methylphenidate increases the effect and toxicity of cyclosporine
DB00091	DB00849	The barbiturate, methylphenobarbital, increases the effect of cyclosporine.
DB00091	DB01233	Metoclopramide increases serum levels of cyclosporine
DB00091	DB00745	Modafinil decreases the effect of cyclosporine
DB00091	DB00075	Muromonab increases the levels of cyclosporine
DB00091	DB00461	Monitor for nephrotoxicity
DB00091	DB00607	Nafcillin alters serum levels of cyclosporine
DB00091	DB00788	Monitor for nephrotoxicity
DB00091	DB01149	The antidepressant increases the effect and toxicity of cyclosporine
DB00091	DB00220	The protease inhibitor, nelfinavir, may increase the effect of cyclosporine.
DB00091	DB00622	Nicardipine increases the effect and toxicity of cyclosporine
DB00091	DB01115	Increased risk of gingivitis
DB00091	DB01059	Norfloxacin may increase the effect and toxicity of cyclosporine.
DB00091	DB00104	Octreotide decreases the effect of cyclosporine
DB00091	DB00338	Omeprazole increases the effect and toxicity of cyclosporine
DB00091	DB01083	Orlistat decreases the effect of cyclosporine
DB00091	DB00991	Monitor for nephrotoxicity
DB00091	DB00776	Oxcarbazepine decreases the effect of cyclosporine
DB00091	DB00312	The barbiturate, pentobarbital, increases the effect of cyclosporine.
DB00091	DB01174	The barbiturate, phenobarbital, may decrease the therapeutic effect of cyclosporine by increasing its metabolism.
DB00091	DB00252	The hydantoin decreases the effect of cyclosporine
DB00091	DB00554	Monitor for nephrotoxicity
DB00091	DB08860	Cyclosporine decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy.
DB00091	DB01263	Increased level of cyclosporine
DB00091	DB00175	Possible myopathy and rhabdomyolysis
DB00091	DB00794	The barbiturate, primidone, increases the effect of cyclosporine.
DB00091	DB01599	Probucol decreases the effect of cyclosporine
DB00091	DB01182	Propafenone increases the effect and toxicity of cyclosporine
DB00091	DB00339	Pyrazinamide decreases the effect of cyclosporine
DB00091	DB01346	The barbiturate, quinidine barbiturate, increases the effect of cyclosporine.
DB00091	DB01369	Synercid increases the effect of cyclosporine
DB00091	DB00912	Cyclosporine may increase the therapeutic and adverse effects of repaglinide.
DB00091	DB00615	The rifamycin decreases the effect of cyclosporine
DB00091	DB01045	The rifamycin decreases the effect of cyclosporine
DB00091	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00091	DB00503	The protease inhibitor, ritonavir, may increase the effect of cyclosporine.
DB00091	DB01098	Cyclosporine may increase the serum concentration of rosuvastatin. Limit rosuvastatin dosing to 5 mg/day and monitor for changes in the therapeutic and adverse effects of rosuvastatin if cyclosporine is initiated, discontinued or dose changed.
DB00091	DB00778	The macrolide, roxithromycin, may increase the effect of cyclosporine.
DB00091	DB01232	The protease inhibitor, saquinavir, may increase the effect of cyclosporine.
DB00091	DB00418	The barbiturate, secobarbital, increases the effect of cyclosporine.
DB00091	DB00658	Sevelamer decreases the effect of cyclosporine
DB00091	DB01105	Sibutramine increases the effect and toxicity of cyclosporine
DB00091	DB00641	Possible myopathy and rhabdomyolysis
DB00091	DB00877	Increases the effect and toxicity of sirolimus
DB00091	DB01323	St. John's Wort decreases the effect of cyclosporine
DB00091	DB00359	The sulfonamide decreases the effect of cyclosporine
DB00091	DB01582	The sulfonamide decreases the effect of cyclosporine
DB00091	DB01015	The sulfonamide decreases the effect of cyclosporine
DB00091	DB00795	The sulfonamide decreases the effect of cyclosporine
DB00091	DB01138	Sulfinpyrazone decreases the effect of cyclosporine
DB00091	DB00605	The NSAID, sulindac, may increase the nephrotoxic effect of cyclosporine. Sulindac may increase the serum concentration of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine levels and nephrotoxicity during concomitant therapy.
DB00091	DB00864	Additive renal impairment may occur during concomitant therapy with cyclosporine. Combination therapy should be avoided.
DB00091	DB00306	The sulfonamide decreases the effect of cyclosporine
DB00091	DB00706	Cyclosporine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cyclosporine is initiated, discontinued, or dose changed.
DB00091	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy.
DB00091	DB00976	Telithromycin may reduce clearance of cyclosporine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of cyclosporine if telithromycin is initiated, discontinued or dose changed.
DB00091	DB00469	Monitor for nephrotoxicity
DB00091	DB00857	Terbinafine may decrease the plasma concentration and therapeutic effect of cyclosporine.
DB00091	DB00894	The androgen, Testolactone, may increase the hepatotoxicity of Cyclosporine. Testolatone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB00091	DB00624	The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB00091	DB01420	The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB00091	DB00599	Thiopental may increase the metabolism and clearance of Cyclosporine. Monitor for changes in the therapeutic/adverse effects of Cyclosporine if Thiopental is initiated, discontinued or dose changed.
DB00091	DB01600	Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy.
DB00091	DB00208	Ticlopidine decreases the effect of cyclosporine
DB00091	DB00932	Tipranavir may affect the efficacy/toxicity of Cyclosporine.
DB00091	DB00684	Increased risk of nephrotoxicity
DB00091	DB08895	Cyclosporin (and other strong immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression and infection. It is recommended to avoid concurrent therapy.
DB00091	DB00500	Tolmetin may increase the serum concentration of cyclosporine and/or increase the nephrotoxicity of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine serum concentration and nephrotoxicity during concomitant therapy.
DB00091	DB01036	Cyclosporine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00091	DB01030	The p-glycoprotein inhibitor, Cyclosporine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00091	DB00193	Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00091	DB00519	The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine.
DB00091	DB05275	The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB00091	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00091	DB00656	The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed.
DB00091	DB00197	Troglitazone decreases the effect of the immunosuppressant
DB00091	DB01361	The macrolide, troleandomycin, may increase the effect of cyclosporine.
DB00091	DB01586	Ursodiol increases the levels of cyclosporine
DB00091	DB00661	Verapamil may increase the serum concentration of cyclosporine by inhibiting CYP3A4-mediated metabolism of cyclosporine. Monitor for changes in the therapeutic/adverse effects of cyclosporine if verapamil is initiated, discontinued or dose changed.
DB00091	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cyclosporine by decreasing its metabolism. Consider reducing the dose of cyclosporine. Monitor cyclosporine serum concentrations and therapeutic and toxic effects if initiating, discontinuing or adjusting voriconazole therapy.
DB00092	DB06168	Increases immunosuppressive effects and risk of infection.
DB00092	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00095	DB01253	The antiretroviral agent may increase the ergot derivative
DB00095	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00095	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00098	DB06168	results in increased immunosuppressive effects; increases the risk of infection.
DB00098	DB06643	Monitor therapy because of the enhanced immunosuppressive effect and increased risk of infections.
DB00098	DB01097	Therapy modification may be required because the combination enhances toxic effects of leflunomide.
DB00098	DB00108	Avoid combination due to enhanced toxic effects of natalizumab.
DB00098	DB00337	Avoid combination due to enhanced immunosuppressive effects and increased risk of infections.
DB00098	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00098	DB01656	Therapy may need to be modified due to enhanced immunosuppressive effects.
DB00098	DB06688	Monitor therapy due to potential decreased therapeutic effect of sipuleucel-T.
DB00098	DB00864	Avoid combination due to increased immunosuppressive effects
DB00098	DB08895	Avoid combination due to enhanced immunosuppressive effects.
DB00098	DB00072	Monitor therapy due to enhanced neutropenic effect
DB00099	DB00290	Monitor therapy due to enhanced adverse effects of bleomycin especially pulmonary toxicity.
DB00099	DB00531	Monitor therapy due to adverse effects of cyclophosphamide, especially pulmonary toxicity.
DB00099	DB01030	Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia.
DB00104	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00104	DB00091	Octreotide decreases the effect of cyclosporine
DB00104	DB01551	Concurrent use may enhance the analgesic effect of dihydrocodeine. It is recommended to monitor therapy, and reduce the dose of dihydrocodeine as appropriate.
DB00104	DB00046	Concomitant therapy with somatostatin analogs may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00104	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00104	DB01369	This combination presents an increased risk of toxicity
DB00104	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00104	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00104	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00104	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00104	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00104	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00104	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00104	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00105	DB01223	Interferon increases the effect and toxicity of theophylline
DB00105	DB00651	Interferon increases the effect and toxicity of theophylline
DB00105	DB01303	Interferon increases the effect and toxicity of theophylline
DB00105	DB00277	Interferon increases the effect and toxicity of theophylline
DB00106	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00106	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00106	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00106	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00106	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00106	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00106	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00106	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00107	DB00429	Avoid combination due to enhanced oxytocic effects.
DB00107	DB00917	Therapy modification should be considered because of enhanced oxytocic effects
DB00107	DB00668	Possible marked increase of arterial pressure
DB00107	DB00834	Consider therapy modification because of potential enhanced effect of Q-Tc prolongation
DB00107	DB00929	Avoid combination. Manufacturer advises not to administer concomitantly due to enhanced adverse effects of oxytocin, especially when given within 4 hours of oxytocin initiation.
DB00107	DB00388	Possible marked increase of arterial pressure
DB00108	DB01281	Avoid combination due to enhanced adverse effects of natalizumab and the risk of infections.
DB00108	DB05773	Avoid combination due to the increased risk of infection.
DB00108	DB00098	Avoid combination due to enhanced toxic effects of natalizumab.
DB00108	DB06681	Avoid infection due to enhanced adverse effects of natalizumab and the risk of infections.
DB00108	DB08879	Avoid combination due to enhance adverse effects of natalizumab such as the risk of concurrent infections.
DB00108	DB00290	Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00108	DB08870	Avoid combination due to the increased risk of concurrent infection.
DB00108	DB06168	Avoid combination due to the increased risk of infection.
DB00108	DB00958	Immunosuppressants such as natalizumab may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00108	DB00262	Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00108	DB08904	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB00108	DB00291	Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00108	DB00515	Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
DB00108	DB00242	Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
DB00108	DB00631	Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
DB00108	DB00005	Avoid combination due to enhanced adverse effects of natalizumab and increased risk of infections.
DB00108	DB00056	Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
DB00108	DB05259	Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
DB00108	DB06674	Avoid combination due to the increased chance of infection.
DB00108	DB04865	Avoid combination due to the increased risk of infection.
DB00108	DB00078	Avoid combination due to increased adverse effects of natalizumab and increased risk of infections.
DB00108	DB00065	Increase adverse effects of natalizumab. Avoid combination
DB00108	DB08935	Avoid combination due to enhanced adverse effects of natalizumab.
DB00108	DB00043	Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
DB00108	DB01229	Avoid combination due to the increased risk of infection.
DB00108	DB00059	Avoid combination because of increased immunosuppressants and risk of infections.
DB00108	DB00864	Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.
DB00108	DB00853	The immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00108	DB06287	Temsirolimus may increase the toxicity of Natalizumab. Concomitant therapy should be avoided.
DB00108	DB00444	The immunosuppressant, Teniposide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00108	DB08880	Avoid combination due to the increased risk of infection.
DB00108	DB01041	Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.
DB00108	DB04572	The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00108	DB00352	The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00108	DB08895	Avoid combination due to the increased risk of infection.
DB00108	DB01030	The immunosuppressant, Topotecan, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00108	DB00081	The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00108	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00108	DB00755	Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided.
DB00108	DB00385	Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided.
DB00108	DB00570	Concomitant Vinblastine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
DB00108	DB00541	Concomitant Vincristine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
DB00108	DB00361	Concomitant Vinorelbine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
DB00111	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00111	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00112	DB08879	Avoid combination due to enhanced adverse effects of bevacizumab
DB00112	DB00363	Avoid combination due to increased adverse effects of clozapine, especially the risk of agranulocytosis.
DB00112	DB00762	Monitor therapy due to increased adverse effects of irinotecan.
DB00112	DB00398	Monitor therapy due to increased adverse effects of sorafenib, especially hand-foot skin reaction.
DB00112	DB01268	Sunitinib may enhance the adverse/toxic effect of bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of sunitinib. This combination is contraindicated.
DB00118	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00118	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00118	DB01009	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB00118	DB00605	S-adenosylmethionine may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
DB00118	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00118	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00118	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00118	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00118	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00118	DB00682	Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
DB00118	DB00315	Use of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00126	DB00746	Vitamin C may increase the adverse effects of deferoxamine. Transient deterioration of left ventricular function has been observed during concomitant therapy. Use caution during concomitant therapy.
DB00126	DB00224	Vitamin C decreases indinavir levels
DB00136	DB00169	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00136	DB00930	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00136	DB00976	Telithromycin may reduce clearance of Calcitriol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Calcitriol if Telithromycin is initiated, discontinued or dose changed.
DB00136	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of calcitriol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of calcitriol if voriconazole is initiated, discontinued or dose changed.
DB00150	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00150	DB01247	Possible severe adverse reaction with this combination
DB00150	DB06684	Due to risks of enhanced serotonin activity and/or adverse reactions (e.g., serotonin syndrome), concomitant use of selective serotonin reuptake inhibitors (SSRIs) and tryptophan is not recommended. Avoid combination.
DB00150	DB00315	Use of two serotonin modulators, such as zolmitriptan and L-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00153	DB00169	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00176	DB00865	Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.
DB00176	DB00564	Fluvoxamine increases the effect of carbamazepine
DB00182	DB01170	Amphetamine may decrease the effect of guanethidine.
DB00182	DB01247	Possible hypertensive crisis
DB00182	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB00153	DB00930	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00158	DB01351	Folic acid decreases the effect of anticonvulsant, amobarbital.
DB00158	DB01352	Folic acid decreases the effect of anticonvulsant, aprobarbital.
DB00158	DB00237	Folic acid decreases the effect of anticonvulsant, butabarbital.
DB00158	DB00241	Folic acid decreases the effect of anticonvulsant, butalbital.
DB00158	DB01353	Folic acid decreases the effect of anticonvulsant, butethal.
DB00158	DB01341	Folic acid decreases the effect of anticonvulsant, dihydroquinidine barbiturate.
DB00158	DB00754	Folic acid decreases the levels of hydantoin
DB00158	DB01320	Folic acid decreases the levels of hydantoin
DB00158	DB01354	Folic acid decreases the effect of anticonvulsant, heptabarbital.
DB00158	DB01355	Folic acid decreases the effect of anticonvulsant, hexobarbital.
DB00158	DB00532	Folic acid decreases the levels of hydantoin
DB00158	DB00474	Folic acid decreases the effect of anticonvulsant, methohexital.
DB00158	DB00849	Folic acid decreases the effect of anticonvulsant, methylphenobarbital.
DB00158	DB00312	Folic acid decreases the effect of anticonvulsant, pentobarbital.
DB00158	DB01174	Folic acid decreases the effect of anticonvulsant, phenobarbital.
DB00158	DB00252	Folic acid may decrease the levels of phenytoin.
DB00158	DB00794	Folic acid decreases the effect of anticonvulsant, primidone.
DB00158	DB01346	Folic acid decreases the effect of anticonvulsant, quinidine barbiturate.
DB00158	DB00418	Folic acid decreases the effect of anticonvulsant, secobarbital.
DB00158	DB00306	Folic acid decreases the effect of anticonvulsant, talbutal.
DB00162	DB00459	Acitretin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking acitretin.
DB00162	DB00307	Bexarotene increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking bexarotene.
DB00162	DB00982	Isotretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking isotretinoin.
DB00162	DB01083	Orlistat may impair the absorption of vitamin A, a fat soluble vitamin. Oral vitamin A should be administered 2 hours prior to or post orlistat administration.
DB00162	DB00755	Tretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking systemic tretinoin.
DB00163	DB00701	Increased serum levels of vitamin E
DB00163	DB01083	Orlistat may impair the absorption of vitamin E, a fat soluble vitamin. Oral vitamin E should be administered 2 hours prior to or post orlistat administration.
DB00169	DB01436	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00169	DB06723	Vitamin D analogs such as cholecalciferol may increase the serum concentration of aluminum hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB00169	DB02300	Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). hough not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00169	DB00136	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00169	DB01432	Bile acid sequestrants such as cholestyramine may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00176	DB00395	Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00176	DB01166	Fluvoxamine increases the effect of cilostazol
DB00182	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB00169	DB00930	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00169	DB00375	Bile acid sequestrants such as colestipol may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00169	DB06410	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00169	DB00153	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00169	DB01083	Orlistat may decrease the serum concentration of Vitamin D analogs. More specifically, orlistat may impair absorption of Vitamin D analogs such as cholecalciferol. Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat.
DB00169	DB00910	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00169	DB00364	Vitamin D analogs such as cholecalciferol may increase the serum concentration of sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB00175	DB01393	Increased risk of myopathy/rhabdomyolysis
DB00175	DB08873	Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored.
DB00175	DB01394	Increased risk of rhabdomyolysis with this combination
DB00175	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Pravastatin. Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.
DB00175	DB00091	Possible myopathy and rhabdomyolysis
DB00175	DB01039	Increased risk of myopathy/rhabdomyolysis
DB00175	DB01241	Increased risk of myopathy/rhabdomyolysis
DB00175	DB00912	Substrates of organic anion transporters may increase levels of repaglinide. Monitor concomitant therapy closely.
DB00175	DB00932	Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy.
DB00176	DB01418	Fluvoxamine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB00176	DB00918	Increased risk of CNS adverse effects
DB00176	DB01223	Fluvoxamine may increase the effect and toxicity of aminophylline.
DB00176	DB00321	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB00543	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB00182	Risk of serotoninergic syndrome
DB00176	DB01125	Fluvoxamine may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB00176	DB06216	Fluvoxamine is a CYP1A2 inhibitor that increases exposure of asenapine by 30%.
DB00176	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00176	DB06769	Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion.
DB00182	DB01551	Amphetamines may enhance analgesic effects of dihydrocodeine. Monitor for enhanced analgesia. Dose reductions of dihydrocodeine may be appropriate.
DB00182	DB00472	Risk of serotoninergic syndrome
DB00176	DB01242	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB00363	The antidepressant increases the effect of clozapine
DB00176	DB01151	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00176	DB01191	Risk of serotoninergic syndrome
DB00176	DB01576	Risk of serotoninergic syndrome
DB00176	DB00266	Fluvoxamine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB00176	DB00937	Risk of serotoninergic syndrome
DB00176	DB00320	Possible ergotism and severe ischemia with this combination
DB00176	DB01142	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB00476	Fluvoxamine increases the effect and toxicity of duloxetine
DB00176	DB00651	Increases the effect and toxicity of theophylline
DB00176	DB00216	Increased risk of CNS adverse effects
DB00176	DB06210	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB00176	DB06210	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB00176	DB00696	Possible ergotism and severe ischemia with this combination
DB00176	DB00754	Increases the effect of hydantoin
DB00176	DB00574	Risk of serotoninergic syndrome
DB00176	DB01320	Fluvoxamine may increase the therapeutic and adverse effects of fosphenytoin.
DB00176	DB00998	Increased risk of CNS adverse effects
DB00176	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00176	DB00458	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB01247	Possible severe adverse reaction with this combination
DB00176	DB01009	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB00176	DB00601	Combination associated with possible serotoninergic syndrome
DB00176	DB01356	The SSRI, fluvoxamine, increases serum levels of lithium.
DB00176	DB00579	Risk of serotoninergic syndrome
DB00176	DB00532	Increases the effect of hydantoin
DB00176	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00176	DB00333	Fluvoxamine increases the effect and toxicity of methadone
DB00176	DB01577	Risk of serotoninergic syndrome
DB00176	DB00379	Fluvoxamine may increase the therapeutic and adverse effects of mexiletine.
DB00176	DB00370	Fluvoxamine may increase the therapeutic and adverse effects of mirtazapine.
DB00176	DB01171	Increased incidence of adverse effects with this association
DB00176	DB00952	Increased risk of CNS adverse effects
DB00176	DB00540	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB00334	Fluvoxamine increases the effect and toxicity of olanzapine
DB00176	DB01303	Fluvoxamine may increase the therapeutic and adverse effects of oxtriphylline.
DB00176	DB00497	Increased risk of serotonin syndrome
DB00176	DB01579	Risk of serotoninergic syndrome
DB00176	DB00780	Possible severe adverse reaction with this combination
DB00176	DB00191	Risk of serotoninergic syndrome
DB00176	DB00397	Risk of serotoninergic syndrome
DB00176	DB00252	Fluvoxamine may increase the therapeutic effect of phenytoin.
DB00176	DB00344	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB00980	Fluvoxamine may increase the serum level and toxicity of ramelteon.
DB00176	DB01367	Possible severe adverse reaction with this combination
DB00176	DB00953	Increased risk of CNS adverse effects
DB00176	DB01656	Increases roflumilast levels.
DB00176	DB00268	Increases the effect and toxicity of ropinirole
DB00176	DB00296	Increases the effect and toxicity of ropivacaine
DB00176	DB01037	Possible severe adverse reaction with this combination
DB00176	DB01105	Risk of serotoninergic syndrome
DB00176	DB01323	St. John's Wort increases the effect and toxicity of the SSRI, fluvoxamine.
DB00176	DB00669	Increased risk of CNS adverse effects
DB00182	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB00182	DB00176	Risk of serotoninergic syndrome
DB00176	DB00382	Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of tacrine.
DB00176	DB00857	Terbinafine may reduce the metabolism and clearance of Fluvoxamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluvoxamine if Terbinafine is initiated, discontinued or dose changed.
DB00176	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00176	DB00277	Fluvoxamine may increase the therapeutic and adverse effects of theophylline.
DB00176	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed.
DB00176	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00176	DB01623	The strong CYP1A2 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB01600	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB00176	DB00697	Fluvoxamine inhibits the metabolism and clearance of tizanidine. Concomitant therapy is contraindicated.
DB00176	DB00500	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00176	DB00193	Tramadol may increase the risk of serotonin syndrome and seizures.
DB00176	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00176	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00176	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy.
DB00176	DB00726	The strong CYP2C19 inhibitor, fluvoxamine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Additive modulation of serotonin activity may also increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome and changes in therapeutic and adverse effects of trimipramine if fluvoxamine is initiated, discontinued or dose changed.
DB00176	DB00427	The CNS depressants, Triprolidine and Fluvoxamine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00176	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00176	DB00682	Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration.
DB00176	DB00315	Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00177	DB01143	Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Valsartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB00177	DB00594	Increased risk of hyperkalemia
DB00177	DB06210	Eltrombopag may increase the therapeutic and/or toxic effects of Valsartan. Increased Valsartan serum concentrations may be caused by inhibition of hepatic uptake and decreased metabolism. Consider dose modification, alternate therapy or monitor for changes in the therapeutic and toxic effects of Valsartan if Eltrombopag is initiated, discontinued or dose changed.
DB00177	DB01356	Valsartan may increase serum lithium concentrations. Monitor serum lithium levels during concomitant therapy to avoid lithium toxicity.
DB00177	DB01345	Increased risk of hyperkalemia
DB00177	DB00073	Additive hypotensive effects may occur. Increased risk of hypotension. Consider withholding Valsartan for 12 hours prior to administration of Rituximab.
DB00177	DB00684	Increased risk of nephrotoxicity
DB00177	DB00519	The angiotensin II receptor blocker, Valsartan, may increase the adverse effects of Trandolapril.
DB00177	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00177	DB00384	Increased risk of hyperkalemia
DB00178	DB00594	Increased risk of hyperkalemia
DB00178	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00178	DB01395	Increased risk of hyperkalemia
DB00178	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00178	DB00046	Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00178	DB01356	The ACE inhibitor increases serum levels of lithium
DB00178	DB01345	Increased risk of hyperkalemia
DB00178	DB00421	Increased risk of hyperkalemia
DB00178	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00178	DB00684	Increased risk of nephrotoxicity
DB00178	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00178	DB00384	Increased risk of hyperkalemia
DB00180	DB00976	Telithromycin may reduce clearance of Flunisolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flunisolide if Telithromycin is initiated, discontinued or dose changed.
DB00180	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flunisolide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flunisolide if voriconazole is initiated, discontinued or dose changed.
DB00181	DB00427	The CNS depressants, Triprolidine and Baclofen, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00182	DB00477	Decreased anorexic effect, may increase psychotic symptoms
DB00182	DB00715	Risk of serotoninergic syndrome
DB00182	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB00182	DB00780	Possible hypertensive crisis
DB00182	DB00433	Decreased anorexic effect, may increase pyschotic symptoms
DB00182	DB01069	Decreased anorexic effect, may increase pyschotic symptoms
DB00182	DB01608	Decreased anorexic effect, may increase pyschotic symptoms
DB00182	DB01367	Possible hypertensive crisis
DB00182	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB00182	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB00185	DB00872	Conivaptan may increase the serum concentration of CYP3A4 substrates such as cevimeline. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00185	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Cevimeline, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00186	DB00363	Increased risk of toxicity
DB00186	DB01322	Kava may increase the effect of the benzodiazepine, lorazepam.
DB00186	DB00427	The CNS depressants, Triprolidine and Lorazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00186	DB00313	Valproic acid may increase the serum concentration of Lorazepam by reducing Lorazepam metabolism. The Lorazepam dose should be reduced by 50% during concomitant therapy. Monitor for increased Lorazepam effects and toxicity.
DB00187	DB00414	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB00672	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB00575	Increased hypertension when clonidine stopped
DB00187	DB00320	Ischemia with risk of gangrene
DB00187	DB00280	The beta-blocker, esmolol, may increase the adverse effects of disopyramide.
DB00187	DB00668	Hypertension, then bradycardia
DB00187	DB01253	Ischemia with risk of gangrene
DB00187	DB00696	Ischemia with risk of gangrene
DB00187	DB01288	Antagonism
DB00187	DB00983	Antagonism
DB00187	DB01120	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01067	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01289	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01016	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01382	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01050	Risk of inhibition of renal prostaglandins
DB00187	DB00328	Risk of inhibition of renal prostaglandins
DB00187	DB01306	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01307	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB00047	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01309	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB00046	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01064	Antagonism
DB00187	DB00281	The beta-blocker, esmolol, may increase the effect and toxicity of lidocaine.
DB00187	DB00247	Ischemia with risk of gangrene
DB00187	DB00816	Antagonism
DB00187	DB00236	Antagonism
DB00187	DB01291	Antagonism
DB00187	DB00554	Risk of inhibition of renal prostaglandins
DB00187	DB00457	Risk of hypotension at the beginning of therapy
DB00187	DB01366	Antagonism
DB00187	DB00912	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01001	Antagonism
DB00187	DB00938	Antagonism
DB00187	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00187	DB00871	Antagonism
DB00187	DB00839	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB01124	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00187	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00187	DB00661	Increased effect of both drugs
DB00188	DB00758	Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel.
DB00188	DB06414	Bortezombib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB00188	DB00976	Telithromycin may reduce clearance of Bortezomib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bortezomib if Telithromycin is initiated, discontinued or dose changed.
DB00188	DB00208	Ticlopidine may decrease the metabolism and clearance of Bortezomib. Consider alternate therapy or monitor for adverse/toxic effects of Bortezomib if Ticlopidine is initiated, discontinued or dose changed.
DB00188	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bortezomib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bortezomib if voriconazole is initiated, discontinued or dose changed.
DB00189	DB01418	Ethchlorvynol may decrease the anticoagulant effect of acenocoumarol.
DB00189	DB01125	Ethchlorvynol may decrease the anticoagulant effect of anisindione.
DB00189	DB00266	Ethchlorvynol may decrease the anticoagulant effect of dicumarol.
DB00189	DB00682	Ethchlorvynol may decrease the anticoagulant effect of warfarin.
DB00191	DB01063	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB01246	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00477	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00392	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00472	Risk of serotoninergic syndrome
DB00191	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00176	Risk of serotoninergic syndrome
DB00191	DB01170	Phentermine may decrease the effect of guanethidine.
DB00191	DB01247	Possible hypertensive crisis
DB00191	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00902	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00715	Risk of serotoninergic syndrome
DB00191	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00780	Possible hypertensive crisis
DB00191	DB00433	Decreased anorexic effect, may increase psychotic symptoms.
DB00191	DB00420	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB01069	Decreased anorexic effect, may increase psychotic symptoms.
DB00191	DB01608	Decreased anorexic effect, may increase psychotic symptoms.
DB00191	DB00777	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB01367	Possible hypertensive crisis
DB00191	DB00372	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00191	DB00519	Phentermine may reduce the efficacy of Trandolapril.
DB00191	DB00752	The MAO inhibitor, tranylcypromine, may increase the vasopressor effect of the amphetamine, phentermine. Concomitant therapy should be avoided.
DB00191	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00508	Decreased anorexic effect, may increase psychotic symptoms
DB00191	DB00427	Triprolidine may reduce the sedative effect of the antihistamine, Phentermine.
DB00191	DB00285	Risk of serotoninergic syndrome
DB00193	DB00918	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00193	DB00357	Aminoglutethimide may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01118	Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00321	Tramadol increases the risk of serotonin syndrome and seizures.
DB00193	DB00543	Tramadol increases the risk of serotonin syndrome and seizures.
DB00193	DB00701	Amprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00673	Aprepitant may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01072	Atazanavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00865	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00559	Bosentan may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01200	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00248	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00564	Carbamazepine may decrease the effect of tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00608	Chloroquine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00477	Chlorpromazine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00501	Cimetidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Cimetidine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01012	Cinacalcet may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00215	The use of two serotonin modulators, such as citalopram and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00193	DB01211	Clarithromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01242	Tramadol increases the risk of serotonin syndrome and seizures. Clomipramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00257	Clotrimazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00363	Clozapine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00907	Cocaine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00872	Conivaptan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00924	Increases risk of seizure.
DB00193	DB00091	Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00496	Darifenacin may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01264	Darunavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00705	Delavirdine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Delavirdine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01151	Tramadol increases the risk of serotonin syndrome and seizures. Desipramine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Desipramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01234	Dexamethasone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01576	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00514	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00320	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00343	Diltiazem may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01075	Diphenhydramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01142	Tramadol increases the risk of serotonin syndrome and seizures.
DB00193	DB00476	Duloxetine may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.
DB00193	DB00625	Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00216	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01049	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01253	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00696	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00199	Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01175	Tramadol may increase the risk of serotonin syndrome and seizures.
DB00193	DB06414	Tramadol,when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration and efficacy due to increased tramadol metabolism and clearance.
DB00193	DB00196	Fluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00472	The use of two serotonin modulators, such as fluoxetine and tramadol, may increase the risk of serotonin syndrome. Fluoxetine may decrease the effect of tramadol by decreasing active metabolite production.
DB00193	DB00176	Tramadol may increase the risk of serotonin syndrome and seizures.
DB00193	DB01319	Fosamprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01320	Fosphenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00998	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00614	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Furazolidone.
DB00193	DB00502	Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00619	Imatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Imatinib may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00458	Tramadol increases the risk of serotonin syndrome and seizures. Imipramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00224	Indinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01247	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid.
DB00193	DB00951	Isoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01167	Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01026	Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01259	Lapatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00281	Lidocaine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lidocaine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00601	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid.
DB00193	DB01255	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01601	Lopinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lopinavir may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00934	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00333	Methadone may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01577	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01403	Additive CNS depressant effects. Decrease dose of tramadol by 50% if initiating methotrimeprazine therapy. Monitor for increased CNS depression and apply further dosage adjustments as required.
DB00193	DB00353	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00916	Metronidazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01110	Miconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Miconazole may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00370	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01171	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide.
DB00193	DB00607	Nafcillin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00952	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01149	Nefazodone may increase tramadol toxicity by decreasing tramadol metabolism and clearance. Increased risk of serotonin syndrome. Monitor for tramadol toxicity and symptoms of serotonin syndrome.
DB00193	DB00220	Nelfinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00238	Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00622	Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB04868	Nilotinib may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01059	Norfloxacin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00540	Tramadol increases the risk of serotonin syndrome and seizures.
DB00193	DB00776	Oxcarbazepine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00715	Tramadol may increase the risk of serotonin syndrome and seizures. Paroxetine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00312	Pentobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01186	Pergolide may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.
DB00193	DB00454	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01579	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00780	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, phenelzine.
DB00193	DB01174	Phenobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00191	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00252	Phenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01132	Pioglitazone may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01263	Posaconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00794	Primidone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01168	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Procarbazine.
DB00193	DB01069	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00344	Tramadol increases the risk of serotonin syndrome and seizures.
DB00193	DB00205	Pyrimethamine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00908	Quinidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Quinidine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00468	Quinine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00243	Ranolazine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01367	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, rasagiline.
DB00193	DB00615	Rifabutin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01045	Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB01201	Rifapentine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00193	DB00503	Ritonavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ritonavir may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00953	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00118	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB01232	Saquinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01037	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Selegiline.
DB00193	DB01104	Tramadol increases the risk of serotonin syndrome and seizures. Sertraline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Sertraline may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB01105	Sibutramine may incrase the serotonergic effect of the Tramadol. Concomitant therapy should be avoided.
DB00193	DB06268	Sitaxsentan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB01323	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00669	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00976	Telithromycin may decrease the metabolism and clearance of tramadol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of tramadol if telithromycin is initiated, discontinued or dose changed.
DB00193	DB00857	Terbinafine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00759	Tetracycline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00679	Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00208	Ticlopidine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00193	DB00752	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, tranylcypromine. Tranylcypromine may decrease the effect of tramadol by decreasing active metabolite production.
DB00193	DB00656	The use of two serotonin modulators, such as trazodone and tramadol, may increase the risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00726	Tramadol may increase the risk of serotonin syndrome and seizures.
DB00193	DB00427	The CNS depressants, Triprolidine and Tramadol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00193	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00193	DB00661	Verapamil may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00193	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tramadol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tramadol if voriconazole is initiated, discontinued or dose changed.
DB00193	DB00315	The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00195	DB00414	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00195	DB00672	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00195	DB00575	Increased hypertension when clonidine stopped
DB00195	DB00320	Ischemia with risk of gangrene
DB00195	DB00280	The beta-blocker, betaxolol, may increase the toxicity of disopyramide.
DB00195	DB00668	Beta-Blockers such as betaxolol may enhance the vasopressor effect of epinephrine. Monitor for increases in pressor effects of alpha-/beta-agonists if used in patients receiving beta-blocker therapy (including ophthalmic products). Beta1-selective (i.e., cardioselective) agents may confer a more limited risk if used in low enough doses to allow them to retain their selectivity. The amount of epinephrine used in dental procedures as part of local anesthetic administration is not likely to be of clinical concern. Infiltrating larger volumes of local anesthetics for other surgical procedures (e.g., more than 0.06mg epinephrine) may cause clinically-relevant problems. Patients with allergies that require carrying and periodically using subcutaneous epinephrine (e.g., bee sting kits) should probably avoid the use of beta blockers.
DB00195	DB00696	Ischemia with risk of gangrene
DB00195	DB01288	Beta-Blockers (Beta-1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like fenoterol.  Therapy should be monitored.
DB00195	DB00983	Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like formoterol. Therapy should be monitored.
DB00195	DB01120	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00195	DB01016	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00195	DB01050	Nonsteroidal Anti-Inflammatory Agents such as ibuprofen may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
DB00195	DB00328	Nonsteroidal Anti-Inflammatory Agents such as indomethacin may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
DB00195	DB00047	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00195	DB06709	Beta-Blockers like betaxolol may worsen brochoconstriction and decrease the effectiveness of agents used to treat the resulting bronchoconstriction. Use of betaxolol and methacholine concomitantly is contraindicated.
DB00195	DB00247	Ischemia with risk of gangrene
DB00195	DB00816	Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like orciprenaline. Therapy should be monitored.
DB00195	DB00236	Antagonism
DB00195	DB00554	Nonsteroidal Anti-Inflammatory Agents such as piroxicam may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
DB00195	DB00457	Beta-Blockers such as betaxolol may enhance the orthostatic hypotensive effect of Alpha1-Blockers such as prazosin. The risk associated with ophthalmic products is probably less than systemic products. Exercise caution if an alpha1-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha1-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha1-blocker is being used to treat BPH, consider using tamsulosin since its alpha1-A selectivity is least likely to cause hypotension.
DB00195	DB00912	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00195	DB00073	Antihypertensives like betaxolol may enhance the hypotensive effect of rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion.
DB00195	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00195	DB00871	Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like terbutaline. Therapy should be monitored.
DB00195	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed
DB00195	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00196	DB01418	Fluconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism.
DB00196	DB00802	Increases the effect and toxicity of alfentanil
DB00196	DB00404	Fluconazole may increase the effect of the benzodiazepine, alprazolam.
DB00196	DB00321	Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00196	DB01125	Fluconazole may increase the serum concentration of anisindione by decreasing its metabolism.
DB00196	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00196	DB01076	Increased risk of myopathy/rhabdomyolysis
DB00196	DB01558	Fluconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if fluconazole is initiated, discontinued or dose changed.
DB00196	DB00564	Fluconazole may increase the therapeutic and adverse effects of carbamazepine.
DB00199	DB01012	The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet.
DB00199	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00196	DB00395	Strong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00196	DB00482	Fluconazole may increase the effect of celecoxib.
DB00196	DB00475	Fluconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00196	DB01166	Fluconazole may decrease the effect of cilostazol.
DB00196	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00196	DB01068	Fluconazole may increase the effect of the benzodiazepine, clonazepam.
DB00196	DB00628	Fluconazole may increase the effect of the benzodiazepine, clorazepate.
DB00196	DB00872	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB00196	DB00531	Fluconazole reduces metabolism and clearance of cyclophosphamide.
DB00196	DB00091	Fluconazole may increase the therapeutic and adverse effects of the cyclosporine.
DB00196	DB00829	Fluconazole may increase the effect of the benzodiazepine, diazepam.
DB00196	DB00266	Fluconazole may increase the serum concentration of dicumarol by decreasing its metabolism.
DB00196	DB00320	Possible ergotism and severe ischemia with this combination
DB00196	DB00700	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB00196	DB00696	Possible ergotism and severe ischemia with this combination
DB00196	DB01215	Fluconazole may increase the effect of the benzodiazepine, estazolam.
DB00196	DB00754	Increases the effect of hydantoin
DB00196	DB01590	Fluconazole may increase everolimus levels/toxicity.
DB00196	DB00813	Fluconazole may increase levels/toxicity of fentanyl.
DB00196	DB06702	Fluconazole is a moderate CYP3A4 inhibitor thus reducing clearance. Monitor for adverse effects when using concomitant therapy with fesoterodine.
DB00196	DB00690	Fluconazole may increase the effect of the benzodiazepine, flurazepam.
DB00196	DB01095	Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed.
DB00196	DB01320	Fluconazole may increase the effect of hydantoin.
DB00196	DB00801	Fluconazole may increase the effect of the benzodiazepine, halazepam.
DB00196	DB00502	Fluconazole may increase the effect and toxicity of haloperidol.
DB00196	DB00458	Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of imipramine if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00196	DB08820	Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction.
DB00196	DB00227	Increased risk of myopathy/rhabdomyolysis
DB00196	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00196	DB00532	Increases the effect of hydantoin
DB00196	DB00683	Fluconazole may increase the effect of the benzodiazepine, midazolam.
DB00196	DB00540	Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00196	DB04938	Fluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with ospemifene. Fluconazole increases the systemic exposure of ospemifene by 2.7-fold. Administration of fluconazole with ospemifene may increase the risk of adverse events.
DB00196	DB00252	Fluconazole may increase the therapeutic and adverse effects of phenytoin.
DB00196	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB00196	DB01589	Fluconazole may increase the effect of the benzodiazepine, quazepam.
DB00196	DB00980	Fluconazole may increase the serum levels and toxcity of ramelteon.
DB00196	DB00243	Increased levels of ranolazine - risk of toxicity
DB00196	DB00615	Fluconazole may increase levels/toxicity of rifabutin.
DB00196	DB01045	Rifampin may decrease the effect of fluconazole.
DB00196	DB06207	Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely.
DB00196	DB00641	Increased risk of myopathy/rhabdomyolysis
DB00196	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The antifungal, fluconazole, may also increase serum concentrations of tacrolimus.
DB00196	DB00675	Fluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole  is initiated, discontinued or dose changed.
DB00196	DB00706	Fluconzole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluconazole is initiated, discontinued, or dose changed.
DB00196	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00196	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00196	DB00932	Fluconazole may increase the serum concentration of Tipranavir. Dose adjustments are not required.
DB00196	DB08895	Fluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily.
DB00199	DB00215	Possible serotoninergic syndrome with this combination
DB00196	DB01124	Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
DB00196	DB01036	Fluconazole may decrease the metabolism and clearance of tolterodine. Adjust tolterodine dose and monitor for efficacy and toxicity.
DB00196	DB06212	Fluconazole is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
DB00196	DB00214	Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluconazole is initiated, discontinued or dose changed.
DB00196	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00196	DB00193	Fluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00196	DB00656	The CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed.
DB00196	DB00897	Fluconazole may increase the effect of the benzodiazepine, triazolam.
DB00196	DB00440	The strong CYP2C9 inhibitor, Fluconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluconazole is initiated, discontinued or dose changed.
DB00196	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Fluconazole, a strong CYP2C19 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Concomitant therapy should be used with caution.
DB00196	DB00580	Fluconazole may increase the effect and toxicity of valdecoxib.
DB00196	DB00661	Fluconazole may increase the serum concentration of Verapamil by decreasing Verapamil metabolism. This likely occurs via Fluconazole-mediated CYP3A4 inhibition. Monitor for changes in the therapeutic/adverse effects of Verapamil if Fluconazole is initiated, discontinued, or dose changed.
DB00196	DB00570	Increases the effect and toxicity of anticancer agent
DB00196	DB00541	Increases the effect and toxicity of anticancer agent
DB00196	DB00582	Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of voriconazole if fluconazole is initiated, discontinued or dose changed.
DB00196	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00196	DB00682	Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed.
DB00196	DB00549	Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluconazole is initiated, discontinued or dose changed.
DB00196	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00196	DB00425	Fluconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fluconazole is initiated, discontinued or dose changed.
DB00196	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00197	DB01432	Decreases the effect of troglitazone
DB00197	DB00091	Troglitazone decreases the effect of the immunosuppressant
DB00197	DB00977	Possible loss of contracepitve effect
DB00197	DB00717	Possible loss of contraceptive effect
DB00199	DB01418	The macrolide, erythromycin, may increase the anticoagulant effect of acenocoumarol.
DB00199	DB00802	The macrolide, erythromycin, may increase the effect and toxicity of alfentanil.
DB00199	DB00404	The macrolide, erythromycin, may increase the effect of the benzodiazepine, alprazolam.
DB00199	DB01223	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
DB00199	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01125	The macrolide, erythromycin, may increase the anticoagulant effect of anisindione.
DB00199	DB00673	Erythromycin, a moderate CYP3A4 inhibitor, may increase the effect and toxicity of aprepitant.
DB00199	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00199	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01076	The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin.
DB00199	DB06237	Co-administration with the moderate CYP3A4 inhibitor erythromycin resulted in an approximate 3.6-fold increase in AUC0-inf and 2.0-fold increase in Cmax of avanafil.
DB00199	DB06769	Decreases metabolism, thus decreasing the effects of bendamustine.
DB00199	DB01158	Increased risk of cardiotoxicity and arryhthmias
DB00199	DB01558	Erythromcyin may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if erythromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00199	DB01200	Erythromycin increases serum levels of bromocriptine
DB00199	DB00490	The macrolide, erythromycin, may increase the effect and toxicity of buspirone.
DB00199	DB00248	Erythromycin increases serum levels and toxicity of cabergoline
DB00199	DB00564	The macrolide, erythromycin, may increase the effect of carbamazepine.
DB00199	DB00439	The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.
DB00199	DB01166	Erythromycin increases the effect of cilostazol
DB00199	DB00363	Erythromycin increases the effect of clozapine
DB00199	DB01394	Severe colchicine toxicity can occur
DB00199	DB00091	The macrolide, erythromycin, may increase the effect of cyclosporine.
DB00199	DB00829	The macrolide, erythromycin, may increase the effect of the benzodiazepine, diazepam.
DB00199	DB00266	The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol..
DB00199	DB00390	The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.
DB00199	DB00320	Possible ergotism and severe ischemia with this combination
DB00199	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01248	Erythromycin may increase the serum levels and toxicity of docetaxel.
DB00199	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB00651	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, dyphylline.
DB00199	DB00216	The macrolide, erythromycin, may increase the effect and toxicity of eletriptan.
DB00199	DB06210	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB00199	DB00700	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB00199	DB01253	Possible ergotism and severe ischemia with this combination
DB00199	DB00696	Possible ergotism and severe ischemia with this combination
DB00199	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00199	DB01590	The macrolide, erythromycin, may increase the serum concentration and toxicity of everolimus.
DB00199	DB01023	Erythromycin increases the effect of felodipine
DB00199	DB00472	Possible serotoninergic syndrome with this combination
DB00199	DB00317	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB00199	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB00619	The macrolide, erythromycin, may increase the serum concentration of imatinib.
DB00199	DB05039	Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events.
DB00199	DB01167	The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.
DB00199	DB08820	Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction.
DB00199	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01627	Possible antagonism of action with this combination.
DB00199	DB00227	The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin.
DB00199	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00199	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB00353	Possible ergotism and severe ischemia with this combination
DB00199	DB00959	The macrolide, erythromycin, may increase the effect of corticosteroid, methylprednisolone.
DB00199	DB00247	Possible ergotism and severe ischemia with this combination
DB00199	DB00683	The macrolide, erythromycin, may increase the effect of the benzodiazepine, midazolam.
DB00199	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01303	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
DB00199	DB06589	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB00199	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB08860	Erythromycin decreases metabolism of pitavastatin. Do not exceed 1 mg per day of pitavastatin or use alternative therapy.
DB00199	DB01224	The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.
DB00199	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01369	This combination presents an increased risk of toxicity
DB00199	DB00243	Increased levels of ranolazine - risk of toxicity
DB00199	DB00912	The macrolide, erythromycin, may increase the effect of repaglinide.
DB00199	DB00615	The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin.
DB00199	DB01045	The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.
DB00199	DB00503	Increased toxicity of both agents
DB00199	DB01656	Increases roflumilast levels.
DB00199	DB06335	Erythromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB00199	DB01104	Possible serotoninergic syndrome with this combination
DB00199	DB01105	Erythromycin increases the effect and toxicity of sibutramine
DB00199	DB00203	The macrolide, erythromycin, may increase the effect and toxicity of sildenafil.
DB00199	DB06207	Erythromycin is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects
DB00199	DB00641	The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin.
DB00199	DB00877	The macrolide, erythromycin, may increase the serum concentration of sirolimus.
DB00199	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, erythromycin, may also increase the blood concentration of tacrolimus.
DB00199	DB00706	Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed.
DB00199	DB00976	Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed.
DB00199	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB00277	The macrolide, erythromycin, may increase the effect and toxicity of theophylline.
DB00199	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00199	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00199	DB06212	Erythromycin is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
DB00199	DB01030	The p-glycoprotein inhibitor, Erythromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00199	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00199	DB00193	Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00199	DB00656	The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed.
DB00199	DB00897	The macrolide, erythromycin, may increase the effect of the benzodiazepine, triazolam.
DB00199	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00199	DB00313	The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed.
DB00199	DB00862	Erythromycin, a moderate CYP3A4 inhibitor, may reduce the metabolism and clearance of vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of vardenafil if erythromycin is initiated, discontinued or dose changed.
DB00199	DB00661	Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of verapamil if erythromycin is initiated, discontinued or dose changed.
DB00199	DB00570	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of vinblastine if erythromycin is initiated, discontinued or dose changed.
DB00199	DB00541	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Erythromycin is initiated, discontinued or dose changed.
DB00199	DB00361	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Erythromycin is initiated, discontinued or dose changed.
DB00199	DB08828	P-glycoprotein inhibitors may increase the chance of adverse drug reactions.
DB00199	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00199	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00199	DB00682	The macrolide, erythromycin, may increase the anticoagulant effect of warfarin.
DB00199	DB00549	Erythromycin may decrease the serum concentration and effect of zafirlukast.
DB00199	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00199	DB01198	The macrolide antibiotic, erythromycin, may increase the serum concentration of zopiclone. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if erythromycin is initiated, discontinued or dose changed.
DB00199	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00201	DB00640	Caffeine may diminish the therapeutic effect of adenosine. Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible.
DB00201	DB00537	Ciprofloxacin may increase the effect and toxicity of caffeine.
DB00201	DB00363	Caffeine increases the effect and toxicity of clozapine
DB00201	DB00872	Conivaptan may increase the serum concentration of CYP3A4 substrates such as caffeine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00201	DB00365	Grepafloxacin may increase the effect and toxicity of caffeine.
DB00201	DB01356	Caffeine decreases serum levels of lithium
DB00201	DB01059	Norfloxacin may increase the effect and toxicity of caffeine.
DB00201	DB06213	Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear.
DB00201	DB00706	Caffeine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Caffeine is initiated, discontinued, or dose changed.
DB00201	DB00857	Terbinafine may increase the plasma concentration of Caffeine.
DB00201	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Caffeine by decreasing Caffeine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Caffeine if Thiabendazole is initiated, discontinued or dose changed.
DB00201	DB01036	Caffeine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00201	DB08881	Vemurafenib increases the AUC of caffeine (CYP1A2 substrate) 2.6-fold.
DB00202	DB00479	The agent increases the effect of muscle relaxant
DB00202	DB01190	The agent increases the effect of muscle relaxant
DB00202	DB00531	Cyclophosphamide may increase the effect of succinylcholine.
DB00202	DB01551	May enhance the bradycardic effect of opioid analgesics. It is recommended to monitor therapy.
DB00202	DB01057	Echothiophate iodide may increase the effect of succinylcholine.
DB00202	DB00798	The agent increases the effect of muscle relaxant
DB00202	DB01627	The agent increases the effect of muscle relaxant
DB00202	DB00955	The agent increases the effect of muscle relaxant
DB00202	DB00319	The agent increases the effect of the muscle relaxant
DB00202	DB00908	The quinine derivative increases the effect of the muscle relaxant
DB00202	DB00468	The quinine derivative increases the effect of the muscle relaxant
DB00202	DB00382	Tacrine may increase the effects of Succinylcholine. Monitor Succinylcholine therapy for increased effects.
DB00202	DB00684	The agent increases the effect of the muscle relaxant
DB00203	DB00701	The protease inhibitor, amprenavir, may increase the effect and toxicity of sildenafil.
DB00203	DB06216	Increased incidence of adverse effects (hypotension) due to pharmacodynamic synergism. Concomitant therapy should be avoided.
DB00203	DB01072	Increases the effect and toxicity of sildenafil
DB00203	DB00501	Increases the effect and toxicity of sildenafil
DB00203	DB00537	Ciprofloxacin may increase the serum level of sildenafil.
DB00203	DB01211	Increases the effect and toxicity of sildenafil
DB00203	DB00872	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Sildenafil. When sildenanfil is used for treatment of pulmonary arterial hypertension, concurrent use with strong CYP3A4 inhibitors is not recommended. When sildenafil is used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking a strong CYP3A4 inhibitor. Due to the particularly strong effects of ritonavir, sildenafil (for erectile dysfunction) doses greater than 25 mg per 48 hours are not recommended. Of note, the interaction between CYP3A4 inhibitors and sildenafil is predicted to be greater with orally administered than with injected sildenafil.
DB00203	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of sildenafil.
DB00203	DB06414	Sildenafil (and other phosphodiesterase 5 inhibitors), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor the efficacy of sildenafil therapy.
DB00203	DB01319	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of sildenafil.
DB00203	DB00224	The protease inhibitor, indinavir, may increase the effect and toxicity of sildenafil.
DB00203	DB00883	Possible significant hypotension with this combination
DB00203	DB01020	Possible significant hypotension with this combination
DB00203	DB01167	Itraconazole may increase the effect and toxicity of sildenafil.
DB00203	DB01026	Ketoconazole may increase the effect and toxicity of sildenafil.
DB00203	DB00220	The protease inhibitor, nelfinavir, may increase the effect and toxicity of sildenafil.
DB00203	DB00727	Possible significant hypotension with this combination
DB00203	DB06154	Possible significant hypotension with this combination
DB00203	DB00976	Telithromycin may reduce clearance of Sildenafil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sildenafil if Telithromycin is initiated, discontinued or dose changed.
DB00203	DB01162	Increased risk of hypotension.
DB00203	DB00932	Tipranavir, co-administered with Ritonavir, may increase the concentration of Sildenafil. Alternate therapy should be considered.
DB00203	DB01080	Increased anticonvulsant effects of vigabatrin due to pharmacodynamic synergism. Monitor for adverse effects during concomitant therapy.
DB00203	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sildenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sildenafil if voriconazole is initiated, discontinued or dose changed.
DB00204	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00204	DB00436	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB00880	Thiazide diuretics such as chlorothiazide may enhance the QTc-prolonging effect of dofetilide. Thiazide diuretics may increase the serum concentration of dofetilide. The concomitant use of hydrochlorothiazide and dofetilide is contraindicated by the manufacturer of dofetilide. Monitor for increased risk of QTc-prolongation and associated ventricular arrythmias during concomitant use of dofetilide and thiazide diuretics.
DB00204	DB00310	Increased risk of cardiotoxicity and arrythmias
DB00204	DB00501	Increases effect/toxicity of dofetilide
DB00204	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB00204	DB00999	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB00808	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB01167	This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide
DB00204	DB01026	This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide
DB00204	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB00524	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB01369	This combination presents an increased risk of toxicity
DB00204	DB00243	Possible additive effect on QT prolongation
DB00204	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00204	DB00976	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00204	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00204	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00204	DB01021	Trichlormethiazide may increase Dofetilide serum concentrations and increase the QTc-prolonging effect of Dofetilide. Increased risk of ventricular arrhythmias.
DB00204	DB00440	Trimethoprim may significantly reduced the clearance of Dofetilide. Trimethoprim is a cation transport inhibitor and may interfere with renal excretion of Dofetilide. Concomitant use is contraindicated.
DB00204	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00204	DB00661	Verapamil may increase the plamsa levels of Dofetilide. Increased risk of torsade de pointes. Concomitant therapy is contraindicated.
DB00204	DB00582	Voriconazole may increase the serum concentration of dofetilide by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00204	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00204	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00204	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00205	DB06697	Pyrimethamine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB00205	DB06708	Pyrimethamine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB00205	DB00675	Pyrimethamine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00205	DB00706	Pyrimethamine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pyrimethamine is initiated, discontinued, or dose changed.
DB00205	DB00193	Pyrimethamine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00206	DB00841	Increased arterial pressure
DB00206	DB00988	Increased arterial pressure
DB00206	DB01363	Increased arterial pressure
DB00206	DB01364	Increased arterial pressure
DB00206	DB00668	Increased arterial pressure
DB00206	DB01288	Increased arterial pressure
DB00206	DB06704	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores
DB00206	DB01064	Increased arterial pressure
DB00206	DB01365	Increased arterial pressure
DB00206	DB00610	Increased arterial pressure
DB00206	DB00723	Increased arterial pressure
DB00206	DB00368	Increased arterial pressure
DB00206	DB00816	Increased arterial pressure
DB00206	DB00388	Increased arterial pressure
DB00206	DB00397	Increased arterial pressure
DB00206	DB01291	Increased arterial pressure
DB00206	DB01366	Increased arterial pressure
DB00206	DB00852	Increased arterial pressure
DB00206	DB01001	Increased arterial pressure
DB00206	DB00871	Increased arterial pressure
DB00206	DB04844	Reserpine may increase the adverse/toxic effects of tetrabenazine as they have similar pharmacologic properties. Concomitant therapy is contraindicated.
DB00206	DB01030	The p-glycoprotein inhibitor, Reserpine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00206	DB00752	Addition of Reserpine to Tranylcypromine therapy may induce paradoxical Reserpine effects, including peripheral hypertension and central exciation. Close monitoring for adverse effects is required. Addition of Tranylcypromine to Reserpine therapy may be less of a concern.
DB00206	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00206	DB00427	The CNS depressants, Triprolidine and Reserpine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00207	DB01418	Azithromycin may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB00207	DB01125	Azithromycin may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB00207	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00207	DB00091	The macrolide, azithromycin, may increase the effect of cyclosporine.
DB00207	DB00266	Azithromycin may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB00207	DB00280	The macrolide, azithromycin, may increase the effect of disopyramide.
DB00207	DB00227	The macrolide antibiotic, azithromycin, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if azithromycin is initiated, discontinued or dose changed.
DB00207	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00207	DB08828	P-glycoprotein inhibitors may increase the chance of adverse drug reactions.
DB00207	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00207	DB00682	Azithromycin may increase the anticoagulant effect of warfarin by increasing its serum concentration.
DB00207	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00207	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00208	DB00945	Increased effect of ticlopidine
DB00208	DB00009	Increased bleeding risk. Monitor for signs of bleeding.
DB00208	DB06403	Ticlopidine may decrease the metabolism and clearance of Ambrisentan. Consider alternate therapy or monitor for adverse/toxic effects of Ambrisentan if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01223	Ticlopidine increases the effect and toxicity of theophylline
DB00208	DB00188	Ticlopidine may decrease the metabolism and clearance of Bortezomib. Consider alternate therapy or monitor for adverse/toxic effects of Bortezomib if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00564	Ticlopidine increases the effect of carbamazepine
DB00208	DB00395	Ticlopidine may decrease the metabolism and clearance of Carisoprodol. Consider alternate therapy or monitor for adverse/toxic effects of Carisoprodol if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01166	Ticlopidine may decrease the metabolism and clearance of Cilostazol. Consider alternate therapy or monitor for adverse/toxic effects of Cilostazol if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00501	Cimetidine may increase Ticlopidine levels. Avoid concomitant therapy.
DB00208	DB00215	Ticlopidine may decrease the metabolism and clearance of Citalopram. Consider alternate therapy or monitor for adverse/toxic effects of Citalopram if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00349	Ticlopidine may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for adverse/toxic effects of Clobazam if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01242	Ticlopidine may decrease the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for adverse/toxic effects of Clomipramine if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00091	Ticlopidine decreases the effect of cyclosporine
DB00208	DB00829	Ticlopidine may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for adverse/toxic effects of Diazepam if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00390	Ticlopidine may decrease Digoxin levels. Monitor for Digoxin levels with Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00651	Ticlopidine increases the effect and toxicity of theophylline
DB00208	DB01175	Ticlopidine may decrease the metabolism and clearance of Escitalopram. Consider alternate therapy or monitor for adverse/toxic effects of Ambrisentan if Escitalopram is initiated, discontinued or dose changed.
DB00208	DB00754	Ticlopidine increases the effect of hydantoin
DB00208	DB01320	Ticlopidine may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for adverse/toxic effects of Fosphenytoin if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00208	DB01109	Increased bleeding risk. Monitor aPTT.
DB00208	DB01181	Ticlopidine may decrease the metabolism and clearance of Ifosfamide. Consider alternate therapy or monitor for adverse/toxic effects of Ifosfamide if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00458	Ticlopidine may decrease the metabolism and clearance of Imipramine. Consider alternate therapy or monitor for adverse/toxic effects of Imipramine if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00532	Ticlopidine increases the effect of hydantoin
DB00208	DB05246	Ticlopidine may decrease the metabolism and clearance of Methsuximide. Consider alternate therapy or monitor for adverse/toxic effects of Methsuximide if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01171	Ticlopidine may decrease the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for adverse/toxic effects of Moclobemide if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00665	Ticlopidine may decrease the metabolism and clearance of Nilutamide. Consider alternate therapy or monitor for adverse/toxic effects of Nilutamide if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01303	Ticlopidine increases the effect and toxicity of theophylline
DB00208	DB00738	Ticlopidine may decrease the metabolism and clearance of Pentamidine. Consider alternate therapy or monitor for adverse/toxic effects of Pentamidine if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01174	Ticlopidine may decrease the metabolism and clearance of Phenobarbital. Consider alternate therapy or monitor for adverse/toxic effects of Phenobarbital if Ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00252	Ticlopidine may decrease the metabolism and clearance of phenytoin. Consider alternate therapy or monitor for adverse/toxic effects of phenytoin if ticlopidine is initiated, discontinued or dose changed.
DB00208	DB01100	Avoid combination with pimozide and other major CYP3A4 substrates due to the potential increase of pimozide concentration.
DB00208	DB00015	Increased bleeding risk. Monitor for signs of bleeding.
DB00208	DB01390	Sodium bicarbonate may decrease Ticlopidine levels. Administer agents 1 to 2 hours apart.
DB00208	DB00086	Increased bleeding risk. Monitor for signs of bleeding.
DB00208	DB00675	Ticlopidine may decrease the therapeutic effect of tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00208	DB00706	Ticlopidine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ticlopidine is initiated, discontinued, or dose changed.
DB00208	DB00031	Increased bleeding risk. Monitor for signs of bleeding.
DB00208	DB00277	Ticlopidine increases the effect and toxicity of theophylline
DB00208	DB00679	Ticlopidine may decrease the metabolism of thioridazine. Concomitant therapy is contraindicated.
DB00208	DB00697	Ticlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00208	DB00193	Ticlopidine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00208	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Ticlopidine. Monitor for increased bleeding during concomitant thearpy.
DB00209	DB01148	Trospium and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00208	DB00726	The strong CYP2C19 inhibitor, ticlopidine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of trimipramine if ticlopidine is initiated, discontinued or dose changed.
DB00208	DB00682	Increased bleeding risk. Monitor INR.
DB00209	DB01063	Trospium and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01246	Trospium and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00321	Trospium and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00543	Trospium and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00572	Trospium and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00972	Trospium and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00245	Trospium and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00810	Trospium and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01237	Trospium and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00835	Trospium and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00748	Trospium and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01114	Trospium and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00477	Trospium and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00283	Trospium and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00771	Trospium and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01242	Trospium and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00363	Trospium and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01176	Trospium and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00924	Trospium and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00979	Trospium and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00434	Trospium and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00496	Trospium and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01151	Trospium and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00967	Trospium and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00405	Trospium and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00804	Trospium and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00985	Trospium and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01075	Trospium and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00843	The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00209	DB01142	Trospium and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00366	Trospium and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00470	Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended.
DB00209	DB00450	Trospium and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00950	Trospium and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00218	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB00209	DB00875	Trospium and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00623	Trospium and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00674	The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00209	DB00986	Trospium and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00502	Trospium and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00725	Trospium and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00557	Trospium and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00424	Trospium and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00458	Trospium and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00332	Trospium and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01247	Trospium and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00920	Trospium and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00455	Trospium and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00408	Trospium and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00934	Trospium and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00737	Trospium and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB04843	Trospium and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00933	Trospium and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00940	Trospium and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00462	Trospium and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01171	Trospium and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01618	Trospium and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00486	Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended.
DB00209	DB00540	Trospium and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00334	Trospium and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01173	Trospium and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01062	Trospium and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00850	Trospium and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00780	Trospium and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01619	Trospium and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01100	Trospium and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB06153	Trospium and Pizotifen, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00761	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trospium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00209	DB01278	The anticholinergic effects of Trospium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB00218	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00209	DB00433	Trospium and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00387	Trospium and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01069	Trospium and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00782	Trospium and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00344	Trospium and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01224	Trospium and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00734	Trospium and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00989	The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00209	DB00747	Trospium and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00021	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00209	DB01591	Trospium and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trospium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00209	DB00679	Trospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01623	Trospium and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01409	Trospium and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01036	Trospium and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00752	Trospium and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00831	Trospium and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00376	Trospium and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00662	Trospium and Trimethobenzamide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00726	Trospium and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB00427	Trospium and Triprolidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00209	DB01624	Trospium and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00211	DB00443	Increased arterial pressure
DB00211	DB01380	Increased arterial pressure
DB00211	DB01234	Increased arterial pressure
DB00211	DB00841	Increased arterial pressure
DB00211	DB00988	Increased arterial pressure
DB00211	DB01363	Increased arterial pressure
DB00211	DB01364	Increased arterial pressure
DB00211	DB00668	Increased arterial pressure
DB00211	DB01288	Increased arterial pressure
DB00211	DB00687	Increased arterial pressure
DB00211	DB00741	Increased arterial pressure
DB00211	DB01247	Possible hypertensive crisis with this combination
DB00211	DB01064	Increased arterial pressure
DB00211	DB01365	Increased arterial pressure
DB00211	DB00610	Increased arterial pressure
DB00211	DB00723	Increased arterial pressure
DB00211	DB00959	Increased arterial pressure
DB00211	DB00368	Increased arterial pressure
DB00211	DB00816	Increased arterial pressure
DB00211	DB01384	Increased arterial pressure
DB00211	DB00780	Possible hypertensive crisis with this combination
DB00211	DB00388	Increased arterial pressure
DB00211	DB00397	Increased arterial pressure
DB00211	DB01291	Increased arterial pressure
DB00211	DB00860	Increased arterial pressure
DB00211	DB00635	Increased arterial pressure
DB00211	DB01366	Increased arterial pressure
DB00211	DB00852	Increased arterial pressure
DB00211	DB01367	Risk of hypertensive crisis.
DB00211	DB01001	Increased arterial pressure
DB00211	DB00871	Increased arterial pressure
DB00211	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Midodrine. Concomitant therapy should be avoided.
DB00211	DB00620	Increased arterial pressure
DB00211	DB00726	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Midodrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00213	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00213	DB01066	Proton pump inhibitors such as pantoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB00213	DB00758	Pantoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent pantoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with pantoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB00213	DB06695	Proton pump inhibitors may decrease the bioavailability of dabigatran by 28% and increase inter-patient pharmacokinetic variability, especially in females. However, dose adjustment is not required.
DB00213	DB08912	Proton pump inhibitors may alter the solubility of dabrafenib and reduce its bioavailability.
DB00213	DB01254	Pantoprazole may decrease the serum level of dasatinib.
DB00213	DB00467	Pantoprazole may decrease the absorption of enoxacin.
DB00213	DB00224	Omeprazole decreases the absorption of indinavir
DB00213	DB01167	The proton pump inhibitor, pantoprazole, may decrease the absorption of itraconazole.
DB00213	DB01026	The proton pump inhibitor, pantoprazole, may decrease the absorption of ketoconazole.
DB00213	DB08864	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB00213	DB01030	The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed.
DB00214	DB01143	Torasemide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Torasemide should be withheld for  24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB00214	DB00479	Increased ototoxicity
DB00214	DB01101	Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed.
DB00214	DB01432	Cholestyramine may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00214	DB00930	Colesevelam may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00214	DB00375	Colestipol may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00214	DB00705	Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Delavirdine is initiated, discontinued or dose changed.
DB00214	DB00322	Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Floxuridine is initiated, discontinued or dose changed.
DB00214	DB00196	Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluconazole is initiated, discontinued or dose changed.
DB00214	DB00544	Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluorouracil is initiated, discontinued or dose changed.
DB00214	DB00712	Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Flurbiprofen is initiated, discontinued or dose changed.
DB00214	DB01241	Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Gemfibrozil is initiated, discontinued or dose changed.
DB00214	DB00798	Increased ototoxicity
DB00214	DB01050	The NSAID, ibuprofen, may decrease the diuretic and antihypertensive effect of the loop diuretic, torasemide.
DB00214	DB00328	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, torasemide.
DB00214	DB01026	Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed.
DB00214	DB00784	Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed.
DB00218	DB01378	Formation of non-absorbable complexes
DB00218	DB01377	Formation of non-absorbable complexes
DB00214	DB01110	Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Miconazole is initiated, discontinued or dose changed.
DB00214	DB00955	Increased ototoxicity
DB00214	DB00622	Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Nicardipine is initiated, discontinued or dose changed.
DB00214	DB00554	Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Piroxicam is initiated, discontinued or dose changed.
DB00214	DB00073	Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Torasemide for 12 hours prior to administration of Rituximab.
DB00214	DB06268	Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sitaxsentan is initiated, discontinued or dose changed.
DB00214	DB00359	Sulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfadiazine is initiated, discontinued or dose changed.
DB00214	DB00263	Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfisoxazole is initiated, discontinued or dose changed.
DB00214	DB00684	Increased ototoxicity
DB00214	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Tolbutamide is initiated, discontinued or dose changed.
DB00214	DB00519	The loop diuretic, Torasemide, may increase the hypotensive effect of Trandolapril. Torasemide may also increase the nephrotoxicity of Trandolapril.
DB00214	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00215	DB01418	The SSRI, citalopram, increases the effect of anticoagulant, acenocoumarol.
DB00215	DB00918	Increased risk of CNS adverse effects
DB00215	DB01125	The SSRI, citalopram, increases the effect of anticoagulant, anisindione.
DB00215	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00215	DB01136	The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB00215	DB01211	Possible serotoninergic syndrome with this combination
DB00215	DB00363	The antidepressant increases the effect of clozapine
DB00215	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00215	DB00266	The SSRI, citalopram, increases the effect of anticoagulant, dicumarol.
DB00215	DB00216	Increased risk of CNS adverse effects
DB00215	DB00199	Possible serotoninergic syndrome with this combination
DB00215	DB06414	Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration. \r\n\r\nIt is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes).
DB00215	DB00998	Increased risk of CNS adverse effects
DB00215	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00215	DB01247	Possible severe adverse reaction with this combination
DB00215	DB01321	Possible serotoninergic sydrome with this combination
DB00215	DB01009	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB00215	DB00601	Combination associated with possible serotoninergic syndrome
DB00215	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00215	DB00264	The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, metoprolol.
DB00215	DB01171	Possible serotoninergic syndrome
DB00215	DB00952	Increased risk of CNS adverse effects
DB00215	DB00497	Increased risk of serotonin syndrome
DB00215	DB00780	Possible severe adverse reaction with this combination
DB00215	DB01100	The SSRI, citalopram, may increase the effect and toxicity of pimozide.
DB00215	DB00571	The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00215	DB01367	Possible severe adverse reaction with this combination
DB00215	DB00953	Increased risk of CNS adverse effects
DB00215	DB01037	Possible severe adverse reaction with this combination
DB00215	DB01105	Risk of serotoninergic syndrome
DB00215	DB01323	St. John's Wort increases the effect and toxicity of the SSRI, citalopram.
DB00215	DB00669	Increased risk of CNS adverse effects
DB00215	DB00976	Telithromycin may reduce clearance of Citalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Citalopram if Telithromycin is initiated, discontinued or dose changed.
DB00215	DB01600	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB00215	DB00208	Ticlopidine may decrease the metabolism and clearance of Citalopram. Consider alternate therapy or monitor for adverse/toxic effects of Citalopram if Ticlopidine is initiated, discontinued or dose changed.
DB00218	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB00215	DB00500	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00215	DB00193	The use of two serotonin modulators, such as citalopram and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00215	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00215	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00215	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Citalopram. Monitor for increased bleeding during concomitant thearpy.
DB00215	DB00726	The SSRI, Citalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Citalopram is initiated, discontinued or dose changed.
DB00215	DB00427	The CNS depressants, Triprolidine and Citalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00215	DB01361	Possible serotoninergic syndrome with this combination
DB00215	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00215	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of citalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of citalopram if voriconazole is initiated, discontinued or dose changed.
DB00215	DB00682	The SSRI, citalopram, increases the effect of anticoagulant, warfarin.
DB00215	DB00246	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB00215	DB00315	The use of two serotonin modulators, such as zolmitriptan and citalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00215	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00216	DB00215	Increased risk of CNS adverse effects
DB00216	DB01211	The macrolide, clarithromycin, may increase the effect and toxicity of eletriptan.
DB00216	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00216	DB00320	Possible severe and prolonged vasoconstriction
DB00216	DB01253	Possible severe and prolonged vasoconstriction
DB00216	DB00696	Possible severe and prolonged vasoconstriction
DB00216	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of eletriptan.
DB00216	DB01175	Increased risk of CNS adverse effects
DB00216	DB00472	Increased risk of CNS adverse effects
DB00216	DB00176	Increased risk of CNS adverse effects
DB00216	DB01167	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB00216	DB01026	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB00216	DB00353	Possible severe and prolonged vasoconstriction
DB00216	DB00247	Possible severe and prolonged vasoconstriction
DB00216	DB01149	Increased risk of CNS adverse effects
DB00216	DB00220	The protease inhibitor, nelfinavir, may increase the effect and toxicity of eletriptan.
DB00216	DB00715	Increased risk of CNS adverse effects
DB00216	DB00503	The protease inhibitor, ritonavir, may increase the effect and toxicity of eletriptan.
DB00216	DB01104	Increased risk of CNS adverse effects
DB00216	DB00976	Telithromycin may reduce clearance of Eletriptan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eletriptan if Telithromycin is initiated, discontinued or dose changed.
DB00216	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00216	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00216	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00216	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00216	DB01361	The macrolide, troleandomycin, may increase the effect and toxicity of eletriptan.
DB00216	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00216	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eletriptan by decreasing its metabolism. Consider avoiding administration of the two agents within 72 hours of each other. Monitor for changes in the therapeutic and adverse effects of eletriptan if voriconazole is initiated, discontinued or dose changed.
DB00216	DB00315	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and eletriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00218	DB01418	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of acenocoumarol.
DB00218	DB01370	Formation of non-absorbable complexes
DB00218	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB01125	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of anisindione.
DB00218	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00218	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB01373	Formation of non-absorbable complexes
DB00218	DB00266	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of dicumarol.
DB00218	DB01341	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB01592	Formation of non-absorbable complexes
DB00218	DB00893	Formation of non-absorbable complexes
DB00218	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB01369	This combination presents an increased risk of toxicity
DB00218	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB00218	DB00364	Formation of non-absorbable complexes
DB00218	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00218	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00218	DB00697	Moxifloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00218	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00218	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00218	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00218	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00218	DB00682	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin.
DB00218	DB01593	Formation of non-absorbable complexes
DB00218	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00218	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00220	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Nelfinavir. The antiviral response should be closely monitored.
DB00220	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB00220	DB01418	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of acenocoumarol.
DB00220	DB00404	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, alprazolam.
DB00220	DB01118	Nelfinavir may increase the effect and toxicity of amiodarone.
DB00220	DB01125	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of anisindione.
DB00220	DB00673	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00220	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00220	DB01076	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nelfinavir is initiated, discontinued or dose changed.
DB00220	DB01558	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nelfinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00220	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB00220	DB00475	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00220	DB01410	Increased effects/toxicity of ciclesonide
DB00220	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00220	DB01068	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clonazepam.
DB00220	DB00628	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clorazepate.
DB00220	DB00091	The protease inhibitor, nelfinavir, may increase the effect of cyclosporine.
DB00220	DB01219	Nelfinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00496	Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of darifenacin/solifenacin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of darifenacin if nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00829	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, diazepam.
DB00220	DB00266	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of dicumarol.
DB00220	DB00320	Nelfinavir increases the effect and toxicity of ergot derivative
DB00220	DB01341	Nelfinavir increases the effect and toxicity of quindine
DB00220	DB00216	The protease inhibitor, nelfinavir, may increase the effect and toxicity of eletriptan.
DB00220	DB00700	The protease inhibitor, nelfinavir, may increase the effect and toxicity of eplerenone.
DB00220	DB00696	Nelfinavir increases the effect and toxicity of ergot derivative
DB00220	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00220	DB01215	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, estazolam.
DB00220	DB00977	Ritonavir could decrease the contraceptive efficacy
DB00220	DB01023	Nelfinavir increases the effect and toxicity of felodipine
DB00220	DB00813	The protease inhibitor, nelfinavir, may increase the effect and toxicity of fentanyl.
DB00220	DB00690	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, flurazepam.
DB00220	DB02703	The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid.
DB00220	DB00801	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, halazepam.
DB00220	DB00227	Nelfinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00220	DB01357	Ritonavir could decrease the contraceptive efficacy
DB00220	DB00333	Nelfinavir decreases the effect of methadone
DB00220	DB00683	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, midazolam.
DB00220	DB00238	Nevirapine may decrease the effect of nelfinavir.
DB00220	DB01100	Nelfinavir increases the effect and toxicity of pimozide
DB00220	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB00220	DB01588	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, prazepam.
DB00220	DB01589	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, quazepam.
DB00220	DB00908	Nelfinavir increases the effect and toxicity of quinidine
DB00220	DB01346	Nelfinavir increases the effect and toxicity of quinidine
DB00220	DB00243	Increased levels of ranolazine - risk of toxicity
DB00220	DB01045	Rifampin decreases the effect of nelfinavir
DB00220	DB06335	Nelfinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB00220	DB00203	The protease inhibitor, nelfinavir, may increase the effect and toxicity of sildenafil.
DB00220	DB00641	Nelfinavir may increase the effect and toxicity of simvastatin. Concomitant therapy should be avoided.
DB00220	DB01591	This potent CYP3A4 inhibitor slows darifenacin / solifenacin metabolism
DB00220	DB01323	St. John's Wort decreases the effect of indinavir
DB00220	DB01268	Possible increase in sunitinib levels
DB00220	DB00864	The protease inhibitor, Nelfinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nelfinavir therapy is initiated, discontinued or altered.
DB00220	DB00820	Nelfinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00220	DB00675	Nelfinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00220	DB00706	Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nelfinavir is initiated, discontinued, or dose changed.
DB00220	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00220	DB00976	Nelfinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00220	DB06287	Nelfinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00220	DB00444	The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00220	DB00906	The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB01036	Nelfinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00220	DB01030	The p-glycoprotein inhibitor, Nelfinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00220	DB00193	Nelfinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00220	DB00656	The protease inhibitor, Nelfinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00897	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, triazolam.
DB00220	DB00726	The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00862	Nelfinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00220	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB00220	DB00285	Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nelfinavir is initiated, discontinued, or dose changed.
DB00220	DB00661	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00570	Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00541	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00361	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00582	Nelfinavir may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of nelfinavir by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased nelfinavir adverse effects during concomitant therapy.
DB00220	DB00682	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin.
DB00224	DB01378	Magnesium may decrease the absorption of indinavir.
DB00224	DB01377	The antacid decreases the absorption of indinavir
DB00220	DB00425	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nelfinavir is initiated, discontinued or dose changed.
DB00220	DB00909	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nelfinavir is initiated, discontinued or dose changed.
DB00220	DB01198	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nelfinavir is initiated, discontinued or dose changed.
DB00221	DB00494	Entacapone increases the effect and toxicity of the sympathomimetic, isoetharine.
DB00222	DB00091	The sulfonylurea, glimepiride, may increase the effect of cyclosporine.
DB00222	DB01241	Gemfibrozil increases the effect and toxicity of rosiglitazone/pioglitazone
DB00222	DB01296	Possible hyperglycemia
DB00222	DB01026	Ketoconazole increases the effect of rosiglitazone
DB00222	DB01045	Rifampin may decrease the effect of sulfonylurea, glimepiride.
DB00222	DB00052	Somatropin may antagonize the hypoglycemic effect of glimepiride. Monitor for changes in fasting and postprandial blood sugars.
DB00222	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glimepiride. Consider alternate therapy or monitor for changes in Glimepiride therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00224	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Indinavir. The antiviral response should be closely monitored.
DB00224	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB00224	DB01418	The protease inhibitor, indinavir, may increase the anticoagulant effect of acenocoumarol.
DB00224	DB00404	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, alprazolam.
DB00224	DB01370	The antacid decreases the absorption of indinavir
DB00224	DB01118	Indinavir increases the effect and toxicity of amiodarone
DB00224	DB01125	The protease inhibitor, indinavir, may increase the anticoagulant effect of anisindione.
DB00224	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00224	DB01072	Increased risk of hyperbilirubinemia with this association
DB00224	DB01076	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00224	DB01558	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if indinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00224	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB00224	DB01373	Calcium may decrease the absorption of indinavir.
DB00224	DB00564	Indinavir increases the effect and toxicity of carbamazepine
DB00224	DB00475	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00224	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00224	DB01211	Indinavir may decrease the effectiveness of clarithromycin by decreasing the formatin of the active metabolite, 14-hydroxy-clarithromycin. Clarithromycin may increase the serum concentration of indinavir. Indinavir may increase the serum concentration of clarithromycin. Consider alternate therapy or monitor the efficacy and adverse effects of both agents more closely during concomitant therapy.
DB00224	DB01068	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clonazepam.
DB00224	DB00628	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clorazepate.
DB00224	DB00091	The protease inhibitor, indinavir, may increase the effect of cyclosporine.
DB00224	DB01219	Indinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if indinavir is initiated, discontinued or dose changed.
DB00224	DB00705	Delavirdine may increase the effect of indinavir.
DB00224	DB00829	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, diazepam.
DB00224	DB00266	The protease inhibitor, indinavir, may increase the anticoagulant effect of dicumarol.
DB00224	DB00320	Indinavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated.
DB00224	DB00625	Efavirenz decreases the effect of indinavir
DB00224	DB00696	Indinavir may increase the serum concentration of ergotamine. Concomitant therapy is contraindicated.
DB00224	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00224	DB00736	Omeprazole decreases the absorption of indinavir
DB00224	DB01215	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, estazolam.
DB00224	DB00813	The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl.
DB00224	DB00690	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, flurazepam.
DB00224	DB02703	Indinavir may increase the effect and toxicity of fusidic acid.
DB00224	DB00801	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, halazepam.
DB00224	DB01026	Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.
DB00224	DB00448	Omeprazole decreases the absorption of indinavir
DB00224	DB00227	Indinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00224	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB00224	DB00683	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, midazolam.
DB00224	DB00338	Omeprazole decreases the absorption of indinavir
DB00224	DB00213	Omeprazole decreases the absorption of indinavir
DB00224	DB01100	The protease inhibitor, indinavir, may increase the effect and toxicity of pimozide.
DB00224	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB00224	DB01588	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, prazepam.
DB00224	DB01589	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, quazepam.
DB00224	DB01369	This combination presents an increased risk of toxicity
DB00224	DB01129	Omeprazole decreases the absorption of indinavir
DB00224	DB00243	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00224	DB00615	Rifabutin decreases the effect of indinavir
DB00224	DB01045	Rifampin decreases the effect of indinavir
DB00224	DB00734	Increased risk of extrapyramidal symptoms
DB00224	DB01232	Possible antagonism of action
DB00224	DB06335	Indinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB00224	DB00203	The protease inhibitor, indinavir, may increase the effect and toxicity of sildenafil.
DB00224	DB06207	Indinavir is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated.
DB00224	DB01323	St. John's Wort decreases the effect of indinavir
DB00224	DB01268	Possible increase in sunitinib levels
DB00224	DB00864	The protease inhibitor, Indinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Indinavir therapy is initiated, discontinued or altered.
DB00224	DB00820	Indinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00224	DB00675	Indinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00224	DB00706	Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Indinavir is initiated, discontinued, or dose changed.
DB00224	DB00976	Indinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00224	DB06287	Indinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00224	DB00444	The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Indinavir is initiated, discontinued or dose changed.
DB00224	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00224	DB00906	The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Indinavir is initiated, discontinued or dose changed.
DB00224	DB01036	Indinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00224	DB00193	Indinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00224	DB00656	The protease inhibitor, Indinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism via CYP3A4. Monitor for changes in Trazodone efficacy/toxicity if Indinavir is initiated, discontinued or dose changed.
DB00224	DB00897	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, triazolam.
DB00224	DB00726	The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Indinavir is initiated, discontinued or dose changed.
DB00224	DB00862	Indinavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB00224	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB00224	DB00285	Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Indinavir is initiated, discontinued, or dose changed.
DB00224	DB00661	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Indinavir is initiated, discontinued or dose changed.
DB00224	DB00570	Indinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Indinavir is initiated, discontinued or dose changed.
DB00224	DB00541	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Indinavir is initiated, discontinued or dose changed.
DB00224	DB00361	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Indinavir is initiated, discontinued or dose changed.
DB00224	DB00126	Vitamin C decreases indinavir levels
DB00224	DB00582	Voriconazole may increase the serum concentration of indinavir by decreasing its metabolism. Indinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00224	DB00682	The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin.
DB00224	DB00425	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if indinavir is initiated, discontinued or dose changed.
DB00224	DB00909	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if indinavir is initiated, discontinued or dose changed.
DB00224	DB01198	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if indinavir is initiated, discontinued or dose changed.
DB00227	DB01418	Lovastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if lovastatin is initiated, discontinued or dose changed.
DB00227	DB00701	Amprenavir may increase the serum concentration of the lovastatin. Concomitant therapy is contraindicated.
DB00227	DB01125	Lovastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if lovastatin if initiated, discontinued or dose changed.
DB00227	DB01072	Atazanavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00227	DB00207	The macrolide antibiotic, azithromycin, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if azithromycin is initiated, discontinued or dose changed.
DB00227	DB01393	Increased risk of myopathy/rhabdomyolysis
DB00227	DB00559	Bosentan may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if bosentan is initiated, discontinued or dose changed.
DB00227	DB00564	Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed.
DB00227	DB01211	The macrolide, clarithromycin, may increase the toxicity of the statin, lovastatin.
DB00227	DB01394	Increased risk of rhabdomyolysis with this combination
DB00227	DB00091	Possible myopathy and rhabdomyolysis
DB00227	DB01406	Risk of severe myopathy/rhabdomyolysis with this combination
DB00227	DB01264	Darunavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00227	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if delavirdine is initiated, discontinued or dose changed.
DB00227	DB00266	Lovastatin may increase the anticoagulant effect dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if lovastatin is initiated, discontinued or dose changed.
DB00227	DB00343	Diltiazem may increase the serum concentration of lovastatin. Lovastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00227	DB00625	Efavirenz may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if efavirenz is initiated, discontinued or dose changed.
DB00227	DB00199	The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin.
DB00227	DB06414	Lovastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of lovastatin therapy.
DB00227	DB01039	Increased risk of myopathy/rhabdomyolysis
DB00227	DB00196	Increased risk of myopathy/rhabdomyolysis
DB00227	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00227	DB01241	Increased risk of myopathy/rhabdomyolysis
DB00227	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if imatinib is initiated, discontinued or dose changed.
DB00227	DB00224	Indinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00227	DB01167	Increased risk of myopathy/rhabdomyolysis
DB00227	DB01321	The macrolide, josamycin, may increase the toxicity of the statin, lovastatin.
DB00227	DB01026	Increased risk of myopathy/rhabdomyolysis
DB00227	DB08827	Lovastatin plasma concentrations may increase by lomitapide.
DB00227	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if nefazodone is initiated, discontinued or dose changed.
DB00227	DB00220	Nelfinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00227	DB00238	The strong CYP3A4 inducer, nevirapine, may decrase the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if nevirapine is initiated, discontinued or dose changed.
DB00227	DB00627	Risk of severe myopathy/rhabdomyolysis with this combination
DB00227	DB01369	This combination presents an increased risk of toxicity
DB00227	DB00615	Rifabutin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifabutin is initiated, discontinued or dose changed.
DB00227	DB01045	Rifampin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifampin is initiated, discontinued or dose changed.
DB00227	DB00503	Ritonavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00227	DB01232	Saquinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00227	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00227	DB00976	Telithromycin may increase the adverse effects of lovastatin by decreasing its metabolism. Concomitant therapy should be avoided.
DB00227	DB08816	Patients receiving more than 40 mg per day of lovastatin may be at increased risk of statin-related adverse effects.
DB00227	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Lovastatin. Concomitant therapy is contraindicated.
DB00227	DB00661	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed.
DB00227	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if voriconazole is initiated, discontinued or dose changed.
DB00227	DB00682	Lovastatin may increase the anticoagulant effect warfarin.  Monitor for changes in the therapeutic and adverse effects of warfarin if lovastatin is initiated, discontinued or dose changed .
DB00228	DB00598	Monitor arterial pressure closely
DB00228	DB05271	Risk of sedation may increase with concomitant therapy. Monitor therapy closely.
DB00230	DB00427	The CNS depressants, Triprolidine and Pregabalin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00231	DB01223	Aminophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Aminophylline is initiated, discontinued or dose changed.
DB00231	DB00363	The benzodiazepine, Temazepam, may increase the adverse effects of Clozapine. Monitor for respiratory depression and hypotension if concomitant therapy is initiated.
DB00231	DB00651	Dyphylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Dyphylline is initiated, discontinued or dose changed.
DB00231	DB01322	Kava may increase the effect of the benzodiazepine, temazepam.
DB00231	DB00277	Theophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Theophylline is initiated, discontinued or dose changed.
DB00231	DB00427	The CNS depressants, Triprolidine and Temazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00232	DB00390	Possible electrolyte variations and arrhythmias
DB00232	DB01356	The thiazide diuretic, methyclothiazide, may increase serum levels of lithium.
DB00232	DB00519	The thiazide diuretic, Methyclothiazide, may increase the hypotensive effect of Trandolapril. Methyclothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00232	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00233	DB00993	Aminosalicylic acid may increase the toxicity of thiopurine, azathioprine.
DB00233	DB01033	Aminosalicylic acid may increase the toxicity of thiopurine, mercaptopurine.
DB00233	DB00605	Risk of additive toxicity (e.g. bleed risk). Aminosalicylic acid may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB00233	DB01600	Increased risk of gastrointestinal bleeding.
DB00233	DB00352	Aminosalicylic acid may increase the toxicity of thiopurine, thioguanine.
DB00233	DB00500	Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy.
DB00233	DB00519	The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed.
DB00233	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy.
DB00233	DB00682	The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin.
DB00236	DB01193	Antagonism
DB00236	DB00335	Antagonism
DB00236	DB00195	Antagonism
DB00236	DB01295	Antagonism
DB00236	DB00612	Antagonism
DB00236	DB00521	Antagonism
DB00236	DB01136	Antagonism
DB00236	DB00187	Antagonism
DB00236	DB00598	Antagonism
DB00236	DB00264	Antagonism
DB00236	DB01203	Antagonism
DB00236	DB01580	Antagonism
DB00236	DB01359	Antagonism
DB00236	DB00960	Antagonism
DB00236	DB01297	Antagonism
DB00236	DB00571	Antagonism
DB00236	DB00489	Antagonism
DB00236	DB00373	Antagonism
DB00237	DB01418	Barbiturates like butabarbital may increase the metabolism of Vitamin K Antagonists like acenocoumarol. onitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes.
DB00237	DB01223	The barbiturate, butabarbital, decreases the effect of aminophylline.
DB00237	DB00321	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00243	DB01167	Increased levels of ranolazine - risk of toxicity
DB00243	DB01026	Increased levels of ranolazine - risk of toxicity
DB00243	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00237	DB00543	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amoxipine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00237	DB06769	Decreases levels of bendamustine by affecting CYP1A2 hepatic enzyme metabolism. May increase concentrations of active metabolites.
DB00237	DB00443	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00237	DB00882	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, clomifene.
DB00237	DB01242	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00237	DB00286	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00237	DB00091	The barbiturate, butabarbital, increases the effect of cyclosporine.
DB00237	DB01151	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00237	DB01234	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB00237	DB00255	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00237	DB00280	arbiturates may increase the metabolism of Disopyramide. Monitor for decreased therapeutic effects of disopyramide if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased.
DB00237	DB01142	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00237	DB00254	The anticonvulsant, butabarbital, decreases the effect of doxycycline.
DB00237	DB00450	Droperidol may enhance the CNS depressant effect of CNS Depressants like butabarbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00237	DB06210	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB00237	DB00783	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, estradiol.
DB00237	DB00977	This product may cause a slight decrease of contraceptive effect
DB00237	DB01023	The barbiturate, butabarbital, decreases the effect of felodipine.
DB00237	DB00687	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00237	DB00158	Folic acid decreases the effect of anticonvulsant, butabarbital.
DB00237	DB00317	The CYP3A4 inducer, butabarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00237	DB00400	The barbiturate, butabarbital, decreases the effect of griseofulvin.
DB00237	DB00741	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00237	DB00557	Hydroxyzine may enhance the CNS depressant effect of barbiturates like butabarbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.
DB00237	DB00458	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00237	DB00555	Barbiturates like butabarbital may decrease the serum concentration of lamotrigine. There are separate patient management guidelines for patients age 12 and under and for patients older than 12 years of age. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased.
DB00237	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00237	DB00603	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00237	DB00351	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, megestrol.
DB00237	DB00333	The barbiturate, butabarbital, decreases the effect of methadone.
DB00237	DB00916	The barbiturate, butabarbital, decreases the effect of metronidazole.
DB00237	DB01115	The barbiturate, butabarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB00237	DB00717	This product may cause a slight decrease of contraceptive effect
DB00237	DB00540	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00237	DB01303	The barbiturate, butabarbital, decreases the effect of oxtriphylline.
DB00237	DB00860	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00237	DB00635	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone.
DB00243	DB00680	Possible additive effect on QT prolongation
DB00243	DB00220	Increased levels of ranolazine - risk of toxicity
DB00237	DB00344	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00237	DB00908	The anticonvulsant, butabarbital, decreases the effect of quinidine.
DB00237	DB00444	Barbiturates like butabarbital may decrease the serum concentration of Teniposide. arbiturates may decrease the serum concentration of Teniposide.
DB00237	DB00277	The barbiturate, butabarbital, decreases the effect of theophylline.
DB00237	DB00620	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00237	DB00726	The barbiturate, Butabarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butabarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00237	DB00427	The CNS depressants, Triprolidine and Butabarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00237	DB00661	Butabarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butabarbital is initiated, discontinued or dose changed.
DB00237	DB00582	Butabarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB00237	DB00682	Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed.
DB00238	DB01418	Nevirapine may decrease the anticoagulant effect of acenocoumarol.
DB00238	DB01125	Nevirapine may decrease the anticoagulant effect of anisindione.
DB00238	DB01072	Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed.
DB00238	DB01076	Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nevirapine is initiated, discontinued or dose changed.
DB00238	DB00266	Nevirapine may decrease the anticoagulant effect of dicumarol.
DB00238	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00238	DB06414	Nevirapine may cause a significant decrease in plasma levels of etravirine and a loss of efficacy. \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy.
DB00238	DB01026	Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed.
DB00238	DB00227	The strong CYP3A4 inducer, nevirapine, may decrase the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if nevirapine is initiated, discontinued or dose changed.
DB00238	DB00333	The antiretroviral agent decreases the effect of methadone
DB00238	DB00220	Nevirapine may decrease the effect of nelfinavir.
DB00238	DB01369	This combination presents an increased risk of toxicity
DB00238	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00238	DB01232	Decreases the effect of saquinavir
DB00238	DB00641	The strong CYP3A4 inducer, nevirapine, may decrase the effect of simvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nevirapine is initiated, discontinued or dose changed.
DB00238	DB01323	St. John's Wort decreases nevirapine effect
DB00238	DB00976	Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00238	DB06287	Nevirapine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00238	DB00932	Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed.
DB00238	DB00193	Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00238	DB00656	The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed.
DB00238	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00238	DB00682	Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4.
DB00241	DB01418	Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes.
DB00241	DB01223	The barbiturate, butalbital, decreases the effect of aminophylline.
DB00241	DB00321	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00243	DB01035	Possible additive effect on QT prolongation
DB00243	DB00908	Possible additive effect on QT prolongation
DB00243	DB00503	Increased levels of ranolazine - risk of toxicity
DB00243	DB01232	Increased levels of ranolazine - risk of toxicity
DB00241	DB00543	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants amoxapine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00241	DB00443	The barbiturate, butalbital, may decrease the effect of the corticosteroid, betamethasone.
DB00241	DB00446	Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased.
DB00241	DB00882	The enzyme inducer, butalbital, decreases the effect of the hormone agent, clomifene.
DB00241	DB01242	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00241	DB00286	The enzyme inducer, butalbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00241	DB00091	The barbiturate, butalbital, increases the effect of cyclosporine.
DB00241	DB01151	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00241	DB01234	The barbiturate, butalbital, may decrease the effect of the corticosteroid, dexamethasone.
DB00241	DB00255	The enzyme inducer, butalbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00241	DB01142	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00241	DB00254	The anticonvulsant, butalbital, decreases the effect of doxycycline.
DB00241	DB00450	Droperidol may enhance the CNS depressant effect of CNS depressants such as butalbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00241	DB06210	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB00241	DB00783	The enzyme inducer, butalbital, decreases the effect of the hormone agent, estradiol.
DB00241	DB00977	This product may cause a slight decrease of contraceptive effect
DB00241	DB01023	The barbiturate, butalbital, decreases the effect of felodipine.
DB00241	DB00687	The barbiturate, butalbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00241	DB00158	Folic acid decreases the effect of anticonvulsant, butalbital.
DB00241	DB00317	The CYP3A4 inducer, butalbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00241	DB00400	The barbiturate, butalbital, decreases the effect of griseofulvin.
DB00241	DB00741	The barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00241	DB00557	Hydroxyzine may enhance the CNS depressant effect of barbiturates such as butalbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.
DB00241	DB00458	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00241	DB00555	Barbiturates such as butalbital may decrease the serum concentration of lamotrigine. There are separate management guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased.
DB00241	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00241	DB00603	The enzyme inducer, butalbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00241	DB00351	The enzyme inducer, butalbital, decreases the effect of the hormone agent, megestrol.
DB00241	DB00333	The barbiturate, butalbital, decreases the effect of methadone.
DB00241	DB00916	The barbiturate, butalbital, decreases the effect of metronidazole.
DB00241	DB01115	The barbiturate, butalbital, decreases the effect of the calcium channel blocker, nifedipine.
DB00241	DB00717	This product may cause a slight decrease of contraceptive effect
DB00241	DB00540	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00241	DB01303	The barbiturate, butalbital, decreases the effect of oxtriphylline.
DB00241	DB00860	The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisolone.
DB00241	DB00635	The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone.
DB00241	DB00344	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00241	DB00908	The anticonvulsant, butalbital, decreases the effect of quinidine.
DB00241	DB00444	Barbiturates such as butalbital may decrease the serum concentration of teniposide. Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely.
DB00241	DB00277	The barbiturate, butalbital, decreases the effect of theophylline.
DB00241	DB00620	The barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00241	DB00726	The barbiturate, Butalbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butalbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00241	DB00427	The CNS depressants, Triprolidine and Butalbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00241	DB00661	Butalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed.
DB00241	DB00582	Butalbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB00241	DB00682	Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed.
DB00242	DB01097	Immunosuppressants such as cladribine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB00242	DB00108	Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
DB00242	DB00337	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cladribine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00242	DB01656	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB00242	DB00864	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as tacrolimus. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00242	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00243	DB01118	Possible additive effect on QT prolongation
DB00243	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentratin of ranolazine by inhibiting its metabolism. Concomitant therapy is contraindicated.
DB00243	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00243	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated.
DB00243	DB01128	CYP3A4 inhibitors like ranolazine may increase the serum concentration of ranolazine. Consider therapy modification.
DB00243	DB01158	Possible additive effect on QT prolongation
DB00243	DB01211	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated.
DB00243	DB00257	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use.
DB00243	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. The manufacturer contraindicates the use of ranolazine and strong CYP3A4 inhibitors (such as the azole antifungals).1 Monitor for increased effects/toxicity of ranolazine during concomitant use.
DB00243	DB00390	Ranolazine may increase the serum level of digoxin. Monitor for changes in the serum level and therapeutic and adverse effects of digoxin if ranolazine is initiated, discontinued or dose changed.
DB00243	DB00343	Diltiazem may increase the serum concentration of ranolazine. Consider alternate therapy or limit ranolazine dose to 500 mg twice daily and monitor for changes in the therapeutic and adverse effects if diltiazem is initiated, discontinued or dose changed.
DB00243	DB00954	Increased levels of ranolazine - risk of toxicity
DB00243	DB00280	Possible additive effect on QT prolongation
DB00243	DB00204	Possible additive effect on QT prolongation
DB00243	DB00199	Increased levels of ranolazine - risk of toxicity
DB00243	DB00196	Increased levels of ranolazine - risk of toxicity
DB00243	DB01319	Increased levels of ranolazine - risk of toxicity
DB00243	DB00308	Possible additive effect on QT prolongation
DB00243	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00243	DB00641	Ranolazine may increase the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if ranolazine is initiated, discontinued or dose changed.
DB00243	DB00489	Possible additive effect on QT prolongation
DB00243	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00243	DB00675	Ranolazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00243	DB00706	Ranolazine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ranolazine is initiated, discontinued, or dose changed.
DB00243	DB00976	Telithromycin may reduce clearance of Ranolazine. Concomitant therapy should be avoided.
DB00243	DB00679	Possible additive effect on QT prolongation
DB00243	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00243	DB00932	Increased levels of ranolazine - risk of toxicity
DB00243	DB01036	Ranolazine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00243	DB01030	The p-glycoprotein inhibitor, Ranolazine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00243	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00243	DB00193	Ranolazine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00243	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00243	DB00661	Verapamil, a CYP3A4 inhibitor, may increase the serum concentration of Ranolazine. Concomitant therapy is contraindicated.
DB00243	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated.
DB00243	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00243	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00243	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00244	DB00993	Mesalazine may increase the toxicity of thiopurine, azathioprine.
DB00244	DB01033	Mesalazine may increase the toxicity of thiopurine, mercaptopurine.
DB00244	DB00352	Mesalazine may increase the toxicity of thiopurine, thioguanine.
DB00245	DB00843	Possible antagonism of action
DB00245	DB00674	Possible antagonism of action
DB00245	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00245	DB00989	Possible antagonism of action
DB00245	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Benztropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00245	DB00662	Trimethobenzamide and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00245	DB00427	Triprolidine and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00245	DB00209	Trospium and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00246	DB00106	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00915	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, amantadine. Consider alternate therapy or monitor for worsening of movement disorder.
DB00246	DB01118	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00321	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00543	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00714	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01169	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00246	DB06216	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00207	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01200	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, bromocriptine. Consider alternate therapy or monitor for worsening of movement disorder.
DB00246	DB00564	Increases the effect and toxicity of ziprasidone
DB00246	DB00477	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00604	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00215	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB00246	DB01211	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00247	DB00315	Possible severe and prolonged vasoconstriction
DB00246	DB01242	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01254	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01151	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00280	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00204	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00757	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01184	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00843	Possible antagonism of action
DB00246	DB01142	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB04855	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB00246	DB00450	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00199	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01175	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB00246	DB01195	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00196	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00472	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00875	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00529	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00674	Possible antagonism of action
DB00246	DB01044	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01218	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00502	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00308	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB04946	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB00246	DB00458	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00808	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00270	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01026	Ketoconazole increases the effect and toxicity of ziprasidone
DB00246	DB01235	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, levodopa. Consider alternate therapy or monitor for worsening of movement disorder.
DB00246	DB01259	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01137	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00408	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00246	DB00934	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00358	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00933	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00333	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01403	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB00246	DB00218	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB04868	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00246	DB01059	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00540	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00104	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB06589	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00738	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00556	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01186	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pergolide. Consider alternate therapy or monitor for worsening of movement disorder.
DB00246	DB01100	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00413	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pramipexole. Consider alternate therapy or monitor for worsening of movement disorder.
DB00248	DB00199	Erythromycin increases serum levels and toxicity of cabergoline
DB00246	DB01599	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01035	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB01182	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00344	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01224	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00908	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00468	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00246	DB00243	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00734	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB06176	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB00246	DB00268	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, ropinirole. Consider alternate therapy or monitor for worsening of movement disorder.
DB00246	DB05271	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, rotigotine. Consider alternate therapy or monitor for worsening of movement disorder.
DB00246	DB00489	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01208	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB01268	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00382	Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Ziprasidone. Monitor for extrapyramidal symptoms.
DB00246	DB00864	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB06402	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00246	DB00976	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB04844	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00679	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB01623	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00539	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00726	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB00427	The CNS depressants, Triprolidine and Ziprasidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00246	DB00582	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB02546	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00246	DB01624	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00247	DB01193	Ischemia with risk of gangrene
DB00247	DB00918	Possible severe and prolonged vasoconstriction
DB00247	DB01612	Possible antagonism of action
DB00247	DB00335	Ischemia with risk of gangrene
DB00247	DB00195	Ischemia with risk of gangrene
DB00247	DB01295	Ischemia with risk of gangrene
DB00247	DB00612	Ischemia with risk of gangrene
DB00247	DB00521	Ischemia with risk of gangrene
DB00247	DB01136	Ischemia with risk of gangrene
DB00247	DB01211	Risk of ergotism and severe ischemia with this association
DB00247	DB00705	The antiretroviral agent may increase the ergot derivative toxicity
DB00247	DB00625	The antiretroviral agent may increase the ergot derivative toxicity
DB00247	DB00216	Possible severe and prolonged vasoconstriction
DB00247	DB01613	Possible antagonism of action
DB00247	DB00199	Possible ergotism and severe ischemia with this combination
DB00247	DB00187	Ischemia with risk of gangrene
DB00247	DB00998	Possible severe and prolonged vasoconstriction
DB00247	DB00883	Possible antagonism of action
DB00247	DB01020	Possible antagonism of action
DB00247	DB01321	Possible ergotism and severe ischemia with this combination
DB00247	DB00598	Ischemia with risk of gangrene
DB00247	DB00264	Ischemia with risk of gangrene
DB00247	DB01203	Ischemia with risk of gangrene
DB00247	DB00952	Possible severe and prolonged vasoconstriction.
DB00247	DB00727	Possible antagonism of action
DB00247	DB01580	Ischemia with risk of gangrene
DB00247	DB01359	Ischemia with risk of gangrene
DB00247	DB06154	Possible antagonism of action
DB00247	DB00960	Ischemia with risk of gangrene
DB00247	DB01263	Contraindicated co-administration
DB00247	DB01297	Ischemia with risk of gangrene
DB00247	DB00571	Ischemia with risk of gangrene
DB00247	DB00953	Possible severe and prolonged vasoconstriction
DB00247	DB01105	Possible serotoninergic syndrome
DB00247	DB00489	Ischemia with risk of gangrene
DB00247	DB00669	Possible severe and prolonged vasoconstriction
DB00247	DB00976	Risk of ergotism and severe ischemia with this association
DB00247	DB00373	Ischemia with risk of gangrene
DB00247	DB01361	Possible ergotism and severe ischemia with this combination
DB00248	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00248	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00248	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00248	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00248	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00248	DB00582	Voriconazole may increase the serum concentration of cabergoline likely by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00248	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \r\nUse of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00250	DB01370	Formation of non-absorbable complexes
DB00250	DB01373	Formation of non-absorbable complexes
DB00250	DB06708	Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions.
DB00250	DB01378	Formation of non-absorbable complexes
DB00250	DB01377	Formation of non-absorbable complexes
DB00250	DB00615	Decreased levels of dapsone
DB00250	DB01045	Decreased levels of dapsone
DB00250	DB00976	Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed.
DB00250	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00250	DB00440	Increased toxicity of both products
DB00250	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed.
DB00252	DB05812	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB00252	DB01418	Increased hydantoin levels and risk of bleeding
DB00252	DB05773	Avoid combination with phenytoin and other strong CYP3A4 inducers due to the likely increase in metabolism of ado-trastuzumab emtansine to its active component, DM1.
DB00252	DB00404	Phenytoin may increase the metabolism of alprazolam via CYP3A4.
DB00252	DB01223	Decreased effect of both products
DB00252	DB01118	Amiodarone may increase the therapeutic and adverse effects of phenytoin.
DB00252	DB01125	Increased hydantoin levels and risk of bleeding
DB00252	DB00673	The CYP3A4 inducer, phenytoin, may decrease the effect of aprepitant.
DB00252	DB06216	Phenytoin is a CYP1A2 inducer and may increase metabolism of asenapine.
DB00252	DB00732	Phenytoin decreases the effect of the muscle relaxant
DB00252	DB06626	Avoid combination with phenytoin and other strong, moderate, or weak CYP3A4 inducers due to the likely decreased levels of axitinib.
DB00252	DB00443	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, betamethasone.
DB00252	DB00290	The antineoplasic agent decreases the effect of hydantoin
DB00252	DB08873	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB00252	DB06772	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB00252	DB08907	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB00252	DB01101	Capecitabine increases the effect of hydantoin
DB00252	DB00958	The antineoplasic agent decreases the effect of hydantoin
DB00252	DB00262	The antineoplasic agent decreases the effect of hydantoin
DB00252	DB00446	Increases phenytoin, modifies chloramphenicol
DB00252	DB00475	Phenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB00252	DB00269	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, chlorotrianisene.
DB00252	DB01114	The antihistamine increases the effect of hydantoin
DB00252	DB00501	Cimetidine may increase the therapeutic effect of phenytoin.
DB00252	DB00537	Ciprofloxacin may decrease the therapeutic effect of phenytoin.
DB00252	DB00515	The antineoplasic agent decreases the effect of hydantoin
DB00252	DB01211	Clarithromycin may increase the therapeutic and adverse effects of phenytoin.
DB00252	DB00882	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, clomifene.
DB00252	DB00628	Phenytoin may increase the metabolism of clorazepate via CYP3A4.
DB00252	DB00363	Phenytoin may decrease the effect of clozapine.
DB00252	DB00930	Colesevelam may decrease the serum concentration of Phenytoin. Phenytoin should be administered at least 4 hours prior to colesevelam.
DB00252	DB00286	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, conjugated estrogens.
DB00252	DB01380	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, cortisone acetate.
DB00252	DB00091	The hydantoin decreases the effect of cyclosporine
DB00252	DB08912	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB00252	DB01254	Phenytoin may decrease the serum level and efficacy of dasatinib.
DB00252	DB00705	The anticonvulsant, phenytoin, decreases the effect of delavirdine.
DB00252	DB01234	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone.
DB00252	DB00829	Phenytoin may increase the metabolism of diazepam via CYP3A4.
DB00252	DB01119	Diazoxide decreases the efficacy of phenytoin.
DB00252	DB00266	Increased hydantoin levels and risk of bleeding
DB00252	DB00255	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00252	DB00280	The hydantoin decreases the effect of disopyramide
DB00252	DB00822	Disulfiram may increase the therapeutic and adverse effects of phenytoin.
DB00252	DB00988	Risk of severe hypotension
DB00252	DB01135	Phenytoin decreases the effect of the muscle relaxant
DB00252	DB00254	The anticonvulsant, phenytoin, may decrease the effect of doxycycline.
DB00252	DB00651	Decreased effect of both products
DB00252	DB00783	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estradiol.
DB00252	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00252	DB04573	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estriol.
DB00252	DB00655	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estrone.
DB00252	DB04574	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estropipate.
DB00252	DB00977	This product may cause a slight decrease of contraceptive effect
DB00252	DB06414	Etravirine, when used concomitantly with phenytoin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00252	DB04953	Ezogabine increases the clearance of phenytoin (30%). The mechanism of this interaction is unknown.
DB00252	DB00949	Increased phenytoin levels and decreased felbamate levels
DB00252	DB01023	The hydantoin decreases the effect of felodipine
DB00252	DB00196	Fluconazole may increase the therapeutic and adverse effects of phenytoin.
DB00252	DB00687	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00252	DB00544	Fluorouracil increases the effect of hydantoin
DB00252	DB00472	Fluoxetine increases the effect of phenytoin
DB00252	DB00690	Phenytoin may increase the metabolism of flurazepam via CYP3A4.
DB00252	DB00176	Fluvoxamine may increase the therapeutic effect of phenytoin.
DB00252	DB00158	Folic acid may decrease the levels of phenytoin.
DB00252	DB00695	The hydantoin decreases the effect of furosemide
DB00252	DB00996	Gabapentin may increase the therapeutic and adverse effects of phenytoin.
DB00252	DB00317	The CYP3A4 inducer, phenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00252	DB00741	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00252	DB00619	The hydantoin decreases the levels of imatinib
DB00252	DB00762	The hydantoin decreases the effect of irinotecan
DB00252	DB00951	Isoniazid increases the effect of phenytoin in 20% of patients
DB00252	DB01167	Phenytoin decreases the effect of itraconazole
DB00252	DB08820	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB00252	DB01235	The hydantoin decreases the effect of levodopa
DB00252	DB00555	Phenytoin may reduce levels of lamotrigine
DB00252	DB00367	Phenytoin decreases the contraceptive effect
DB00252	DB01601	Levels of both drugs are affected
DB00252	DB00643	The hydantoin decreases the efficiency of mebendazole
DB00252	DB00603	The enzyme inducer, phenytoin, may decrease the effect of medroxyprogesterone.
DB00252	DB00351	The enzyme inducer, phenytoin, may decrease the effect of megestrol.
DB00252	DB01357	This product may cause a slight decrease of contraceptive effect
DB00252	DB00333	The hydantoin decreases the effect of methadone
DB00252	DB00563	The antineoplasic agent decreases the effect of hydantoin
DB00252	DB00553	The hydantoin decreases the effect of psoralene
DB00252	DB00959	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, methylprednisolone.
DB00252	DB01336	Phenytoin decreases the effect of the muscle relaxant
DB00252	DB01011	The combination renders the test invalid
DB00252	DB00379	The hydantoin decreases the effect of mexiletine
DB00252	DB00683	Phenytoin may increase the metabolism of midazolam via CYP3A4.
DB00252	DB00370	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB00252	DB01226	Phenytoin decreases the effect of the muscle relaxant
DB00252	DB00401	Phenytoin decreases the efficiency of nisoldipine
DB00252	DB00717	This product may cause a slight decrease of contraceptive effect
DB00252	DB00338	Omeprazole increases the effect of hydantoin
DB00252	DB00776	Oxcarbazepine increases the effect of hydantoin
DB00252	DB01303	Decreased effect of both products
DB00252	DB03585	The NSAID, oxphenbutazone, may increase the therapeutic and adverse effects of phenytoin.
DB00252	DB01337	Phenytoin decreases the effect of the muscle relaxant
DB00252	DB01384	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, paramethasone.
DB00252	DB08883	Avoid combination with phenytoin or other strong CYP3A4 inducers due to the likely decrease of perampanel concentration. If the combination must be used, an increase in perampanel dose is necessary.
DB00252	DB00812	The NSAID, phenylbutazone, may increase the therapeutic and adverse effects of phenytoin.
DB00252	DB08901	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB00252	DB08901	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB00252	DB01263	Modifications of drug levels for both agents
DB00252	DB01058	Markedly lower praziquantel levels
DB00252	DB00860	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisolone.
DB00252	DB00635	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone.
DB00252	DB01224	Phenytoin decreases the effect of quetiapine
DB00252	DB04575	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, quinestrol.
DB00252	DB00908	The anticonvulsant, phenytoin, decreases the effect of quinidine.
DB00252	DB08896	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB00252	DB01045	Rifampin may decrease the therapeutic and adverse effects of phenytoin.
DB00252	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB00252	DB06201	Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.
DB00252	DB01104	Sertraline increases the effect of hydantoin
DB00252	DB00877	The hydantoin decreases sirolimus levels
DB00252	DB00364	Sucralfate decreases the effect of hydantoin
DB00252	DB00359	The sulfonamide increases the effect of hydantoin
DB00252	DB00576	The sulfonamide increases the effect of hydantoin
DB00252	DB01268	Possible decrease in sunitinib levels
DB00252	DB00864	Phenytoin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenytoin therapy is initiated, discontinued or altered.
DB00252	DB00976	Phenytoin may decrease the plasma concentration of Telithromycin by increasing its metabolism. Consider alternate therapy.
DB00252	DB06287	Phenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00252	DB00277	Decreased effect of both products
DB00252	DB04572	Possible increase in thiotepa levels
DB00252	DB00208	Ticlopidine may decrease the metabolism and clearance of phenytoin. Consider alternate therapy or monitor for adverse/toxic effects of phenytoin if ticlopidine is initiated, discontinued or dose changed.
DB00252	DB00932	Phenytoin decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy.
DB00252	DB00684	Increased risk of nephrotoxicity
DB00252	DB08895	Avoid combination with phenytoin and other strong CYP3A4 inducers due to the potential decrease in tofacitinib serum levels.
DB00252	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00252	DB06212	Phenytoin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB00252	DB00273	Increased phenytoin/decreased topiramate
DB00252	DB00193	Phenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00252	DB00656	The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed.
DB00252	DB00755	The strong CYP2C8 inducer, Phenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenytoin is initiated, discontinued or dose changed.
DB00252	DB00620	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone.
DB00252	DB00897	Phenytoin may increase the metabolism of triazolam via CYP3A4.
DB00252	DB00440	Trimethoprim increases the effect of hydantoin
DB00252	DB04571	The hydantoin decreases the effect of psoralene
DB00252	DB00427	The CNS depressants, Triprolidine and Phenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00252	DB01199	Phenytoin decreases the effect of the muscle relaxant
DB00252	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB00252	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00252	DB01339	Phenytoin decreases the effect of the muscle relaxant
DB00252	DB08881	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB00252	DB00661	Verapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed.
DB00252	DB01080	Vigabatrin reduces plasma levels of phenytoin by 16-20% which may be due to induction of CYP2C. Consider dosage adjustment.
DB00252	DB00570	The antineoplasic agent decreases the effect of hydantoin
DB00252	DB00582	Voriconazole may increase the serum concentration of phenytoin by decreasing its metabolism. Phenytoin may increase the serum concentration of voriconazole by increasing its metabolism. Consider alternate antifungal therapy or monitor for voriconazole therapy failure and phenytoin toxicity.
DB00252	DB00682	Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy.
DB00254	DB01418	The tetracycline, doxycycline, may increase the anticoagulant effect of acenocoumarol.
DB00254	DB00459	Increased risk of intracranial hypertension
DB00254	DB01370	Formation of non-absorbable complexes
DB00254	DB01351	The anticonvulsant, amobarbital, decreases the effect of doxycycline.
DB00254	DB01060	Possible antagonism of action
DB00254	DB00415	Possible antagonism of action
DB00254	DB01125	The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione.
DB00254	DB01352	The anticonvulsant, aprobarbital, decreases the effect of doxycycline.
DB00254	DB01574	Formation of non-absorbable complexes
DB00254	DB01061	Possible antagonism of action
DB00254	DB00355	Possible antagonism of action
DB00254	DB01602	Possible antagonism of action
DB00254	DB01053	Possible antagonism of action
DB00254	DB00307	Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB00254	DB00237	The anticonvulsant, butabarbital, decreases the effect of doxycycline.
DB00254	DB00241	The anticonvulsant, butalbital, decreases the effect of doxycycline.
DB00254	DB01353	The anticonvulsant, butethal, decreases the effect of doxycycline.
DB00254	DB01373	Formation of non-absorbable complexes
DB00254	DB00258	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00254	DB01164	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00254	DB00564	The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline.
DB00254	DB00578	Possible antagonism of action
DB00254	DB00766	Possible antagonism of action
DB00254	DB01147	Possible antagonism of action
DB00254	DB00930	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00254	DB01000	Possible antagonism of action
DB00254	DB00485	Possible antagonism of action
DB00254	DB00266	The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol.
DB00254	DB01341	The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline.
DB00254	DB00977	Doxycycline may decrease the contraceptive effect of ethinyl estradiol.
DB00254	DB00754	The anticonvulsant, ethotoin, decreases the effect of doxycycline.
DB00254	DB00926	Increased risk of intracranial hypertension
DB00254	DB00301	Possible antagonism of action
DB00254	DB01320	The anticonvulsant, fosphenytoin, decreases the effect of doxycycline.
DB00254	DB01354	The anticonvulsant, heptabarbital, decreases the effect of doxycycline.
DB00254	DB00739	Possible antagonism of action
DB00254	DB01355	The anticonvulsant, hexobarbital, decreases the effect of doxycycline.
DB00254	DB01592	Formation of non-absorbable complexes
DB00254	DB00893	Formation of non-absorbable complexes
DB00254	DB00982	Increased risk of intracranial hypertension
DB00254	DB01378	Formation of non-absorbable complexes
DB00254	DB01377	Formation of non-absorbable complexes
DB00254	DB00532	The anticonvulsant, mephenytoin, decreases the effect of doxycycline.
DB00254	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00254	DB00474	The anticonvulsant, methohexital, decreases the effect of doxycycline.
DB00254	DB00563	The tetracycline, doxycycline, may increase methotrexate toxicity.
DB00254	DB00849	The anticonvulsant, methylphenobarbital, decreases the effect of doxycycline.
DB00254	DB01603	Possible antagonism of action
DB00254	DB00948	Possible antagonism of action
DB00254	DB00607	Possible antagonism of action
DB00254	DB00713	Possible antagonism of action
DB00254	DB00417	Possible antagonism of action
DB00254	DB00312	The anticonvulsant, pentobarbital, decreases the effect of doxycycline.
DB00254	DB01174	The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline.
DB00254	DB00252	The anticonvulsant, phenytoin, may decrease the effect of doxycycline.
DB00254	DB00319	Possible antagonism of action
DB00254	DB01604	Possible antagonism of action
DB00254	DB01605	Possible antagonism of action
DB00254	DB00794	The anticonvulsant, primidone, decreases the effect of doxycycline.
DB00254	DB01346	The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline.
DB00254	DB00615	The rifamycin decreases the effect of doxycycline
DB00254	DB01045	The rifamycin decreases the effect of doxycycline
DB00254	DB00418	The anticonvulsant , secobarbital, decreases the effect of doxycycline.
DB00254	DB00306	The anticonvulsant, talbutal, decreases the effect of doxycycline.
DB00254	DB00706	Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed.
DB00254	DB01606	Possible antagonism of action
DB00254	DB00599	Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered.
DB00254	DB01607	Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline.
DB00254	DB01036	Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00254	DB00755	Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00254	DB00682	The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin.
DB00254	DB01593	Formation of non-absorbable complexes
DB00255	DB01351	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB01352	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00237	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00241	The enzyme inducer, butalbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB01353	The enzyme inducer, butethal, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00754	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB01320	The enzyme inducer, fosphenytoin, may decrease the therapeutic effect of diethylstilbestrol.
DB00255	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB01354	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB01355	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00532	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00474	The enzyme inducer, methohexital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00849	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00312	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB01174	The enzyme inducer, phenobarbital, may decrease the therapeutic effect of diethylstilbestrol.
DB00255	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00860	The estrogenic agent, diethylstilbestrol, may increase the effect of the corticosteroid, prednisolone.
DB00255	DB00635	The estrogenic agent, diethylstilbestrol, may increase the effect of corticosteroid, prednisone.
DB00255	DB00794	The enzyme inducer, primidone, may decrease the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00481	Association not recommended
DB00255	DB00418	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00306	The enzyme inducer, talbutal, decreases the effect of the hormone agent, diethylstilbestrol.
DB00255	DB00932	Diethylstilbestrol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Diethylstilbestrol. Monitor estrogen levels during concomitant therapy.
DB00255	DB01586	Estrogens decreases the effect of ursodiol
DB00257	DB06274	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB00257	DB01222	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a moderate CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess.
DB00257	DB01394	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function.
DB00257	DB01590	CYP3A4 Inhibitors (Moderate)such as clotrimazole may increase the serum concentration of everolimus. The prescribing information for the Afinitor branded everolimus product lists indication-specific recommendations for managing this interaction.
DB00257	DB00813	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.
DB00257	DB01218	CYP3A4 Inhibitors (Moderate) such as clotrmazole may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).
DB00257	DB08815	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor.
DB00257	DB00243	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use.
DB00257	DB00864	The antifungal, Clotrimazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Clotrimazole therapy is initiated, discontinued or altered.
DB00257	DB00706	Clotrimazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clotrimazole is initiated, discontinued, or dose changed.
DB00257	DB01036	Clotrimazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00257	DB06212	CYP3A4 Inhibitors (Moderate) may increase the serum concentration of tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated.
DB00257	DB00193	Clotrimazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00257	DB00656	The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed.
DB00258	DB00630	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as alendronate. Avoid administration of oral calcium supplements within 30 minutes after alendronate.
DB00258	DB06724	Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
DB00277	DB00537	Ciprofloxacin may increase the effect of theophylline.
DB00258	DB01164	Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
DB00258	DB01212	Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
DB00258	DB00537	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00258	DB00720	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB00258	DB00618	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as demeoclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00258	DB00254	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00258	DB06210	Calcium Salts such as calcium acetate may decrease the serum concentration of Eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.
DB00258	DB01196	Calcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk.
DB00258	DB01077	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB00258	DB01155	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as gemifloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00258	DB00710	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as ibandronate. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate.
DB00258	DB01137	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00258	DB00451	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB00258	DB00279	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB00258	DB01583	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB00258	DB00978	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as lomefloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00258	DB01017	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00258	DB00779	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00266	DB01101	Capecitabine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB00258	DB01059	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00258	DB01165	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00258	DB00884	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate.
DB00258	DB01208	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as sparfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00258	DB00759	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00258	DB01133	The divalent cation of oral Calcium Acetate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
DB00258	DB06824	Calcium salts such as calcium acetate may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of Calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk.
DB00258	DB00685	Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containining agent to minimize the interaction.
DB00261	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00261	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Anagrelide. Monitor for increased bleeding during concomitant thearpy.
DB00262	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00262	DB00501	Increases myelosuppression caused by carmustine
DB00262	DB00390	The antineoplasic agent decreases the effect of digoxin
DB00262	DB01320	The antineoplasic agent decreases the effect of hydantoin
DB00262	DB01097	Immunosuppressants such as carmustine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB00262	DB00108	Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00262	DB00252	The antineoplasic agent decreases the effect of hydantoin
DB00262	DB00337	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00262	DB01656	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB00262	DB00864	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00262	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00263	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00263	DB00563	The sulfamide increases the toxicity of methotrexate
DB00263	DB00675	Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed.
DB00263	DB01124	Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
DB00263	DB00214	Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfisoxazole is initiated, discontinued or dose changed.
DB00263	DB00440	The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed.
DB00270	DB01369	This combination presents an increased risk of toxicity
DB00263	DB00582	Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed.
DB00263	DB00682	Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed.
DB00263	DB00549	Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed.
DB00264	DB00414	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB00672	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB00501	Cimetidine may increase the serum concentration of metoprolol by decreasing its metabolism.
DB00264	DB00215	The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, metoprolol.
DB00264	DB00575	Increased hypertension when clonidine stopped
DB00264	DB00320	Ischemia with risk of gangrene
DB00264	DB00343	Increased risk of bradycardia
DB00264	DB00280	The beta-blocker, metoprolol, may increase adverse effects of disopyramide.
DB00264	DB04855	Metoprolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase metoprolol exposure 1.6-fold. Lower dose of metoprolol.
DB00264	DB00668	Hypertension, then bradycardia
DB00264	DB01253	Ischemia with risk of gangrene
DB00264	DB00696	Ischemia with risk of gangrene
DB00264	DB01175	The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, metoprolol.
DB00264	DB01288	Antagonism
DB00264	DB00472	The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, metoprolol.
DB00264	DB00983	Antagonism
DB00264	DB01120	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01067	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01289	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01016	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01382	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01275	Increased effect of both drugs
DB00264	DB01050	Risk of inhibition of renal prostaglandins
DB00264	DB00328	Risk of inhibition of renal prostaglandins
DB00264	DB00047	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01064	Antagonism
DB00264	DB00281	The beta-blocker, metoprolol, may increase the effect and toxicity of lidocaine
DB00264	DB00247	Ischemia with risk of gangrene
DB00264	DB08893	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB00264	DB00816	Antagonism
DB00264	DB00715	The SSRI increases the effect of the beta-blocker
DB00264	DB01174	The barbiturate decreases the effect of the metabolized beta-blocker
DB00264	DB00236	Antagonism
DB00264	DB01291	Antagonism
DB00264	DB00554	Risk of inhibition of renal prostaglandins
DB00264	DB00457	Risk of hypotension at the beginning of therapy
DB00264	DB00794	The barbiturate decreases the effect of metabolized beta-blocker
DB00264	DB01366	Antagonism
DB00264	DB01182	Propafenone may increase the effect of beta-blocker, metoprolol.
DB00264	DB00912	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01045	Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism.
DB00264	DB01001	Antagonism
DB00264	DB00938	Antagonism
DB00264	DB01104	The SSRI increases the effect of the beta-blocker
DB00264	DB00976	Telithromycin may possibly increase metoprolol effect
DB00264	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00264	DB00857	Terbinafine may reduce the metabolism and clearance of Metoprolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Metoprolol if Terbinafine is initiated, discontinued or dose changed.
DB00264	DB00871	Antagonism
DB00264	DB00839	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB01124	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00264	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00264	DB00661	Increased effect of both drugs
DB00266	DB00316	Acetaminophen may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if acetaminophen is initiated, discontinued or dose changed.
DB00266	DB00414	Dicumarol may increase the effect of sulfonylurea, acetohexamide.
DB00266	DB00945	Acetylsalicylic acid increases effect of the anticoagulant, dicumarol.
DB00266	DB00437	Allopurinol may increase the anticoagulant effect of dicumarol.
DB00266	DB00357	Aminoglutethimide may decrease the anticoagulant effect of dicumarol.
DB00266	DB01118	Amiodarone may increase the anticoagulant effect of dicumarol.
DB00266	DB00701	Amprenavir may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB00266	DB00673	Aprepitant may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.
DB00266	DB01072	The protease inhibitor, atazanavir, may increase the anticoagulant effect of dicumarol.
DB00266	DB00993	Azathioprine may decrease the anticoagulant effect of dicumarol.
DB00266	DB00207	Azithromycin may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB00266	DB00443	The corticosteroid, betamethasone, alters the anticoagulant effect of dicumarol.
DB00266	DB00559	Bosentan may decrease the anticoagulant effect of dicumarol by increasing its metabolism.
DB00266	DB00564	Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.
DB00266	DB01330	The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol.
DB00266	DB01331	The cephalosporin, cefoxitin, may increase the anticoagulant effect of dicumarol.
DB00266	DB01212	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of dicumarol.
DB00266	DB00482	Celecoxib may increase the anticoagulant effect of dicumarol.
DB00266	DB00672	Dicumarol may increase the effect of sulfonylurea, chlorpropamide.
DB00266	DB01432	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of dicumarol by decreasing its absorption.
DB00266	DB00501	Cimetidine may increase the anticoagulant effect of dicumarol.
DB00266	DB00537	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol.
DB00266	DB00604	Cisapride may increase the anticoagulant effect of dicumarol.
DB00266	DB00215	The SSRI, citalopram, increases the effect of anticoagulant, dicumarol.
DB00266	DB01211	The macrolide, clarithromycin, may increase the anticoagulant effect of dicumarol.
DB00266	DB00636	The fibrate increases the anticoagulant effect
DB00266	DB00375	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of dicumarol by decreasing its absorption.
DB00266	DB00531	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of dicumarol.
DB00266	DB01406	The androgen, danazol, may increase the anticoagulant effect of dicumarol.
DB00266	DB00618	The tetracycline, demeclocycline, may increase the anticoagulant effect of dicumarol.
DB00266	DB01234	The corticosteroid, dexamethasone, alters the anticoagulant effect of dicumarol.
DB00266	DB00647	Propoxyphene may increase the anticoagulant effect of dicumarol.
DB00266	DB00509	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of dicumarol.
DB00266	DB00586	The NSAID, diclofenac, may increase the anticoagulant effect of dicumarol.
DB00266	DB00485	Dicloxacillin may decrease the anticoagulant effect of dicumarol.
DB00266	DB00861	The NSAID, diflunisal, may increase the anticoagulant effect of dicumarol.
DB00266	DB00822	Disulfiram may increase the anticoagulant effect of dicumarol.
DB00266	DB00254	The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol.
DB00266	DB00199	The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol..
DB00266	DB00189	Ethchlorvynol may decrease the anticoagulant effect of dicumarol.
DB00266	DB00977	Increased thrombotic risk due to estrogen
DB00266	DB00749	The NSAID, etodolac, may increase the anticoagulant effect of dicumarol.
DB00266	DB01628	Etoricoxib may increase the anticoagulant effect of dicumarol.
DB00266	DB01039	Fenofibrate may increase the anticoagulant effect of dicumarol.
DB00266	DB00573	The NSAID, fenoprofen, may increase the anticoagulant effect of dicumarol.
DB00266	DB00196	Fluconazole may increase the serum concentration of dicumarol by decreasing its metabolism.
DB00266	DB00687	The corticosteroid, fludrocortisone, alters the anticoagulant effect of dicumarol.
DB00266	DB00544	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of dicumarol.
DB00266	DB00472	The SSRI, fluoxetine, increases the effect of anticoagulant, dicumarol.
DB00266	DB01185	The androgen, fluoxymesterone, may increase the anticoagulant effect of dicumarol.
DB00266	DB00712	The NSAID, flurbiprofen, may increase the anticoagulant effect of dicumarol.
DB00266	DB01095	Fluvastatin may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if fluvastatin if initiated, discontinued or dose changed.
DB00266	DB00176	Fluvoxamine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB00266	DB01319	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of dicumarol.
DB00266	DB01320	Increased hydantoin levels and risk of bleeding
DB00266	DB00317	Gefitinib may increase the anticoagulant effect of dicumarol.
DB00266	DB00441	Gemcitabine may increase the anticoagulant effect of dicumarol.
DB00266	DB01241	Gemfibrozil may increase the anticoagulant effect of dicumarol.
DB00266	DB01120	Dicumarol may increase the effect of sulfonylurea, gliclazide.
DB00266	DB01437	Glutethimide may decrease the anticoagulant effect of dicumarol.
DB00266	DB01016	Dicumarol may increase the effect of sulfonylurea, glibenclamide.
DB00266	DB00400	Griseofulvin may decrease the anticoagulant effect of dicumarol.
DB00266	DB00741	The corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol.
DB00266	DB01050	The NSAID, ibuprofen, may increase the anticoagulant effect of dicumarol.
DB00266	DB00619	Imatinib may increase the anticoagulant effect of dicumarol.
DB00266	DB00224	The protease inhibitor, indinavir, may increase the anticoagulant effect of dicumarol.
DB00266	DB00328	The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol.
DB00266	DB00951	Isoniazid may increase the anticoagulant effect of dicumarol.
DB00266	DB01167	Itraconazole may increase the anticoagulant effect of dicumarol.
DB00266	DB01026	Ketoconazole may increase the anticoagulant effect of dicumarol.
DB00266	DB01009	The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol.
DB00266	DB00465	The NSAID, ketorolac, may increase the anticoagulant effect of dicumarol.
DB00266	DB01097	Leflunomide may increase the anticoagulant effect of dicumarol.
DB00266	DB00848	Levamisole may increase the anticoagulant effect of dicumarol.
DB00266	DB01137	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of dicumarol.
DB00266	DB00451	The thyroid hormone, levothyroxine, increase the anticoagulant effect of dicumarol.
DB00266	DB00227	Lovastatin may increase the anticoagulant effect dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if lovastatin is initiated, discontinued or dose changed.
DB00266	DB01283	Lumiracoxib may increase the anticoagulant effect of dicumarol.
DB00266	DB00603	Medroxyprogesterone may increase the anticoagulant effect of dicumarol.
DB00266	DB00784	The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol.
DB00266	DB00358	Mefloquine may increase the anticoagulant effect of dicumarol.
DB00266	DB00814	Meloxicam may increase the anticoagulant effect of dicumarol.
DB00266	DB01033	Mercaptopurine may decrease the anticoagulant effect of dicumarol.
DB00266	DB00763	The antithyroid agent, methimazole, may decrease the anticoagulant effect of dicumarol.
DB00266	DB00916	Metronidazole may increase the anticoagulant effect of dicumarol.
DB00266	DB01110	Miconazole may increase the serum concentration of dicumarol by decreasing its metabolism.
DB00266	DB01017	The tetracycline, minocycline, may increase the anticoagulant effect of dicumarol.
DB00266	DB00648	Mitotane may decrease the anticoagulant effect of dicumarol.
DB00266	DB00218	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of dicumarol.
DB00266	DB00461	The NSAID, nabumetone, may increase the anticoagulant effect of dicumarol.
DB00266	DB00779	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of dicumarol.
DB00266	DB00788	The NSAID, naproxen, may increase the anticoagulant effect of dicumarol.
DB00266	DB00220	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of dicumarol.
DB00266	DB00238	Nevirapine may decrease the anticoagulant effect of dicumarol.
DB00266	DB01059	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of dicumarol.
DB00266	DB01165	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol.
DB00266	DB01083	Orlistat may increase the anticoagulant effect of dicumarol.
DB00266	DB00991	The NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol.
DB00266	DB03585	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of dicumarol.
DB00266	DB00715	The SSRI, paroxetine, increases the effect of anticoagulant, dicumarol.
DB00266	DB00806	Pentoxifylline may increase the anticoagulant effect of dicumarol.
DB00266	DB01174	The barbiturate, phenobarbital, decreases the anticoagulant effect, dicumarol.
DB00266	DB00812	The NSAID, phenylbutazone, may increase the anticoagulant effect of dicumarol.
DB00266	DB00252	Increased hydantoin levels and risk of bleeding
DB00266	DB00554	The NSAID, piroxicam, may increase the anticoagulant effect of dicumarol.
DB00266	DB00860	The corticosteroid, prednisolone, alters the anticoagulant effect of dicumarol.
DB00266	DB00635	The corticosteroid, prednisone, alters the anticoagulant effect of dicumarol.
DB00266	DB00794	The barbiturate, primidone, decreases the anticoagulant effect, dicumarol.
DB00266	DB01182	Propafenone may increase the anticoagulant effect of dicumarol.
DB00266	DB00550	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of dicumarol.
DB00266	DB00908	Quinidine may increase the anticoagulant effect of dicumarol.
DB00266	DB00468	Quinine may increase the anticoagulant effect of dicumarol.
DB00266	DB00863	Ranitidine may increase the anticoagulant effect of dicumarol. (Conflicting evidence)
DB00266	DB00615	Rifabutin may decrease the anticoagulant effect of dicumarol.
DB00266	DB01045	Rifampin may decrease the anticoagulant effect of dicumarol.
DB00266	DB00976	Telithromycin may increase the anticoagulant effect of dicumarol.
DB00266	DB00469	The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol.
DB00266	DB00624	The androgen may increase the anticoagulant effect of dicumarol.
DB00266	DB00759	Tetracycline may increase the anticoagulant effect of dicumarol.
DB00266	DB00560	Tigecycline may increase the anticoagulant effect of dicumarol.
DB00266	DB00620	The corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol.
DB00268	DB00537	Ciprofloxacin may increase the effect and toxicity of ropinirole.
DB00268	DB01551	Dihydrocodeine may enhance the sedative effect of ropinirole. It is recommended to monitor therapy
DB00268	DB00176	Increases the effect and toxicity of ropinirole
DB00268	DB01267	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, ropinirole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB00268	DB01623	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Ropinirole. Consider alternate therapy or monitor for decreased effects of both agents.
DB00268	DB00246	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, ropinirole. Consider alternate therapy or monitor for worsening of movement disorder.
DB00268	DB01624	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB00269	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, chlorotrianisene.
DB00269	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent,  chlorotrianisene.
DB00269	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, chlorotrianisene.
DB00269	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, chlorotrianisene.
DB00269	DB00860	The estrogenic agent, chlorotrianisene, may increase the effect of the corticosteroid, prednisolone.
DB00269	DB00635	The estrogenic agent, chlorotrianisene, may increase the effect of corticosteroid, prednisone.
DB00269	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, chlorotrianisene.
DB00269	DB00481	Association not recommended
DB00270	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00270	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00270	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00270	DB00976	Telithromycin may reduce clearance of Isradipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isradipine if Telithromycin is initiated, discontinued or dose changed.
DB00270	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Isradipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Isradipine if Thiopental is initiated, discontinued or dose changed.
DB00270	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00270	DB00932	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Isradipine. Monitor for changes in Isradipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB00270	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00270	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00270	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00270	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isradipine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of isradipine if voriconazole is initiated, discontinued or dose changed.
DB00270	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00270	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00270	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00273	DB00819	Additive renal carbonic anhydrase inhibition may occur increasing the risk of crystaluria and renal calculi. Increased risk of nephrolithiasis. Consider altnerate therapy.
DB00273	DB01194	As both brinzolamide and topiramate are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB00273	DB00564	Carbamazepine may decrease the effectiveness of Topiramate by increase its clearance. Monitor for changes in the therapeutic and adverse effects of Topiramate if Carbamazepine is initiated, discontinued or dose changed. Adverse effects related to CNS depression have also been observed during concomitant therapy.
DB00273	DB00880	Thiazide diuretics such as chlorothiazide may enhance the hypokalemic effect of topiramate. Thiazide diuretics may increase the serum concentration of topiramate. Monitor for increased topiramate concentrations/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.
DB00273	DB00977	Topiramate may decrease the effect of the oral contraceptive, Ethinyl estradiol. An alternate form of contraception should be used during concomitant therapy.
DB00273	DB01320	Increased phenytoin/decreased topiramate
DB00273	DB01356	Topiramate could modify lithium levels
DB00273	DB04835	Topiramate, a CYP3A4 inducer, may decrease the serum concentration of Maraviroc by increasing Maraviroc metabolism and clearance. A dose adjustment of Maraviroc may be required. Monitor for changes in Maraviroc therapeutic and adverse effects if Topiramate is initiated, discontinued or dose changed.
DB00273	DB01357	Topiramate may decrease the effect of the oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy.
DB00273	DB00252	Increased phenytoin/decreased topiramate
DB00273	DB00684	Increased risk of nephrotoxicity
DB00273	DB00427	The CNS depressants, Triprolidine and Topiramate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00273	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB00274	DB01032	Probenecid may increase the serum level of cefmatzole.
DB00275	DB01395	Increased risk of hyperkalemia
DB00275	DB00684	Increased risk of nephrotoxicity
DB00275	DB00519	The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril.
DB00275	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00276	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00277	DB00787	Acyclovir may increase the effect and toxicity of theophylline.
DB00277	DB00640	Theophylline may decrease the effect of adenosine.
DB00277	DB01351	The barbiturate, amobarbital, decreases the effect of theophylline.
DB00277	DB01352	The barbiturate, aprobarbital, decreases the effect of theophylline.
DB00277	DB00732	Theophylline decreases the effect of the muscle relaxant
DB00277	DB01558	Theophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if theophylline is initiated, discontinued or dose changed.
DB00277	DB00237	The barbiturate, butabarbital, decreases the effect of theophylline.
DB00277	DB00241	The barbiturate, butalbital, decreases the effect of theophylline.
DB00277	DB01353	The barbiturate, butethal, decreases the effect of theophylline.
DB00277	DB00564	Carbamazepine may decrease the serum concentration of theophylline. Theophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00277	DB00521	Antagonism of action and increased effect of theophylline
DB00277	DB00501	Cimetidine may increase the effect of theophylline.
DB00277	DB01211	Clarithromycin may increase the therapeutic and adverse effects of theophylline.
DB00277	DB01341	The barbiturate, dihydroquinidine barbiturate, decreases the effect of theophylline.
DB00277	DB00822	Disulfiram may increase the effect and toxicity of theophylline.
DB00277	DB01135	Theophylline decreases the effect of the muscle relaxant
DB00277	DB00467	Enoxacin may increase the effect of theophylline.
DB00277	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of theophylline.
DB00277	DB00977	The contraceptive increases the effect and toxicity of theophylline
DB00277	DB00754	Decreased effect of both products
DB00277	DB04854	Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes.
DB00277	DB00176	Fluvoxamine may increase the therapeutic and adverse effects of theophylline.
DB00277	DB01320	Decreased effect of both products
DB00277	DB00365	Grepafloxacin may increase the effect of theophylline.
DB00277	DB01159	Increased risk of cardiac arrhythmia
DB00277	DB01354	The barbiturate, heptabarbital, decreases the effect of theophylline.
DB00277	DB01355	The barbiturate, hexobarbital, decreases the effect of theophylline.
DB00277	DB00034	Interferon increases the effect and toxicity of theophylline
DB00277	DB00105	Interferon increases the effect and toxicity of theophylline
DB00277	DB00011	Interferon increases the effect and toxicity of theophylline
DB00277	DB00951	Isoniazid may increase the therapeutic and adverse effects of theophylline.
DB00277	DB01321	The macrolide, josamycin, may increase the effect and toxicity of theophylline.
DB00277	DB01356	Theophylline decreases serum levels of lithium
DB00277	DB00532	Decreased effect of both products
DB00277	DB01357	The contraceptive increases the effect and toxicity of theophylline
DB00277	DB00474	The barbiturate, methohexital, decreases the effect of theophylline.
DB00277	DB00849	The barbiturate, methylphenobarbital, decreases the effect of theophylline.
DB00277	DB01336	Theophylline decreases the effect of the muscle relaxant
DB00277	DB00379	Mexiletine increases the effect and toxicity of theophylline
DB00277	DB01226	Theophylline decreases the effect of the muscle relaxant
DB00277	DB01203	Antagonism of action and increased effect of theophylline
DB00277	DB01059	Norfloxacin may increase the effect of theophylline.
DB00277	DB01337	Theophylline decreases the effect of the muscle relaxant
DB00277	DB00487	Pefloxacin may increase the effect of theophylline.
DB00277	DB00008	Interferon increases the effect and toxicity of theophylline
DB00277	DB00022	Interferon increases the effect and toxicity of theophylline
DB00277	DB01359	Antagonism of action and increased effect of theophylline
DB00277	DB00312	The barbiturate, pentobarbital, decreases the effect of theophylline.
DB00277	DB00806	Pentoxifylline increases the effect and toxicity of theophylline
DB00277	DB01174	The barbiturate, phenobarbital, decreases the effect of theophylline.
DB00277	DB00252	Decreased effect of both products
DB00277	DB00960	Antagonism of action and increased effect of theophylline
DB00277	DB00794	The barbiturate, primidone, decreases the effect of theophylline.
DB00277	DB01182	Propafenone increases the effect of theophylline
DB00277	DB00571	Antagonism of action and increased effect of theophylline
DB00277	DB01346	The barbiturate, quinidine barbiturate, decreases the effect of theophylline.
DB00277	DB06213	Non-specific adenosine receptor antagonist may interfere with the vasodilation activity of regadenoson. Avoid methylxanthines for at least 12 hours before administration of regadenoson.
DB00277	DB01045	Rifampin decreases the effect of theophylline
DB00277	DB00503	Ritonavir decreases the effect of theophylline
DB00277	DB00533	Rofecoxib increases the effect and toxicity of theophylline
DB00277	DB00418	The barbiturate, secobarbital, decreases the effect of theophylline.
DB00277	DB00489	Antagonism of action and increased effect of theophylline
DB00277	DB01323	St. John's Wort decreases the effect of theophylline
DB00277	DB00382	Tacrine may reduce the elimination rate of Theophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed.
DB00277	DB00306	The barbiturate, talbutal, decreases the effect of theophylline.
DB00277	DB00976	Telithromycin may reduce clearance of Theophylline. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Theophylline if Telithromycin is initiated, discontinued or dose changed.
DB00277	DB00231	Theophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Theophylline is initiated, discontinued or dose changed.
DB00277	DB00857	Terbinafine increases the effect and toxicity of theophylline
DB00277	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Theophylline by decreasing Theophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Theophylline if Thiabendazole is initiated, discontinued or dose changed.
DB00277	DB00208	Ticlopidine increases the effect and toxicity of theophylline
DB00277	DB00373	Antagonism of action and increased effect of theophylline
DB00277	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the concentration of Theophylline.
DB00277	DB01361	The macrolide, troleandomycin, may increase the effect and toxicity of theophylline.
DB00277	DB01199	Theophylline decreases the effect of the muscle relaxant
DB00277	DB01339	Theophylline decreases the effect of the muscle relaxant
DB00277	DB00661	Verapamil increases the effect of theophylline
DB00277	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of theophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of theophylline if voriconazole is initiated, discontinued or dose changed.
DB00277	DB00549	Zafirlukast serum concentrations may be decreased by Theophylline.
DB00277	DB00744	Zileuton may increase the therapeutic and adverse effects of theophylline by increasing its serum concentration. Monitor for changes in the therapeutic and adverse effects of theophylline if zileuton is initiated, discontinued or dose changed. Dose alterations should be considered.
DB00278	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00278	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy.
DB00279	DB00258	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB00279	DB01164	Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB00279	DB01432	The resin, cholestyramine, decreases the absorption of the thyroid hormones, liothyronine.
DB00279	DB00375	The resin, colestipol, decreases the absorption of the thyroid hormone, liothyronine.
DB00279	DB00390	The thyroid hormone, liothyronine, decreases the effect of digoxin.
DB00279	DB00682	Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed.
DB00280	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB00280	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00280	DB00335	The beta-blocker, atenolol, may increase the toxicity of disopyramide.
DB00280	DB00207	The macrolide, azithromycin, may increase the effect of disopyramide.
DB00280	DB00195	The beta-blocker, betaxolol, may increase the toxicity of disopyramide.
DB00280	DB01295	The beta-blocker, bevantolol, may increase the toxicity of disopyramide.
DB00280	DB00612	The beta-blocker, bisoprolol, may increase the toxicity of disopyramide.
DB00280	DB00237	arbiturates may increase the metabolism of Disopyramide. Monitor for decreased therapeutic effects of disopyramide if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased.
DB00280	DB00521	The beta-blocker, carteolol, may increase the toxicity of disopyramide.
DB00280	DB01136	The beta-blocker, carvedilol, may increase the toxicity of disopyramide.
DB00280	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB00280	DB00843	Possible antagonism of action
DB00280	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB00187	The beta-blocker, esmolol, may increase the adverse effects of disopyramide.
DB00280	DB00754	The hydantoin decreases the effect of disopyramide
DB00280	DB06414	Disopyramide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for disopyramide therapy.
DB00280	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB00280	DB01320	The hydantoin decreases the effect of disopyramide
DB00280	DB00674	Possible antagonism of action
DB00280	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB00046	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00280	DB00598	The beta-blocker, labetolol, may increase the toxicity of disopyramide.
DB00280	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB00532	The hydantoin decreases the effect of disopyramide
DB00280	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB00264	The beta-blocker, metoprolol, may increase adverse effects of disopyramide.
DB00280	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB01203	The beta-blocker, nadolol, may increase the toxicity of disopyramide.
DB00280	DB00338	The beta-blocker increases toxicity of disopyramide
DB00280	DB01580	The beta-blocker, oxprenolol, may increase the toxicity of disopyramide.
DB00280	DB01359	The beta-blocker, penbutolol,  may increase the toxicity of disopyramide.
DB00280	DB01174	Phenobarbital decreases levels of disopyramide
DB00280	DB00252	The hydantoin decreases the effect of disopyramide
DB00280	DB00960	The beta-blocker, pindolol, may increase the toxicity of disopyramide.
DB00280	DB01297	The beta-blocker, practolol, may increase the toxicity of disopyramide.
DB00280	DB00571	The beta-blocker, propranolol, may increase the toxicity of disopyramide.
DB00280	DB01369	This combination presents an increased risk of toxicity
DB00280	DB00243	Possible additive effect on QT prolongation
DB00280	DB01045	Rifampin decreases the effect of disopyramide
DB00280	DB00989	Possible antagonism of action
DB00280	DB00489	The beta-blocker, sotalol, may increase the toxicity of disopyramide.
DB00280	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00280	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00280	DB00976	Telithromycin may reduce clearance of Disopyramide. Concomitant therapy should be avoided.
DB00280	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB00599	Thiopental may increase the metabolism and clearance of Disopyramide. Monitor for changes in therapeutic/adverse effects of Disopyramide if Thiopental is inititaed, discontinued or dose changed.
DB00280	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00280	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00280	DB00373	The beta-blocker, timolol, may increase the toxicity of disopyramide.
DB00280	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00280	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00280	DB00582	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed.
DB00280	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00280	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00280	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00281	DB01193	The beta-blocker, acebutolol, may increase the effect and toxicity of lidocaine.
DB00281	DB01072	Increased risk of cardiotoxicity and arrhythmias
DB00281	DB00335	The beta-blocker, atenolol, may increase the effect and toxicity of lidocaine.
DB00281	DB00612	The beta-blocker, bisoprolol, may increase the effect and toxicity of lidocaine.
DB00281	DB01136	The beta-blocker, carvedilol, may increase the effect and toxicity of lidocaine.
DB00281	DB00501	Increases the effect and toxicity of lidocaine
DB00281	DB01264	Possible increase in lidocaine levels
DB00281	DB00187	The beta-blocker, esmolol, may increase the effect and toxicity of lidocaine.
DB00281	DB06414	Lidocaine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor lidocaine therapy.
DB00281	DB00598	The beta-blocker, labetalol, may increase the effect and toxicity of lidocaine.
DB00281	DB00264	The beta-blocker, metoprolol, may increase the effect and toxicity of lidocaine
DB00281	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB00281	DB01580	The beta-blocker increases the effect and toxicity of lidocaine
DB00281	DB01359	Penbutolol increases the volume of distribution of lidocaine in normal subjects. This could result in a requirement for higher loading doses of lidocaine.
DB00281	DB00960	The beta-blocker increases the effect and toxicity of lidocaine
DB00281	DB00571	The beta-blocker, propranolol, may increase the effect and toxicity of lidocaine.
DB00281	DB01369	This combination presents an increased risk of toxicity
DB00281	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Lidocaine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Lidocaine is initiated, discontinued or if the dose is changed.
DB00281	DB00675	Lidocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00281	DB00706	Lidocaine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lidocaine is initiated, discontinued, or dose changed.
DB00281	DB00976	Telithromycin may reduce clearance of Lidocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lidocaine if Telithromycin is initiated, discontinued or dose changed.
DB00281	DB00857	Terbinafine may reduce the metabolism and clearance of Lidocaine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lidocaine if Terbinafine is initiated, discontinued or dose changed.
DB00281	DB01623	The strong CYP1A2 inhibitor, Lidocaine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Lidocaine is initiated, discontinued or dose changed.
DB00281	DB00373	The beta-blocker, timolol, may increase the effect and toxicity of lidocaine.
DB00281	DB00697	Lidocaine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00281	DB01036	Lidocaine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00281	DB00193	Lidocaine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lidocaine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00281	DB00656	The CYP3A4 inhibitor, Lidocaine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lidocaine is initiated, discontinued or dose changed.
DB00281	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lidocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lidocaine if voriconazole is initiated, discontinued or dose changed.
DB00283	DB00843	Possible antagonism of action
DB00283	DB00674	Possible antagonism of action
DB00283	DB00989	Possible antagonism of action
DB00289	DB00623	Risk of additive CNS depressant effects. Monitor for increased CNS depression during concomitant therapy.
DB00283	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clemastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00283	DB00662	Trimethobenzamide and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00283	DB00427	Concomitant therapy with triprolidine and clemastine, two anticholinergics and CNS depressants, may result in additive  adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy.
DB00283	DB00209	Trospium and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00284	DB00390	Acarbose may decrease the serum levels of digoin. It is thought that acarbose reduces digoin absorption. Monitor for changes in digoxin serum levels and therapeutic and adverse effects if acarbose is initiated, discontinued or dose changed.
DB00284	DB00052	Somatropin may antagonize the hypoglycemic effect of acarbose. Monitor for changes in fasting and postprandial blood sugars.
DB00285	DB00918	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00321	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00543	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00701	Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Amprenavir is initiated, discontinued, or dose changed.
DB00285	DB01072	Atazanavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Atazanavir is initiated, discontinued, or dose changed.
DB00285	DB01200	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00490	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00248	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00477	Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Chlorpromazine is initiated, discontinued, or dose changed.
DB00285	DB01012	Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cinacalcet is initiated, discontinued, or dose changed.
DB00285	DB00215	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01211	Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Clarithromycin is initiated, discontinued, or dose changed.
DB00285	DB01242	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00907	Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cocaine is initiated, discontinued, or dose changed.
DB00285	DB00872	Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Conivaptan is initiated, discontinued, or dose changed.
DB00285	DB01264	Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Darunavir is initiated, discontinued, or dose changed.
DB00285	DB00705	Delaviridine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Delavirdine is initiated, discontinued, or dose changed.
DB00285	DB01151	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01191	Risk of serotoninergic syndrome
DB00285	DB00514	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00937	Risk of serotoninergic syndrome
DB00285	DB00320	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00449	Venlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00285	DB01142	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00476	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00216	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01364	Venlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00285	DB00668	Venlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00285	DB01049	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01253	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00696	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01175	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00574	Risk of serotoninergic syndrome
DB00285	DB00472	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00176	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00289	DB01075	Diphenhydramine, a moderate CYP2D6 inhibitor, may increase the therapeutic and adverse effects of atomoxetine by decreasing its metabolism.
DB00285	DB01319	Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Fosamprenavir is initiated, discontinued, or dose changed.
DB00285	DB00998	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00614	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00285	DB00619	Imatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Imatinib is initiated, discontinued, or dose changed.
DB00285	DB00458	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00224	Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Indinavir is initiated, discontinued, or dose changed.
DB00285	DB01247	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00285	DB00951	Isoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed.
DB00285	DB01167	Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed.
DB00285	DB01026	Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed.
DB00285	DB00601	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00285	DB01356	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01601	Lopinavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Lopinavir is initiated, discontinued, or dose changed.
DB00285	DB00934	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00579	Risk of serotoninergic syndrome
DB00285	DB00353	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01233	Possible serotoninergic syndrome with this combination
DB00285	DB01110	Miconazole, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Miconazole is initiated, discontinued, or dose changed.
DB00285	DB04896	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00370	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01171	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00285	DB00952	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01149	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00220	Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nelfinavir is initiated, discontinued, or dose changed.
DB00285	DB00622	Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed.
DB00285	DB00368	Venlafaxine may increase the tachycardic and vasopressor effects of Norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00285	DB00540	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00715	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01186	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00454	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00780	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00285	DB00191	Risk of serotoninergic syndrome
DB00285	DB00397	Risk of serotoninergic syndrome
DB00285	DB01263	Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Posaconazole is initiated, discontinued, or dose changed.
DB00285	DB01168	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00285	DB01069	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01182	Propafenone increases the effect and toxicity of venlafaxine
DB00285	DB00344	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00852	Venlafaxine may increase the tachycardic and vasopressor effects of Pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00285	DB00908	Quinidine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Quinidine is initiated, discontinued, or dose changed.
DB00285	DB01369	This combination presents an increased risk of toxicity
DB00285	DB01367	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00289	DB00472	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB01247	Possible severe adverse reaction with this combination
DB00285	DB00503	Ritonavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ritonavir is initiated, discontinued, or dose changed.
DB00285	DB00953	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00118	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01232	Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Saquinavir is initiated, discontinued, or dose changed.
DB00285	DB01037	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00285	DB01104	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB01105	Increased risk of serotonin syndrome. Concurrent therapy should be avoided.
DB00285	DB01323	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00669	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00976	Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Telithromycin is initiated, discontinued, or dose changed.
DB00285	DB00857	Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Terbinafine is initiated, discontinued, or dose changed.
DB00285	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00285	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00285	DB00427	The CNS depressants, Triprolidine and Venlafaxine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00285	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of venlafaxine if voriconazole is initiated, discontinued or dose changed.
DB00285	DB00315	Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00286	DB01351	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB01352	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00237	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00241	The enzyme inducer, butalbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB01353	The enzyme inducer, butethal, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00754	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB01354	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB01355	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00532	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00474	The enzyme inducer, methohexital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00849	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00312	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00860	The estrogenic agent may increase the effect of the corticosteroid, prednisolone.
DB00286	DB00635	The estrogenic agent may increase the effect of corticosteroid, prednisone.
DB00286	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00481	Association not recommended
DB00286	DB00418	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00306	The enzyme inducer, talbutal, decreases the effect of the hormone agent, conjugated estrogens.
DB00286	DB00932	Conjugated estrogens may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Conjugated estrogens. Monitor for estrogen deficiency during concomitant therapy.
DB00286	DB01586	Estrogens decreases the effect of ursodiol
DB00289	DB01118	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00608	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00907	CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor.
DB00289	DB00647	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00502	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB01206	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB01388	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00715	The CYP2D6 inhibitor, paroxetine, may increase the effect and toxicity of atomoxetine.
DB00289	DB00850	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00780	Possible severe adverse reaction with this combination
DB00289	DB01103	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00908	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB01346	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00468	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB01367	Possible severe adverse reaction with this combination
DB00289	DB00503	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00857	Terbinafine, a CYP2D6 inhibitor, may reduce the metabolism and clearance of Atomoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Atomoxetine if Terbinafine is initiated, discontinued or dose changed.
DB00289	DB00679	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB00752	The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Atomoxetine. These agents should not be administered within 14 days of each other.
DB00289	DB00427	The CNS depressants, Triprolidine and Atomoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00289	DB00361	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00289	DB01392	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00290	DB08870	Pulmonary toxicity of bleomycin may be increased. Avoid combination.
DB00290	DB00390	The antineoplasic agent decreases the effect of digoxin
DB00290	DB00099	Monitor therapy due to enhanced adverse effects of bleomycin especially pulmonary toxicity.
DB00290	DB01320	The antineoplasic agent decreases the effect of hydantoin
DB00290	DB01097	Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity.
DB00290	DB00108	Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00290	DB00252	The antineoplasic agent decreases the effect of hydantoin
DB00290	DB00337	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants like bleomycin. This combination is contraindicated
DB00290	DB01656	Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning.
DB00290	DB00864	Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00290	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00291	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00291	DB01097	Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB00291	DB00108	Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00291	DB00337	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as chlorambucil. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00291	DB01656	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as chlorambucil. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB00291	DB00864	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants sucb as chlorambucil. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00291	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00294	DB06697	Artemether may decrease the effectiveness of etonogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00294	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of etonogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00294	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00306	DB00158	Folic acid decreases the effect of anticonvulsant, talbutal.
DB00294	DB00599	Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00294	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Etonogestrel. An alternate form of contraception should be used during concomitant therapy.
DB00294	DB00682	Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed.
DB00295	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00295	DB06210	Eltrombopag increases Morphine levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00295	DB01045	Rifampin decreases the effect of morphine/codeine
DB00295	DB00427	The CNS depressants, Triprolidine and Morphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00295	DB00685	Morphine may reduce serum levels of Trovafloxacin decreasing the efficacy of the antibiotic. IV doses of morphine should be administered at least 2 hours after a dose of Trovafloxacin given in a fasting state or 4 hours after if given in a fed state.
DB00296	DB00176	Increases the effect and toxicity of ropivacaine
DB00297	DB00872	Conivaptan may increase the serum concentration of CYP3A4 Substrates such as bupivacaine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00298	DB00706	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Dapiprazole, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00299	DB01370	The multivalent agent decreases the effect of penicillamine
DB00299	DB01574	The multivalent agent decreases the effect of penicillamine
DB00299	DB00390	The multivalent agent decreases the effect of penicillamine
DB00299	DB01592	The multivalent agent decreases the effect of penicillamine
DB00299	DB01575	The multivalent agent decreases the effect of penicillamine
DB00300	DB01072	Concomitant therapy may result in decreased serum levels of Atazanavir and increased levels of Tenofovir. Concomitant therapy should only be used with the inclusion of Ritonavir.
DB00300	DB00900	Tenofovir may decrease the therapeutic effects and increase the adverse effects of Didanosine. Monitor for changes in virologic response and Didanosine toxicity during concomitant therapy.
DB00300	DB01610	The excretion rates of Valganciclovir and/or Tenofovir may decrease as both drugs are eliminated by active tubular secretion. Monitor for increased serum concentrations and toxicity of both agents.
DB00301	DB00618	Possible antagonism of action
DB00301	DB00254	Possible antagonism of action
DB00301	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00301	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00301	DB00931	Possible antagonism of action
DB00301	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00301	DB01017	Possible antagonism of action
DB00301	DB00595	Possible antagonism of action
DB00301	DB01301	Possible antagonism of action
DB00301	DB00759	Possible antagonism of action
DB00304	DB06697	Artemether may decrease the effectiveness of desogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00304	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of desogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00304	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00304	DB00555	The oral contraceptive decreases the effect of lamotrigine
DB00304	DB00599	Thiopental may decrease the effect of Desogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00304	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Desogestrel. An alternate form of contraception should be used during concomitant therapy.
DB00304	DB00682	Desogestrol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if desogestrol is initiated, discontinued or dose changed.
DB00305	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00305	DB00570	Potentially severe lung toxicity
DB00305	DB00541	Potentially severe lung toxicity
DB00305	DB00309	Potentially severe lung toxicity
DB00306	DB01223	The barbiturate, talbutal, decreases the effect of aminophylline.
DB00306	DB00443	The barbiturate, talbutal, may decrease the effect of the corticosteroid, betamethasone.
DB00306	DB00882	The enzyme inducer, talbutal, decreases the effect of the hormone agent, clomifene.
DB00306	DB00286	The enzyme inducer, talbutal, decreases the effect of the hormone agent, conjugated estrogens.
DB00306	DB00091	The sulfonamide decreases the effect of cyclosporine
DB00306	DB01234	The barbiturate, talbutal, may decrease the effect of the corticosteroid, dexamethasone.
DB00306	DB00255	The enzyme inducer, talbutal, decreases the effect of the hormone agent, diethylstilbestrol.
DB00306	DB00254	The anticonvulsant, talbutal, decreases the effect of doxycycline.
DB00306	DB00783	The enzyme inducer, talbutal, decreases the effect of the hormone agent, estradiol.
DB00306	DB00977	This product may cause a slight decrease of contraceptive effect
DB00306	DB01023	The barbiturate, talbutal, decreases the effect of felodipine.
DB00306	DB00687	The barbiturate, talbutal, may decrease the effect of the corticosteroid, fludrocortisone.
DB00306	DB00317	The CYP3A4 inducer, talbutal, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00306	DB00400	The barbiturate, talbutal, decreases the effect of griseofulvin.
DB00306	DB00741	The barbiturate, talbutal, may decrease the effect of the corticosteroid, hydrocortisone.
DB00306	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00306	DB00603	The enzyme inducer, talbutal, decreases the effect of the hormone agent, medroxyprogesterone.
DB00306	DB00351	The enzyme inducer, talbutal, decreases the effect of the hormone agent, megestrol.
DB00306	DB00333	The barbiturate, talbutal, decreases the effect of methadone.
DB00306	DB00916	The barbiturate, talbutal, decreases the effect of metronidazole.
DB00306	DB01115	The barbiturate, talbutal, decreases the effect of the calcium channel blocker, nifedipine.
DB00306	DB00717	This product may cause a slight decrease of contraceptive effect
DB00306	DB01303	The barbiturate, talbutal, decreases the effect of oxtriphylline.
DB00306	DB00860	The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisolone.
DB00306	DB00635	The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisone.
DB00306	DB00908	The anticonvulsant, talbutal, decreases the effect of quinidine.
DB00306	DB00277	The barbiturate, talbutal, decreases the effect of theophylline.
DB00306	DB00620	The barbiturate, talbutal, may decrease the effect of the corticosteroid, triamcinolone.
DB00307	DB00872	Conivaptan may increase the serum concentration of CYP3A4 substrates such as bexarotene. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Consider therapy modification.
DB00307	DB00618	Tetracycline derivatives like demeclocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB00307	DB00304	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of desogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB00254	Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB00307	DB01395	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of drospirenone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB00823	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of ethynodiol diacetate it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB00294	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of etonogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB01241	Gemfibrozil may increase the serum concentration of bexarotene. This combination should be avoided.
DB00307	DB00367	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of levonorgestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB00603	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of medroxyprogesterone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB01017	Tetracycline derivatives like minocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB00307	DB06713	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norelgestromin, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB00717	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norethindrone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB00957	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norgestimate, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00307	DB00759	Tetracycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB00307	DB00560	Tigecycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri (intracranial hypertension) is of particular concern. Avoid this combination.
DB00307	DB00162	Bexarotene increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking bexarotene.
DB00308	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00308	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00308	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB00308	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00308	DB00243	Possible additive effect on QT prolongation
DB00308	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00308	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00308	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00308	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00308	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00308	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00308	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00308	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00308	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00309	DB00305	Potentially severe lung toxicity
DB00309	DB01369	This combination presents an increased risk of toxicity
DB00310	DB01078	Possible electrolyte variations and arrhythmias
DB00310	DB01119	Significant hyperglycemic effect
DB00310	DB01396	Possible electrolyte variations and arrhythmias
DB00310	DB00390	Possible electrolyte variations and arrhythmias
DB00310	DB00204	Increased risk of cardiotoxicity and arrythmias
DB00310	DB05039	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB00310	DB01356	The thiazide diuretic, chlorthalidone, may increase serum levels of lithium.
DB00310	DB00469	Tenoxicam may antagonize the blood pressure lowering effect of Chlorthalidone. Monitor for changes in the therapeutic effect of Chlorthalidone if Tenoxicam is initiated, discontinued or dose changed.
DB00310	DB00519	The thiazide diuretic, Chlorthalidone, may increase the hypotensive effect of Trandolapril. Chlorthalidone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00310	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00312	DB01223	The barbiturate, pentobarbital, decreases the effect of aminophylline.
DB00312	DB06769	Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine.
DB00312	DB00443	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00312	DB00882	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, clomifene.
DB00312	DB00286	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00312	DB00091	The barbiturate, pentobarbital, increases the effect of cyclosporine.
DB00312	DB01234	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB00312	DB00255	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00312	DB00254	The anticonvulsant, pentobarbital, decreases the effect of doxycycline.
DB00312	DB00783	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, estradiol.
DB00312	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00312	DB00977	This product may cause a slight decrease of contraceptive effect
DB00312	DB01023	The barbiturate, pentobarbital, decreases the effect of felodipine.
DB00312	DB00687	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00312	DB00158	Folic acid decreases the effect of anticonvulsant, pentobarbital.
DB00312	DB00317	The CYP3A4 inducer, pentobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00312	DB00400	The barbiturate, pentobarbital, decreases the effect of griseofulvin.
DB00312	DB00741	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00312	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00312	DB00603	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00312	DB00351	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, megestrol.
DB00312	DB00333	The barbiturate, pentobarbital, decreases the effect of methadone.
DB00312	DB00916	The barbiturate, pentobarbital, decreases the effect of metronidazole.
DB00312	DB01115	The barbiturate, pentobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB00312	DB00717	This product may cause a slight decrease of contraceptive effect
DB00312	DB01303	The barbiturate, pentobarbital, decreases the effect of oxtriphylline.
DB00312	DB00860	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00312	DB00635	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00312	DB00908	The anticonvulsant, pentobarbital, decreases the effect of quinidine.
DB00312	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00312	DB00976	Pentobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00312	DB06287	Pentobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00312	DB00277	The barbiturate, pentobarbital, decreases the effect of theophylline.
DB00312	DB00193	Pentobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00320	DB01295	Ischemia with risk of gangrene
DB00312	DB00656	The CYP3A4 inducer, Pentobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Pentobarbital is initiated, discontinued or dose changed.
DB00312	DB00620	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00312	DB00726	The barbiturate, Pentobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Pentobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00312	DB00427	The CNS depressants, Triprolidine and Pentobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00312	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00312	DB00661	Pentobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Pentobarbital is initiated, discontinued or dose changed.
DB00312	DB00682	Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed.
DB00313	DB00945	Acetylsalicylic acid increases the effect of valproic acid.
DB00313	DB06216	Valproate completely inhibits the glucuronidation of asenapine but does not effect its exposure. Dose adjustment is not necessary with concomitant therapy.
DB00313	DB00564	Decreases the effect of valproic acid
DB00313	DB01211	The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Clarithromycin is initiated, discontinued or dose changed.
DB00313	DB06210	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB00313	DB00199	The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed.
DB00313	DB00949	Felbamate, a CYP2C19 inhibitor, may decrease the metabolism of Valproic acid, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Felbamate is initiated, discontinued or dose changed.
DB00313	DB08909	Valproic acid may induce hyperammonemia. Monitor ammonia levels closely when use of valproic acid is necessary in UCD patients.
DB00313	DB06218	Valproic acid toxicity may occur at any time during the treatment course and should be considered in patients with acute changes in mentation, especially if there has been a recent change in antiepileptic therapy.
DB00313	DB00555	Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed.
DB00313	DB00186	Valproic acid may increase the serum concentration of Lorazepam by reducing Lorazepam metabolism. The Lorazepam dose should be reduced by 50% during concomitant therapy. Monitor for increased Lorazepam effects and toxicity.
DB00313	DB00393	Valproic acid increases the effect of nimodipine
DB00313	DB01045	Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed.
DB00313	DB06201	Valproic acid may increase the therapeutic/toxic effects of Rufinamide. Consider alternate therapy or monitor for changes in Rufinamide serum concentrations, therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. Decreases clearance of rufinamide and is a selective inhibitor of human carboxylesterase thus increasing serum concentrations.
DB00313	DB06207	Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely.
DB00313	DB00976	The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Telithromycin is initiated, discontinued or dose changed.
DB00313	DB00932	Tipranavir decreases the concentration of Valproic acid. Monitor Valproid acid efficacy.
DB00313	DB01080	Vigabatrin reduces serum concentrations of valproic acid by 8%.
DB00315	DB00918	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and almotriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB00321	Use of two serotonin modulators, such as zolmitriptan and amitriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00543	Use of two serotonin modulators, such as zolmitriptan and amoxapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB01200	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \r\nUse of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00490	Use of two serotonin modulators, such as zolmitriptan and buspirone, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00248	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \r\nUse of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00215	The use of two serotonin modulators, such as zolmitriptan and citalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00317	DB01341	The CYP3A4 inducer, dihydroquinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00315	DB01242	Use of two serotonin modulators, such as zolmitriptan and clomipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB03225	Use of two serotonin modulators, such as zolmitriptan and D-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB01151	Use of two serotonin modulators, such as zolmitriptan and desipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00315	DB00514	Use of two serotonin modulators, such as zolmitriptan and dextromethorphan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00320	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB01142	Use of two serotonin modulators, such as zolmitriptan and doxepin, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00476	Use of two serotonin modulators, such as zolmitriptan and duloxetine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00216	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and eletriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB01049	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergoloid mesylate, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB01253	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB00696	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB01175	Use of two serotonin modulators, such as zolmitriptan and escitalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00472	Use of two serotonin modulators, such as zolmitriptan and fluoxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00176	Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00998	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and frovatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB00614	The MAO inhibitor, furazolidine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing furazolidine are contraindicated.
DB00315	DB00458	Use of two serotonin modulators, such as zolmitriptan and imipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB01247	The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated.
DB00315	DB00150	Use of two serotonin modulators, such as zolmitriptan and L-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00601	The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated.
DB00315	DB01356	Use of two serotonin modulators, such as zolmitriptan and lithium, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00934	Use of two serotonin modulators, such as zolmitriptan and maprotiline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00353	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, methylergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB00247	Possible severe and prolonged vasoconstriction
DB00315	DB04896	Use of two serotonin modulators, such as zolmitriptan and milnacipran, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00370	Use of two serotonin modulators, such as zolmitriptan and mirtazapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB01171	The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated.
DB00315	DB00952	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and naratriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB01149	Use of two serotonin modulators, such as zolmitriptan and nafazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00540	Use of two serotonin modulators, such as zolmitriptan and nortriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00715	Use of two serotonin modulators, such as zolmitriptan and paroxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00317	DB00199	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB00320	DB00612	Ischemia with risk of gangrene
DB00315	DB01186	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, pergolide, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB00454	Use of two serotonin modulators, such as zolmitriptan and meperidine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00780	The MAO inhibitor, phenelzine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing phenelzine are contraindicated.
DB00315	DB01168	The MAO inhibitor, procarbazine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing procarbazine are contraindicated.
DB00315	DB01069	Use of two serotonin modulators, such as zolmitriptan and promethazine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00344	Use of two serotonin modulators, such as zolmitriptan and protriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB01367	The MAO inhibitor, rasagiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing rasagiline are contraindicated.
DB00315	DB00953	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and rizatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB00118	Use of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB01037	The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated.
DB00315	DB01104	Use of two serotonin modulators, such as zolmitriptan and sertraline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB01105	Use of sibutramine, which inhibits serotonin reuptake, and zolmitriptan, a serotonin 5-HT1D receptor agonist, may cause serotonin syndrome. Concomitant therapy is contraindicated.
DB00315	DB01323	Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00669	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and sumatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00315	DB06204	Use of two serotonin modulators, such as zolmitriptan and tapentadol, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00193	The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00752	The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated.
DB00315	DB00656	Use of two serotonin modulators, such as zolmitriptan and trazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00726	Use of two serotonin modulators, such as zolmitriptan and trimipramine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00315	DB00285	Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00316	DB01418	Acetaminophen may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if acetaminophen is initiated, discontinued or dose changed.
DB00316	DB01125	Acetaminophen increases the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if acetaminophen is initiated, discontinued or dose changed.
DB00316	DB00266	Acetaminophen may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if acetaminophen is initiated, discontinued or dose changed.
DB00316	DB06210	Eltrombopag increases acetaminophen levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00316	DB00619	Increased hepatic toxicity of both agents
DB00316	DB00951	Risk of hepatotoxicity
DB00316	DB06655	These agents may have decreased C max and a delayed T max during coadministration.
DB00316	DB00682	Acetaminophen increases the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if acetaminophen is initiated, discontinued or dose changed.
DB00317	DB01418	Gefitinib may increase the anticoagulant effect of acenocoumarol.
DB00317	DB01351	The CYP3A4 inducer, amobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01125	Gefitinib may increase the anticoagulant effect of anisindione.
DB00317	DB01352	The CYP3A4 inducer, aprobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00237	The CYP3A4 inducer, butabarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00241	The CYP3A4 inducer, butalbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01353	The CYP3A4 inducer, butethal, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00564	The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01211	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB00317	DB00266	Gefitinib may increase the anticoagulant effect of dicumarol.
DB00320	DB00195	Ischemia with risk of gangrene
DB00317	DB00754	The CYP3A4 inducer, ethotoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB06414	Gefitinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase gefitinib dosage, if clinically appropriate, and to monitor for gefitinib therapy for efficacy and toxicity.
DB00317	DB01320	The CYP3A4 inducer, fosphenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01354	The CYP3A4 inducer, heptabarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01355	The CYP3A4 inducer, hexobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01167	Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of gefitinib. Monitor for changes in the therapeutic and adverse effects of gefitinib if itraconazole is initiated, discontinued or dose changed.
DB00317	DB01026	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB00317	DB00532	The CYP3A4 inducer, mephenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00474	The CYP3A4 inducer, methohexital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00849	The CYP3A4 inducer, methylphenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00312	The CYP3A4 inducer, pentobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01174	The CYP3A4 inducer, phenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00252	The CYP3A4 inducer, phenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00794	The CYP3A4 inducer, primidone, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01346	The CYP3A4 inducer, quinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01045	Rifampin reduces levels and efficacy of gefitinib
DB00317	DB00503	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB00317	DB00418	The CYP3A4 inducer, secobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB01323	The CYP3A4 inducer, St. John's Wort, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00306	The CYP3A4 inducer, talbutal, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00317	DB00976	Telithromycin may reduce clearance of Gefitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Gefitinib if Telithromycin is initiated, discontinued or dose changed.
DB00317	DB01030	The BCRP/ABCG2 inhibitor, Gefitnib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Gefitinib is initiated, discontinued or dose changed.
DB00317	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00317	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of gefitinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of gefitinib if voriconazole is initiated, discontinued or dose changed.
DB00317	DB00682	Gefitinib may increase the anticoagulant effect of warfarin.
DB00318	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00318	DB00501	Cimetidine may decrease the therapeutic effect of codeine by decreasing its metabolism to its active metabolite, morphine. Monitor for changes in the therapeutic effect of codeine if cimetidine is initiated, discontinued or dose changed.
DB00318	DB01341	Quinidine decreases the analgesic effect of codeine
DB00318	DB00908	Quinidine decreases the analgesic effect of codeine
DB00318	DB01346	Quinidine decreases the analgesic effect of codeine
DB00318	DB00857	Terbinafine may decrease the efficacy of Codeine by inhibiting active metabolite production. Consider an alternate analgesic or monitor for effectiveness of Codeine.
DB00318	DB00427	The CNS depressants, Triprolidine and Codeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00319	DB00732	The agent increases the effect of the muscle relaxant
DB00319	DB00618	Possible antagonism of action
DB00319	DB01135	The agent increases the effect of the muscle relaxant
DB00319	DB00254	Possible antagonism of action
DB00319	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00319	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00319	DB00931	Possible antagonism of action
DB00319	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00319	DB01336	The agent increases the effect of the muscle relaxant
DB00319	DB01017	Possible antagonism of action
DB00319	DB01226	The agent increases the effect of the muscle relaxant
DB00319	DB00595	Possible antagonism of action
DB00319	DB01337	The agent increases the effect of the muscle relaxant
DB00319	DB01338	The agent increases the effect of the muscle relaxant
DB00319	DB00728	The agent increases the effect of the muscle relaxant
DB00319	DB01301	Possible antagonism of action
DB00319	DB00202	The agent increases the effect of the muscle relaxant
DB00319	DB00759	Possible antagonism of action
DB00319	DB01199	The agent increases the effect of the muscle relaxant
DB00319	DB01339	The agent increases the effect of the muscle relaxant
DB00320	DB01193	Ischemia with risk of gangrene
DB00320	DB00918	Possible severe and prolonged vasoconstriction
DB00320	DB00701	Amprenavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated.
DB00320	DB01612	Possible antagonism of action
DB00320	DB01072	Atazanavir may increase the therapeutic and adverse effects of dihydroergotamine.
DB00320	DB00335	Ischemia with risk of gangrene
DB00320	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00320	DB00521	Ischemia with risk of gangrene
DB00320	DB01136	Ischemia with risk of gangrene
DB00320	DB01211	Risk of ergotism and severe ischemia with this association
DB00320	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dihydroergotamine if delavirdine is initiated, discontinued or dose changed.
DB00320	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00320	DB00625	Efavirenze may increase the adverse/toxic effects of dihydroergotamine. Concomitant therapy is contraindicated.
DB00320	DB00216	Possible severe and prolonged vasoconstriction
DB00320	DB01613	Possible antagonism of action
DB00320	DB00199	Possible ergotism and severe ischemia with this combination
DB00320	DB00187	Ischemia with risk of gangrene
DB00320	DB00196	Possible ergotism and severe ischemia with this combination
DB00320	DB00472	Possible ergotism and severe ischemia with this combination
DB00320	DB00176	Possible ergotism and severe ischemia with this combination
DB00320	DB01319	Amprenavir increases the effect and toxicity of ergot derivative
DB00320	DB00998	Possible severe and prolonged vasoconstriction
DB00320	DB00224	Indinavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated.
DB00320	DB00883	Possible antagonism of action
DB00320	DB01020	Possible antagonism of action
DB00320	DB01167	Possible ergotism and severe ischemia with this combination
DB00320	DB01321	Possible ergotism and severe ischemia with this combination
DB00320	DB01026	Possible ergotism and severe ischemia with this combination
DB00320	DB00598	Ischemia with risk of gangrene
DB00320	DB00264	Ischemia with risk of gangrene
DB00320	DB01203	Ischemia with risk of gangrene.
DB00320	DB00952	Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated.
DB00320	DB01149	Possible ergotism and severe ischemia with this combination
DB00320	DB00220	Nelfinavir increases the effect and toxicity of ergot derivative
DB00320	DB00727	Possible antagonism of action
DB00320	DB01580	Ischemia with risk of gangrene
DB00320	DB01359	Ischemia with risk of gangrene
DB00320	DB06154	Possible antagonism of action
DB00320	DB00960	Ischemia with risk of gangrene
DB00320	DB01263	Contraindicated co-administration
DB00320	DB01297	Ischemia with risk of gangrene
DB00320	DB00571	Ischemia with risk of gangrene
DB00320	DB00503	The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.
DB00320	DB00953	Possible severe and prolonged vasoconstriction
DB00320	DB01232	The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.
DB00320	DB01105	Possible serotoninergic syndrome with this combination
DB00320	DB00489	Ischemia with risk of gangrene
DB00320	DB00669	Possible severe and prolonged vasoconstriction
DB00320	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00320	DB00976	Telithromycin may reduce clearance of Dihydroergotamine. Concomitant therapy is contraindicated.
DB00320	DB00373	Ischemia with risk of gangrene
DB00320	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Dihydroergotamine. Concomitant therapy is contraindicated.
DB00320	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00320	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00320	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00320	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00320	DB01361	Possible ergotism and severe ischemia with this combination
DB00320	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00320	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00320	DB00744	Possible ergotism and severe ischemia with this combination
DB00320	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00321	DB00488	Risk of severe hypotension
DB00321	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00321	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if atazanavir if initiated, discontinued or dose changed.
DB00321	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00321	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00328	DB01297	Risk of inhibition of renal prostaglandins
DB00321	DB00564	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if carbamazepine is initiated, discontinued or dose changed.
DB00321	DB00501	Cimetidine may increase the effect of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if cimetidine is initiated, discontinued or dose changed.
DB00321	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00321	DB00575	The tricyclic antidepressant, amitriptyline, decreases the effect of clonidine.
DB00321	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00321	DB01341	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, amitriptyline.
DB00321	DB00841	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dobutamine.
DB00321	DB00843	Possible antagonism of action
DB00321	DB00988	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dopamine.
DB00321	DB00476	Possible increase in the levels of this agent when used with duloxetine
DB00321	DB01363	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedra.
DB00321	DB01364	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedrine.
DB00321	DB00668	The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of epinephrine.
DB00321	DB01288	The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of fenoterol.
DB00321	DB00196	Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00321	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluoxetine is initiated, discontinued or dose changed.
DB00321	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed.
DB00321	DB00674	Possible antagonism of action
DB00321	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00321	DB01170	The tricyclic antidepressant, amitriptyline, decreases the effect of guanethidine.
DB00321	DB05039	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB00321	DB06704	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function
DB00321	DB01247	Possibility of severe adverse effects
DB00321	DB01064	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of isoproterenol.
DB00321	DB01026	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed.
DB00321	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00321	DB01365	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of mephentermine.
DB00321	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00321	DB00610	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of metaraminol.
DB00321	DB00723	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of methoxamine.
DB00321	DB01171	Possible severe adverse reaction with this combination
DB00321	DB00368	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of norepinephrine.
DB00321	DB00816	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of orciprenaline.
DB00321	DB00780	Possibility of severe adverse effects
DB00321	DB00388	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylephrine.
DB00321	DB00397	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylpropanolamine.
DB00321	DB01291	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pirbuterol.
DB00321	DB01366	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of procaterol.
DB00321	DB00852	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pseudoephedrine.
DB00321	DB00908	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00321	DB01346	Quinidine barbiturate increases the effect of tricyclic antidepressant, amitriptyline.
DB00321	DB01367	Possibility of severe adverse effects
DB00321	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifabutin is initiated, discontinued or dose changed.
DB00321	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed.
DB00321	DB00503	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ritonavir if initiated, discontinued or dose changed.
DB00321	DB00989	Possible antagonism of action
DB00321	DB01001	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of salbutamol.
DB00321	DB01105	Increased risk of CNS adverse effects
DB00321	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00321	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amitriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00321	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00321	DB00857	Terbinafine may reduce the metabolism and clearance of Amitryptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Terbinafine is initiated, discontinued or dose changed.
DB00321	DB00871	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of terbutaline.
DB00321	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00321	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00321	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00321	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00321	DB00193	Tramadol increases the risk of serotonin syndrome and seizures.
DB00321	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00321	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00321	DB00662	Trimethobenzamide and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00321	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00321	DB00427	Triprolidine and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00321	DB00209	Trospium and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00321	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00321	DB06684	Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved.
DB00321	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00321	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00321	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00321	DB00315	Use of two serotonin modulators, such as zolmitriptan and amitriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00321	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00322	DB00675	Floxuridine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Floxiridine is initiated, discontinued or dose changed.
DB00322	DB01124	Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Floxuridine is initiated, discontinued or dose changed.
DB00322	DB00214	Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Floxuridine is initiated, discontinued or dose changed.
DB00322	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00322	DB00440	The strong CYP2C9 inhibitor, Floxuridine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Floxuridine is initiated, discontinued or dose changed.
DB00322	DB00582	Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if floxuridine is initiated, discontinued or dose changed.
DB00322	DB00682	Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if floxuridine is initiated, discontinued or dose changed.
DB00322	DB00549	Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if floxuridine is initiated, discontinued or dose changed.
DB00323	DB00614	Tolcapone and Furazolidone decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00328	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00323	DB01247	Tolcapone and Isocarboxazid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB00601	Tolcapone and Linezolid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB01171	Tolcapone and Moclobemide decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB00780	Tolcapone and Phenelzine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB01168	Tolcapone and Procarbazine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB01367	Tolcapone and Rasagiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB01037	Tolcapone and Selegiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB00752	Tolcapone and Tranylcypromine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00323	DB00427	The CNS depressants, Triprolidine and Tolcapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00325	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00326	DB00685	Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction.
DB00327	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00327	DB06210	Increases levels of Hydromorphone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00327	DB00427	The CNS depressants, Triprolidine and Hydromorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00328	DB01193	Risk of inhibition of renal prostaglandins
DB00328	DB01418	The NSAID, indomethacin, may increase the anticoagulant effect of acenocoumarol.
DB00328	DB00630	Increased risk of gastric toxicity
DB00328	DB01125	The NSAID, indomethacin, may increase the anticoagulant effect of anisindione.
DB00328	DB00335	Risk of inhibition of renal prostaglandins
DB00328	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00328	DB00195	Nonsteroidal Anti-Inflammatory Agents such as indomethacin may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
DB00328	DB01295	Risk of inhibition of renal prostaglandins
DB00328	DB00612	Risk of inhibition of renal prostaglandins
DB00328	DB00887	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, bumetanide.
DB00328	DB00521	Risk of inhibition of renal prostaglandins
DB00328	DB01136	Risk of inhibition of renal prostaglandins
DB00328	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00328	DB00091	Monitor for nephrotoxicity
DB00328	DB00266	The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol.
DB00328	DB00861	Concomitant therapy with the two NSAIDs, indomethacin and diflunisal, increases the risk of NSAID-related adverse effects (e.g. GI ulcers, bleeds, increased blood pressure).
DB00328	DB06210	Increases levels of Indomethacin via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00328	DB00187	Risk of inhibition of renal prostaglandins
DB00328	DB00903	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid.
DB00328	DB00695	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide.
DB00328	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00328	DB00040	Monitor therapy due to diminished therapeutic effect of glucagon.
DB00328	DB00598	Risk of inhibition of renal prostaglandins
DB00328	DB01356	The NSAID, indomethacin, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00328	DB00678	Indomethacin decreases the effect of losartan
DB00328	DB00563	The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00328	DB00264	Risk of inhibition of renal prostaglandins
DB00328	DB01203	Risk of inhibition of renal prostaglandins
DB00328	DB01580	Risk of inhibition of renal prostaglandins
DB00328	DB01359	Risk of inhibition of renal prostaglandins
DB00328	DB00960	Risk of inhibition of renal prostaglandins
DB00328	DB01032	Probenecid increases the effect/toxicity of indomethacin
DB00328	DB00571	Risk of inhibition of renal prostaglandins
DB00328	DB00489	Risk of inhibition of renal prostaglandins
DB00328	DB00675	Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed.
DB00328	DB00966	Concomitant use of Telmisartan and Indomethacin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00328	DB00373	Risk of inhibition of renal prostaglandins
DB00328	DB01124	Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed.
DB00328	DB00214	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, torasemide.
DB00328	DB00519	The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed.
DB00328	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy.
DB00328	DB00384	Risk of acute renal impairment with this combination
DB00328	DB00440	The strong CYP2C9 inhibitor, Indomethacine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Indomethacine is initiated, discontinued or dose changed.
DB00328	DB00582	Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if indomethacin is initiated, discontinued or dose changed.
DB00328	DB00682	Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed.
DB00331	DB00501	Cimetidine may increase the therapeutic and adverse effects of metformin by increasing its serum concentration. Consider alternate therapy.
DB00331	DB01296	Possible hyperglycemia
DB00331	DB00052	Somatropin may antagonize the hypoglycemic effect of metformin. Monitor for changes in fasting and postprandial blood sugars.
DB00332	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ipratropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00332	DB00662	Trimethobenzamide and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00332	DB00427	Triprolidine and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00332	DB00209	Trospium and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00333	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00333	DB01351	The barbiturate, amobarbital, decreases the effect of methadone.
DB00333	DB00701	The protease inhibitor, amprenavir, may decrease the effect of methadone.
DB00333	DB01352	The barbiturate, aprobarbital, decreases the effect of methadone.
DB00333	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00333	DB00237	The barbiturate, butabarbital, decreases the effect of methadone.
DB00333	DB00241	The barbiturate, butalbital, decreases the effect of methadone.
DB00333	DB01353	The barbiturate, butethal, decreases the effect of methadone.
DB00333	DB00564	Carbamazepine may decrease the serum level of methadone. Monitor for changes in the therapeutic and adverse effects of methadone if carbamazepine is initiated, discontinued or dose changed.
DB00333	DB00501	Cimetidine, a moderate CYP3A4 inhibitor, may increase the serum concentration of metahdone, a CYP3A4 substrate. Monitor for changes in the therapeutic and adverse effects of methadone if cimetidine is initiatied, discontinued or dose changed.
DB00333	DB01341	The barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone.
DB00333	DB00625	Efavirenz may decrease the serum concentration of methadone by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of methadone if efavirenz is initiated, discontinued or dose changed.
DB00333	DB06210	Increases levels of Methadone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00333	DB00754	The hydantoin decreases the effect of methadone
DB00333	DB06414	Methadone, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor methadone therapy for decrease effectiveness and symptoms of withdrawal.
DB00333	DB00176	Fluvoxamine increases the effect and toxicity of methadone
DB00333	DB01319	The protease inhibitor, fosamprenavir, may decrease the effect of methadone.
DB00333	DB01320	The hydantoin decreases the effect of methadone
DB00333	DB01354	The barbiturate, heptabarbital, decreases the effect of methadone.
DB00333	DB01355	The barbiturate, hexobarbital, decreases the effect of methadone.
DB00333	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00333	DB00532	The hydantoin decreases the effect of methadone
DB00333	DB00474	The barbiturate, methohexital, decreases the effect of methadone.
DB00333	DB00849	The barbiturate, methylphenobarbital, decreases the effect of methadone.
DB00333	DB00220	Nelfinavir decreases the effect of methadone
DB00333	DB00238	The antiretroviral agent decreases the effect of methadone
DB00333	DB00312	The barbiturate, pentobarbital, decreases the effect of methadone.
DB00333	DB01174	The barbiturate, phenobarbital, decreases the effect of methadone.
DB00333	DB00252	The hydantoin decreases the effect of methadone
DB00333	DB00794	The barbiturate, primidone, decreases the effect of methadone.
DB00333	DB01346	The barbiturate, quinidine barbiturate, decreases the effect of methadone.
DB00333	DB00615	The rifamycin decreases the effect of methadone
DB00333	DB01045	The rifamycin decreases the effect of methadone
DB00333	DB01201	The rifamycin decreases the effect of methadone
DB00333	DB08864	Dose adjustment and clinical monitoring of rilpivirine may be necessary if coadministered with methadone.
DB00333	DB00503	The protease inhibitor, ritonavir, may decrease the effect of methadone.
DB00333	DB00418	The barbiturate, secobarbital, decreases the effect of methadone.
DB00333	DB01323	St. John's Wort decreases levels/effect of methadone
DB00333	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00333	DB00306	The barbiturate, talbutal, decreases the effect of methadone.
DB00333	DB00675	Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00333	DB00706	Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed.
DB00333	DB05521	Telaprevir decreases exposure of methane by 30% however opioid withdrawal was not observed in patients.
DB00333	DB00976	Telithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed.
DB00333	DB00599	Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur.
DB00333	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00333	DB00932	Tipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal.
DB00333	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00333	DB00193	Methadone may decrease the effect of Tramadol by decreasing active metabolite production.
DB00333	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00333	DB00427	The CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00333	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed.
DB00333	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00333	DB00495	Methadone increases the effect and toxicity of zidovudine
DB00333	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00333	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00334	DB00843	Possible antagonism of action
DB00334	DB00176	Fluvoxamine increases the effect and toxicity of olanzapine
DB00334	DB00674	Possible antagonism of action
DB00334	DB00503	Ritonavir decreases the effect of olanzapine
DB00334	DB00989	Possible antagonism of action
DB00334	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Olanzapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00334	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00334	DB00662	Trimethobenzamide and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00334	DB00427	Triprolidine and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00334	DB00209	Trospium and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00335	DB00414	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB00415	Ampicillin decreases bioavailability of atenolol
DB00335	DB00672	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB00575	Increased hypertension when clonidine stopped
DB00335	DB00320	Ischemia with risk of gangrene
DB00335	DB00343	Increased risk of bradycardia
DB00335	DB00280	The beta-blocker, atenolol, may increase the toxicity of disopyramide.
DB00335	DB00668	Hypertension, then bradycardia
DB00335	DB01253	Ischmeia with risk of gangrene
DB00335	DB00696	Ischemia with risk of gangrene
DB00335	DB01288	Antagonism
DB00335	DB00983	Antagonism
DB00335	DB01120	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01067	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01289	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01016	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01382	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01050	Risk of inhibition of renal prostaglandins
DB00335	DB05039	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB00335	DB00328	Risk of inhibition of renal prostaglandins
DB00335	DB01306	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01307	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB00047	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01309	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB00046	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01064	Antagonism
DB00335	DB00281	The beta-blocker, atenolol, may increase the effect and toxicity of lidocaine.
DB00335	DB00247	Ischemia with risk of gangrene
DB00335	DB00816	Antagonism
DB00335	DB00236	Antagonism
DB00335	DB01291	Antagonism
DB00335	DB00554	Risk of inhibition of renal prostaglandins
DB00335	DB00457	Risk of hypotension at the beginning of therapy
DB00335	DB01366	Antagonism
DB00335	DB00912	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01001	Antagonism
DB00335	DB00938	Antagonism
DB00335	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00335	DB00871	Antagonism
DB00335	DB00839	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB01124	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00335	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00335	DB00661	Increased effect of both drugs
DB00337	DB01281	Avoid combination due to enhanced adverse effects of immunosuppressive agents.
DB00337	DB05773	Avoid combination due to the increase in immunosuppressant side effects.
DB00337	DB00098	Avoid combination due to enhanced immunosuppressive effects and increased risk of infections.
DB00337	DB06681	Avoid combination due to enhanced effects of immunosuppressants.
DB00337	DB08879	Avoid combination due to enhanced toxic effects of immunosuppressants.
DB00337	DB00290	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants like bleomycin. This combination is contraindicated
DB00337	DB08870	Avoid combination due to the potential enhancement of toxic effects of immunosuppressants
DB00337	DB06168	Avoid combination due the potential increase in immunosuppressant adverse effects.
DB00337	DB00958	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00337	DB00262	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00337	DB00291	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as chlorambucil. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00337	DB00515	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cisplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00337	DB00242	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cladribine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00337	DB00631	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00337	DB00005	Avoid combination due to enhanced immunosuppressive effects.
DB00337	DB00056	Avoid combination due to toxic effects of immunosuppressants.
DB00337	DB05259	Avoid combination due to enhanced immunosuppressive effects.
DB00337	DB06674	Avoid combination due to enhancement of side effects from immunosuppressants.
DB00337	DB04865	Avoid combination as there is potential to increase immunosuppressant adverse effects.
DB00337	DB00078	Avoid combination due to increased immunosuppressive effects.
DB00337	DB00065	Pimecrolimus enhances the adverse effects of immune suppressants thus the combination should be avoided.
DB00337	DB08935	Avoid combination due to enhanced immunosuppressive effects.
DB00337	DB00043	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB00337	DB01229	Avoid combination due to the enhancement of adverse effects of immunosuppressants.
DB00337	DB00059	Avoid combination because pimecrolimus enhances the adverse effects of immunosuppressants.
DB00337	DB08880	Avoid combination due to the increased toxic effects of immunosuppressants.
DB00337	DB08895	Avoid combination due to the potential increase in immunosuppressant associated adverse effects.
DB00338	DB00404	Omeprazole may increase the effect of the benzodiazepine, alprazolam.
DB00338	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00338	DB06237	Nineteen healthy male volunteers received a single 40 omeprazole delayed-release capsule once daily for 8 days (Days 1-8), and a single 200 mg avanafil on Day 8. Twelve hour pharmacokinetics of omeprazole on Days 7 and 8 were compared. Co-administration with avanafil resulted in an approximate 5.9% increase in AUC0-inf and 8.6% increase in Cmax of omeprazole.
DB00338	DB06769	Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion.
DB00338	DB01066	Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB00338	DB00475	Omeprazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00338	DB01166	Omeprazole increases the effect of cilostazol
DB00338	DB01068	Omeprazole may increase the effect of the benzodiazepine, clonazepam.
DB00338	DB00758	Omeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness.
DB00338	DB00628	Omeprazole may increase the effect of the benzodiazepine, clorazepate.
DB00338	DB00091	Omeprazole increases the effect and toxicity of cyclosporine
DB00338	DB01254	Omeprazole may decrease the serum level of dasatinib.
DB00338	DB00829	Omeprazole may increase the effect of the benzodiazepine, diazepam.
DB00338	DB00280	The beta-blocker increases toxicity of disopyramide
DB00338	DB00467	Omeprazole may decrease the absorption of enoxacin.
DB00338	DB01215	Omeprazole may increase the effect of the benzodiazepine, estazolam.
DB00338	DB00754	Omeprazole increases the effect of hydantoin
DB00338	DB00690	Omeprazole may increase the effect of the benzodiazepine, flurazepam.
DB00338	DB01320	Omeprazole increases the effect of hydantoin
DB00338	DB00801	Omeprazole may increase the effect of the benzodiazepine, halazepam.
DB00338	DB00224	Omeprazole decreases the absorption of indinavir
DB00338	DB01167	The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole.
DB00338	DB01587	Omeprazole may increase the effect of the benzodiazepine, ketazolam.
DB00338	DB01026	The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.
DB00338	DB00532	Omeprazole increases the effect of hydantoin
DB00338	DB00563	Omeprazole increases the levels of methotrexate
DB00338	DB00683	Omeprazole may increase the effect of the benzodiazepine, midazolam.
DB00338	DB04938	Moderate CYP2C19 inhibitors may increase levels of ospemifene. Monitor concomitant therapy closely.
DB00338	DB00252	Omeprazole increases the effect of hydantoin
DB00338	DB01588	Omeprazole may increase the effect of the benzodiazepine, prazepam.
DB00338	DB01589	Omeprazole may increase the effect of the benzodiazepine, quazepam.
DB00338	DB08864	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB00338	DB01656	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB00338	DB01323	St. John's Wort decreases the levels/effects of omeprazole
DB00338	DB00864	Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered.
DB00338	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response.
DB00338	DB06273	Omeprazole is a CYP2C19 and CYP3A4 substrate. Exposure of omeprazole decreases following administration of tocilizumab..
DB00338	DB00897	Omeprazole may increase the effect of the benzodiazepine, triazolam.
DB00338	DB00726	The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed.
DB00338	DB08828	Vismodegib serum concentrations may be decreased by proton pump inhibitors such as omeprazole.
DB00338	DB00582	Voriconazole increases the effect and toxicity of omeprazole
DB00339	DB00091	Pyrazinamide decreases the effect of cyclosporine
DB00342	DB01063	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01246	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00321	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00543	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00701	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00673	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00501	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01242	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00705	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01151	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00343	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01142	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00625	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01195	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00196	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00472	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00623	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00176	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01319	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00458	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00224	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01167	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01026	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00902	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01403	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00379	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01388	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01149	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00220	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00622	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00540	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00850	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01263	Contraindicated co-administration
DB00342	DB01035	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00433	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00420	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01069	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01182	Increased risk of cardiotoxicity and arrhythmias.
DB00342	DB01608	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00777	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00344	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00468	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01369	This combination presents an increased risk of toxicity
DB00342	DB00503	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01232	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00342	DB00976	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00372	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Terfenadine. Concomitant therapy is contraindicated.
DB00342	DB01056	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00831	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00508	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00726	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB01361	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00661	Increased risk of cardiotoxicity and arrhythmias
DB00342	DB00582	Increased risk of cardiotoxicity and arrhythmias
DB00343	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00343	DB00381	Diltiazem may increase the serum concentration of amlodipine. Concomitant therapy will result in additive hypotensive effects. Monitor for changes in the hypotensive effect of amlodipine if diltiazem is initiated, discontinued or dose changed.
DB00343	DB00673	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00343	DB01072	Atazanavir may increase the therapeutic and adverse effects of diltiazem resulting in increased risk of AV block. Consider alternate therapy, a 50% dose reduction of diltiazem and monitor for changes in the therapeutic and adverse effects of diltiazem if atazanavir is initiated, discontinued or dose changed.
DB00343	DB00335	Increased risk of bradycardia
DB00343	DB01076	Diltiazem may increase the serum concentration of atorvastatin. Atorvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00343	DB01558	Diltiazem may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if diltiazem is initiated, discontinued or dose changed.
DB00343	DB00490	The calcium channel blocker, diltiazem, increases the effect and toxicity of buspirone.
DB00343	DB00564	Carbamazepine may decrease the serum concentration of diltiazem by increasing its metabolism. Diltiazem may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if dosages are changed.
DB00343	DB00439	Diltiazem may increase the serum concentration of cerivastatin. Cerivastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00343	DB01166	Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cilostazol if diltiazem is initiated, discontinued or dose changed.
DB00343	DB00604	Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cisapride by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cisapride if diltiazem is initiated, discontinued or dose changed.
DB00343	DB00091	Diltiazem may increase the effect and toxicity of cyclosporine.
DB00343	DB01341	Increases the effect and toxicity of quinidine
DB00343	DB04855	Diltiazem is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker.
DB00343	DB06210	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB00343	DB00227	Diltiazem may increase the serum concentration of lovastatin. Lovastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00343	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00343	DB00264	Increased risk of bradycardia
DB00343	DB00683	The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00343	DB00680	Increased effect/toxicity of moricizine
DB00343	DB00960	Increased risk of bradycardia
DB00343	DB00571	Increased risk of bradycardia
DB00343	DB00908	Diltiazem may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if diltiazem is initiated, discontinued or dose changed.
DB00343	DB01346	Increases the effect and toxicity of quinidine
DB00343	DB01369	This combination presents an increased risk of toxicity
DB00343	DB00243	Diltiazem may increase the serum concentration of ranolazine. Consider alternate therapy or limit ranolazine dose to 500 mg twice daily and monitor for changes in the therapeutic and adverse effects if diltiazem is initiated, discontinued or dose changed.
DB00343	DB01045	Rifampin decreases levels of diltiazem
DB00343	DB00503	Ritonavir increases diltiazem levels
DB00343	DB06335	Diltiazem is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 109%. Exposure of the active metabolite decreased by 34%. However, these changes in pharmacokinetics are not clinical significant.
DB00343	DB06207	Moderate inhibitors of CYP3A4 may increase levels of silodosin. Monitor concomitant therapy closely.
DB00343	DB00641	Diltiazem may increase the serum concentration of simvastatin. Simvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00343	DB00877	Increases the effect and toxicity of sirolimus
DB00343	DB00864	Diltiazem may increase the serum concentration of tacrolimus by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tacrolimus if diltiazem therapy is initiated, discontinued or dose changed.
DB00343	DB00706	Diltiazem, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diltiazem is initiated, discontinued, or dose changed.
DB00343	DB00976	Telithromycin may reduce clearance of Diltiazem. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diltiazem if Telithromycin is initiated, discontinued or dose changed.
DB00343	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00343	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Diltiazem, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Diltiazem if Thiopental is initiated, discontinued or dose changed.
DB00343	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00343	DB00373	Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block.
DB00343	DB00932	Tipranavir, co-administered with Ritonavir, may alter the concentration of Diltiazem. Monitor for efficacy and adverse/toxic effects of Diltiazem.
DB00343	DB01036	Diltiazem may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00343	DB06212	Diltiazem is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
DB00343	DB00193	Diltiazem may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00343	DB00656	The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed.
DB00343	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00343	DB00897	The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00343	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of diltiazem by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of diltiazem if voriconazole is initiated, discontinued or dose changed.
DB00344	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00344	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if atazanavir if initiated, discontinued or dose changed.
DB00344	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00344	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00344	DB00501	Cimetidine may increase the effect of tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed.
DB00344	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00344	DB00575	The tricyclic antidepressant, protriptyline, decreases the effect of clonidine.
DB00344	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00344	DB00843	Possible antagonism of action
DB00344	DB00668	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of epinephrine.
DB00344	DB01288	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of fenoterol.
DB00344	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluoxetine is initiated, discontinued or dose changed.
DB00346	DB00706	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Alfuzosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00353	DB00199	Possible ergotism and severe ischemia with this combination
DB00344	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed.
DB00344	DB00674	Possible antagonism of action
DB00344	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00344	DB01170	The tricyclic antidepressant, protriptyline, decreases the effect of guanethidine.
DB00344	DB01247	Possibility of severe adverse effects
DB00344	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00344	DB01171	Possible severe adverse reaction with this combination
DB00344	DB00816	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of orciprenaline.
DB00344	DB00780	Possibility of severe adverse effects
DB00344	DB00388	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylephrine.
DB00344	DB00397	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylpropanolamine.
DB00344	DB00852	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of pseudoephedrine.
DB00344	DB00908	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00344	DB01367	Possibility of severe adverse effects
DB00344	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifabutin is initiated, discontinued or dose changed.
DB00344	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifampin is initiated, discontinued or dose changed.
DB00344	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Protriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00344	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00344	DB00857	Terbinafine may reduce the metabolism and clearance of Protriptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Protriptyline if Terbinafine is initiated, discontinued or dose changed.
DB00344	DB00871	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of terbutaline.
DB00344	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00344	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00344	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00344	DB00193	Tramadol increases the risk of serotonin syndrome and seizures.
DB00344	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00344	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00344	DB00662	Trimethobenzamide and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00344	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00344	DB00427	Triprolidine and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00344	DB00209	Trospium and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00344	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00344	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00344	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00344	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00344	DB00315	Use of two serotonin modulators, such as zolmitriptan and protriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00344	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00346	DB09026	Monitor therapy due to enhanced hypotensive effect of aliskiren.
DB00346	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00346	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. Concomitant use of alfuzosin with a strong CYP3A4 inhibitor is a listed contraindication according to alfuzosin prescribing information.
DB00346	DB01167	The antifungal increases the effect of alfuzosin
DB00346	DB01026	The antifungal increases the effect of alfuzosin
DB00346	DB00503	Ritonavir increases the effect/toxicity of alfuzosin
DB00346	DB00820	Tadalafil may enhance the hypotensive effect of Alfusozin. Monitor for hypotension during concomitant therapy.
DB00346	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00346	DB00976	Telithromycin may reduce clearance of Alfuzosin. Consider alternate therapy.
DB00346	DB01162	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.
DB00346	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Alfuzosin, may occur. Monitor for hypotension during concomitant therapy.
DB00346	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfuzosin by decreasing its metabolism. Use of alfuzosin with strong CYP3A4 inhibitors is contraindicated by the manufacturer.
DB00347	DB00822	Disulfiram, a strong CYP2E1 inhibitor, may decrease the metabolism and clearance of Trimethadione, a CYP2E1 substrate. Consider alternate therapy or monitor for changes in Trimethadione therapeutic and adverse effects if Disulfiram is initiated, discontinued or dose changed.
DB00347	DB00427	The CNS depressants, Triprolidine and Trimethadione, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00349	DB06626	Clobazam decreases levels by affecting CYP3A4 metabolism. Consider alternate therapy.
DB00349	DB00363	Increased risk of toxicity
DB00349	DB01322	Kava may increase the effect of the benzodiazepine, clobazam.
DB00349	DB01026	Clobazam may increase levels by affecting CYP2C19 metabolism. Interaction is significant so monitor closely. Dose adjustment may be necessary.
DB00349	DB00683	Clobazam decrease the Cmax and AUC of midazolam by approximately 25% of both and increases the Cmax and AUC of its metabolite. Dose adjustment is not necessary.
DB00349	DB05271	Concomitant therapy may potentiate adverse CNS effects such as increased sedation or respiratory depression. Monitor therapy closely.
DB00349	DB00976	Telithromycin may reduce clearance of Clobazam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clobazam if Telithromycin is initiated, discontinued or dose changed.
DB00349	DB00208	Ticlopidine may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for adverse/toxic effects of Clobazam if Ticlopidine is initiated, discontinued or dose changed.
DB00349	DB00932	Tipranavir may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for Clobazam toxic effects if Tipranavir is initiated or dose increased.
DB00349	DB00427	The CNS depressants, Triprolidine and Clobazam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00349	DB00582	Voriconazole may increase the serum concentration of clobazam by decreasing its metabolism. Monitor for clobazam toxicity if voriconazole is initiated or dose increased.
DB00350	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00351	DB01351	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB01352	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB00237	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB00241	The enzyme inducer, butalbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB01353	The enzyme inducer, butethal, decreases the effect of the hormone agent, megestrol.
DB00351	DB00754	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, megestrol.
DB00351	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, megestrol.
DB00351	DB00400	The enzyme inducer, griseofulvin, may decrease the effect of the hormone, megestrol.
DB00351	DB01354	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB01355	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB00532	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, megestrol.
DB00351	DB00474	The enzyme inducer, methohexital, decreases the effect of the hormone agent, megestrol.
DB00351	DB00849	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB00312	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB01174	The enzyme inducer, phenobarbital, may decrease the effect of the hormone, megestrol.
DB00351	DB00252	The enzyme inducer, phenytoin, may decrease the effect of megestrol.
DB00351	DB00794	The enzyme inducer, primidone, may decrease the effect of the hormone, megestrol.
DB00351	DB00418	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, megestrol.
DB00351	DB00306	The enzyme inducer, talbutal, decreases the effect of the hormone agent, megestrol.
DB00352	DB00233	Aminosalicylic acid may increase the toxicity of thiopurine, thioguanine.
DB00352	DB01008	Busulfan increases the hepatoxicity of Thioguanine during long-term concomitant therapy.
DB00352	DB01033	Complete cross resistance may occur.
DB00352	DB00244	Mesalazine may increase the toxicity of thiopurine, thioguanine.
DB00352	DB00108	The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00352	DB01250	Olsalazine may increase the toxicity of thiopurine, thioguanine.
DB00352	DB00795	Sulfasalazine may increase the toxicity of thiopurine, thioguanine.
DB00352	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00353	DB00918	Possible severe and prolonged vasoconstriction
DB00353	DB01072	Increases the effect and toxicity of ergot derivative
DB00353	DB00705	The antiretroviral agent may increase the ergot derivative toxicity
DB00353	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00353	DB00625	The antiretroviral agent may increase the ergot derivative toxicity
DB00353	DB00216	Possible severe and prolonged vasoconstriction
DB00353	DB00668	Possible marked increase of arterial pressure
DB00353	DB00998	Possible severe and prolonged vasoconstriction
DB00353	DB00883	Possible antagonism of action
DB00353	DB01020	Possible antagonism of action
DB00353	DB00952	Possible severe and prolonged vasocontriction
DB00353	DB00727	Possible antagonism of action
DB00353	DB06154	Possible antagonism of action
DB00353	DB00388	Possible marked increase of arterial pressure
DB00353	DB00976	Telithromycin may reduce clearance of Methylergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methylergonovine if Telithromycin is initiated, discontinued or dose changed.
DB00353	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Methylergonovine. Concomitant therapy is contraindicated.
DB00353	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00353	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00353	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00353	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00353	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00353	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methylergonovine  by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00353	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, methylergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00355	DB00618	Possible antagonism of action
DB00355	DB00254	Possible antagonism of action
DB00355	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00355	DB01017	Possible antagonism of action
DB00355	DB00759	Possible antagonism of action
DB00356	DB00822	Disulfiram may increase the serum level of chlorzoxazone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorzoxazone if diltiazem is initiated, discontinued or dose changed.
DB00356	DB00427	The CNS depressants, Triprolidine and Chlorzoxazone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00357	DB01418	Aminoglutethimide may decrease the anticoagulant effect of acenocoumarol.
DB00357	DB01125	Aminoglutethimide may decrease the anticoagulant effect of anisindione.
DB00357	DB01234	Aminoglutethimide may decrease the effect of dexamethasone.
DB00357	DB00266	Aminoglutethimide may decrease the anticoagulant effect of dicumarol.
DB00357	DB00675	Aminoglutethimide may increase Tamoxifen clearance decreasing its therapeutic effect. Consider alternate therapy or monitor for changes in Tamoxifen effects when Aminoglutethimide is initiated, discontinued or dose changed.
DB00357	DB00976	Aminoglutethimide may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00357	DB06287	Aminoglutethimide may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00357	DB00193	Aminoglutethimide may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00357	DB00656	The CYP3A4 inducer, Aminoglutethimide, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aminoglutethimide is initiated, discontinued or dose changed.
DB00357	DB00682	Aminoglutethimide may decrease the anticoagulant effect of warfarin by increasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if aminoglutethimide is initiated, discontinued or dose changed.
DB00358	DB01418	Mefloquine may increase the anticoagulant effect of acenocoumarol.
DB00358	DB01125	Mefloquine may increase the anticoagulant effect of anisindione.
DB00358	DB06697	Mefloquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB00358	DB00266	Mefloquine may increase the anticoagulant effect of dicumarol.
DB00358	DB01218	Increased risk of cardiac toxicity
DB00358	DB06708	Mefloquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB00358	DB01045	Rifampin lowers mefloquine levels
DB00358	DB00503	Mefloquine decreases the effect of ritonavir
DB00358	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00358	DB00976	Telithromycin may reduce clearance of Mefloquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mefloquine if Telithromycin is initiated, discontinued or dose changed.
DB00358	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00358	DB00906	Mefloquine increases the risk of seizure and is contraindicated in persons with a history of convulsions. Possible reduction in the therapeutic effect of Tiagabine when used for other indications may also occur.
DB00358	DB01030	The p-glycoprotein inhibitor, Mefloquine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00358	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00358	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00358	DB01080	Mefloquine may decrease the serum concentration of Vigabatrin. This may increase the risk of seizure in patients receiving Vigabatrin to prevent seizures. Consider alternate therapy or monitor for changes in Vigabatrin serum concentration, therapeutic or adverse effects if Mefloquin is initiated, discontinued or dose changed.
DB00363	DB01594	Increased risk of toxicity
DB00363	DB00537	Ciprofloxacin may increase clozapine serum levels
DB00358	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mefloquine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of mefloquine if voriconazole is initiated, discontinued or dose changed.
DB00358	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00358	DB00682	Mefloquine may increase the anticoagulant effect of warfarin.
DB00358	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00358	DB00909	Mefloquine may decrease the serum concentration and therapeutic effect of zonisamide. Concomitant therapy is contraindicated in patients with history of convulsions.
DB00358	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00359	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00359	DB00091	The sulfonamide decreases the effect of cyclosporine
DB00359	DB01320	The sulfonamide increases the effect of hydantoin
DB00359	DB06146	Possible crystallization of urates with this combination
DB00359	DB00563	The sulfamide increases the toxicity of methotrexate
DB00359	DB00252	The sulfonamide increases the effect of hydantoin
DB00359	DB00675	Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed.
DB00359	DB01124	Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
DB00359	DB00214	Sulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfadiazine is initiated, discontinued or dose changed.
DB00359	DB00440	The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed.
DB00359	DB00682	Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed.
DB00359	DB00549	Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed.
DB00361	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Amprenavir is initiated, discontinued or dose changed.
DB00361	DB00673	Aprepitant may change levels of the chemotherapy agent, vinorelbine.
DB00361	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Atazanavir is initiated, discontinued or dose changed.
DB00361	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00361	DB01211	Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Clarithromycin is initiated, discontinued or dose changed.
DB00361	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Conivaptan is initiated, discontinued or dose changed.
DB00361	DB01264	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Darunavir is initiated, discontinued or dose changed.
DB00361	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Delavirdine is initiated, discontinued or dose changed.
DB00361	DB00954	Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Dirithromycin is initiated, discontinued or dose changed.
DB00361	DB00199	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Erythromycin is initiated, discontinued or dose changed.
DB00361	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Fosamprenavir is initiated, discontinued or dose changed.
DB00361	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Imatinib is initiated, discontinued or dose changed.
DB00361	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Indinavir is initiated, discontinued or dose changed.
DB00361	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Isoniazid is initiated, discontinued or dose changed.
DB00361	DB01167	Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Itraconazole is initiated, discontinued or dose changed.
DB00361	DB01026	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed.
DB00361	DB01097	Vinorelbine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinorelbine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.
DB00361	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Lopinavir is initiated, discontinued or dose changed.
DB00361	DB01110	Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Miconazole is initiated, discontinued or dose changed.
DB00361	DB00108	Concomitant Vinorelbine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
DB00361	DB01149	Nafazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nefazodone is initiated, discontinued or dose changed.
DB00361	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nelfinavir is initiated, discontinued or dose changed.
DB00361	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nicardipine is initiated, discontinued or dose changed.
DB00361	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Posaconazole is initiated, discontinued or dose changed.
DB00361	DB00908	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Quinidine is initiated, discontinued or dose changed.
DB00361	DB01369	This combination presents an increased risk of toxicity
DB00361	DB00503	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ritonavir is initiated, discontinued or dose changed.
DB00361	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Saquinavir is initiated, discontinued or dose changed.
DB00361	DB06145	Spiramycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Spiramycine is initiated, discontinued or dose changed.
DB00361	DB00976	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Telithromycin is initiated, discontinued or dose changed.
DB00361	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00361	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Voriconazole is initiated, discontinued or dose changed.
DB00363	DB05773	Avoid combination due to the increased potential for agranulocytosis.
DB00363	DB08885	Avoid combination with systemic aflibercept due to enhanced adverse effects of clozapine, including the risk of agranulocytosis
DB00363	DB00041	Avoid combination due to enhanced adverse effects of clozapine, especially the risk of agranulocytosis.
DB00363	DB00404	Increased risk of toxicity
DB00363	DB00112	Avoid combination due to increased adverse effects of clozapine, especially the risk of agranulocytosis.
DB00363	DB01558	Bromazepam may increase the adverse effects of clozapine. Consider alternate therapy or a reduction in the bromazepam dose. Monitor for respiratory depression and hypotension if concomitant therapy is initiated.
DB00363	DB00201	Caffeine increases the effect and toxicity of clozapine
DB00363	DB00564	Carbamazepine may decrease the serum concentration of clozapine by increasing its metabolism. Concomitant therapy should also be avoided due to increased risk of bone marrow suppression. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if carbamazepine is initiated, discontinued or dose changed.
DB00363	DB00475	Increased risk of toxicity
DB00363	DB00501	Cimetidine may increase the serum concentratin of clozapine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if cimetidine is initiated, discontinued or dose changed.
DB00363	DB00215	The antidepressant increases the effect of clozapine
DB00363	DB00349	Increased risk of toxicity
DB00363	DB01068	Increased risk of toxicity
DB00363	DB00628	Increased risk of toxicity
DB00363	DB00829	Increased risk of toxicity
DB00363	DB01551	CNS depressants may enhance the adverse effects and toxicity of other CNS depressants. It is recommended to monitor therapy.
DB00363	DB00843	Possible antagonism of action
DB00363	DB00199	Erythromycin increases the effect of clozapine
DB00363	DB01215	Increased risk of toxicity
DB00363	DB00754	Hydantoin decreases the effect of clozapine
DB00363	DB01544	Increased risk of toxicity
DB00363	DB00472	The antidepressant increases the effect of clozapine
DB00363	DB00690	Increased risk of toxicity
DB00363	DB00176	The antidepressant increases the effect of clozapine
DB00363	DB01320	Hydantoin decreases the effect of clozapine
DB00363	DB00674	Possible antagonism of action
DB00363	DB00056	Avoid combination due to adverse effects of clozapine including the risk of agranulocytosis.
DB00363	DB00801	Increased risk of toxicity
DB00363	DB00502	Clozapine, a moderate CYP2D6 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive CNS despresant and anticholinergic effects may also occur. Monitor for changes in the therapeutic and adverse effects of haloperidol if clozapine is initiated, discontinued or dose changed. Also monitor for increased CNS depressant and anticholinergic effects during concomitant therapy.
DB00363	DB00078	Avoid combination due to enhanced adverse effects of clozapine, including agranulocytosis.
DB00363	DB01321	Erythromycin increases the effect of clozapine
DB00363	DB01587	Increased risk of toxicity
DB00363	DB00555	Lamotrigine increases the effect and toxicity of clozapine
DB00363	DB00186	Increased risk of toxicity
DB00363	DB00532	Hydantoin decreases the effect of clozapine
DB00363	DB00683	Increased risk of toxicity
DB00363	DB00745	Modafinil increases the effect and toxicity of clozapine
DB00363	DB01595	Increased risk of toxicity
DB00363	DB01059	Ciprofloxacin may increase clozapine serum levels
DB00363	DB08935	Risk of agranulocytosis may be increased due to enhanced adverse effects of clozapine by myelosuppressive agents. It is recommanded that combination may be avoided.
DB00363	DB00842	Increased risk of toxicity
DB00363	DB01229	Avoid combination due to the potential enhancement of agranulocytosis by clozapine.
DB00363	DB00252	Phenytoin may decrease the effect of clozapine.
DB00363	DB01588	Increased risk of toxicity
DB00363	DB01589	Increased risk of toxicity
DB00363	DB00615	Rifabutin decreases the effect of clozapine
DB00363	DB01045	Rifampin decreases the effect of clozapine
DB00363	DB00503	Ritonavir increases the effect and toxicity of clozapine
DB00363	DB00989	Possible antagonism of action
DB00363	DB01104	The antidepressant increases the effect of clozapine
DB00363	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Clozapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00363	DB00675	Clozapine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00363	DB00706	Clozapine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clozapine is initiated, discontinued, or dose changed.
DB00363	DB00231	The benzodiazepine, Temazepam, may increase the adverse effects of Clozapine. Monitor for respiratory depression and hypotension if concomitant therapy is initiated.
DB00363	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB00363	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clozapine by decreasing Clozapine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clozapine if Thiabendazole is initiated, discontinued or dose changed.
DB00363	DB08895	Avoid combination due to the increased risk of clozapine induced agranulocytosis.
DB00363	DB00193	Clozapine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00363	DB00897	Increased risk of toxicity
DB00363	DB00662	Trimethobenzamide and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00363	DB00427	Triprolidine and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00363	DB00209	Trospium and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00363	DB06684	Selective Serotonin Reuptake Inhibitors may decrease the metabolism of clozapine. If concurrent use of these agents is employed, monitor for increased toxic effects of clozapine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased effects if a SSRI is discontinued/dose decreased.
DB00364	DB02300	Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB00370	DB01320	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB00364	DB00169	Vitamin D analogs such as cholecalciferol may increase the serum concentration of sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB00364	DB00537	Formation of non-absorbable complexes
DB00364	DB00720	Formation of non-absorbable complexes
DB00364	DB01077	Formation of non-absorbable complexes
DB00364	DB01320	Sucralfate decreases the effect of hydantoin
DB00364	DB01044	Formation of non-absorbable complexes
DB00364	DB01155	Formation of non-absorbable complexes
DB00364	DB00365	Formation of non-absorbable complexes
DB00364	DB00710	Formation of non absorbable complexes
DB00364	DB01167	Sucralfate may decrease the absorption of itraconazole.
DB00364	DB01026	Sucralfate may decrease the absorption of ketoconazole.
DB00364	DB00448	Sucralfate decreases the effect of lansoprazole
DB00364	DB01137	Formation of non-absorbable complexes
DB00364	DB00451	Sucralfate decreases the effect of levothyroxine
DB00364	DB00218	Formation of non-absorbable complexes
DB00364	DB01059	Formation of non-absorbable complexes
DB00364	DB01165	Formation of non-absorbable complexes
DB00364	DB00252	Sucralfate decreases the effect of hydantoin
DB00364	DB00685	Sucralfate may decrease the absorption of orally administered Trovafloxacin. The Sucralfate formulation contains aluminum ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sucralfate dose to minimize the interaction.
DB00364	DB00682	Sucralfate may reduce the absorption of warfarin. Warfarin should be administered at least 2 hours before or 6 hours after sucralfate administration. Monitor for changes in prothrombin time if sucralfate is initiated, discontinued or dose changed.
DB00365	DB01370	Formation of non-absorbable complexes
DB00365	DB01223	Grepafloxacin may increase the effect of aminophylline.
DB00365	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00321	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00543	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00201	Grepafloxacin may increase the effect and toxicity of caffeine.
DB00365	DB01373	Calcium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours.
DB00365	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01242	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01151	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01341	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01142	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00651	Grepafloxacin may increase the effect of dyphylline.
DB00365	DB06210	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB00365	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00623	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00458	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01592	Formation of non-absorbable complexes
DB00365	DB00893	Formation of non-absorbable complexes
DB00365	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01378	Magnesium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours.
DB00365	DB01377	Formation of non-absorbable complexes
DB00365	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01403	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00540	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01303	Grepafloxacin may increase the effect of oxtriphylline.
DB00365	DB00850	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00433	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00420	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01069	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00777	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00344	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01369	This combination presents an increased risk of toxicity
DB00365	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00364	Formation of non-absorbable complexes
DB00365	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00277	Grepafloxacin may increase the effect of theophylline.
DB00365	DB00372	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00831	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00508	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB00726	Increased risk of cardiotoxicity and arrhythmias
DB00365	DB01593	Formation of non-absorbable complexes
DB00366	DB00843	Possible antagonism of action
DB00366	DB00674	Possible antagonism of action
DB00366	DB01278	May cause additive slowing of GI motility.
DB00370	DB00674	Possible antagonism of action
DB00370	DB01247	Possible severe adverse reaction with this combination
DB00366	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxylamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00366	DB00662	Trimethobenzamide and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00366	DB00427	Triprolidine and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00366	DB00209	Trospium and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00367	DB01351	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB01352	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB06697	Artemether may decrease the effectiveness of levonorgestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00367	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of levonorgestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00367	DB00237	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00241	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB01353	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00564	Carbamazepine may decrease the contraceptive effect of levonorgestrel.
DB00367	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00367	DB01341	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00754	Phenytoin decreases the contraceptive effect
DB00367	DB01320	Phenytoin decreases the contraceptive effect
DB00367	DB01354	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB01355	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00532	Phenytoin decreases the contraceptive effect
DB00367	DB00474	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00849	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00312	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB01174	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00252	Phenytoin decreases the contraceptive effect
DB00367	DB00794	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB01346	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00418	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00306	Phenobarbital decreases the effect of levonorgestrel
DB00367	DB00599	Thiopental may decrease the effect of Levonorgestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00367	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Levonorgestrel. An alternate form of contraception should be used during concomitant therapy.
DB00367	DB00682	Levonorgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if levonorgestrel is initiated, discontinued or dose changed.
DB00368	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of norepinephrine.
DB00368	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of norepinephrine.
DB00368	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of norepinephrine.
DB00368	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of norepinephrine.
DB00368	DB06700	Desvenlafaxine may increase the tachycardic and vasopressor effects of norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00368	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of norepinephrine.
DB00368	DB00494	Entacapone increases the effect and toxicity of the sympathomimetic, norepinephrine.
DB00368	DB01170	Norepinephrine may decrease the effect of guanethidine.
DB00368	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of norepinephrine.
DB00368	DB01247	Increased arterial pressure
DB00368	DB00601	Possible increase of arterial pressure
DB00368	DB00968	Increased arterial pressure
DB00368	DB00211	Increased arterial pressure
DB00368	DB01171	Moclobemide increases the sympathomimetic effect of norepinephrine.
DB00368	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of norepinephrine.
DB00368	DB00780	Increased arterial pressure
DB00368	DB01367	Increased arterial pressure
DB00368	DB00206	Increased arterial pressure
DB00368	DB00726	Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Norepinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00368	DB00285	Venlafaxine may increase the tachycardic and vasopressor effects of Norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00370	DB00575	Possible hypertensive crisis
DB00370	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00370	DB00843	Possible antagonism of action
DB00370	DB00754	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB00370	DB00176	Fluvoxamine may increase the therapeutic and adverse effects of mirtazapine.
DB00370	DB00532	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB00370	DB00780	Possible severe adverse reaction with this combination
DB00370	DB00252	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB00370	DB01367	Possible severe adverse reaction with this combination
DB00370	DB00989	Possible antagonism of action
DB00370	DB00976	Telithromycin may reduce clearance of Mirtazapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mirtazapine if Telithromycin is initiated, discontinued or dose changed.
DB00370	DB00857	Terbinafine may reduce the metabolism and clearance of Mirtazapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mirtazapine if Terbinafine is initiated, discontinued or dose changed.
DB00370	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00370	DB00752	The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Mirtazapine. These agents should not be administered within 14 days of each other.
DB00370	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00370	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00370	DB00427	The CNS depressants, Triprolidine and Mirtazapine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00370	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00370	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mirtazapine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of mirtazapine if voriconazole is initiated, discontinued or dose changed.
DB00370	DB00315	Use of two serotonin modulators, such as zolmitriptan and mirtazapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00372	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00372	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00372	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00372	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00372	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00372	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00372	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00372	DB01170	Thiethylperazine may decrease the effect of guanethidine.
DB00372	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00372	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00372	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00372	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00372	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00373	DB00414	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01223	Antagonism of action and increased effect of theophylline
DB00373	DB00482	The NSAID, Celecoxib, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00672	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB00501	Cimetidine may increase the serum concentration of timolol by decreasing its metabolism.
DB00373	DB00575	Increased hypertension when clonidine stopped
DB00373	DB00586	The NSAID, Diclofenac, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00861	The NSAID, Diflunisal, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00320	Ischemia with risk of gangrene
DB00373	DB00343	Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block.
DB00373	DB00280	The beta-blocker, timolol, may increase the toxicity of disopyramide.
DB00373	DB00651	Antagonism of action and increased effect of theophylline
DB00373	DB00668	Hypertension, then bradycardia
DB00373	DB01253	Ischemia with risk of gangrene
DB00373	DB00696	Ischemia with risk of gangrene
DB00373	DB00749	The NSAID, Etodolac, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00573	The NSAID, Fenoprofen, may antagonize the antihypertensive effect of Timolol.
DB00373	DB01288	Antagonism
DB00373	DB00712	The NSAID, Flurbiprofen, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00983	Antagonism
DB00373	DB01120	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01067	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01289	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01016	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01382	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB00328	Risk of inhibition of renal prostaglandins
DB00373	DB00047	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB05334	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01064	Antagonism
DB00373	DB01009	The NSAID, Ketoprofen, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00465	The NSAID, Ketorolac, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00281	The beta-blocker, timolol, may increase the effect and toxicity of lidocaine.
DB00373	DB01283	The NSAID, Lumiracoxib, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00939	The NSAID, Meclofenamate, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00814	The NSAID, Meloxicam, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00968	Possible hypertensive crisis
DB00373	DB00247	Ischemia with risk of gangrene
DB00373	DB00461	The NSAID, Nabumetone, may antagonize the antihypertensive effect of Timolol.
DB00388	DB01367	Increased arterial pressure
DB00373	DB00788	The NSAID, Naproxen, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00816	Antagonism
DB00373	DB00991	The NSAID, Oxaprozin, may antagonize the antihypertensive effect of Timolol.
DB00373	DB01303	Antagonism of action and increased effect of theophylline
DB00373	DB00236	Antagonism
DB00373	DB01291	Antagonism
DB00373	DB00554	Risk of inhibition of renal prostaglandins
DB00373	DB00457	Risk of hypotension at the beginning of therapy
DB00373	DB01366	Antagonism
DB00373	DB00912	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01001	Antagonism
DB00373	DB00938	Antagonism
DB00373	DB00605	The NSAID, Sulindac, may antagonize the antihypertensive effect of Timolol.
DB00373	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00373	DB00857	Terbinafine may reduce the metabolism and clearance of Timolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Timolol is initiated, discontinued or dose changed.
DB00373	DB00871	Antagonism
DB00373	DB00277	Antagonism of action and increased effect of theophylline
DB00373	DB01600	The NSAID, Tiaprofenic acid, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00839	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB01124	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00373	DB00500	The NSAID, Tolmetin, may antagonize the antihypertensive effect of Timolol.
DB00373	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00373	DB00661	Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block.
DB00374	DB00054	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01193	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01418	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Acenocoumarol. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00819	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00945	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Acetylsalicylic acid. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00594	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00233	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00381	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01612	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00261	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Anagrelide. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00964	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00278	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00335	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00542	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00436	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00195	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00612	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00006	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant therapy.
DB00374	DB00484	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00887	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00796	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01197	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00521	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01136	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00482	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Celecoxib. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB04846	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00880	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00310	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01340	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01166	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Cilostazol. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00215	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Citalopram. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB04920	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00575	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00758	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Clopidogrel. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB04838	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00633	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00586	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diclofenac. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01144	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00861	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diflunisal. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00343	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00975	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00590	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01395	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00055	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Drotrecogin alfa. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00584	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01225	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Exoxaparin. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00700	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00876	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00063	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Eptifibatide. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01175	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Escitalopram. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00187	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00903	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00749	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Etodolac. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01023	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00573	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Fenoprofen. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00472	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluoxetine. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00712	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Flurbiprofen. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00176	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00492	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00695	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00629	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01018	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01109	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Heparin. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01275	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00999	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00774	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01050	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ibuprofen. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00808	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00328	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01029	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00883	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01020	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00270	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01009	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00465	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketorolac. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00598	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00001	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01210	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00722	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00678	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01283	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Lumiracoxib. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00742	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00939	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meclofenamate. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00784	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00814	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meloxicam. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00703	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00232	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01214	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00524	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00264	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00350	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00691	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00461	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Nabumetone. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01203	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00788	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Naproxen. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB04861	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB04899	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00622	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01115	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00393	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00401	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01054	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00727	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00325	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00275	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00991	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01580	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01113	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00715	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Paroxetine. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01359	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00790	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00925	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00692	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00960	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00554	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Piroxicam. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01324	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00457	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00881	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00178	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00206	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB06228	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Rivaroxaban. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01399	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Salsalate. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB01104	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Sertraline. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00489	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00421	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00605	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Sulindac. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00966	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01162	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01600	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00208	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Ticlopidine. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00373	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00388	DB00206	Increased arterial pressure
DB00421	DB00876	Increased risk of hyperkalemia
DB00374	DB00775	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Tirofiban. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00697	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00797	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00500	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tolmetin. Monitor for increased bleeding during concomitant thearpy.
DB00374	DB00214	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00519	The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril.
DB00374	DB00384	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB01021	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB03904	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00177	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00661	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00374	DB00682	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy.
DB00375	DB01418	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption.
DB00375	DB01125	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of anisindione by decreasing its absorption.
DB00375	DB00880	Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction.
DB00375	DB00169	Bile acid sequestrants such as colestipol may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00375	DB00266	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of dicumarol by decreasing its absorption.
DB00375	DB00390	The resin decreases the effect of digoxin
DB00375	DB01095	Increased/decreased effect according to spacing
DB00375	DB00741	Cholestyramine decreases the effect of hydrocortisone
DB00375	DB00451	The resin, colestipol, decreases the absorption of the thyroid hormone, levothyroxine.
DB00375	DB00279	The resin, colestipol, decreases the absorption of the thyroid hormone, liothyronine.
DB00375	DB01583	The resin, colestipol, decreases the absorption of the thyroid hormone, liotrix.
DB00375	DB08827	Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours.
DB00375	DB00481	The resin decreases the effect of raloxifene
DB00375	DB00605	The bile acid sequestrant, colestipol, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if colestipol is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions.
DB00375	DB01584	The resin, colestipol, decreases the absorption of the thyroid hormone, thyroglobulin.
DB00375	DB01600	The bile acid sequestrant, Colestipol, may reduce Tiaprofenic acid absorption and therapeutic effect.
DB00375	DB00500	Colestipol may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00375	DB00214	Colestipol may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00375	DB01021	The bile acid sequestrant, Colestipol, may inhibit the absorption of Trichlormethiazide.
DB00375	DB01586	The resin decreases the effect of ursodiol
DB00375	DB00682	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of warfarin by decreasing its absorption.
DB00376	DB00843	Possible antagonism of action
DB00376	DB00674	Possible antagonism of action
DB00376	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00376	DB00761	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trihexyphenidyl, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00376	DB01278	The anticholinergic effects of Trihexyphenidyl may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB00376	DB00989	Possible antagonism of action
DB00376	DB00021	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00421	DB00390	Increased digoxin levels and decreased effect in presence of spironolactone
DB00376	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trihexyphenidyl, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00376	DB00662	Trimethobenzamide and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00376	DB00427	Triprolidine and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00376	DB00209	Trospium and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00379	DB01223	Mexiletine increases the effect and toxicity of theophylline
DB00379	DB06769	Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion.
DB00379	DB00651	Mexiletine increases the effect and toxicity of theophylline
DB00379	DB06210	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB00379	DB00754	The hydantoin decreases the effect of mexiletine
DB00379	DB06414	Mexiletine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor mexiletine therapy for reduced effectiveness.
DB00379	DB00176	Fluvoxamine may increase the therapeutic and adverse effects of mexiletine.
DB00379	DB01320	The hydantoin decreases the effect of mexiletine
DB00379	DB00532	The hydantoin decreases the effect of mexiletine
DB00379	DB01303	Mexiletine increases the effect and toxicity of theophylline
DB00379	DB00252	The hydantoin decreases the effect of mexiletine
DB00379	DB01182	Propafenone may increase the effect and toxicity of mexilitine.
DB00379	DB00980	Mexiletine increases levels/toxicity of ramelteon
DB00379	DB01045	Rifampin decreases the effect of mexiletine
DB00379	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Mexiletine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Mexiletine is initiated, discontinued or if the dose is changed.
DB00379	DB00857	Terbinafine may reduce the metabolism and clearance of Mexiletine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mexiletine if Terbinafine is initiated, discontinued or dose changed.
DB00379	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00379	DB00277	Mexiletine increases the effect and toxicity of theophylline
DB00379	DB01623	The strong CYP1A2 inhibitor, Mexiletine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Mexiletine is initiated, discontinued or dose changed.
DB00379	DB00697	Mexilitene may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00379	DB06684	Monitor for increased serum concentrations/toxic effects of mexiletine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased concentrations/effects if an SSRI is discontinued/dose decreased.
DB00381	DB00343	Diltiazem may increase the serum concentration of amlodipine. Concomitant therapy will result in additive hypotensive effects. Monitor for changes in the hypotensive effect of amlodipine if diltiazem is initiated, discontinued or dose changed.
DB00381	DB01369	This combination presents an increased risk of toxicity
DB00381	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Amlopidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Amlopidine is initiated, discontinued or if the dose is changed.
DB00381	DB05521	Telaprevir inhibits the metabolism of amlodipine and concomitant therapy is contraindicated.
DB00381	DB00976	Telithromycin may reduce clearance of Amlopidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amlopidine if Telithromycin is initiated, discontinued or dose changed.
DB00381	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Amlodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Amlodipine if Thiopental is initiated, discontinued or dose changed.
DB00381	DB00932	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Amlopidine. Monitor for changes in Amlopidine therapeutic and toxic effects if Tipranavir is initiated, discontinued or dose changed.
DB00381	DB00697	Amlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00381	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00381	DB00582	Voriconazole may increase the serum concentration of amlodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amlodipine if voriconazole is initiated, discontinued or dose changed.
DB00382	DB01063	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Acetophenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB03128	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Acetylcholine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00382	DB01246	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimeprazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01122	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Ambenonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00382	DB01223	Tacrine may reduce the elimination rate of Aminophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed.
DB00421	DB00584	Increased risk of hyperkalemia
DB00382	DB00321	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amitriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00381	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Amlopidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Amlopidine is initiated, discontinued or if the dose is changed.
DB00382	DB00543	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amoxapine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01238	Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Aripiprazole. Monitor for extrapyramidal symptoms.
DB00382	DB00572	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Atropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00972	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Azelastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB06769	CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine.
DB00382	DB00245	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Benztropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00443	Tacrine and Betamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB01019	The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Bethanecol, a cholinergic agonist. Monitor for increased cholinergic effects.
DB00382	DB00810	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Biperidin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01237	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Bromodiphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00835	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Brompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00411	The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Carbachol, a cholinergic agonist. Monitor for increased cholinergic effects.
DB00382	DB00748	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Carbinoxamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00185	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Cevimeline, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00382	DB01114	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Chlorpheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00477	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Chlorpromazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00501	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Cimetidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Cimetidine is initiated, discontinued or if the dose is changed.
DB00382	DB00537	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ciprofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ciprofloxacin is initiated, discontinued or if the dose is changed.
DB00382	DB00283	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clemastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00771	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clidinium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01242	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clomipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00363	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Clozapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB01285	Tacrine and Corticotropin may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB01380	Tacrine and Cortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB01176	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00924	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclobenzaprine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00979	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclopentolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00434	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyproheptadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00496	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Darifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00944	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Demcarium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00382	DB01151	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00967	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desloratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01234	Tacrine and Dexamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB00405	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dexbrompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00586	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Diclofenac, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Diclofenac is initiated, discontinued or if the dose is changed.
DB00382	DB00804	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dicyclomine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00985	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dimenhydrinate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01075	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Diphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01142	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxepin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00366	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxylamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00450	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Droperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB01010	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Edrophonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00382	DB00950	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Fexofenadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01148	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Flavoxate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00687	Tacrine and Fludrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB00472	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Fluoxetine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Fluoxetine is initiated, discontinued or if the dose is changed.
DB00382	DB00875	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Flupenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00623	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Fluphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00176	Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of tacrine.
DB00382	DB01241	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Gemfibrozil, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Gemfibrozil is initiated, discontinued or if the dose is changed.
DB00382	DB01381	Ginkgo biloba may cause additive/toxic cholinergic effects when administered with Tacrine. Monitor for cholinergic toxicity.
DB00382	DB00986	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Glycopyrrolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00536	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Guanidine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00382	DB00502	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Haloperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00725	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Homatropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00741	Tacrine and Hydrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB00557	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hydroxyzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00424	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hyoscyamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00458	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Imipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00332	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ipratropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01247	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01026	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed.
DB00382	DB00920	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ketotifen, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00281	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Lidocaine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Lidocaine is initiated, discontinued or if the dose is changed.
DB00382	DB00455	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Loratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00408	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Loxapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00934	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Maprotiline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00737	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Meclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB04843	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Mepenzolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00933	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Mesoridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00940	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00553	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Methoxsalen. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Methoxsalen is initiated, discontinued or if the dose is changed.
DB00382	DB00959	Tacrine and Methylprednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB00462	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methylscopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00388	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Concomitant therapy should be avoided.
DB00382	DB00379	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Mexiletine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Mexiletine is initiated, discontinued or if the dose is changed.
DB00382	DB01110	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Miconazole, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Miconazole is initiated, discontinued or if the dose is changed.
DB00382	DB01171	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Moclobemide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01618	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Molindone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB01115	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Nifedipine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Nifedipine is initiated, discontinued or if the dose is changed.
DB00382	DB01059	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Norfloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Norfloxacin is initiated, discontinued or if the dose is changed.
DB00382	DB00540	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Nortriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01165	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ofloxacin is initiated, discontinued or if the dose is changed.
DB00382	DB00334	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Olanzapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB01173	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Orphenadrine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01303	Tacrine increases the effect and toxicity of theophylline
DB00382	DB01062	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Oxybutynin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01267	Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Paliperidone. Monitor for extrapyramidal symptoms.
DB00382	DB00850	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Perphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00780	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenelzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01619	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenindamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01085	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Pilocarpine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00382	DB01100	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Pimozide, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB06153	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Pizotifen, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00860	Tacrine and Prednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB00635	Tacrine and Prednisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB01087	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Primaquine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Primaquine is initiated, discontinued or if the dose is changed.
DB00382	DB00433	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Prochlorperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00387	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Procyclidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01069	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Promethazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00782	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Propantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00818	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Propofol, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Propofol is initiated, discontinued or if the dose is changed.
DB00382	DB00344	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Protriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01224	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Quetiapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00980	Tacrine increases levels/toxicity of ramelteon
DB00382	DB00734	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Risperidone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00747	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Scopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01591	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Solifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00202	Tacrine may increase the effects of Succinylcholine. Monitor Succinylcholine therapy for increased effects.
DB00382	DB00277	Tacrine may reduce the elimination rate of Theophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed.
DB00382	DB00730	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Thiabendazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Thiabendazole is initiated, discontinued or if the dose is changed.
DB00382	DB00679	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB01623	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thiothixene, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB01409	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tiotropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB01036	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tolterodine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00752	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tranylcypromine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Tranylcypromine, a CYP1A2 inhibitor. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00382	DB00620	Tacrine and Triamcinolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00382	DB00831	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Trifluoperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00382	DB00376	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trihexyphenidyl, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00662	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimethobenzamide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00726	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00427	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Triprolidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00209	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trospium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00382	DB00246	Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Ziprasidone. Monitor for extrapyramidal symptoms.
DB00382	DB01624	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Zuclopenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00383	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00384	DB00542	Increased risk of hyperkalemia
DB00384	DB00796	Increased risk of hyperkalemia
DB00384	DB01197	Increased risk of hyperkalemia
DB00384	DB01340	Increased risk of hyperkalemia
DB00384	DB01395	Increased risk of hyperkalemia
DB00384	DB00584	Increased risk of hyperkalemia
DB00384	DB00700	This association presents an increased risk of hyperkalemia
DB00384	DB00876	Increased risk of hyperkalemia
DB00384	DB01342	Increased risk of hyperkalemia
DB00384	DB00492	Increased risk of hyperkalemia
DB00384	DB00328	Risk of acute renal impairment with this combination
DB00384	DB01029	Increased risk of hyperkalemia
DB00384	DB00722	Increased risk of hyperkalemia
DB00384	DB00678	Increased risk of hyperkalemia
DB00384	DB00691	Increased risk of hyperkalemia
DB00384	DB00790	Increased risk of hyperkalemia
DB00384	DB01344	Antagonism of action
DB00384	DB01345	Increased risk of hyperkalemia
DB00384	DB00881	Increased risk of hyperkalemia
DB00384	DB00178	Increased risk of hyperkalemia
DB00384	DB01347	Increased risk of hyperkalemia
DB00384	DB01348	Increased risk of hyperkalemia
DB00384	DB01349	Increased risk of hyperkalemia
DB00384	DB00966	Telmisartan may increase the hyperkalemic effect of Triamterene. Monitor for increased serum potassium concentrations during concomitant therapy.
DB00384	DB00519	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00384	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00384	DB00177	Increased risk of hyperkalemia
DB00385	DB01248	The taxane derivative, Docetaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
DB00385	DB00108	Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided.
DB00385	DB01229	The taxane derivative, Paclitaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
DB00385	DB00072	Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00386	DB00668	Increased arterial pressure
DB00386	DB01288	Increased arterial pressure
DB00386	DB00816	Increased arterial pressure
DB00386	DB00388	Increased arterial pressure
DB00386	DB00397	Increased arterial pressure
DB00386	DB00852	Increased arterial pressure
DB00386	DB00871	Increased arterial pressure
DB00387	DB00843	Possible antagonism of action
DB00387	DB00674	Possible antagonism of action
DB00387	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00387	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Procyclidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00387	DB00662	Trimethobenzamide and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00387	DB00427	Triprolidine and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00387	DB00209	Trospium and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00388	DB00386	Increased arterial pressure
DB00388	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylephrine.
DB00388	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylephrine.
DB00388	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylephrine.
DB00388	DB01089	Increased arterial pressure
DB00388	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylephrine.
DB00388	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylephrine.
DB00388	DB01253	Possible marked increase of arterial pressure
DB00388	DB01170	Phenylephrine may decrease the effect of guanethidine.
DB00388	DB00070	Avoid combination because hyaluronidase can potentiate the vasoconstrictive effect of phenylephrine.
DB00388	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylephrine.
DB00388	DB06704	Sympathomimetic that increase chances of producing a false negative imaging result
DB00388	DB01247	Increased arterial pressure
DB00388	DB00601	Possible increase of arterial pressure
DB00388	DB00968	Increased arterial pressure
DB00388	DB00353	Possible marked increase of arterial pressure
DB00388	DB00211	Increased arterial pressure
DB00388	DB01171	Moclobemide increases the sympathomimetic effect of phenylephrine.
DB00388	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylephrine.
DB00388	DB00107	Possible marked increase of arterial pressure
DB00388	DB01626	Increased arterial pressure
DB00388	DB00780	Increased arterial pressure
DB00388	DB00344	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylephrine.
DB00388	DB00726	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00390	DB00284	Acarbose may decrease the serum levels of digoin. It is thought that acarbose reduces digoin absorption. Monitor for changes in digoxin serum levels and therapeutic and adverse effects if acarbose is initiated, discontinued or dose changed.
DB00390	DB00404	The benzodiazepine, alprazolam, may increase the effect of digoxin.
DB00390	DB01118	Amiodarone may increase the effect of digoxin.
DB00390	DB00436	Possible electrolyte variations and arrhythmias
DB00390	DB00562	Possible electrolyte variations and arrhythmias
DB00390	DB00290	The antineoplasic agent decreases the effect of digoxin
DB00390	DB06616	Bosutinib is a substrate and inhibitor of p-glycoprotein (p-gp) and may increase levels of other p-gp substrates.
DB00390	DB00887	Possible electrolyte variations and arrhythmias
DB00390	DB08907	When coadministered with 300 mg canagliflozin, the AUC and mean peak drug concentration of digoxin increased. Monitor concomitant therapy closely.
DB00390	DB00262	The antineoplasic agent decreases the effect of digoxin
DB00390	DB01136	Carvedilol may increase the serum levels and effect of digoxin.
DB00390	DB00880	Possible electrolyte variations and arrhythmias
DB00390	DB00310	Possible electrolyte variations and arrhythmias
DB00390	DB01432	The resin decreases the effect of digoxin
DB00390	DB08810	Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.
DB00390	DB01211	The macrolide, clarithromycin, may increase the effect of digoxin in 10% of patients.
DB00390	DB00375	The resin decreases the effect of digoxin
DB00390	DB00531	The antineoplasic agent decreases the effect of digoxin
DB00390	DB00091	Cyclosporine may increase the effect of digoxin.
DB00390	DB00606	Possible electrolyte variations and arrhythmias
DB00390	DB00987	The antineoplasic agent decreases the effect of digoxin
DB00390	DB00509	The thyroid hormone, dextrothyroxine, decreases the effect of digoxin.
DB00390	DB00829	The benzodiazepine, diazepam, may increase the effect of digoxin.
DB00390	DB01341	Quinine/quinidine increases the effect of digoxin
DB00390	DB00997	The antineoplasic agent decreases the effect of digoxin
DB00390	DB04855	Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of digoxin 2.5-fold.
DB00390	DB00199	The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.
DB00390	DB00903	Possible electrolyte variations and arrhythmias
DB00390	DB06414	Digoxin, when administered concomitantly with etravirine, may experience an increase in serum concentration. It is recommended to monitor serum levels of digoxin and titrate dosage to achieve desired therapeutic range. Pre-emptive dose adjustments are not required.
DB00390	DB00695	Possible electrolyte variations and arrhythmias
DB00390	DB01044	Gatifloxacin increases the effect of digoxin
DB00390	DB01404	Changes in digoxin serum levels
DB00390	DB00999	Possible electrolyte variations and arrhythmias
DB00390	DB00774	Possible electrolyte variations and arrhythmias
DB00390	DB01611	Hydroxychloroquine increases the effect of digoxin
DB00390	DB00808	Possible electrolyte variations and arrhythmias
DB00390	DB01167	Itraconazole increases the effect of digoxin
DB00390	DB01321	The macrolide, josamycin, may increase the effect of digoxin in 10% of patients.
DB00390	DB00451	The thyroid hormone, levothyroxine, decreases the effect of digoxin.
DB00390	DB00279	The thyroid hormone, liothyronine, decreases the effect of digoxin.
DB00390	DB01583	The thyroid hormone, liotrix, decreases the effect of digoxin.
DB00390	DB06655	These agents may have decreased C max and a delayed T max during coadministration.
DB00390	DB00763	The antithyroid agent increases the effect of digoxin
DB00390	DB00563	The antineoplasic agent decreases the effect of digoxin
DB00390	DB00232	Possible electrolyte variations and arrhythmias
DB00390	DB00524	Possible electrolyte variations and arrhythmias
DB00390	DB04896	Use of Savella concomitantly with digoxin may be associated with potentiation of adverse hemodynamic effects. Co-administration of Savella and intravenous digoxin should be avoided.
DB00390	DB08893	Mirabegron increased Cmax and AUC of digoxin. Initiate therapy with digoxin at lowest possible dose. Monitor concomitant therapy closely.
DB00390	DB01359	Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.
DB00390	DB00299	The multivalent agent decreases the effect of penicillamine
DB00390	DB00859	Penicillamine decreases the effect of digoxin
DB00390	DB01324	Possible electrolyte variations and arrhythmias
DB00390	DB00457	Prazosin increases the effect of digoxin
DB00390	DB01168	The antineoplasic agent decreases the effect of digoxin
DB00390	DB01182	Propafenone increases the effect of digoxin
DB00390	DB00550	The antithyroid agent may increase the effect of digoxin.
DB00390	DB01325	Possible electrolyte variations and arrhythmias
DB00390	DB00908	Quinine/quinidine increases the effect of digoxin
DB00390	DB01346	Quinine/quinidine increases the effect of digoxin
DB00390	DB00468	Quinine/quinidine increases the effect of digoxin
DB00390	DB01129	Rabeprazole increases the effect of digoxin
DB00390	DB00243	Ranolazine may increase the serum level of digoxin. Monitor for changes in the serum level and therapeutic and adverse effects of digoxin if ranolazine is initiated, discontinued or dose changed.
DB00390	DB00503	Ritonavir increases levels/effect of digoxin
DB00390	DB00421	Increased digoxin levels and decreased effect in presence of spironolactone
DB00390	DB01323	St. John's Wort decreases the effect of digoxin
DB00390	DB00795	Sulfasalazine may decrease the effect of digoxin.
DB00398	DB00112	Monitor therapy due to increased adverse effects of sorafenib, especially hand-foot skin reaction.
DB00390	DB05521	Telaprevir is a substrate of p-glycoprotein and thus increases the AUC and Cmax of digoxin. This indicates an increased absorption of digoxin. Lowest dose of digoxin should be used first and levels be closely monitored.
DB00390	DB00976	Telithromycin may increase the plasma concentration of Digoxin. Monitor for changes in Digoxin efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
DB00390	DB00966	Telmisartan may increase plasma Digoxin concentrations. Monitor Digoxin levels and adjust dose as required if Telmisartan is initiated, discontinued or dose changed.
DB00390	DB01584	The thyroid hormone, thyroglobulin, decreases the effect of digoxin.
DB00390	DB00208	Ticlopidine may decrease Digoxin levels. Monitor for Digoxin levels with Ticlopidine is initiated, discontinued or dose changed.
DB00390	DB01124	Tolbutamide increases the effect of digoxin
DB00390	DB06212	Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects.
DB00390	DB01021	Possible electrolyte variations and arrhythmias
DB00390	DB01157	The absorption of Digoxin, a cardiac glycoside, may be decreased by antineoplastic agents such as Trimetrexate. Liquid forms of Digoxin do not appear to be significantly affected. Monitor Digoxin tablet efficacy if Trimetrexate therapy is initiated, discontinued or if the dose is altered.
DB00390	DB00661	Verapamil may increase the serum concentration of Digoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digoxin if Verpamail is initiated, discontinued or dose changed.
DB00390	DB00541	The antineoplasic agent decreases the effect of digoxin
DB00390	DB00582	Voriconazole may increase the serum concentration of digoxin. Monitor for increased serum concentrations and toxic effects of digoxin if voriconazole is initiated or dose increased.
DB00392	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00392	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00392	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00392	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00392	DB00843	Possible antagonism of action
DB00392	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00392	DB00674	Possible antagonism of action
DB00392	DB01170	Ethopropazine may decrease the effect of guanethidine.
DB00392	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00392	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00392	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00392	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00393	DB00501	Cimetidine increases the effect of the calcium channel blocker, nimodipine.
DB00393	DB01369	This combination presents an increased risk of toxicity
DB00393	DB00976	Telithromycin may reduce clearance of Nimodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nimodipine if Telithromycin is initiated, discontinued or dose changed.
DB00393	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nimodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nimodipine if Thiopental is initiated, discontinued or dose changed.
DB00393	DB00932	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nimodipine. Monitor for changes in Nimodipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB00393	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00393	DB00313	Valproic acid increases the effect of nimodipine
DB00393	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nimodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nimodipine if voriconazole is initiated, discontinued or dose changed.
DB00395	DB00705	Strong CYP2C19 inhibitors such as delavirdine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00395	DB00450	Droperidol may enhance the CNS depressant effect of carisoprodol. Consider dose reductions of droperidol or of other CNS agents with concomitant use.
DB00395	DB00196	Strong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00395	DB00176	Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00395	DB01241	Strong CYP2C19 inhibitors such as gemfibrozil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00417	DB00254	Possible antagonism of action
DB00421	DB00700	This association presents an increased risk of hyperkalemia
DB00395	DB00951	Strong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00395	DB01403	Carisoprodol, a CNS depressant, may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants like carisoprodol. Reduce the dosage of CNS depressants by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose has been established. Monitor for increased CNS depression with concomitant therapy.
DB00395	DB00745	Strong CYP2C19 inhibitors such as modafinil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00395	DB06268	Strong CYP2C19 inhibitors such as sitaxentan may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00395	DB00208	Ticlopidine may decrease the metabolism and clearance of Carisoprodol. Consider alternate therapy or monitor for adverse/toxic effects of Carisoprodol if Ticlopidine is initiated, discontinued or dose changed.
DB00395	DB00427	The CNS depressants, Triprolidine and Carisoprodol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00396	DB01030	The p-glycoprotein inhibitor, Progesterone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00397	DB01063	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB01246	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00386	Increased arterial pressure
DB00397	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB01200	The sympathomimetic, phenylpropanolamine, increases the toxicity of bromocriptine.
DB00397	DB00477	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB01089	Increased arterial pressure
DB00397	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB00392	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00472	Risk of serotoninergic syndrome
DB00397	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00176	Risk of serotoninergic syndrome
DB00397	DB01170	Phenylpropanolamine may decrease the effect of guanethidine.
DB00397	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB06704	Sympathomimetic that increase chances of producing a false negative imaging result
DB00397	DB01247	Increased arterial pressure
DB00397	DB00601	Possible increase of arterial pressure
DB00397	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00902	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00968	Increased arterial pressure
DB00397	DB00211	Increased arterial pressure
DB00397	DB01171	Moclobemide increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB01626	Increased arterial pressure
DB00397	DB00715	Risk of serotoninergic syndrome
DB00397	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00780	Increased arterial pressure
DB00397	DB00433	Decreased anorexic effect, may increase psychotic symptoms.
DB00397	DB00420	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB01069	Decreased anorexic effect, may increase psychotic symptoms.
DB00397	DB01608	Decreased anorexic effect, may increase psychotic symptoms.
DB00397	DB00777	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00344	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB01367	Increased arterial pressure
DB00397	DB00206	Increased arterial pressure
DB00397	DB00372	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00752	Increased arterial pressure
DB00397	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00508	Decreased anorexic effect, may increase psychotic symptoms
DB00397	DB00726	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB00397	DB00285	Risk of serotoninergic syndrome
DB00398	DB00958	Sorafenib may enhance the adverse/toxic effect of carboplatin. Concurrent use of sorafenib with carboplatin and placlitaxel in patients with squamous cell lung cancer is contraindicated. The use of this combination in other settings is not specifically contraindicated, but any such use should be approached with added caution.
DB00398	DB06414	Sorafebib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00398	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00398	DB00755	The strong CYP2C8 inhibitor, Sorafenib, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Sorafenib is initiated, discontinued to dose changed.
DB00400	DB01418	Griseofulvin may decrease the anticoagulant effect of acenocoumarol.
DB00400	DB00945	Griseofulvin may decrease the efficacy of acetylsalicylic acid.
DB00400	DB01351	The barbiturate, amobarbital, decreases the effect of griseofulvin.
DB00400	DB01125	Griseofulvin may decrease the anticoagulant effect of anisindione.
DB00400	DB01352	The barbiturate, aprobarbital, decreases the effect of griseofulvin.
DB00400	DB00237	The barbiturate, butabarbital, decreases the effect of griseofulvin.
DB00400	DB00241	The barbiturate, butalbital, decreases the effect of griseofulvin.
DB00400	DB01353	The barbiturate, butethal, decreases the effect of griseofulvin.
DB00400	DB00269	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent,  chlorotrianisene.
DB00400	DB00882	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, clomifene.
DB00400	DB00286	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, conjugated estrogens.
DB00400	DB00091	Griseofulvin decreases the effect of cyclosporine
DB00400	DB00266	Griseofulvin may decrease the anticoagulant effect of dicumarol.
DB00400	DB00255	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00400	DB01341	The barbiturate, dihydroquinidine barbiturate, decreases the effect of griseofulvin.
DB00400	DB00783	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estradiol.
DB00400	DB04573	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estriol.
DB00400	DB00655	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estrone.
DB00400	DB04574	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estropipate.
DB00400	DB00977	This product may cause a slight decrease of contraceptive effect
DB00400	DB01354	The barbiturate, heptabarbital, decreases the effect of griseofulvin.
DB00400	DB01355	The barbiturate, hexobarbital, decreases the effect of griseofulvin.
DB00400	DB06655	Cmax may be increased.
DB00400	DB00603	The enzyme inducer, griseofulvin, may decrease the effect of the hormone, medroxyprogesterone.
DB00400	DB00351	The enzyme inducer, griseofulvin, may decrease the effect of the hormone, megestrol.
DB00400	DB01357	This product may cause a slight decrease of contraceptive effect
DB00400	DB00474	The barbiturate, methohexital, decreases the effect of griseofulvin.
DB00400	DB00849	The barbiturate, methylphenobarbital, decreases the effect of griseofulvin.
DB00400	DB00717	This product may cause a slight decrease of contraceptive effect
DB00400	DB00312	The barbiturate, pentobarbital, decreases the effect of griseofulvin.
DB00400	DB01174	The barbiturate, phenobarbital, decreases the effect of griseofulvin.
DB00400	DB00794	The barbiturate, primidone, decreases the effect of griseofulvin.
DB00400	DB04575	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, quinestrol.
DB00400	DB01346	The barbiturate, quinidine barbiturate, decreases the effect of griseofulvin.
DB00400	DB00418	The barbiturate, secobarbital, decreases the effect of griseofulvin.
DB00400	DB00306	The barbiturate, talbutal, decreases the effect of griseofulvin.
DB00400	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB00400	DB00682	Griseofulvin may decrease the anticoagulant effect of warfarin.
DB00401	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. Avoid concurrent use of nisoldipine with strong inhibitors of CYP3A4, as the combination may lead to substantial increases in nisoldipine concentrations.
DB00401	DB06414	Nisoldipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00401	DB01320	Phenytoin decreases the efficiency of nisoldipine
DB00401	DB00252	Phenytoin decreases the efficiency of nisoldipine
DB00401	DB01369	This combination presents an increased risk of toxicity
DB00401	DB00976	Telithromycin may reduce clearance of Nisoldipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nisoldipine if Telithromycin is initiated, discontinued or dose changed.
DB00401	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nisoldipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nisoldipine if Thiopental is initiated, discontinued or dose changed.
DB00401	DB00932	Tipranavir, co-administered with Ritonavir, may alter the concentration of Nisoldipine. Monitor for efficacy and adverse/toxic effects of Nisoldipine.
DB00401	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00401	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nisoldipine by decreasing its metabolism. Concomitant therapy should be avoided.
DB00402	DB00976	Telithromycin may reduce clearance of Eszopiclone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eszopiclone if Telithromycin is initiated, discontinued or dose changed.
DB00402	DB00427	The CNS depressants, Triprolidine and Eszopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00402	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eszopiclone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of eszopiclone if voriconazole is initiated, discontinued or dose changed.
DB00404	DB00701	Amprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00404	DB00673	Aprepitant may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00404	DB00564	Carbamazepine may decrease the effect of the benzodiazepine, alprazolam.
DB00404	DB00501	Cimetidine may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01211	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB00363	Increased risk of toxicity
DB00404	DB00705	The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00404	DB00390	The benzodiazepine, alprazolam, may increase the effect of digoxin.
DB00404	DB00625	The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00404	DB00199	The macrolide, erythromycin, may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB00754	Ethotoin may increase the metabolism of alprazolam via CYP3A4.
DB00404	DB00196	Fluconazole may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01319	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00404	DB01320	Fosphenytoin may increase the metabolism of alprazolam via CYP3A4.
DB00404	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01167	Itraconazole may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01321	The macrolide, josamycin, may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01322	Kava may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01026	Ketoconazole may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB00532	Mephenytoin may increase the metabolism of alprazolam via CYP3A4.
DB00404	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB00338	Omeprazole may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB00252	Phenytoin may increase the metabolism of alprazolam via CYP3A4.
DB00404	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, alprazolam.
DB00404	DB01323	St. John's Wort may decrease the effect of the benzodiazepine, alprazolam.
DB00404	DB05521	Telaprevir inhibits systemic metabolism of alprazolam and dose adjustment may be necessary.
DB00404	DB00976	Telithromycin may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00404	DB00932	Tipranavir may decrease the metabolism and clearance of Alprazolam. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased.
DB00404	DB00427	The CNS depressants, Triprolidine and Alprazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00404	DB00582	Voriconazole may increase the serum concentration of alprazolam by decreasing its metabolism. Monitor for alprazolam toxicity if voriconazole is initiated or dose increased.
DB00405	DB00843	Possible antagonism of action
DB00405	DB00674	Possible antagonism of action
DB00405	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dexbrompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00405	DB00662	Trimethobenzamide and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00405	DB00427	Triprolidine and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00405	DB00209	Trospium and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00408	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00408	DB00843	Possible antagonism of action
DB00408	DB00674	Possible antagonism of action
DB00408	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00408	DB00989	Possible antagonism of action
DB00408	DB05271	Pharmacodynamic antagonism may decrease the effects of rotigotine. Consider alternate therapy.
DB00408	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Loxapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00408	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00408	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00408	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00408	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00408	DB00662	Trimethobenzamide and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00408	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00408	DB00427	Triprolidine and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00408	DB00209	Trospium and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00408	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00408	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00408	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00408	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00411	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Carbachol, a cholinergic agonist. Monitor for increased cholinergic effects.
DB00412	DB06237	Co-administration with avanafil resulted in an approximate 2.0% increase in AUC0-inf and 14% decrease in Cmax of rosiglitazone.
DB00412	DB00930	Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents.
DB00412	DB01241	Increases the effect and toxicity of rosiglitazone/pioglitazone
DB00412	DB01026	Ketoconazole increases the effect of rosiglitazone
DB00412	DB01045	Rifampin reduces levels and efficacy of rosiglitazone
DB00412	DB00052	Somatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars.
DB00412	DB00755	The moderate CYP2C8 inhibitor, Rosiglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rosiglitazone is initiated, discontinued to dose changed.
DB00413	DB00501	Cimetidine may increase the effect and toxicity of pramipexole.
DB00413	DB01551	Dihydrocodeine may enhance the sedative effect of pramipexole. It is recommended to monitor therapy
DB00413	DB01267	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, pramipexole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB00413	DB01623	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pramipexole. Consider alternate therapy or monitor for decreased effects of both agents.
DB00413	DB00427	The CNS depressants, Triprolidine and Pramipexole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00413	DB00246	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pramipexole. Consider alternate therapy or monitor for worsening of movement disorder.
DB00413	DB01624	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pramipexole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB00414	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB00414	DB00945	Acetylsalicylic acid increases the effect of sulfonylurea, acetohexamide.
DB00414	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00414	DB00195	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00414	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00414	DB00521	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00414	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB00414	DB00446	Chloramphenicol may increase the effect of sulfonylurea, acetohexamide.
DB00414	DB00636	Clofibrate may increase the effect of sulfonylurea, acetohexamide.
DB00414	DB00266	Dicumarol may increase the effect of sulfonylurea, acetohexamide.
DB00414	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00414	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00414	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00414	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB00414	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB00414	DB00812	Phenylbutazone may increase the effect of acetohexamide.
DB00414	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00414	DB01297	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB00414	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00414	DB01045	Rifampin may decrease the effect of sulfonylurea, acetohexamide.
DB00414	DB00489	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00414	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00415	DB00335	Ampicillin decreases bioavailability of atenolol
DB00415	DB00618	Possible antagonism of action
DB00415	DB00254	Possible antagonism of action
DB00415	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00415	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00415	DB00931	Possible antagonism of action
DB00415	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00415	DB01017	Possible antagonism of action
DB00415	DB00595	Possible antagonism of action
DB00415	DB01301	Possible antagonism of action
DB00415	DB00759	Possible antagonism of action
DB00417	DB00618	Possible antagonism of action
DB00417	DB02703	Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid.
DB00417	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00417	DB00931	Possible antagonism of action
DB00417	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00417	DB01017	Possible antagonism of action
DB00417	DB00595	Possible antagonism of action
DB00417	DB01301	Possible antagonism of action
DB00417	DB00759	Possible antagonism of action
DB00418	DB01223	The barbiturate, secobarbital, decreases the effect of aminophylline.
DB00418	DB06769	CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine.
DB00418	DB00443	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00418	DB00882	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, clomifene.
DB00418	DB00286	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00418	DB00091	The barbiturate, secobarbital, increases the effect of cyclosporine.
DB00418	DB01234	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB00418	DB00255	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00418	DB00254	The anticonvulsant , secobarbital, decreases the effect of doxycycline.
DB00418	DB00783	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, estradiol.
DB00418	DB00977	This product may cause a slight decrease of contraceptive effect
DB00418	DB01023	The barbiturate, secobarbital, decreases the effect of felodipine.
DB00418	DB00687	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00418	DB00158	Folic acid decreases the effect of anticonvulsant, secobarbital.
DB00418	DB00317	The CYP3A4 inducer, secobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00418	DB00400	The barbiturate, secobarbital, decreases the effect of griseofulvin.
DB00418	DB00741	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00418	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00418	DB00603	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00418	DB00351	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, megestrol.
DB00418	DB00333	The barbiturate, secobarbital, decreases the effect of methadone.
DB00418	DB00916	The barbiturate, secobarbital, decreases the effect of metronidazole.
DB00418	DB01115	The barbiturate, secobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB00418	DB00717	This product may cause a slight decrease of contraceptive effect
DB00418	DB01303	The barbiturate, secobarbital, decreases the effect of oxtriphylline.
DB00418	DB00860	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00418	DB00635	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00418	DB00908	The anticonvulsant, secobarbital, decreases the effect of quinidine.
DB00418	DB00277	The barbiturate, secobarbital, decreases the effect of theophylline.
DB00418	DB00755	The strong CYP2C8 inducer, Secobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Secobarbital is initiated, discontinued or dose changed.
DB00418	DB00620	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00418	DB00726	The barbiturate, Secobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Secobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00418	DB00427	The CNS depressants, Triprolidine and Secobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00418	DB00661	Secobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Secobarbital is initiated, discontinued or dose changed.
DB00418	DB00682	Secobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if secobarbital is initiated, discontinued or dose changed.
DB00420	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00420	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00420	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00420	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00420	DB00843	Possible antagonism of action
DB00420	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00420	DB00674	Possible antagonism of action
DB00420	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00420	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00420	DB01170	Promazine may decrease the effect of guanethidine.
DB00420	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00420	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00420	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00420	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00420	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00421	DB00542	Increased risk of hyperkalemia
DB00421	DB00796	Increased risk of hyperkalemia
DB00421	DB01197	Increased risk of hyperkalemia
DB00421	DB01432	Increased risk of acidosis and hyperkalemia
DB00421	DB01340	Increased risk of hyperkalemia
DB00421	DB00492	Increased risk of hyperkalemia
DB00421	DB01029	Increased risk of hyperkalemia
DB00421	DB00722	Increased risk of hyperkalemia
DB00421	DB00678	Increased risk of hyperkalemia
DB00421	DB00648	Spironolactone antagonizes the effect of mitotane
DB00421	DB00790	Increased risk of hyperkalemia
DB00421	DB01344	Risk of alkalosis in renal impairment
DB00421	DB01345	Increased risk of hyperkalemia
DB00421	DB00881	Increased risk of hyperkalemia
DB00421	DB00178	Increased risk of hyperkalemia
DB00421	DB00966	Telmisartan may increase the hyperkalemic effect of Spironolactone. Monitor for increased serum potassium concentrations during concomitant therapy.
DB00421	DB00684	Increased risk of nephrotoxicity
DB00421	DB00519	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00421	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00422	DB09026	Monitor therapy due to reduced antihypertensive effect of aliskiren.
DB00422	DB00564	Carbamazepine may decrease the effect of methylphendiate.
DB00422	DB00091	Methylphenidate increases the effect and toxicity of cyclosporine
DB00422	DB01170	Methylphenidate may decrease the effect of guanethidine.
DB00422	DB01247	Possible hypertensive crisis with this combination
DB00422	DB00780	Possible hypertensive crisis with this combination
DB00422	DB01367	Possible hypertensive crisis with this combination.
DB00422	DB00519	Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed.
DB00422	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Methylphenidate. Concomitant therapy is contraindicated.
DB00423	DB00427	The CNS depressants, Triprolidine and Methocarbamol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00424	DB00843	Possible antagonism of action
DB00424	DB00674	Possible antagonism of action
DB00424	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00424	DB00989	Possible antagonism of action
DB00424	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hyoscyamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00424	DB00662	Trimethobenzamide and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00424	DB00427	Triprolidine and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00424	DB00209	Trospium and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00425	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if amprenavir is initiated, discontinued or dose changed.
DB00425	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if atazanavir is initiated, discontinued or dose changed.
DB00425	DB01211	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if clarithromycin is initiated, discontinued or dose changed.
DB00425	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if conivaptan is initiated, discontinued or dose changed.
DB00425	DB01264	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if darunavir is initiated, discontinued or dose changed.
DB00425	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if delavirdine is initiated, discontinued or dose changed.
DB00425	DB01551	Enhanced CNS depressant effects contraindicates concurrent use for certain brand name formulations of zolpidem.
DB00425	DB00196	Fluconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fluconazole is initiated, discontinued or dose changed.
DB00425	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fosamprenavir is initiated, discontinued or dose changed.
DB00425	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if indinavir is initiated, discontinued or dose changed.
DB00425	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if isoniazid is initiated, discontinued or dose changed.
DB00425	DB01167	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if itraconazole is initiated, discontinued or dose changed.
DB00427	DB01558	The CNS depressants, Triprolidine and Bromazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00502	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00425	DB01026	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed.
DB00425	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if lopinavir is initiated, discontinued or dose changed.
DB00425	DB01403	Additive CNS depressant effects. Reduce zolpidem dose by half upon initiation of methotrimeprazine. Zolpidem dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.
DB00425	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nefazodone is initiated, discontinued or dose changed.
DB00425	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nelfinavir is initiated, discontinued or dose changed.
DB00425	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nicardipine is initiated, discontinued or dose changed.
DB00425	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if posaconazole is initiated, discontinued or dose changed.
DB00425	DB00908	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if quinidine is initiated, discontinued or dose changed.
DB00425	DB00503	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ritonavir is initiated, discontinued or dose changed.
DB00425	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if saquinavir is initiated, discontinued or dose changed.
DB00425	DB00976	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if telithromycin is initiated, discontinued or dose changed.
DB00425	DB00427	The CNS depressants, Triprolidine and Zolpidem, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00425	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if voriconazole is initiated, discontinued or dose changed.
DB00427	DB00819	The CNS depressants, Triprolidine and Acetazolamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01063	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Acetophenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00802	The CNS depressants, Triprolidine and Alfentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01246	Triprolidine and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00404	The CNS depressants, Triprolidine and Alprazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00321	Triprolidine and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01351	The CNS depressants, Triprolidine and Amobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00543	Triprolidine and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01238	The CNS depressants, Triprolidine and Aripiprazole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00289	The CNS depressants, Triprolidine and Atomoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00572	Triprolidine and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00972	Concomitant therapy with triprolidine and azelastine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy.
DB00427	DB00181	The CNS depressants, Triprolidine and Baclofen, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00245	Triprolidine and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00865	Triprolidine may reduce the sedative effect of the antihistamine, Benzphetamine.
DB00427	DB00810	Triprolidine and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00604	DB00623	Increased risk of cardiotoxicity and arrhythmias
DB00427	DB01237	Triprolidine and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00835	Triprolidine and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00921	The CNS depressants, Triprolidine and Buprenorphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01156	The CNS depressants, Triprolidine and Bupropion, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00237	The CNS depressants, Triprolidine and Butabarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00241	The CNS depressants, Triprolidine and Butalbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00611	The CNS depressants, Triprolidine and Butorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00564	The CNS depressants, Triprolidine and Carbamazepine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00748	Triprolidine and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00395	The CNS depressants, Triprolidine and Carisoprodol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01563	The CNS depressants, Triprolidine and Chloral hydrate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00475	The CNS depressants, Triprolidine and Chlordiazepoxide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01114	Triprolidine and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00856	The CNS depressants, Triprolidine and Chlorphenesin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00477	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Chlorpromazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00356	The CNS depressants, Triprolidine and Chlorzoxazone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00215	The CNS depressants, Triprolidine and Citalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00283	Concomitant therapy with triprolidine and clemastine, two anticholinergics and CNS depressants, may result in additive  adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy.
DB00427	DB00771	Triprolidine and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00349	The CNS depressants, Triprolidine and Clobazam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01242	Triprolidine and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01068	The CNS depressants, Triprolidine and Clonazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00628	The CNS depressants, Triprolidine and Clorazepate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00363	Triprolidine and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00318	The CNS depressants, Triprolidine and Codeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01176	Triprolidine and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00924	Triprolidine and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00979	Triprolidine and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00434	Triprolidine and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01219	The CNS depressants, Triprolidine and Dantrolene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00496	Triprolidine and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB01320	The CNS depressants, Triprolidine and Fosphenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01151	Triprolidine and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00967	Triprolidine and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00405	Triprolidine and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01576	Triprolidine may reduce the sedative effect of the antihistamine, Dextroamphetamine.
DB00427	DB00647	The CNS depressants, Triprolidine and Propoxyphene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01209	The CNS depressants, Triprolidine and Dezocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00829	The CNS depressants, Triprolidine and Diazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00804	Triprolidine and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB01551	The CNS depressants, Triprolidine and Dihydrocodeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00985	Triprolidine and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01075	Triprolidine and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00843	Possible antagonism of action
DB00427	DB01142	Triprolidine and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00366	Triprolidine and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00450	Triprolidine and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00476	The CNS depressants, Triprolidine and Duloxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00494	The CNS depressants, Triprolidine and Entacapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01175	The CNS depressants, Triprolidine and Escitalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01215	The CNS depressants, Triprolidine and Estazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00402	The CNS depressants, Triprolidine and Eszopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00898	Triprolidine may enhance the CNS depressant effects of Ethanol.
DB00427	DB00593	The CNS depressants, Triprolidine and Ethosuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00754	The CNS depressants, Triprolidine and Ethotoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00949	The CNS depressants, Triprolidine and Felbamate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00813	The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00950	Triprolidine and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01148	Triprolidine and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB04841	The CNS depressants, Triprolidine and Flunarizine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00472	The CNS depressants, Triprolidine and Fluoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00875	Triprolidine and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00623	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Fluphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00690	The CNS depressants, Triprolidine and Flurazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00176	The CNS depressants, Triprolidine and Fluvoxamine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00458	DB01364	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedrine.
DB00427	DB00996	The CNS depressants, Triprolidine and Gabapentin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00674	Possible antagonism of action
DB00427	DB01437	The CNS depressants, Triprolidine and Glutethimide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00986	Triprolidine and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00502	Triprolidine and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00725	Triprolidine and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00956	The CNS depressants, Triprolidine and Hydrocodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00327	The CNS depressants, Triprolidine and Hydromorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00557	Triprolidine and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00424	Triprolidine and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00458	Triprolidine and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00332	Triprolidine and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB01247	Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00920	Triprolidine and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00555	The CNS depressants, Triprolidine and Lamotrigine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01202	The CNS depressants, Triprolidine and Levetiracetam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00854	The CNS depressants, Triprolidine and Levorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01255	Triprolidine may reduce the sedative effect of the antihistamine, Lisdexamfetamine.
DB00427	DB00455	Triprolidine and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00186	The CNS depressants, Triprolidine and Lorazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00408	Triprolidine and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00653	The CNS depressants, Triprolidine and Magnesium sulfate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00934	Triprolidine and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00737	Triprolidine and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB04843	Triprolidine and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00933	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Mesoridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00660	The CNS depressants, Triprolidine and Metaxalone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00333	The CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01577	Triprolidine may reduce the sedative effect of the antihistamine, Methamphetamine.
DB00427	DB00940	Triprolidine and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00423	The CNS depressants, Triprolidine and Methocarbamol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00474	The CNS depressants, Triprolidine and Methohexital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB05246	The CNS depressants, Triprolidine and Methsuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00458	DB00668	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of epinephrine.
DB00427	DB00462	Triprolidine and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00683	The CNS depressants, Triprolidine and Midazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00370	The CNS depressants, Triprolidine and Mirtazapine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01171	Triprolidine and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01618	Triprolidine and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00295	The CNS depressants, Triprolidine and Morphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00486	The CNS depressants, Triprolidine and Nabilone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00844	The CNS depressants, Triprolidine and Nalbuphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01149	The CNS depressants, Triprolidine and Nefazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00540	Triprolidine and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00334	Triprolidine and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01173	Triprolidine and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00842	The CNS depressants, Triprolidine and Oxazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01062	Triprolidine and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00497	The CNS depressants, Triprolidine and Oxycodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01192	The CNS depressants, Triprolidine and Oxymorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01267	The CNS depressants, Triprolidine and Paliperidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00715	The CNS depressants, Triprolidine and Paroxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00652	The CNS depressants, Triprolidine and Pentazocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00312	The CNS depressants, Triprolidine and Pentobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00850	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Perphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00454	The CNS depressants, Triprolidine and Meperidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01579	Triprolidine may reduce the sedative effect of the antihistamine, Phendimetrazine.
DB00427	DB00780	Triprolidine and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01619	Triprolidine and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01174	The CNS depressants, Triprolidine and Phenobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00191	Triprolidine may reduce the sedative effect of the antihistamine, Phentermine.
DB00427	DB00252	The CNS depressants, Triprolidine and Phenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01100	Triprolidine and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01621	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Pipotiazine. Monitor for symptoms of ventricular arrhythmias.
DB00427	DB06153	Concomitant therapy with triprolidine and pizotifen, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy.
DB00427	DB00413	The CNS depressants, Triprolidine and Pramipexole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00323	The CNS depressants, Triprolidine and Tolcapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00608	DB01373	The antiacid decreases the absorption of chloroquine
DB00427	DB01278	The anticholinergic effects of Triprolidine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB00427	DB01588	The CNS depressants, Triprolidine and Prazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00230	The CNS depressants, Triprolidine and Pregabalin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00794	The CNS depressants, Triprolidine and Primidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00433	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Prochlorperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00387	Triprolidine and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB01069	Triprolidine and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00782	Triprolidine and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00344	Triprolidine and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01589	The CNS depressants, Triprolidine and Quazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01224	Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00980	The CNS depressants, Triprolidine and Ramelteon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00899	The CNS depressants, Triprolidine and Remifentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00206	The CNS depressants, Triprolidine and Reserpine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00734	Triprolidine and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB05271	The CNS depressants, Triprolidine and Rotigotine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00747	Triprolidine and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00418	The CNS depressants, Triprolidine and Secobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01104	The CNS depressants, Triprolidine and Sertraline, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01591	Triprolidine and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00708	The CNS depressants, Triprolidine and Sufentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Triprolidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00427	DB00231	The CNS depressants, Triprolidine and Temazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB04844	The CNS depressants, Triprolidine and Tetrabenazine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01041	The CNS depressants, Triprolidine and Thalidomide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00599	The CNS depressants, Triprolidine and Thiopental, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00679	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB01623	Triprolidine and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00906	The CNS depressants, Triprolidine and Tiagabine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01409	Triprolidine and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00697	The CNS depressants, Triprolidine and Tizanidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00446	DB00414	Chloramphenicol may increase the effect of sulfonylurea, acetohexamide.
DB00612	DB00554	Risk of inhibition of renal prostaglandins
DB00427	DB01036	Triprolidine and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00273	The CNS depressants, Triprolidine and Topiramate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00193	The CNS depressants, Triprolidine and Tramadol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00752	Concomitant therapy with triprolidine and tranylcypromine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy.
DB00427	DB00656	The CNS depressants, Triprolidine and Trazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00897	The CNS depressants, Triprolidine and Triazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00831	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Trifluoperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00376	Triprolidine and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00347	The CNS depressants, Triprolidine and Trimethadione, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00662	Concomitant therapy with Triprolidine and Trimethobenzamide, two anticholinergics, may result in additive anticholinergic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00726	Triprolidine and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00427	DB00209	Trospium and Triprolidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00427	DB00285	The CNS depressants, Triprolidine and Venlafaxine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01080	The CNS depressants, Triprolidine and Vigabatrin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00962	The CNS depressants, Triprolidine and Zaleplon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB06283	The CNS depressants, Triprolidine and Ziconotide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00246	The CNS depressants, Triprolidine and Ziprasidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00425	The CNS depressants, Triprolidine and Zolpidem, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB00909	The CNS depressants, Triprolidine and Zonisamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01198	The CNS depressants, Triprolidine and Zopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00427	DB01624	Triprolidine and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00428	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00428	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00429	DB00107	Avoid combination due to enhanced oxytocic effects.
DB00433	DB00182	Decreased anorexic effect, may increase pyschotic symptoms
DB00433	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00433	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00433	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00433	DB01191	Decreased anorexic effect, may increase psychotic symptoms.
DB00433	DB01576	Decreased anorexic effect, may increase pyschotic symptoms
DB00433	DB00937	Decreased anorexic effect, may increase psychotic symptoms.
DB00433	DB00843	Possible antagonism of action
DB00433	DB00574	Decreased anorexic effect, may increase psychotic symptoms.
DB00433	DB00674	Possible antagonism of action
DB00433	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00433	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00433	DB01170	Prochlorperazine may decrease the effect of guanethidine.
DB00433	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00433	DB00579	Decreased anorexic effect, may increase psychotic symptoms.
DB00433	DB01577	Decreased anorexic effect, may increase pyschotic symptoms
DB00433	DB01578	Increased risk of convulsions
DB00433	DB01579	Decreased anorexic effect, may increase pyschotic symptoms
DB00433	DB00830	Decreased anorexic effect, may increase pyschotic symptoms
DB00433	DB00191	Decreased anorexic effect, may increase psychotic symptoms.
DB00433	DB00397	Decreased anorexic effect, may increase psychotic symptoms.
DB00433	DB00989	Possible antagonism of action
DB00433	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00454	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00433	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Prochlorperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00433	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00433	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00433	DB00662	Trimethobenzamide and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00433	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Prochlorperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00433	DB00209	Trospium and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00434	DB00843	Possible antagonism of action
DB00434	DB00472	Possible antagonism of action
DB00434	DB00674	Possible antagonism of action
DB00434	DB01011	This combination renders test invalid
DB00434	DB00989	Possible antagonism of action
DB00434	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyproheptadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00434	DB00427	Triprolidine and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00434	DB00209	Trospium and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00436	DB01078	Possible electrolyte variations and arrhythmias
DB00436	DB01119	Significant hyperglycemic effect
DB00436	DB01396	Possible electrolyte variations and arrhythmias
DB00436	DB00390	Possible electrolyte variations and arrhythmias
DB00436	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00436	DB01356	The thiazide diuretic, bendroflumethiazide, may increase serum levels of lithium.
DB00436	DB00519	The thiazide diuretic, Bendroflumethiazide, may increase the hypotensive effect of Trandolapril. Bendroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00436	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00437	DB01418	Allopurinol may increase the anticoagulant effect of acenocoumarol.
DB00437	DB01125	Allopurinol may increase the anticoagulant effect of anisindione.
DB00437	DB00993	Allopurinol may increase the effect of thiopurine, azathioprine.
DB00437	DB00091	Allopurinol increases the effect and toxicity of cyclosporine
DB00437	DB00266	Allopurinol may increase the anticoagulant effect of dicumarol.
DB00437	DB01033	Allopurinol may increase the effect of thiopurine, mercaptopurine.
DB00437	DB00519	The ACE inhibitor, Trandolapril, may increase the risk of hypersensitivity reactions to Allopurinol.
DB00437	DB00682	Allopurinol may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin times and therapeutic effects of warfarin if allopurinol is initiated, discontinued or dose changed.
DB00438	DB00479	Increased risk of nephrotoxicity
DB00438	DB00798	Increased risk of nephrotoxicity
DB00438	DB01172	Increased risk of nephrotoxicity
DB00438	DB00994	Increased risk of nephrotoxicity
DB00438	DB00955	Increased risk of nephrotoxicity
DB00438	DB01082	Increased risk of nephrotoxicity
DB00438	DB00684	Increased risk of nephrotoxicity
DB00439	DB01393	Increased risk of myopathy/rhabdomyolysis
DB00439	DB00559	Bosentan may decrease the serum concentration of cerivastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if bosentan is initiated, discontinued or dose changed.
DB00439	DB01211	The macrolide, clarithromycin, may increase the toxicity of the statin, cerivastatin.
DB00439	DB01394	Increased risk of rhabdomyolysis with this combination
DB00439	DB00091	Possible myopathy and rhabdomyolysis
DB00439	DB00343	Diltiazem may increase the serum concentration of cerivastatin. Cerivastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00439	DB00199	The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.
DB00439	DB01039	Increased risk of myopathy/rhabdomyolysis
DB00439	DB01241	Increased risk of myopathy/rhabdomyolysis
DB00439	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if imatinib is initiated, discontinued or dose changed.
DB00439	DB01167	Increased risk of myopathy/rhabdomyolysis
DB00439	DB01321	The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin.
DB00439	DB01026	Increased risk of myopathy/rhabdomyolysis
DB00439	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if nefazodone is initiated, discontinued or dose changed.
DB00439	DB01369	This combination presents an increased risk of toxicity
DB00439	DB00615	Rifabutin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifabutin is initiated, discontinued or dose changed.
DB00439	DB01045	Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed.
DB00440	DB01101	The strong CYP2C9 inhibitor, Capecitabine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Capecitabine is initiated, discontinued or dose changed.
DB00440	DB00250	Increased toxicity of both products
DB00440	DB00705	The strong CYP2C9 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Delavirdine is initiated, discontinued or dose changed.
DB00440	DB00204	Trimethoprim may significantly reduced the clearance of Dofetilide. Trimethoprim is a cation transport inhibitor and may interfere with renal excretion of Dofetilide. Concomitant use is contraindicated.
DB00440	DB00322	The strong CYP2C9 inhibitor, Floxuridine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Floxuridine is initiated, discontinued or dose changed.
DB00440	DB00196	The strong CYP2C9 inhibitor, Fluconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluconazole is initiated, discontinued or dose changed.
DB00440	DB00544	The strong CYP2C9 inhibitor, Fluorouracil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluorouracil is initiated, discontinued or dose changed.
DB00440	DB00712	The strong CYP2C9 inhibitor, Flurbiprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Flurbiprofen is initiated, discontinued or dose changed.
DB00440	DB01320	Trimethoprim increases the effect of hydantoin
DB00440	DB01241	The strong CYP2C9 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Gemfibrozil is initiated, discontinued or dose changed.
DB00440	DB01050	The strong CYP2C9 inhibitor, Ibuprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ibuprofen is initiated, discontinued or dose changed.
DB00440	DB00328	The strong CYP2C9 inhibitor, Indomethacine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Indomethacine is initiated, discontinued or dose changed.
DB00440	DB01026	The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed.
DB00440	DB00650	The efficacy of Trimethoprim may be reduced by Leucovorin (folinic acid). The antibiotic, Trimethoprim, acts by blocking bacterial folic acid metabolism. Leucovorin may reduce the efficacy of Trimethoprim by providing an alternate source of folic acid. The therapeutic effect of Trimethoprim should be closely monitored.
DB00440	DB00784	The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed.
DB00440	DB00563	Trimethoprim may increase the adverse/toxic effects of Methotrexate (e.g. bone marrow suppression). Concomitant use should be avoided or closely monitored for Methotrexate toxicity.
DB00440	DB01110	The strong CYP2C9 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Miconazole is initiated, discontinued or dose changed.
DB00440	DB00622	The strong CYP2C9 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Nicardipine is initiated, discontinued or dose changed.
DB00440	DB00252	Trimethoprim increases the effect of hydantoin
DB00440	DB00554	The strong CYP2C9 inhibitor, Piroxicam, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Piroxicam is initiated, discontinued or dose changed.
DB00440	DB01035	Trimethoprim may reduce the clearance of Procainamide. Alternative treatments should be considered. If Trimethoprim is initiated or the dose is increased, monitor for increased toxicity of Procainamide (e.g. QTc intervals, EKG, serum drug concentrations). If Trimethoprim is discontinued or the dose decreased, monitor for reduced effects of Procainamide.
DB00440	DB01045	Rifampin decreases the effect of trimethoprim
DB00440	DB06268	The strong CYP2C9 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sitaxsentan is initiated, discontinued or dose changed.
DB00440	DB00359	The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed.
DB00440	DB00263	The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed.
DB00440	DB00684	Increased risk of nephrotoxicity
DB00440	DB01124	The strong CYP2C9 inhibitor, Tolbutamide, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Tolbutamide is initiated, discontinued or dose changed.
DB00440	DB00519	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00440	DB00755	The moderate CYP2C8 inhibitor, Trimethoprim, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Trimethoprim is initiated, discontinued to dose changed.
DB00441	DB01418	Gemcitabine may increase the anticoagulant effect of acenocoumarol.
DB00441	DB01125	Gemcitabine may increase the anticoagulant effect of anisindione.
DB00441	DB00006	Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity.
DB00441	DB00266	Gemcitabine may increase the anticoagulant effect of dicumarol.
DB00441	DB01229	Paclitaxel increases the effect/toxicity of gemcitabine
DB00441	DB06287	Co-administration of Temsirolimus and Gemcitabine may result in serious adverse drug reactions.
DB00441	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00441	DB00682	Gemcitabine may increase the anticoagulant effect of warfarin.
DB00443	DB01418	The corticosteroid, betamethasone, alters the anticoagulant effect, acenocoumarol.
DB00443	DB00945	The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00443	DB01122	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, ambenonium.
DB00443	DB01351	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01125	The corticosteroid, betamethasone, alters the anticoagulant effect of anisindione.
DB00443	DB01352	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01294	The corticosteroid, betamethasone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB00443	DB00237	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00241	The barbiturate, butalbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01353	The barbiturate, butethal, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00266	The corticosteroid, betamethasone, alters the anticoagulant effect of dicumarol.
DB00443	DB01341	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01010	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, edrophonium.
DB00443	DB00754	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01354	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01355	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB05039	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB00443	DB01397	The corticosteroid, betamethasone, may decrease the effect of magnesium salicylate.
DB00443	DB00532	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00474	The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00849	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00211	Increased arterial pressure
DB00443	DB00312	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00545	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00443	DB01346	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB01398	The corticosteroid, betamethasone, may decrease the effect of the salicylate, salicylate-sodium.
DB00443	DB01399	The corticosteroid, betamethasone, may decrease the effect of the salicylate, salsalate.
DB00443	DB00418	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00382	Tacrine and Betamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00443	DB00306	The barbiturate, talbutal, may decrease the effect of the corticosteroid, betamethasone.
DB00443	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00443	DB01401	The corticosteroid, betamethasone, may decrease the effect of the salicylate, trisalicylate-choline.
DB00443	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB00443	DB00682	The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin.
DB00444	DB00701	The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Amprenavir is initiated, discontinued or dose changed.
DB00444	DB01072	The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Atazanavir is initiated, discontinued or dose changed.
DB00444	DB00237	Barbiturates like butabarbital may decrease the serum concentration of Teniposide. arbiturates may decrease the serum concentration of Teniposide.
DB00458	DB01363	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedra.
DB00444	DB00241	Barbiturates such as butalbital may decrease the serum concentration of teniposide. Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely.
DB00444	DB01211	The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Clarithromycin is initiated, discontinued or dose changed.
DB00444	DB00872	The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Conivaptan is initiated, discontinued or dose changed.
DB00444	DB01264	The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Darunavir is initiated, discontinued or dose changed.
DB00444	DB00705	The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Delavirdine is initiated, discontinued or dose changed.
DB00444	DB01319	The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Fosamprenavir is initiated, discontinued or dose changed.
DB00444	DB00619	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Imatinib is initiated, discontinued or dose changed.
DB00444	DB00224	The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Indinavir is initiated, discontinued or dose changed.
DB00444	DB00951	The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Isoniazid is initiated, discontinued or dose changed.
DB00444	DB01167	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Itraconazole is initiated, discontinued or dose changed.
DB00444	DB01026	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed.
DB00444	DB01601	The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Lopinavir is initiated, discontinued or dose changed.
DB00444	DB01110	The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Miconazole is initiated, discontinued or dose changed.
DB00444	DB00108	The immunosuppressant, Teniposide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00444	DB01149	The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nefazodone is initiated, discontinued or dose changed.
DB00444	DB00220	The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nelfinavir is initiated, discontinued or dose changed.
DB00444	DB00622	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nicardipine is initiated, discontinued or dose changed.
DB00444	DB01263	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Posaconazole is initiated, discontinued or dose changed.
DB00444	DB00908	The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Quinidine is initiated, discontinued or dose changed.
DB00444	DB01369	This combination presents an increased risk of toxicity
DB00444	DB00503	The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ritonavir is initiated, discontinued or dose changed.
DB00444	DB01232	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Saquinavir is initiated, discontinued or dose changed.
DB00444	DB00976	The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Telithromycin is initiated, discontinued or dose changed.
DB00444	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00444	DB00582	The strong CYP3A4 inhibitor, Voriconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Voriconazole is initiated, discontinued or dose changed.
DB00445	DB00501	Cimetidine can increase epirubicin levels
DB00445	DB00072	Trastuzumab may increase the cardiotoxicity of Epirubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00446	DB00241	Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased.
DB00446	DB00672	Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide.
DB00446	DB00091	Chloramphenicol may increase the effect of cyclosporine.
DB00446	DB00754	Increases phenytoin, modifies chloramphenicol
DB00446	DB01320	Increases phenytoin, modifies chloramphenicol
DB00446	DB01120	Chloramphenicol may increase the effect of sulfonylurea, gliclazide.
DB00446	DB01067	Chloramphenicol may increase the effect of sulfonylurea, glipizide.
DB00446	DB01289	Chloramphenicol may increase the effect of sulfonylurea, glisoxepide.
DB00446	DB01016	Chloramphenicol may increase the effect of sulfonylurea, glibenclamide.
DB00446	DB01382	Chloramphenicol may increase the effect of sulfonylurea, glycodiazine.
DB00446	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB00446	DB00532	Increases phenytoin, modifies chloramphenicol
DB00446	DB00252	Increases phenytoin, modifies chloramphenicol
DB00446	DB01045	Rifampin decreases the effect of chloramphenicol
DB00446	DB06207	Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated.
DB00446	DB00864	Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered.
DB00446	DB00599	Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted.
DB00446	DB00839	Chloramphenicol may increase the effect of sulfonylurea, tolazamide.
DB00446	DB01124	Chloramphenicol may increase the effect of sulfonylurea, tolbutamide.
DB00447	DB01032	Probenecid may increase the serum level of loracarbef.
DB00448	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00448	DB06616	Concomitant lansoprazole (PPI) decreased bosutinib Cmax by 46% and AUC by 26% compared to bosutinib alone. Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours.
DB00448	DB01066	Proton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB00448	DB00758	Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB00448	DB00467	Lansoprazole may decrease the absorption of enoxacin.
DB00448	DB00224	Omeprazole decreases the absorption of indinavir
DB00448	DB01167	The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole.
DB00448	DB01026	The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.
DB00448	DB06209	Lansoprazole is a CYP2C19 substrate which decreases AUC and Cmax of prasugrel. Despite these decreases, there was no significant reduction of inhibition of platelet aggregation.
DB00448	DB08864	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB00448	DB00364	Sucralfate decreases the effect of lansoprazole
DB00449	DB06700	Desvenlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00449	DB00285	Venlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00450	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00450	DB00484	Droperidol may enhance the CNS depressant effect of brimonidine. Consider therapy modification.
DB00450	DB00921	Droperidol may enhance the CNS depressant effect of CNS Depressants like buprenorphine. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00450	DB00237	Droperidol may enhance the CNS depressant effect of CNS Depressants like butabarbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00450	DB00241	Droperidol may enhance the CNS depressant effect of CNS depressants such as butalbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00450	DB00611	Droperidol may enhance the CNS depressant effect of butorphanol. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00450	DB00395	Droperidol may enhance the CNS depressant effect of carisoprodol. Consider dose reductions of droperidol or of other CNS agents with concomitant use.
DB00450	DB01551	Enhanced CNS depressant effects are possible. Consider dose reduction of a CNS agent, if concurrent use is not avoidable.
DB00450	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00450	DB01369	This combination presents an increased risk of toxicity
DB00450	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Droperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00450	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00450	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB00450	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00450	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00450	DB00662	Trimethobenzamide and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00450	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00450	DB00427	Triprolidine and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00450	DB00209	Trospium and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00450	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00450	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00450	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00450	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00451	DB01418	The thyroid hormone, levothyroxine, increase the anticoagulant effect of acenocoumarol.
DB00451	DB01125	The thyroid hormone, levothyroxine, increase the anticoagulant effect of anisindione.
DB00451	DB01373	Calcium decreases absorption of levothyroxine
DB00451	DB00258	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB00451	DB01164	Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB00451	DB01432	The resin, cholestyramine, decreases the absorption of the thyroid hormone, levothyroxine.
DB00451	DB00375	The resin, colestipol, decreases the absorption of the thyroid hormone, levothyroxine.
DB00451	DB00266	The thyroid hormone, levothyroxine, increase the anticoagulant effect of dicumarol.
DB00451	DB00390	The thyroid hormone, levothyroxine, decreases the effect of digoxin.
DB00451	DB01592	Iron decreases absorption of levothyroxine
DB00451	DB00893	Iron decreases the absorption of levothyroxine
DB00451	DB00481	Raloxifene decreases absorption of levothyroxine
DB00451	DB00364	Sucralfate decreases the effect of levothyroxine
DB00451	DB00682	Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed.
DB00454	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00454	DB00477	Increased sedation and hypotension
DB00454	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00454	DB00843	Possible antagonism of action
DB00454	DB06210	Increases levels of Meperidine via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00454	DB00674	Possible antagonism of action
DB00454	DB01247	Potentially fatal adverse effects
DB00454	DB00951	Possible episodes of hypotension
DB00454	DB01171	Increased CNS toxicity (can cause death)
DB00454	DB00780	Potentially fatal adverse effects
DB00454	DB01367	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB00454	DB00503	Ritonavir increases the levels of analgesic
DB00454	DB00989	Possible antagonism of action
DB00454	DB01037	Potentially fatal adverse effects
DB00454	DB01105	Possible serotoninergic syndrome
DB00454	DB00932	Tipranavir may increase the adverse/toxic effects of Meperidine. Consider alternate therapy or monitor for Meperidine toxicity during concomitant use.
DB00454	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00454	DB00752	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB00454	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00454	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00454	DB00427	The CNS depressants, Triprolidine and Meperidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00454	DB00315	Use of two serotonin modulators, such as zolmitriptan and meperidine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00455	DB01149	Increased risk of cardiotoxicity
DB00455	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Loratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00455	DB00662	Trimethobenzamide and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00455	DB00427	Triprolidine and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00455	DB00209	Trospium and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00456	DB00479	Increased risk of nephrotoxicity
DB00457	DB01193	Risk of hypotension at the beginning of therapy
DB00457	DB00335	Risk of hypotension at the beginning of therapy
DB00457	DB00195	Beta-Blockers such as betaxolol may enhance the orthostatic hypotensive effect of Alpha1-Blockers such as prazosin. The risk associated with ophthalmic products is probably less than systemic products. Exercise caution if an alpha1-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha1-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha1-blocker is being used to treat BPH, consider using tamsulosin since its alpha1-A selectivity is least likely to cause hypotension.
DB00457	DB01295	Risk of hypotension at the beginning of therapy
DB00457	DB00612	Risk of hypotension at the beginning of therapy
DB00457	DB00521	Risk of hypotension at the beginning of therapy
DB00457	DB01136	Risk of hypotension at the beginning of therapy
DB00457	DB06695	P-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB00457	DB00390	Prazosin increases the effect of digoxin
DB00457	DB00187	Risk of hypotension at the beginning of therapy
DB00457	DB00598	Risk of hypotension at the beginning of therapy
DB00457	DB00264	Risk of hypotension at the beginning of therapy
DB00457	DB01203	Risk of hypotension at the beginning of therapy
DB00457	DB01580	Risk of hypotension at the beginning of therapy
DB00457	DB01359	Risk of hypotension at the beginning of therapy
DB00457	DB00960	Risk of hypotension at the beginning of therapy
DB00457	DB01297	Risk of hypotension at the beginning of therapy
DB00457	DB00571	Risk of hypotension at the beginning of therapy
DB00457	DB00489	Risk of hypotension at the beginning of therapy
DB00457	DB00820	Tadalafil may enhance the hypotensive effect of Prazosin. Monitor for hypotension during concomitant therapy.
DB00457	DB00706	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Prazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00457	DB00373	Risk of hypotension at the beginning of therapy
DB00457	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00457	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Prazosin, may occur. Monitor for hypotension during concomitant therapy.
DB00457	DB00661	Risk of hypotension at the beginning of therapy
DB00458	DB00488	Risk of severe hypotension
DB00458	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00458	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if atazanavir if initiated, discontinued or dose changed.
DB00458	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00458	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00458	DB00564	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed.
DB00458	DB00501	Cimetidine may increase the effect of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if cimetidine is initiated, discontinued or dose changed.
DB00458	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00458	DB00575	The tricyclic antidepressant, imipramine, decreases the effect of clonidine.
DB00458	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00458	DB01341	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, imipramine.
DB00458	DB00841	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dobutamine.
DB00458	DB00843	Possible antagonism of action
DB00458	DB00988	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dopamine.
DB00458	DB00476	Possible increase in the levels of this agent when used with duloxetine
DB00458	DB01288	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of fenoterol.
DB00458	DB00196	Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of imipramine if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00458	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed.
DB00458	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed.
DB00458	DB00674	Possible antagonism of action
DB00458	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00458	DB01170	The tricyclic antidepressant, imipramine, may increase the sympathomimetic effect of guanethidine.
DB00458	DB06704	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function
DB00458	DB01247	Possibility of severe adverse effects
DB00458	DB01064	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of isoproterenol.
DB00458	DB01026	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed.
DB00458	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00458	DB01365	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of mephentermine.
DB00458	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00458	DB00610	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of metaraminol.
DB00458	DB00723	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of methoxamine.
DB00458	DB01171	Possible severe adverse reaction with this combination
DB00458	DB00368	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of norepinephrine.
DB00458	DB00816	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of orciprenaline.
DB00458	DB00780	Possibility of severe adverse effects
DB00458	DB00388	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylephrine.
DB00458	DB00397	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB00458	DB01291	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pirbuterol.
DB00458	DB01366	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of procaterol.
DB00458	DB00852	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pseudoephedrine.
DB00458	DB00908	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00458	DB01346	Quinidine barbiturate increases the effect of tricyclic antidepressant, imipramine.
DB00458	DB01367	Possibility of severe adverse effects
DB00458	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifabutin is initiated, discontinued or dose changed.
DB00458	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed.
DB00458	DB00503	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ritonavir if initiated, discontinued or dose changed.
DB00458	DB00989	Possible antagonism of action
DB00458	DB01001	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of salbutamol.
DB00458	DB01105	Increased risk of CNS adverse effects
DB00458	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00458	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Imipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00458	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00458	DB00675	Imipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00458	DB00706	Imipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imipramine is initiated, discontinued, or dose changed.
DB00458	DB00857	Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if terbinafine is initiated, discontinued or dose changed.
DB00458	DB00871	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of terbutaline.
DB00458	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00458	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00612	DB00457	Risk of hypotension at the beginning of therapy
DB00458	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00458	DB00208	Ticlopidine may decrease the metabolism and clearance of Imipramine. Consider alternate therapy or monitor for adverse/toxic effects of Imipramine if Ticlopidine is initiated, discontinued or dose changed.
DB00458	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00458	DB00193	Tramadol increases the risk of serotonin syndrome and seizures. Imipramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00458	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00458	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00458	DB00662	Trimethobenzamide and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00458	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00458	DB00427	Triprolidine and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00458	DB00209	Trospium and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00458	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00458	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00458	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00458	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00458	DB00315	Use of two serotonin modulators, such as zolmitriptan and imipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00458	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00459	DB00618	Increased risk of intracranial hypertension
DB00459	DB00254	Increased risk of intracranial hypertension
DB00459	DB00931	Increased risk of intracranial hypertension
DB00459	DB00563	Acitretin/etretinate increases the effect and toxicity of methotrexate
DB00459	DB01017	Increased risk of intracranial hypertension.
DB00459	DB00717	Acitretine may cause a loss of contraceptive effect
DB00459	DB00595	Increased risk of intracranial hypertension
DB00459	DB01301	Increased risk of intracranial hypertension
DB00459	DB00759	Increased risk of intracranial hypertension
DB00459	DB00162	Acitretin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking acitretin.
DB00461	DB01418	The NSAID, nabumetone, may increase the anticoagulant effect of acenocoumarol.
DB00461	DB00630	Increased risk of gastric toxicity
DB00461	DB01125	The NSAID, nabumetone, may increase the anticoagulant effect anisindione.
DB00461	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00461	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00461	DB00091	Monitor for nephrotoxicity
DB00461	DB00266	The NSAID, nabumetone, may increase the anticoagulant effect of dicumarol.
DB00461	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00461	DB00563	The NSAID, nabumetone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00461	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00461	DB00966	Concomitant use of Telmisartan and Nabumetone may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00461	DB00373	The NSAID, Nabumetone, may antagonize the antihypertensive effect of Timolol.
DB00461	DB00519	The NSAID, Nabumetone, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Nabumetone is initiated, discontinued or dose changed.
DB00461	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Nabumetone. Monitor for increased bleeding during concomitant thearpy.
DB00461	DB00682	The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00462	DB08810	Anticholinergic agents like methylscopolamine may reduce the action of cinitapride.
DB00462	DB00843	Possible antagonism of action
DB00462	DB00674	Possible antagonism of action
DB00462	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methylscopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00612	DB01366	Antagonism
DB00462	DB00662	Trimethobenzamide and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00462	DB00427	Triprolidine and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00462	DB00209	Trospium and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00465	DB01418	The NSAID, ketorolac, may increase the anticoagulant effect of acenocoumarol.
DB00465	DB00945	Acetylsalicylic acid may increase the adverse GI effects ketorolac.
DB00465	DB00630	Increased risk of gasrtic toxicity
DB00465	DB01125	The NSAID, ketorolac, may increase the anticoagulant effect of anisindione.
DB00465	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00465	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00465	DB00266	The NSAID, ketorolac, may increase the anticoagulant effect of dicumarol.
DB00465	DB06781	NSAIDs may slow healing.
DB00465	DB06210	Increases levels of Ketorolac via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00465	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00465	DB01009	Concomitant use of ketoprofen and ketorolac, two NSAIDs, is contraindicated due to the risk of additive or synergistic NSAID toxicities (e.g. GI bleeding, ulceration, renal dysfunction, etc).
DB00465	DB01356	The NSAID, ketorolac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00465	DB00563	The NSAID, ketorolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00465	DB01032	Probenecid increases toxicity of ketorolac
DB00465	DB00605	May cause additive or synergistic NSAID toxicities (e.g. GI bleeding, renal dysfunction, etc.). Concomitant therapy is contraindicated.
DB00465	DB00966	Concomitant use of Telmisartan and Ketorolac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00465	DB01600	Concomitant therapy is contraindicated due to the risk of synergistic NSAID toxicity.
DB00465	DB00373	The NSAID, Ketorolac, may antagonize the antihypertensive effect of Timolol.
DB00465	DB00500	Risk of adverse NSAID toxic effects (e.g. GI bleeding, renal dysfunction). Concomitant therapy is contraindicated.
DB00465	DB00519	The NSAID, Ketorolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketorolac is initiated, discontinued or dose changed.
DB00465	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketorolac. Monitor for increased bleeding during concomitant thearpy.
DB00465	DB06684	Increased risk of bleeding with concomitant use of vilazodone and ketorolac
DB00465	DB00682	The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00467	DB01223	Enoxacin may increase the effect of aminophylline.
DB00467	DB01373	Formation of non-absorbable complexes
DB00467	DB00501	Cimetidine may decrease the absorption of enoxacin.
DB00467	DB06210	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB00467	DB00736	Esomeprazole may decrease the absorption of enoxacin.
DB00467	DB00927	Famotidine may decrease the absorption of enoxacin.
DB00467	DB00893	Formation of non-absorbable complexes
DB00467	DB00448	Lansoprazole may decrease the absorption of enoxacin.
DB00467	DB01378	Formation of non-absorbable complexes
DB00467	DB00585	Nizatidine may decrease the absorption of enoxacin.
DB00467	DB00338	Omeprazole may decrease the absorption of enoxacin.
DB00467	DB01303	Enoxacin may increase the effect of oxtriphylline.
DB00467	DB00213	Pantoprazole may decrease the absorption of enoxacin.
DB00467	DB01129	Rabeprazole may decrease the absorption of enoxacin.
DB00467	DB00980	Enoxacin increases levels/toxicity of ramelteon
DB00467	DB00277	Enoxacin may increase the effect of theophylline.
DB00468	DB01418	Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of acenocoumarol by decreasing its metabolism via CYP2C9.
DB00468	DB01125	Quinine may increase the anticoagulant effect of anisindione.
DB00468	DB06697	Quinine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB00468	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00468	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00468	DB00732	The quinine derivative increases the effect of the muscle relaxant
DB00468	DB00266	Quinine may increase the anticoagulant effect of dicumarol.
DB00468	DB01396	Quinine/quinidine increases the effect of digoxin
DB00468	DB00390	Quinine/quinidine increases the effect of digoxin
DB00468	DB06708	Quinine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB00468	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00468	DB01336	The quinine derivative increases the effect of the muscle relaxant
DB00468	DB01337	The quinine derivative increases the effect of the muscle relaxant
DB00468	DB00202	The quinine derivative increases the effect of the muscle relaxant
DB00468	DB00675	Quinine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00468	DB00706	Quinine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinine is initiated, discontinued, or dose changed.
DB00468	DB00976	Telithromycin may reduce clearance of Quinine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quinine if Telithromycin is initiated, discontinued or dose changed.
DB00468	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00468	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00468	DB01623	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB00468	DB00539	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00468	DB00193	Quinine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00468	DB00519	May cause additive hypotensive effects. Monitor for changes in blood pressure if Quinine is initiated, discontinued or dose changed.
DB00468	DB00755	The moderate CYP2C8 inhibitor, Quinine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Quinine is initiated, discontinued to dose changed.
DB00468	DB01339	Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided.
DB00468	DB00582	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB00468	DB02546	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB00468	DB00682	Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9.
DB00468	DB00246	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00468	DB01624	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.
DB00469	DB01418	The NSAID, tenoxicam, may increase the anticoagulant effect of acenocoumarol.
DB00469	DB00630	Increased risk of gastric toxicity
DB00469	DB01125	The NSAID, tenoxicam, may increase the anticoagulant effect of anisindione.
DB00469	DB00310	Tenoxicam may antagonize the blood pressure lowering effect of Chlorthalidone. Monitor for changes in the therapeutic effect of Chlorthalidone if Tenoxicam is initiated, discontinued or dose changed.
DB00469	DB01432	Cholestyramine may decrease the serum concentration of Tenoxicam by increasing clearance. Monitor for changes in Tenoxicam therapeutic and adverse effects if Cholestyramine is initiated, discontinued or dose changed.
DB00469	DB00091	Monitor for nephrotoxicity
DB00469	DB00266	The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol.
DB00469	DB00999	Tenoxicam may antagonize the blood pressure lowering effect of Hydrochlorothiazide. Monitor for changes in the therapeutic effect of Hydrochlorothiazide if Tenoxicam is initiated, discontinued or dose changed.
DB00469	DB01356	Tenoxicam may increase the serum concentration of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed.
DB00469	DB00563	Tenoxicam may increase the serum concentration of Methotrexate by reducing renal tubular secretion of Methotrexate. Monitor for changes in Methotrexate therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed.
DB00469	DB00524	Tenoxicam may antagonize the blood pressure lowering effect of Metolazone. Monitor for changes in the therapeutic effect of Metolazone if Tenoxicam is initiated, discontinued or dose changed.
DB00469	DB00682	The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin.
DB00470	DB00662	Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended.
DB00470	DB00209	Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended.
DB00471	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Montelukast. Consider alternate therapy or monitor for changes in Montelukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00472	DB01418	The SSRI, fluoxetine, increases the effect of anticoagulant, acenocoumarol.
DB00472	DB00918	Increased risk of CNS adverse effects
DB00472	DB00321	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB00543	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB00182	Risk of serotoninergic syndrome
DB00472	DB01125	The SSRI, fluoxetine, increases the effect of anticoagulant, anisindione.
DB00472	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00472	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00472	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00472	DB00865	Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.
DB00472	DB00564	Carbamazepine may decrease the serum concentration of fluoxetine by increasing its metabolism. Fluoxetine may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses are changed.
DB00472	DB01136	The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB00472	DB01166	Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB01211	Possible serotoninergic syndrome with this combination
DB00472	DB01242	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB00363	The antidepressant increases the effect of clozapine
DB00472	DB00091	The antidepressant increases the effect and toxicity of cyclosporine
DB00472	DB00434	Possible antagonism of action
DB00472	DB01151	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00472	DB01191	Risk of serotoninergic syndrome
DB00472	DB01576	Risk of serotoninergic syndrome
DB00472	DB00514	Combination associated with possible serotoninergic syndrome
DB00472	DB00266	The SSRI, fluoxetine, increases the effect of anticoagulant, dicumarol.
DB00472	DB00937	Risk of serotoninergic syndrome
DB00472	DB00320	Possible ergotism and severe ischemia with this combination
DB00472	DB01142	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB00216	Increased risk of CNS adverse effects
DB00472	DB00696	Possible ergotism and severe ischemia with this combination
DB00472	DB00199	Possible serotoninergic syndrome with this combination
DB00472	DB00754	Fluoxetine increases the effect of phenytoin
DB00472	DB00574	Risk of serotoninergic syndrome
DB00472	DB01320	Fluoxetine increases the effect of phenytoin
DB00472	DB00998	Increased risk of CNS adverse effects
DB00472	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00472	DB04946	Fluoxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50%
DB00472	DB00458	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB00046	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00472	DB01247	Possible severe adverse reaction with this combination
DB00472	DB01321	Possible serotoninergic syndrome with this combination
DB00472	DB01009	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB00472	DB00601	Linezolide, a MAO inhibitor, may increase the serotonergic effect of fluoxetine, a SSRI. Increased for of serotonin syndrome. Concomitant therapy should be avoided.
DB00472	DB01356	The SSRI, fluoxetine, increases serum levels of lithium.
DB00472	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00472	DB00579	Risk of serotoninergic syndrome
DB00472	DB00532	Fluoxetine increases the effect of phenytoin
DB00472	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00472	DB01577	Risk of serotoninergic syndrome
DB00472	DB00264	The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, metoprolol.
DB00472	DB01171	Risk of serotoninergic syndrome
DB00472	DB00952	Increased risk of CNS adverse effects
DB00472	DB00540	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB00497	Increased risk of serotonin syndrome
DB00472	DB01579	Risk of serotoninergic syndrome
DB00472	DB00780	Possible severe adverse reaction with this combination
DB00472	DB00191	Risk of serotoninergic syndrome
DB00472	DB00397	Risk of serotoninergic syndrome
DB00472	DB00252	Fluoxetine increases the effect of phenytoin
DB00472	DB01182	Additive QTc-prolongation may occur increasing the risk of serious life-threatening arrhythmias. Fluoxetine may also increase the serum concentration of propafenone. Use caution during concomitant therapy and monitor for QTc-prolongation.
DB00472	DB00571	The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00472	DB00344	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluoxetine is initiated, discontinued or dose changed.
DB00472	DB01367	Possible severe adverse reaction with this combination
DB00472	DB00734	The SSRI, fluoxetine, increases the effect and toxicity of risperidone.
DB00472	DB00503	Increased risk of serotonin syndrome
DB00472	DB00953	Increased risk of CNS adverse effects
DB00472	DB01037	Possible severe adverse reaction with this combination
DB00472	DB01105	Risk of serotoninergic syndrome
DB00472	DB01323	St. John's Wort increases the effect and toxicity of the SSRI, fluoxetine.
DB00472	DB00669	Increased risk of CNS adverse effects
DB00472	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Fluoxetine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Fluoxetine is initiated, discontinued or if the dose is changed.
DB00472	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00472	DB00675	Fluoxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00472	DB00706	Fluoxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluoxetine is initiated, discontinued, or dose changed.
DB00472	DB00857	Terbinafine may reduce the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluoxetine if Terbinafine is initiated, discontinued or dose changed.
DB00472	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00472	DB04844	Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose.
DB00472	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00472	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00472	DB01600	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB00472	DB00932	Tipranavir increases the concentration of Fluoxetine. The Fluoxetine dose may require an adjustment.
DB00472	DB00697	Fluoxetine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00472	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for changes in Fluoxetine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00472	DB00500	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00472	DB01036	Fluoxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB00472	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00472	DB00193	The use of two serotonin modulators, such as fluoxetine and tramadol, may increase the risk of serotonin syndrome. Fluoxetine may decrease the effect of tramadol by decreasing active metabolite production.
DB00472	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00472	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00472	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluoxetine. Monitor for increased bleeding during concomitant thearpy.
DB00472	DB00726	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, trimipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used cautiously.
DB00472	DB00427	The CNS depressants, Triprolidine and Fluoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00472	DB01361	Possible serotoninergic syndrome with this combination
DB00472	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00472	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00472	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00472	DB00682	The SSRI, fluoxetine, increases the effect of anticoagulant, warfarin.
DB00472	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00472	DB00315	Use of two serotonin modulators, such as zolmitriptan and fluoxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00472	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Fluoxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if fluoxetine is initiated, discontinued or dose changed.
DB00474	DB01223	The barbiturate, methohexital, decreases the effect of aminophylline.
DB00474	DB00443	The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone.
DB00474	DB00882	The enzyme inducer, methohexital, decreases the effect of the hormone agent, clomifene.
DB00474	DB00286	The enzyme inducer, methohexital, decreases the effect of the hormone agent, conjugated estrogens.
DB00474	DB00091	The barbiturate, methohexital, increases the effect of cyclosporine.
DB00474	DB01234	The barbiturate, methohexital, may decrease the effect of the corticosteroid, dexamethasone.
DB00474	DB00255	The enzyme inducer, methohexital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00474	DB00254	The anticonvulsant, methohexital, decreases the effect of doxycycline.
DB00474	DB00783	The enzyme inducer, methohexital, decreases the effect of the hormone agent, estradiol.
DB00474	DB00977	This product may cause a slight decrease of contraceptive effect
DB00474	DB01023	The barbiturate, methohexital, decreases the effect of felodipine.
DB00474	DB00687	The barbiturate, methohexital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00474	DB00158	Folic acid decreases the effect of anticonvulsant, methohexital.
DB00474	DB00317	The CYP3A4 inducer, methohexital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00474	DB00400	The barbiturate, methohexital, decreases the effect of griseofulvin.
DB00474	DB00741	The barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00474	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00474	DB00603	The enzyme inducer, methohexital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00474	DB00351	The enzyme inducer, methohexital, decreases the effect of the hormone agent, megestrol.
DB00474	DB00333	The barbiturate, methohexital, decreases the effect of methadone.
DB00474	DB00916	The barbiturate, methohexital, decreases the effect of metronidazole.
DB00474	DB01115	The barbiturate, methohexital, decreases the effect of the calcium channel blocker, nifedipine.
DB00474	DB00717	This product may cause a slight decrease of contraceptive effect
DB00474	DB01303	The barbiturate, methohexital, decreases the effect of oxtriphylline.
DB00474	DB00860	The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisolone.
DB00474	DB00635	The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone.
DB00474	DB00908	The anticonvulsant, methohexital, decreases the effect of quinidine.
DB00474	DB00277	The barbiturate, methohexital, decreases the effect of theophylline.
DB00474	DB00620	The barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone.
DB00474	DB00726	The barbiturate, Methohexital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Methohexital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00474	DB00427	The CNS depressants, Triprolidine and Methohexital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00474	DB00661	Methohexital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methohexital is initiated, discontinued or dose changed.
DB00474	DB00682	Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed.
DB00475	DB00501	Cimetidine may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB00363	Increased risk of toxicity
DB00475	DB00754	Ethotoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB00475	DB00196	Fluconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB01320	Fosphenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB00475	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB01167	Itraconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB01322	Kava may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB01026	Ketoconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB00532	Mephenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB00475	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB00338	Omeprazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB00252	Phenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB00475	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00475	DB00976	Telithromycin may reduce clearance of Chlordiazepoxide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlordiazepoxide if Telithromycin is initiated, discontinued or dose changed.
DB00475	DB00932	Tipranavir may decrease the metabolism and clearance of Chlordiazepoxide. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased.
DB00475	DB00427	The CNS depressants, Triprolidine and Chlordiazepoxide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00475	DB00582	Voriconazole may increase the serum concentration of chlordiazepoxide by decreasing its metabolism. Monitor for chlordiazepoxide toxicity if voriconazole is initiated or dose increased.
DB00476	DB00041	Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
DB00476	DB09026	Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
DB00476	DB00321	Possible increase in the levels of this agent when used with duloxetine
DB00476	DB00537	Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of duloxetine. Monitor for changes in the therapeutic and adverse effects of duloxetine if ciprofloxacin is initiated or discontinued.
DB00476	DB01151	Possible increase in the levels of this agent when used with duloxetine
DB00476	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00476	DB01195	Possible increase in the levels of this agent when used with duloxetine
DB00476	DB00176	Fluvoxamine increases the effect and toxicity of duloxetine
DB00476	DB00458	Possible increase in the levels of this agent when used with duloxetine
DB00476	DB01247	Possible severe adverse reaction with this combination
DB00476	DB00540	Possible increase in the levels of this agent when used with duloxetine
DB00476	DB00780	Possible severe adverse reaction with this combination
DB00476	DB01182	Possible increase in the levels of this agent when used with duloxetine
DB00476	DB01367	Possible severe adverse reaction with this combination
DB00476	DB00675	Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00476	DB00706	Duloxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Duloxetine is initiated, discontinued, or dose changed.
DB00476	DB00857	Terbinafine may reduce the metabolism and clearance of Duloxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Duloxetine if Terbinafine is initiated, discontinued or dose changed.
DB00476	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed.
DB00476	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00476	DB00193	Duloxetine may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.
DB00476	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00476	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00476	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00476	DB00427	The CNS depressants, Triprolidine and Duloxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00476	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00476	DB00315	Use of two serotonin modulators, such as zolmitriptan and duloxetine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00477	DB00182	Decreased anorexic effect, may increase psychotic symptoms
DB00477	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00477	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00477	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00477	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB01191	Decreased anorexic effect, may increase psychotic symptoms.
DB00477	DB01576	Decreased anorexic effect, may increases psychotic symptoms
DB00477	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00477	DB01551	Phenothiazines may enhance hypotensive effects of opioid analgesics. It is recommended to monitor patients for hypotension.
DB00477	DB00843	Possible antagonism of action
DB00477	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00477	DB00674	Possible antagonism of action
DB00477	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB01170	Chlorpromazine may decrease the effect of guanethidine.
DB00477	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00477	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00477	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB01577	Decreased anorexic effect, may increases psychotic symptoms
DB00477	DB01578	Increased risk of convulsions
DB00477	DB00454	Increased sedation and hypotension
DB00477	DB01579	Decreased anorexic effect, may increases psychotic symptoms
DB00477	DB00830	Decreased anorexic effect, may increase psychotic symptoms
DB00477	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00477	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00477	DB00960	Increased effect of both drugs
DB00477	DB00571	Increased effect of both drugs
DB00477	DB00989	Possible antagonism of action
DB00477	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Chlorpromazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00477	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00477	DB00675	Chlorpromazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00477	DB00706	Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chlorpromazine is initiated, discontinued, or dose changed.
DB00477	DB00857	Terbinafine may reduce the metabolism and clearance of Chlorpromazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chlorpromazine if Terbinafine is initiated, discontinued or dose changed.
DB00477	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB04844	May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB00477	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00477	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00618	DB01602	Possible antagonism of action
DB00477	DB01036	Chlorpromazine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB00477	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00477	DB00193	Chlorpromazine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00477	DB00662	Trimethobenzamide and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00477	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Chlorpromazine, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Caution should be used during concomitant therapy.
DB00477	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Chlorpromazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00477	DB00209	Trospium and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00477	DB00285	Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Chlorpromazine is initiated, discontinued, or dose changed.
DB00477	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00477	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00477	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed.
DB00479	DB00732	The agent increases the effect of muscle relaxant
DB00479	DB00887	Increased ototoxicity
DB00479	DB00456	Increased risk of nephrotoxicity
DB00479	DB01326	Increased risk of nephrotoxicity
DB00479	DB01139	Increased risk of nephrotoxicity
DB00479	DB01327	Increased risk of nephrotoxicity
DB00479	DB01328	Increased risk of nephrotoxicity
DB00479	DB01329	Increased risk of nephrotoxicity
DB00479	DB00923	Increased risk of nephrotoxicity
DB00479	DB00493	Increased risk of nephrotoxicity
DB00479	DB01330	Increased risk of nephrotoxicity
DB00479	DB01331	Increased risk of nephrotoxicity
DB00479	DB01333	Increased risk of nephrotoxicity
DB00479	DB00438	Increased risk of nephrotoxicity
DB00479	DB01332	Increased risk of nephrotoxicity
DB00479	DB01212	Increased risk of nephrotoxicity
DB00479	DB01112	Increased risk of nephrotoxicity
DB00479	DB00515	Increased risk of nephrotoxicity
DB00479	DB01111	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB00479	DB01135	The agent increases the effect of muscle relaxant
DB00479	DB00903	Increased ototoxicity
DB00479	DB00695	Increased ototoxicity
DB00479	DB01336	The agent increases the effect of muscle relaxant
DB00479	DB01226	The agent increases the effect of muscle relaxant
DB00479	DB01337	The agent increases the effect of muscle relaxant
DB00479	DB01338	The agent increases the effect of muscle relaxant
DB00479	DB00728	The agent increases the effect of muscle relaxant
DB00479	DB00202	The agent increases the effect of muscle relaxant
DB00479	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Amikacin. Use caution during concomitant therapy.
DB00479	DB01041	Thalidomide increases the renal toxicity of the aminoglycoside
DB00479	DB01607	Ticarcillin may reduce the serum concentration of Amikacin. Ticarcillin may inactivate Amikacin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB00479	DB00214	Increased ototoxicity
DB00479	DB01199	The agent increases the effect of muscle relaxant
DB00479	DB01339	The agent increases the effect of muscle relaxant
DB00480	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00481	DB00269	Association not recommended
DB00481	DB01432	The resin decreases the effect of raloxifene
DB00481	DB00882	Association not recommended
DB00481	DB00930	Bile Acid Sequestrants may decrease the absorption of Raloxifene. It would seem prudent to separate the doses of raloxifene and bile acid sequestrants by at least 2 hours. The manufacturer of raloxifene recommends against coadministration of these agents.1 The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00481	DB00375	The resin decreases the effect of raloxifene
DB00481	DB00286	Association not recommended
DB00481	DB00255	Association not recommended
DB00481	DB00783	Association not recommended
DB00481	DB04573	Association not recommended
DB00481	DB04574	Association not recommended
DB00481	DB00977	Association not recommended
DB00481	DB00451	Raloxifene decreases absorption of levothyroxine
DB00481	DB01357	Association not recommended
DB00482	DB01418	Celecoxib may increase the anticoagulant effect of acenocoumarol.
DB00482	DB01125	Celecoxib may increase the anticoagulant effect of anisindione.
DB00482	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00482	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00482	DB00266	Celecoxib may increase the anticoagulant effect of dicumarol.
DB00482	DB06210	Eltrombopag increases levels of Celecoxib via metabolism decrease.
DB00482	DB00196	Fluconazole may increase the effect of celecoxib.
DB00482	DB01356	The COX-2 inhibitor increases serum levels of lithium
DB00482	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00482	DB01045	Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed.
DB00482	DB00966	Concomitant use of Telmisartan and Celecoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00482	DB00373	The NSAID, Celecoxib, may antagonize the antihypertensive effect of Timolol.
DB00482	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00482	DB00519	The NSAID, Celecoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Celecoxib is initiated, discontinued or dose changed.
DB00482	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Celecoxib. Monitor for increased bleeding during concomitant thearpy.
DB00482	DB00755	The moderate CYP2C8 inhibitor, Celecoxib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Celecoxib is initiated, discontinued to dose changed.
DB00482	DB06684	Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). To minimize the risk of bleeding associated with this combination, consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent, such as a proton pump inhibitor for the time that combined selective serotonin reuptake inhibitor (SSRIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) is necessary.
DB00482	DB00682	Celecoxib may increase the anticoagulant effect of warfarin.
DB00484	DB09026	Monitor therapy because of enhanced hypotensive effect.
DB00484	DB00450	Droperidol may enhance the CNS depressant effect of brimonidine. Consider therapy modification.
DB00484	DB01247	MAO Inhibitors like isocarboxazid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00484	DB00601	MAO Inhibitors like linezolid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00484	DB01403	Brimonidine may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of brimonidine. Consider therapy modification.
DB00484	DB01171	MAO Inhibitors like moclobemide may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00484	DB00780	MAO Inhibitors like phenelzine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00484	DB01168	MAO Inhibitors like procarbazine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00484	DB01367	MAO Inhibitors like rasagiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00484	DB01037	MAO Inhibitors like selegiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00484	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Brimonidine. Concomitant therapy is contraindicated.
DB00484	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00485	DB01418	Dicloxacillin may decrease the anticoagulant effect of acenocoumarol.
DB00485	DB01125	Dicloxacillin may decrease the anticoagulant effect of anisindione.
DB00485	DB00618	Possible antagonism of action
DB00485	DB00266	Dicloxacillin may decrease the anticoagulant effect of dicumarol.
DB00485	DB00254	Possible antagonism of action
DB00485	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00485	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00485	DB00931	Possible antagonism of action
DB00485	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00485	DB01017	Possible antagonism of action
DB00485	DB00595	Possible antagonism of action
DB00485	DB01301	Possible antagonism of action
DB00485	DB00759	Possible antagonism of action
DB00485	DB00682	Dicloxacillin may decrease the anticoagulant effect of warfarin.
DB00486	DB00662	Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended.
DB00486	DB00427	The CNS depressants, Triprolidine and Nabilone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00486	DB00209	Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended.
DB00487	DB01223	Pefloxacin may increase the effect of aminophylline.
DB00487	DB01373	Formation of non-absorbable complexes
DB00487	DB00893	Formation of non-absorbable complexes
DB00487	DB01378	Formation of non-absorbable complexes
DB00487	DB01303	Pefloxacin may increase the effect of oxtriphylline.
DB00487	DB00277	Pefloxacin may increase the effect of theophylline.
DB00488	DB00321	Risk of severe hypotension
DB00488	DB00543	Risk of severe hypotension
DB00488	DB01242	Risk of severe hypotension
DB00488	DB01151	Risk of severe hypotension
DB00488	DB01142	Risk of severe hypotension
DB00488	DB00458	Risk of severe hypotension
DB00488	DB01247	Risk of severe hypotension
DB00488	DB00540	Risk of hypotension
DB00488	DB00780	Risk of severe hypotension
DB00488	DB01367	Risk of severe hypotension
DB00488	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00489	DB00414	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00489	DB01223	Antagonism of action and increased effect of theophylline
DB00489	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00489	DB00672	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00489	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB00575	Increased hypertension when clonidine stopped
DB00489	DB00320	Ischemia with risk of gangrene
DB00489	DB00280	The beta-blocker, sotalol, may increase the toxicity of disopyramide.
DB00489	DB00668	Hypertension, then bradycardia
DB00489	DB00696	Ischemia with risk of gangrene
DB00489	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB01288	Antagonism
DB00489	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB00489	DB00983	Antagonism
DB00489	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB01120	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00489	DB01016	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00489	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB01050	Risk of inhibition of renal prostaglandins
DB00489	DB00328	Risk of inhibition of renal prostaglandins
DB00489	DB00047	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00489	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00489	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB00968	Possible hypertensive crisis
DB00489	DB00247	Ischemia with risk of gangrene
DB00489	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB00816	Antagonism
DB00489	DB01303	Antagonism of action and increased effect of theophylline
DB00489	DB00236	Antagonism
DB00489	DB00554	Risk of inhibition of renal prostaglandins
DB00489	DB00457	Risk of hypotension at the beginning of therapy
DB00489	DB00243	Possible additive effect on QT prolongation
DB00489	DB00912	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00489	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00489	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00489	DB00976	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00489	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00489	DB00871	Antagonism
DB00489	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB00277	Antagonism of action and increased effect of theophylline
DB00489	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00489	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00489	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00489	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00489	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00489	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00489	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00489	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00489	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00490	DB01211	Clarithromycin may increase the effect and toxicity of buspirone.
DB00490	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00490	DB00343	The calcium channel blocker, diltiazem, increases the effect and toxicity of buspirone.
DB00490	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of buspirone.
DB00490	DB01247	Possible blood pressure elevation
DB00490	DB01321	The macrolide, josamycin, may increase the effect and toxicity of buspirone.
DB00490	DB01149	Nefazodone increases the effect of buspirone
DB00490	DB00780	Possible blood pressure elevation
DB00490	DB01367	Possible blood pressure elevation
DB00490	DB00615	Rifabutin decreases the effect of buspirone
DB00490	DB01045	Rifampin decreases the effect of buspirone
DB00490	DB00503	Ritonavir increases the effect and toxicity of buspirone
DB00490	DB00976	Telithromycin may reduce clearance of Buspirone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buspirone if Telithromycin is initiated, discontinued or dose changed.
DB00490	DB00752	Buspirone may increase the adverse effects of Tranylcypromine. Elevation of blood pressure may occur. Concomitant therapy also may increase the risk of serotonin syndrome. Concomitant therapy should be avoided.
DB00490	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00490	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00490	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00490	DB00661	Verapamil may increase the serum concentration of Buspirone. The likely occurs via Verapamil-mediated CYP3A4 inhibition resulting in decreased Buspirone metabolism. Monitor for changes in the therapeutic/adverse effects of Buspirone if Verpamil is initiated, discontinued or dose changed.
DB00490	DB00582	Voriconazole may increase the serum concentration of buspirone likely by decreasing its metabolism via CYP3A4. Monitor for changes in the therapeutic and adverse effects of buspirone if voriconazole is initiated, discontinued or dose changed.
DB00490	DB00315	Use of two serotonin modulators, such as zolmitriptan and buspirone, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00491	DB01296	Possible hyperglycemia
DB00491	DB00052	Somatropin may antagonize the hypoglycemic effect of miglitol. Monitor for changes in fasting and postprandial blood sugars.
DB00492	DB00594	Increased risk of hyperkalemia
DB00492	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00492	DB01395	Increased risk of hyperkalemia
DB00492	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00492	DB01356	The ACE inhibitor increases serum levels of lithium
DB00492	DB01345	Increased risk of hyperkalemia
DB00492	DB00421	Increased risk of hyperkalemia
DB00492	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00492	DB00684	Increased risk of nephrotoxicity
DB00492	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00492	DB00384	Increased risk of hyperkalemia
DB00493	DB00479	Increased risk of nephrotoxicity
DB00493	DB00798	Increased risk of nephrotoxicity
DB00493	DB01172	Increased risk of nephrotoxicity
DB00493	DB00994	Increased risk of nephrotoxicity
DB00493	DB00955	Increased risk of nephrotoxicity
DB00493	DB01032	Probenecid may increase the serum level of cefotaxime.
DB00493	DB01082	Increased risk of nephrotoxicity
DB00493	DB00684	Increased risk of nephrotoxicity
DB00494	DB00714	Entacapone increases the effect and toxicity of the sympathomimetic, apomorphine.
DB00494	DB00901	Entacapone may increase the effect and toxicity of bitolterol.
DB00494	DB00841	Entacapone increases the effect and toxicity of the sympathomimetic, dobutamine.
DB00494	DB00988	Entacapone increases the effect and toxicity of the sympathomimetic, dopamine.
DB00494	DB00668	Entacapone may increase the effect and toxicity of the sympathomimetic, epinephrine.
DB00494	DB01247	Possible hypertensive crisis with this combination
DB00494	DB00221	Entacapone increases the effect and toxicity of the sympathomimetic, isoetharine.
DB00494	DB01064	Entacapone increases the effect and toxicity of the sympathomimetic, isoproterenol.
DB00494	DB00968	Entacapone may increase the effect and toxicity of the sympathomimetic, methyldopa.
DB00494	DB00368	Entacapone increases the effect and toxicity of the sympathomimetic, norepinephrine.
DB00494	DB00780	Possible hypertensive crisis with this combination
DB00494	DB00752	Additive inhibition of endogenous catecholamine metabolism may increase the therapeutic/adverse effects of both agents. Concomitant therapy should be avoided.
DB00494	DB00427	The CNS depressants, Triprolidine and Entacapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00495	DB01117	Atovaquone increases the effect and toxicity of zidovudine
DB00495	DB01211	Clarithromycin may decrease the serum concentration of zidovudine. Increased myelosuppression in mice has been observed. Consider staggering doses during concomitant therapy and closely monitor response to zidovudine therapy.
DB00495	DB00997	Additive myelosuppression may occur. Doxorubicin may decrease the efficacy of zidovudine. Concomitant therapy should be avoided.
DB00495	DB01004	Increased risk of hematologic toxicity. Concomitant therapy should be avoided.
DB00495	DB00068	The interferon increases the effect and toxicity of zidovudine
DB00495	DB00333	Methadone increases the effect and toxicity of zidovudine
DB00495	DB01032	Rash, malaise, myalgia
DB00495	DB00811	Increased risk or severity of anemia. Consider alternate therapy or monitor more closely for anemia.
DB00495	DB00615	The rifamycin decreases levels of zidovudine
DB00502	DB01026	Ketoconazole may increase the effect and toxicity of haloperidol.
DB00618	DB01053	Possible antagonism of action
DB00495	DB01045	Rifampin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifampin is initiated, discontinued or dose changed.
DB00495	DB01201	Rifapentin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifapentin is initiated, discontinued or dose changed.
DB00495	DB00649	Zidovudine may decrease the efficacy of stavudine. Concomitant therapy should be avoided.
DB00495	DB00932	Tipranavir decreases the concentration of Zidovudine.
DB00495	DB01610	The adverse/toxic effects of Zidovudine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided.
DB00496	DB01211	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB00496	DB00843	Possible antagonism of action
DB00496	DB00674	Possible antagonism of action
DB00496	DB01167	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB00496	DB01026	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB00496	DB01149	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB00496	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of darifenacin/solifenacin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of darifenacin if nelfinavir is initiated, discontinued or dose changed.
DB00496	DB00503	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB00496	DB00989	Possible antagonism of action
DB00496	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Darifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00496	DB00675	Darifenacin may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00496	DB00706	Darifenacin, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darifenacin is initiated, discontinued, or dose changed.
DB00496	DB00976	Telithromycin may reduce clearance of Darifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Darifenacin if Telithromycin is initiated, discontinued or dose changed.
DB00496	DB00193	Darifenacin may decrease the effect of Tramadol by decreasing active metabolite production.
DB00496	DB00427	Triprolidine and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00496	DB00209	Trospium and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00496	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of darifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of darifenacin  if voriconazole is initiated, discontinued or dose changed.
DB00497	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00497	DB00501	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of oxycodone. Monitor for changes in the therapeutic and adverse effects of oxycodone if cimetidine is initiated, discontinued or dose changed.
DB00497	DB00215	Increased risk of serotonin syndrome
DB00497	DB01175	Increased risk of serotonin syndrome
DB00497	DB00472	Increased risk of serotonin syndrome
DB00497	DB00176	Increased risk of serotonin syndrome
DB00497	DB00715	Increased risk of serotonin syndrome
DB00497	DB01104	Increased risk of serotonin syndrome
DB00497	DB00427	The CNS depressants, Triprolidine and Oxycodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00499	DB00976	Telithromycin may reduce clearance of Flutamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flutamide if Telithromycin is initiated, discontinued or dose changed.
DB00499	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Flutamide by decreasing Flutamide metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Flutamide if Thiabendazole is initiated, discontinued or dose changed.
DB00499	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flutamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flutamide if voriconazole is initiated, discontinued or dose changed.
DB00500	DB01418	Increased risk of bleeding. Monitor for signs and symptoms of bleeding.
DB00500	DB00945	Additive adverse effects increase the risk of gastrointestinal bleeding. Possible decrease in the cardioprotective effect of acetylsalicylic acid. Monitor for increased bleeding risk during concomitant therapy.
DB00500	DB00233	Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy.
DB00500	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00500	DB01432	Cholestyramine may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00500	DB00215	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00500	DB00930	Colesevelam may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00500	DB00375	Colestipol may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00500	DB00091	Tolmetin may increase the serum concentration of cyclosporine and/or increase the nephrotoxicity of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine serum concentration and nephrotoxicity during concomitant therapy.
DB00500	DB00055	Increased risk of bleeding. Monitor for increased bleeding during concomitant therapy.
DB00500	DB01175	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00500	DB00472	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00500	DB00176	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00500	DB01381	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB00500	DB01404	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB00500	DB00465	Risk of adverse NSAID toxic effects (e.g. GI bleeding, renal dysfunction). Concomitant therapy is contraindicated.
DB00500	DB01356	Tolmetin may increase the risk of Lithium toxicity by decreasing the renal elminiation of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tolmetin is initiated, discontinued or dose changed.
DB00500	DB00563	Tolmetin may decrease the renal excretion of Methotrexate. Alternate therapy should be considered. Otherwise, monitor for hemotologic and renal toxicities.
DB00500	DB00715	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00500	DB00642	Tolmetin may decrease the renal excretion of Pemetrexed in patients with decreased creatinine clearance. Tolmetin may be withheld in these patients from 2 days before to 2 days after Pemetrexed administration.
DB00500	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00500	DB01399	Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy.
DB00500	DB01104	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00500	DB00966	Concomitant use of Telmisartan and Tolmetin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00500	DB00373	The NSAID, Tolmetin, may antagonize the antihypertensive effect of Timolol.
DB00500	DB00519	The NSAID, Tolmetin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tolmetin is initiated, discontinued or dose changed.
DB00500	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tolmetin. Monitor for increased bleeding during concomitant thearpy.
DB00500	DB00682	The antiplatelet effects of tolmetin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00501	DB01418	Cimetidine may increase the anticoagulant effect of acenocoumarol.
DB00501	DB00802	Increases the effect of the narcotic
DB00501	DB00404	Cimetidine may increase the effect of the benzodiazepine, alprazolam.
DB00501	DB01223	Cimetidine may increase the serum concentration of aminophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aminophylline if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00321	Cimetidine may increase the effect of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00543	Cimetidine may increase the effect of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01125	Cimetidine may increase the anticoagulant effect of anisindione.
DB00501	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00501	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00501	DB06769	CA1A2 hepatic enzyme metabolism is affected by increased amounts of bendamustine by cimetidine. In addition, decreased conversion of bendamustine to active metabolites occurs. Amounts of active metabolites may be decreased. Decreased conversion of bendamustine to active metabolites also occurs.
DB00501	DB01558	Co-administration with cimetidine will cause a reduction in bromazepam clearance and increases half-life.
DB00501	DB00564	Cimetidine may increase the serum concentration of carbamazepine during the first few days of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of carbamazepine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00262	Increases myelosuppression caused by carmustine
DB00501	DB01066	H2-Antagonists such as cimetidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB00501	DB00475	Cimetidine may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00501	DB01242	Cimetidine may increase the effect of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01068	Cimetidine may increase the effect of the benzodiazepine, clonazepam.
DB00501	DB00628	Cimetidine may increase the effect of the benzodiazepine, clorazepate.
DB00502	DB01356	Possible extrapyramidal effects and neurotoxicity with this combination
DB00501	DB00363	Cimetidine may increase the serum concentratin of clozapine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00318	Cimetidine may decrease the therapeutic effect of codeine by decreasing its metabolism to its active metabolite, morphine. Monitor for changes in the therapeutic effect of codeine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01151	Cimetidine may increase the effect of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00647	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of propoxyphene. Monitor for changes in the therapeutic and adverse effects of propoxyphene if cimetidine is intitiated, discontinued or dose changed.
DB00501	DB00829	Cimetidine may increase the effect of the benzodiazepine, diazepam.
DB00501	DB00266	Cimetidine may increase the anticoagulant effect of dicumarol.
DB00501	DB01341	Increases the effect of quinidine
DB00501	DB00204	Increases effect/toxicity of dofetilide
DB00501	DB00843	Possible antagonism of action
DB00501	DB01142	Cimetidine may increase the effect of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00651	Increases the effect of theophylline
DB00501	DB06210	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB00501	DB00467	Cimetidine may decrease the absorption of enoxacin.
DB00501	DB00445	Cimetidine can increase epirubicin levels
DB00501	DB01215	Cimetidine may increase the effect of the benzodiazepine, estazolam.
DB00501	DB00754	Increases the effect of hydantoin
DB00501	DB00813	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of fentanyl. Closely monitor changes in the therapeutic and adverse effects of fentanyl if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01195	Cimetidine, a moderate CYP2D6 inhibitor, may decrease the metabolism of flecainide.
DB00501	DB00690	Cimetidine may increase the effect of the benzodiazepine, flurazepam.
DB00501	DB01320	Cimetidine may increase the serum concentration of fosphenytoin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fosphenytoin if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00674	Possible antagonism of action
DB00501	DB00801	Cimetidine may increase the effect of the benzodiazepine, halazepam.
DB00501	DB01452	Cimetidine increases the effect of the narcotic
DB00501	DB00458	Cimetidine may increase the effect of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01167	The H2-receptor antagonist, cimetidine, may decrease the absorption of itraconazole.
DB00501	DB01587	Cimetidine may increase the effect of the benzodiazepine, ketazolam.
DB00501	DB01026	The H2-receptor antagonist, cimetidine, may decrease the absorption of ketoconazole.
DB00501	DB00598	Cimetidine may increase the serum concentration of labetolol by decreasing its metabolism.
DB00501	DB00281	Increases the effect and toxicity of lidocaine
DB00501	DB00532	Increases the effect of hydantoin
DB00501	DB00331	Cimetidine may increase the therapeutic and adverse effects of metformin by increasing its serum concentration. Consider alternate therapy.
DB00501	DB00333	Cimetidine, a moderate CYP3A4 inhibitor, may increase the serum concentration of metahdone, a CYP3A4 substrate. Monitor for changes in the therapeutic and adverse effects of methadone if cimetidine is initiatied, discontinued or dose changed.
DB00501	DB00264	Cimetidine may increase the serum concentration of metoprolol by decreasing its metabolism.
DB00501	DB00683	Cimetidine may increase the effect of the benzodiazepine, midazolam.
DB00501	DB01171	Cimetidine may increase the serum concentration of moclobemide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moclobemide if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00844	Increases the effect of the narcotic
DB00501	DB01115	Cimetidine may increase the effect of the calcium channel blocker, nifedipine.
DB00501	DB00393	Cimetidine increases the effect of the calcium channel blocker, nimodipine.
DB00501	DB01054	Cimetidine increases the effect of the calcium channel blocker, nitrendipine.
DB00501	DB00540	Cimetidine may increase the effect of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01303	Cimetidine may increase the serum concentration of oxtriphylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of oxtriphylline if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00497	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of oxycodone. Monitor for changes in the therapeutic and adverse effects of oxycodone if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01192	Increases the effect of the narcotic
DB00501	DB06589	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB00501	DB00252	Cimetidine may increase the therapeutic effect of phenytoin.
DB00501	DB01263	Significant decrease of posaconazole levels
DB00501	DB00413	Cimetidine may increase the effect and toxicity of pramipexole.
DB00501	DB01588	Cimetidine may increase the effect of the benzodiazepine, prazepam.
DB00501	DB01035	The histamine H2-receptor antagonist, cimetidine, may increase the effect of procainamide.
DB00501	DB00571	Cimetidine may increase the serum concentration of propranolol by decreasing its metabolism.
DB00502	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00502	DB04843	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00501	DB00344	Cimetidine may increase the effect of tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01589	Cimetidine may increase the effect of the benzodiazepine, quazepam.
DB00501	DB00908	Cimetidine may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB01346	Increases the effect of quinidine
DB00501	DB00989	Possible antagonism of action
DB00501	DB01656	Increases roflumilast levels.
DB00501	DB00203	Increases the effect and toxicity of sildenafil
DB00501	DB00708	Increases the effect of the narcotic
DB00501	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Cimetidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Cimetidine is initiated, discontinued or if the dose is changed.
DB00501	DB00864	Cimetidine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Cimetidine therapy is initiated, discontinued or altered.
DB00501	DB00675	Cimetidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00501	DB00706	Cimetidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cimetidine is initiated, discontinued, or dose changed.
DB00501	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00501	DB00277	Cimetidine may increase the effect of theophylline.
DB00501	DB00208	Cimetidine may increase Ticlopidine levels. Avoid concomitant therapy.
DB00501	DB00373	Cimetidine may increase the serum concentration of timolol by decreasing its metabolism.
DB00501	DB00697	Cimetidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00501	DB00797	Anticipated loss of efficacy of tolazoline
DB00501	DB01036	Cimetidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00501	DB00193	Cimetidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Cimetidine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00501	DB00656	The CYP3A4 inhibitor, Cimetidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cimetidine is initiated, discontinued or dose changed.
DB00501	DB00897	Cimetidine may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of triazolam if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00726	Cimetidine may increase the effect of tricyclic antidepressant, trimipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed.
DB00501	DB06684	Cimetidine may decrease the metabolism of Selective Serotonin Reuptake Inhibitors. Consider using an alternative H2-antagonist to avoid the risk of selective serotonin reuptake inhibitor (SSRI) toxicity. Monitor for increased therapeutic or toxic effects of SSRI if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.
DB00501	DB00682	Cimetidine may increase the serum concentration of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if cimetidine is initiated, discontinued or dose changed.
DB00501	DB00962	Cimetidine may increase the serum concentration of zaleplon by decreasing its metabolism. Reduce the initial dose of zaleplon to 5 mg in patients receiving cimetidine.
DB00502	DB00517	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00502	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00502	DB00572	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00245	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00810	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00564	Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed.
DB00502	DB00771	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00363	Clozapine, a moderate CYP2D6 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive CNS despresant and anticholinergic effects may also occur. Monitor for changes in the therapeutic and adverse effects of haloperidol if clozapine is initiated, discontinued or dose changed. Also monitor for increased CNS depressant and anticholinergic effects during concomitant therapy.
DB00502	DB00804	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00392	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00196	Fluconazole may increase the effect and toxicity of haloperidol.
DB00502	DB08909	Haloperidol may induce hyperammonemia. Monitor ammonia levels closely when use of haloperidol is necessary in UCD patients.
DB00502	DB00986	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB01170	Haloperidol may decrease the effect of guanethidine.
DB00502	DB00725	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00424	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB05039	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB00502	DB01625	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB01167	Itraconazole may increase the effect and toxicity of haloperidol.
DB00502	DB00940	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00968	Methyldopa increases haloperidol effect or risk of psychosis
DB00502	DB01173	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00383	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00387	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00782	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00571	Increased effect of both drugs
DB00502	DB00615	The rifamycin decreases the effect of haloperidol
DB00502	DB01045	The rifamycin decreases the effect of haloperidol
DB00502	DB00747	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Haloperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00502	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00502	DB00675	Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00502	DB00706	Haloperidol, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Haloperidol is initiated, discontinued, or dose changed.
DB00502	DB00976	Telithromycin may reduce clearance of Haloperidol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Haloperidol if Telithromycin is initiated, discontinued or dose changed.
DB00502	DB00857	Terbinafine may reduce the metabolism and clearance of Haloperidol. Consider alternate therapy or monitor for therapeutic/adverse effects of Haloperidol if Terbinafine is initiated, discontinued or dose changed.
DB00502	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB00502	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00502	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00502	DB01036	Haloperidol may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00502	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00502	DB00193	Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production.
DB00502	DB00656	The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed.
DB00502	DB00505	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00376	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00502	DB00662	Trimethobenzamide and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00502	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00502	DB00427	Triprolidine and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00502	DB00209	Trospium and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00502	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of haloperidol if voriconazole is initiated, discontinued or dose changed.
DB00502	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00502	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00502	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00503	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Ritonavir. The antiviral response should be closely monitored.
DB00503	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB00503	DB00346	Ritonavir increases the effect/toxicity of alfuzosin
DB00503	DB00404	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, alprazolam.
DB00503	DB01223	Ritonavir decreases the effect of theophylline
DB00503	DB01118	Ritonavir increases the effect and toxicity of amiodarone
DB00503	DB00321	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ritonavir if initiated, discontinued or dose changed.
DB00503	DB00543	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if ritonavir if initiated, discontinued or dose changed.
DB00637	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00503	DB06605	Avoid combination. Otherwise, ritonavir will likely increase apixaban serum concentration.
DB00503	DB00673	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00503	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00503	DB01072	Association with dose adjustment
DB00503	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00503	DB01076	Ritonavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if ritonavir is initiated, discontinued or dose changed.
DB00503	DB06237	Co-administration with the strong CYP3A4 inhibitor ritonavir resulted in an approximate 13-fold increase in AUC0-inf and 2.4-fold increase in Cmax of avanafil.
DB00503	DB01244	Ritonavir increases the effect and toxicity of bepridil
DB00503	DB01558	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if ritonavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00503	DB01156	Ritonavir increases the effect and toxicity of bupropion
DB00503	DB00490	Ritonavir increases the effect and toxicity of buspirone
DB00503	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB00503	DB08907	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB00503	DB00564	Ritonavir increases the effect of carbamazepine
DB00503	DB00475	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB00503	DB01410	Increased effects/toxicity of ciclesonide
DB00503	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00503	DB01242	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if ritonavir if initiated, discontinued or dose changed.
DB00503	DB01068	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clonazepam.
DB00503	DB00628	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clorazepate.
DB00503	DB00363	Ritonavir increases the effect and toxicity of clozapine
DB00503	DB00091	The protease inhibitor, ritonavir, may increase the effect of cyclosporine.
DB00503	DB01219	Ritonavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ritonavir is initiated, discontinued or dose changed.
DB00503	DB00496	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB00503	DB00705	Increases the effect of ritonavir
DB00503	DB01151	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if ritonavir if initiated, discontinued or dose changed.
DB00503	DB00647	Ritonavir increases the levels of analgesic
DB00503	DB00829	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, diazepam.
DB00503	DB00390	Ritonavir increases levels/effect of digoxin
DB00503	DB00320	The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.
DB00503	DB00343	Ritonavir increases diltiazem levels
DB00503	DB01142	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if ritonavir if initiated, discontinued or dose changed.
DB00503	DB04855	Ritonavir is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB00503	DB00216	The protease inhibitor, ritonavir, may increase the effect and toxicity of eletriptan.
DB00503	DB00700	This protease inhibitor, ritonavir, may increase the effect and toxicity of eplerenone.
DB00503	DB00696	The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, ergotamine.
DB00503	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00503	DB00199	Increased toxicity of both agents
DB00503	DB01215	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, estazolam.
DB00503	DB00977	Ritonavir could decrease the contraceptive efficacy
DB00503	DB00813	Ritonavir increases the effect and toxicity of fentanyl/alfentanyl
DB00503	DB01195	Ritonavir increases the toxicity of the anti-arrhythmic
DB00503	DB00472	Increased risk of serotonin syndrome
DB00503	DB00690	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, flurazepam.
DB00503	DB08906	Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Consider alternative therapy.
DB00503	DB02703	The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid.
DB00503	DB00317	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB00503	DB00458	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ritonavir if initiated, discontinued or dose changed.
DB00503	DB05039	Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events.
DB00503	DB01167	Itraconazole may increase the effect and toxicity of ritonavir.
DB00503	DB01026	Ketoconazole may increase the effect and toxicity of ritonavir.
DB00503	DB08882	CYP3A4 inhibitors may increase levels of linagliptin. Monitor concomitant therapy closely.
DB00503	DB00227	Ritonavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB00503	DB00358	Mefloquine decreases the effect of ritonavir
DB00503	DB00333	The protease inhibitor, ritonavir, may decrease the effect of methadone.
DB00503	DB00683	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, midazolam.
DB00503	DB00540	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ritonavir if initiated, discontinued or dose changed.
DB00503	DB00334	Ritonavir decreases the effect of olanzapine
DB00503	DB01303	Ritonavir decreases the effect of theophylline
DB00503	DB06589	Ritonavir is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib.
DB00503	DB00454	Ritonavir increases the levels of analgesic
DB00503	DB01100	The protease inhibitor, ritonavir, may increase the effect and toxicity of pimozide.
DB00503	DB00554	Ritonavir increases the toxicity of piroxicam
DB00503	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB00503	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB00503	DB06209	Ritonavir is a inhibitor of CYP3A4, thus blocking the bioactivation of prasugrel. As a result, a reduction in prasugrel efficiency may be observed in patients.
DB00503	DB01182	Ritonavir increases the effect and toxicity of propafenone
DB00503	DB00908	Ritonavir increases the effect and toxicity of quinidine
DB00503	DB01369	This combination presents an increased risk of toxicity
DB00503	DB00243	Increased levels of ranolazine - risk of toxicity
DB00503	DB00615	Rifabutin decreases the effect of ritonavir
DB00503	DB01045	Rifampin decreases the effect of ritonavir
DB00503	DB06228	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 like ritonavir and P-glycoproteins are contraindicated.
DB00503	DB01656	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB00503	DB06335	Ritonavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB00503	DB06207	Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated.
DB00503	DB00864	The protease inhibitor, Ritonavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ritonavir therapy is initiated, discontinued or altered.
DB00503	DB00820	Ritonavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00503	DB00675	Ritonavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00503	DB00706	Ritonavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ritonavir is initiated, discontinued, or dose changed.
DB00503	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00503	DB00976	Ritonavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00503	DB06287	Ritonavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00503	DB00444	The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ritonavir is initiated, discontinued or dose changed.
DB00503	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00503	DB00277	Ritonavir decreases the effect of theophylline
DB00503	DB00906	The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ritonavir is initiated, discontinued or dose changed.
DB00503	DB01036	Ritonavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00503	DB06212	Ritonavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB00503	DB01030	The p-glycoprotein inhibitor, Ritonavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00503	DB00193	Ritonavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ritonavir may decrease the effect of Tramadol by decreasing active metabolite production.
DB00503	DB00656	The protease inhibitor, Ritonavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Ritonavir is initiated, discontinued or dose changed.
DB00503	DB00755	The strong CYP2C8 inhibitor, Ritonavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Ritonavir is initiated, discontinued to dose changed.
DB00503	DB00897	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, triazolam.
DB00503	DB00726	The strong CYP3A4/CYP2D6 inhibitor, Ritonavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ritonavir is initiated, discontinued or dose changed.
DB00503	DB00862	Ritonavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB00503	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB00503	DB00285	Ritonavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ritonavir is initiated, discontinued, or dose changed.
DB00503	DB00661	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ritonavir is initiated, discontinued or dose changed.
DB00521	DB00277	Antagonism of action and increased effect of theophylline
DB00637	DB00472	Increased risk of cardiotoxicity and arrhythmias
DB00503	DB00570	Ritonavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ritonavir is initiated, discontinued or dose changed.
DB00503	DB00541	Ritonavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ritonavir is initiated, discontinued or dose changed.
DB00503	DB00361	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ritonavir is initiated, discontinued or dose changed.
DB00503	DB00582	Ritonavir may decrease the serum concentration of voriconazole by increasing its metabolism. Concomitant therapy with high dose ritonavir is contraindicated. Caution should be used with lower doses as decreased voriconazole efficacy may occur.
DB00503	DB00425	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ritonavir is initiated, discontinued or dose changed.
DB00503	DB00909	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ritonavir is initiated, discontinued or dose changed.
DB00503	DB01198	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ritonavir is initiated, discontinued or dose changed.
DB00503	DB01624	Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed.
DB00505	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00508	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00508	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00508	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00508	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00508	DB00843	Possible antagonism of action
DB00508	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00508	DB00674	Possible antagonism of action
DB00508	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00508	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00508	DB01170	Triflupromazine may decrease the effect of guanethidine.
DB00508	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00508	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00508	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00508	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00508	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00509	DB01418	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of acenocoumarol.
DB00509	DB01125	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of anisindione.
DB00509	DB00266	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of dicumarol.
DB00509	DB00390	The thyroid hormone, dextrothyroxine, decreases the effect of digoxin.
DB00509	DB00682	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of warfarin.
DB00512	DB01111	Additive nephrotoxic effects may occur. Consider alternate therapy or monitor for renal function during concomitant therapy.
DB00512	DB05260	Additive nephrotoxic effects may occur. Avoid concomitant therapy.
DB00512	DB00684	Increased risk of nephrotoxicity
DB00514	DB05812	Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely.
DB00514	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00514	DB01341	Quinidine increases the toxicity of dextromethorphan
DB00514	DB00472	Combination associated with possible serotoninergic syndrome
DB00514	DB01247	Possible severe adverse reaction
DB00514	DB01171	Increased CNS toxicity
DB00514	DB00715	Combination associated with possible serotoninergic syndrome
DB00514	DB00780	Possible severe adverse reaction
DB00514	DB00908	Quinidine increases the toxicity of dextromethorphan
DB00514	DB01346	Quinidine increases the toxicity of dextromethorphan
DB00514	DB01367	Possible severe adverse reaction
DB00514	DB01037	Combination associated with possible serotoninergic syndrome
DB00514	DB01105	Combination associated with possible serotoninergic syndrome
DB00514	DB00857	Terbinafine may reduce the metabolism and clearance of Dextromethorphan. Consider alternate therapy or monitor for therapeutic/adverse effects of Dextromethorphan if Terbinafine is initiated, discontinued or dose changed.
DB00514	DB06273	Dextromethorphan is a CYP2D6 and CYP3A4 substrate. Exposure of dextromethorphan decreases following administration of tocilizumab.
DB00514	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00514	DB00752	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB00514	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00514	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00514	DB08881	Vemurafenib increases the AUC (CYP2D6 substrate) by 47% .
DB00514	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00519	DB00482	The NSAID, Celecoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Celecoxib is initiated, discontinued or dose changed.
DB00514	DB06684	Consideration should be given to avoiding the concomitant use of dextromethorphan and selective serotonin reuptake inhibitors (SSRI). Monitor for toxic effects of dextromethorphan (eg, CNS, Cardiovascular) if an SSRI is initiated or the dose is increased. SSRIs, other than fluoxetine and paroxetine, may be safer alternatives due to lesser CYP2D6 inhibition; however, the mechanism for the interaction is not fully understood, and caution is still advised.
DB00514	DB00315	Use of two serotonin modulators, such as zolmitriptan and dextromethorphan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00515	DB00479	Increased risk of nephrotoxicity
DB00515	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00515	DB00887	Increased ototoxicity
DB00515	DB06772	Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as cabazitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity.Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent.
DB00515	DB01248	Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent.
DB00515	DB00903	Increased ototoxicity
DB00515	DB01320	The antineoplasic agent decreases the effect of hydantoin
DB00515	DB00695	Increased ototoxicity
DB00515	DB00798	Increased risk of nephrotoxicity
DB00515	DB01097	Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB00515	DB00563	Cisplatin increases methotrexate toxicity
DB00515	DB00108	Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
DB00515	DB00955	Increased risk of nephrotoxicity
DB00515	DB01229	Cisplatin increases the effect and toxicity of paclitaxel
DB00515	DB00252	The antineoplasic agent decreases the effect of hydantoin
DB00515	DB00337	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cisplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00515	DB01656	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cisplatin. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB00515	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Cisplatin. Use caution during concomitant therapy.
DB00515	DB00684	Increased risk of nephrotoxicity
DB00515	DB01030	Administration of Topotecan after Cisplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed.
DB00515	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00517	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00519	DB00945	Acetylsalicylic acid may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Acetylsalicylic acid is initiated, discontinued or dose changed.
DB00519	DB00437	The ACE inhibitor, Trandolapril, may increase the risk of hypersensitivity reactions to Allopurinol.
DB00519	DB01143	Trandolapril may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trandolapril should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB00519	DB00594	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00519	DB00233	The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed.
DB00519	DB00993	Trandolapril may increase the risk of neutropenia. Monitor for increased toxic effects of Azathioprine if Trandolapril is initiated or dose increased.
DB00519	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00519	DB00436	The thiazide diuretic, Bendroflumethiazide, may increase the hypotensive effect of Trandolapril. Bendroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00865	Benzphetamine may reduce the efficacy of Trandolapril.
DB00519	DB00887	The loop diuretic, Bumetanide, may increase the hypotensive effect of Trandolapril. Bumetanide may also increase the nephrotoxicity of Trandolapril.
DB00519	DB00796	The angiotensin II receptor blocker, Candesartan, may increase the adverse effects of Trandolapril.
DB00519	DB00422	Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed.
DB00519	DB00880	The thiazide diuretic, Chlorothiazide, may increase the hypotensive effect of Trandolapril. Chlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00310	The thiazide diuretic, Chlorthalidone, may increase the hypotensive effect of Trandolapril. Chlorthalidone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00091	The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine.
DB00519	DB01576	Dextroamphetamine may reduce the efficacy of Trandolapril.
DB00519	DB01119	Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure.
DB00519	DB00586	The NSAID, Diclofenac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diclofenac is initiated, discontinued or dose changed.
DB00519	DB00861	The NSAID, Diflunisal, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diflunisal is initiated, discontinued or dose changed.
DB00519	DB01395	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00519	DB01363	Ephedra may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy.
DB00519	DB00700	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00519	DB01240	The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect of Trandolapril.
DB00519	DB00876	The angiotensin II receptor blocker, Eprosartan, may increase the adverse effects of Trandolapril.
DB00519	DB00903	The loop diuretic, Ethacrynic acid, may increase the hypotensive effect of Trandolapril. Ethacrynic acid may also increase the nephrotoxicity of Trandolapril.
DB00519	DB00749	The NSAID, Etodolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Etodolac is initiated, discontinued or dose changed.
DB00519	DB00573	The NSAID, Fenoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Fenoprofen is initiated, discontinued or dose changed.
DB00519	DB00712	The NSAID, Flurbiprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Flurbiprofen is initiated, discontinued or dose changed.
DB00519	DB00695	The loop diuretic, Furosemide, may increase the hypotensive effect of Trandolapril. Furosemide may also increase the nephrotoxicity of Trandolapril.
DB00519	DB01404	Ginseng may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy.
DB00519	DB00999	The thiazide diuretic, Hydrochlorothiazide, may increase the hypotensive effect of Trandolapril. Hydrochlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00774	The thiazide diuretic, Hydroflumethiazide, may increase the hypotensive effect of Trandolapril. Hydroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB01050	The NSAID, Ibuprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ibuprofen is initiated, discontinued or dose changed.
DB00519	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00519	DB01088	The prostacyclin analogue, Iloprost, may increase the hypotensive effect of Trandolapril.
DB00519	DB00808	The thiazide diuretic, Indapamide, may increase the hypotensive effect of Trandolapril. Indapamide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00328	The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed.
DB00519	DB01029	The angiotensin II receptor blocker, Irbesartan, may increase the adverse effects of Trandolapril.
DB00519	DB01009	The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed.
DB00519	DB00465	The NSAID, Ketorolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketorolac is initiated, discontinued or dose changed.
DB00519	DB01255	Lisdexamfetamine may reduce the efficacy of Trandolapril.
DB00519	DB01356	Trandolapril may increase the serum concentration of Lithium increasing the risk of Lithium toxicity. Monitor for changes in Lithium serum concentrations, toxicity and efficacy if Trandolapril is initiated, discontinued or dose changed.
DB00519	DB00678	The angiotensin II receptor blocker, Losartan, may increase the adverse effects of Trandolapril.
DB00519	DB01283	The NSAID, Lumiracoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Lumiracoxib is initiated, discontinued or dose changed.
DB00519	DB00939	The NSAID, Meclofenamate, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meclofenamate is initiated, discontinued or dose changed.
DB00519	DB00784	The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.
DB00519	DB00814	The NSAID, Meloxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meloxicam is initiated, discontinued or dose changed.
DB00519	DB01577	Methamphetamine may reduce the efficacy of Trandolapril.
DB00519	DB00232	The thiazide diuretic, Methyclothiazide, may increase the hypotensive effect of Trandolapril. Methyclothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00524	The thiazide diuretic, Metolazone, may increase the hypotensive effect of Trandolapril. Metolazone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00461	The NSAID, Nabumetone, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Nabumetone is initiated, discontinued or dose changed.
DB00519	DB00788	The NSAID, Naproxen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Naproxen is initiated, discontinued or dose changed.
DB00519	DB00275	The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril.
DB00519	DB00991	The NSAID, Oxaprozin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Oxaprozin is initiated, discontinued or dose changed.
DB00519	DB01579	Phendimetrazine may reduce the efficacy of Trandolapril.
DB00519	DB00191	Phentermine may reduce the efficacy of Trandolapril.
DB00519	DB00554	The NSAID, Piroxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Piroxicam is initiated, discontinued or dose changed.
DB00519	DB01324	The thiazide diuretic, Polythiazide, may increase the hypotensive effect of Trandolapril. Polythiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB01345	Increased risk of hyperkalemia
DB00519	DB00761	The potassium salt may increase the hyperkalemic effect of Trandolapril.
DB00519	DB00468	May cause additive hypotensive effects. Monitor for changes in blood pressure if Quinine is initiated, discontinued or dose changed.
DB00519	DB00073	Trandolapril may incresae the hypotensive effect of Rituximab.
DB00519	DB01399	The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Salsalate is initiated, discontinued or dose changed.
DB00519	DB00877	Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema.
DB00519	DB01390	Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced.
DB00519	DB00421	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00519	DB00605	The NSAID, Sulindac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Sulindac is initiated, discontinued or dose changed.
DB00519	DB00966	The angiotensin II receptor blocker, Telmisartan, may increase the adverse effects of Trandolapril.
DB00519	DB06287	Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema.
DB00519	DB01600	The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed.
DB00519	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00519	DB00500	The NSAID, Tolmetin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tolmetin is initiated, discontinued or dose changed.
DB00519	DB00214	The loop diuretic, Torasemide, may increase the hypotensive effect of Trandolapril. Torasemide may also increase the nephrotoxicity of Trandolapril.
DB00519	DB00374	The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril.
DB00519	DB00384	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00519	DB01021	The thiazide diuretic, Trichlormethiazide, may increase the hypotensive effect of Trandolapril. Trichlormethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00519	DB00440	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00519	DB00177	The angiotensin II receptor blocker, Valsartan, may increase the adverse effects of Trandolapril.
DB00520	DB00091	Cyclosporine increases the effect and toxicity of caspofungin
DB00520	DB01045	Decreased levels/effects of caspofungin
DB00520	DB00864	Caspofungin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Caspofungin therapy is initiated, discontinued or altered.
DB00521	DB00414	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00521	DB01223	Antagonism of action and increased effect of theophylline
DB00521	DB00672	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00521	DB00575	Increased hypertension when clonidine stopped
DB00521	DB00320	Ischemia with risk of gangrene
DB00521	DB00280	The beta-blocker, carteolol, may increase the toxicity of disopyramide.
DB00521	DB00668	Hypertension, then bradycardia
DB00521	DB00696	Ischemia with risk of gangrene
DB00521	DB01288	Antagonism
DB00521	DB00983	Antagonism
DB00521	DB01120	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00521	DB01016	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00521	DB01050	Risk of inhibition of renal prostaglandins
DB00521	DB00328	Risk of inhibition of renal prostaglandins
DB00521	DB00047	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00521	DB00968	Possible hypertensive crisis
DB00521	DB00247	Ischemia with risk of gangrene
DB00521	DB00816	Antagonism
DB00521	DB01303	Antagonism of action and increased effect of theophylline
DB00521	DB00236	Antagonism
DB00521	DB00554	Risk of inhibition of renal prostaglandins
DB00521	DB00457	Risk of hypotension at the beginning of therapy
DB00521	DB00912	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00521	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00521	DB00871	Antagonism
DB00521	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00524	DB01078	Possible electrolyte variations and arrhythmias
DB00524	DB01396	Possible electrolyte variations and arrhythmias
DB00524	DB00390	Possible electrolyte variations and arrhythmias
DB00524	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00524	DB01356	The thiazide diuretic, metolazone, may increase serum levels of lithium.
DB00524	DB00469	Tenoxicam may antagonize the blood pressure lowering effect of Metolazone. Monitor for changes in the therapeutic effect of Metolazone if Tenoxicam is initiated, discontinued or dose changed.
DB00524	DB00519	The thiazide diuretic, Metolazone, may increase the hypotensive effect of Trandolapril. Metolazone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00524	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00526	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00526	DB01030	Administration of Topotecan after Oxaliplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed.
DB00526	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00528	DB01369	This combination presents an increased risk of toxicity
DB00529	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00529	DB00537	Increased risk of convulsions
DB00529	DB00091	Monitor for nephrotoxicity
DB00529	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00529	DB01059	Increased risk of convulsions
DB00529	DB01165	Increased risk of convulsions
DB00529	DB01369	This combination presents an increased risk of toxicity
DB00529	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00529	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00529	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00529	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00529	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00529	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00529	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00529	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00530	DB01072	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB01211	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB00199	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB00224	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB01167	Itraconazole may decrease the metabolism of erlotinib. Monitor for changes in the therapeutic and adverse effects of erlotinib if itraconazole is initiated, discontinued or dose changed.
DB00530	DB01026	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB01149	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB00220	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB00615	Decreased levels/effect of erlotinib
DB00530	DB01045	Decreased levels/effect of erlotinib
DB00530	DB01201	Decreased levels/effect of erlotinib
DB00530	DB00503	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB01232	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB01323	Decreased levels/effect of erlotinib
DB00530	DB00976	Telithromycin may reduce clearance of Erlotinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erlotinib if Telithromycin is initiated, discontinued or dose changed.
DB00530	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00530	DB01361	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB00530	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erlotinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of erlotinib if voriconazole is initiated, discontinued or dose changed.
DB00531	DB01418	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of acenocoumarol.
DB00531	DB01125	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of anisindione.
DB00531	DB08879	Avoid combination due to enhanced toxic effects of cyclophosphamide.
DB00531	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00531	DB00266	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of dicumarol.
DB00531	DB00390	The antineoplasic agent decreases the effect of digoxin
DB00531	DB00005	Avoid combination due to enhanced adverse effects of cyclophosphasmide and increased risk of solid cancer development.
DB00531	DB00099	Monitor therapy due to adverse effects of cyclophosphamide, especially pulmonary toxicity.
DB00531	DB00196	Fluconazole reduces metabolism and clearance of cyclophosphamide.
DB00531	DB00552	Increased toxicity of cyclophosphamide
DB00531	DB00202	Cyclophosphamide may increase the effect of succinylcholine.
DB00533	DB00277	Rofecoxib increases the effect and toxicity of theophylline
DB00531	DB04572	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Cyclophosphamide, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Cyclophosphamide if Thiotepa is initiated, discontinued or dose changed.
DB00531	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00531	DB00682	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of warfarin.
DB00532	DB00404	Mephenytoin may increase the metabolism of alprazolam via CYP3A4.
DB00532	DB01223	Decreased effect of both products
DB00532	DB01118	Increases the effect of hydantoin
DB00532	DB00673	The CYP3A4 inducer, mephenytoin, may decrease the effect of aprepitant.
DB00532	DB00443	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, betamethasone.
DB00532	DB01101	Capecitabine increases the effect of hydantoin
DB00532	DB00446	Increases phenytoin, modifies chloramphenicol
DB00532	DB00475	Mephenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB00532	DB01114	The antihistamine increases the effect of hydantoin
DB00532	DB00501	Increases the effect of hydantoin
DB00532	DB00537	Decreases the hydantoin effect
DB00532	DB00882	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, clomifene.
DB00532	DB00628	Mephenytoin may increase the metabolism of clorazepate via CYP3A4.
DB00532	DB00363	Hydantoin decreases the effect of clozapine
DB00532	DB00286	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, conjugated estrogens.
DB00532	DB00091	The hydantoin decreases the effect of cyclosporine
DB00532	DB01234	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, dexamethasone.
DB00532	DB00829	Mephenytoin may increase the metabolism of diazepam via CYP3A4.
DB00532	DB00255	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00532	DB00280	The hydantoin decreases the effect of disopyramide
DB00532	DB00822	Increases the effect of phenytoin
DB00532	DB00254	The anticonvulsant, mephenytoin, decreases the effect of doxycycline.
DB00532	DB00783	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, estradiol.
DB00532	DB00977	This product may cause a slight decrease of contraceptive effect
DB00532	DB00949	Increased phenytoin levels and decreased felbamate levels
DB00532	DB01023	The hydantoin decreases the effect of felodipine
DB00532	DB00196	Increases the effect of hydantoin
DB00532	DB00687	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00532	DB00544	Fluorouracil increases the effect of hydantoin
DB00532	DB00472	Fluoxetine increases the effect of phenytoin
DB00532	DB00690	Mephenytoin may increase the metabolism of flurazepam via CYP3A4.
DB00532	DB00176	Increases the effect of hydantoin
DB00532	DB00158	Folic acid decreases the levels of hydantoin
DB00532	DB00695	The hydantoin decreases the effect of furosemide
DB00532	DB00996	Increases the effect of hydantoin
DB00532	DB00317	The CYP3A4 inducer, mephenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00532	DB00741	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00532	DB00619	The hydantoin decreases the levels of imatinib
DB00532	DB00951	Isoniazid increases the effect of phenytoin in 20% of patients
DB00532	DB01167	Phenytoin decreases the effect of itraconazole
DB00532	DB00555	Phenytoin may reduce levels of lamotrigine
DB00532	DB00367	Phenytoin decreases the contraceptive effect
DB00532	DB00643	The hydantoin decreases the efficiency of mebendazole
DB00532	DB00603	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, medroxyprogesterone.
DB00532	DB00351	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, megestrol.
DB00532	DB00333	The hydantoin decreases the effect of methadone
DB00532	DB00563	The antineoplasic agent decreases the effect of hydantoin
DB00532	DB00553	The hydantoin decreases the effect of psoralene
DB00532	DB00379	The hydantoin decreases the effect of mexiletine
DB00532	DB00683	Mephenytoin may increase the metabolism of midazolam via CYP3A4.
DB00532	DB00370	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB00532	DB00717	This product may cause a slight decrease of contraceptive effect
DB00532	DB00338	Omeprazole increases the effect of hydantoin
DB00532	DB00776	Oxcarbazepine increases the effect of hydantoin
DB00532	DB01303	Decreased effect of both products
DB00532	DB03585	The NSAID, oxyphenbutazone, may increase the hydantoin effect of mephenytoin.
DB00532	DB00812	The NSAID, phenylbutazone, may increase the hydantoin effect of mephenytoin.
DB00532	DB00860	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisolone.
DB00532	DB00635	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisone.
DB00532	DB01224	Phenytoin decreases the effect of quetiapine
DB00532	DB01045	Rifampin decreases the effect of the hydantoin
DB00532	DB00277	Decreased effect of both products
DB00532	DB00208	Ticlopidine increases the effect of hydantoin
DB00532	DB00620	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, triamcinolone.
DB00532	DB00897	Mephenytoin may increase the metabolism of triazolam via CYP3A4.
DB00533	DB01223	Rofecoxib increases the effect and toxicity of theophylline
DB00533	DB01356	The COX-2 inhibitor increases serum levels of lithium
DB00533	DB00563	Rofecoxib increases the levels of methotrexate
DB00533	DB01303	Rofecoxib increases the effect and toxicity of theophylline
DB00536	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Guanidine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00537	DB01418	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of acenocoumarol.
DB00537	DB01370	Formation of non-absorbable complexes
DB00537	DB01223	Ciprofloxacin may increase the effect of aminophylline.
DB00537	DB01125	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of anisindione.
DB00537	DB06769	Decreases metabolism, thus INCREASING levels of bendamustine. Decreased conversion of bendamustine to active metabolites. Concurrent administration of Ciproflaxacin or other CYP1A2 inhibitors may also increase the levels of bendamustine into active metabolites.
DB00537	DB00201	Ciprofloxacin may increase the effect and toxicity of caffeine.
DB00537	DB01373	Formation of non-absorbable complexes
DB00537	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00537	DB00363	Ciprofloxacin may increase clozapine serum levels
DB00537	DB00091	Ciprofloxacin may increase the effect and toxicity of cyclosporine.
DB00537	DB00266	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol.
DB00537	DB01375	Formation of non-absorbable complexes
DB00537	DB00476	Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of duloxetine. Monitor for changes in the therapeutic and adverse effects of duloxetine if ciprofloxacin is initiated or discontinued.
DB00537	DB00651	Ciprofloxacin may increase the effect of dyphylline.
DB00537	DB06210	Affects hepatic CYP1A2 metabolism, will increase effect/level of eltrombopag.
DB00537	DB00754	Decreases the hydantoin effect
DB00537	DB00529	Increased risk of convulsions
DB00537	DB01592	Formation of non-absorbable complexes
DB00537	DB00893	Formation of non-absorbable complexes
DB00537	DB08827	The effect of coadminstration of lomipatide with ciproflaxacin, and other moderate CYP3A4 inhibitors (such as aprepitant, amprenavir, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) is unknown. However, as coadministration is likely to increase serum concentrations of lomipatide, concomitant use is contraindicated.
DB00537	DB01378	Formation of non-absorbable complexes
DB00537	DB01377	Formation of non-absorbable complexes
DB00537	DB00532	Decreases the hydantoin effect
DB00537	DB00563	Ciprofloxacine may decrease the metabolism of methotrexate. Monitor for changes adverse effects of methotrexate if ciprofloxacin is initiated.
DB00537	DB01303	Ciprofloxacin may increase the effect of oxtriphylline.
DB00537	DB00252	Ciprofloxacin may decrease the therapeutic effect of phenytoin.
DB00537	DB01035	Ciprofloxacin may increase the effect of procainamide.
DB00537	DB00980	Ciprofloxacin increases levels/toxicity of ramelteon
DB00537	DB01367	Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of rasagiline. Monitor for changes in the therapeutic and adverse effects of rasagiline if ciprofloxacin is initiated or discontinued.
DB00537	DB00268	Ciprofloxacin may increase the effect and toxicity of ropinirole.
DB00537	DB00658	Sevelamer decreases ciprofloxacin bioavailability
DB00537	DB00203	Ciprofloxacin may increase the serum level of sildenafil.
DB00537	DB00364	Formation of non-absorbable complexes
DB00537	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ciprofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ciprofloxacin is initiated, discontinued or if the dose is changed.
DB00537	DB00277	Ciprofloxacin may increase the effect of theophylline.
DB00537	DB01623	The strong CYP1A2 inhibitor, Ciprofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ciprofloxacin is initiated, discontinued or dose changed.
DB00537	DB00697	Ciprofloxacin inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated.
DB00537	DB00682	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin.
DB00537	DB01593	Formation of non-absorbable complexes
DB00539	DB00106	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01118	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00321	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00543	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00714	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01169	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00539	DB06216	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00539	DB00477	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00541	DB00390	The antineoplasic agent decreases the effect of digoxin
DB00539	DB00604	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01211	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01242	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00872	CYP3A4 Inhibitors (Strong) such as conivaptan may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. Concurrent use of toremifene with strong CYP3A4 inhibitors should be avoided.
DB00539	DB01254	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01151	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00280	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00204	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00757	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01184	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01142	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00450	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00199	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB06414	Toremifene, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00539	DB01195	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00196	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00472	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00875	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00529	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01044	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01218	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00502	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00308	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00458	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00808	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00270	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01259	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01137	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00408	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00539	DB00934	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00358	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00933	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00541	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00539	DB00333	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00218	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB04868	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00539	DB01059	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00540	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00104	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB06589	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00539	DB00738	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00556	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01100	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01599	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01035	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01182	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00344	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01224	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00908	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00468	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00539	DB00243	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00615	The rifamycin decreases the effect of anti-estrogen
DB00539	DB01045	The rifamycin decreases the effect of anti-estrogen
DB00539	DB00734	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00489	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01208	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB01268	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00864	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00976	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB04844	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00539	DB00679	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00539	DB01623	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00582	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB02546	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00539	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00539	DB01624	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00540	DB00488	Risk of hypotension
DB00540	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00540	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if atazanavir if initiated, discontinued or dose changed.
DB00552	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00637	DB00176	Increased risk of cardiotoxicity and arrhythmias
DB00540	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00540	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00540	DB00564	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if carbamazepine is initiated, discontinued or dose changed.
DB00540	DB00501	Cimetidine may increase the effect of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if cimetidine is initiated, discontinued or dose changed.
DB00540	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00540	DB00575	The tricyclic antidepressant, nortriptyline, decreases the effect of clonidine.
DB00540	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00540	DB01341	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline.
DB00540	DB00841	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dobutamine.
DB00540	DB00843	Possible antagonism of action
DB00540	DB00988	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dopamine.
DB00540	DB00476	Possible increase in the levels of this agent when used with duloxetine
DB00540	DB01363	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedra.
DB00540	DB01364	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedrine.
DB00540	DB00668	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of epinephrine.
DB00540	DB01288	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of fenoterol.
DB00540	DB00196	Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00540	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluoxetine is initiated, discontinued or dose changed.
DB00540	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed.
DB00540	DB00674	Possible antagonism of action
DB00540	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00540	DB01170	The tricyclic antidepressant, nortriptyline, decreases the effect of guanethidine.
DB00540	DB01247	Possibility of severe adverse effects
DB00540	DB01064	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of isoproterenol.
DB00540	DB01026	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed.
DB00540	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00540	DB01365	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of mephentermine.
DB00540	DB00610	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of metaraminol.
DB00540	DB00723	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of methoxamine.
DB00540	DB01171	Possible severe adverse reaction with this combination
DB00540	DB00368	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of norepinephrine.
DB00540	DB00816	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of orciprenaline.
DB00540	DB00780	Possibility of severe adverse effects
DB00540	DB00388	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylephrine.
DB00540	DB00397	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylpropanolamine.
DB00540	DB01291	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pirbuterol.
DB00540	DB01366	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of procaterol.
DB00540	DB00852	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pseudoephedrine.
DB00540	DB00908	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00540	DB01346	Quinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline.
DB00540	DB01367	Possibility of severe adverse effects
DB00553	DB01320	The hydantoin decreases the effect of psoralene
DB00553	DB00532	The hydantoin decreases the effect of psoralene
DB00553	DB00252	The hydantoin decreases the effect of psoralene
DB00540	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifabutin is initiated, discontinued or dose changed.
DB00540	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed.
DB00540	DB00503	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ritonavir if initiated, discontinued or dose changed.
DB00540	DB00989	Possible antagonism of action
DB00540	DB01001	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of salbutamol.
DB00540	DB01105	Increased risk of CNS adverse effects
DB00540	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00540	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Nortriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00540	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00540	DB00857	Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if terbinafine is initiated, discontinued or dose changed.
DB00540	DB00871	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of terbutaline.
DB00540	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00540	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00540	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00540	DB00193	Tramadol increases the risk of serotonin syndrome and seizures.
DB00540	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00540	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00540	DB00662	Trimethobenzamide and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00540	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00540	DB00427	Triprolidine and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00540	DB00209	Trospium and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00540	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00540	DB06684	Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved.
DB00540	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00540	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00540	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00540	DB00315	Use of two serotonin modulators, such as zolmitriptan and nortriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00540	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00541	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Amprenavir is initiated, discontinued or dose changed.
DB00541	DB00673	Aprepitant may change levels of the chemotherapy agent, vincristine.
DB00541	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Atazanavir is initiated, discontinued or dose changed.
DB00541	DB01211	Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Clarithromycin is initiated, discontinued or dose changed.
DB00541	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Conivaptan is initiated, discontinued or dose changed.
DB00541	DB01264	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Darunavir is initiated, discontinued or dose changed.
DB00541	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Delavirdine is initiated, discontinued or dose changed.
DB00541	DB00954	Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Dirithromycin is initiated, discontinued or dose changed.
DB00541	DB00199	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Erythromycin is initiated, discontinued or dose changed.
DB00541	DB06414	Vincristine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00541	DB00196	Increases the effect and toxicity of anticancer agent
DB00541	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Fosamprenavir is initiated, discontinued or dose changed.
DB00541	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Imatinib is initiated, discontinued or dose changed.
DB00541	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Indinavir is initiated, discontinued or dose changed.
DB00541	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Isoniazid is initiated, discontinued or dose changed.
DB00541	DB01167	Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Itraconazole is initiated, discontinued or dose changed.
DB00541	DB01026	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed.
DB00541	DB01097	Vincristine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vincristine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.
DB00541	DB01601	Lopinavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Lopinavir is initiated, discontinued or dose changed.
DB00541	DB01110	Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Miconazole is initiated, discontinued or dose changed.
DB00541	DB00305	Potentially severe lung toxicity
DB00541	DB00108	Concomitant Vincristine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
DB00541	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nefazodone is initiated, discontinued or dose changed.
DB00541	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nelfinavir is initiated, discontinued or dose changed.
DB00541	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nicardipine is initiated, discontinued or dose changed.
DB00541	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Posaconazole is initiated, discontinued or dose changed.
DB00541	DB00908	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Quinidine is initiated, discontinued or dose changed.
DB00541	DB01369	This combination presents an increased risk of toxicity
DB00541	DB00503	Ritonavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ritonavir is initiated, discontinued or dose changed.
DB00541	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Saquinavir is initiated, discontinued or dose changed.
DB00541	DB06145	Spiramycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Spiramycin is initiated, discontinued or dose changed.
DB00541	DB00976	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Telithromycin is initiated, discontinued or dose changed.
DB00541	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Voriconazole is initiated, discontinued or dose changed.
DB00542	DB00594	Increased risk of hyperkalemia
DB00542	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00542	DB01395	Increased risk of hyperkalemia
DB00542	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00542	DB01356	The ACE inhibitor increases serum levels of lithium
DB00542	DB01345	Increased risk of hyperkalemia
DB00542	DB00421	Increased risk of hyperkalemia
DB00542	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00542	DB00684	Increased risk of nephrotoxicity
DB00542	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00542	DB00384	Increased risk of hyperkalemia
DB00543	DB00488	Risk of severe hypotension
DB00543	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00543	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if atazanavir if initiated, discontinued or dose changed.
DB00543	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amoxipine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00543	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants amoxapine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB00543	DB00501	Cimetidine may increase the effect of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if cimetidine is initiated, discontinued or dose changed.
DB00543	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00543	DB00575	The tricyclic antidepressant, amoxapine, decreases the effect of clonidine.
DB00543	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00543	DB00841	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dobutamine.
DB00543	DB00843	Possible antagonism of action
DB00543	DB00988	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dopamine.
DB00543	DB01363	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedra.
DB00543	DB01364	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedrine.
DB00543	DB00668	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of epinephrine.
DB00543	DB01288	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of fenoterol.
DB00543	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed.
DB00543	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed.
DB00543	DB00674	Possible antagonism of action
DB00543	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00543	DB01170	The tricyclic antidepressant, amoxapine, decreases the effect of guanethidine.
DB00543	DB01247	Possibility of severe adverse effects
DB00543	DB01064	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of isoproterenol.
DB00543	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00543	DB01365	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of mephentermine.
DB00543	DB00610	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of metaraminol.
DB00543	DB00723	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of methoxamine.
DB00543	DB01171	Possible severe adverse reaction with this combination
DB00543	DB00368	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of norepinephrine.
DB00543	DB00816	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of orciprenaline.
DB00543	DB00780	Possibility of severe adverse effects
DB00543	DB00388	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylephrine.
DB00543	DB00397	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylpropanolamine.
DB00543	DB01291	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pirbuterol.
DB00543	DB01366	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of procaterol.
DB00543	DB00852	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pseudoephedrine.
DB00543	DB01367	Possibility of severe adverse effects
DB00563	DB06210	Increases levels of Methotrexate via metabolism decrease. OATP transporter protein inhibition.
DB00563	DB00754	The antineoplasic agent decreases the effect of hydantoin
DB00543	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifabutin is initiated, discontinued or dose changed.
DB00543	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed.
DB00543	DB00503	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if ritonavir if initiated, discontinued or dose changed.
DB00543	DB00989	Possible antagonism of action
DB00543	DB01001	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of salbutamol.
DB00543	DB01105	Increased risk of CNS adverse effects
DB00543	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00543	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amoxapine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00543	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00543	DB00857	Terbinafine may reduce the metabolism and clearance of Amoxapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Amoxapine if Terbinafine is initiated, discontinued or dose changed.
DB00543	DB00871	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of terbutaline.
DB00543	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00543	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00543	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00543	DB00193	Tramadol increases the risk of serotonin syndrome and seizures.
DB00543	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00543	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00543	DB00662	Trimethobenzamide and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00543	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00543	DB00427	Triprolidine and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00543	DB00209	Trospium and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00543	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00543	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00543	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00543	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00543	DB00315	Use of two serotonin modulators, such as zolmitriptan and amoxapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00543	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00544	DB01418	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of acenocoumarol.
DB00544	DB01125	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of anisindione.
DB00544	DB00266	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of dicumarol.
DB00544	DB00754	Fluorouracil increases the effect of hydantoin
DB00544	DB01320	Fluorouracil increases the effect of hydantoin
DB00544	DB00532	Fluorouracil increases the effect of hydantoin
DB00544	DB00916	Risk of 5-FU toxicity when associated with metronidazole
DB00544	DB00252	Fluorouracil increases the effect of hydantoin
DB00544	DB00675	Fluorouracil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluorouracil is initiated, discontinued or dose changed.
DB00544	DB06287	Co-administration of Temsirolimus and Fluorouracil may result in serious adverse drug reactions.
DB00544	DB01124	Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Fluorouracil is initiated, discontinued or dose changed.
DB00544	DB00214	Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluorouracil is initiated, discontinued or dose changed.
DB00544	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00544	DB00440	The strong CYP2C9 inhibitor, Fluorouracil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluorouracil is initiated, discontinued or dose changed.
DB00563	DB00749	The NSAID, etodolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00544	DB00582	Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if fluorouracil is initiated, discontinued or dose changed.
DB00544	DB00682	Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed.
DB00544	DB00549	Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluorouracil is initiated, discontinued or dose changed.
DB00545	DB00443	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB01285	The corticosteroid, corticotropin, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB01380	The corticosteroid, cortisone acetate, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB01234	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB00959	The corticosteroid, methylprednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB01384	The corticosteroid, paramethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB00860	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB00635	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00545	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00549	DB01418	Zafirlukast may inhibit the metabolism of the vitamin K antagonist Acenocoumarol and increase INR and risk of bleeding.
DB00549	DB01223	Zafirlukast serum concentrations may be decreased by the theophylline derivative Aminophylline.
DB00549	DB01101	Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if capecitabine is initiated, discontinued or dose changed.
DB00549	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00549	DB00705	Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if delavirdine is initiated, discontinued or dose changed.
DB00549	DB00199	Erythromycin may decrease the serum concentration and effect of zafirlukast.
DB00549	DB00322	Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if floxuridine is initiated, discontinued or dose changed.
DB00549	DB00196	Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluconazole is initiated, discontinued or dose changed.
DB00549	DB00544	Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluorouracil is initiated, discontinued or dose changed.
DB00549	DB01241	Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if gemfibrozil is initiated, discontinued or dose changed.
DB00549	DB01026	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed.
DB00549	DB00622	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if nicardipine is initiated, discontinued or dose changed.
DB00549	DB01656	Increases roflumilast levels.
DB00549	DB06268	Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sitaxentan is initiated, discontinued or dose changed.
DB00549	DB00359	Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed.
DB00549	DB00263	Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed.
DB00549	DB00277	Zafirlukast serum concentrations may be decreased by Theophylline.
DB00549	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if tolbutamide is initiated, discontinued or dose changed.
DB00550	DB01418	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of acenocoumarol.
DB00550	DB01125	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of anisindione.
DB00550	DB00266	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of dicumarol.
DB00550	DB00390	The antithyroid agent may increase the effect of digoxin.
DB00550	DB00682	Propylthiouracil may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if propylthiouracil is initiated, discontinued or dose changed.
DB00552	DB00531	Increased toxicity of cyclophosphamide
DB00552	DB01073	Unacceptable pulmonary toxicity
DB00552	DB00061	Avoid combination due to decreased effect of both drugs
DB00553	DB00754	The hydantoin decreases the effect of psoralene
DB00553	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Methoxsalen. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Methoxsalen is initiated, discontinued or if the dose is changed.
DB00553	DB01623	The strong CYP1A2 inhibitor, Methoxsalen, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Methoxsalen is initiated, discontinued or dose changed.
DB00553	DB00697	Methoxsalen may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00554	DB01193	Risk of inhibition of renal prostaglandins
DB00554	DB01418	The NSAID, piroxicam, may increase the anticoagulant effect of acenocoumarol.
DB00554	DB00630	Increased risk of gastric toxicity
DB00554	DB01125	The NSAID, piroxicam, may increase the anticoagulant effect of anisindione.
DB00554	DB00335	Risk of inhibition of renal prostaglandins
DB00554	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00554	DB00195	Nonsteroidal Anti-Inflammatory Agents such as piroxicam may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
DB00554	DB01295	Risk of inhibition of renal prostaglandins
DB00554	DB00612	Risk of inhibition of renal prostaglandins
DB00554	DB00521	Risk of inhibition of renal prostaglandins
DB00554	DB01136	Risk of inhibition of renal prostaglandins
DB00554	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00554	DB00091	Monitor for nephrotoxicity
DB00554	DB00266	The NSAID, piroxicam, may increase the anticoagulant effect of dicumarol.
DB00554	DB00187	Risk of inhibition of renal prostaglandins
DB00554	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00554	DB00598	Risk of inhibition of renal prostaglandins
DB00554	DB01356	The NSAID, piroxicam, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00554	DB00563	The NSAID, piroxicam, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00554	DB00264	Risk of inhibition of renal prostaglandins
DB00554	DB01203	Risk of inhibition of renal prostaglandins
DB00554	DB01580	Risk of inhibition of renal prostaglandins
DB00554	DB01359	Risk of inhibition of renal prostaglandins
DB00554	DB00960	Risk of inhibition of renal prostaglandins
DB00554	DB01297	Risk of inhibition of renal prostaglandins
DB00554	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00554	DB00571	Risk of inhibition of renal prostaglandins
DB00554	DB00503	Ritonavir increases the toxicity of piroxicam
DB00554	DB00489	Risk of inhibition of renal prostaglandins
DB00554	DB00675	Piroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed.
DB00554	DB00966	Concomitant use of Telmisartan and Piroxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00554	DB00373	Risk of inhibition of renal prostaglandins
DB00554	DB01124	Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Piroxicam is initiated, discontinued or dose changed.
DB00554	DB00214	Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Piroxicam is initiated, discontinued or dose changed.
DB00554	DB00519	The NSAID, Piroxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Piroxicam is initiated, discontinued or dose changed.
DB00554	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Piroxicam. Monitor for increased bleeding during concomitant thearpy.
DB00554	DB08814	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of glisentide to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB00554	DB00440	The strong CYP2C9 inhibitor, Piroxicam, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Piroxicam is initiated, discontinued or dose changed.
DB00554	DB06684	Increased risk of bleeding with concomitant use of NSAIDs and vilazodone
DB00554	DB00582	Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if piroxicam is initiated, discontinued or dose changed.
DB00554	DB00682	Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed.
DB00555	DB00237	Barbiturates like butabarbital may decrease the serum concentration of lamotrigine. There are separate patient management guidelines for patients age 12 and under and for patients older than 12 years of age. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased.
DB00555	DB00241	Barbiturates such as butalbital may decrease the serum concentration of lamotrigine. There are separate management guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased.
DB00555	DB00564	Lamotrigine may increase the adverse effects of carbamazepine by increasing the concentration of its active metabolite, carbamazepine-epoxide. Carbamazepine may decrease the therapeutic effect of lamotrigine by increasing its metabolism. Lamotrigine doses should be adjusted accordingly. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinue or doses are changed.
DB00555	DB00363	Lamotrigine increases the effect and toxicity of clozapine
DB00555	DB00304	The oral contraceptive decreases the effect of lamotrigine
DB00555	DB00977	The oral contraceptive decreases the effect of lamotrigine
DB00555	DB00754	Phenytoin may reduce levels of lamotrigine
DB00555	DB04953	In healthy adults, the AUCs of lamotrigine and ezogabine were both increased. The clinical significance of this is still unknown. Multiple doses of ezogabine also increase the clearance and decrease the terminal half-life of lamotrigine.
DB00555	DB01320	Phenytoin may reduce levels of lamotrigine
DB00555	DB00532	Phenytoin may reduce levels of lamotrigine
DB00555	DB01357	The oral contraceptive decreases the effect of lamotrigine
DB00555	DB05246	Methsuximide decreases the effect of lamotrigine
DB00555	DB00717	The oral contraceptive decreases the effect of lamotrigine
DB00555	DB00252	Phenytoin may reduce levels of lamotrigine
DB00555	DB01045	Rifampin decreases levels of lamotrigine
DB00555	DB00599	Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated.
DB00555	DB00427	The CNS depressants, Triprolidine and Lamotrigine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00555	DB00313	Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed.
DB00556	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00556	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00556	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00556	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00556	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00556	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00556	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00556	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00556	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00556	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00557	DB00237	Hydroxyzine may enhance the CNS depressant effect of barbiturates like butabarbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.
DB00557	DB00241	Hydroxyzine may enhance the CNS depressant effect of barbiturates such as butalbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.
DB00557	DB01551	May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy.
DB00557	DB00843	Possible antagonism of action
DB00557	DB00674	Possible antagonism of action
DB00557	DB00989	Possible antagonism of action
DB00557	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hydroxyzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00557	DB00662	Trimethobenzamide and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00557	DB00427	Triprolidine and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00557	DB00209	Trospium and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00559	DB01418	Bosentan may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.
DB00559	DB01125	Bosentan may decrease the anticoagulant effect of anisindione by increasing its metabolism.
DB00563	DB00926	Acitretin/etretinate increases the effect and toxicity of methotrexate
DB00637	DB01319	Increased risk of cardiotoxicity and arrhythmias
DB00559	DB01076	Bosentan may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if bosentan is initiated, discontinued or dose changed.
DB00559	DB00439	Bosentan may decrease the serum concentration of cerivastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if bosentan is initiated, discontinued or dose changed.
DB00559	DB00091	Cyclosporine may increase the effect and toxicity of bosentan.
DB00559	DB00266	Bosentan may decrease the anticoagulant effect of dicumarol by increasing its metabolism.
DB00559	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00559	DB00977	Bosentan may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
DB00559	DB01016	Increased risk of hepatic toxicity
DB00559	DB01167	Itraconazole may increase the effect and toxicity of bosentan.
DB00559	DB01026	Ketoconazole may increase the effect and toxicity of bosentan.
DB00559	DB00227	Bosentan may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if bosentan is initiated, discontinued or dose changed.
DB00559	DB08815	Concomitant therapy with a CYP3A4 substrate and inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB00559	DB00603	Bosentan may decrease the contraceptive effect of medroxyprogesterone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
DB00559	DB01357	Decreases the effect of contraceptive
DB00559	DB00717	Bosentan may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
DB00559	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00559	DB00641	Bosentan may decrease the serum concentration of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if bosentan is initiated, discontinued or dose changed.
DB00559	DB00976	Co-administration may cause decreased Telithromycin and increased Bosentan plasma concentrations. Consider alternate therapy.
DB00559	DB06287	Bosentan may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00559	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Bosentan. Consider alternate therapy or monitor for changes in Bosentan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00559	DB00193	Bosentan may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00559	DB00656	The CYP3A4 inducer, Bosentan, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Bosentan is initiated, discontinued or dose changed.
DB00559	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB00559	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00559	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bosentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bosentan if voriconazole is initiated, discontinued or dose changed.
DB00559	DB00682	Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism.
DB00560	DB01418	Tigecycline may increase the anticoagulant effect of acenocoumarol.
DB00560	DB01125	Tigecycline may increase the anticoagulant effect of anisindione.
DB00560	DB00307	Tigecycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri (intracranial hypertension) is of particular concern. Avoid this combination.
DB00560	DB00266	Tigecycline may increase the anticoagulant effect of dicumarol.
DB00560	DB00755	Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00560	DB00682	Tigecycline may increase the serum concentration of warfarin.
DB00562	DB00390	Possible electrolyte variations and arrhythmias
DB00562	DB01356	The thiazide diuretic, benzthiazide, may increase serum levels of lithium.
DB00563	DB00945	Acetylsalicylic acid increases the effect and toxicity of methotrexate.
DB00563	DB00459	Acitretin/etretinate increases the effect and toxicity of methotrexate
DB00563	DB01060	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00415	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB01602	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB01053	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB01294	The salicylate, bismuth subsalicylate, increases the effect and toxicity of methotrexate.
DB00563	DB00578	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB01432	Decreased levels of methotrexate
DB00563	DB00537	Ciprofloxacine may decrease the metabolism of methotrexate. Monitor for changes adverse effects of methotrexate if ciprofloxacin is initiated.
DB00563	DB00515	Cisplatin increases methotrexate toxicity
DB00563	DB00766	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB01147	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00091	Cyclosporine may increase the effect and toxicity of methotrexate.
DB00563	DB00586	The NSAID, diclofenac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00485	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00861	The NSAID, diflunisal, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00390	The antineoplasic agent decreases the effect of digoxin
DB00563	DB00254	The tetracycline, doxycycline, may increase methotrexate toxicity.
DB00637	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00563	DB00573	The NSAID, fenoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00301	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00712	The NSAID, flurbiprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB01320	The antineoplasic agent decreases the effect of hydantoin
DB00563	DB01611	Hydroxychloroquine increases the effect and toxicity of methotrexate
DB00563	DB01050	The NSAID, ibuprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00328	The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB01009	The NSAID, ketoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00465	The NSAID, ketorolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB01397	The salicylate, magnesium salicylate, increases the effect and toxicity of methotrexate.
DB00563	DB00939	The NSAID, meclofenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00784	The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00532	The antineoplasic agent decreases the effect of hydantoin
DB00563	DB02443	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00948	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00461	The NSAID, nabumetone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00607	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00788	The NSAID, naproxen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00338	Omeprazole increases the levels of methotrexate
DB00563	DB00991	The NSAID, oxaprozin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00417	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00812	The NSAID, phenylbutazone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB00252	The antineoplasic agent decreases the effect of hydantoin
DB00563	DB00319	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00554	The NSAID, piroxicam, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00563	DB01604	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB01032	Probenecid increases the effect and toxicity of methotrexate
DB00563	DB01168	Increased nephrotoxicity with this combination
DB00563	DB06372	Rilonacept and methotrexate both increase immunosuppressive effects; combination may increase risk of myelosuppression.
DB00563	DB00533	Rofecoxib increases the levels of methotrexate
DB00563	DB01398	The salicylate, salicylate-sodium, increases the effect and toxicity of methotrexate.
DB00563	DB01399	The salicylate, salsalate, increases the effect and toxicity of methotrexate.
DB00563	DB01298	The sulfamide increases the toxicity of methotrexate
DB00563	DB00359	The sulfamide increases the toxicity of methotrexate
DB00563	DB06150	The sulfamide increases the toxicity of methotrexate
DB00563	DB01299	The sulfamide increases the toxicity of methotrexate
DB00563	DB01581	The sulfamide increases the toxicity of methotrexate
DB00563	DB01582	The sulfamide increases the toxicity of methotrexate
DB00563	DB00576	The sulfamide increases the toxicity of methotrexate
DB00563	DB01015	The sulfamide increases the toxicity of methotrexate
DB00563	DB00891	The sulfamide increases the toxicity of methotrexate
DB00563	DB06147	The sulfamide increases the toxicity of methotrexate
DB00563	DB00263	The sulfamide increases the toxicity of methotrexate
DB00563	DB00605	The NSAID, sulindac, may decrease the clearance methotrexate. Consider alternate therapy, especially in patients receiving high antineoplastic doses of methotrexate. Otherwise, monitor for hematologic and renal toxicities.
DB00563	DB00469	Tenoxicam may increase the serum concentration of Methotrexate by reducing renal tubular secretion of Methotrexate. Monitor for changes in Methotrexate therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed.
DB00563	DB00759	Tetracycline may increase methotrexate toxicity.
DB00563	DB01600	Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity.
DB00563	DB01607	The penicillin increases the effect and toxicity of methotrexate
DB00563	DB00500	Tolmetin may decrease the renal excretion of Methotrexate. Alternate therapy should be considered. Otherwise, monitor for hemotologic and renal toxicities.
DB00563	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00563	DB00440	Trimethoprim may increase the adverse/toxic effects of Methotrexate (e.g. bone marrow suppression). Concomitant use should be avoided or closely monitored for Methotrexate toxicity.
DB00563	DB01401	The salicylate, trisalicylate-choline, increases the effect and toxicity of methotrexate.
DB00564	DB05812	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB00564	DB01418	Carbamazepine may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration.
DB00564	DB00404	Carbamazepine may decrease the effect of the benzodiazepine, alprazolam.
DB00564	DB01223	Carbamazepine may decrease the serum concentration of aminophylline. Aminophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00564	DB00502	Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00321	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB01125	Carbamazepine may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.
DB00564	DB00673	The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant.
DB00564	DB01238	Carbamazepine, a strong CYP3A4 inducer, may decrease the serum concentration of aripiprazole by increasing its metabolism.
DB00564	DB06216	Carbamazepine is a CYP1A2 inducer that decreases asenapine's exposure by 20%.
DB00564	DB01076	Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of atorvastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00732	Decreases the effect of muscle relaxant
DB00564	DB06769	Decreases levels of bendamustine by affecting CYP1A2 hepatic enzyme metabolism. May increase concentrations of active metabolites.
DB00564	DB08873	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB00564	DB01156	Carbamazepine, a strong CYP2B6 inducer, may increase the metabolism of bupropion. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bupropion if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB06772	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB00564	DB00501	Cimetidine may increase the serum concentration of carbamazepine during the first few days of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of carbamazepine if cimetidine is initiated, discontinued or dose changed.
DB00564	DB01211	Clarithromycin may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic or adverse effects of carbamazepine if clarithromycin is initiated, discontinued or dose changed.
DB00564	DB00363	Carbamazepine may decrease the serum concentration of clozapine by increasing its metabolism. Concomitant therapy should also be avoided due to increased risk of bone marrow suppression. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00091	Carbamazepine may decrease the therapeutic effect of cyclosporine.
DB00564	DB06695	P-Glycoprotein inducers such as carbamazepine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB00564	DB08912	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB00564	DB01406	Danazol may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of carbamazepine if danazol is initiated, discontinued or dose changed.
DB00564	DB00705	The anticonvulsant, carbamazepine, decreases the effect of delavirdine.
DB00564	DB01151	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00647	Propoxyphene increases the effect of carbamazepine
DB00564	DB00266	Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.
DB00564	DB00343	Carbamazepine may decrease the serum concentration of diltiazem by increasing its metabolism. Diltiazem may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if dosages are changed.
DB00564	DB01135	Decreases the effect of muscle relaxant
DB00564	DB01142	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00254	The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline.
DB00564	DB00651	Carbamazepine may decrease the serum concentration of diphylline. Diphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00564	DB06210	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB00564	DB00199	The macrolide, erythromycin, may increase the effect of carbamazepine.
DB00564	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00564	DB00977	Carbamazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with carbamazepine.
DB00564	DB06414	Carbamazepine, when used concomitantly with certain NNRTIs (ie. efavirenz), may experience a decrease in serum concentration. \r\n\r\nEtravirine, and other NNRTIs, when used concomitantly with carbamazepine, may experience an increase in serum concentration. \r\n\r\nIt is recommended to avoid this combination.
DB00564	DB04953	Ezogabine increases the clearance of carbamazepine (30%). The mechanism of this interaction is unknown.
DB00564	DB00949	Decreased effect of both products
DB00564	DB01023	Carbamazepine may increase the metabolism of felodipine. Monitor for changes in the therapeutic and adverse effects of felodipine if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00196	Fluconazole may increase the therapeutic and adverse effects of carbamazepine.
DB00564	DB00472	Carbamazepine may decrease the serum concentration of fluoxetine by increasing its metabolism. Fluoxetine may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses are changed.
DB00564	DB00176	Fluvoxamine increases the effect of carbamazepine
DB00564	DB00317	The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00571	DB00280	The beta-blocker, propranolol, may increase the toxicity of disopyramide.
DB00637	DB00224	Increased risk of cardiotoxicity and arrhythmias
DB00564	DB00619	Carbamazepine, a strong CYP3A4 inducer, may increase the metabolism of imatinib. Imatinib, a strong CYP3A4 inhibitor, may increase the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00564	DB00458	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00224	Indinavir increases the effect and toxicity of carbamazepine
DB00564	DB00951	Carbamazepine effect is increased as is isoniazid toxicity
DB00564	DB00982	Isotretinoine decreases the effect of carbamazepine
DB00564	DB01167	Itraconazole may increase the effect of carbamazepine.
DB00564	DB08820	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB00564	DB01321	The macrolide, josamycin, may increase the effect of carbamazepine.
DB00564	DB01026	Ketoconazole may increase the effect of carbamazepine.
DB00564	DB00555	Lamotrigine may increase the adverse effects of carbamazepine by increasing the concentration of its active metabolite, carbamazepine-epoxide. Carbamazepine may decrease the therapeutic effect of lamotrigine by increasing its metabolism. Lamotrigine doses should be adjusted accordingly. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinue or doses are changed.
DB00564	DB01202	Concomitant therapy may results in additive adverse CNS effects.
DB00564	DB00367	Carbamazepine may decrease the contraceptive effect of levonorgestrel.
DB00564	DB08882	CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely.
DB00564	DB00227	Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB08815	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB00564	DB01357	This product may cause a slight decrease of contraceptive effect
DB00564	DB00333	Carbamazepine may decrease the serum level of methadone. Monitor for changes in the therapeutic and adverse effects of methadone if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00422	Carbamazepine may decrease the effect of methylphendiate.
DB00564	DB01336	Decreases the effect of muscle relaxant
DB00564	DB00916	Metronidazole increases the effect of carbamazepine
DB00564	DB00683	Carbamazepine may decrease the effect of the benzodiazepine, midazolam.
DB00564	DB01226	Decrease the effect of muscle relaxant
DB00564	DB01149	Nefazodone increases the effect of carbamazepine
DB00564	DB00717	This product may cause a slight decrease of contraceptive effect
DB00564	DB00540	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB01303	Carbamazepine may decrease the serum concentration of oxtriphylline. Oxtriphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00564	DB01062	Oxybutynin may cause carbamazepine toxicity
DB00564	DB01337	Decreases the effect of muscle relaxant
DB00564	DB06589	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB00564	DB08901	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB00564	DB08901	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB00564	DB01058	Markedly lower praziquantel levels
DB00564	DB01369	This combination presents an increased risk of toxicity
DB00564	DB08896	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB00564	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB00564	DB00734	Decreases the effect of risperidone
DB00564	DB00503	Ritonavir increases the effect of carbamazepine
DB00564	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB00564	DB06201	Decrease concentration of rufinamide thus monitor therapy
DB00564	DB01104	Sertraline increases the effect of carbamazepine
DB00564	DB00641	Carbamazepine, a p-glycoprotein inducer, may decrease the effect of simvastatin by increasing its efflux. Monitor for changes in the therapeutic and adverse effects of simvastatin if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB01268	Possible decrease in sunitinib levels
DB00564	DB00864	Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.
DB00564	DB00976	Co-administration may cause decreased Telithromycin and increased Carbemazepine plasma concentrations. Consider alternate therapy.
DB00564	DB06287	Carbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00564	DB00277	Carbamazepine may decrease the serum concentration of theophylline. Theophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00564	DB00208	Ticlopidine increases the effect of carbamazepine
DB00564	DB00932	Concomitant use may result in decreased Tipranavir and increased Carbamazepine concentrations.
DB00564	DB06212	Carbamazepine is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB00571	DB04855	Propranolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase propranolol exposure 1.3-fold. Lower dose of metoprolol.
DB00571	DB00651	Antagonism of action and increased effect of theophylline
DB00564	DB00273	Carbamazepine may decrease the effectiveness of Topiramate by increase its clearance. Monitor for changes in the therapeutic and adverse effects of Topiramate if Carbamazepine is initiated, discontinued or dose changed. Adverse effects related to CNS depression have also been observed during concomitant therapy.
DB00564	DB00193	Carbamazepine may decrease the effect of tramadol by increasing Tramadol metabolism and clearance.
DB00564	DB00656	The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00755	The strong CYP2C8 inducer, Carbamazepine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00427	The CNS depressants, Triprolidine and Carbamazepine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00564	DB01361	The macrolide, troleandomycin, may increase the effect of carbamazepine.
DB00564	DB01199	Decreases the effect of muscle relaxant
DB00564	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB00564	DB00313	Decreases the effect of valproic acid
DB00564	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00564	DB01339	Decreases the effect of muscle relaxant
DB00564	DB08881	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB00564	DB00661	Verapamil may increase the serum concentration of Carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Carbamazepine if Verapamil is initiated, discontinued or dose changed.
DB00564	DB06684	Carbamazepine may increase the metabolism of Selective Serotonin Reuptake Inhibitors (SSRI). Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Carbamazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
DB00564	DB00582	Carbamazepine may reduce serum concentrations and efficacy of voriconazole likely by increasing its metabolism. Concomitant voriconazole and carbamazepine therapy is contraindicated.
DB00564	DB00682	Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed.
DB00564	DB00246	Increases the effect and toxicity of ziprasidone
DB00565	DB01111	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB00567	DB01032	Probenecid may increase the serum level of cephalexin.
DB00569	DB00055	Drotrecogin alfa may increase the adverse effects of fondaparinux, resulting in excessive bleeding. Concomitant use should be avoided.
DB00569	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00570	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Amprenavir is initiated, discontinued or dose changed.
DB00570	DB00673	Aprepitant may change levels of the chemotherapy agent, vinblastine.
DB00570	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Atazanavir is initiated, discontinued or dose changed.
DB00570	DB01211	Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Clarithromycin is initiated, discontinued or dose changed.
DB00570	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Conivaptan is initiated, discontinued or dose changed.
DB00570	DB06695	P-Glycoprotein inducers such as vinblastine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB00570	DB01264	Darunavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Darunavir is initiated, discontinued or dose changed.
DB00570	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Delavirdine is initiated, discontinued or dose changed.
DB00570	DB00954	Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Dirithromycin is initiated, discontinued or dose changed.
DB00570	DB00199	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of vinblastine if erythromycin is initiated, discontinued or dose changed.
DB00570	DB00196	Increases the effect and toxicity of anticancer agent
DB00570	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Fosamprenavir is initiated, discontinued or dose changed.
DB00570	DB01320	The antineoplasic agent decreases the effect of hydantoin
DB00571	DB00668	Hypertension, then bradycardia
DB00571	DB01253	Ischemia with risk of gangrene
DB00571	DB00696	Ischemia with risk of gangrene
DB00570	DB00619	Imatinib, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Imatinib is initiated, discontinued or dose changed.
DB00570	DB00224	Indinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Indinavir is initiated, discontinued or dose changed.
DB00570	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Isoniazid is initiated, discontinued or dose changed.
DB00570	DB01167	Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Itraconazole is initiated, discontinued or dose changed.
DB00570	DB01026	Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed.
DB00570	DB01097	Vinblastine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinblastine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.
DB00570	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Lopinavir is initiated, discontinued or dose changed.
DB00570	DB01110	Miconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Miconazole is initiated, discontinued or dose changed.
DB00570	DB00305	Potentially severe lung toxicity
DB00570	DB00108	Concomitant Vinblastine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
DB00570	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nefazodone is initiated, discontinued or dose changed.
DB00570	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nelfinavir is initiated, discontinued or dose changed.
DB00570	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nicardipine is initiated, discontinued or dose changed.
DB00570	DB00252	The antineoplasic agent decreases the effect of hydantoin
DB00570	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Posaconazole is initiated, discontinued or dose changed.
DB00570	DB00908	Quinidine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Quinidine is initiated, discontinued or dose changed.
DB00570	DB01369	This combination presents an increased risk of toxicity
DB00570	DB00503	Ritonavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ritonavir is initiated, discontinued or dose changed.
DB00570	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Saquinavir is initiated, discontinued or dose changed.
DB00570	DB06145	Spiramycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Spiramycin is initiated, discontinued or dose changed.
DB00570	DB00976	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed.
DB00570	DB01036	Vinblastine, a CYP3A4 inhibitor, may increase the serum concentration of Tolterodine by decreasing its metabolism. Poor CYP2D6 metabolizers metabolize Tolterodine via CYP3A4. A dose adjustment of Tolterodine may be required. Monitor for changes in the therapeutic/adverse effects of Tolterodine if Vinblastine is initiated, discontinued or dose changed.
DB00570	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00570	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Voriconazole is initiated, discontinued or dose changed.
DB00571	DB00414	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01223	Antagonism of action and increased effect of theophylline
DB00571	DB01558	Co-administration with propranolol will cause a reduction in bromazepam clearance and increases half-life.
DB00571	DB00477	Increased effect of both drugs
DB00571	DB00672	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB00501	Cimetidine may increase the serum concentration of propranolol by decreasing its metabolism.
DB00571	DB00215	The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00571	DB00575	Increased hypertension when clonidine stopped
DB00571	DB00320	Ischemia with risk of gangrene
DB00571	DB00343	Increased risk of bradycardia
DB00637	DB01167	Increased risk of cardiotoxicity and arrhythmias
DB00571	DB01175	The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00571	DB01288	Antagonism
DB00571	DB00472	The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00571	DB00983	Antagonism
DB00571	DB01120	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01067	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01289	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01016	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01382	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB00502	Increased effect of both drugs
DB00571	DB01275	Increased effect of both drugs
DB00571	DB01050	Risk of inhibition of renal prostaglandins
DB00571	DB05039	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB00571	DB00328	Risk of inhibition of renal prostaglandins
DB00571	DB00047	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01064	Antagonism
DB00571	DB00281	The beta-blocker, propranolol, may increase the effect and toxicity of lidocaine.
DB00571	DB00934	Propranolol increases the serum levels of cisapride
DB00571	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00571	DB00968	Possible hypertensive crisis
DB00571	DB00247	Ischemia with risk of gangrene
DB00571	DB00816	Antagonism
DB00571	DB01303	Antagonism of action and increased effect of theophylline
DB00571	DB00715	The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00571	DB01174	The barbiturate decreases the effect of the metabolized beta-blocker
DB00571	DB00236	Antagonism
DB00571	DB01291	Antagonism
DB00571	DB00554	Risk of inhibition of renal prostaglandins
DB00571	DB00457	Risk of hypotension at the beginning of therapy
DB00571	DB00794	The barbiturate decreases the effect of metabolized beta-blocker
DB00571	DB01366	Antagonism
DB00571	DB01182	Propafenone may increase the effect of the beta-blocker, propranolol.
DB00571	DB00912	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01045	Rifampin may decrease the serum concentration of propranolol by increasing its metabolism.
DB00571	DB00953	Propranolol increases the effect and toxicity of rizatriptan
DB00571	DB01001	Antagonism
DB00571	DB00938	Antagonism
DB00571	DB01104	The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00571	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00571	DB00857	Terbinafine may reduce the metabolism and clearance of Propranolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Propranolol if Terbinafine is initiated, discontinued or dose changed.
DB00571	DB00871	Antagonism
DB00571	DB00277	Antagonism of action and increased effect of theophylline
DB00571	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00571	DB00839	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01124	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00571	DB01030	The p-glycoprotein inhibitor, Propranolol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00571	DB00661	Increased effect of both drugs
DB00572	DB08810	Anticholinergic agents like atropine may reduce the action of cinitapride.
DB00572	DB00843	Possible antagonism of action
DB00572	DB00674	Possible antagonism of action
DB00572	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00572	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Atropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00572	DB00662	Trimethobenzamide and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00572	DB00427	Triprolidine and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00572	DB00209	Trospium and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00573	DB01418	The NSAID, fenoprofen, may increase the anticoagulant effect of acenocoumarol.
DB00573	DB00630	Increased risk of gastric toxicity
DB00573	DB01125	The NSAID, fenoprofen, may increase the anticoagulant effect of anisindione.
DB00573	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00573	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00573	DB00091	Monitor for nephrotoxicity
DB00573	DB00266	The NSAID, fenoprofen, may increase the anticoagulant effect of dicumarol.
DB00573	DB06210	Increases levels of Fenoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB00573	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00573	DB00563	The NSAID, fenoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00573	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00573	DB00966	Concomitant use of Telmisartan and Fenoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00573	DB00373	The NSAID, Fenoprofen, may antagonize the antihypertensive effect of Timolol.
DB00573	DB00519	The NSAID, Fenoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Fenoprofen is initiated, discontinued or dose changed.
DB00573	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Fenoprofen. Monitor for increased bleeding during concomitant thearpy.
DB00573	DB00682	The antiplatelet effects of fenoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00574	DB01063	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB01246	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00477	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00392	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00472	Risk of serotoninergic syndrome
DB00574	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00176	Risk of serotoninergic syndrome
DB00574	DB01170	Fenfluramine may decrease the effect of guanethidine.
DB00574	DB01306	Fenfluramine increases the effect of insulin
DB00574	DB01307	Fenfluramine increases the effect of insulin
DB00574	DB01309	Fenfluramine increases the effect of insulin
DB00574	DB01247	Possible hypertensive crisis
DB00574	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00902	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00715	Risk of serotoninergic syndrome
DB00574	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00780	Possible hypertensive crisis
DB00574	DB00433	Decreased anorexic effect, may increase psychotic symptoms.
DB00574	DB00420	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB01069	Decreased anorexic effect, may increase psychotic symptoms.
DB00574	DB01608	Decreased anorexic effect, may increase psychotic symptoms.
DB00574	DB00777	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB01367	Possible hypertensive crisis
DB00574	DB00372	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00752	Possible hypertensive crisis
DB00574	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00508	Decreased anorexic effect, may increase psychotic symptoms
DB00574	DB00285	Risk of serotoninergic syndrome
DB00575	DB01193	Increased hypertension when clonidine stopped
DB00575	DB00321	The tricyclic antidepressant, amitriptyline, decreases the effect of clonidine.
DB00575	DB00543	The tricyclic antidepressant, amoxapine, decreases the effect of clonidine.
DB00575	DB00335	Increased hypertension when clonidine stopped
DB00575	DB00195	Increased hypertension when clonidine stopped
DB00575	DB01295	Increased hypertension when clonidine stopped
DB00575	DB00612	Increased hypertension when clonidine stopped
DB00575	DB00521	Increased hypertension when clonidine stopped
DB00575	DB01136	Increased hypertension when clonidine stopped
DB00575	DB01242	The tricyclic antidepressant, clomipramine, may decrease the effect of clonidine.
DB00575	DB01151	The tricyclic antidepressant, desipramine, decreases the effect of clonidine.
DB00575	DB01142	The tricyclic antidepressant, doxepin, decreases the effect of clonidine.
DB00575	DB00187	Increased hypertension when clonidine stopped
DB00575	DB00458	The tricyclic antidepressant, imipramine, decreases the effect of clonidine.
DB00575	DB00598	Increased hypertension when clonidine stopped
DB00575	DB00264	Increased hypertension when clonidine stopped
DB00575	DB04896	Because Savella inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine's anti-hypertensive effect.
DB00575	DB00370	Possible hypertensive crisis
DB00575	DB01203	Increased hypertension when clonidine stopped
DB00575	DB00540	The tricyclic antidepressant, nortriptyline, decreases the effect of clonidine.
DB00575	DB01580	Increased hypertension when clonidine stopped
DB00575	DB01359	Increased hypertension when clonidine stopped
DB00575	DB00960	Increased hypertension when clonidine stopped
DB00575	DB01297	Increased hypertension when clonidine stopped
DB00575	DB00571	Increased hypertension when clonidine stopped
DB00575	DB00344	The tricyclic antidepressant, protriptyline, decreases the effect of clonidine.
DB00575	DB00489	Increased hypertension when clonidine stopped
DB00575	DB00373	Increased hypertension when clonidine stopped
DB00575	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00575	DB00726	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Clonidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Clonidine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00576	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00576	DB01320	The sulfonamide increases the effect of hydantoin
DB00576	DB06146	Possible crystallization of urates with this combination
DB00576	DB00563	The sulfamide increases the toxicity of methotrexate
DB00576	DB00252	The sulfonamide increases the effect of hydantoin
DB00578	DB00618	Possible antagonism of action
DB00578	DB00254	Possible antagonism of action
DB00578	DB01357	This anti-infectious agent could decreases the effect of the oral contraceptive
DB00578	DB00931	Possible antagonism of action
DB00578	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00578	DB01017	Possible antagonism of action
DB00578	DB00595	Possible antagonism of action
DB00578	DB01301	Possible antagonism of action
DB00578	DB00759	Possible antagonism of action
DB00579	DB01063	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB01246	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00477	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00392	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00472	Risk of serotoninergic syndrome
DB00579	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00176	Risk of serotoninergic syndrome
DB00579	DB01170	Mazindol may decrease the effect of guanethidine.
DB00579	DB01247	Possible hypertensive crisis
DB00579	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00902	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00715	Risk of serotoninergic syndrome
DB00579	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00780	Possible hypertensive crisis
DB00579	DB00433	Decreased anorexic effect, may increase psychotic symptoms.
DB00579	DB00420	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB01069	Decreased anorexic effect, may increase psychotic symptoms.
DB00579	DB01608	Decreased anorexic effect, may increase psychotic symptoms.
DB00579	DB00777	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB01367	Possible hypertensive crisis
DB00579	DB00372	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00752	Possible hypertensive crisis
DB00579	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00508	Decreased anorexic effect, may increase psychotic symptoms
DB00579	DB00285	Risk of serotoninergic syndrome
DB00580	DB00196	Fluconazole may increase the effect and toxicity of valdecoxib.
DB00580	DB01026	Ketoconazole may increase the effect and toxicity of valdecoxib.
DB00580	DB01356	The COX-2 inhibitor increases serum levels of lithium
DB00582	DB00106	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB00582	DB00802	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfentanil by decreasing its metabolism. Monitor for increased anesthetic and respiratory depressant effects and consider using lower alfentanil doses or alternate anesthetic.
DB00582	DB00346	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfuzosin by decreasing its metabolism. Use of alfuzosin with strong CYP3A4 inhibitors is contraindicated by the manufacturer.
DB00582	DB00918	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of almotriptan by decreasing its metabolism. The initial and maximum doses should not exceed 6.25 mg and 12.5 mg, respectively during concomitant therapy. Concomitant therapy should be avoided in patients with impaired hepatic or renal function.
DB00582	DB00404	Voriconazole may increase the serum concentration of alprazolam by decreasing its metabolism. Monitor for alprazolam toxicity if voriconazole is initiated or dose increased.
DB00582	DB06403	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ambrisentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01118	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amiodarone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of amiodarone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00321	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00381	Voriconazole may increase the serum concentration of amlodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amlodipine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01351	Amobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB00582	DB00543	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00701	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amprenavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by amprenavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00582	DB06605	Avoid combination. Otherwise, voriconazole will likely increase apixaban serum concentration.
DB00582	DB00714	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00673	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aprepitant by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aprepitant if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01238	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aripiprazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aripiprazole if voriconazole is initiated, discontinued or dose changed.
DB00582	DB06413	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of armodafinil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of armodafinil if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01169	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00582	DB06216	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00582	DB01072	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00582	DB01076	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00865	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of benzphetamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of benzphetamine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00612	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bisoprolol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bisoprolol if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00188	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bortezomib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bortezomib if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00559	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bosentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bosentan if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01558	Voriconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01200	Voriconazole may increase the serum concentration of bromocriptine likely by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB01222	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of budesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of budesonide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00921	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of buprenorphine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of buprenorphine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00490	Voriconazole may increase the serum concentration of buspirone likely by decreasing its metabolism via CYP3A4. Monitor for changes in the therapeutic and adverse effects of buspirone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01008	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of busulfan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of busulfan if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00237	Butabarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB00582	DB00241	Butalbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB00582	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB00582	DB00248	Voriconazole may increase the serum concentration of cabergoline likely by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00136	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of calcitriol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of calcitriol if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01101	Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if capecitabine is initiated, discontinued or dose changed.
DB00582	DB00564	Carbamazepine may reduce serum concentrations and efficacy of voriconazole likely by increasing its metabolism. Concomitant voriconazole and carbamazepine therapy is contraindicated.
DB00582	DB00475	Voriconazole may increase the serum concentration of chlordiazepoxide by decreasing its metabolism. Monitor for chlordiazepoxide toxicity if voriconazole is initiated or dose increased.
DB00582	DB00608	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chloroquine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chloroquine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01114	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chlorpheniramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorpheniramine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00672	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01410	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ciclesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ciclesonide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01166	Voriconzole may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for increased therapeutic/adverse effects of cilostazol and consider reducing the dose during concomitant therapy.
DB00582	DB01012	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cinacalcet by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cinacalcet if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00604	Voriconazole may increase the serum concentration and toxicity of cisapride likely by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated.
DB00582	DB00215	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of citalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of citalopram if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01211	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of clarithromycin by decreasing its metabolism. Clarithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00582	DB00349	Voriconazole may increase the serum concentration of clobazam by decreasing its metabolism. Monitor for clobazam toxicity if voriconazole is initiated or dose increased.
DB00582	DB01242	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01068	Voriconazole may increase the serum concentration of clonazepam by decreasing its metabolism. Monitor for clonazepam toxicity if voriconazole is initiated or dose increased.
DB00582	DB00628	Voriconazole may increase the serum concentration of clorazepate by decreasing its metabolism. Monitor for clorazepate toxicity if voriconazole is initiated or dose increased.
DB00582	DB00907	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cocaine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01394	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of colchicine by decreasing its metabolism. A dose reduction of colchicine is recommended along with increased monitoring for colchicine toxicity. Concomitant therapy is contraindicated in patients with renal and/or hepatic impairment.
DB00582	DB00872	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of conivaptan by inhibiting its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00091	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cyclosporine by decreasing its metabolism. Consider reducing the dose of cyclosporine. Monitor cyclosporine serum concentrations and therapeutic and toxic effects if initiating, discontinuing or adjusting voriconazole therapy.
DB00582	DB01219	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00250	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00496	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of darifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of darifenacin  if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01264	Darunavir may reduce serum concentrations and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy.
DB00582	DB01254	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00705	Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if delavirdine is initiated, discontinued or dose changed.
DB00582	DB01151	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01234	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dexamethasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dexamethasone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00829	Voriconazole may increase the serum concentration of diazepam by decreasing its metabolism. Monitor for diazepam toxicity if voriconazole is initiated or dose increased.
DB00582	DB00586	Voriconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of diclofenac by decreasing its metabolism. Renal impairment may increase the risk of diclofenac adverse effects. Monitor for changes in therapeutic and adverse effects of diclofenac if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00900	Didanosine may interfere with the absorption of orally administered voriconazole. Enteric coated didanosine does not exert this effect. Didanosine buffered formulations should be administered at least 2 hours from oral voriconazole administration.
DB00582	DB01396	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of digitoxin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of digitoxin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00390	Voriconazole may increase the serum concentration of digoxin. Monitor for increased serum concentrations and toxic effects of digoxin if voriconazole is initiated or dose increased.
DB00582	DB00320	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00343	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of diltiazem by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of diltiazem if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01195	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00598	DB01120	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00582	DB00280	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01248	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of docetaxel by decreasing its metabolism. Consider using a non-interacting antifungal or monitor for changes in the therapeutic and adverse effects of docetaxel if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00204	Voriconazole may increase the serum concentration of dofetilide by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00757	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01142	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00997	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of doxorubicin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxorubicin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB04855	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated.
DB00582	DB04855	Voriconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB00582	DB00450	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00625	Efavirenze may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of efavirenz by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased efavirenz adverse effects during concomitant therapy.
DB00582	DB00216	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eletriptan by decreasing its metabolism. Consider avoiding administration of the two agents within 72 hours of each other. Monitor for changes in the therapeutic and adverse effects of eletriptan if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00700	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eplerenone by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB01049	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergoloid mesylates by decreasing their metabolism. Concomitant therapy is contraindicated.
DB00582	DB01253	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergonovine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00696	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergotamine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00530	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erlotinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of erlotinib if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00199	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00582	DB01175	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of escitalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of escitalopram if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01215	Voriconazole may increase the serum concentration of estazolam by decreasing its metabolism. Monitor for estazolam toxicity if voriconazole is initiated or dose increased.
DB00582	DB00402	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eszopiclone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of eszopiclone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00593	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ethosuximide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00773	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of etoposide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of etoposide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB06414	Etravirine, when used concomitantly with variconazole, may experience an increase in serum concentration due to decreased metabolism of etravirine. \r\n\r\nVoriconazole, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in serum concentration. \r\n\r\nMonitor for changes in efficacy and toxicity of both agents if concomitant therapy is initiated, modified or discontinued.
DB00582	DB01590	Voriconzole, a strong CYP3A4 inhibitor, may increase the serum concentration of everolimus by decreasing its metabolism. Concurrent therapy should be avoided.
DB00582	DB00949	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felbamate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felbamate if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01023	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felodipine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00813	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed.
DB00598	DB01067	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00582	DB00322	Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if floxuridine is initiated, discontinued or dose changed.
DB00582	DB00196	Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of voriconazole if fluconazole is initiated, discontinued or dose changed.
DB00582	DB00180	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flunisolide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flunisolide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00544	Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if fluorouracil is initiated, discontinued or dose changed.
DB00582	DB00472	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00875	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00690	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flurazepam by decreasing its metabolism. Monitor for flurazepam toxicity if voriconazole is initiated or dose increased.
DB00582	DB00712	Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if flurbiprofen is initiated, discontinued or dose changed.
DB00582	DB00499	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flutamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flutamide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00588	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fluticasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluticasone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01319	Voriconazole may increase the serum concentration of fosamprenavir by decreasing its metabolism. Fosamprenavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00582	DB00529	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01320	The hydantoin decreases the effect of voriconazole
DB00582	DB01044	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00317	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of gefitinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of gefitinib if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01241	Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if gemfibrozil is initiated, discontinued or dose changed.
DB00582	DB01218	Voriconazole may increase the serum concentration of halofantrine by decreasing its metabolism by CYP3A4.  Concomitant therapy should be avoided due to the concentration-dependent risk of QTc prolongation related to halofantrine.
DB00582	DB00502	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of haloperidol if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01050	Ibuprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ibuprofen is initiated, discontinued or dose changed.
DB00582	DB00308	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01181	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ifosfamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ifosfamide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00619	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of imatinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of imatinib if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00458	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00808	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00224	Voriconazole may increase the serum concentration of indinavir by decreasing its metabolism. Indinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00582	DB00328	Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if indomethacin is initiated, discontinued or dose changed.
DB00582	DB00762	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of irinotecan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of irinotecan if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00883	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide dinitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide dinitrate if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00820	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tadalafil by decreasing its metabolism. Concomitant therapy should be avoided if possible due to high risk of tadalafil toxicity.
DB00582	DB01020	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide mononitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide mononitrate if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00270	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isradipine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of isradipine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB08820	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB00582	DB04845	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ixabepilone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ixabepilone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01221	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ketamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ketamine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01026	Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed.
DB00582	DB01259	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lapatinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lapatinib if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01137	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00281	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lidocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lidocaine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01601	Lopinavir may reduce serum concentration and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy.
DB00582	DB00227	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00408	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00582	DB00934	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB04835	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of maraviroc by decreasing its metabolism. A dose reduction in maraviroc is warranted. Monitor for changes in the therapeutic and adverse effects of maraviroc if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00784	Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if mefanamic acid is initiated, discontinued or dose changed.
DB00582	DB00358	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mefloquine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of mefloquine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00814	Voriconazole may increase the serum concentration of meloxicam by decreasing its metabolism via CYP2C9 and CYP3A4. Monitor for changes in the therapeutic and adverse effects of meloxicam if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00933	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00333	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01403	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00353	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methylergonovine  by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB01110	Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if miconazole is initiated, discontinued or dose changed.
DB00582	DB00683	Voriconazole may increase the serum concentration of midazolam by decreasing its metabolism. Monitor for midazolam toxicity if voriconazole is initiated or dose increased.
DB00582	DB00370	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mirtazapine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of mirtazapine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00745	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of modafinil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of modafinil if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00680	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of moricizine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moricizine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00218	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00731	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nateglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nateglinide if voriconazole is initiated, discontinued or dose changed.
DB00588	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended.
DB00582	DB01149	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nefazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nefazodone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00220	Nelfinavir may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of nelfinavir by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased nelfinavir adverse effects during concomitant therapy.
DB00582	DB00622	Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nicardipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole and nicardipine if concomitant therapy is initiated, discontinued or doses are changed.
DB00582	DB01115	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nifedipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nifedipine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB04868	Voriconazole may increase the serum concentration of nilotinib by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Concomitant therapy should be avoided.
DB00582	DB00393	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nimodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nimodipine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00401	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nisoldipine by decreasing its metabolism. Concomitant therapy should be avoided.
DB00582	DB01054	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nitrendipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nitrendipine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01059	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00540	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00104	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00338	Voriconazole increases the effect and toxicity of omeprazole
DB00582	DB01229	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of paclitaxel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of paclitaxel if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00738	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00556	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01186	Voriconazole may increase the serum concentration of pergolide likely by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB03575	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of phencyclidine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of phencyclidine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01174	Phenobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB00582	DB00252	Voriconazole may increase the serum concentration of phenytoin by decreasing its metabolism. Phenytoin may increase the serum concentration of voriconazole by increasing its metabolism. Consider alternate antifungal therapy or monitor for voriconazole therapy failure and phenytoin toxicity.
DB00582	DB01100	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pimozide by decreasing its metabolism. Increased risk of QTc prolongation and development arrhythmias. Concomitant use is contraindicated.
DB00582	DB01621	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pipotiazine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of pipotiazine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00554	Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if piroxicam is initiated, discontinued or dose changed.
DB00582	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB00582	DB01588	Voriconazole may increase the serum concentration of prazepam by decreasing its metabolism. Monitor for prazepam toxicity if voriconazole is initiated or dose increased.
DB00582	DB01058	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of praziquantel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of praziquantel if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00794	The barbiturate, primidone, decreases the effect of voriconazole.
DB00582	DB01599	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01035	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01182	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00344	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01224	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00675	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamoxifen by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamoxifen if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00908	Voriconazole may increase the serum concentration of quinidine likely by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the serum concentration and toxic effects of quinidine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00468	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB00582	DB00243	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated.
DB00582	DB08896	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB00582	DB00912	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of repaglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of repaglinide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00615	Rifabutin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifabutin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.
DB00582	DB01045	Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.
DB00582	DB01201	Rifapentine may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifapentin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.
DB00582	DB00734	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00503	Ritonavir may decrease the serum concentration of voriconazole by increasing its metabolism. Concomitant therapy with high dose ritonavir is contraindicated. Caution should be used with lower doses as decreased voriconazole efficacy may occur.
DB00582	DB06228	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of rivaroxaban by decreasing its metabolism. Increased bleed risks may occur. Consider alternate therapy.
DB00582	DB08877	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
DB00582	DB00938	Voriconazole, a strong CYP3A4 inhibitor may increase the serum concentration of salmeterol by decreasing its metabolism. Consider alternate therapy.
DB00582	DB01232	Voriconazole may increase the serum concentration of saquinavir by decreasing its metabolism. Saquinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00582	DB06335	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of saxagliptin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of saxagliptin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01105	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sibutramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sibutramine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00203	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sildenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sildenafil if voriconazole is initiated, discontinued or dose changed.
DB00582	DB06207	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00641	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastain if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00877	Voriconazole may increase the serum concentration of sirolimus likely by inhibition of CYP3A4-mediated metabolism or p-glyprotein transport of sirolimus. Consider alternate therapy or reduce the dose of sirolimus and monitor serum levels during concomitant therapy.
DB00582	DB06268	Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sitaxsentan is initiated, discontinued or dose changed.
DB00582	DB01591	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of solifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of solifenacin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00489	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB01208	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB06145	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of spiramycin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of spiramycin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01323	St. John's Wort may decrease the serum concentration of voriconazole by increasing its elimination. Concomitant therapy is contraindicated.
DB00582	DB00708	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sufentanil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sufentanil if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00263	Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed.
DB00582	DB01268	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sunitinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of sunitinib if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00864	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tacrolimus by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of tacrolimus if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00706	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamsulosin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamsulosin if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00976	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of telithromycin by decreasing its metabolism. Telithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. QTc interval prolongation may also occur.
DB00582	DB06287	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of temsirolimus and its active metabolite, sirolimus, by decreasing their metabolism. Concomitant therapy should be avoided.
DB00582	DB00444	The strong CYP3A4 inhibitor, Voriconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Voriconazole is initiated, discontinued or dose changed.
DB00582	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00582	DB04844	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB00582	DB00277	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of theophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of theophylline if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00679	Additive QTc prolongation may occur. Concomitant use is contraindicated.
DB00582	DB01623	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00906	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tiagabine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tiagabine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00932	Voriconazole may increase the serum concentration of tipranavir by decreasing its metabolism. Tipranavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00582	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00582	DB01036	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tolterodine by decreasing its metabolism. Tolterodine is mainly metabolized via the CYP2D6 pathway. This interaction is likely only a concern in patients who are poor CYP2D6 metabolizers. Monitor for changes in the therapeutic and adverse effects of tolterodine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB06212	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00582	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00582	DB00193	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tramadol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tramadol if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00656	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trazodone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00897	Voriconazole may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for triazolam toxicity if voriconazole is initiated or dose increased.
DB00582	DB00726	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trimipramine by decreasing its metabolism. Additive QTc prolongation may also occur. Monitor for changes in the therapeutic and adverse effects of trimipramine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00862	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of vardenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of vardenafil if voriconazole is initiated, discontinued or dose changed.
DB00582	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB00582	DB00285	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of venlafaxine if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00661	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of verapamil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of verapamil if voriconazole is initiated, discontinued or dose changed.
DB00582	DB06684	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB00582	DB00570	Voriconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Voriconazole is initiated, discontinued or dose changed.
DB00582	DB00541	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Voriconazole is initiated, discontinued or dose changed.
DB00582	DB00361	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Voriconazole is initiated, discontinued or dose changed.
DB00582	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00582	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00588	DB08865	Concurrent use with crizotinib may prolong QTc interval. Consider alternative therapy.
DB00582	DB00425	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if voriconazole is initiated, discontinued or dose changed.
DB00582	DB00909	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01198	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if voriconazole is initiated, discontinued or dose changed.
DB00582	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00584	DB00594	Increased risk of hyperkalemia
DB00584	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00584	DB01395	Increased risk of hyperkalemia
DB00584	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00584	DB00046	Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00584	DB01356	The ACE inhibitor increases serum levels of lithium
DB00584	DB01345	Increased risk of hyperkalemia
DB00584	DB01045	Rifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed.
DB00584	DB00421	Increased risk of hyperkalemia
DB00584	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00584	DB00684	Increased risk of nephrotoxicity
DB00584	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00584	DB00384	Increased risk of hyperkalemia
DB00585	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00585	DB01066	H2-Antagonists such as nizatidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB00585	DB00467	Nizatidine may decrease the absorption of enoxacin.
DB00585	DB01167	The H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole.
DB00585	DB01026	The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole.
DB00586	DB00630	Increased risk of gastric toxicity
DB00586	DB01125	The NSAID, diclofenac, may increase the anticoagulant effect of anisindione.
DB00586	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00586	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00586	DB00091	Monitor for nephrotoxicity
DB00586	DB00266	The NSAID, diclofenac, may increase the anticoagulant effect of dicumarol.
DB00586	DB06781	NSAIDs may slow healing.
DB00586	DB06210	Eltrombopag increases levels of Diclofenac via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB00586	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00586	DB01356	The NSAID, diclofenac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00586	DB00563	The NSAID, diclofenac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00586	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00586	DB01045	Rifampin, a CYP2C9 inducer, may increase the metabolism of diclofenac.
DB00586	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Diclofenac, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Diclofenac is initiated, discontinued or if the dose is changed.
DB00586	DB00966	Concomitant use of Telmisartan and Diclofenac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00586	DB00373	The NSAID, Diclofenac, may antagonize the antihypertensive effect of Timolol.
DB00586	DB00697	Diclofenac may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00586	DB00519	The NSAID, Diclofenac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diclofenac is initiated, discontinued or dose changed.
DB00586	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diclofenac. Monitor for increased bleeding during concomitant thearpy.
DB00586	DB06684	Increased risk of bleeding with concomitant use of NSAIDs with vilazodone.
DB00586	DB00582	Voriconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of diclofenac by decreasing its metabolism. Renal impairment may increase the risk of diclofenac adverse effects. Monitor for changes in therapeutic and adverse effects of diclofenac if voriconazole is initiated, discontinued or dose changed.
DB00586	DB00682	The antiplatelet effects of oral diclofenac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00637	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB00588	DB00976	Telithromycin may reduce clearance of Fluticasone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fluticasone if Telithromycin is initiated, discontinued or dose changed.
DB00588	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Fluticasone propionate. Concomitant therapy should be avoided if possible.
DB00588	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fluticasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluticasone if voriconazole is initiated, discontinued or dose changed.
DB00590	DB00820	Tadalafil may enhance the hypotensive effect of Doxazosin. Monitor for hypotension during concomitant therapy.
DB00590	DB00706	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Doxazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00590	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00590	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Doxazosin, may occur. Monitor for hypotension during concomitant therapy.
DB00593	DB00976	Telithromycin may reduce clearance of Ethosuximide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ethosuximide if Telithromycin is initiated, discontinued or dose changed.
DB00593	DB00427	The CNS depressants, Triprolidine and Ethosuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00593	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ethosuximide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed.
DB00594	DB00542	Increased risk of hyperkalemia
DB00594	DB00796	Increased risk of hyperkalemia
DB00594	DB01197	Increased risk of hyperkalemia
DB00594	DB01340	Increased risk of hyperkalemia
DB00594	DB01341	Decreases the antiarrhythmic effect of quinidine
DB00594	DB00584	Increased risk of hyperkalemia
DB00594	DB00700	Increased risk of hyperkalemia. Monitor serum potassium levels during concomitant threapy.
DB00594	DB00876	Increased risk of hyperkalemia
DB00594	DB01342	Increased risk of hyperkalemia
DB00594	DB00492	Increased risk of hyperkalemia
DB00594	DB01029	Increased risk of hyperkalemia
DB00594	DB00722	Increased risk of hyperkalemia
DB00594	DB00678	Increased risk of hyperkalemia
DB00594	DB00691	Increased risk of hyperkalemia
DB00594	DB00790	Increased risk of hyperkalemia
DB00594	DB01344	Risk of alkalosis in renal impairment
DB00594	DB01345	Increased risk of hyperkalemia
DB00594	DB00881	Increased risk of hyperkalemia
DB00594	DB00908	Amiloride may decrease the therapeutic effect of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if amiloride if initiated, discontinued or dose changed.
DB00594	DB01346	Decreases the antiarrhythmic effect of quinidine
DB00594	DB00178	Increased risk of hyperkalemia
DB00594	DB01347	Increased risk of hyperkalemia
DB00594	DB01348	Increased risk of hyperkalemia
DB00594	DB01349	Increased risk of hyperkalemia
DB00594	DB00966	Telmisartan may increase the hyperkalemic effect of Amiloride. Monitor for increased serum potassium concentrations during concomitant therapy.
DB00594	DB00519	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00594	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00594	DB00177	Increased risk of hyperkalemia
DB00595	DB00459	Increased risk of intracranial hypertension
DB00595	DB01060	Possible antagonism of action
DB00595	DB00415	Possible antagonism of action
DB00595	DB01053	Possible antagonism of action
DB00595	DB01373	Formation of non-absorbable complexes
DB00595	DB00578	Possible antagonism of action
DB00595	DB00766	Possible antagonism of action
DB00595	DB01147	Possible antagonism of action
DB00595	DB00485	Possible antagonism of action
DB00595	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00595	DB00926	Increased risk of intracranial hypertension
DB00595	DB00301	Possible antagonism of action
DB00595	DB00893	Formation of non-absorbable complexes
DB00595	DB00982	Increased risk of intracranial hypertension
DB00595	DB01378	Formation of non-absorbable complexes
DB00595	DB00417	Possible antagonism of action
DB00595	DB00319	Possible antagonism of action
DB00595	DB01604	Possible antagonism of action
DB00595	DB01605	Possible antagonism of action
DB00595	DB01607	Oxytetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Oxytetracycline.
DB00595	DB00755	Oxytetracycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00598	DB00414	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB00672	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB00501	Cimetidine may increase the serum concentration of labetolol by decreasing its metabolism.
DB00598	DB00575	Increased hypertension when clonidine stopped
DB00598	DB00320	Ischemia with risk of gangrene
DB00598	DB00280	The beta-blocker, labetolol, may increase the toxicity of disopyramide.
DB00598	DB00228	Monitor arterial pressure closely
DB00598	DB00668	Hypertension, then bradycardia
DB00598	DB01253	Ischemia with risk of gangrene
DB00598	DB00696	Ischemia with risk of gangrene
DB00598	DB01288	Antagonism
DB00598	DB00983	Antagonism
DB00637	DB01026	Increased risk of cardiotoxicity and arrhythmias
DB00598	DB01289	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB01016	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB01382	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB01159	Monitor arterial pressure closely
DB00598	DB01050	Risk of inhibition of renal prostaglandins
DB00598	DB00328	Risk of inhibition of renal prostaglandins
DB00598	DB00047	The beta-blocker, labetolol, may decrease symptoms of hypoglycemia.
DB00598	DB06704	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores
DB00598	DB00753	Monitor arterial pressure closely
DB00598	DB01064	Antagonism
DB00598	DB00281	The beta-blocker, labetalol, may increase the effect and toxicity of lidocaine.
DB00598	DB00247	Ischemia with risk of gangrene
DB00598	DB00816	Antagonism
DB00598	DB00236	Antagonism
DB00598	DB01291	Antagonism
DB00598	DB00554	Risk of inhibition of renal prostaglandins
DB00598	DB00457	Risk of hypotension at the beginning of therapy
DB00598	DB01366	Antagonism
DB00598	DB00912	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB01001	Antagonism
DB00598	DB00938	Antagonism
DB00598	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00598	DB00871	Antagonism
DB00598	DB00839	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB01124	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00598	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00598	DB00661	Increased effect of both drugs
DB00599	DB01418	Thiopental may increase the metabolism of the Vitamin K antagonist, Acenocoumarol. Acenocoumarol dose adjustment may be required.
DB00599	DB00381	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Amlodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Amlodipine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00446	Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted.
DB00599	DB00091	Thiopental may increase the metabolism and clearance of Cyclosporine. Monitor for changes in the therapeutic/adverse effects of Cyclosporine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00304	Thiopental may decrease the effect of Desogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB00343	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Diltiazem, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Diltiazem if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00280	Thiopental may increase the metabolism and clearance of Disopyramide. Monitor for changes in therapeutic/adverse effects of Disopyramide if Thiopental is inititaed, discontinued or dose changed.
DB00599	DB00254	Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered.
DB00599	DB01395	Thiopental may decrease the effect of Drospirenone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB00977	Thiopental may decrease the effect of Ethinyl estradiol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB00823	Thiopental may decrease the effect of Ethynodiol diacetate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB00294	Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB01023	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00270	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Isradipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Isradipine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00555	Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated.
DB00599	DB00367	Thiopental may decrease the effect of Levonorgestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB00603	Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB01357	Thiopental may decrease the effect of Mestranol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB00333	Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur.
DB00599	DB00622	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB01115	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nifedipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nifedipine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00393	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nimodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nimodipine if Thiopental is initiated, discontinued or dose changed.
DB00603	DB01125	Medroxyprogesterone may increase the anticoagulant effect of anisindione.
DB00599	DB00401	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nisoldipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nisoldipine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB01054	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nitrendipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nitrendipine if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00717	Thiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB00957	Thiopental may decrease the effect of Norgestimate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00599	DB01182	Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated.
DB00599	DB00908	Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated.
DB00599	DB00726	The barbiturate, Thiopental, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Thiopental is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00599	DB00427	The CNS depressants, Triprolidine and Thiopental, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00599	DB00661	Thiopental, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Thiopental is initiated, discontinued or dose changed.
DB00599	DB00682	Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed.
DB00601	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like linezolid.
DB00601	DB00484	MAO Inhibitors like linezolid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00601	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00601	DB00215	Combination associated with possible serotoninergic syndrome
DB00601	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00601	DB00841	Possible increase of arterial pressure
DB00601	DB00988	Possible increase of arterial pressure
DB00601	DB01363	Possible increase of arterial pressure
DB00601	DB01364	Possible increase of arterial pressure
DB00601	DB00668	Possible increase of arterial pressure
DB00601	DB01175	Combination associated with possible serotoninergic syndrome
DB00601	DB01288	Possible increase of arterial pressure
DB00601	DB00472	Linezolide, a MAO inhibitor, may increase the serotonergic effect of fluoxetine, a SSRI. Increased for of serotonin syndrome. Concomitant therapy should be avoided.
DB00601	DB00176	Combination associated with possible serotoninergic syndrome
DB00601	DB01064	Possible increase of arterial pressure
DB00601	DB01365	Possible increase of arterial pressure
DB00601	DB00610	Possible increase of arterial pressure
DB00601	DB00723	Possible increase of arterial pressure
DB00601	DB01149	Combination associated with possible serotoninergic syndrome
DB00601	DB00368	Possible increase of arterial pressure
DB00601	DB00816	Possible increase of arterial pressure
DB00601	DB00715	Combination associated with possible serotoninergic syndrome
DB00601	DB00388	Possible increase of arterial pressure
DB00601	DB00397	Possible increase of arterial pressure
DB00601	DB01291	Possible increase of arterial pressure
DB00601	DB01366	Possible increase of arterial pressure
DB00601	DB00852	Possible increase of arterial pressure
DB00601	DB01001	Possible increase of arterial pressure
DB00601	DB01104	Combination associated with possible serotoninergic syndrome
DB00601	DB00871	Possible increase of arterial pressure
DB00601	DB04844	Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated.
DB00601	DB00323	Tolcapone and Linezolid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00601	DB00193	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid.
DB00601	DB00752	The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Linezolid. These agents should not be administered within 14 days of each other.
DB00601	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00601	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00601	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00601	DB06684	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
DB00601	DB00315	The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated.
DB00603	DB01418	Medroxyprogesterone may increase the anticoagulant effect of acenocoumarol.
DB00603	DB01351	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00604	DB00196	Increased risk of cardiotoxicity and arrhythmias
DB00603	DB01352	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB06697	Artemether may decrease the effectiveness of medroxyprogesterone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00603	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of medroxyprogesterone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00603	DB00559	Bosentan may decrease the contraceptive effect of medroxyprogesterone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
DB00603	DB00237	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00241	The enzyme inducer, butalbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB01353	The enzyme inducer, butethal, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00603	DB00266	Medroxyprogesterone may increase the anticoagulant effect of dicumarol.
DB00603	DB00754	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, medroxyprogesterone.
DB00603	DB00400	The enzyme inducer, griseofulvin, may decrease the effect of the hormone, medroxyprogesterone.
DB00603	DB01354	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB01355	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00532	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00474	The enzyme inducer, methohexital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00849	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00312	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB01174	The enzyme inducer, phenobarbital, may decrease the effect of the hormone, medroxyprogesterone.
DB00603	DB00252	The enzyme inducer, phenytoin, may decrease the effect of medroxyprogesterone.
DB00603	DB00794	The enzyme inducer, primidone, may decrease the effect of the hormone, medroxyprogesterone.
DB00603	DB00418	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00306	The enzyme inducer, talbutal, decreases the effect of the hormone agent, medroxyprogesterone.
DB00603	DB00599	Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00603	DB00682	Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed.
DB00604	DB01418	Cisapride may increase the anticoagulant effect of acenocoumarol.
DB00604	DB01063	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01246	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00321	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00543	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00701	Amprenavir may increase the effect and toxicity of cisapride.
DB00604	DB01125	Cisapride may increase the anticoagulant effect of anisindione.
DB00604	DB00673	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00604	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01072	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00604	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01242	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB08865	Concurrent use with drugs that prolong QTc interval is contraindicated.
DB00604	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the metabolism of cisapride. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cisapride if delavirdine is initiated, discontinued or dose changed.
DB00604	DB01151	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00266	Cisapride may increase the anticoagulant effect of dicumarol.
DB00604	DB01341	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00343	Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cisapride by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cisapride if diltiazem is initiated, discontinued or dose changed.
DB00604	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01142	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00625	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01228	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00392	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00950	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01195	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01319	Amprenavir increases the effect and toxicity of cisapride
DB00604	DB00308	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00458	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00224	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01167	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01026	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00604	DB00934	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00902	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01403	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01388	Mibefradil increases levels of cisapride
DB00604	DB01149	Nefazodone increases serum levels of cisapride
DB00604	DB00220	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01115	Cisapride may increase the effect and toxicity of nifedipine.
DB00604	DB00540	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00850	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01263	Contraindicated co-administration
DB00604	DB01035	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00433	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00420	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01069	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01182	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00777	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00344	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01369	This combination presents an increased risk of toxicity
DB00604	DB00503	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01232	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Cisapride may also increase the concentration of Tacrolimus in the blood.
DB00604	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00604	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00604	DB00976	Telithromycin may reduce clearance of Cisapride. Concomitant therapy is contraindicated.
DB00604	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00372	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00604	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Cisapride. Concomitant therapy is contraindicated.
DB00604	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00604	DB00831	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00508	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00604	DB01361	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00582	Voriconazole may increase the serum concentration and toxicity of cisapride likely by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated.
DB00604	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00604	DB00682	Cisapride may increase the anticoagulant effect of warfarin.
DB00604	DB00549	Increased risk of cardiotoxicity and arrhythmias
DB00604	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00604	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00605	DB01418	The NSAID, sulindac, may increase the anticoagulant effect of acenocoumarol. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00605	DB00945	Risk of additive toxicity (e.g. bleed risk). Acetylsalicylic acid may decrease the serum concentration of sulindac. Sulindac may counteract the cardioprotective effects of acetylsalicylic acid. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB00605	DB00233	Risk of additive toxicity (e.g. bleed risk). Aminosalicylic acid may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB00605	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00605	DB00887	The NSAID, sulindac, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide.
DB00605	DB01432	The bile acid sequestrant, cholestyramine, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if cholestyramine is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions.
DB00605	DB00930	The bile acid sequestrant, colesevelam, may decrease the absorption of the NSAID, sulindac. Sulindac should be administered at least 1 hour before or 4 hours after colesevelam. Monitor for changes in the therapeutic and adverse effects of sulindac if colesevelam is initiated, discontinued or dose changed.
DB00605	DB00375	The bile acid sequestrant, colestipol, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if colestipol is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions.
DB00605	DB00091	The NSAID, sulindac, may increase the nephrotoxic effect of cyclosporine. Sulindac may increase the serum concentration of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine levels and nephrotoxicity during concomitant therapy.
DB00605	DB00903	The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacryninc acid.
DB00605	DB00695	The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide.
DB00605	DB01381	Ginkgo biloba may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
DB00605	DB01404	Ginseng may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
DB00605	DB00465	May cause additive or synergistic NSAID toxicities (e.g. GI bleeding, renal dysfunction, etc.). Concomitant therapy is contraindicated.
DB00605	DB00563	The NSAID, sulindac, may decrease the clearance methotrexate. Consider alternate therapy, especially in patients receiving high antineoplastic doses of methotrexate. Otherwise, monitor for hematologic and renal toxicities.
DB00605	DB00642	The NSAID, sulindac, may increase the serum concentration of pemetrexed by decreasing its elimination. This interaction more prevalent in patients with mild to moderate renal insufficiency. Consider alternate therapy or monitor for pemetrexed toxicity during concomitant therapy.
DB00605	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00605	DB00118	S-adenosylmethionine may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
DB00605	DB01398	Risk of additive toxicity (e.g. bleed risk). Salicylate-sodium may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB00605	DB01399	Risk of additive toxicity (e.g. bleed risk). Salsalate may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB00605	DB00966	Concomitant use of Telmisartan and Sulindac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00605	DB00373	The NSAID, Sulindac, may antagonize the antihypertensive effect of Timolol.
DB00605	DB00519	The NSAID, Sulindac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Sulindac is initiated, discontinued or dose changed.
DB00605	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Sulindac. Monitor for increased bleeding during concomitant thearpy.
DB00605	DB00682	The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00606	DB00390	Possible electrolyte variations and arrhythmias
DB00606	DB01356	The thiazide diuretic, cyclothiazide, may increase serum levels of lithium.
DB00607	DB00091	Nafcillin alters serum levels of cyclosporine
DB00607	DB00618	Possible antagonism of action
DB00607	DB00254	Possible antagonism of action
DB00607	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00607	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00607	DB08815	Concomitant therapy will decrease levels of lurasidone via effects on CYP 3A4. Concomitant therapy is contraindicated.
DB00607	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00607	DB01017	Possible antagonism of action
DB00607	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00607	DB00976	Nafcillin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00607	DB06287	Nafcillin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00607	DB00759	Possible antagonism of action
DB00607	DB00193	Nafcillin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00607	DB00656	The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed.
DB00607	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00607	DB00661	Nafcillin may decrease the serum concentration of Verapamil by increasing its metabolism via CYP3A4. Monitor for changes in the therapeutic/adverse effects of Verapamil if Nafcillin is initiated, discontinued or dose changed.
DB00607	DB00682	Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed.
DB00608	DB01370	The antiacid decreases the absorption of chloroquine
DB00608	DB06697	Chloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB00608	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00608	DB01574	The antiacid decreases the absorption of chloroquine
DB00608	DB00091	Chloroquine may increase the therapeutic and adverse effects of cyclosporine.
DB00608	DB01375	The antiacid decreases the absorption of chloroquine
DB00608	DB01575	The antiacid decreases the absorption of chloroquine
DB00608	DB06708	Chloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB00608	DB01378	The antiacid decreases the absorption of chloroquine
DB00608	DB01377	The antiacid decreases the absorption of chloroquine
DB00608	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00608	DB01058	Markedly lower praziquantel levels
DB00608	DB00675	Chloroquine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00608	DB00706	Chloroquine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chloroquine is initiated, discontinued, or dose changed.
DB00608	DB00976	Telithromycin may reduce clearance of Chloroquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chloroquine if Telithromycin is initiated, discontinued or dose changed.
DB00608	DB00857	Terbinafine may reduce the metabolism and clearance of Chloroquine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chloroquine if Terbinafine is initiated, discontinued or dose changed.
DB00608	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00608	DB00193	Chloroquine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00608	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chloroquine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chloroquine if voriconazole is initiated, discontinued or dose changed.
DB00610	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of metaraminol.
DB00610	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of metaraminol.
DB00610	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of metaraminol.
DB00610	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of metaraminol.
DB00610	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol.
DB00610	DB01170	Metaraminol may decrease the effect of guanethidine.
DB00610	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of metaraminol.
DB00610	DB01247	Increased arterial pressure
DB00610	DB00601	Possible increase of arterial pressure
DB00610	DB00968	Increased arterial pressure
DB00610	DB00211	Increased arterial pressure
DB00610	DB01171	Moclobemide increases the sympathomimetic effect of metaraminol.
DB00610	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of metaraminol.
DB00610	DB00780	Increased arterial pressure
DB00610	DB01367	Increased arterial pressure
DB00610	DB00206	Increased arterial pressure
DB00611	DB06274	Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan.
DB00611	DB00450	Droperidol may enhance the CNS depressant effect of butorphanol. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00611	DB00427	The CNS depressants, Triprolidine and Butorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00612	DB00414	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB00672	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB00575	Increased hypertension when clonidine stopped
DB00612	DB00320	Ischemia with risk of gangrene
DB00612	DB00280	The beta-blocker, bisoprolol, may increase the toxicity of disopyramide.
DB00612	DB00668	Hypertension, then bradycardia
DB00612	DB01253	Ischemia with risk of gangrene
DB00612	DB00696	Ischemia with risk of gangrene
DB00612	DB01288	Antagonism
DB00612	DB00983	Antagonism
DB00612	DB01120	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01067	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01289	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01016	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01382	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01050	Risk of inhibition of renal prostaglandins
DB00612	DB05039	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB00612	DB00328	Risk of inhibition of renal prostaglandins
DB00612	DB01306	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01307	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB00047	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01309	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB00046	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01064	Antagonism
DB00612	DB00281	The beta-blocker, bisoprolol, may increase the effect and toxicity of lidocaine.
DB00612	DB00247	Ischemia with risk of gangrene
DB00612	DB00816	Antagonism
DB00612	DB00236	Antagonism
DB00612	DB01291	Antagonism
DB00612	DB00912	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01045	Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism.
DB00612	DB01001	Antagonism
DB00612	DB00938	Antagonism
DB00612	DB00976	Telithromycin may reduce clearance of Bisoprolol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bisoprolol if Telithromycin is initiated, discontinued or dose changed.
DB00612	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00612	DB00871	Antagonism
DB00612	DB00839	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB01124	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00612	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00612	DB00661	Increased effect of both drugs
DB00612	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bisoprolol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bisoprolol if voriconazole is initiated, discontinued or dose changed.
DB00614	DB04896	Increase serotonin levels. Combination therapy is contraindicated.
DB00614	DB04844	Tetrabenazine may increase the adverse/toxic effects of Furazolidine. Concomitant therapy is contraindicated.
DB00614	DB00323	Tolcapone and Furazolidone decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00614	DB00193	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Furazolidone.
DB00614	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00614	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00614	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00614	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00614	DB00315	The MAO inhibitor, furazolidine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing furazolidine are contraindicated.
DB00615	DB05812	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB00615	DB01418	Rifabutin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.
DB00615	DB00321	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifabutin is initiated, discontinued or dose changed.
DB00615	DB00543	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifabutin is initiated, discontinued or dose changed.
DB00615	DB00701	Amprenavir may increase the effect and toxicity of rifabutin.
DB00615	DB01125	Rifabutin, may decrease the anticoagulant effect of anisindione.
DB00615	DB01072	Atazanavir may increase levels/toxicity of rifabutin.
DB00615	DB01076	Rifabutin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifabutin is initiated, discontinued or dose changed.
DB00615	DB01117	Rifabutin decreases the effect of atovaquone
DB00615	DB01558	Rifabutin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifabutin is initiated, discontinued or dose changed.
DB00615	DB01156	Rifampin reduces bupropion levels
DB00615	DB00490	Rifabutin decreases the effect of buspirone
DB00615	DB06772	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB00615	DB00439	Rifabutin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifabutin is initiated, discontinued or dose changed.
DB00615	DB01211	The rifamycin, rifabutin, may decrease the effect of the macrolide, clarithromycin.
DB00615	DB01242	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifabutin is initiated, discontinued or dose changed.
DB00615	DB00363	Rifabutin decreases the effect of clozapine
DB00615	DB00091	The rifamycin decreases the effect of cyclosporine
DB00615	DB00250	Decreased levels of dapsone
DB00615	DB00705	Rifabutin decreases the effect of delavirdine
DB00615	DB01151	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifabutin is initiated, discontinued or dose changed.
DB00615	DB00266	Rifabutin may decrease the anticoagulant effect of dicumarol.
DB00615	DB01142	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifabutin is initiated, discontinued or dose changed.
DB00615	DB00254	The rifamycin decreases the effect of doxycycline
DB00615	DB00530	Decreased levels/effect of erlotinib
DB00615	DB00199	The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin.
DB00615	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00615	DB00977	Rifabutin may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.
DB00635	DB04573	The estrogenic agent, estriol, may increase the effect of corticosteroid, prednisone.
DB00615	DB06414	Etravirine may experience a decrease in serum concentration. It is recommended to monitor etravirine therapy for efficacy. The combination of rifabutin and etravirine therapy is contraindicated if a protease inhibitor which is ritonavir boosted is also being used.
DB00615	DB00196	Fluconazole may increase levels/toxicity of rifabutin.
DB00615	DB01095	Rifabutin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifabutin is initiated, discontinued or dose changed.
DB00615	DB01319	Amprenavir increases the effect and toxicity of rifabutin
DB00615	DB00502	The rifamycin decreases the effect of haloperidol
DB00615	DB00458	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifabutin is initiated, discontinued or dose changed.
DB00615	DB00224	Rifabutin decreases the effect of indinavir
DB00615	DB01167	Rifabutin decreases the effect of itraconazole
DB00615	DB08820	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB00615	DB01321	The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin.
DB00615	DB00227	Rifabutin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifabutin is initiated, discontinued or dose changed.
DB00615	DB01357	This product may cause a slight decrease of the contraceptive effect
DB00615	DB00333	The rifamycin decreases the effect of methadone
DB00615	DB00717	Rifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.
DB00615	DB00540	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifabutin is initiated, discontinued or dose changed.
DB00615	DB06589	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB00615	DB01263	Modification of drug levels for both agents
DB00615	DB01182	Rifampin decreases the effect of propafenone
DB00615	DB00344	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifabutin is initiated, discontinued or dose changed.
DB00615	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB00615	DB00503	Rifabutin decreases the effect of ritonavir
DB00615	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00615	DB01232	Rifabutin decreases the effect of saquinavir
DB00615	DB00641	Rifabutin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic effect of simvastatin if rifabutin is initiated, discontinued or dose changed.
DB00615	DB00877	The rifamycin decreases the effect of sirolimus
DB00615	DB01268	Possible decrease in sunitinib levels
DB00615	DB00864	Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.
DB00615	DB00675	The rifamycin decreases the effect of anti-estrogen
DB00615	DB00976	Rifabutin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00615	DB06287	Rifabutin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00615	DB00857	Rifabutin may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided.
DB00615	DB00932	Tipranavir increases the concentration of Rifabutin. Adjust Rifabutin dose and monitor for adverse/toxic effects.
DB00615	DB06212	Rifabutin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB00615	DB00539	The rifamycin decreases the effect of anti-estrogen
DB00615	DB00193	Rifabutin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00615	DB00656	The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed.
DB00615	DB00726	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifabutin is initiated, discontinued or dose changed.
DB00615	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00615	DB08881	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB00615	DB00661	Rifabutin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifabutin is initiated, discontinued or dose changed.
DB00615	DB00582	Rifabutin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifabutin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.
DB00615	DB00682	Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism.
DB00615	DB00495	The rifamycin decreases levels of zidovudine
DB00618	DB01418	The tetracycline, demeclocycline, may increase the anticoagulant effect of acenocoumarol.
DB00618	DB00459	Increased risk of intracranial hypertension
DB00618	DB01370	Formation of non-absorbable complexes
DB00618	DB01060	Possible antagonism of action
DB00618	DB00415	Possible antagonism of action
DB00618	DB01125	The tetracycline, demeclocycline, may increase the anticoagulant effect of anisindione.
DB00618	DB01574	Formation of non-absorbable complexes
DB00618	DB01061	Possible antagonism of action
DB00618	DB00355	Possible antagonism of action
DB00618	DB00307	Tetracycline derivatives like demeclocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB00618	DB01373	Formation of non-absorbable complexes
DB00618	DB00258	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as demeoclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00618	DB01164	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as demeclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00618	DB00578	Possible antagonism of action
DB00618	DB00766	Possible antagonism of action
DB00618	DB01147	Possible antagonism of action
DB00618	DB00930	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00618	DB01000	Possible antagonism of action
DB00618	DB00485	Possible antagonism of action
DB00618	DB00266	The tetracycline, demeclocycline, may increase the anticoagulant effect of dicumarol.
DB00618	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00618	DB00926	Increased risk of intracranial hypertension
DB00618	DB00301	Possible antagonism of action
DB00618	DB00739	Possible antagonism of action
DB00618	DB01592	Formation of non-absorbable complexes
DB00618	DB00893	Formation of non-absorbable complexes
DB00618	DB00982	Increased risk of intracranial hypertension
DB00618	DB01378	Formation of non-absorbable complexes
DB00618	DB01377	Formation of non-absorbable complexes
DB00618	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00618	DB01028	The tetracycline, demeclocycline, may increase the renal toxicity of methoxyflurane.
DB00618	DB01603	Possible antagonism of action
DB00618	DB00948	Possible antagonism of action
DB00618	DB00607	Possible antagonism of action
DB00618	DB00713	Possible antagonism of action
DB00618	DB00417	Possible antagonism of action
DB00618	DB00319	Possible antagonism of action
DB00618	DB01604	Possible antagonism of action
DB00618	DB01605	Possible antagonism of action
DB00618	DB01606	Possible antagonism of action
DB00618	DB01607	Demeclocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Demeclocycline.
DB00618	DB00755	Demeclocycline may increase the adverse effects of oral Tretinoin. Increased risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00618	DB00682	The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin.
DB00618	DB01593	Formation of non-absorbable complexes
DB00619	DB01418	Imatinib may increase the anticoagulant effect of acenocoumarol.
DB00619	DB00316	Increased hepatic toxicity of both agents
DB00619	DB01125	Imatinib may increase the anticoagulant effect of anisindione.
DB00619	DB00673	Aprepitant may change levels of the chemotherapy agent, imatinib.
DB00619	DB01076	Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if imatinib is initiated, discontinued or dose changed.
DB00619	DB01558	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if imatinib is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00619	DB00564	Carbamazepine, a strong CYP3A4 inducer, may increase the metabolism of imatinib. Imatinib, a strong CYP3A4 inhibitor, may increase the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00619	DB00439	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if imatinib is initiated, discontinued or dose changed.
DB00619	DB01211	The macrolide, clarithromycin, may increase the serum concentration of imatinib.
DB00619	DB00091	Imatinib increases the effect and toxicity of cyclosporine
DB00619	DB01219	Imatinib may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if imatinib is initiated, discontinued or dose changed.
DB00619	DB01234	Dexamethasone may decrease levels of imatinib.
DB00619	DB00266	Imatinib may increase the anticoagulant effect of dicumarol.
DB00619	DB00199	The macrolide, erythromycin, may increase the serum concentration of imatinib.
DB00619	DB00754	The hydantoin decreases the levels of imatinib
DB00622	DB00864	The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered.
DB00619	DB06414	Imatinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by a minimum of 50%, and to monitor therapy.
DB00619	DB01320	The hydantoin decreases the levels of imatinib
DB00619	DB01167	Itraconazole may increase the levels of imatinib.
DB00619	DB01321	The macrolide, josamycin, may increase the serum concentration of imatinib.
DB00619	DB01026	Ketoconazole may increase the levels of imatinib.
DB00619	DB00227	Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if imatinib is initiated, discontinued or dose changed.
DB00619	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB00619	DB00532	The hydantoin decreases the levels of imatinib
DB00619	DB01115	Imatinib increases the effect and toxicity of nifedipine
DB00619	DB01174	Phenobarbital decreases levels of imatinib
DB00619	DB00252	The hydantoin decreases the levels of imatinib
DB00619	DB01100	Imatinib may increase the effect and toxicity of pimozide.
DB00619	DB01045	Rifampin decreases levels of imatinib
DB00619	DB00641	Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if imatinib is initiated, discontinued or dose changed.
DB00619	DB01323	St. John's Wort decreases levels of imatinib
DB00619	DB00864	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00820	Imatinib may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00619	DB00675	Imatinib may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Imatinib may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00706	Imatinib, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imatinib is initiated, discontinued, or dose changed.
DB00619	DB00976	Co-administration may result in altered plasma concentrations of Imatinib and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00619	DB06287	Imatinib may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00619	DB00444	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00906	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Imatinib is initiated, discontinued or dose changed.
DB00619	DB01036	Imatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00619	DB01030	The BCRP/ABCG2 inhibitor, Imatinib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00193	Imatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Imatinib may decrease the effect of Tramadol by decreasing active metabolite production.
DB00619	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00619	DB00656	The CYP3A4 inhibitor, Imatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00726	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00862	Imatinib, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00619	DB00285	Imatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Imatinib is initiated, discontinued, or dose changed.
DB00619	DB00661	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00570	Imatinib, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00541	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Imatinib is initiated, discontinued or dose changed.
DB00619	DB00361	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Imatinib is initiated, discontinued or dose changed.
DB00622	DB00820	Nicardipine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00637	DB00625	Increased risk of cardiotoxicity and arrhythmias
DB00619	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of imatinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of imatinib if voriconazole is initiated, discontinued or dose changed.
DB00619	DB00682	Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed.
DB00619	DB00909	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if imatinib is initiated, discontinued or dose changed.
DB00619	DB01198	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if imatinib is initiated, discontinued or dose changed.
DB00620	DB01418	The corticosteroid, triamcinolone, alters the anticoagulant effect, acenocoumarol.
DB00620	DB00945	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00620	DB01122	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, ambenonium.
DB00620	DB01351	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01125	The corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione.
DB00620	DB01352	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01294	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB00620	DB00237	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00241	The barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01353	The barbiturate, butethal, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00266	The corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol.
DB00620	DB01341	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01010	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium.
DB00620	DB00754	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01354	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01355	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01397	The corticosteroid, triamcinolone, may decrease the effect of magnesium salicylate.
DB00620	DB00532	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00474	The barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00849	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00211	Increased arterial pressure
DB00620	DB01400	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine.
DB00620	DB00312	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00545	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00620	DB01346	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB01398	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salicylate-sodium.
DB00620	DB01399	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate.
DB00620	DB00418	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00382	Tacrine and Triamcinolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00620	DB00306	The barbiturate, talbutal, may decrease the effect of the corticosteroid, triamcinolone.
DB00620	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00620	DB01401	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, trisalicylate-choline.
DB00620	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB00620	DB00682	The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin.
DB00621	DB00682	Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed.
DB00622	DB01558	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nicardipine is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00622	DB00091	Nicardipine increases the effect and toxicity of cyclosporine
DB00622	DB01219	Nicardipine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nicardipine is initiated, discontinued or dose changed.
DB00622	DB01369	This combination presents an increased risk of toxicity
DB00622	DB00675	Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00706	Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed.
DB00622	DB00976	Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00622	DB06287	Nicardipine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00622	DB00444	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00622	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed.
DB00622	DB00906	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00932	Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine.
DB00622	DB01124	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB01036	Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00622	DB01030	The p-glycoprotein inhibitor, Nicardipine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00622	DB00214	Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00193	Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00622	DB00656	The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00622	DB00440	The strong CYP2C9 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00726	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00862	Nicardipine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00622	DB00285	Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed.
DB00622	DB00661	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00570	Nicardipine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00541	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00361	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nicardipine is initiated, discontinued or dose changed.
DB00622	DB00582	Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nicardipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole and nicardipine if concomitant therapy is initiated, discontinued or doses are changed.
DB00622	DB00682	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed.
DB00622	DB00549	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if nicardipine is initiated, discontinued or dose changed.
DB00622	DB00425	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nicardipine is initiated, discontinued or dose changed.
DB00622	DB00909	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed.
DB00622	DB01198	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nicardipine is initiated, discontinued or dose changed.
DB00623	DB00182	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB00289	Risk of additive CNS depressant effects. Monitor for increased CNS depression during concomitant therapy.
DB00623	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00623	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00623	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00623	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB01576	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00623	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00623	DB01170	Fluphenazine may decrease the effect of guanethidine.
DB00623	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00623	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB01577	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB01578	Increased risk of convulsions
DB00623	DB01579	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB00830	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00623	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00623	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Fluphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00623	DB00857	Terbinafine may reduce the metabolism and clearance of Fluphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluphenazine if Terbinafine is initiated, discontinued or dose changed.
DB00623	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00623	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB00623	DB00662	Trimethobenzamide and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00623	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Fluphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00623	DB00209	Trospium and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00624	DB01418	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed.
DB00624	DB01125	The androgen may increase the anticoagulant effect of anisindione.
DB00624	DB00091	The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB00624	DB00266	The androgen may increase the anticoagulant effect of dicumarol.
DB00624	DB01248	Testosterone may increase the serum levels and toxicity of docetaxel.
DB00624	DB00682	Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed.
DB00625	DB00404	The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00625	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00625	DB01072	Efavirenz decreases the levels/effects of atazanavir
DB00625	DB01076	Efavirenz may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if efavirenz is initiated, discontinued or dose changed.
DB00625	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00625	DB01211	Efavirenz decreases levels of clarithromycin
DB00625	DB00091	Efavirenz decreases the levels of cyclosporine
DB00625	DB00320	Efavirenze may increase the adverse/toxic effects of dihydroergotamine. Concomitant therapy is contraindicated.
DB00625	DB06210	Affects hepatic enzyme CYP2C9/10 metabolism and may increase the level of eltrombopag.
DB00625	DB00696	The antiretroviral agent may increase the ergot derivative toxicity
DB00625	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00625	DB06414	Etravirine, when used concomitantly with Efavirenz, may experience a  significant decrease in plasma levels and a loss of efficacy. \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination.
DB00625	DB00224	Efavirenz decreases the effect of indinavir
DB00629	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00625	DB00227	Efavirenz may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if efavirenz is initiated, discontinued or dose changed.
DB00625	DB00333	Efavirenz may decrease the serum concentration of methadone by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of methadone if efavirenz is initiated, discontinued or dose changed.
DB00625	DB00353	The antiretroviral agent may increase the ergot derivative toxicity
DB00625	DB00247	The antiretroviral agent may increase the ergot derivative toxicity
DB00625	DB00683	The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00625	DB08864	Concentration of rilpivirine decreases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's.
DB00625	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00625	DB01232	Efavirenz decreases the effect of saquinavir
DB00625	DB00641	Efavirenz may decrease the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if efavirenz is initiated, discontinued or dose changed.
DB00625	DB01323	St. John's Wort decreases the antiretroviral effect
DB00625	DB00706	Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed.
DB00625	DB05521	Inducers of CYP3A enzymes will decrease telaprevir levels.
DB00625	DB00976	Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00625	DB06287	Efavirenz may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00625	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00625	DB00932	Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed.
DB00625	DB01036	Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00625	DB00193	Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00625	DB00656	The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed.
DB00625	DB00897	The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00625	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00625	DB00582	Efavirenze may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of efavirenz by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased efavirenz adverse effects during concomitant therapy.
DB00627	DB00930	Bile Acid Sequestrants may decrease the absorption of Niacin. It may be prudent to separate the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for reduced efficacy of these agents. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00627	DB00227	Risk of severe myopathy/rhabdomyolysis with this combination
DB00627	DB08860	Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both niacin and pitavastatin via pharmacodynamic synergism. Use alternative therapy.
DB00628	DB00701	Amprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate.
DB00628	DB00501	Cimetidine may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB00363	Increased risk of toxicity
DB00628	DB00754	Ethotoin may increase the metabolism of clorazepate via CYP3A4.
DB00628	DB00196	Fluconazole may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB01319	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate.
DB00628	DB01320	Fosphenytoin may increase the metabolism of clorazepate via CYP3A4.
DB00628	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB01167	Itraconazole may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB01322	Kava may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB01026	Ketoconazole may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB00532	Mephenytoin may increase the metabolism of clorazepate via CYP3A4.
DB00628	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB00338	Omeprazole may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB00252	Phenytoin may increase the metabolism of clorazepate via CYP3A4.
DB00628	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clorazepate.
DB00628	DB00976	Telithromycin may reduce clearance of Clorazepate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clorazepate if Telithromycin is initiated, discontinued or dose changed.
DB00628	DB00932	Tipranavir may decrease the metabolism and clearance of Clorazepate. Consider alternate therapy or monitor for Clorazepate toxic effects if Tipranavir is initiated or dose increased.
DB00628	DB00427	The CNS depressants, Triprolidine and Clorazepate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00628	DB00582	Voriconazole may increase the serum concentration of clorazepate by decreasing its metabolism. Monitor for clorazepate toxicity if voriconazole is initiated or dose increased.
DB00629	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Guanabenz by decreasing Guanabenz metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Guanabenz if Thiabendazole is initiated, discontinued or dose changed.
DB00629	DB00726	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanabenz. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanabenz should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00630	DB01373	Formation of non-absorbable complexes
DB00630	DB00258	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as alendronate. Avoid administration of oral calcium supplements within 30 minutes after alendronate.
DB00630	DB01164	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate.
DB00630	DB00586	Increased risk of gastric toxicity
DB00630	DB00861	Increased risk of gastric toxicity
DB00630	DB00749	Increased risk of gastric toxicity
DB00630	DB00573	Increased risk of gastric toxicity
DB00630	DB00712	Increased risk of gastric toxicity
DB00630	DB01050	Increased risk of gastric toxicity
DB00630	DB00328	Increased risk of gastric toxicity
DB00630	DB00893	Formation of non-absorbable complexes
DB00630	DB00465	Increased risk of gasrtic toxicity
DB00630	DB01378	Formation of non-absorbable complexes
DB00630	DB00784	Increased risk of gastric toxicity
DB00630	DB00461	Increased risk of gastric toxicity
DB00630	DB00788	Increased risk of gastric toxicity
DB00630	DB00991	Increased risk of gastric toxicity
DB00630	DB03585	Increased risk of gastric toxicity
DB00630	DB00554	Increased risk of gastric toxicity
DB00630	DB00469	Increased risk of gastric toxicity
DB00631	DB01097	Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB00631	DB00108	Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
DB00631	DB00337	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00631	DB01656	Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB00631	DB00864	Tacrolimus (topical) may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00631	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00633	DB00752	Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Dexmedetomidine.
DB00633	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00633	DB00726	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Dexmedetomidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Dexmedetomidine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00635	DB01418	The corticosteroid, prednisone, alters the anticoagulant effect, acenocoumarol.
DB00635	DB00945	The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00635	DB01122	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, ambenonium.
DB00635	DB01351	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01125	The corticosteroid, prednisone, alters the anticoagulant effect of anisindione.
DB00635	DB01352	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01294	The corticosteroid, prednisone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB00635	DB00237	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00241	The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01353	The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00269	The estrogenic agent, chlorotrianisene, may increase the effect of corticosteroid, prednisone.
DB00635	DB00882	The estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone.
DB00635	DB00286	The estrogenic agent may increase the effect of corticosteroid, prednisone.
DB00635	DB00266	The corticosteroid, prednisone, alters the anticoagulant effect of dicumarol.
DB00635	DB00255	The estrogenic agent, diethylstilbestrol, may increase the effect of corticosteroid, prednisone.
DB00635	DB01341	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01010	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium.
DB00635	DB00783	The estrogenic agent, estradiol, may increase the effect of corticosteroid, prednisone.
DB00635	DB00655	The estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone.
DB00635	DB04574	The estrogenic agent, estropipate, may increase the effect of corticosteroid, prednisone.
DB00635	DB00977	The estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone.
DB00635	DB00754	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB06223	decreases the effect of cortisone by metabolism alteration.
DB00635	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB08909	Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol pehnylbutyrate are used concomitantly.
DB00635	DB01354	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01355	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB05039	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB00635	DB00046	Concomitant therapy with corticosteriods may reduce the blood-glucose-lowering effect of insulin lispro.
DB00635	DB01167	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
DB00635	DB01026	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
DB00635	DB08882	CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely.
DB00635	DB01397	The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate.
DB00635	DB00532	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01357	The estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone.
DB00635	DB00474	The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00849	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00211	Increased arterial pressure
DB00635	DB01400	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine.
DB00635	DB00312	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00545	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00635	DB04575	The estrogenic agent, quinestrol, may increase the effect of corticosteroid, prednisone.
DB00635	DB01346	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB01398	The corticosteroid, prednisone, may decrease the effect of the salicylate, salicylate-sodium.
DB00635	DB01399	The corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate.
DB00635	DB00418	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00382	Tacrine and Prednisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00635	DB00306	The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisone.
DB00635	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00635	DB01401	The corticosteroid, prednisone, may decrease the effect of the salicylate, trisalicylate-choline.
DB00635	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB00635	DB00682	The corticosteroid, prednisone, alters the anticoagulant effect of warfarin.
DB00636	DB01418	The fibrate increases the anticoagulant effect
DB00636	DB00414	Clofibrate may increase the effect of sulfonylurea, acetohexamide.
DB00636	DB01125	The fibrate increases the anticoagulant effect
DB00636	DB00672	Clofibrate may increase the effect of sulfonylurea, chlorpropamide.
DB00636	DB00266	The fibrate increases the anticoagulant effect
DB00636	DB01120	Clofibrate may increase the effect of sulfonylurea, gliclazide.
DB00636	DB01067	Clofibrate may increase the effect of sulfonylurea, glipizide.
DB00636	DB01289	Clofibrate may increase the effect of sulfonylurea, glisoxepide.
DB00636	DB01016	Clofibrate may increase the effect of sulfonylurea, glibenclamide.
DB00636	DB01382	Clofibrate may increase the effect of sulfonylurea, glycodiazine.
DB00636	DB01306	Increases the effect of insulin
DB00636	DB01307	Increases the effect of insulin
DB00636	DB01309	Increases the effect of insulin
DB00636	DB00839	Clofibrate may increase the effect of sulfonylurea, tolazamide.
DB00636	DB01124	Clofibrate may increase the effect of sulfonylurea, tolbutamide.
DB00636	DB01586	The fibric acid derivative decreases the effect of ursodiol
DB00636	DB00682	The fibrate increases the anticoagulant effect
DB00637	DB00701	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00673	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00501	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00705	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01388	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01149	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00220	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01263	Contraindicated co-administration
DB00637	DB00468	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01369	This combination presents an increased risk of toxicity
DB00637	DB00503	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01232	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00637	DB00976	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated.
DB00637	DB01361	Increased risk of cardiotoxicity and arrhythmias
DB00637	DB00582	Increased risk of cardiotoxicity and arrhythmias
DB00640	DB01223	This xanthine decreases the effect of adenosine
DB00640	DB00201	Caffeine may diminish the therapeutic effect of adenosine. Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible.
DB00640	DB00975	Dipyridamole may increase the effect/toxicity of adenosine.
DB00640	DB00651	This xanthine decreases the effect of adenosine
DB00640	DB01303	This xanthine decreases the effect of adenosine
DB00640	DB00277	Theophylline may decrease the effect of adenosine.
DB00641	DB01118	Increased risk of rhabdomyolysis
DB00641	DB00701	Amprenavir may increase the effect and toxicity of simvastatin. Concomitant therapy is contraindicated.
DB00641	DB01072	Increased risk of myopathy/rhabdomyolysis
DB00641	DB00559	Bosentan may decrease the serum concentration of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if bosentan is initiated, discontinued or dose changed.
DB00641	DB00564	Carbamazepine, a p-glycoprotein inducer, may decrease the effect of simvastatin by increasing its efflux. Monitor for changes in the therapeutic and adverse effects of simvastatin if carbamazepine is initiated, discontinued or dose changed.
DB00641	DB01211	The macrolide, clarithromycin, may increase the toxicity of the statin, simvastatin.
DB00641	DB01394	Increased risk of rhabdomyolysis with this combination
DB00641	DB00091	Possible myopathy and rhabdomyolysis
DB00641	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if delavirdine is initiated, discontinued or dose changed.
DB00641	DB00343	Diltiazem may increase the serum concentration of simvastatin. Simvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00641	DB04855	Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of simvastatin 4-fold. Lower doses of simvastatin and doses should not exceed 20 mg to avoid statin-induced toxicities like myopathy. Consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone.
DB00641	DB00625	Efavirenz may decrease the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if efavirenz is initiated, discontinued or dose changed.
DB00641	DB00199	The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin.
DB00641	DB06414	Simvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of simvastatin therapy.
DB00641	DB01039	Increased risk of myopathy/rhabdomyolysis
DB00641	DB00196	Increased risk of myopathy/rhabdomyolysis
DB00641	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if fosamprenavir is initiated, discontinued or dose changed.
DB00641	DB02703	Increased risk of myopathy/rhabdomyolysis
DB00641	DB01241	Increased risk of myopathy/rhabdomyolysis
DB00641	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if imatinib is initiated, discontinued or dose changed.
DB00641	DB01167	Increased risk of myopathy/rhabdomyolysis
DB00641	DB01026	Increased risk of myopathy/rhabdomyolysis
DB00641	DB08827	Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions.
DB00641	DB01149	Nefazodone may increase the effect and toxicity of simvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nefazodone is initiated, discontinued or dose changed.
DB00641	DB00220	Nelfinavir may increase the effect and toxicity of simvastatin. Concomitant therapy should be avoided.
DB00641	DB00238	The strong CYP3A4 inducer, nevirapine, may decrase the effect of simvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nevirapine is initiated, discontinued or dose changed.
DB00641	DB06589	Elevated liver enzyme levels may be observed with concomitant therapy with pazopanib. Monitor closely for adverse effects.
DB00641	DB01369	This combination presents an increased risk of toxicity
DB00641	DB00243	Ranolazine may increase the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if ranolazine is initiated, discontinued or dose changed.
DB00641	DB00615	Rifabutin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic effect of simvastatin if rifabutin is initiated, discontinued or dose changed.
DB00641	DB01045	Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed.
DB00641	DB06335	Simvastatin is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 12%. Exposure of the active metabolite decreased by 2%. However, these changes in pharmacokinetics are not clinical significant.
DB00641	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00641	DB00976	Telithromycin may increase the adverse effects of simvastatin by decreasing its metabolism. Concomitant therapy should be avoided.
DB00641	DB08816	Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects.
DB00641	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Simvastatin. Concomitant therapy is contraindicated.
DB00641	DB06273	Simvastatin is a CYP3A4 and OATP1B1 substrate. Exposure of simvastatin decreases following administration of tocilizumab.
DB00641	DB00661	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed.
DB00641	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastain if voriconazole is initiated, discontinued or dose changed.
DB00642	DB01009	The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy.
DB00642	DB00605	The NSAID, sulindac, may increase the serum concentration of pemetrexed by decreasing its elimination. This interaction more prevalent in patients with mild to moderate renal insufficiency. Consider alternate therapy or monitor for pemetrexed toxicity during concomitant therapy.
DB00642	DB01600	Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered.
DB00642	DB00500	Tolmetin may decrease the renal excretion of Pemetrexed in patients with decreased creatinine clearance. Tolmetin may be withheld in these patients from 2 days before to 2 days after Pemetrexed administration.
DB00643	DB00754	The hydantoin decreases the efficiency of mebendazole
DB00643	DB01320	The hydantoin decreases the efficiency of mebendazole
DB00643	DB00532	The hydantoin decreases the efficiency of mebendazole
DB00643	DB00252	The hydantoin decreases the efficiency of mebendazole
DB00647	DB01418	Propoxyphene may increase the anticoagulant effect of acenocoumarol.
DB00647	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00647	DB01125	Propoxyphene may increase the anticoagulant effect of anisindione.
DB00647	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00647	DB00564	Propoxyphene increases the effect of carbamazepine
DB00647	DB00501	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of propoxyphene. Monitor for changes in the therapeutic and adverse effects of propoxyphene if cimetidine is intitiated, discontinued or dose changed.
DB00647	DB00266	Propoxyphene may increase the anticoagulant effect of dicumarol.
DB00647	DB00046	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00647	DB00503	Ritonavir increases the levels of analgesic
DB00647	DB00752	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB00647	DB00427	The CNS depressants, Triprolidine and Propoxyphene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00647	DB00682	Propoxyphene may increase the anticoagulant effect of warfarin.
DB00648	DB01418	Mitotane may decrease the anticoagulant effect of acenocoumarol.
DB00648	DB01125	Mitotane may decrease the anticoagulant effect of anisindione.
DB00648	DB00266	Mitotane may decrease the anticoagulant effect of dicumarol.
DB00648	DB00421	Spironolactone antagonizes the effect of mitotane
DB00648	DB00682	Mitotane may decrease the anticoagulant effect of warfarin.
DB00649	DB00495	Zidovudine may decrease the efficacy of stavudine. Concomitant therapy should be avoided.
DB00650	DB08898	Do not administer leucovorin within 2 hours of glucarpidase due to the fact that leucovorin is degraded by glucarpidase.
DB00650	DB00440	The efficacy of Trimethoprim may be reduced by Leucovorin (folinic acid). The antibiotic, Trimethoprim, acts by blocking bacterial folic acid metabolism. Leucovorin may reduce the efficacy of Trimethoprim by providing an alternate source of folic acid. The therapeutic effect of Trimethoprim should be closely monitored.
DB00651	DB00787	Acyclovir increases the effect and toxicity of dyphylline.
DB00651	DB00640	This xanthine decreases the effect of adenosine
DB00651	DB01558	Dyphylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if dyphylline is initiated, discontinued or dose changed.
DB00651	DB00564	Carbamazepine may decrease the serum concentration of diphylline. Diphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB00651	DB00501	Increases the effect of theophylline
DB00651	DB00537	Ciprofloxacin may increase the effect of dyphylline.
DB00651	DB01211	Increases the effect and toxicity of theophylline
DB00651	DB00822	Increases the effect and toxicity of theophylline
DB00651	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, dyphylline.
DB00651	DB00977	The contraceptive increases the effect and toxicity of theophylline
DB00651	DB00176	Increases the effect and toxicity of theophylline
DB00651	DB01320	Decreased effect of both products
DB00651	DB00365	Grepafloxacin may increase the effect of dyphylline.
DB00651	DB00034	Interferon increases the effect and toxicity of theophylline
DB00651	DB00105	Interferon increases the effect and toxicity of theophylline
DB00651	DB00011	Interferon increases the effect and toxicity of theophylline
DB00651	DB00951	Increases the effect and toxicity of theophylline
DB00651	DB01356	Theophylline decreases serum levels of lithium
DB00651	DB00379	Mexiletine increases the effect and toxicity of theophylline
DB00651	DB01203	Antagonism of action and increased effect of theophylline
DB00651	DB01059	Norfloxacin may increase the effect of dyphylline.
DB00651	DB00008	Interferon increases the effect and toxicity of theophylline
DB00651	DB00022	Interferon increases the effect and toxicity of theophylline
DB00651	DB00806	Pentoxifylline increases the effect and toxicity of theophylline
DB00651	DB01174	The barbiturate, phenobarbital, decreases the effect of dyphylline.
DB00651	DB00252	Decreased effect of both products
DB00651	DB00960	Antagonism of action and increased effect of theophylline
DB00651	DB00794	The barbiturate, primidone, decreases the effect of dyphylline.
DB00651	DB01182	Propafenone increases the effect of theophylline
DB00651	DB00571	Antagonism of action and increased effect of theophylline
DB00651	DB01045	Rifampin decreases the effect of theophylline
DB00651	DB00231	Dyphylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Dyphylline is initiated, discontinued or dose changed.
DB00651	DB00857	Terbinafine increases the effect and toxicity of theophylline
DB00651	DB00208	Ticlopidine increases the effect and toxicity of theophylline
DB00651	DB00373	Antagonism of action and increased effect of theophylline
DB00652	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00652	DB00427	The CNS depressants, Triprolidine and Pentazocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00653	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00653	DB01551	May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy.
DB00653	DB06210	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB00653	DB01133	The divalent cation of oral Magnesium sulfate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
DB00653	DB00427	The CNS depressants, Triprolidine and Magnesium sulfate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00653	DB00685	Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.
DB00654	DB00905	The concomitant use of bimatoprost and latanoprost may result in increased intraocular pressure. Consider avoiding this combination of therapy. Monitor for paradoxical increases in intraocular pressure during concomitant use.
DB00655	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estrone.
DB00655	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estrone.
DB00655	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estrone.
DB00655	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estrone.
DB00655	DB00860	The estrogenic agent, estrone, may increase the effect of the corticosteroid, prednisolone.
DB00655	DB00635	The estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone.
DB00655	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, estrone.
DB00655	DB00932	Estropipate may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estropipate. Monitor for estrogen deficiency during concomitant therapy.
DB00656	DB00918	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00357	The CYP3A4 inducer, Aminoglutethimide, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aminoglutethimide is initiated, discontinued or dose changed.
DB00656	DB01118	The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed.
DB00656	DB00321	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00543	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00701	The protease inhibitor, Amprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amprenavir is initiated, discontinued or dose changed.
DB00656	DB00673	The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed.
DB00656	DB01072	The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed.
DB00668	DB01580	Hypertension, then bradycardia
DB00656	DB00559	The CYP3A4 inducer, Bosentan, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Bosentan is initiated, discontinued or dose changed.
DB00656	DB01200	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00490	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00248	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00564	The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed.
DB00656	DB00501	The CYP3A4 inhibitor, Cimetidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cimetidine is initiated, discontinued or dose changed.
DB00656	DB00215	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01211	The CYP3A4 inhibitor, Clarithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Clarithromycin is initiated, discontinued or dose changed.
DB00656	DB01242	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00257	The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed.
DB00656	DB00872	The CYP3A4 inhibitor, Conivaptan, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Conivaptan is initiated, discontinued or dose changed.
DB00656	DB00091	The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed.
DB00656	DB06695	P-Glycoprotein inducers such as trazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB00656	DB01264	The protease inhibitor, Darunavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Darunavir is initiated, discontinued or dose changed.
DB00656	DB00705	The CYP3A4 inhibitor, Delavirdine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Delavirdine is initiated, discontinued or dose changed.
DB00656	DB01151	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01234	The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed.
DB00656	DB00514	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00320	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00343	The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed.
DB00656	DB00843	Possible antagonism of action
DB00656	DB01142	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00476	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00625	The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed.
DB00656	DB00216	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01049	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01253	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00696	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00199	The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed.
DB00656	DB01175	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB06414	The CYP3A4 inducer, Etravirene, may decrease Trazodone efficacy/toxicity by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Etravirine is initiated, discontinued or dose changed.
DB00656	DB00196	The CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed.
DB00656	DB00472	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00176	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01319	The protease inhibitor, Fosamprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosamprenavir is initiated, discontinued or dose changed.
DB00656	DB01320	The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed.
DB00656	DB00998	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00614	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00674	Possible antagonism of action
DB00656	DB01381	Increased effect and toxicity of both agents
DB00668	DB00107	Possible marked increase of arterial pressure
DB00656	DB00502	The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed.
DB00656	DB00619	The CYP3A4 inhibitor, Imatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Imatinib is initiated, discontinued or dose changed.
DB00656	DB00458	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00224	The protease inhibitor, Indinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism via CYP3A4. Monitor for changes in Trazodone efficacy/toxicity if Indinavir is initiated, discontinued or dose changed.
DB00656	DB01247	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00951	The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed.
DB00656	DB01167	The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed.
DB00656	DB01026	The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed.
DB00656	DB01259	The CYP3A4 inhibitor, Lapatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lapatinib is initiated, discontinued or dose changed.
DB00656	DB00281	The CYP3A4 inhibitor, Lidocaine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lidocaine is initiated, discontinued or dose changed.
DB00656	DB00601	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01356	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01601	The protease inhibitor, Lopinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lopinavir is initiated, discontinued or dose changed.
DB00656	DB00934	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00353	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00916	The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed.
DB00656	DB01110	The CYP3A4 inhibitor, Miconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Miconazole is initiated, discontinued or dose changed.
DB00656	DB00370	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01171	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00607	The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed.
DB00656	DB00952	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01149	Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Nefazodone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for symtpoms of sertonin syndrome and changes in Trazodone efficacy/toxicity if Nefazodone is initiated, discontinued or dose changed.
DB00656	DB00220	The protease inhibitor, Nelfinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nelfinavir is initiated, discontinued or dose changed.
DB00656	DB00238	The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed.
DB00656	DB00622	The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed.
DB00656	DB01059	The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed.
DB00656	DB00540	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00776	The CYP3A4 inducer, Oxcarbazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Oxcarbazepine is initiated, discontinued or dose changed.
DB00656	DB00715	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00312	The CYP3A4 inducer, Pentobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Pentobarbital is initiated, discontinued or dose changed.
DB00656	DB01186	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00454	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00780	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01174	The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed.
DB00661	DB01590	Concomitant administration may increase the serum concentrations of both agents. Concurrent use should be avoided.
DB00656	DB00252	The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed.
DB00656	DB01263	The CYP3A4 inhibitor, Posaconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Posaconazole is initiated, discontinued or dose changed.
DB00656	DB00794	The CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed.
DB00656	DB01168	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01069	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00344	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00908	The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed.
DB00656	DB01367	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00615	The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed.
DB00656	DB01045	The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed.
DB00656	DB01201	The CYP3A4 inducer, Rifapentine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifapentine is initiated, discontinued or dose changed.
DB00656	DB00503	The protease inhibitor, Ritonavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Ritonavir is initiated, discontinued or dose changed.
DB00656	DB00989	Possible antagonism of action
DB00656	DB00953	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00118	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01232	The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed.
DB00656	DB01037	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01104	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB01105	Increased risk of serotonin syndrome. Avoid concomitant therapy.
DB00656	DB06268	The CYP3A4 inhibitor, Sitaxsenten, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed.
DB00656	DB01323	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00669	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00675	Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00656	DB00706	Trazodone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Trazodone is initiated, discontinued, or dose changed.
DB00656	DB00976	The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
DB00656	DB00759	The CYP3A4 inhibitor, Tetracycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tetracycline is initiated, discontinued or dose changed.
DB00656	DB00932	The protease inhibitor, Tipranavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tipranavir is initiated, discontinued or dose changed.
DB00656	DB00193	The use of two serotonin modulators, such as trazodone and tramadol, may increase the risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00656	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00427	The CNS depressants, Triprolidine and Trazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00656	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00656	DB00661	The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed.
DB00656	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trazodone if voriconazole is initiated, discontinued or dose changed.
DB00656	DB00315	Use of two serotonin modulators, such as zolmitriptan and trazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00658	DB00537	Sevelamer decreases ciprofloxacin bioavailability
DB00658	DB00091	Sevelamer decreases the effect of cyclosporine
DB00658	DB00685	Sevelamer may decrease the absorption of orally administered Trovafloxacin. The Sevelamer formulation contains iron that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sevelamer dose to minimize the interaction.
DB00661	DB00794	The barbiturate, primidone, decreases the effect of the calcium channel blocker, verapamil.
DB00660	DB00427	The CNS depressants, Triprolidine and Metaxalone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00661	DB01193	Increased effect of both drugs
DB00661	DB09026	Monitor therapy due to increased concentration of aliskiren.
DB00661	DB01143	Verapamil may enhance the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Verapamil should be withheld for 24 hours prior to Amifostine administration. Caution should be used at lower Amifostine doses used during radiotherapy, but routine interruption of Verapamil therapy is not recommended.
DB00661	DB01223	Verapamil increases the effect of theophylline
DB00661	DB01118	Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed.
DB00661	DB01351	Amobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Amobarbital is initiated, discontinued or dose changed.
DB00661	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Amprenavir is initiated, discontinued or dose changed.
DB00661	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed.
DB00661	DB00335	Increased effect of both drugs
DB00661	DB01076	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed.
DB00661	DB00612	Increased effect of both drugs
DB00661	DB01558	Verapamil may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if verapamil is initiated, discontinued or dose changed.
DB00661	DB00490	Verapamil may increase the serum concentration of Buspirone. The likely occurs via Verapamil-mediated CYP3A4 inhibition resulting in decreased Buspirone metabolism. Monitor for changes in the therapeutic/adverse effects of Buspirone if Verpamil is initiated, discontinued or dose changed.
DB00661	DB00237	Butabarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butabarbital is initiated, discontinued or dose changed.
DB00661	DB00241	Butalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed.
DB00661	DB00564	Verapamil may increase the serum concentration of Carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Carbamazepine if Verapamil is initiated, discontinued or dose changed.
DB00661	DB01136	Increased effect of both drugs
DB00661	DB01211	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Clarithromycin is initiated, discontinued or dose changed.
DB00661	DB01394	Verapamil may increase the serum concentration of Colchicine. This likely occurs via Verapamil-mediated inhibition of CYP3A4 and p-glycoprotein-mediated transport. Monitor for changes in the therapeutic/adverse effects of Colchicine if Verapamil is initiated, discontinued or dose changed.
DB00661	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed.
DB00661	DB00091	Verapamil may increase the serum concentration of cyclosporine by inhibiting CYP3A4-mediated metabolism of cyclosporine. Monitor for changes in the therapeutic/adverse effects of cyclosporine if verapamil is initiated, discontinued or dose changed.
DB00661	DB06695	Verapamil may increase serum concentrations of the active metabolite(s) of dabigatran etexilate, resulting in an increased risk of bleeding. It is also a strong p-glycoprotein inhibitor. Therapy modification should be considered.
DB00661	DB01264	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Darunavir is initiated, discontinued or dose changed.
DB00661	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Delavirdine is initiated, discontinued or dose changed.
DB00661	DB01396	Verapamil may increase the serum concentration of Digitoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digitoxin if Verpamail is initiated, discontinued or dose changed.
DB00661	DB00390	Verapamil may increase the serum concentration of Digoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digoxin if Verpamail is initiated, discontinued or dose changed.
DB00661	DB00204	Verapamil may increase the plamsa levels of Dofetilide. Increased risk of torsade de pointes. Concomitant therapy is contraindicated.
DB00661	DB04855	Verapamil is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker.
DB00661	DB00700	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB00661	DB00199	Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of verapamil if erythromycin is initiated, discontinued or dose changed.
DB00661	DB00187	Increased effect of both drugs
DB00661	DB00196	Fluconazole may increase the serum concentration of Verapamil by decreasing Verapamil metabolism. This likely occurs via Fluconazole-mediated CYP3A4 inhibition. Monitor for changes in the therapeutic/adverse effects of Verapamil if Fluconazole is initiated, discontinued, or dose changed.
DB00661	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed.
DB00661	DB01218	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Halofantrine by decreasing its metabolism. Extreme caution with increased cardiac status monitoring should be used during concomitant therapy.
DB00661	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Imatinib is initiated, discontinued or dose changed.
DB00661	DB05039	Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events.
DB00661	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Indinavir is initiated, discontinued or dose changed.
DB00661	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed.
DB00661	DB01167	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed.
DB00661	DB01026	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed.
DB00661	DB00598	Increased effect of both drugs
DB00661	DB01356	Signs of lithium toxicity
DB00661	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Lopinavir is initiated, discontinued or dose changed.
DB00661	DB00227	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed.
DB00661	DB00474	Methohexital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methohexital is initiated, discontinued or dose changed.
DB00661	DB00849	Methylphenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methylphenobarbital is initiated, discontinued or dose changed.
DB00661	DB00264	Increased effect of both drugs
DB00661	DB01110	Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Miconazole is initiated, discontinued or dose changed.
DB00661	DB00683	Verapamil may increase the serum concentration of Midazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Midazolam.
DB00661	DB01203	Increased effect of both drugs
DB00661	DB00607	Nafcillin may decrease the serum concentration of Verapamil by increasing its metabolism via CYP3A4. Monitor for changes in the therapeutic/adverse effects of Verapamil if Nafcillin is initiated, discontinued or dose changed.
DB00661	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed.
DB00661	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nelfinavir is initiated, discontinued or dose changed.
DB00661	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed.
DB00661	DB01580	Increased effect of both drugs
DB00661	DB01303	Verapamil increases the effect of theophylline
DB00661	DB00312	Pentobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Pentobarbital is initiated, discontinued or dose changed.
DB00661	DB01174	Phenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Phenobarbital is initiated, discontinued or dose changed.
DB00661	DB00252	Verapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed.
DB00661	DB00960	Increased effect of both drugs
DB00661	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed.
DB00661	DB00457	Risk of hypotension at the beginning of therapy
DB00661	DB00571	Increased effect of both drugs
DB00661	DB00908	Concurrent therapy may result in increased serum levels of both agents. Both agents are CYP3A4 inhibitors and substrates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of the agent if the other is initiated, discontinued or dose changed.
DB00661	DB01369	This combination presents an increased risk of toxicity
DB00661	DB00243	Verapamil, a CYP3A4 inhibitor, may increase the serum concentration of Ranolazine. Concomitant therapy is contraindicated.
DB00661	DB00615	Rifabutin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifabutin is initiated, discontinued or dose changed.
DB00661	DB01045	Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed.
DB00661	DB01201	Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed.
DB00661	DB00503	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ritonavir is initiated, discontinued or dose changed.
DB00661	DB00073	Verapamil may increase the hypotensive effects of Rituximab. Consider withholding Verapamil therapy for 12 hours prior to Rituximab infusion.
DB00661	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Saquinavir is initiated, discontinued or dose changed.
DB00661	DB00418	Secobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Secobarbital is initiated, discontinued or dose changed.
DB00661	DB06207	Verapamil is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects
DB00661	DB00641	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed.
DB00661	DB00864	The calcium channel blocker, Verapamil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Verapamil therapy is initiated, discontinued or altered.
DB00661	DB00706	Verapamil, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Verapamil is initiated, discontinued, or dose changed.
DB00661	DB00976	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed.
DB00661	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00661	DB00277	Verapamil increases the effect of theophylline
DB00661	DB00599	Thiopental, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Thiopental is initiated, discontinued or dose changed.
DB00661	DB00373	Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block.
DB00661	DB00932	Tipranavir, co-administered with Ritonavir, may alter the concentration of Verapamil. Monitor for efficacy and adverse/toxic effects of Verapamil.
DB00661	DB01036	Verapamil may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00661	DB06212	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan. Concomitant therapy is contraindicated.
DB00661	DB01030	The p-glycoprotein inhibitor, Verapamil, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00661	DB00193	Verapamil may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00661	DB00656	The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed.
DB00661	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00661	DB00897	Verapamil may increase the serum concentration of Triazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Triazolam.
DB00661	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of verapamil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of verapamil if voriconazole is initiated, discontinued or dose changed.
DB00662	DB01063	Trimethobenzamide and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01246	Trimethobenzamide and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00321	Trimethobenzamide and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00543	Trimethobenzamide and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00572	Trimethobenzamide and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00668	DB01203	Hypertension, then bradycardia
DB00662	DB00972	Trimethobenzamide and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00245	Trimethobenzamide and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00810	Trimethobenzamide and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01237	Trimethobenzamide and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00835	Trimethobenzamide and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00748	Trimethobenzamide and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01114	Trimethobenzamide and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00477	Trimethobenzamide and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00283	Trimethobenzamide and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00771	Trimethobenzamide and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01242	Trimethobenzamide and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00363	Trimethobenzamide and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01176	Trimethobenzamide and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00405	Trimethobenzamide and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00804	Trimethobenzamide and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00985	Trimethobenzamide and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01075	Trimethobenzamide and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00843	The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00662	DB01142	Trimethobenzamide and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00366	Trimethobenzamide and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00470	Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended.
DB00662	DB00450	Trimethobenzamide and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00950	Trimethobenzamide and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01148	Trimethobenzamide and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00875	Trimethobenzamide and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00623	Trimethobenzamide and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00674	The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00662	DB00986	Trimethobenzamide and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00502	Trimethobenzamide and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00725	Trimethobenzamide and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00557	Trimethobenzamide and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00424	Trimethobenzamide and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00458	Trimethobenzamide and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00332	Trimethobenzamide and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01247	Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00920	Trimethobenzamide and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00455	Trimethobenzamide and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00408	Trimethobenzamide and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00934	Trimethobenzamide and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00737	Trimethobenzamide and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB04843	Trimethobenzamide and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00933	Trimethobenzamide and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00940	Trimethobenzamide and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00462	Trimethobenzamide and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01171	Trimethobenzamide and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01618	Trimethobenzamide and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00486	Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended.
DB00662	DB00540	Trimethobenzamide and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00334	Trimethobenzamide and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01173	Trimethobenzamide and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01062	Trimethobenzamide and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00850	Trimethobenzamide and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00780	Trimethobenzamide and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01619	Trimethobenzamide and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01100	Trimethobenzamide and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB06153	Trimethobenzamide and Pizotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00761	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trimethobenzamide, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00662	DB01278	The anticholinergic effects of Trimethobenzamide may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB00662	DB00433	Trimethobenzamide and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00387	Trimethobenzamide and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01069	Trimethobenzamide and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00782	Trimethobenzamide and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00344	Trimethobenzamide and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01224	Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00734	Trimethobenzamide and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00989	The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00668	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of epinephrine.
DB00662	DB00747	Trimethobenzamide and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00021	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB00662	DB01591	Trimethobenzamide and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimethobenzamide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00662	DB00679	Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01623	Trimethobenzamide and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01409	Trimethobenzamide and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01036	Trimethobenzamide and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00752	Trimethobenzamide and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00831	Trimethobenzamide and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00376	Trimethobenzamide and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00726	Trimethobenzamide and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00427	Concomitant therapy with Triprolidine and Trimethobenzamide, two anticholinergics, may result in additive anticholinergic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB00209	Trospium and Trimethobenzamide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00662	DB01624	Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00665	DB00208	Ticlopidine may decrease the metabolism and clearance of Nilutamide. Consider alternate therapy or monitor for adverse/toxic effects of Nilutamide if Ticlopidine is initiated, discontinued or dose changed.
DB00668	DB01193	Hypertension, then bradycardia
DB00668	DB00386	Increased arterial pressure
DB00668	DB00321	The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of epinephrine.
DB00668	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of epinephrine.
DB00668	DB00335	Hypertension, then bradycardia
DB00668	DB00195	Beta-Blockers such as betaxolol may enhance the vasopressor effect of epinephrine. Monitor for increases in pressor effects of alpha-/beta-agonists if used in patients receiving beta-blocker therapy (including ophthalmic products). Beta1-selective (i.e., cardioselective) agents may confer a more limited risk if used in low enough doses to allow them to retain their selectivity. The amount of epinephrine used in dental procedures as part of local anesthetic administration is not likely to be of clinical concern. Infiltrating larger volumes of local anesthetics for other surgical procedures (e.g., more than 0.06mg epinephrine) may cause clinically-relevant problems. Patients with allergies that require carrying and periodically using subcutaneous epinephrine (e.g., bee sting kits) should probably avoid the use of beta blockers.
DB00668	DB01295	Hypertension, then bradycardia
DB00668	DB00612	Hypertension, then bradycardia
DB00668	DB00521	Hypertension, then bradycardia
DB00668	DB01136	Hypertension, then bradycardia
DB00668	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of epinephrine.
DB00668	DB01089	Increased arterial pressure
DB00668	DB01151	Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00668	DB06700	Desvenlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00668	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of epinephrine.
DB00668	DB00494	Entacapone may increase the effect and toxicity of the sympathomimetic, epinephrine.
DB00668	DB01253	Possible marked increase of arterial pressure
DB00668	DB00187	Hypertension, then bradycardia
DB00668	DB01170	Epinephrine may decrease the effect of guanethidine.
DB00668	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of epinephrine.
DB00668	DB00046	Concomitant therapy with sympathomimetic agents may reduce the blood-glucose-lowering effect of insulin lispro.
DB00668	DB01247	Increased arterial pressure
DB00668	DB00598	Hypertension, then bradycardia
DB00668	DB00601	Possible increase of arterial pressure
DB00668	DB08815	Epinephrine increases toxicity (enhance hypotensive effects) of lurasidone by pharmacodynamic synergism.
DB00668	DB00968	Increased arterial pressure
DB00668	DB00353	Possible marked increase of arterial pressure
DB00668	DB00264	Hypertension, then bradycardia
DB00668	DB00211	Increased arterial pressure
DB00668	DB01171	Moclobemide increases the sympathomimetic effect of epinephrine.
DB00668	DB01626	Increased arterial pressure
DB00668	DB01359	Hypertension, then bradycardia
DB00668	DB00780	Increased arterial pressure
DB00668	DB00960	Hypertension, then bradycardia
DB00668	DB01297	Hypertension, then bradycardia
DB00668	DB00571	Hypertension, then bradycardia
DB00668	DB00344	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of epinephrine.
DB00668	DB01367	Increased arterial pressure
DB00668	DB00206	Increased arterial pressure
DB00668	DB00489	Hypertension, then bradycardia
DB00668	DB00373	Hypertension, then bradycardia
DB00668	DB00752	Increased arterial pressure
DB00668	DB00726	Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00668	DB00285	Venlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00669	DB00215	Increased risk of CNS adverse effects
DB00669	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00669	DB00320	Possible severe and prolonged vasoconstriction
DB00669	DB00696	Possible severe and prolonged vasoconstriction
DB00669	DB01175	Increased risk of CNS adverse effects
DB00669	DB00472	Increased risk of CNS adverse effects
DB00669	DB00176	Increased risk of CNS adverse effects
DB00669	DB01247	The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated.
DB00669	DB01356	Possible serotoninergic syndrome with this combination
DB00669	DB00247	Possible severe and prolonged vasoconstriction
DB00669	DB01149	Increased risk of CNS adverse effects
DB00669	DB00715	Increased risk of CNS adverse effects
DB00669	DB00780	The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated.
DB00669	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00669	DB00752	The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Sumatriptan. Risk of serotonin syndrome and Sumatriptan toxicity. Concomitant therapy should be avoided.
DB00669	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00669	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00669	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00669	DB06684	Increased risk of serotonin syndrome
DB00669	DB00315	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and sumatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00671	DB01032	Probenecid may increase the serum level of cefixime.
DB00672	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB00672	DB00945	Acetylsalicylic acid may increase the effect of the sulfonylurea, chlorpropamide.
DB00672	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00672	DB00195	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00672	DB01295	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB00672	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00672	DB00521	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00672	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB00672	DB00446	Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide.
DB00672	DB00636	Clofibrate may increase the effect of sulfonylurea, chlorpropamide.
DB00672	DB01119	Antagonism.
DB00672	DB00266	Dicumarol may increase the effect of sulfonylurea, chlorpropamide.
DB00672	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00672	DB01296	Possible hyperglycemia
DB00672	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00672	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00672	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB00672	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB00672	DB01359	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB00672	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB00672	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00672	DB01297	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB00672	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00672	DB01045	Rifampin may decrease the effect of sulfonylurea, chlorpropamide.
DB00672	DB01399	The salicylate, salsalate, increases the effect of the sulfonylurea, chlorpropamide.
DB00672	DB00052	Somatropin may antagonize the hypoglycemic effect of chlorpropamide. Monitor for changes in fasting and postprandial blood sugars.
DB00672	DB00489	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00672	DB01298	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB00359	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB01299	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB01581	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB01582	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB00576	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB01015	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB00891	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB00795	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB00263	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00672	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00672	DB01401	The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, chlorpropamide.
DB00672	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00673	DB01418	Aprepitant may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration.
DB00673	DB00404	Aprepitant may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00673	DB01125	Aprepitant may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.
DB00673	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00673	DB00564	The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant.
DB00673	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00673	DB01211	The CYP3A4 inhibitor, clarithromycin, may increase the effect and toxicity of aprepitant.
DB00673	DB01285	Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen.
DB00673	DB01234	Aprepitant may increase the effect and toxicity of dexamethasone.
DB00673	DB00266	Aprepitant may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.
DB00673	DB00343	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00673	DB01248	Aprepitant may change levels of the chemotherapy agent, docetaxel.
DB00673	DB00199	Erythromycin, a moderate CYP3A4 inhibitor, may increase the effect and toxicity of aprepitant.
DB00673	DB00977	Aprepitant could decrease the effect of the oral contraceptive
DB00673	DB00754	The CYP3A4 inducer, ethotoin, may decrease the effect of aprepitant.
DB00673	DB00773	Aprepitant may change levels of the chemotherapy agent, etoposide.
DB00673	DB01320	The CYP3A4 inducer, fosphenytoin, may decrease the effect of aprepitant.
DB00673	DB01181	Aprepitant may change levels of the chemotherapy agent, ifosfamide.
DB00673	DB00619	Aprepitant may change levels of the chemotherapy agent, imatinib.
DB00673	DB00762	Aprepitant may change levels of the chemotherapy agent, irinotecan.
DB00673	DB01167	This CYP3A4 inhibitor, itraconazole, may increase the effect and toxicity of aprepitant.
DB00673	DB01026	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00673	DB00532	The CYP3A4 inducer, mephenytoin, may decrease the effect of aprepitant.
DB00673	DB01357	Aprepitant could decrease the effect of the oral contraceptive
DB00673	DB00959	Increases the effect and toxicity of methylprednisolone
DB00673	DB00683	Aprepitant may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00673	DB01149	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00673	DB00220	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00673	DB01229	Aprepitant may change levels of the chemotherapy agent, paclitaxel.
DB00673	DB00252	The CYP3A4 inducer, phenytoin, may decrease the effect of aprepitant.
DB00673	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB00673	DB01045	The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant.
DB00673	DB00503	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00673	DB00706	Aprepitant, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Aprepitant is initiated, discontinued, or dose changed.
DB00673	DB00976	Telithromycin may reduce clearance of Aprepitant. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aprepitant if Telithromycin is initiated, discontinued or dose changed.
DB00673	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00673	DB01036	Aprepitant may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00673	DB00193	Aprepitant may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00673	DB00656	The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed.
DB00673	DB00897	Aprepitant may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00673	DB01361	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB00673	DB00570	Aprepitant may change levels of the chemotherapy agent, vinblastine.
DB00673	DB00541	Aprepitant may change levels of the chemotherapy agent, vincristine.
DB00673	DB00361	Aprepitant may change levels of the chemotherapy agent, vinorelbine.
DB00673	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aprepitant by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aprepitant if voriconazole is initiated, discontinued or dose changed.
DB00673	DB00682	Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration.
DB00674	DB01614	Possible antagonism of action
DB00674	DB01615	Possible antagonism of action
DB00674	DB01246	Possible antagonism of action
DB00674	DB01616	Possible antagonism of action
DB00674	DB00915	Possible antagonism of action
DB00674	DB00321	Possible antagonism of action
DB00674	DB00543	Possible antagonism of action
DB00674	DB00572	Possible antagonism of action
DB00674	DB00719	Possible antagonism of action
DB00674	DB00245	Possible antagonism of action
DB00674	DB00810	Possible antagonism of action
DB00674	DB00835	Possible antagonism of action
DB00674	DB00748	Possible antagonism of action
DB00674	DB01114	Possible antagonism of action
DB00674	DB00477	Possible antagonism of action
DB00674	DB01239	Possible antagonism of action
DB00674	DB00501	Possible antagonism of action
DB00674	DB00283	Possible antagonism of action
DB00674	DB00771	Possible antagonism of action
DB00674	DB01242	Possible antagonism of action
DB00674	DB00363	Possible antagonism of action
DB00674	DB01176	Possible antagonism of action
DB00674	DB00924	Possible antagonism of action
DB00674	DB00434	Possible antagonism of action
DB00674	DB00496	Possible antagonism of action
DB00674	DB01151	Possible antagonism of action
DB00674	DB00405	Possible antagonism of action
DB00674	DB00804	Possible antagonism of action
DB00674	DB00985	Possible antagonism of action
DB00674	DB01075	Possible antagonism of action
DB00674	DB01081	Possible antagonism of action
DB00674	DB01146	Possible antagonism of action
DB00674	DB00280	Possible antagonism of action
DB00674	DB01142	Possible antagonism of action
DB00674	DB00366	Possible antagonism of action
DB00674	DB00392	Possible antagonism of action
DB00674	DB01148	Possible antagonism of action
DB00674	DB00875	Possible antagonism of action
DB00674	DB01437	Possible antagonism of action
DB00674	DB00986	Possible antagonism of action
DB00674	DB00557	Possible antagonism of action
DB00674	DB00424	Possible antagonism of action
DB00674	DB00458	Possible antagonism of action
DB00674	DB01247	Possible antagonism of action
DB00674	DB01625	Possible antagonism of action
DB00674	DB01026	Ketoconazole increases the effect and toxicity of galantamine
DB00674	DB00408	Possible antagonism of action
DB00674	DB00934	Possible antagonism of action
DB00674	DB00737	Possible antagonism of action
DB00674	DB00933	Possible antagonism of action
DB00674	DB00902	Possible antagonism of action
DB00674	DB01403	Possible antagonism of action
DB00674	DB00462	Possible antagonism of action
DB00674	DB00370	Possible antagonism of action
DB00674	DB01171	Possible antagonism of action
DB00674	DB01618	Possible antagonism of action
DB00674	DB00540	Possible antagonism of action
DB00674	DB00334	Possible antagonism of action
DB00674	DB01173	Possible antagonism of action
DB00674	DB01062	Possible antagonism of action
DB00674	DB00715	Paroxetine increases the effect and toxicity of galantamine
DB00674	DB00850	Possible antagonism of action
DB00674	DB00454	Possible antagonism of action
DB00674	DB00780	Possible antagonism of action
DB00674	DB01619	Possible antagonism of action
DB00674	DB01100	Possible antagonism of action
DB00674	DB01621	Possible antagonism of action
DB00674	DB01035	Possible antagonism of action
DB00674	DB00433	Possible antagonism of action
DB00674	DB00387	Possible antagonism of action
DB00674	DB00420	Possible antagonism of action
DB00674	DB01069	Possible antagonism of action
DB00674	DB00782	Possible antagonism of action
DB00674	DB01608	Possible antagonism of action
DB00674	DB00344	Possible antagonism of action
DB00674	DB01224	Possible antagonism of action
DB00674	DB00908	Possible antagonism of action
DB00674	DB01346	Possible antagonism of action
DB00674	DB00734	Possible antagonism of action
DB00674	DB00747	Possible antagonism of action
DB00674	DB01104	Possible antagonism of action
DB00674	DB01591	Possible antagonism of action
DB00674	DB01622	Possible antagonism of action
DB00674	DB00679	Possible antagonism of action
DB00674	DB01623	Possible antagonism of action
DB00674	DB00697	Possible antagonism of action
DB00674	DB01036	Possible antagonism of action
DB00674	DB00752	Possible antagonism of action
DB00674	DB00656	Possible antagonism of action
DB00674	DB00831	Possible antagonism of action
DB00674	DB00508	Possible antagonism of action
DB00674	DB00376	Possible antagonism of action
DB00674	DB00662	The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00674	DB00726	Possible antagonism of action
DB00674	DB00792	Possible antagonism of action
DB00674	DB00427	Possible antagonism of action
DB00674	DB00209	The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00674	DB00246	Possible antagonism of action
DB00674	DB01624	Possible antagonism of action
DB00675	DB01418	Tamoxifen may increase the serum concentration of Acenocoumarol increasing the risk of bleeding. Concomitant therapy should be avoided.
DB00675	DB00357	Aminoglutethimide may increase Tamoxifen clearance decreasing its therapeutic effect. Consider alternate therapy or monitor for changes in Tamoxifen effects when Aminoglutethimide is initiated, discontinued or dose changed.
DB00679	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB00675	DB01118	Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00701	Amprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB01072	Atazanavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB01101	Capecitabine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Capecitabine is initiated, discontinued or dose changed.
DB00675	DB00608	Chloroquine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00477	Chlorpromazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB00501	Cimetidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01012	Cinacalcet may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB01211	Clarithromycin may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB01242	Clomipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00363	Clozapine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00907	Cocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB00872	Conivaptan may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB00496	Darifenacin may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01264	Darunavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB00705	Delavirdine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB01151	Desipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01075	Diphenhydramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00476	Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00322	Floxuridine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Floxiridine is initiated, discontinued or dose changed.
DB00675	DB00196	Fluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole  is initiated, discontinued or dose changed.
DB00675	DB00544	Fluorouracil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluorouracil is initiated, discontinued or dose changed.
DB00675	DB00472	Fluoxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB00712	Flurbiprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Flurbiprofen is initiated, discontinued or dose changed.
DB00675	DB01319	Fosmprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB01241	Gemfibrozil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Gemfibrozil  is initiated, discontinued or dose changed.
DB00675	DB00502	Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01050	Ibuprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Ibuprofen is initiated, discontinued or dose changed.
DB00675	DB00619	Imatinib may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Imatinib may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Imatinib is initiated, discontinued or dose changed.
DB00675	DB00458	Imipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00224	Indinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB00328	Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed.
DB00675	DB00951	Isoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed.
DB00675	DB01167	Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB01026	Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed.
DB00675	DB00281	Lidocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01601	Lopinavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00679	DB00960	Increased risk of cardiotoxicity and arrhythmias
DB00675	DB06708	Lumefantrine, a moderate CYP2D6 inhibitor, may decrease the formation of highly potent tamoxifen metabolites. Concomitant therapy may decrease the effectiveness of tamoxifen. Consider alternate therapy.
DB00675	DB00784	Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed.
DB00675	DB00333	Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00763	Methimazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01110	Miconazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB01149	Nefazodone may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB00220	Nelfinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB00622	Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed.
DB00675	DB04868	Nilotinib may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00715	Paroxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB01186	Pergolide may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB01132	Pioglitazone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00554	Piroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed.
DB00675	DB01263	Posaconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB00205	Pyrimethamine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00908	Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB00468	Quinine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01369	This combination presents an increased risk of toxicity
DB00675	DB00243	Ranolazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00615	The rifamycin decreases the effect of anti-estrogen
DB00675	DB01045	The rifamycin decreases the effect of anti-estrogen
DB00675	DB00503	Ritonavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB06228	Tamoxifen may increase serum concentrations of Rivaroxaban increasing the risk of bleeding. Concomitant therapy should be avoided.
DB00675	DB01232	Saquinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00675	DB01104	Sertraline may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB06268	Sitaxsentan may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sitaxsentan is initiated, discontinued or dose changed.
DB00675	DB00359	Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed.
DB00675	DB00263	Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed.
DB00675	DB00976	Telithromycin may reduce clearance of Tamoxifen. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tamoxifen if Telithromycin is initiated, discontinued or dose changed.
DB00675	DB00857	Terbinafine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00675	DB00679	Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00208	Ticlopidine may decrease the therapeutic effect of tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tamoxifen. Consider alternate therapy or monitor for changes in Tamoxifen therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00675	DB01030	The p-glycoprotein inhibitor, Tamoxifen, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00675	DB00752	The CYP2D6 inhibitor, Tranylcypromine, may decrease the efficacy of Tamoxifen by reducing active metabolite production. Consider alternate therapy.
DB00675	DB00656	Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00675	DB00755	The moderate CYP2C8 inhibitor, Tamoxifen, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Tamoxifen is initiated, discontinued to dose changed.
DB00675	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamoxifen by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamoxifen if voriconazole is initiated, discontinued or dose changed.
DB00679	DB01035	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01182	Increased risk of cardiotoxicity and arrhythmias.
DB00675	DB00682	Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk.
DB00678	DB00594	Increased risk of hyperkalemia
DB00678	DB01395	Increased risk of hyperkalemia
DB00678	DB00328	Indomethacin decreases the effect of losartan
DB00678	DB00046	Concomitant therapy with angiotensin II receptor blockers may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00678	DB01356	Losartan increases serum levels of lithium
DB00678	DB01345	Increased risk of hyperkalemia
DB00678	DB01369	This combination presents an increased risk of toxicity
DB00678	DB01045	Rifampin decreases the effect of losartan
DB00678	DB00421	Increased risk of hyperkalemia
DB00678	DB00684	Increased risk of nephrotoxicity
DB00678	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Losartan. Consider alternate therapy or monitor for changes in Losartan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00678	DB00519	The angiotensin II receptor blocker, Losartan, may increase the adverse effects of Trandolapril.
DB00678	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00678	DB00755	The moderate CYP2C8 inhibitor, Losartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Losartan is initiated, discontinued to dose changed.
DB00678	DB00384	Increased risk of hyperkalemia
DB00679	DB05812	Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely.
DB00679	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00321	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00182	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB06697	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB00679	DB06216	Thioridazine is a CYP2D6 substrate in which concomitant therapy with asenapine will increase serum levels of thioridazine. Consider alternative therapy.
DB00679	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00679	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00679	DB01053	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00679	DB01156	Bupropion may increase the effect and toxicity of thioridazine.
DB00679	DB00608	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB08865	Concurrent use with drugs that prolong QTc interval is contraindicated.
DB00679	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB01576	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB00343	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01075	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00843	Possible antagonism of action
DB00679	DB01142	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00476	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB01195	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00472	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00176	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00674	Possible antagonism of action
DB00679	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01170	Thioridazine may decrease the effect of guanethidine.
DB00679	DB01218	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00502	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00458	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB04871	Avoid combination.The combination is likely to reduce the metabolism of Thioridazine.
DB00679	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00679	DB00934	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB01577	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB01578	Increased risk of convulsions
DB00679	DB08893	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB00679	DB00715	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00738	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01579	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB00830	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00679	DB00571	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00468	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00243	Possible additive effect on QT prolongation
DB00679	DB00989	Possible antagonism of action
DB00679	DB06144	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB06145	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00679	DB00864	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00679	DB00675	Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00679	DB00706	Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed.
DB00679	DB00976	Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided.
DB00679	DB00857	Terbinafine may increase serum concentrations of Thioridazine. Concomitant therapy is contraindicated.
DB00679	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00679	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00679	DB01623	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00679	DB00208	Ticlopidine may decrease the metabolism of thioridazine. Concomitant therapy is contraindicated.
DB00679	DB00539	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00679	DB00193	Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00679	DB00752	Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated.
DB00679	DB00662	Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00679	DB00726	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00679	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00679	DB00209	Trospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00679	DB06684	Thioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes.  Avoid combination.
DB00679	DB00582	Additive QTc prolongation may occur. Concomitant use is contraindicated.
DB00679	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00679	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00679	DB01624	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
DB00680	DB00343	Increased effect/toxicity of moricizine
DB00680	DB00243	Possible additive effect on QT prolongation
DB00680	DB00976	Telithromycin may reduce clearance of Moricizine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Moricizine if Telithromycin is initiated, discontinued or dose changed.
DB00680	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of moricizine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moricizine if voriconazole is initiated, discontinued or dose changed.
DB00681	DB01111	Amphotericin B may enhance the nephrotoxic effect of Colistimethate. Due to the potential for additive or synergistic nephrotoxicity between colistimethate and other nephrotoxic drugs, such as amphotericin B, this combination should be avoided whenever possible. If these agents must be used together, patients' renal function should be monitored closely.
DB00681	DB00091	Monitor for nephrotoxicity
DB00681	DB00864	Additive renal impairment may occur during concomitant therapy with Amphotericin B. Use caution during concomitant therapy.
DB00681	DB00684	Increased risk of nephrotoxicity
DB00682	DB00316	Acetaminophen increases the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if acetaminophen is initiated, discontinued or dose changed.
DB00682	DB00945	The antiplatelet effects of acetylsalicylic acid may increase the bleed risk associated with warfarin.
DB00682	DB00437	Allopurinol may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin times and therapeutic effects of warfarin if allopurinol is initiated, discontinued or dose changed.
DB00682	DB00357	Aminoglutethimide may decrease the anticoagulant effect of warfarin by increasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if aminoglutethimide is initiated, discontinued or dose changed.
DB00682	DB00233	The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin.
DB00682	DB01118	Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed.
DB00682	DB01351	Amobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if amobarbital is initiated, discontinued or dose changed.
DB00682	DB00701	Amprenavir may increase the anticoagulant effect of warfarin by increasing its serum concentration.
DB00682	DB00673	Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration.
DB00682	DB01072	The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin.
DB00682	DB06237	Co-administration with avanafil resulted in an approximate 1.6% increase in AUC(0-inf) and 5.2% decrease in Cmax of S-warfarin.
DB00682	DB00993	Azathioprine may decrease the anticoagulant effect of warfarin.
DB00682	DB00207	Azithromycin may increase the anticoagulant effect of warfarin by increasing its serum concentration.
DB00682	DB00443	The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin.
DB00682	DB01393	Bezafibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if bezafibrate is initiated, discontinued or dose changed.
DB00682	DB00559	Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism.
DB00682	DB00237	Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed.
DB00682	DB00241	Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed.
DB00682	DB01101	Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect.
DB00682	DB00564	Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed.
DB00682	DB01330	The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin.
DB00682	DB01331	The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin.
DB00682	DB01212	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of warfarin.
DB00682	DB00482	Celecoxib may increase the anticoagulant effect of warfarin.
DB00682	DB01432	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of warfarin by decreasing its absorption.
DB00682	DB00501	Cimetidine may increase the serum concentration of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if cimetidine is initiated, discontinued or dose changed.
DB00682	DB00537	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin.
DB00682	DB00604	Cisapride may increase the anticoagulant effect of warfarin.
DB00682	DB00215	The SSRI, citalopram, increases the effect of anticoagulant, warfarin.
DB00682	DB01211	The macrolide, clarithromycin, may increase the anticoagulant effect of warfarin.
DB00682	DB00636	The fibrate increases the anticoagulant effect
DB00682	DB00758	Increased bleed risk may occur as a result of additive anticoagulant effects. Increase monitoring for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00375	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of warfarin by decreasing its absorption.
DB00682	DB00531	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of warfarin.
DB00682	DB01406	Danazol may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if danazol is initiated, discontinued or dose changed.
DB00682	DB00705	Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if delavirdine is initiated, discontinued or dose changed.
DB00682	DB00618	The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin.
DB00682	DB00304	Desogestrol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if desogestrol is initiated, discontinued or dose changed.
DB00682	DB01234	The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin.
DB00682	DB00647	Propoxyphene may increase the anticoagulant effect of warfarin.
DB00682	DB00509	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of warfarin.
DB00682	DB00586	The antiplatelet effects of oral diclofenac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00485	Dicloxacillin may decrease the anticoagulant effect of warfarin.
DB00682	DB00861	The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00822	Disulfiram may increase the anticoagulant effect of warfarin.
DB00682	DB00254	The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin.
DB00682	DB04855	Dronedarone is a moderate inhibitor of CYP3A4 which is responsible for warfarin metabolism. Increases serum concentration of S-isomer warfarin by 1.2 fold
DB00682	DB01395	Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed.
DB00682	DB00055	Increased risk of bleeding.
DB00682	DB00199	The macrolide, erythromycin, may increase the anticoagulant effect of warfarin.
DB00682	DB00189	Ethchlorvynol may decrease the anticoagulant effect of warfarin.
DB00682	DB00977	Ethinyl estradiol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethinyl estradiol is initiated, discontinued or dose changed.
DB00682	DB00823	Ethynodiol diacetate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethynodiol diacetate is initiated, discontinued or dose
DB00682	DB00469	The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin.
DB00682	DB00749	The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00294	Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed.
DB00682	DB01628	Etoricoxib may increase the anticoagulant effect of warfarin.
DB00682	DB00973	If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.
DB00682	DB06223	decreases the effect of cortisone by metabolism alteration.
DB00682	DB01039	Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed.
DB00682	DB00573	The antiplatelet effects of fenoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00322	Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if floxuridine is initiated, discontinued or dose changed.
DB00682	DB00196	Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed.
DB00682	DB00687	The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin.
DB00682	DB00544	Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed.
DB00682	DB00472	The SSRI, fluoxetine, increases the effect of anticoagulant, warfarin.
DB00682	DB01185	Fluoxymesterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if fluoxymesterone is initiated, discontinued or dose changed.
DB00682	DB00712	Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed.
DB00682	DB01095	Fluvastatin may increase the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if fluvastatin is initiated, discontinued or dose changed.
DB00682	DB00176	Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration.
DB00682	DB01319	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of warfarin.
DB00682	DB01320	Increased hydantoin levels and risk of bleeding
DB00682	DB06705	In a clinical trial of 10 patients receiving a stable dose of warfarin, a single dose of ABLAVAR (0.05 mmol/kg) did not alter \r\nthe anticoagulant activity of warfarin as measured by the International Normalized Ratio (INR).
DB00682	DB00317	Gefitinib may increase the anticoagulant effect of warfarin.
DB00682	DB00441	Gemcitabine may increase the anticoagulant effect of warfarin.
DB00682	DB01241	Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if gemfibrozil is initiated, discontinued or dose changed.
DB00682	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00682	DB01404	Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
DB00682	DB00040	Monitor therapy due to enhanced anticoagulant effects.
DB00682	DB01296	Possible interaction and enhanced antiplatelet activity of warfarin
DB00682	DB01437	Glutethimide may decrease the serum concentration of warfarin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if glutethimide is initiated, discontinued or dose changed.
DB00682	DB00400	Griseofulvin may decrease the anticoagulant effect of warfarin.
DB00682	DB04865	Avoid combination with warfarin and other anticoagulants due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
DB00682	DB00741	The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin.
DB00682	DB01050	Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed.
DB00682	DB00619	Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed.
DB00682	DB00224	The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin.
DB00682	DB00328	Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed.
DB00682	DB00951	Isoniazid may increase the anticoagulant effect of warfarin.
DB00682	DB01167	Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism.
DB00682	DB01026	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.
DB00682	DB01009	The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00687	DB00418	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00682	DB00465	The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB01097	Leflunomide may increase the anticoagulant effect of warfarin.
DB00682	DB00848	Levamisole may increase the anticoagulant effect of warfarin.
DB00682	DB01137	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin.
DB00682	DB00367	Levonorgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if levonorgestrel is initiated, discontinued or dose changed.
DB00682	DB00451	Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed.
DB00682	DB00279	Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed.
DB00682	DB01583	Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed.
DB00682	DB08827	Warfarin plasma concentrations may increase by lomitapide by 30%..\r\nINR levels may increase by 22%. Regular INR monitoring is required.
DB00682	DB00227	Lovastatin may increase the anticoagulant effect warfarin.  Monitor for changes in the therapeutic and adverse effects of warfarin if lovastatin is initiated, discontinued or dose changed .
DB00682	DB01283	Lumiracoxib may increase the anticoagulant effect of warfarin.
DB00682	DB00939	The antiplatelet effects of meclofenamic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00603	Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed.
DB00682	DB00784	Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed.
DB00682	DB00358	Mefloquine may increase the anticoagulant effect of warfarin.
DB00682	DB00814	The antiplatelet effects of meloxicam may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB01033	Mercaptopurine may decrease the anticoagulant effect of warfarin.
DB00682	DB01357	Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed.
DB00682	DB00763	Methimazole may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if methimazole is initiated, discontinued or dose changed.
DB00682	DB00474	Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed.
DB00682	DB00916	Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed.
DB00682	DB01110	Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if miconazole is initiated, discontinued or dose changed.
DB00682	DB01017	The tetracycline, minocycline, may increase the anticoagulant effect of warfarin.
DB00682	DB08893	Mirabegron increased Cmax and AUC of S- and R-warfarin. Monitor concomitant therapy closely.
DB00682	DB00648	Mitotane may decrease the anticoagulant effect of warfarin.
DB00682	DB00218	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin.
DB00682	DB00461	The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00607	Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed.
DB00682	DB00779	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin.
DB00682	DB08804	Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.
DB00682	DB00984	Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.
DB00682	DB00788	The antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00220	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin.
DB00682	DB00238	Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4.
DB00682	DB00622	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed.
DB00682	DB00717	Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed.
DB00682	DB01059	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin.
DB00682	DB00957	Norgestimate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestimate is initiated, discontinued or dose changed.
DB00682	DB01165	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin.
DB00682	DB01083	Orlistat may increase the anticoagulant effect of warfarin.
DB00682	DB00621	Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed.
DB00682	DB00991	The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB06412	Oxymetholone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxymetholone is initiated, discontinued or dose changed.
DB00682	DB03585	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin.
DB00682	DB00715	The SSRI, paroxetine, increases the effect of the anticoagulant, warfarin.
DB00682	DB00312	Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed.
DB00682	DB00806	Pentoxifylline may increase the anticoagulant effect of warfarin.
DB00682	DB01174	Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed.
DB00682	DB00812	The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin.
DB00682	DB00252	Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy.
DB00682	DB01022	Phytonadione (vitamin K) may antagonize the anticoagulant effects of warfarin. Monitor for changes in prothrombin time if phytonadione intake (either via supplements or vitamin K-rich foods) is increased or decreased.
DB00682	DB00554	Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed.
DB00682	DB06209	Coadministration with warfarin may increase the risk of bleeding.
DB00682	DB00860	The corticosteroid, prednisolone, alters the anticoagulant effect of warfarin.
DB00682	DB00635	The corticosteroid, prednisone, alters the anticoagulant effect of warfarin.
DB00682	DB00794	The barbiturate, primidone, decreases the anticoagulant effect of warfarin.
DB00682	DB01182	Propafenone may increase the anticoagulant effect of warfarin.
DB00682	DB00550	Propylthiouracil may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if propylthiouracil is initiated, discontinued or dose changed.
DB00682	DB00908	Quinidine may increase the anticoagulant effect of warfarin.
DB00682	DB00468	Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9.
DB00682	DB00863	Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence)
DB00682	DB00615	Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism.
DB00682	DB01045	Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism.
DB00682	DB00118	Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
DB00682	DB01398	The antiplatelet effects of sodium salicylate may increase the bleed risk associated with warfarin.
DB00682	DB00418	Secobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if secobarbital is initiated, discontinued or dose changed.
DB00682	DB06268	Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Warfarin doses should be decreased by 80% upon initiated of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of warfarin if sitaxentan is initiated, discontinued or dose changed.
DB00682	DB01323	St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed.
DB00682	DB00364	Sucralfate may reduce the absorption of warfarin. Warfarin should be administered at least 2 hours before or 6 hours after sucralfate administration. Monitor for changes in prothrombin time if sucralfate is initiated, discontinued or dose changed.
DB00682	DB00359	Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed.
DB00682	DB01015	Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed.
DB00682	DB01138	Sulfinpyrazone may increase the anticoagulant effect of warfarin by decreasing its metabolism and protein binding.
DB00682	DB00263	Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed.
DB00682	DB00605	The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00675	Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk.
DB00682	DB00976	Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy.
DB00682	DB00894	Testolactone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testolactone is initiated, discontinued or dose changed.
DB00682	DB00624	Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed.
DB00682	DB01420	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.
DB00682	DB00759	Tetracycline may increase the anticoagulant effect of warfarin.
DB00682	DB00599	Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed.
DB00682	DB01600	The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB00208	Increased bleeding risk. Monitor INR.
DB00682	DB00560	Tigecycline may increase the serum concentration of warfarin.
DB00682	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed.
DB00682	DB00500	The antiplatelet effects of tolmetin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00682	DB05275	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.
DB00682	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy.
DB00682	DB00620	The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin.
DB00682	DB08814	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of warfarin to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB00682	DB01157	The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use.
DB00682	DB01401	The antiplatelet effects of trisalicylate-choline may increase the bleed risk associated with warfarin.
DB00682	DB08881	Vemurafenib increases the AUC of S-warfarin (CYP2C9 substrate). Monitor concomitant therapy closely.
DB00682	DB06684	Increased risk of bleeding with concomitant use of warfarin and vilazodone.
DB00683	DB00701	Amprenavir may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB00673	Aprepitant may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB01072	Atazanavir may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00683	DB05631	BXT-51072 weakly inhibits midazolam clearance.
DB00683	DB00564	Carbamazepine may decrease the effect of the benzodiazepine, midazolam.
DB00683	DB00501	Cimetidine may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01211	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, midazolam.
DB00683	DB00349	Clobazam decrease the Cmax and AUC of midazolam by approximately 25% of both and increases the Cmax and AUC of its metabolite. Dose adjustment is not necessary.
DB00683	DB00363	Increased risk of toxicity
DB00683	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
DB00683	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
DB00683	DB08912	Dabrafenib decreased the maximum concentration (Cmax) and area under the curve (AUC) of midazolam (a substrate of CYP3A4) by 61% and 74%, respectively.
DB00683	DB00705	The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB00343	The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB01248	Midazolam may increase the serum levels and toxicity of docetaxel.
DB00683	DB00625	The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB00199	The macrolide, erythromycin, may increase the effect of the benzodiazepine, midazolam.
DB00683	DB00754	Ethotoin may increase the metabolism of midazolam via CYP3A4.
DB00683	DB00196	Fluconazole may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01319	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB01320	Fosphenytoin may increase the metabolism of midazolam via CYP3A4.
DB00683	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01167	Itraconazole may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01321	The macrolide, josamycin, may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01322	Kava may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01026	Ketoconazole may increase the effect of the benzodiazepine, midazolam.
DB00683	DB00532	Mephenytoin may increase the metabolism of midazolam via CYP3A4.
DB00683	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, midazolam.
DB00683	DB00338	Omeprazole may increase the effect of the benzodiazepine, midazolam.
DB00683	DB00252	Phenytoin may increase the metabolism of midazolam via CYP3A4.
DB00683	DB01369	This combination presents an increased risk of toxicity
DB00720	DB00893	Formation of non-absorbable complexes
DB00683	DB01045	Rifampin may increase the metabolism of midazolam. Monitor for changes in the therapeutic and adverse effects of midazolam if rifampin is initiated, discontinued or dose changed.
DB00683	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, midazolam.
DB00683	DB01323	St. John's Wort may decrease the effect of the benzodiazepine, midazolam.
DB00683	DB05521	Telaprevir increases AUC and Cmax of oral midazolam by approximately 9-fold and 3-fold respectively.
DB00683	DB00976	Telithromycin may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00683	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Midazolam. Concomitant therapy is contraindicated.
DB00683	DB00427	The CNS depressants, Triprolidine and Midazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00683	DB08881	Vemurafenib decreases the AUC (CYP3A4 substrate) by 39%.
DB00683	DB00661	Verapamil may increase the serum concentration of Midazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Midazolam.
DB00683	DB00582	Voriconazole may increase the serum concentration of midazolam by decreasing its metabolism. Monitor for midazolam toxicity if voriconazole is initiated or dose increased.
DB00684	DB00819	Increased risk of nephrotoxicity
DB00684	DB00681	Increased risk of nephrotoxicity
DB00684	DB00732	The agent increases the effect of the muscle relaxant
DB00684	DB00542	Increased risk of nephrotoxicity
DB00684	DB00887	Increased ototoxicity
DB00684	DB00796	Increased risk of nephrotoxicity
DB00684	DB01197	Increased risk of nephrotoxicity
DB00684	DB01326	Increased risk of nephrotoxicity
DB00684	DB01139	Increased risk of nephrotoxicity
DB00684	DB01327	Increased risk of nephrotoxicity
DB00684	DB01328	Increased risk of nephrotoxicity
DB00684	DB01329	Increased risk of nephrotoxicity
DB00684	DB00923	Increased risk of nephrotoxicity
DB00684	DB00493	Increased risk of nephrotoxicity
DB00684	DB01330	Increased risk of nephrotoxicity
DB00684	DB01331	Increased risk of nephrotoxicity
DB00684	DB01333	Increased risk of nephrotoxicity
DB00684	DB00438	Increased risk of nephrotoxicity
DB00684	DB01332	Increased risk of nephrotoxicity
DB00684	DB01212	Increased risk of nephrotoxicity
DB00684	DB01112	Increased risk of nephrotoxicity
DB00684	DB03450	Increased risk of nephrotoxicity
DB00684	DB00515	Increased risk of nephrotoxicity
DB00684	DB01111	Increased risk of nephrotoxicity
DB00684	DB00091	Increased risk of nephrotoxicity
DB00684	DB00900	Increased risk of nephrotoxicity
DB00684	DB01135	The agent increases the effect of the muscle relaxant
DB00684	DB00584	Increased risk of nephrotoxicity
DB00684	DB00903	Increased ototoxicity
DB00684	DB00492	Increased risk of nephrotoxicity
DB00684	DB00695	Increased ototoxicity
DB00684	DB01109	Increased risk of nephrotoxicity
DB00684	DB01029	Increased risk of nephrotoxicity
DB00684	DB00709	Increased risk of nephrotoxicity
DB00684	DB00722	Increased risk of nephrotoxicity
DB00684	DB01356	Increased risk of nephrotoxicity
DB00684	DB00678	Increased risk of nephrotoxicity
DB00684	DB01336	The agent increases the effect of the muscle relaxant
DB00684	DB01226	The agent increases the effect of the muscle relaxant
DB00684	DB00275	Increased risk of nephrotoxicity
DB00684	DB01337	The agent increases the effect of the muscle relaxant
DB00684	DB00790	Increased risk of nephrotoxicity
DB00684	DB00252	Increased risk of nephrotoxicity
DB00684	DB01338	The agent increases the effect of the muscle relaxant
DB00684	DB00881	Increased risk of nephrotoxicity
DB00684	DB00178	Increased risk of nephrotoxicity
DB00684	DB00728	The agent increases the effect of the muscle relaxant
DB00684	DB00421	Increased risk of nephrotoxicity
DB00684	DB00202	The agent increases the effect of the muscle relaxant
DB00684	DB01015	Increased risk of nephrotoxicity
DB00684	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Tobramycin. Use caution during concomitant therapy.
DB00684	DB00966	Increased risk of nephrotoxicity
DB00684	DB01041	Thalidomide increases the renal toxicity of the aminoglycoside
DB00684	DB01607	Ticarcillin may reduce the serum concentration of Tobramycin. Ticarcillin may inactivate Tobramycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB00684	DB00273	Increased risk of nephrotoxicity
DB00684	DB00214	Increased ototoxicity
DB00684	DB00440	Increased risk of nephrotoxicity
DB00684	DB01199	The agent increases the effect of the muscle relaxant
DB00684	DB00177	Increased risk of nephrotoxicity
DB00684	DB00512	Increased risk of nephrotoxicity
DB00684	DB01339	The agent increases the effect of the muscle relaxant
DB00685	DB01370	Aluminum may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the aluminum containing agent to minimize the interaction.
DB00685	DB01373	Formation of non-absorbable complexes
DB00685	DB00258	Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containining agent to minimize the interaction.
DB00720	DB01378	Formation of non-absorbable complexes
DB00685	DB01164	Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction.
DB00685	DB00326	Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction.
DB00685	DB00900	Didanosine may decrease the absorption of orally administered Trovafloxacin. The Didanosine formulation contains magnesium and aluminum ions that intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Didanosine dose to minimize the interaction. This interaction is not observed with enteric coated Didanosine.
DB00685	DB01592	Iron may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the iron containing agent to minimize the interaction.
DB00685	DB00893	Formation of non-absorbable complexes
DB00685	DB01378	Formation of non-absorbable complexes
DB00685	DB01377	Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.
DB00685	DB00653	Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.
DB00685	DB00295	Morphine may reduce serum levels of Trovafloxacin decreasing the efficacy of the antibiotic. IV doses of morphine should be administered at least 2 hours after a dose of Trovafloxacin given in a fasting state or 4 hours after if given in a fed state.
DB00685	DB00881	Quinapril may decrease the absorption of orally administered Trovafloxacin. The Quinapril formulation contains magnesium ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Quinapril dose to minimize the interaction.
DB00685	DB00658	Sevelamer may decrease the absorption of orally administered Trovafloxacin. The Sevelamer formulation contains iron that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sevelamer dose to minimize the interaction.
DB00685	DB00364	Sucralfate may decrease the absorption of orally administered Trovafloxacin. The Sucralfate formulation contains aluminum ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sucralfate dose to minimize the interaction.
DB00685	DB01593	Zinc may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the zinc containing agent to minimize the interaction.
DB00686	DB00063	Pentosan can potentiate adverse effects of antiplatelet agents and thus increase bleeding risk. Combination must be used with caution.
DB00687	DB01418	The corticosteroid, fludrocortisone, alters the anticoagulant effect, acenocoumarol.
DB00687	DB00945	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00687	DB01122	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, ambenonium.
DB00687	DB01351	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01125	The corticosteroid, fludrocortisone, alters the anticoagulant effect of anisindione.
DB00687	DB01352	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01294	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB00687	DB00237	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00241	The barbiturate, butalbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01353	The barbiturate, butethal, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00266	The corticosteroid, fludrocortisone, alters the anticoagulant effect of dicumarol.
DB00687	DB01341	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01010	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, edrophonium.
DB00687	DB00754	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01354	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01355	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01397	The corticosteroid, fludrocortisone, may decrease the effect of magnesium salicylate.
DB00687	DB00532	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00474	The barbiturate, methohexital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00849	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00211	Increased arterial pressure
DB00687	DB01400	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, neostigmine.
DB00687	DB00312	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00545	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00687	DB01346	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB01398	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salicylate-sodium.
DB00687	DB01399	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salsalate.
DB00720	DB01377	Formation of non-absorbable complexes
DB00687	DB00382	Tacrine and Fludrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00687	DB00306	The barbiturate, talbutal, may decrease the effect of the corticosteroid, fludrocortisone.
DB00687	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00687	DB01401	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, trisalicylate-choline.
DB00687	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB00687	DB00682	The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin.
DB00688	DB06681	Belatacept increases the Cmax and AUC of mycophenolate mofetil.
DB00688	DB01373	Formation of non-absorbable complexes
DB00688	DB01592	Oral iron decreases the absorption of mycophenolate-mofetil
DB00688	DB00893	Oral iron decreases the absorption of mycophenolate-mofetil
DB00688	DB01045	Rifampin may decrease the serum concentration of mycophenolate. Concomitant therapy should be avoided.
DB00688	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00688	DB00864	Tacrolimus may increase the plasma concentration of Mycophenolic acid. Monitor and adjust the dose of Mycophenolate mofetil to the therapeutic range.
DB00688	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00688	DB01610	The excretion rates of Valganciclovir and/or Mycophenolate mofetil may decrease. Monitor for increased serum concentrations and toxicity of both agents.
DB00689	DB01032	Probenecid may increase the serum level of cephaloglycin.
DB00690	DB00701	Amprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam.
DB00690	DB00501	Cimetidine may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB00363	Increased risk of toxicity
DB00690	DB00754	Ethotoin may increase the metabolism of flurazepam via CYP3A4.
DB00690	DB00196	Fluconazole may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB01319	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam.
DB00690	DB01320	Fosphenytoin may increase the metabolism of flurazepam via CYP3A4.
DB00690	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB01167	Itraconazole may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB01322	Kava may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB01026	Ketoconazole may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB00532	Mephenytoin may increase the metabolism of flurazepam via CYP3A4.
DB00690	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB00338	Omeprazole may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB00252	Phenytoin may increase the metabolism of flurazepam via CYP3A4.
DB00690	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, flurazepam.
DB00690	DB00976	Telithromycin may reduce clearance of Flurazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flurazepam if Telithromycin is initiated, discontinued or dose changed.
DB00690	DB00932	Tipranavir may decrease the metabolism and clearance of Flurazepam. Consider alternate therapy or monitor for Flurazepam toxic effects if Tipranavir is initiated or dose increased.
DB00690	DB00427	The CNS depressants, Triprolidine and Flurazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00690	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flurazepam by decreasing its metabolism. Monitor for flurazepam toxicity if voriconazole is initiated or dose increased.
DB00691	DB00594	Increased risk of hyperkalemia
DB00691	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00691	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00691	DB01356	The ACE inhibitor increases serum levels of lithium
DB00691	DB01345	Increased risk of hyperkalemia
DB00691	DB01369	This combination presents an increased risk of toxicity
DB00691	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00691	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00691	DB00384	Increased risk of hyperkalemia
DB00692	DB00820	Tadalafil may enhance the hypotensive effect of Phentolamine. Monitor for hypotension during concomitant therapy.
DB00692	DB00706	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phentolamine, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00692	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00692	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phentolamine, may occur. Monitor for hypotension during concomitant therapy.
DB00694	DB00072	Trastuzumab may increase the cardiotoxicity of Daunorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00695	DB09026	Monitor therapy due to potential decreased serum concentration of furosemide.
DB00695	DB00479	Increased ototoxicity
DB00695	DB00515	Increased ototoxicity
DB00696	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergotamine. Concomitant therapy is contraindicated.
DB00696	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00695	DB00930	Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as furosemide.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00695	DB01078	Possible electrolyte variations and arrhythmias
DB00695	DB01396	Possible electrolyte variations and arrhythmias
DB00695	DB00390	Possible electrolyte variations and arrhythmias
DB00695	DB00754	The hydantoin decreases the effect of furosemide
DB00695	DB01320	The hydantoin decreases the effect of furosemide
DB00695	DB00798	Increased ototoxicity
DB00695	DB01404	Ginseng decreases the therapeutic effect
DB00695	DB01050	The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, furosemide.
DB00695	DB05039	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB00695	DB00328	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide.
DB00695	DB01172	Increased ototoxicity
DB00695	DB00532	The hydantoin decreases the effect of furosemide
DB00695	DB00955	Increased ototoxicity
DB00695	DB00252	The hydantoin decreases the effect of furosemide
DB00695	DB01082	Increased ototoxicity
DB00695	DB00605	The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide.
DB00695	DB00684	Increased ototoxicity
DB00695	DB00519	The loop diuretic, Furosemide, may increase the hypotensive effect of Trandolapril. Furosemide may also increase the nephrotoxicity of Trandolapril.
DB00695	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00696	DB01193	Ischemia with risk of gangrene
DB00696	DB00918	Possible severe and prolonged vasoconstriction
DB00696	DB00701	Amprenavir may increase the effect and toxicity of ergotamine.
DB00696	DB01612	Possible antagonism of action
DB00696	DB01072	Atazanavir may increase the effect and toxicity of ergotamine.
DB00696	DB00335	Ischemia with risk of gangrene
DB00696	DB00195	Ischemia with risk of gangrene
DB00696	DB01295	Ischemia with risk of gangrene
DB00696	DB00612	Ischemia with risk of gangrene
DB00696	DB00521	Ischemia with risk of gangrene
DB00696	DB01136	Ischemia with risk of gangrene
DB00696	DB01211	Risk of ergotism and severe ischemia with this association
DB00696	DB00705	The antiretroviral agent may increase the ergot derivative toxicity
DB00696	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00696	DB00625	The antiretroviral agent may increase the ergot derivative toxicity
DB00696	DB00216	Possible severe and prolonged vasoconstriction
DB00696	DB01613	Possible antagonism of action
DB00696	DB00199	Possible ergotism and severe ischemia with this combination
DB00696	DB00187	Ischemia with risk of gangrene
DB00696	DB00196	Possible ergotism and severe ischemia with this combination
DB00696	DB00472	Possible ergotism and severe ischemia with this combination
DB00696	DB00176	Possible ergotism and severe ischemia with this combination
DB00696	DB01319	Amprenavir increases the effect and toxicity of ergot derivative
DB00696	DB00998	Possible severe and prolonged vasoconstriction
DB00696	DB00224	Indinavir may increase the serum concentration of ergotamine. Concomitant therapy is contraindicated.
DB00696	DB00883	Possible antagonism of action
DB00696	DB01020	Possible antagonism of action
DB00696	DB01167	Possible ergotism and severe ischemia with this combination
DB00696	DB01321	Possible ergotism and severe ischemia with this combination
DB00696	DB01026	Possible ergotism and severe ischemia with this combination.
DB00696	DB00598	Ischemia with risk of gangrene
DB00696	DB04871	Avoid all combinations with any ergot derivative such as ergotamine. The combination can increase the risk of developing serotonin syndrome and/or valvular heart disease.
DB00696	DB00264	Ischemia with risk of gangrene
DB00696	DB01203	Ischemia with risk of gangrene
DB00696	DB00952	Possible severe and prolonged vasoconstriction.
DB00696	DB01149	Possible ergotism and severe ischemia with this combination
DB00696	DB00220	Nelfinavir increases the effect and toxicity of ergot derivative
DB00696	DB00727	Possible antagonism of action
DB00696	DB01580	Ischemia with risk of gangrene
DB00696	DB01359	Ischemia with risk of gangrene
DB00696	DB06154	Possible antagonism of action
DB00696	DB00960	Ischemia with risk of gangrene
DB00696	DB01263	Contraindicated co-administration
DB00696	DB01297	Ischemia with risk of gangrene
DB00696	DB00571	Ischemia with risk of gangrene
DB00696	DB00503	The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, ergotamine.
DB00696	DB00953	Possible severe and prolonged vasoconstriction
DB00696	DB01232	The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, ergotamine.
DB00696	DB01105	Possible serotoninergic syndrome with this combination
DB00696	DB00489	Ischemia with risk of gangrene
DB00696	DB00669	Possible severe and prolonged vasoconstriction
DB00696	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00696	DB00976	Telithromycin may reduce clearance of Ergotamine. Concomitant therapy is contraindicated.
DB00696	DB00373	Ischemia with risk of gangrene
DB00720	DB00364	Formation of non-absorbable complexes
DB00696	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00696	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00696	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00696	DB01361	Possible ergotism and severe ischemia with this combination
DB00696	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00696	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergotamine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00696	DB00744	Possible ergotism and severe ischemia with this combination
DB00696	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00697	DB01118	Amiodarone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00381	Amlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00542	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB01197	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB01340	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB00501	Cimetidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00537	Ciprofloxacin inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated.
DB00697	DB00586	Diclofenac may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00843	Possible antagonism of action
DB00697	DB00584	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB00898	Ethanol increases the adverse effects of Tizanidine. The CNS depressant effects of these agents are additive.
DB00697	DB00977	Ethinyl estradiol may increase the serum concentration of tizanidine. Monitor for changes in the therapeutic and adverse effects of tizanidine if ethinyl estradiol is initiated, discontinued or dose changed.
DB00697	DB00472	Fluoxetine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00176	Fluvoxamine inhibits the metabolism and clearance of tizanidine. Concomitant therapy is contraindicated.
DB00697	DB00492	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB00674	Possible antagonism of action
DB00697	DB01241	Gemfibrozil may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB01026	Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00281	Lidocaine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00722	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB01357	Oral contraceptives decrease the clearance of Tizanidine.
DB00697	DB00553	Methoxsalen may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00379	Mexilitene may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB01110	Miconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00691	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB00218	Moxifloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB01115	Nifedipine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00717	The contraceptive increases the effect of tizanidine
DB00697	DB01059	Norfloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB01165	Ofloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00790	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB01087	Primaquine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB01182	Propafenone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00818	Propofol may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00881	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB01369	This combination presents an increased risk of toxicity
DB00697	DB00178	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB00989	Possible antagonism of action
DB00697	DB01348	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Tizanidine by decreasing Tizanidine metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Tizanidine if Thiabendazole is initiated, discontinued or dose changed.
DB00697	DB00208	Ticlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00519	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00697	DB00752	Tranylcypromine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00697	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00697	DB00726	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Tizandine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Tizandine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00697	DB00427	The CNS depressants, Triprolidine and Tizanidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00700	DB00594	Increased risk of hyperkalemia. Monitor serum potassium levels during concomitant threapy.
DB00700	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of eplerenone. A lower starting dose of eplerenone (25 mg once daily) is recommended in patients with hypertension who are also taking drugs that are moderate inhibitors of CYP3A4.
DB00700	DB01211	The macrolide, clarithromycin, may increase the effect and toxicity of eplerenone.
DB00700	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. The combination of eplerenone with any strong CYP3A4 inhibitor is contraindicated.
DB00700	DB00199	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB00700	DB00196	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB00700	DB01167	Itraconazole may increase the effect and toxicity of eplerenone.
DB00700	DB01026	Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone.
DB00700	DB01356	Eplerenone increases serum levels of lithium
DB00700	DB01149	Nefazodone increases the effect and toxicity of eplerenone
DB00700	DB00220	The protease inhibitor, nelfinavir, may increase the effect and toxicity of eplerenone.
DB00700	DB01344	Risk of alkalosis in renal impairment
DB00700	DB01345	This association presents an increased risk of hyperkalemia
DB00700	DB00503	This protease inhibitor, ritonavir, may increase the effect and toxicity of eplerenone.
DB00700	DB01232	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB00700	DB00421	This association presents an increased risk of hyperkalemia
DB00700	DB00976	Telithromycin may reduce clearance of Eplerenone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eplerenone if Telithromycin is initiated, discontinued or dose changed.
DB00700	DB00519	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB00700	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00700	DB00384	This association presents an increased risk of hyperkalemia
DB00700	DB01361	The macrolide, troleandomycin, may increase the effect and toxicity of eplerenone.
DB00700	DB00661	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB00700	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eplerenone by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00701	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Amprenavir. The antiviral response should be closely monitored.
DB00701	DB01418	Amprenavir may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB00701	DB00404	Amprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00701	DB01370	The antiacid decreases the absorption of amprenavir
DB00701	DB01118	The protease inhibitor, amprenavir, may increase the effect and toxicity of amiodarone.
DB00701	DB01125	Amprenavir may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB00701	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00701	DB01076	Amprenavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB00701	DB01244	Amprenavir may increase the effect and toxicity of bepridil.
DB00701	DB01294	The antiacid decreases the absorption of amprenavir
DB00701	DB01373	The antiacid decreases the absorption of amprenavir
DB00701	DB00604	Amprenavir may increase the effect and toxicity of cisapride.
DB00701	DB00628	Amprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate.
DB00701	DB00091	The protease inhibitor, amprenavir, may increase the effect of cyclosporine.
DB00701	DB00705	Decreased levels of delavirdine with increased levels of amprenavir
DB00701	DB00829	Amprenavir may increase the effect and toxicity of the benzodiazepine, diazepam.
DB00701	DB00266	Amprenavir may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB00701	DB00320	Amprenavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated.
DB00701	DB01375	The antiacid decreases the absorption of amprenavir
DB00701	DB00822	Increased irsk of side effects (oral solution)
DB00701	DB00696	Amprenavir may increase the effect and toxicity of ergotamine.
DB00701	DB00977	Ritonavir could decrease the contraceptive efficacy
DB00701	DB00813	The protease inhibitor, amprenavir, may increase the effect and toxicity of fentanyl.
DB00701	DB00690	Amprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam.
DB00701	DB02703	The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid.
DB00701	DB00227	Amprenavir may increase the serum concentration of the lovastatin. Concomitant therapy is contraindicated.
DB00701	DB01378	The antiacid decreases the absorption of amprenavir
DB00701	DB01377	The antiacid decreases the absorption of amprenavir
DB00701	DB01357	Ritonavir could decrease the contraceptive efficacy
DB00701	DB00333	The protease inhibitor, amprenavir, may decrease the effect of methadone.
DB00701	DB00916	Increased risk of side effects (oral solution)
DB00701	DB00683	Amprenavir may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00701	DB01100	Amprenavir may increase the effect and toxicity of pimozide.
DB00722	DB00594	Increased risk of hyperkalemia
DB00701	DB00243	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentratin of ranolazine by inhibiting its metabolism. Concomitant therapy is contraindicated.
DB00701	DB00615	Amprenavir may increase the effect and toxicity of rifabutin.
DB00701	DB01045	In presence of rifampin anticipate decrease of amprenavir efficiency
DB00701	DB00203	The protease inhibitor, amprenavir, may increase the effect and toxicity of sildenafil.
DB00701	DB00641	Amprenavir may increase the effect and toxicity of simvastatin. Concomitant therapy is contraindicated.
DB00701	DB01323	St. John's Wort decreases the effect of indinavir
DB00701	DB00864	The protease inhibitor, Amprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Amprenavir therapy is initiated, discontinued or altered.
DB00701	DB00820	Amprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00701	DB00675	Amprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00701	DB00706	Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amprenavir is initiated, discontinued, or dose changed.
DB00701	DB00976	Co-administration may result in altered plasma concentrations of Amprenavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00701	DB06287	Amprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00701	DB00444	The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00701	DB00906	The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB01036	Amprenavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity.
DB00701	DB00193	Amprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00701	DB00656	The protease inhibitor, Amprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB00897	Amprenavir may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00701	DB00726	The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB00862	Amprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00701	DB00285	Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Amprenavir is initiated, discontinued, or dose changed.
DB00701	DB00661	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB00570	Amprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB00541	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB00361	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Amprenavir is initiated, discontinued or dose changed.
DB00701	DB00163	Increased serum levels of vitamin E
DB00701	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amprenavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by amprenavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00701	DB00682	Amprenavir may increase the anticoagulant effect of warfarin by increasing its serum concentration.
DB00701	DB00425	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if amprenavir is initiated, discontinued or dose changed.
DB00701	DB00909	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if amprenavir is initiated, discontinued or dose changed.
DB00701	DB01198	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if amprenavir is initiated, discontinued or dose changed.
DB00703	DB00945	Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB00703	DB01294	The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB00705	DB00675	Delavirdine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00732	DB01190	The agent increases the effect of muscle relaxant
DB00703	DB01194	As both brinzolamide and methazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB00703	DB01397	The salicylate, magnesium salicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB00703	DB01043	Possible increased levels of memantine
DB00703	DB01398	The salicylate, salicylate-sodium, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB00703	DB01399	The salicylate, salsalate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB00703	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00703	DB01401	The salicylate, trisalicylate-choline, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB00705	DB00404	The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00705	DB01370	The antiacid decreases the effect of delavirdine
DB00705	DB00701	Decreased levels of delavirdine with increased levels of amprenavir
DB00705	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00705	DB01076	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if delavirdine is initiated, discontinued or dose changed.
DB00705	DB01558	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if delavirdine is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00705	DB01373	The antiacid decreases the effect of delavirdine
DB00705	DB00564	The anticonvulsant, carbamazepine, decreases the effect of delavirdine.
DB00705	DB00395	Strong CYP2C19 inhibitors such as delavirdine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00705	DB00604	Delavirdine, a strong CYP3A4 inhibitor, may increase the metabolism of cisapride. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cisapride if delavirdine is initiated, discontinued or dose changed.
DB00705	DB01219	Delavirdine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if delavirdine is initiated, discontinued or dose changed.
DB00705	DB00320	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dihydroergotamine if delavirdine is initiated, discontinued or dose changed.
DB00705	DB01253	The antiretroviral agent may increase the ergot derivative toxicity
DB00705	DB00696	The antiretroviral agent may increase the ergot derivative toxicity
DB00705	DB06414	Etravirine, when used concomitantly with Delaviridine, may experience an increase in serum concentration.  \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination.
DB00705	DB01319	Decreased levels of delavirdine with increased levels of amprenavir
DB00705	DB01320	The anticonvulsant, fosphenytoin, decreases the effect of delavirdine.
DB00705	DB00224	Delavirdine may increase the effect of indinavir.
DB00705	DB00227	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if delavirdine is initiated, discontinued or dose changed.
DB00705	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB00705	DB01378	Magnesium antacids may decrease the absorption of delavirdine.
DB00705	DB01377	The antiacid decreases the effect of delavirdine
DB00705	DB00353	The antiretroviral agent may increase the ergot derivative toxicity
DB00705	DB00849	The anticonvulsant, methylphenobarbital, decreases the effect of delavirdine.
DB00705	DB00247	The antiretroviral agent may increase the ergot derivative toxicity
DB00705	DB00683	The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00705	DB01174	The anticonvulsant, phenobarbital, decreases the effect of delavirdine.
DB00705	DB00252	The anticonvulsant, phenytoin, decreases the effect of delavirdine.
DB00705	DB01369	This combination presents an increased risk of toxicity
DB00705	DB00615	Rifabutin decreases the effect of delavirdine
DB00705	DB01045	Rifampin decreases the effect of delavirdine
DB00705	DB08864	Concentration of rilpivirine increases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's.
DB00705	DB00503	Increases the effect of ritonavir
DB00705	DB01232	Increases the effect of saquinavir and hepatic toxicity
DB00705	DB00641	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if delavirdine is initiated, discontinued or dose changed.
DB00705	DB01323	St. John's Wort decreases the antiretroviral effect
DB00705	DB00864	The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00820	Delavirdine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00705	DB00706	Delavirdine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Delavirdine is initiated, discontinued, or dose changed.
DB00705	DB00976	Delavirdine may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00705	DB06287	Delavirdine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00705	DB00444	The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00705	DB00906	The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00932	Concomitant use may result in increased Tipranavir and decreased Delavirdine concentrations. Monitor for altered therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.
DB00705	DB01124	Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB01036	Delavirdine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00705	DB00214	Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00193	Delavirdine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Delavirdine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00705	DB00656	The CYP3A4 inhibitor, Delavirdine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00897	The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00705	DB00440	The strong CYP2C9 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00726	The strong CYP3A4/CYP2D6 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00862	Delavirdine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00705	DB00285	Delaviridine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Delavirdine is initiated, discontinued, or dose changed.
DB00705	DB00661	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00570	Delavirdine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00541	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00361	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Delavirdine is initiated, discontinued or dose changed.
DB00705	DB00582	Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if delavirdine is initiated, discontinued or dose changed.
DB00705	DB00682	Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if delavirdine is initiated, discontinued or dose changed.
DB00705	DB00549	Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if delavirdine is initiated, discontinued or dose changed.
DB00705	DB00425	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if delavirdine is initiated, discontinued or dose changed.
DB00705	DB00909	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if delavirdine is initiated, discontinued or dose changed.
DB00705	DB01198	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if delavirdine is initiated, discontinued or dose changed.
DB00705	DB01624	Delavirdine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if delavirdine is initiated, discontinued or dose changed.
DB00706	DB00346	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Alfuzosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00706	DB01118	Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed.
DB00706	DB00701	Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amprenavir is initiated, discontinued, or dose changed.
DB00706	DB00673	Aprepitant, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Aprepitant is initiated, discontinued, or dose changed.
DB00706	DB01072	Atazanvir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Atazanavir is initiated, discontinued, or dose changed.
DB00706	DB00201	Caffeine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Caffeine is initiated, discontinued, or dose changed.
DB00706	DB00608	Chloroquine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chloroquine is initiated, discontinued, or dose changed.
DB00706	DB00477	Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chlorpromazine is initiated, discontinued, or dose changed.
DB00706	DB00501	Cimetidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cimetidine is initiated, discontinued, or dose changed.
DB00706	DB01012	Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cinacalcet is initiated, discontinued, or dose changed.
DB00706	DB01211	Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clarithromycin is initiated, discontinued, or dose changed.
DB00706	DB01242	Clomipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clomipramine is initiated, discontinued, or dose changed.
DB00706	DB00257	Clotrimazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clotrimazole is initiated, discontinued, or dose changed.
DB00706	DB00363	Clozapine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clozapine is initiated, discontinued, or dose changed.
DB00706	DB00907	Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cocaine is initiated, discontinued, or dose changed.
DB00706	DB00872	Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Conivaptan is initiated, discontinued, or dose changed.
DB00706	DB00091	Cyclosporine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cyclosporine is initiated, discontinued, or dose changed.
DB00706	DB00298	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Dapiprazole, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00706	DB00496	Darifenacin, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darifenacin is initiated, discontinued, or dose changed.
DB00706	DB01264	Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darunavir is initiated, discontinued, or dose changed.
DB00706	DB00705	Delavirdine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Delavirdine is initiated, discontinued, or dose changed.
DB00706	DB01151	Desipramine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Desipramine is initiated, discontinued, or dose changed.
DB00706	DB00343	Diltiazem, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diltiazem is initiated, discontinued, or dose changed.
DB00706	DB01075	Diphenhydramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diphenhydramine is initiated, discontinued, or dose changed.
DB00706	DB00590	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Doxazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00706	DB00254	Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed.
DB00706	DB00476	Duloxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Duloxetine is initiated, discontinued, or dose changed.
DB00706	DB00625	Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed.
DB00706	DB00199	Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed.
DB00737	DB00674	Possible antagonism of action
DB00706	DB06414	Etravirine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Etravirine is initiated, discontinued, or dose changed.
DB00706	DB00196	Fluconzole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluconazole is initiated, discontinued, or dose changed.
DB00706	DB00472	Fluoxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluoxetine is initiated, discontinued, or dose changed.
DB00706	DB01319	Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fosamprenavir is initiated, discontinued, or dose changed.
DB00706	DB00502	Haloperidol, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Haloperidol is initiated, discontinued, or dose changed.
DB00706	DB00619	Imatinib, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imatinib is initiated, discontinued, or dose changed.
DB00706	DB00458	Imipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imipramine is initiated, discontinued, or dose changed.
DB00706	DB00224	Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Indinavir is initiated, discontinued, or dose changed.
DB00706	DB00951	Isoniazid, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Isoniazid is initiated, discontinued, or dose changed.
DB00706	DB01167	Itraconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Itraconazole is initiated, discontinued, or dose changed.
DB00706	DB01026	Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed.
DB00706	DB01259	Lapatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lapatinib is initiated, discontinued, or dose changed.
DB00706	DB00281	Lidocaine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lidocaine is initiated, discontinued, or dose changed.
DB00706	DB01601	Lopinavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lopinavir is initiated, discontinued, or dose changed.
DB00706	DB00333	Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed.
DB00706	DB00763	Methimazole, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methimazole is initiated, discontinued, or dose changed.
DB00706	DB00916	Metronidazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Metronidazole is initiated, discontinued, or dose changed.
DB00706	DB01110	Miconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Miconazole is initiated, discontinued, or dose changed.
DB00706	DB01149	Nefazodone, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nefazodone is initiated, discontinued, or dose changed.
DB00706	DB00220	Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nelfinavir is initiated, discontinued, or dose changed.
DB00706	DB00622	Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed.
DB00706	DB04868	Nilotinib, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nilotinib is initiated, discontinued, or dose changed.
DB00706	DB01059	Norfloxacin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Norfloxacin is initiated, discontinued, or dose changed.
DB00706	DB00715	Paroxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Paroxetine is initiated, discontinued, or dose changed.
DB00706	DB01186	Pergolide, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pergolide is initiated, discontinued, or dose changed.
DB00706	DB00925	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phenoxybenzamine, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00706	DB00692	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phentolamine, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00706	DB01132	Pioglitazone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pioglitazone is initiated, discontinued, or dose changed.
DB00710	DB00258	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as ibandronate. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate.
DB00706	DB01263	Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Posaconazole is initiated, discontinued, or dose changed.
DB00706	DB00457	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Prazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00706	DB00205	Pyrimethamine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pyrimethamine is initiated, discontinued, or dose changed.
DB00706	DB00908	Quinidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinidine is initiated, discontinued, or dose changed.
DB00706	DB00468	Quinine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinine is initiated, discontinued, or dose changed.
DB00706	DB00243	Ranolazine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ranolazine is initiated, discontinued, or dose changed.
DB00706	DB00503	Ritonavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ritonavir is initiated, discontinued, or dose changed.
DB00706	DB01232	Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Saquinavir is initiated, discontinued, or dose changed.
DB00706	DB01104	Sertraline, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sertraline is initiated, discontinued, or dose changed.
DB00706	DB06207	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy is not recommended.
DB00706	DB06268	Sitaxsentan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sitaxsentan is initiated, discontinued, or dose changed.
DB00706	DB00820	Tadalafil may enhance the hypotensive effect of Tamsulosin. Monitor for hypotension during concomitant therapy.
DB00706	DB00976	Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Telithromycin is initiated, discontinued, or dose changed.
DB00706	DB01162	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Terazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00706	DB00857	Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Terbinafine is initiated, discontinued, or dose changed.
DB00706	DB00759	Tetracycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tetracycline is initiated, discontinued, or dose changed.
DB00706	DB00679	Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed.
DB00706	DB00208	Ticlopidine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ticlopidine is initiated, discontinued, or dose changed.
DB00706	DB00752	Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tranylcypromine is initiated, discontinued, or dose changed.
DB00706	DB00656	Trazodone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Trazodone is initiated, discontinued, or dose changed.
DB00706	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Tamsulosin, may occur. Monitor for hypotension during concomitant therapy.
DB00706	DB00661	Verapamil, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Verapamil is initiated, discontinued, or dose changed.
DB00706	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamsulosin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamsulosin if voriconazole is initiated, discontinued or dose changed.
DB00708	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00708	DB00501	Increases the effect of the narcotic
DB00708	DB00976	Telithromycin may reduce clearance of Sufentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sufentanil if Telithromycin is initiated, discontinued or dose changed.
DB00708	DB00752	Possible increased risk of serotonin syndrome.
DB00708	DB00427	The CNS depressants, Triprolidine and Sufentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00708	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sufentanil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sufentanil if voriconazole is initiated, discontinued or dose changed.
DB00709	DB00684	Increased risk of nephrotoxicity
DB00709	DB01610	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB00709	DB00943	Lamivudine may reduce the efficacy of zalcitabine. Combination therapy is not recommended.
DB00710	DB01370	Formation of non absorbable complexes
DB00710	DB01373	Formation of non-absorbable complexes
DB00720	DB01375	Formation of non-absorbable complexes
DB00710	DB01164	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate.
DB00710	DB01592	Formation of non absorbable complexes
DB00710	DB00893	Formation of non-absorbable complexes
DB00710	DB01378	Formation of non-absorbable complexes
DB00710	DB01377	Formation of non absorbable complexes
DB00710	DB00364	Formation of non absorbable complexes
DB00712	DB01418	The NSAID, flurbiprofen, may increase the anticoagulant effect of acenocoumarol.
DB00712	DB00630	Increased risk of gastric toxicity
DB00712	DB01125	The NSAID, flurbiprofen, may increase the anticoagulant effect anisindione.
DB00712	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00712	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00712	DB00091	Monitor for nephrotoxicity
DB00712	DB00266	The NSAID, flurbiprofen, may increase the anticoagulant effect of dicumarol.
DB00712	DB06781	NSAIDs may slow healing.
DB00712	DB06210	Increases levels of Flurbiprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB00712	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00712	DB00563	The NSAID, flurbiprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00712	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00712	DB00675	Flurbiprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Flurbiprofen is initiated, discontinued or dose changed.
DB00712	DB00966	Concomitant use of Telmisartan and Flurbiprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00712	DB00373	The NSAID, Flurbiprofen, may antagonize the antihypertensive effect of Timolol.
DB00712	DB01124	Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Flurbiprofen is initiated, discontinued or dose changed.
DB00712	DB00214	Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Flurbiprofen is initiated, discontinued or dose changed.
DB00712	DB00519	The NSAID, Flurbiprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Flurbiprofen is initiated, discontinued or dose changed.
DB00712	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Flurbiprofen. Monitor for increased bleeding during concomitant thearpy.
DB00712	DB00440	The strong CYP2C9 inhibitor, Flurbiprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Flurbiprofen is initiated, discontinued or dose changed.
DB00712	DB00582	Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if flurbiprofen is initiated, discontinued or dose changed.
DB00712	DB00682	Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed.
DB00713	DB00618	Possible antagonism of action
DB00713	DB00254	Possible antagonism of action
DB00713	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00713	DB01017	Possible antagonism of action
DB00713	DB00759	Possible antagonism of action
DB00714	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00714	DB00494	Entacapone increases the effect and toxicity of the sympathomimetic, apomorphine.
DB00714	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00714	DB01267	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, apomorphine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB00714	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00714	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Thiothixene may also antagonize the effects of the anti-Parkinsonian agent, Apomorphine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses changed.
DB00714	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00714	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00714	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00714	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00714	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Antagonism may also occur between zuclopenthixol, a dopamine D2 receptor antagonist, and apomorphine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB00715	DB01418	The SSRI, paroxetine, increases the effect of the anticoagulant, acenocoumarol.
DB00715	DB00918	Increased risk of CNS adverse effects
DB00715	DB00182	Risk of serotoninergic syndrome
DB00715	DB01125	The SSRI, paroxetine, increases the effect of the anticoagulant, anisindione.
DB00715	DB06216	Paroxetine is a substrate of CYP2D6 and concomitant therapy with asenapine (CYP2D6 inhibitor) increases concentrations of paroxetine 2-fold. May require dosing adjustments.
DB00715	DB00289	The CYP2D6 inhibitor, paroxetine, may increase the effect and toxicity of atomoxetine.
DB00715	DB00865	Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.
DB00715	DB01136	The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB00715	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00715	DB01191	Risk of serotoninergic syndrome
DB00715	DB01576	Risk of serotoninergic syndrome
DB00715	DB00514	Combination associated with possible serotoninergic syndrome
DB00715	DB00266	The SSRI, paroxetine, increases the effect of anticoagulant, dicumarol.
DB00715	DB00937	Risk of serotoninergic syndrome
DB00715	DB01551	Opioid analgesics may enhance the 5HT effects of SSRIs to cause serotonin syndrome. It is recommended to monitor therapy.
DB00715	DB00216	Increased risk of CNS adverse effects
DB00715	DB00574	Risk of serotoninergic syndrome
DB00715	DB00998	Increased risk of CNS adverse effects
DB00715	DB00674	Paroxetine increases the effect and toxicity of galantamine
DB00715	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00715	DB04946	Paroxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50%
DB00715	DB01247	Possible severe adverse reaction with this combination
DB00715	DB01009	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB00715	DB00601	Combination associated with possible serotoninergic syndrome
DB00715	DB00579	Risk of serotoninergic syndrome
DB00715	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00715	DB01577	Risk of serotoninergic syndrome
DB00715	DB00264	The SSRI increases the effect of the beta-blocker
DB00715	DB01171	Possible severe adverse reaction with this combination
DB00715	DB00952	Increased risk of CNS adverse effects
DB00715	DB00497	Increased risk of serotonin syndrome
DB00715	DB01579	Risk of serotoninergic syndrome
DB00715	DB00780	Possible severe adverse reaction with this combination
DB00715	DB00191	Risk of serotoninergic syndrome
DB00715	DB00397	Risk of serotoninergic syndrome
DB00715	DB01100	Increased risk of cardiotoxicity and arrhythmias.
DB00715	DB01182	Paroxetine may increase the effect and toxicity of propafenone.
DB00715	DB00571	The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, propranolol.
DB00715	DB01367	Possible severe adverse reaction with this combination
DB00715	DB00734	The SSRI, paroxetine, increases the effect and toxicity of risperidone.
DB00715	DB00953	Increased risk of CNS adverse effects
DB00715	DB01037	Possible severe adverse reaction with this combination
DB00715	DB01105	Risk of serotoninergic syndrome
DB00715	DB01323	St. John's Wort increases the effect and toxicity of the SSRI, paroxetine.
DB00715	DB00669	Increased risk of CNS adverse effects
DB00715	DB00675	Paroxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00715	DB00706	Paroxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Paroxetine is initiated, discontinued, or dose changed.
DB00715	DB00857	Terbinafine may reduce the metabolism and clearance of Paroxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Paroxetine if Terbinafine is initiated, discontinued or dose changed.
DB00715	DB04844	Paroxetine is a strong CYP2D6 inhibitor thus increasing half life of dihydrotetrabenazine moieties. Dose of tetrabenazine should be reduced
DB00715	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00715	DB01600	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB00715	DB00932	Tipranavir increases the concentration of Paroxetine. The Paroxetine dose may require an adjustment.
DB00715	DB00500	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB00715	DB01036	Paroxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB00715	DB00193	Tramadol may increase the risk of serotonin syndrome and seizures. Paroxetine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00715	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00715	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00720	DB01196	Clodronate may increase the levels of estramustine.
DB00720	DB01592	Formation of non-absorbable complexes
DB00715	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Paroxetine. Monitor for increased bleeding during concomitant thearpy.
DB00715	DB00726	The SSRI, Paroxetine, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Paroxetine is initiated, discontinued or dose changed.
DB00715	DB00427	The CNS depressants, Triprolidine and Paroxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00715	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00715	DB00682	The SSRI, paroxetine, increases the effect of the anticoagulant, warfarin.
DB00715	DB00315	Use of two serotonin modulators, such as zolmitriptan and paroxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00715	DB01624	Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed.
DB00717	DB00459	Acitretine may cause a loss of contraceptive effect
DB00717	DB01351	This product may cause a slight decrease of contraceptive effect
DB00717	DB01352	This product may cause a slight decrease of contraceptive effect
DB00717	DB06697	Artemether may decrease the effectiveness of norethindrone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00717	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norethindrone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00717	DB00559	Bosentan may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
DB00717	DB00237	This product may cause a slight decrease of contraceptive effect
DB00717	DB00241	This product may cause a slight decrease of contraceptive effect
DB00717	DB01353	This product may cause a slight decrease of contraceptive effect
DB00717	DB00564	This product may cause a slight decrease of contraceptive effect
DB00717	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00717	DB00754	This product may cause a slight decrease of contraceptive effect
DB00717	DB01320	This product may cause a slight decrease of contraceptive effect
DB00717	DB00400	This product may cause a slight decrease of contraceptive effect
DB00717	DB01354	This product may cause a slight decrease of contraceptive effect
DB00717	DB01355	This product may cause a slight decrease of contraceptive effect
DB00717	DB00555	The oral contraceptive decreases the effect of lamotrigine
DB00717	DB00532	This product may cause a slight decrease of contraceptive effect
DB00717	DB00474	This product may cause a slight decrease of contraceptive effect
DB00717	DB00849	This product may cause a slight decrease of contraceptive effect
DB00717	DB00312	This product may cause a slight decrease of contraceptive effect
DB00717	DB01174	This product may cause a slight decrease of contraceptive effect
DB00717	DB00252	This product may cause a slight decrease of contraceptive effect
DB00717	DB01132	Possible loss of contraceptive effect
DB00717	DB00794	This product may cause a slight decrease of contraceptive effect
DB00717	DB00615	Rifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.
DB00717	DB01045	This product may cause a slight decrease of contraceptive effect
DB00717	DB01201	This product may cause a slight decrease of contraceptive effect
DB00717	DB06201	Rufinamide decreases plasma concentrations of norethindrone, thus consider therapy modification
DB00717	DB00418	This product may cause a slight decrease of contraceptive effect
DB00717	DB01323	St. John's Wort could reduce the contraceptive effect
DB00717	DB00306	This product may cause a slight decrease of contraceptive effect
DB00717	DB00599	Thiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00717	DB00697	The contraceptive increases the effect of tizanidine
DB00717	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Norethindrone. An alternate form of contraception should be used during concomitant therapy.
DB00717	DB00197	Possible loss of contraceptive effect
DB00717	DB00682	Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed.
DB00718	DB01610	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Adefovir Dipivoxil, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB00719	DB00843	Possible antagonism of action
DB00719	DB00674	Possible antagonism of action
DB00719	DB00989	Possible antagonism of action
DB00720	DB01370	Formation of non-absorbable complexes
DB00720	DB01373	Formation of non-absorbable complexes
DB00720	DB00258	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB00720	DB01164	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB00722	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00722	DB01395	Increased risk of hyperkalemia
DB00722	DB01356	The ACE inhibitor increases serum levels of lithium
DB00722	DB01345	Increased risk of hyperkalemia
DB00722	DB00421	Increased risk of hyperkalemia
DB00722	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00722	DB00684	Increased risk of nephrotoxicity
DB00722	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00722	DB00384	Increased risk of hyperkalemia
DB00723	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of methoxamine.
DB00723	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of methoxamine.
DB00723	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of methoxamine.
DB00723	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of methoxamine.
DB00723	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of methoxamine.
DB00723	DB01170	Methoxamine may decrease the effect of guanethidine.
DB00723	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of methoxamine.
DB00723	DB01247	Increased arterial pressure
DB00723	DB00601	Possible increase of arterial pressure
DB00723	DB00968	Increased arterial pressure
DB00723	DB00211	Increased arterial pressure
DB00723	DB01171	Moclobemide increases the sympathomimetic effect of methoxamine.
DB00723	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of methoxamine.
DB00723	DB00780	Increased arterial pressure
DB00723	DB01367	Increased arterial pressure
DB00723	DB00206	Increased arterial pressure
DB00723	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Concomitant therapy should be avoided.
DB00723	DB00726	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00725	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00725	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Homatropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00725	DB00662	Trimethobenzamide and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00725	DB00427	Triprolidine and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00725	DB00209	Trospium and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00726	DB00106	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00918	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01118	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00321	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01351	The barbiturate, Amobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Amobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB00543	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00701	The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Amprenavir is initiated, discontinued or dose changed.
DB00726	DB01169	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00726	DB01072	The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Atazanavir is initiated, discontinued or dose changed.
DB00726	DB01200	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00490	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00237	The barbiturate, Butabarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butabarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB00241	The barbiturate, Butalbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butalbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB00248	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00477	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Chlorpromazine, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Caution should be used during concomitant therapy.
DB00737	DB00989	Possible antagonism of action
DB00726	DB00501	Cimetidine may increase the effect of tricyclic antidepressant, trimipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed.
DB00726	DB01012	The strong CYP2D6 inhibitor, Cinacalcet, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Cinacalcet is initiated, discontinued or dose changed.
DB00726	DB00604	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00215	The SSRI, Citalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Citalopram is initiated, discontinued or dose changed.
DB00726	DB01211	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Clarithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution.
DB00726	DB01242	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00575	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Clonidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Clonidine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00726	DB00907	The strong CYP2D6 inhibitor, Cocaine, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate.
DB00726	DB01264	The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Darunavir is initiated, discontinued or dose changed.
DB00726	DB01254	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00705	The strong CYP3A4/CYP2D6 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Delavirdine is initiated, discontinued or dose changed.
DB00726	DB01151	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00633	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Dexmedetomidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Dexmedetomidine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00726	DB00514	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00320	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00280	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00204	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00757	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01184	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00843	Possible antagonism of action
DB00726	DB01142	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00450	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00476	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00216	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00668	Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00726	DB01049	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01253	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00696	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00199	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01175	The SSRI, Escitalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Escitalopram is initiated, discontinued or dose changed.
DB00726	DB01288	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of fenoterol.
DB00726	DB01195	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00196	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Fluconazole, a strong CYP2C19 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Concomitant therapy should be used with caution.
DB00726	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, trimipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used cautiously.
DB00726	DB00875	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00176	The strong CYP2C19 inhibitor, fluvoxamine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Additive modulation of serotonin activity may also increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome and changes in therapeutic and adverse effects of trimipramine if fluvoxamine is initiated, discontinued or dose changed.
DB00726	DB01319	The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Fosamprenavir is initiated, discontinued or dose changed.
DB00726	DB00529	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00998	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00614	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB00674	Possible antagonism of action
DB00726	DB01044	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01241	The strong CYP2C19 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Gemfibrozil is initiated, discontinued or dose changed.
DB00726	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00726	DB00629	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanabenz. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanabenz should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00726	DB01170	The tricyclic antidepressant, trimipramine, decreases the effect of guanethidine.
DB00726	DB01018	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanfacine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanfacine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00726	DB01218	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00502	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00308	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00619	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Imatinib is initiated, discontinued or dose changed.
DB00726	DB00458	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00808	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00224	The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Indinavir is initiated, discontinued or dose changed.
DB00726	DB01247	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB00951	The strong CYP3A4/CYP2C19 inhibitor, Isoniazide, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Isoniazid is initiated, discontinued or dose changed.
DB00726	DB00270	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01167	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Itraconazole is initiated, discontinued or dose changed.
DB00726	DB01026	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed.
DB00726	DB01259	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01137	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00601	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB01356	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01601	The strong CYP3A4/CYP2D6 inhibitor, Lopinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Lopinavir is initiated, discontinued or dose changed.
DB00726	DB00408	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00726	DB00388	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00726	DB00934	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00358	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01365	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00726	DB00933	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00333	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00474	The barbiturate, Methohexital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Methohexital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB00723	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00726	DB00353	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01110	The strong CYP3A4/2D6/2C19 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/2D6/2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Miconazole is initiated, discontinued or dose changed.
DB00726	DB00211	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Midodrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00726	DB00370	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01171	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB00745	The strong CYP2C19 inhibitor, Modafinil, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Modafinil is initiated, discontinued or dose changed.
DB00726	DB00218	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00952	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01149	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Nefazodone, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nefazodone is initiated, discontinued or dose changed.
DB00726	DB00220	The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nelfinavir is initiated, discontinued or dose changed.
DB00726	DB00622	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nicardipine is initiated, discontinued or dose changed.
DB00726	DB04868	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00726	DB00368	Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Norepinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB00726	DB01059	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00540	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00104	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00338	The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed.
DB00726	DB00816	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of orciprenaline.
DB00726	DB00715	The SSRI, Paroxetine, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Paroxetine is initiated, discontinued or dose changed.
DB00726	DB00738	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00312	The barbiturate, Pentobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Pentobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB00556	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01186	Increased risk of serotonin syndrome. Pergolide, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Monitor for symptoms of serotonin syndrome and changes in Trimipramine therapeutic and adverse effects if Pergolide is initiated, discontinued or dose changed.
DB00726	DB00454	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00780	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB01174	The barbiturate, Phenobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Phenobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB00397	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB00726	DB01100	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01263	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Posaconazole is initiated, discontinued or dose changed.
DB00726	DB01278	The anticholinergic effects of Trimipramine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB00726	DB01599	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01035	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01168	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB01069	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01182	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00344	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00852	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of pseudoephedrine.
DB00726	DB01224	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00908	Additive QTc-prolonging effects may occur, increasing the risk of serious cardiac arrhythmias. Quinidine, a CYP2D6/CYP3A4 inhibitor, may also inhibit the metabolism of Trimipramine, a CYP2D6/CYP3A4 substrate. Monitor for signs of cardiac arrhythmias and for changes in Trimipramine efficacy and toxicity if Quinidine is initiated, discontinued or dose changed.
DB00726	DB00243	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01367	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifabutin is initiated, discontinued or dose changed.
DB00726	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifampin is initiated, discontinued or dose changed.
DB00726	DB00734	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00503	The strong CYP3A4/CYP2D6 inhibitor, Ritonavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ritonavir is initiated, discontinued or dose changed.
DB00726	DB00953	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00118	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01232	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Saquinavir is initiated, discontinued or dose changed.
DB00726	DB00418	The barbiturate, Secobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Secobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB01037	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB01104	The SSRI, Sertraline, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Sertraline is initiated, discontinued or dose changed.
DB00726	DB01105	Increased risk of serotonin syndrome. Concomitant therapy is contraindicated.
DB00726	DB06268	The strong CYP2C19 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Sitaxsentan is initiated, discontinued or dose changed.
DB00726	DB00489	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01208	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB01323	St. John's Wort may decrease serum concentrations of Trimipramine. Possible increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if St. John's Wort is initiated, discontinued or dose changed.
DB00726	DB00669	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB01268	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00726	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00726	DB00976	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Telithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution.
DB00726	DB00857	Terbinafine may decrease the metabolism and clearance of Trimipramine. Consider alternate therapy or monitor for changes in Trimipramine efficacy and toxicity if Terbinafine is initiated, discontinued or dose changed. Alteration in Trimipramine dose may be required.
DB00726	DB00871	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of terbutaline.
DB00726	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00726	DB04844	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB00726	DB00599	The barbiturate, Thiopental, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Thiopental is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB00726	DB00679	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00726	DB01623	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00726	DB00208	The strong CYP2C19 inhibitor, ticlopidine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of trimipramine if ticlopidine is initiated, discontinued or dose changed.
DB00726	DB00697	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Tizandine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Tizandine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB00726	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00726	DB00193	Tramadol may increase the risk of serotonin syndrome and seizures.
DB00726	DB00752	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00726	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00662	Trimethobenzamide and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00726	DB00427	Triprolidine and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00726	DB00209	Trospium and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00726	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00726	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trimipramine by decreasing its metabolism. Additive QTc prolongation may also occur. Monitor for changes in the therapeutic and adverse effects of trimipramine if voriconazole is initiated, discontinued or dose changed.
DB00726	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00726	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00726	DB00315	Use of two serotonin modulators, such as zolmitriptan and trimipramine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00726	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00727	DB00009	IV nitroglycerin may decrease the effect of alteplase.
DB00727	DB06237	Additive vasodilation. Concomitant therapy is contraindicated.
DB00727	DB08822	Pharmacodynamic synergist- increases effects.
DB00727	DB00320	Possible antagonism of action
DB00727	DB01253	Possible antagonism of action
DB00727	DB00696	Possible antagonism of action
DB00727	DB00353	Possible antagonism of action
DB00727	DB00247	Possible antagonism of action
DB00727	DB00203	Possible significant hypotension with this combination
DB00727	DB00820	The vasodilatory effects of Nitroglycerin may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00727	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00727	DB06267	The vasodilatory effects of Nitroglycerin may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00727	DB00862	The vasodilatory effects of Nitroglycerin may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00728	DB00479	The agent increases the effect of muscle relaxant
DB00728	DB01190	The agent increases the effect of muscle relaxant
DB00728	DB01111	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB00728	DB00798	The agent increases the effect of muscle relaxant
DB00728	DB01627	The agent increases the effect of muscle relaxant
DB00728	DB00955	The agent increases the effect of muscle relaxant
DB00728	DB00319	The agent increases the effect of the muscle relaxant
DB00728	DB00684	The agent increases the effect of the muscle relaxant
DB00741	DB00312	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00748	DB00674	Possible antagonism of action
DB00730	DB01418	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Acenocoumarol by decreasing Acenocoumarol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Acenocoumarol if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00969	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB01223	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Aminophylline by decreasing Aminophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Aminophylline if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00195	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed
DB00730	DB00201	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Caffeine by decreasing Caffeine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Caffeine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB01242	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clomipramine by decreasing Clomipramine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clomipramine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00363	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clozapine by decreasing Clozapine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clozapine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00924	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Cyclobenzaprine by decreasing Cyclobenzaprine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Cyclobenzaprine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00851	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB01142	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Doxepin if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00476	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00499	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Flutamide by decreasing Flutamide metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Flutamide if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00176	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00629	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Guanabenz by decreasing Guanabenz metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Guanabenz if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB01303	Thiabendazole increases the effect and toxicity of theophylline
DB00730	DB00980	Thiabendazole increases levels/toxicity of ramelteon
DB00730	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Thiabendazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Thiabendazole is initiated, discontinued or if the dose is changed.
DB00730	DB00277	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Theophylline by decreasing Theophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Theophylline if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB01623	The strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed.
DB00730	DB00697	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Tizanidine by decreasing Tizanidine metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Tizanidine if Thiabendazole is initiated, discontinued or dose changed.
DB00730	DB00831	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed.
DB00731	DB01296	Possible hyperglycemia
DB00731	DB00052	Somatropin may antagonize the hypoglycemic effect of nateglinide. Monitor for changes in fasting and postprandial blood sugars.
DB00731	DB00976	Telithromycin may reduce clearance of Nateglenide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nateglenide if Telithromycin is initiated, discontinued or dose changed.
DB00731	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Nateglinide. Consider alternate therapy or monitor for changes in Nateglinide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB00731	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nateglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nateglinide if voriconazole is initiated, discontinued or dose changed.
DB00732	DB00479	The agent increases the effect of muscle relaxant
DB00732	DB01223	Theophylline decreases the effect of muscle relaxant
DB00732	DB00993	The agent decreases the effect of the muscle relaxant
DB00732	DB00564	Decreases the effect of muscle relaxant
DB00732	DB01111	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB00732	DB01320	Phenytoin decreases the effect of muscle relaxant
DB00732	DB00798	The agent increases the effect of muscle relaxant
DB00732	DB01627	The agent increases the effect of muscle relaxant
DB00732	DB01033	The agent dereases the effect of the muscle relaxant
DB00732	DB00955	The agent increases the effect of muscle relaxant
DB00732	DB01303	Theophylline decreases the effect of muscle relaxant
DB00732	DB00252	Phenytoin decreases the effect of the muscle relaxant
DB00732	DB00319	The agent increases the effect of the muscle relaxant
DB00732	DB00908	The quinine derivative increases the effect of the muscle relaxant
DB00732	DB00468	The quinine derivative increases the effect of the muscle relaxant
DB00732	DB00277	Theophylline decreases the effect of the muscle relaxant
DB00732	DB00684	The agent increases the effect of the muscle relaxant
DB00734	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00734	DB00564	Decreases the effect of risperidone
DB00734	DB00843	Possible antagonism of action
DB00734	DB00472	The SSRI, fluoxetine, increases the effect and toxicity of risperidone.
DB00734	DB00674	Possible antagonism of action
DB00734	DB00224	Increased risk of extrapyramidal symptoms
DB00734	DB01167	Increases the level of risperidone
DB00734	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00734	DB01267	Paliperidone is the active metabolite of risperidone, 9-OH-risperidone. Concomitant therapy may increase the adverse effects of paliperidone due to additive paliperidone exposure. Consider alternate therapy.
DB00734	DB00715	The SSRI, paroxetine, increases the effect and toxicity of risperidone.
DB00734	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Risperidone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00734	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00734	DB00857	Terbinafine may reduce the metabolism and clearance of Risperidone. Consider alternate therapy or monitor for therapeutic/adverse effects of Risperidone if Terbinafine is initiated, discontinued or dose changed.
DB00734	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00734	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00734	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00734	DB00662	Trimethobenzamide and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00734	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00734	DB00427	Triprolidine and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00734	DB00209	Trospium and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00734	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00734	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00734	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00734	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00736	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00736	DB01066	Proton pump inhibitors such as esomeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB00736	DB00758	Esomeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent esomeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with esomeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB00736	DB00467	Esomeprazole may decrease the absorption of enoxacin.
DB00736	DB00224	Omeprazole decreases the absorption of indinavir
DB00736	DB01167	The proton pump inhibitor, esomeprazole, may decrease the absorption of itraconazole.
DB00736	DB01026	The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole.
DB00736	DB08864	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB00736	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Esomeprazole. Consider alternate therapy or increase the dose of Esomeprazole based on the therapeutic response.
DB00737	DB00843	Possible antagonism of action
DB00737	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Meclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00737	DB00662	Trimethobenzamide and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00737	DB00427	Triprolidine and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00737	DB00209	Trospium and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00738	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00738	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00738	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00738	DB01369	This combination presents an increased risk of toxicity
DB00738	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00738	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00738	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00738	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00738	DB00208	Ticlopidine may decrease the metabolism and clearance of Pentamidine. Consider alternate therapy or monitor for adverse/toxic effects of Pentamidine if Ticlopidine is initiated, discontinued or dose changed.
DB00738	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00738	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00738	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00738	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00738	DB00943	Additive risk of pancreatitis. Concomitant therapy should be avoided.
DB00738	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00738	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00739	DB00618	Possible antagonism of action
DB00739	DB00254	Possible antagonism of action
DB00739	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00739	DB01017	Possible antagonism of action
DB00739	DB00759	Possible antagonism of action
DB00741	DB01418	The corticosteroid, hydrocortisone, alters the anticoagulant effect, acenocoumarol.
DB00741	DB00945	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00741	DB01122	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, ambenonium.
DB00741	DB01351	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01125	The corticosteroid, hydrocortisone, alters the anticoagulant effect of anisindione.
DB00741	DB01352	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01294	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB00741	DB00237	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00241	The barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01353	The barbiturate, butethal, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01432	Cholestyramine may decrease the effect of hydrocortisone.
DB00741	DB00375	Cholestyramine decreases the effect of hydrocortisone
DB00741	DB00266	The corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol.
DB00741	DB01341	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01010	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, edrophonium.
DB00741	DB00754	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01354	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01355	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB05039	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB00741	DB08882	CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely.
DB00741	DB01397	The corticosteroid, hydrocortisone, may decrease the effect of magnesium salicylate.
DB00741	DB00532	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00474	The barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00849	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00211	Increased arterial pressure
DB00741	DB01400	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine.
DB00748	DB00843	Possible antagonism of action
DB00741	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00545	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00741	DB01346	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB01398	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salicylate-sodium.
DB00741	DB01399	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salsalate.
DB00741	DB00418	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00382	Tacrine and Hydrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00741	DB00306	The barbiturate, talbutal, may decrease the effect of the corticosteroid, hydrocortisone.
DB00741	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00741	DB01401	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, trisalicylate-choline.
DB00741	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB00741	DB00682	The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin.
DB00742	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00744	DB01223	Zileuton increases the effect and toxicity of theophylline
DB00744	DB06769	CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine.
DB00744	DB00320	Possible ergotism and severe ischemia with this combination
DB00744	DB06210	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB00744	DB00696	Possible ergotism and severe ischemia with this combination
DB00744	DB01303	Zileuton increases the effect and toxicity of theophylline
DB00744	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB00744	DB00980	Zileuton increases levels/toxicity of ramelteon
DB00744	DB00277	Zileuton may increase the therapeutic and adverse effects of theophylline by increasing its serum concentration. Monitor for changes in the therapeutic and adverse effects of theophylline if zileuton is initiated, discontinued or dose changed. Dose alterations should be considered.
DB00745	DB00395	Strong CYP2C19 inhibitors such as modafinil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00745	DB00363	Modafinil increases the effect and toxicity of clozapine
DB00745	DB00091	Modafinil decreases the effect of cyclosporine
DB00745	DB00977	Modafinil may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on during concomitant therapy with modafinil.
DB00745	DB01357	Modafinil decreases the effect of the contraceptive
DB00745	DB01656	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB00745	DB00976	Telithromycin may reduce clearance of Modafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Modafinil if Telithromycin is initiated, discontinued or dose changed.
DB00745	DB00897	Modafinil decreases the effect of triazolam
DB00745	DB00726	The strong CYP2C19 inhibitor, Modafinil, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Modafinil is initiated, discontinued or dose changed.
DB00745	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of modafinil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of modafinil if voriconazole is initiated, discontinued or dose changed.
DB00746	DB00126	Vitamin C may increase the adverse effects of deferoxamine. Transient deterioration of left ventricular function has been observed during concomitant therapy. Use caution during concomitant therapy.
DB00747	DB08810	Anticholinergic agents like scopolamine may reduce the action of cinitapride.
DB00747	DB00843	Possible antagonism of action
DB00747	DB00674	Possible antagonism of action
DB00747	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00747	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Scopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00747	DB00662	Trimethobenzamide and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00747	DB00427	Triprolidine and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00747	DB00209	Trospium and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00748	DB00895	Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects.
DB00748	DB01278	Pramlintide may enhance the anticholinergic effect of Anticholinergics such as carbinoxamine. These effects are specific to the gastrointestinal tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced gastrointestinal motility may occur.
DB00748	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Carbinoxamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00748	DB00662	Trimethobenzamide and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00748	DB00427	Triprolidine and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00748	DB00209	Trospium and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00749	DB01418	The NSAID, etodolac, may increase the anticoagulant effect or acenocoumarol.
DB00749	DB00630	Increased risk of gastric toxicity
DB00749	DB01125	The NSAID, etodolac, may increase the anticoagulant effect of anisindione.
DB00749	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00749	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00749	DB00091	Monitor for nephrotoxicity
DB00749	DB00266	The NSAID, etodolac, may increase the anticoagulant effect of dicumarol.
DB00749	DB06210	Increases levels of Etodolac via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB00749	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00749	DB00563	The NSAID, etodolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00749	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00749	DB00373	The NSAID, Etodolac, may antagonize the antihypertensive effect of Timolol.
DB00749	DB00519	The NSAID, Etodolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Etodolac is initiated, discontinued or dose changed.
DB00749	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Etodolac. Monitor for increased bleeding during concomitant thearpy.
DB00749	DB00682	The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00752	DB00802	Possible increased risk of serotonin syndrome.
DB00752	DB00918	The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Almotriptan. Risk of serotonin syndrome and Almotriptan toxicity. Concomitant therapy should be avoided.
DB00752	DB00321	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00543	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00964	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Apraclonidine. Concomitant therapy is contraindicated.
DB00752	DB00289	The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Atomoxetine. These agents should not be administered within 14 days of each other.
DB00752	DB00865	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Benzphetamine. Concomitant therapy should be avoided.
DB00752	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like tranylcypromine.
DB00752	DB00484	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Brimonidine. Concomitant therapy is contraindicated.
DB00752	DB01200	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like tranylcypromine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00752	DB01156	The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Bupropion. These agents should not be administered within 14 days of each other.
DB00752	DB00490	Buspirone may increase the adverse effects of Tranylcypromine. Elevation of blood pressure may occur. Concomitant therapy also may increase the risk of serotonin syndrome. Concomitant therapy should be avoided.
DB00752	DB00248	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00215	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB01242	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00924	Increased risk of serotonin syndrome. Concomitant use should be avoided. These agents should not be administered within 14 days of each other.
DB00752	DB01171	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01151	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00752	DB01191	Possible hypertensive crisis
DB00752	DB00633	Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Dexmedetomidine.
DB00752	DB01576	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Dextroamphetamine. Concomitant therapy should be avoided.
DB00752	DB00514	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB00752	DB00647	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB00752	DB00937	Possible hypertensive crisis
DB00752	DB00320	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00843	Possible antagonism of action
DB00752	DB01142	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00476	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00216	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00494	Additive inhibition of endogenous catecholamine metabolism may increase the therapeutic/adverse effects of both agents. Concomitant therapy should be avoided.
DB00752	DB01364	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Ephedrine. Concomitant therapy should be avoided.
DB00752	DB00668	Increased arterial pressure
DB00752	DB01049	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01253	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00696	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01175	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00574	Possible hypertensive crisis
DB00752	DB01288	Increased arterial pressure
DB00752	DB00813	Possible increased risk of serotonin syndrome.
DB00752	DB00472	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00176	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00998	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00614	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00674	Possible antagonism of action
DB00752	DB01170	Tranylcypromine may decrease the effect of guanethidine.
DB00752	DB01181	Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Ifosmadine.
DB00752	DB00458	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB01247	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01235	Levodopa may increase the adverse effects of Tranylcypromine. Risk of severe hypertension. Concomitant therapy should be avoided or monitored closely for adverse effects of Tranylcypromine.
DB00752	DB00601	The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Linezolid. These agents should not be administered within 14 days of each other.
DB00752	DB01255	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Lisdexamfetamine. Concomitant therapy should be avoided.
DB00752	DB01356	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00934	Maprotiline may increase the adverse effects of the MAO inhibitor, Tranylcypromine. These agents should not be administered within 14 days of each other.
DB00752	DB00579	Possible hypertensive crisis
DB00752	DB01365	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Concomitant therapy should be avoided.
DB00752	DB01577	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Methamphetamine. Concomitant therapy should be avoided.
DB00752	DB01403	Possible severe adverse reaction with this combination
DB00752	DB00723	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Concomitant therapy should be avoided.
DB00752	DB00968	The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Methyldopa. Concomitant therapy is contraindicated.
DB00752	DB00353	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00422	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Methylphenidate. Concomitant therapy is contraindicated.
DB00752	DB00211	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Midodrine. Concomitant therapy should be avoided.
DB00752	DB04896	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00370	The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Mirtazapine. These agents should not be administered within 14 days of each other.
DB00754	DB00277	Decreased effect of both products
DB00752	DB00952	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01149	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00540	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00816	Increased arterial pressure
DB00752	DB00935	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Oxymetazoline. Concomitant therapy should be avoided.
DB00752	DB00715	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB01186	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00454	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB00752	DB01579	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Phendimetrazine. Concomitant therapy should be avoided.
DB00752	DB00780	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00191	The MAO inhibitor, tranylcypromine, may increase the vasopressor effect of the amphetamine, phentermine. Concomitant therapy should be avoided.
DB00752	DB00388	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Concomitant therapy should be avoided.
DB00752	DB00397	Increased arterial pressure
DB00752	DB01278	The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB00752	DB01168	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01069	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00344	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB00852	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Pseudoephedrine. Concomitant therapy should be avoided.
DB00752	DB01367	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00899	Possible increased risk of serotonin syndrome.
DB00752	DB00206	Addition of Reserpine to Tranylcypromine therapy may induce paradoxical Reserpine effects, including peripheral hypertension and central exciation. Close monitoring for adverse effects is required. Addition of Tranylcypromine to Reserpine therapy may be less of a concern.
DB00752	DB00953	The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Rizatriptan. Risk of serotonin syndrome and Rizatriptan toxicity. Concomitant therapy should be avoided.
DB00752	DB00118	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01037	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB01104	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB01105	Increased risk of serotonin syndrome. Avoid concomitant therapy.
DB00752	DB01323	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00708	Possible increased risk of serotonin syndrome.
DB00752	DB00669	The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Sumatriptan. Risk of serotonin syndrome and Sumatriptan toxicity. Concomitant therapy should be avoided.
DB00752	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tranylcypromine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Tranylcypromine, a CYP1A2 inhibitor. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00752	DB00675	The CYP2D6 inhibitor, Tranylcypromine, may decrease the efficacy of Tamoxifen by reducing active metabolite production. Consider alternate therapy.
DB00752	DB00706	Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tranylcypromine is initiated, discontinued, or dose changed.
DB00752	DB00871	Increased arterial pressure
DB00752	DB04844	Tetrabenazine may increase the adverse/toxic effects of Tranylcypromine. Concomitant therapy is contraindicated.
DB00752	DB00679	Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated.
DB00752	DB00697	Tranylcypromine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00752	DB00323	Tolcapone and Tranylcypromine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00752	DB00193	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, tranylcypromine. Tranylcypromine may decrease the effect of tramadol by decreasing active metabolite production.
DB00752	DB00656	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00752	DB00662	Trimethobenzamide and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00752	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00752	DB00427	Concomitant therapy with triprolidine and tranylcypromine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy.
DB00752	DB00209	Trospium and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00752	DB00285	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB00752	DB06684	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.
DB00752	DB00315	The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated.
DB00753	DB00598	Monitor arterial pressure closely
DB00754	DB00404	Ethotoin may increase the metabolism of alprazolam via CYP3A4.
DB00754	DB01223	Decreased effect of both products
DB00754	DB01118	Increases the effect of hydantoin
DB00754	DB00673	The CYP3A4 inducer, ethotoin, may decrease the effect of aprepitant.
DB00754	DB00443	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, betamethasone.
DB00754	DB01101	Capecitabine increases the effect of hydantoin
DB00754	DB00446	Increases phenytoin, modifies chloramphenicol
DB00754	DB00475	Ethotoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB00754	DB01114	The antihistamine increases the effect of hydantoin
DB00754	DB00501	Increases the effect of hydantoin
DB00754	DB00537	Decreases the hydantoin effect
DB00754	DB00882	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, clomifene.
DB00754	DB00628	Ethotoin may increase the metabolism of clorazepate via CYP3A4.
DB00754	DB00363	Hydantoin decreases the effect of clozapine
DB00754	DB00286	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, conjugated estrogens.
DB00754	DB00091	The hydantoin decreases the effect of cyclosporine
DB00754	DB01234	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, dexamethasone.
DB00754	DB00829	Ethotoin may increase the metabolism of diazepam via CYP3A4.
DB00754	DB00255	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, diethylstilbestrol.
DB00754	DB00280	The hydantoin decreases the effect of disopyramide
DB00754	DB00822	Increases the effect of phenytoin
DB00754	DB00254	The anticonvulsant, ethotoin, decreases the effect of doxycycline.
DB00754	DB00783	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, estradiol.
DB00754	DB00977	This product may cause a slight decrease of contraceptive effect
DB00754	DB00949	Increased phenytoin levels and decreased felbamate levels
DB00754	DB01023	The hydantoin decreases the effect of felodipine
DB00754	DB00196	Increases the effect of hydantoin
DB00754	DB00687	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB00754	DB00544	Fluorouracil increases the effect of hydantoin
DB00754	DB00472	Fluoxetine increases the effect of phenytoin
DB00754	DB00690	Ethotoin may increase the metabolism of flurazepam via CYP3A4.
DB00754	DB00176	Increases the effect of hydantoin
DB00754	DB00158	Folic acid decreases the levels of hydantoin
DB00754	DB00695	The hydantoin decreases the effect of furosemide
DB00754	DB00996	Increases the effect of hydantoin
DB00754	DB00317	The CYP3A4 inducer, ethotoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00754	DB00741	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB00754	DB00619	The hydantoin decreases the levels of imatinib
DB00754	DB00951	Isoniazid increases the effect of phenytoin in 20% of patients
DB00754	DB01167	Phenytoin decreases the effect of itraconazole
DB00754	DB00555	Phenytoin may reduce levels of lamotrigine
DB00754	DB00367	Phenytoin decreases the contraceptive effect
DB00754	DB00643	The hydantoin decreases the efficiency of mebendazole
DB00754	DB00603	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, medroxyprogesterone.
DB00754	DB00351	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, megestrol.
DB00754	DB00333	The hydantoin decreases the effect of methadone
DB00754	DB00563	The antineoplasic agent decreases the effect of hydantoin
DB00754	DB00553	The hydantoin decreases the effect of psoralene
DB00754	DB00379	The hydantoin decreases the effect of mexiletine
DB00754	DB00683	Ethotoin may increase the metabolism of midazolam via CYP3A4.
DB00754	DB00370	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB00754	DB00717	This product may cause a slight decrease of contraceptive effect
DB00754	DB00338	Omeprazole increases the effect of hydantoin
DB00754	DB00776	Oxcarbazepine increases the effect of hydantoin
DB00754	DB01303	Decreased effect of both products
DB00754	DB03585	The NSAID, oxyphenbutazone, may increase the hydantoin effect of ethotoin.
DB00754	DB00812	The NSAID, phenylbutazone, may increase the hydantoin effect of ethotoin.
DB00754	DB00860	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisolone.
DB00754	DB00635	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone.
DB00754	DB01224	Phenytoin decreases the effect of quetiapine
DB00754	DB01045	Rifampin decreases the effect of the hydantoin
DB00754	DB00208	Ticlopidine increases the effect of hydantoin
DB00754	DB00620	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone.
DB00754	DB00897	Ethotoin may increase the metabolism of triazolam via CYP3A4.
DB00754	DB00427	The CNS depressants, Triprolidine and Ethotoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00755	DB01072	The strong CYP2C8 inhibitor, Atazanavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Atazanavir is initiated, discontinued to dose changed.
DB00755	DB00564	The strong CYP2C8 inducer, Carbamazepine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Carbamazepine is initiated, discontinued or dose changed.
DB00755	DB00482	The moderate CYP2C8 inhibitor, Celecoxib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Celecoxib is initiated, discontinued to dose changed.
DB00755	DB00618	Demeclocycline may increase the adverse effects of oral Tretinoin. Increased risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00755	DB00304	Oral Tretinoin may decrease the effect of oral contraceptive, Desogestrel. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB00254	Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00755	DB01395	Oral Tretinoin may decrease the effect of oral contraceptive, Drospirenone. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB06210	The moderate CYP2C8 inhibitor, Eltrombopag, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Eltrombopag is initiated, discontinued or dose changed.
DB00755	DB00977	Oral Tretinoin may decrease the effect of the oral contraceptive, Ethinyl Estradiol. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB00823	Oral Tretinoin may decrease the effect of oral contraceptive, Ethynodiol Diacetate. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB00294	Oral Tretinoin may decrease the effect of oral contraceptive, Etonogestrel. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB01023	The moderate CYP2C8 inhibitor, Felopidine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Felopidine is initiated, discontinued to dose changed.
DB00755	DB01320	The strong CYP2C8 inducer, Fosphenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Fosphenytoin is initiated, discontinued or dose changed.
DB00755	DB01241	The strong CYP2C8 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Gemfibrozil is initiated, discontinued to dose changed.
DB00755	DB01029	The moderate CYP2C8 inhibitor, Irbesartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Irbesartan is initiated, discontinued to dose changed.
DB00755	DB01259	The moderate CYP2C8 inhibitor, Lapatinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Lapatinib is initiated, discontinued to dose changed.
DB00755	DB00367	Oral Tretinoin may decrease the effect of oral contraceptive, Levonorgestrel. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB00678	The moderate CYP2C8 inhibitor, Losartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Losartan is initiated, discontinued to dose changed.
DB00755	DB01357	Oral Tretinoin may decrease the effect of oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB01017	Minocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00755	DB00108	Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided.
DB00755	DB04868	The moderate CYP2C8 inhibitor, Nilotinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Nilotinib is initiated, discontinued to dose changed.
DB00755	DB00717	Oral Tretinoin may decrease the effect of oral contraceptive, Norethindrone. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB00957	Oral Tretinoin may decrease the effect of oral contraceptive, Norgestimate. An alternate form of contraception should be used during concomitant therapy.
DB00755	DB00595	Oxytetracycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00755	DB01174	The strong CYP2C8 inducer, Phenobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenobarbital is initiated, discontinued or dose changed.
DB00755	DB00252	The strong CYP2C8 inducer, Phenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenytoin is initiated, discontinued or dose changed.
DB00755	DB01132	The moderate CYP2C8 inhibitor, Pioglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Pioglitazone is initiated, discontinued to dose changed.
DB00755	DB00794	The strong CYP2C8 inducer, Primidone, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Primidone is initiated, discontinued or dose changed.
DB00759	DB01605	Possible antagonism of action
DB00755	DB00468	The moderate CYP2C8 inhibitor, Quinine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Quinine is initiated, discontinued to dose changed.
DB00755	DB01129	The moderate CYP2C8 inhibitor, Rabaprazole, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rabaprazole is initiated, discontinued to dose changed.
DB00755	DB01045	The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed.
DB00755	DB01201	The strong CYP2C8 inducer, Rifapentine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifapentine is initiated, discontinued or dose changed.
DB00755	DB00503	The strong CYP2C8 inhibitor, Ritonavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Ritonavir is initiated, discontinued to dose changed.
DB00755	DB00412	The moderate CYP2C8 inhibitor, Rosiglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rosiglitazone is initiated, discontinued to dose changed.
DB00755	DB00418	The strong CYP2C8 inducer, Secobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Secobarbital is initiated, discontinued or dose changed.
DB00755	DB00398	The strong CYP2C8 inhibitor, Sorafenib, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Sorafenib is initiated, discontinued to dose changed.
DB00755	DB00675	The moderate CYP2C8 inhibitor, Tamoxifen, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Tamoxifen is initiated, discontinued to dose changed.
DB00755	DB00759	Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00755	DB00560	Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00755	DB00072	Increased risk of leukopenia and anemia due to synergistic effects. Monitor for signs and symptoms of adverse events during concomitant therapy.
DB00755	DB00440	The moderate CYP2C8 inhibitor, Trimethoprim, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Trimethoprim is initiated, discontinued to dose changed.
DB00755	DB00162	Tretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking systemic tretinoin.
DB00757	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00757	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00757	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00757	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00757	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00757	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00757	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00757	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00757	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00758	DB00188	Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel.
DB00758	DB00055	Antiplatelet agents such as clopidogrel may enhance the adverse/toxic effect of Drotrecogin Alfa. Bleeding may occur. Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.
DB00758	DB00736	Esomeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent esomeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with esomeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB00758	DB06414	Clopidogrel, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in the serum concentrations of it's active metabolites. \r\n\r\nCaution and close monitoring for decreased efficacy of clopidogrel is recommended.
DB00758	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00758	DB00448	Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB00758	DB00338	Omeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness.
DB00758	DB00213	Pantoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent pantoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with pantoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB00758	DB01129	Rabeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent rabeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with rabeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB00758	DB06228	Antiplatelet agents such as clopidogrel may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding. Canadian rivaroxaban labeling recommends avoiding concurrent use with any antiplatelet agent, while the U.S. rivaroxaban labeling recommends caution and increased monitoring if used with any other antiplatelet agent. Any combined use should only be undertaken with increased monitoring for evidence of bleeding.
DB00758	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Clopidogrel. Monitor for increased bleeding during concomitant thearpy.
DB00758	DB00682	Increased bleed risk may occur as a result of additive anticoagulant effects. Increase monitoring for signs and symptoms of bleeding during concomitant therapy.
DB00759	DB01418	Tetracycline may increase the anticoagulant effect of acenocoumarol.
DB00759	DB00459	Increased risk of intracranial hypertension
DB00759	DB01370	Formation of non-absorbable complexes
DB00759	DB01060	Possible antagonism of action
DB00759	DB00415	Possible antagonism of action
DB00759	DB01125	Tetracycline may increase the anticoagulant effect of anisindione.
DB00759	DB01117	Tetracycline may decrease the effect of atovaquone.
DB00759	DB01574	Formation of non-absorbable complexes
DB00759	DB01061	Possible antagonism of action
DB00759	DB00355	Possible antagonism of action
DB00759	DB01602	Possible antagonism of action
DB00759	DB01053	Possible antagonism of action
DB00759	DB00307	Tetracycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB00759	DB01294	Formation of non-absorbable complexes
DB00759	DB01373	Formation of non-absorbable complexes
DB00759	DB00258	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00759	DB01164	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB00759	DB00578	Possible antagonism of action
DB00759	DB00766	Possible antagonism of action
DB00759	DB01147	Possible antagonism of action
DB00759	DB00930	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00759	DB01000	Possible antagonism of action
DB00759	DB00485	Possible antagonism of action
DB00759	DB00266	Tetracycline may increase the anticoagulant effect of dicumarol.
DB00759	DB01375	Formation of non-absorbable complexes
DB00759	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00759	DB00926	Increased risk of intracranial hypertension
DB00759	DB00301	Possible antagonism of action
DB00759	DB00739	Possible antagonism of action
DB00759	DB01592	Formation of non-absorbable complexes
DB00759	DB00893	Formation of non-absorbable complexes
DB00759	DB00982	Increased risk of intracranial hypertension
DB00759	DB01378	Formation of non-absorbable complexes
DB00759	DB01397	Formation of non-absorbable complexes
DB00759	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00759	DB02443	Possible antagonism of action
DB00759	DB00563	Tetracycline may increase methotrexate toxicity.
DB00759	DB01028	Tetracycline may increase the renal toxicity of methoxyflurane.
DB00759	DB00948	Possible antagonism of action
DB00759	DB00607	Possible antagonism of action
DB00759	DB00713	Possible antagonism of action
DB00759	DB00417	Possible antagonism of action
DB00759	DB00319	Possible antagonism of action
DB00759	DB01604	Possible antagonism of action
DB00759	DB00881	Quinapril may decrease the absorption of tetracycline.
DB00759	DB00706	Tetracycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tetracycline is initiated, discontinued, or dose changed.
DB00759	DB01606	Possible antagonism of action
DB00759	DB01607	Tetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Tetracycline.
DB00759	DB01036	Tetracycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00759	DB00193	Tetracycline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00759	DB00656	The CYP3A4 inhibitor, Tetracycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tetracycline is initiated, discontinued or dose changed.
DB00759	DB00755	Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB00759	DB01401	Formation of non-absorbable complexes
DB00759	DB00682	Tetracycline may increase the anticoagulant effect of warfarin.
DB00759	DB01593	Formation of non-absorbable complexes
DB00761	DB00771	Anticholinergic agents such as clidinium may enhance the ulcerogenic effect of potassium chloride. Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride; liquid or effervescent potassium preparations are possible alternatives.
DB00761	DB00966	Potassium Chloride may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use.
DB00761	DB01409	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Tiotropium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00761	DB01036	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00761	DB00519	The potassium salt may increase the hyperkalemic effect of Trandolapril.
DB00761	DB00376	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trihexyphenidyl, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00761	DB00662	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trimethobenzamide, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00761	DB00209	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trospium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB00762	DB00673	Aprepitant may change levels of the chemotherapy agent, irinotecan.
DB00762	DB01072	Increases levels/effect of irinotecan
DB00762	DB00112	Monitor therapy due to increased adverse effects of irinotecan.
DB00762	DB01320	The hydantoin decreases the effect of irinotecan
DB00762	DB01026	Ketoconazole increases the effect and toxicity of irinotecan
DB00762	DB06589	Irinotecan is an uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) substrate and serum concentrations may increase if administered concurrently with pazopanib, an UGT1A1 inhibitor.
DB00762	DB00252	The hydantoin decreases the effect of irinotecan
DB00762	DB08896	Regorafenib may increase levels of irinotecan, a UGT1A1 substrate.
DB00762	DB00976	Telithromycin may reduce clearance of Irinotecan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Irinotecan if Telithromycin is initiated, discontinued or dose changed.
DB00762	DB04572	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Irinotecan, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Irinotecan if Thiotepa is initiated, discontinued or dose changed.
DB00762	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00762	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of irinotecan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of irinotecan if voriconazole is initiated, discontinued or dose changed.
DB00763	DB01418	The antithyroid agent, methimazole, may decrease the anticoagulant effect of acenocoumarol.
DB00763	DB01125	The antithyroid agent, methimazole, may decrease the anticoagulant effect of anisindione.
DB00763	DB00266	The antithyroid agent, methimazole, may decrease the anticoagulant effect of dicumarol.
DB00763	DB00390	The antithyroid agent increases the effect of digoxin
DB00763	DB00675	Methimazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB00763	DB00706	Methimazole, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methimazole is initiated, discontinued, or dose changed.
DB00763	DB00682	Methimazole may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if methimazole is initiated, discontinued or dose changed.
DB00765	DB01551	Concurrent use may enhance the sedative effect of Metyrosine.  It is recommended to monitor therapy.
DB00766	DB00618	Possible antagonism of action
DB00766	DB00254	Possible antagonism of action
DB00766	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00766	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00766	DB00931	Possible antagonism of action
DB00766	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00766	DB01017	Possible antagonism of action
DB00766	DB00595	Possible antagonism of action
DB00766	DB01301	Possible antagonism of action
DB00766	DB00759	Possible antagonism of action
DB00771	DB00843	Possible antagonism of action
DB00771	DB00674	Possible antagonism of action
DB00771	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00771	DB00761	Anticholinergic agents such as clidinium may enhance the ulcerogenic effect of potassium chloride. Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride; liquid or effervescent potassium preparations are possible alternatives.
DB00771	DB01278	Pramlintide may enhance the anticholinergic effect of anticholinergics such as clidinium. These effects are specific to the GI tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur.
DB00771	DB00021	Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.
DB00771	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clidinium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00771	DB00662	Trimethobenzamide and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00771	DB00427	Triprolidine and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00771	DB00209	Trospium and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00773	DB00673	Aprepitant may change levels of the chemotherapy agent, etoposide.
DB00773	DB00091	Cyclosporine may increase the therapeutic and adverse effects of etoposide.
DB00773	DB01369	This combination presents an increased risk of toxicity
DB00773	DB00976	Telithromycin may reduce clearance of Etoposide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Etoposide if Telithromycin is initiated, discontinued or dose changed.
DB00773	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00773	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of etoposide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of etoposide if voriconazole is initiated, discontinued or dose changed.
DB00774	DB00390	Possible electrolyte variations and arrhythmias
DB00774	DB01356	The thiazide diuretic, hydroflumethiazide, may increase serum levels of lithium.
DB00774	DB00519	The thiazide diuretic, Hydroflumethiazide, may increase the hypotensive effect of Trandolapril. Hydroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00774	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00775	DB00054	Additive effects. Concomitant use is contraindicated.
DB00775	DB00063	Additive effects. Concomitant use is contraindicated.
DB00775	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00775	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Tirofiban. Monitor for increased bleeding during concomitant thearpy.
DB00776	DB00091	Oxcarbazepine decreases the effect of cyclosporine
DB00776	DB00977	Oxcarbazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied upon during concomitant therapy with oxcarbazepine.
DB00776	DB00754	Oxcarbazepine increases the effect of hydantoin
DB00776	DB01023	Oxcarbazepine decreases the levels of felodipine
DB00776	DB01320	Oxcarbazepine increases the effect of hydantoin
DB00776	DB00532	Oxcarbazepine increases the effect of hydantoin
DB00776	DB01357	Oxcarbazepine decreases the effect of the contraceptive
DB00776	DB00252	Oxcarbazepine increases the effect of hydantoin
DB00776	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB00776	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB00776	DB00976	Oxcarbazepine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00776	DB06287	Oxcarbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00776	DB00193	Oxcarbazepine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00776	DB00656	The CYP3A4 inducer, Oxcarbazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Oxcarbazepine is initiated, discontinued or dose changed.
DB00783	DB00532	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, estradiol.
DB00776	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB00777	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00777	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00777	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00777	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00777	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00777	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00777	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00777	DB01170	Propiomazine may decrease the effect of guanethidine.
DB00777	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00777	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00777	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00777	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00777	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00778	DB00091	The macrolide, roxithromycin, may increase the effect of cyclosporine.
DB00779	DB01418	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of acenocoumarol.
DB00779	DB01125	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of anisindione.
DB00779	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00779	DB00266	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of dicumarol.
DB00779	DB00682	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin.
DB00780	DB00918	The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.
DB00780	DB00488	Risk of severe hypotension
DB00780	DB00321	Possibility of severe adverse effects
DB00780	DB00543	Possibility of severe adverse effects
DB00780	DB00182	Possible hypertensive crisis
DB00780	DB00289	Possible severe adverse reaction with this combination
DB00780	DB00865	MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents.
DB00780	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like phenelzine.
DB00780	DB00484	MAO Inhibitors like phenelzine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB00780	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like phenelzine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00780	DB01156	Possible severe adverse reaction with this combination
DB00780	DB00490	Possible blood pressure elevation
DB00780	DB00215	Possible severe adverse reaction with this combination
DB00780	DB01242	Possibility of severe adverse effects
DB00780	DB01151	Possibility of severe adverse effects
DB00780	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00780	DB01191	Possible hypertensive crisis
DB00780	DB01576	Possible hypertensive crisis
DB00780	DB00514	Possible severe adverse reaction
DB00780	DB00937	Possible hypertensive crisis
DB00780	DB00841	Increased arterial pressure
DB00780	DB00843	Possible antagonism of action
DB00780	DB00988	Increased arterial pressure
DB00780	DB01142	Possibility of severe adverse effects
DB00780	DB00476	Possible severe adverse reaction with this combination
DB00780	DB00494	Possible hypertensive crisis with this combination
DB00780	DB01363	Increased arterial pressure
DB00780	DB01364	Increased arterial pressure
DB00780	DB00668	Increased arterial pressure
DB00780	DB01175	Possible severe adverse reaction with this combination
DB00780	DB00574	Possible hypertensive crisis
DB00780	DB01288	Increased arterial pressure
DB00780	DB00472	Possible severe adverse reaction with this combination
DB00780	DB00176	Possible severe adverse reaction with this combination
DB00780	DB00674	Possible antagonism of action
DB00780	DB01170	Phenelzine may decrease the effect of guanethidine.
DB00780	DB00458	Possibility of severe adverse effects
DB00780	DB01064	Increased arterial pressure
DB00780	DB01235	Possible hypertensive crisis
DB00780	DB00579	Possible hypertensive crisis
DB00780	DB01365	Increased arterial pressure
DB00780	DB00610	Increased arterial pressure
DB00780	DB01577	Possible hypertensive crisis
DB00780	DB01403	Possible severe adverse reaction with this combination
DB00780	DB00723	Increased arterial pressure
DB00780	DB00422	Possible hypertensive crisis with this combination
DB00780	DB00211	Possible hypertensive crisis with this combination
DB00780	DB04896	Increase serotonin levels. Combination therapy is contraindicated.
DB00780	DB00370	Possible severe adverse reaction with this combination
DB00783	DB00474	The enzyme inducer, methohexital, decreases the effect of the hormone agent, estradiol.
DB00780	DB00952	The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.
DB00780	DB01149	Possible severe adverse reaction with this combination
DB00780	DB00368	Increased arterial pressure
DB00780	DB00540	Possibility of severe adverse effects
DB00780	DB00816	Increased arterial pressure
DB00780	DB00715	Possible severe adverse reaction with this combination
DB00780	DB00454	Potentially fatal adverse effects
DB00780	DB01579	Possible hypertensive crisis
DB00780	DB00191	Possible hypertensive crisis
DB00780	DB00388	Increased arterial pressure
DB00780	DB00397	Increased arterial pressure
DB00780	DB01291	Increased arterial pressure
DB00780	DB01366	Increased arterial pressure
DB00780	DB00344	Possibility of severe adverse effects
DB00780	DB00852	Increased arterial pressure
DB00780	DB00989	Possible antagonism of action
DB00780	DB00953	The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
DB00780	DB01001	Increased arterial pressure
DB00780	DB01104	Possible severe adverse reaction with this combination
DB00780	DB01105	Possible serotoninergic syndrome with this combination
DB00780	DB00669	The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated.
DB00780	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenelzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00780	DB00871	Increased arterial pressure
DB00780	DB04844	Tetrabenazine may increase the adverse/toxic effects of Phenelzine. Concomitant therapy is contraindicated.
DB00780	DB00323	Tolcapone and Phenelzine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB00780	DB00193	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, phenelzine.
DB00780	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00780	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00780	DB00662	Trimethobenzamide and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00780	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB00780	DB00427	Triprolidine and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00780	DB00209	Trospium and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00780	DB01831	Possible severe adverse reaction with this combination
DB00780	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB00780	DB06684	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.
DB00780	DB00315	The MAO inhibitor, phenelzine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing phenelzine are contraindicated.
DB00781	DB01339	Polymyxin B may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
DB00782	DB00843	Possible antagonism of action
DB00782	DB00674	Possible antagonism of action
DB00782	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00782	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Propantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00782	DB00662	Trimethobenzamide and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00782	DB00427	Triprolidine and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00782	DB00209	Trospium and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00783	DB01351	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB01352	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB00237	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB00241	The enzyme inducer, butalbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB01353	The enzyme inducer, butethal, decreases the effect of the hormone agent, estradiol.
DB00783	DB00754	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, estradiol.
DB00783	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estradiol.
DB00783	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estradiol.
DB00783	DB01354	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB01355	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB00849	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB00312	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estradiol.
DB00783	DB00860	The estrogenic agent, estradiol, may increase the effect of the corticosteroid, prednisolone.
DB00783	DB00635	The estrogenic agent, estradiol, may increase the effect of corticosteroid, prednisone.
DB00783	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, estradiol.
DB00783	DB00481	Association not recommended
DB00783	DB00418	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, estradiol.
DB00783	DB00306	The enzyme inducer, talbutal, decreases the effect of the hormone agent, estradiol.
DB00783	DB00932	Estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estradiol. Use an alternate form of contraception or monitor for estrogen deficiency if Estradiol is used for hormone replacement therapy.
DB00783	DB01586	Estrogens decreases the effect of ursodiol
DB00784	DB01418	The NSAID, mefanamic acid, may increase the anticoagulant effect of acenocoumarol.
DB00784	DB00630	Increased risk of gastric toxicity
DB00784	DB01125	The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione.
DB00784	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00784	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00784	DB00091	Monitor for nephrotoxicity
DB00784	DB00266	The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol.
DB00784	DB06210	Increases levels of Mefenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00784	DB01356	The NSAID, mefenamic acid, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00784	DB00563	The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00784	DB00675	Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed.
DB00784	DB01124	Mefanamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Mefanamic acid is initiated, discontinued or dose changed.
DB00784	DB00214	Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed.
DB00784	DB00519	The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.
DB00784	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy.
DB00784	DB00440	The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed.
DB00784	DB00582	Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if mefanamic acid is initiated, discontinued or dose changed.
DB00784	DB00682	Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed.
DB00787	DB01223	Acyclovir increases the effect and toxicity of theophylline
DB00787	DB00651	Acyclovir increases the effect and toxicity of dyphylline.
DB00787	DB01303	Aciclovir may increase the effect and toxicity of oxtriphylline.
DB00787	DB00277	Acyclovir may increase the effect and toxicity of theophylline.
DB00788	DB01418	The NSAID, naproxen, may increase the anticoagulant effect of acenocoumarol.
DB00788	DB00630	Increased risk of gastric toxicity
DB00788	DB01125	The NSAID, naproxen, may increase the anticoagulant effect of anisindione.
DB00788	DB06605	Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy.
DB00788	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00788	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00788	DB00091	Monitor for nephrotoxicity
DB00788	DB00266	The NSAID, naproxen, may increase the anticoagulant effect of dicumarol.
DB00788	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00798	DB01135	The agent increases the effect of muscle relaxant
DB00788	DB01356	The NSAID, naproxen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00788	DB00563	The NSAID, naproxen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00788	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00788	DB06204	Increases the AUC of tapentadol by 17%. These changes are not considered clinically relevant and no change in dose is required.
DB00788	DB00966	Concomitant use of Telmisartan and Naproxen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00788	DB00373	The NSAID, Naproxen, may antagonize the antihypertensive effect of Timolol.
DB00788	DB00519	The NSAID, Naproxen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Naproxen is initiated, discontinued or dose changed.
DB00788	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Naproxen. Monitor for increased bleeding during concomitant thearpy.
DB00788	DB08814	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of naproxen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB00788	DB06684	Increased risk of bleeding with concomitant use of NSAIDs with vilazodone.
DB00788	DB00682	The antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00790	DB00594	Increased risk of hyperkalemia
DB00790	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00790	DB01395	Increased risk of hyperkalemia
DB00790	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00790	DB01356	The ACE inhibitor increases serum levels of lithium
DB00790	DB01345	Increased risk of hyperkalemia
DB00790	DB00421	Increased risk of hyperkalemia
DB00790	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00790	DB00684	Increased risk of nephrotoxicity
DB00790	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00790	DB00384	Increased risk of hyperkalemia
DB00792	DB00843	Possible antagonism of action
DB00792	DB00674	Possible antagonism of action
DB00794	DB01418	The barbiturate, primidone, decreases the anticoagulant effect of acenocoumarol.
DB00794	DB01223	The barbiturate, primidone, decreases the effect of aminophylline.
DB00794	DB01125	The barbiturate, primidone, decreases the anticoagulant effect of anisindione.
DB00794	DB06216	Primidone is a CYP1A2 inducer and may increase metabolism of asenapine.
DB00794	DB06769	CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine.
DB00794	DB00443	The barbiturate, primidone, may decrease the effect of the corticosteroid, betamethasone.
DB00794	DB00269	The enzyme inducer, primidone, decreases the effect of the hormone agent, chlorotrianisene.
DB00794	DB00882	The enzyme inducer, primidone, decreases the effect of the hormone agent, clomifene.
DB00794	DB00286	The enzyme inducer, primidone, decreases the effect of the hormone agent, conjugated estrogens.
DB00794	DB01380	The barbiturate, primidone, may decrease the effect of the corticosteroid, cortisone acetate.
DB00794	DB00091	The barbiturate, primidone, increases the effect of cyclosporine.
DB00794	DB01234	The barbiturate, primidone, may decrease the effect of the corticosteroid, dexamethasone.
DB00794	DB00266	The barbiturate, primidone, decreases the anticoagulant effect, dicumarol.
DB00794	DB00255	The enzyme inducer, primidone, may decrease the effect of the hormone agent, diethylstilbestrol.
DB00794	DB00254	The anticonvulsant, primidone, decreases the effect of doxycycline.
DB00794	DB00651	The barbiturate, primidone, decreases the effect of dyphylline.
DB00794	DB00783	The enzyme inducer, primidone, decreases the effect of the hormone agent, estradiol.
DB00794	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB00794	DB04573	The enzyme inducer, primidone, decreases the effect of the hormone agent, estriol.
DB00794	DB00655	The enzyme inducer, primidone, decreases the effect of the hormone agent, estrone.
DB00794	DB04574	The enzyme inducer, primidone, decreases the effect of the hormone agent, estropipate.
DB00794	DB00977	This product may cause a slight decrease of contraceptive effect
DB00794	DB06414	Etravirine, when used concomitantly with Primidone (primarily metabolized to phenobarbital), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00794	DB00949	Felbamate may increase the effect and toxicity of primidone.
DB00794	DB01023	The barbiturate, primidone, decreases the effect of felodipine.
DB00794	DB00687	The barbiturate, primidone, may decrease the effect of the corticosteroid, fludrocortisone.
DB00794	DB00158	Folic acid decreases the effect of anticonvulsant, primidone.
DB00794	DB00317	The CYP3A4 inducer, primidone, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00794	DB00400	The barbiturate, primidone, decreases the effect of griseofulvin.
DB00794	DB00741	The barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone.
DB00794	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00794	DB00603	The enzyme inducer, primidone, may decrease the effect of the hormone, medroxyprogesterone.
DB00794	DB00351	The enzyme inducer, primidone, may decrease the effect of the hormone, megestrol.
DB00794	DB01357	This product may cause a slight decrease of contraceptive effect
DB00794	DB00333	The barbiturate, primidone, decreases the effect of methadone.
DB00794	DB01028	The barbiturate, primidone, increases the renal toxicity of methoxyflurane.
DB00794	DB00959	The barbiturate, primidone, may decrease the effect of the corticosteroid, methylprednisolone.
DB00794	DB00264	The barbiturate decreases the effect of metabolized beta-blocker
DB00794	DB00916	The barbiturate, primidone, decreases the effect of metronidazole.
DB00794	DB01115	The barbiturate, primidone, decreases the effect of the calcium channel blocker, nifedipine.
DB00794	DB00717	This product may cause a slight decrease of contraceptive effect
DB00794	DB01303	The barbiturate, primidone, decreases the effect of oxtriphylline.
DB00794	DB01384	The barbiturate, primidone, may decrease the effect of the corticosteroid, paramethasone.
DB00794	DB00860	The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisolone.
DB00794	DB00635	The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone.
DB00794	DB00571	The barbiturate decreases the effect of metabolized beta-blocker
DB00794	DB04575	The enzyme inducer, primidone, decreases the effect of the hormone agent, quinestrol.
DB00794	DB00908	The anticonvulsant, primidone, decreases the effect of quinidine.
DB00794	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB00794	DB06201	Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.
DB00794	DB00976	Primidone may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00794	DB06287	Primidone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB00794	DB00277	The barbiturate, primidone, decreases the effect of theophylline.
DB00794	DB00193	Primidone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB00794	DB00656	The CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed.
DB00794	DB00755	The strong CYP2C8 inducer, Primidone, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Primidone is initiated, discontinued or dose changed.
DB00794	DB00620	The barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone.
DB00794	DB00427	The CNS depressants, Triprolidine and Primidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00794	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB00794	DB00661	The barbiturate, primidone, decreases the effect of the calcium channel blocker, verapamil.
DB00794	DB00582	The barbiturate, primidone, decreases the effect of voriconazole.
DB00794	DB00682	The barbiturate, primidone, decreases the anticoagulant effect of warfarin.
DB00795	DB00993	Sulfasalazine may increase the toxicity of thiopurine, azathioprine.
DB00795	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00795	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00795	DB00091	The sulfonamide decreases the effect of cyclosporine
DB00795	DB00390	Sulfasalazine may decrease the effect of digoxin.
DB00795	DB01033	Sulfasalazine may increase the toxicity of thiopurine, mercaptopurine.
DB00795	DB00352	Sulfasalazine may increase the toxicity of thiopurine, thioguanine.
DB00796	DB00594	Increased risk of hyperkalemia
DB00796	DB01395	Increased risk of hyperkalemia
DB00796	DB01356	The ARB increases serum levels of lithium
DB00796	DB01345	Increased risk of hyperkalemia
DB00796	DB00421	Increased risk of hyperkalemia
DB00796	DB00684	Increased risk of nephrotoxicity
DB00796	DB00519	The angiotensin II receptor blocker, Candesartan, may increase the adverse effects of Trandolapril.
DB00796	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00796	DB00384	Increased risk of hyperkalemia
DB00797	DB00501	Anticipated loss of efficacy of tolazoline
DB00797	DB00863	Anticipated loss of efficacy of tolazoline
DB00797	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00798	DB00732	The agent increases the effect of muscle relaxant
DB00798	DB00887	Increased ototoxicity
DB00798	DB01326	Increased risk of nephrotoxicity
DB00798	DB01139	Increased risk of nephrotoxicity
DB00798	DB01327	Increased risk of nephrotoxicity
DB00798	DB01328	Increased risk of nephrotoxicity
DB00798	DB01329	Increased risk of nephrotoxicity
DB00798	DB00923	Increased risk of nephrotoxicity
DB00798	DB00493	Increased risk of nephrotoxicity
DB00798	DB01330	Increased risk of nephrotoxicity
DB00798	DB01331	Increased risk of nephrotoxicity
DB00798	DB01333	Increased risk of nephrotoxicity
DB00798	DB00438	Increased risk of nephrotoxicity
DB00798	DB01332	Increased risk of nephrotoxicity
DB00798	DB01212	Increased risk of nephrotoxicity
DB00798	DB01112	Increased risk of nephrotoxicity
DB00798	DB03450	Increased risk of nephrotoxicity
DB00798	DB00515	Increased risk of nephrotoxicity
DB00798	DB01111	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB00798	DB00903	Increased ototoxicity
DB00798	DB01336	The agent increases the effect of muscle relaxant
DB00798	DB01226	The agent increases the effect of muscle relaxant
DB00798	DB01337	The agent increases the effect of muscle relaxant
DB00798	DB01338	The agent increases the effect of muscle relaxant
DB00798	DB00728	The agent increases the effect of muscle relaxant
DB00798	DB00202	The agent increases the effect of muscle relaxant
DB00798	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Gentamicin. Use caution during concomitant therapy.
DB00798	DB01041	Thalidomide increases the renal toxicity of the aminoglycoside
DB00798	DB01607	Ticarcillin may reduce the serum concentration of Gentamicin. Ticarcillin may inactivate Gentamicin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB00798	DB00214	Increased ototoxicity
DB00798	DB01199	The agent increases the effect of muscle relaxant
DB00798	DB01339	The agent increases the effect of muscle relaxant
DB00801	DB00501	Cimetidine may increase the effect of the benzodiazepine, halazepam.
DB00801	DB00363	Increased risk of toxicity
DB00801	DB00196	Fluconazole may increase the effect of the benzodiazepine, halazepam.
DB00801	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, halazepam.
DB00801	DB01167	Itraconazole may increase the effect of the benzodiazepine, halazepam.
DB00801	DB01026	Ketoconazole may increase the effect of the benzodiazepine, halazepam.
DB00801	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, halazepam.
DB00801	DB00338	Omeprazole may increase the effect of the benzodiazepine, halazepam.
DB00802	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00802	DB00501	Increases the effect of the narcotic
DB00802	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of alfentanil.
DB00802	DB00196	Increases the effect and toxicity of alfentanil
DB00802	DB01167	Itraconazole may increase the effect and toxicity of alfentanil.
DB00802	DB01026	Ketoconazole may increase the effect and toxicity of alfentanil.
DB00802	DB01045	Rifampin reduces levels and efficacy of alfentanil
DB00802	DB00976	Telithromycin may reduce clearance of Alfentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Alfentanil if Telithromycin is initiated, discontinued or dose changed.
DB00802	DB00752	Possible increased risk of serotonin syndrome.
DB00802	DB00427	The CNS depressants, Triprolidine and Alfentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00802	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfentanil by decreasing its metabolism. Monitor for increased anesthetic and respiratory depressant effects and consider using lower alfentanil doses or alternate anesthetic.
DB00804	DB00843	Possible antagonism of action
DB00804	DB00674	Possible antagonism of action
DB00804	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00804	DB00989	Possible antagonism of action
DB00804	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dicyclomine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00804	DB00662	Trimethobenzamide and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00804	DB00427	Triprolidine and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00804	DB00209	Trospium and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00806	DB01418	Pentoxifylline may increase the anticoagulant effect of acenocoumarol.
DB00806	DB09026	Monitor therapy due to enhanced antihypertensive effects of aliskiren.
DB00806	DB01223	Pentoxifylline may increase the effect and toxicity of aminophylline.
DB00806	DB01125	Pentoxifylline may increase the anticoagulant effect of anisindione.
DB00806	DB00266	Pentoxifylline may increase the anticoagulant effect of dicumarol.
DB00806	DB00651	Pentoxifylline increases the effect and toxicity of theophylline
DB00806	DB00063	Monitor therapy due to enhanced antiplatelet effect.
DB00806	DB00046	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB00806	DB01303	Pentoxifylline increases the effect and toxicity of theophylline
DB00806	DB00277	Pentoxifylline increases the effect and toxicity of theophylline
DB00806	DB00682	Pentoxifylline may increase the anticoagulant effect of warfarin.
DB00808	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00808	DB01078	Possible electrolyte variations and arrhythmias
DB00808	DB01119	Significant hyperglycemic effect
DB00808	DB01396	Possible electrolyte variations and arrhythmias
DB00808	DB00390	Possible electrolyte variations and arrhythmias
DB00808	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00808	DB01356	The thiazide diuretic, indapamide, may increase serum levels of lithium.
DB00808	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00808	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00808	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00813	DB06210	Increases levels of Fentanyl via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB00808	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00808	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00808	DB00519	The thiazide diuretic, Indapamide, may increase the hypotensive effect of Trandolapril. Indapamide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00808	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00808	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00808	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00808	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00808	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00808	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00810	DB00843	Possible antagonism of action
DB00810	DB00674	Possible antagonism of action
DB00810	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00810	DB00989	Possible antagonism of action
DB00810	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Biperidin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00810	DB00662	Trimethobenzamide and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00810	DB00427	Triprolidine and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00810	DB00209	Trospium and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00811	DB01048	Ribavirin may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.
DB00811	DB00943	Ribavirin may increase the hepatotoxicity of zalcitabine. May cause lactic acidosis. MOnitor for lactic acidosis during concomitant therapy.
DB00811	DB00495	Increased risk or severity of anemia. Consider alternate therapy or monitor more closely for anemia.
DB00812	DB01418	The NSAID, phenylbutazone, may increase the anticoagulant effect of acenocoumarol.
DB00812	DB00414	Phenylbutazone may increase the effect of acetohexamide.
DB00812	DB01125	The NSAID, phenylbutazone, may increase the anticoagulant effect of anisindione.
DB00812	DB00672	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB00266	The NSAID, phenylbutazone, may increase the anticoagulant effect of dicumarol.
DB00812	DB00754	The NSAID, phenylbutazone, may increase the hydantoin effect of ethotoin.
DB00812	DB01320	The NSAID, phenylbutazone, may increase the hydantoin effect of fosphenytoin.
DB00812	DB01120	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB01067	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB01289	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB01016	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB01382	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB01356	The NSAID, phenylbutazone, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00812	DB00532	The NSAID, phenylbutazone, may increase the hydantoin effect of mephenytoin.
DB00812	DB00563	The NSAID, phenylbutazone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00812	DB00252	The NSAID, phenylbutazone, may increase the therapeutic and adverse effects of phenytoin.
DB00812	DB00839	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB01124	Phenylbutazone increases the effect of the hypoglycemic agent
DB00812	DB00682	The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin.
DB00813	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00813	DB01118	Possible bradycardia, hypotension
DB00813	DB00701	The protease inhibitor, amprenavir, may increase the effect and toxicity of fentanyl.
DB00813	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of fentanyl. The risk of prolonged adverse effects, including potentially fatal respiratory depression is increased. Consider therapy modification.
DB00813	DB00501	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of fentanyl. Closely monitor changes in the therapeutic and adverse effects of fentanyl if cimetidine is initiated, discontinued or dose changed.
DB00813	DB00257	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.
DB00813	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.
DB00813	DB00196	Fluconazole may increase levels/toxicity of fentanyl.
DB00813	DB01319	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fentanyl.
DB00813	DB00224	The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl.
DB00813	DB01167	Itraconazole may increase levels/toxicity of fentanyl.
DB00813	DB01026	Ketoconazole may increase levels/toxicity of fentanyl.
DB00813	DB00220	The protease inhibitor, nelfinavir, may increase the effect and toxicity of fentanyl.
DB00813	DB01045	Rifampin may decrease the serum level and therapeutic effect of fentanyl.
DB00813	DB00503	Ritonavir increases the effect and toxicity of fentanyl/alfentanyl
DB00813	DB05271	Pharmacodynamic synergism may increase the effects of rotigotine. Monitor therapy closely.
DB00813	DB01232	The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl.
DB00813	DB00976	Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed.
DB00813	DB00752	Possible increased risk of serotonin syndrome.
DB00813	DB00427	The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00813	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed.
DB00814	DB01418	Meloxicam may increase the anticoagulant effect of acenocoumarol.
DB00814	DB01125	Meloxicam may increase the anticoagulant effect of anisindione.
DB00814	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00814	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00814	DB00266	Meloxicam may increase the anticoagulant effect of dicumarol.
DB00814	DB06210	Increases levels of Meloxicam via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00814	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00814	DB01356	Meloxicam increases serum levels of lithium
DB00814	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00814	DB00966	Concomitant use of Telmisartan and Meloxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00814	DB00373	The NSAID, Meloxicam, may antagonize the antihypertensive effect of Timolol.
DB00814	DB00519	The NSAID, Meloxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meloxicam is initiated, discontinued or dose changed.
DB00814	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meloxicam. Monitor for increased bleeding during concomitant thearpy.
DB00814	DB00582	Voriconazole may increase the serum concentration of meloxicam by decreasing its metabolism via CYP2C9 and CYP3A4. Monitor for changes in the therapeutic and adverse effects of meloxicam if voriconazole is initiated, discontinued or dose changed.
DB00814	DB00682	The antiplatelet effects of meloxicam may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00816	DB01193	Antagonism
DB00816	DB00386	Increased arterial pressure
DB00816	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of orciprenaline.
DB00816	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of orciprenaline.
DB00816	DB00335	Antagonism
DB00816	DB00195	Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like orciprenaline. Therapy should be monitored.
DB00816	DB01295	Antagonism
DB00816	DB00612	Antagonism
DB00816	DB00521	Antagonism
DB00816	DB01136	Antagonism
DB00816	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of orciprenaline.
DB00816	DB01089	Increased arterial pressure
DB00816	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of orciprenaline.
DB00816	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of orciprenaline.
DB00816	DB00187	Antagonism
DB00816	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of orciprenaline.
DB00816	DB01247	Increased arterial pressure
DB00816	DB00598	Antagonism
DB00816	DB00601	Possible increase of arterial pressure
DB00816	DB00968	Increased arterial pressure
DB00816	DB00264	Antagonism
DB00816	DB00211	Increased arterial pressure
DB00816	DB01171	Moclobemide increases the sympathomimetic effect of orciprenaline.
DB00816	DB01203	Antagonism
DB00816	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of orciprenaline.
DB00816	DB01580	Antagonism
DB00816	DB01626	Increased arterial pressure
DB00816	DB01359	Antagonism
DB00816	DB00780	Increased arterial pressure
DB00816	DB00960	Antagonism
DB00816	DB01297	Antagonism
DB00816	DB00571	Antagonism
DB00816	DB00344	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of orciprenaline.
DB00816	DB01367	Increased arterial pressure
DB00816	DB00206	Increased arterial pressure
DB00816	DB00489	Antagonism
DB00816	DB00373	Antagonism
DB00816	DB00752	Increased arterial pressure
DB00816	DB00726	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of orciprenaline.
DB00818	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Propofol, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Propofol is initiated, discontinued or if the dose is changed.
DB00818	DB00697	Propofol may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB00819	DB00945	Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide.
DB00819	DB01294	The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide.
DB00819	DB01194	As both brinzolamide and acetazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB00819	DB00091	Acetazolamide may increase the effect and toxicity of cyclosporine.
DB00819	DB01043	Possible increased levels of memantine
DB00819	DB00684	Increased risk of nephrotoxicity
DB00819	DB00273	Additive renal carbonic anhydrase inhibition may occur increasing the risk of crystaluria and renal calculi. Increased risk of nephrolithiasis. Consider altnerate therapy.
DB00819	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00819	DB00427	The CNS depressants, Triprolidine and Acetazolamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00820	DB00346	Tadalafil may enhance the hypotensive effect of Alfusozin. Monitor for hypotension during concomitant therapy.
DB00820	DB00701	Amprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01072	Atazanavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB08822	Pharmacodynamic synergist- increases effects.
DB00820	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00820	DB01211	Clarithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00872	Conivaptan may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01264	Darunavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00705	Delavirdine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00590	Tadalafil may enhance the hypotensive effect of Doxazosin. Monitor for hypotension during concomitant therapy.
DB00820	DB01319	Fosamprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00619	Imatinib may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00224	Indinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00951	Isoniazid may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00883	The vasodilatory effects of Isosorbide dinitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00820	DB01020	The vasodilatory effects of Isosobide mononitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00820	DB01167	Itraconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01026	Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01601	Lopinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01110	Miconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01149	Nefazodone may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00220	Nelfinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00622	Nicardipine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00727	The vasodilatory effects of Nitroglycerin may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00820	DB06154	Possible significant hypotension with this combination
DB00820	DB00925	Tadalafil may enhance the hypotensive effect of Phenoxybenzamine. Monitor for hypotension during concomitant therapy.
DB00820	DB00692	Tadalafil may enhance the hypotensive effect of Phentolamine. Monitor for hypotension during concomitant therapy.
DB00820	DB01263	Posaconzole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00457	Tadalafil may enhance the hypotensive effect of Prazosin. Monitor for hypotension during concomitant therapy.
DB00820	DB00908	Quinidine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01045	Rifampin may reduce Tadalafil plasma concentrations and efficacy.
DB00820	DB00503	Ritonavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01232	Saquinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00706	Tadalafil may enhance the hypotensive effect of Tamsulosin. Monitor for hypotension during concomitant therapy.
DB00820	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00820	DB00976	Telithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB01162	Tadalafil may enhance the hypotensive effect of Terazosin. Monitor for hypotension during concomitant therapy.
DB00820	DB00932	Tipranavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00820	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tadalafil by decreasing its metabolism. Concomitant therapy should be avoided if possible due to high risk of tadalafil toxicity.
DB00822	DB01418	Disulfiram may increase the anticoagulant effect of acenocoumarol.
DB00822	DB01223	Disulfiram may increase the effect and toxicity of aminophylline.
DB00822	DB00701	Increased irsk of side effects (oral solution)
DB00822	DB01125	Disulfiram may increase the anticoagulant effect of anisindione.
DB00822	DB00356	Disulfiram may increase the serum level of chlorzoxazone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorzoxazone if diltiazem is initiated, discontinued or dose changed.
DB00822	DB00907	Increases the cardiac toxicity of cocaine
DB00822	DB00266	Disulfiram may increase the anticoagulant effect of dicumarol.
DB00822	DB00651	Increases the effect and toxicity of theophylline
DB00822	DB00754	Increases the effect of phenytoin
DB00822	DB01320	Disulfiram may increase the effect of fosphenytoin.
DB00822	DB00951	Increased risk of CNS adverse effects
DB00822	DB00532	Increases the effect of phenytoin
DB00822	DB00916	Possible acute psychosis and confusion
DB00822	DB01303	Disulfiram may increase the effect and toxicity of oxtriphylline.
DB00822	DB00252	Disulfiram may increase the therapeutic and adverse effects of phenytoin.
DB00822	DB00277	Disulfiram may increase the effect and toxicity of theophylline.
DB00822	DB00932	Disulfiram may cause Tipranavir (Aptivus brand) toxicity by inhibiting alcohol metabolism. Aptivus capsules contain alcohol.
DB00822	DB00347	Disulfiram, a strong CYP2E1 inhibitor, may decrease the metabolism and clearance of Trimethadione, a CYP2E1 substrate. Consider alternate therapy or monitor for changes in Trimethadione therapeutic and adverse effects if Disulfiram is initiated, discontinued or dose changed.
DB00822	DB00682	Disulfiram may increase the anticoagulant effect of warfarin.
DB00823	DB06697	Artemether may decrease the effectiveness of ethynodiol diacetate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00823	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of ethynodiol diacetate it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00823	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00823	DB00599	Thiopental may decrease the effect of Ethynodiol diacetate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00823	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Ethynodiol Diacetate. An alternate form of contraception should be used during concomitant therapy.
DB00823	DB00682	Ethynodiol diacetate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethynodiol diacetate is initiated, discontinued or dose
DB00829	DB00701	Amprenavir may increase the effect and toxicity of the benzodiazepine, diazepam.
DB00829	DB00501	Cimetidine may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01211	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, diazepam.
DB00829	DB00363	Increased risk of toxicity
DB00829	DB00390	The benzodiazepine, diazepam, may increase the effect of digoxin.
DB00829	DB00199	The macrolide, erythromycin, may increase the effect of the benzodiazepine, diazepam.
DB00829	DB00754	Ethotoin may increase the metabolism of diazepam via CYP3A4.
DB00829	DB06414	Diazepam (a CYP21C9 and CYP3A4 substrate), when administered concomitantly with etravirine, may experience an increase (via CYP21C9 inhibition) or a decrease(via CYP3A4 induction) in serum concentration. Overall clinical significance is unknown. It is recommended to monitor diazepam therapy.
DB00829	DB00196	Fluconazole may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01319	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, diazepam.
DB00829	DB01320	Fosphenytoin may increase the metabolism of diazepam via CYP3A4.
DB00829	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01167	Itraconazole may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01321	The macrolide, josamycin, may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01322	Kava may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01026	Ketoconazole may increase the effect of the benzodiazepine, diazepam.
DB00829	DB00532	Mephenytoin may increase the metabolism of diazepam via CYP3A4.
DB00829	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, diazepam.
DB00829	DB00338	Omeprazole may increase the effect of the benzodiazepine, diazepam.
DB00829	DB00252	Phenytoin may increase the metabolism of diazepam via CYP3A4.
DB00829	DB01369	This combination presents an increased risk of toxicity
DB00829	DB01045	Rifampin may decrease the effect of the benzodiazepine, diazepam.
DB00829	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, diazepam.
DB00829	DB01323	St. John's Wort may decrease the effect of the benzodiazepine, diazepam.
DB00829	DB00976	Telithromycin may reduce clearance of Diazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diazepam if Telithromycin is initiated, discontinued or dose changed.
DB00829	DB00208	Ticlopidine may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for adverse/toxic effects of Diazepam if Ticlopidine is initiated, discontinued or dose changed.
DB00829	DB00932	Tipranavir may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for Diazepam toxic effects if Tipranavir is initiated or dose increased.
DB00829	DB00427	The CNS depressants, Triprolidine and Diazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00829	DB00582	Voriconazole may increase the serum concentration of diazepam by decreasing its metabolism. Monitor for diazepam toxicity if voriconazole is initiated or dose increased.
DB00830	DB00477	Decreased anorexic effect, may increase psychotic symptoms
DB00830	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB00830	DB01170	Phenmetrazine may decrease the effect of guanethidine.
DB00830	DB01247	Possible hypertensive crisis
DB00830	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB00830	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB00830	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB00830	DB00433	Decreased anorexic effect, may increase pyschotic symptoms
DB00830	DB01069	Decreased anorexic effect, may increase pyschotic symptoms
DB00830	DB01608	Decreased anorexic effect, may increase pyschotic symptoms
DB00830	DB01367	Possible hypertensive crisis
DB00830	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB00830	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00182	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00831	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00831	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00831	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB01576	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00843	Possible antagonism of action
DB00831	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00674	Possible antagonism of action
DB00831	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00831	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00831	DB01170	Trifluoperazine may decrease the effect of guanethidine.
DB00831	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00831	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB01577	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB01578	Increased risk of convulsions
DB00831	DB01579	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00830	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00831	DB00989	Possible antagonism of action
DB00831	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00831	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Trifluoperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00831	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00831	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00831	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed.
DB00831	DB00662	Trimethobenzamide and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00831	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Trifluoperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00831	DB00209	Trospium and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00833	DB01032	Probenecid may increase the serum level of cefaclor.
DB00834	DB06719	Buserelin moderately contributes to Q-Tc prolongation. Combination must be avoided because mifepristone can further enhance that effect.
DB00834	DB06695	May lead to excessive post-abortion bleeding in patients on anticoagulant therapy. Concomitant therapy is contraindicated.
DB00834	DB06699	Enhance QTc-prolonging effect
DB00834	DB06414	Mifepristone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB00834	DB00107	Consider therapy modification because of potential enhanced effect of Q-Tc prolongation
DB00834	DB06663	Avoid combination with mifepristone and other moderate to high risk QTc prolonging agents. The combinaton may enhance the QTc-prolonging effect of these drugs.
DB00834	DB08895	Mifepristone, when used in combination with tofacitinib, may increase tofacitinib concentrations. It is recommended to adjust therapy by using a minimized dose of tofacitinib, and monitoring for increased tofacitinib concentrations and signs of toxicity, during and 2 weeks after discontinuation of mifepristone therapy.
DB00835	DB00843	Possible antagonism of action
DB00835	DB00674	Possible antagonism of action
DB00835	DB00989	Possible antagonism of action
DB00835	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Brompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00835	DB00662	Trimethobenzamide and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00835	DB00427	Triprolidine and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00835	DB00209	Trospium and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00838	DB00041	Corticosteroids such as clocortolone may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
DB00838	DB05521	Corticosteroids such as clocortolone may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of Corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects.
DB00839	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB00839	DB00945	Acetylsalicylic acid increases the effect of the sulfonylurea, tolazamide.
DB00839	DB01143	Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Tolazamide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB00839	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00839	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00839	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB00839	DB00446	Chloramphenicol may increase the effect of sulfonylurea, tolazamide.
DB00839	DB00636	Clofibrate may increase the effect of sulfonylurea, tolazamide.
DB00839	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00839	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00839	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00839	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB00839	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB00839	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB00839	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00839	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00839	DB01045	Rifampin may decrease the effect of sulfonylurea, tolazamide.
DB00839	DB00073	Additive hypotensive effects may occur. Consider withholding Tolazamide for 12 hours prior to administration of Rituximab.
DB00839	DB00052	Somatropin may antagonize the hypoglycemic effect of Tolazamide. Dose adjustments of Tolazamide may be required.
DB00839	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00841	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dobutamine.
DB00841	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dobutamine.
DB00841	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dobutamine.
DB00841	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dobutamine.
DB00841	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dobutamine.
DB00841	DB00494	Entacapone increases the effect and toxicity of the sympathomimetic, dobutamine.
DB00841	DB01170	Dobutamine may decrease the effect of guanethidine.
DB00841	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dobutamine.
DB00841	DB01247	Increased arterial pressure
DB00841	DB00601	Possible increase of arterial pressure
DB00841	DB00968	Increased arterial pressure
DB00841	DB00211	Increased arterial pressure
DB00841	DB01171	Moclobemide increases the sympathomimetic effect of dobutamine.
DB00841	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dobutamine.
DB00841	DB00780	Increased arterial pressure
DB00841	DB01367	Increased arterial pressure
DB00841	DB00206	Increased arterial pressure
DB00842	DB00363	Increased risk of toxicity
DB00842	DB01322	Kava may increase the effect of the benzodiazepine, oxazepam.
DB00842	DB00427	The CNS depressants, Triprolidine and Oxazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00843	DB01614	Possible antagonism of action
DB00843	DB01615	Possible antagonism of action
DB00843	DB01246	Possible antagonism of action
DB00843	DB01616	Possible antagonism of action
DB00843	DB00915	Possible antagonism of action
DB00843	DB00321	Possible antagonism of action
DB00843	DB00543	Possible antagonism of action
DB00843	DB00572	Possible antagonism of action
DB00843	DB00719	Possible antagonism of action
DB00843	DB00245	Possible antagonism of action
DB00843	DB00810	Possible antagonism of action
DB00843	DB00835	Possible antagonism of action
DB00843	DB00748	Possible antagonism of action
DB00843	DB01114	Possible antagonism of action
DB00843	DB00477	Possible antagonism of action
DB00843	DB01239	Possible antagonism of action
DB00843	DB00501	Possible antagonism of action
DB00843	DB00283	Possible antagonism of action
DB00843	DB00771	Possible antagonism of action
DB00843	DB01242	Possible antagonism of action
DB00843	DB00363	Possible antagonism of action
DB00843	DB01176	Possible antagonism of action
DB00843	DB00924	Possible antagonism of action
DB00843	DB00434	Possible antagonism of action
DB00843	DB00496	Possible antagonism of action
DB00843	DB01151	Possible antagonism of action
DB00843	DB00405	Possible antagonism of action
DB00843	DB00804	Possible antagonism of action
DB00843	DB00985	Possible antagonism of action
DB00843	DB01075	Possible antagonism of action
DB00843	DB01081	Possible antagonism of action
DB00843	DB01146	Possible antagonism of action
DB00843	DB00280	Possible antagonism of action
DB00843	DB01142	Possible antagonism of action
DB00843	DB00366	Possible antagonism of action
DB00843	DB00392	Possible antagonism of action
DB00843	DB01148	Possible antagonism of action
DB00843	DB00875	Possible antagonism of action
DB00843	DB01437	Possible antagonism of action
DB00843	DB00986	Possible antagonism of action
DB00843	DB00557	Possible antagonism of action
DB00843	DB00424	Possible antagonism of action
DB00843	DB00458	Possible antagonism of action
DB00843	DB01247	Possible antagonism of action
DB00843	DB01625	Possible antagonism of action
DB00843	DB00408	Possible antagonism of action
DB00843	DB00934	Possible antagonism of action
DB00843	DB00737	Possible antagonism of action
DB00843	DB00933	Possible antagonism of action
DB00843	DB00902	Possible antagonism of action
DB00843	DB01403	Possible antagonism of action
DB00843	DB00462	Possible antagonism of action
DB00843	DB00370	Possible antagonism of action
DB00843	DB01171	Possible antagonism of action
DB00843	DB01618	Possible antagonism of action
DB00843	DB00540	Possible antagonism of action
DB00843	DB00334	Possible antagonism of action
DB00843	DB01173	Possible antagonism of action
DB00843	DB01062	Possible antagonism of action
DB00843	DB00850	Possible antagonism of action
DB00843	DB00454	Possible antagonism of action
DB00843	DB00780	Possible antagonism of action
DB00843	DB01619	Possible antagonism of action
DB00843	DB01100	Possible antagonism of action
DB00843	DB01621	Possible antagonism of action
DB00843	DB01035	Possible antagonism of action
DB00843	DB00433	Possible antagonism of action
DB00843	DB00387	Possible antagonism of action
DB00843	DB00420	Possible antagonism of action
DB00843	DB01069	Possible antagonism of action
DB00843	DB00782	Possible antagonism of action
DB00843	DB01608	Possible antagonism of action
DB00843	DB00344	Possible antagonism of action
DB00843	DB01224	Possible antagonism of action
DB00843	DB00908	Possible antagonism of action
DB00843	DB01346	Possible antagonism of action
DB00843	DB00734	Possible antagonism of action
DB00843	DB00747	Possible antagonism of action
DB00843	DB01104	Possible antagonism of action
DB00843	DB01591	Possible antagonism of action
DB00843	DB01622	Possible antagonism of action
DB00843	DB00679	Possible antagonism of action
DB00843	DB01623	Possible antagonism of action
DB00843	DB00697	Possible antagonism of action
DB00843	DB01036	Possible antagonism of action
DB00843	DB00752	Possible antagonism of action
DB00843	DB00656	Possible antagonism of action
DB00843	DB00831	Possible antagonism of action
DB00843	DB00508	Possible antagonism of action
DB00843	DB00376	Possible antagonism of action
DB00843	DB00662	The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00843	DB00726	Possible antagonism of action
DB00843	DB00792	Possible antagonism of action
DB00843	DB00427	Possible antagonism of action
DB00843	DB00209	The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00843	DB00246	Possible antagonism of action
DB00843	DB01624	Possible antagonism of action
DB00844	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00844	DB00501	Increases the effect of the narcotic
DB00844	DB00427	The CNS depressants, Triprolidine and Nalbuphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00848	DB01418	Levamisole may increase the anticoagulant effect of acenocoumarol.
DB00848	DB01125	Levamisole may increase the anticoagulant effect of anisindione.
DB00848	DB00266	Levamisole may increase the anticoagulant effect of dicumarol.
DB00848	DB00682	Levamisole may increase the anticoagulant effect of warfarin.
DB00849	DB01223	The barbiturate, methylphenobarbital, decreases the effect of aminophylline.
DB00849	DB00443	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB00849	DB00882	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, clomifene.
DB00849	DB00286	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB00849	DB00091	The barbiturate, methylphenobarbital, increases the effect of cyclosporine.
DB00849	DB00705	The anticonvulsant, methylphenobarbital, decreases the effect of delavirdine.
DB00849	DB01234	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB00849	DB00255	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB00849	DB00254	The anticonvulsant, methylphenobarbital, decreases the effect of doxycycline.
DB00849	DB00783	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, estradiol.
DB00849	DB00977	This product may cause a slight decrease of contraceptive effect
DB00849	DB01023	The barbiturate, methylphenobarbital, decreases the effect of felodipine.
DB00849	DB00687	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB00849	DB00158	Folic acid decreases the effect of anticonvulsant, methylphenobarbital.
DB00849	DB00317	The CYP3A4 inducer, methylphenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB00849	DB00400	The barbiturate, methylphenobarbital, decreases the effect of griseofulvin.
DB00849	DB00741	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB00849	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB00849	DB00603	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB00849	DB00351	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, megestrol.
DB00849	DB00333	The barbiturate, methylphenobarbital, decreases the effect of methadone.
DB00849	DB00916	The barbiturate, methylphenobarbital, decreases the effect of metronidazole.
DB00849	DB01115	The barbiturate, methylphenobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB00849	DB00717	This product may cause a slight decrease of contraceptive effect
DB00849	DB01303	The barbiturate, methylphenobarbital, decreases the effect of oxtriphylline.
DB00849	DB00860	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00849	DB00635	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisone.
DB00849	DB00908	The anticonvulsant, methylphenobarbital, decreases the effect of quinidine.
DB00849	DB00277	The barbiturate, methylphenobarbital, decreases the effect of theophylline.
DB00849	DB00620	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB00849	DB00661	Methylphenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methylphenobarbital is initiated, discontinued or dose changed.
DB00850	DB00182	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00850	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00850	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00850	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00850	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB01576	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00843	Possible antagonism of action
DB00850	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00674	Possible antagonism of action
DB00850	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00850	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00850	DB01170	Perphenazine may decrease the effect of guanethidine.
DB00850	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00850	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB01577	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB01578	Increased risk of convulsions
DB00850	DB01579	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00830	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00850	DB00989	Possible antagonism of action
DB00850	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00850	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Perphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00850	DB00857	Terbinafine may reduce the metabolism and clearance of Perphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Perphenazine if Terbinafine is initiated, discontinued or dose changed.
DB00850	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00850	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00850	DB00662	Trimethobenzamide and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00850	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Perphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00850	DB00209	Trospium and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00851	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00851	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed.
DB00851	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00852	DB00386	Increased arterial pressure
DB00852	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB01200	The sympathomimetic, pseudoephedrine, increases the toxicity of bromocriptine.
DB00852	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB01089	Increased arterial pressure
DB00852	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB06700	Desvenlafaxine may increase the tachycardic and vasopressor effects of pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00852	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB01170	Pseudoephedrine may decrease the effect of guanethidine.
DB00852	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB06704	Sympathomimetic that increase chances of producing a false negative imaging result
DB00852	DB01247	Increased arterial pressure
DB00852	DB00601	Possible increase of arterial pressure
DB00852	DB00968	Increased arterial pressure
DB00852	DB00211	Increased arterial pressure
DB00852	DB01171	Moclobemide increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB01626	Increased arterial pressure
DB00852	DB00780	Increased arterial pressure
DB00852	DB00344	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB01367	Increased arterial pressure
DB00852	DB00206	Increased arterial pressure
DB00852	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Pseudoephedrine. Concomitant therapy should be avoided.
DB00852	DB00726	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of pseudoephedrine.
DB00852	DB00285	Venlafaxine may increase the tachycardic and vasopressor effects of Pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB00853	DB00108	The immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB00853	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00854	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00854	DB06210	Increases levels of Levorphanol via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00854	DB00427	The CNS depressants, Triprolidine and Levorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00856	DB00427	The CNS depressants, Triprolidine and Chlorphenesin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00857	DB01223	Terbinafine increases the effect and toxicity of theophylline
DB00857	DB00321	Terbinafine may reduce the metabolism and clearance of Amitryptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00543	Terbinafine may reduce the metabolism and clearance of Amoxapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Amoxapine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01238	Terbinafine may reduce the metabolism and clearance of Aripiprazole. Consider alternate therapy or monitor for therapeutic/adverse effects of Aripiprazole if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00289	Terbinafine, a CYP2D6 inhibitor, may reduce the metabolism and clearance of Atomoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Atomoxetine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00201	Terbinafine may increase the plasma concentration of Caffeine.
DB00857	DB01197	Terbinafine may reduce the metabolism and clearance of Captopril. Consider alternate therapy or monitor for therapeutic/adverse effects of Captopril if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01136	Terbinafine may reduce the metabolism and clearance of Carvedilol. Consider alternate therapy or monitor for therapeutic/adverse effects of Carvedilol if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00608	Terbinafine may reduce the metabolism and clearance of Chloroquine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chloroquine if Terbinafine is initiated, discontinued or dose changed.
DB00893	DB00968	Iron decreases the absorption of dopa derivatives
DB00857	DB00477	Terbinafine may reduce the metabolism and clearance of Chlorpromazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chlorpromazine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01242	Terbinafine may reduce the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for therapeutic/adverse effects of Clomipramine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00318	Terbinafine may decrease the efficacy of Codeine by inhibiting active metabolite production. Consider an alternate analgesic or monitor for effectiveness of Codeine.
DB00857	DB00091	Terbinafine may decrease the plasma concentration and therapeutic effect of cyclosporine.
DB00857	DB01151	Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of desipramine if terbinafine is initiated, discontinued or dose changed.
DB00857	DB00514	Terbinafine may reduce the metabolism and clearance of Dextromethorphan. Consider alternate therapy or monitor for therapeutic/adverse effects of Dextromethorphan if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01142	Terbinafine may reduce the metabolism and clearance of Doxepin. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Doxepin is initiated, discontinued or dose changed.
DB00857	DB00997	Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB05331	Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00476	Terbinafine may reduce the metabolism and clearance of Duloxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Duloxetine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00651	Terbinafine increases the effect and toxicity of theophylline
DB00857	DB01195	Terbinafine may reduce the metabolism and clearance of Flecainide. Consider alternate therapy or monitor for therapeutic/adverse effects of Flecainide if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00472	Terbinafine may reduce the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluoxetine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00623	Terbinafine may reduce the metabolism and clearance of Fluphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluphenazine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00176	Terbinafine may reduce the metabolism and clearance of Fluvoxamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluvoxamine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00502	Terbinafine may reduce the metabolism and clearance of Haloperidol. Consider alternate therapy or monitor for therapeutic/adverse effects of Haloperidol if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00458	Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if terbinafine is initiated, discontinued or dose changed.
DB00857	DB00281	Terbinafine may reduce the metabolism and clearance of Lidocaine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lidocaine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01206	Terbinafine may reduce the metabolism and clearance of Lomustine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lomustine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00934	Terbinafine may reduce the metabolism and clearance of Maprotiline. Consider alternate therapy or monitor for therapeutic/adverse effects of Maprotiline if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01577	Terbinafine may reduce the metabolism and clearance of Methamphetamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Methamphetamine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00264	Terbinafine may reduce the metabolism and clearance of Metoprolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Metoprolol if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00379	Terbinafine may reduce the metabolism and clearance of Mexiletine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mexiletine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00370	Terbinafine may reduce the metabolism and clearance of Mirtazapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mirtazapine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01171	Terbinafine may reduce the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for therapeutic/adverse effects of Moclobemide if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01149	Terbinafine may reduce the metabolism and clearance of Nefazodone. Consider alternate therapy or monitor for therapeutic/adverse effects of Nefazodone if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00540	Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if terbinafine is initiated, discontinued or dose changed.
DB00857	DB01303	Terbinafine increases the effect and toxicity of theophylline
DB00857	DB00715	Terbinafine may reduce the metabolism and clearance of Paroxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Paroxetine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00850	Terbinafine may reduce the metabolism and clearance of Perphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Perphenazine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01621	Terbinafine may reduce the metabolism and clearance of Pipotiazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Pipotiazine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01035	Terbinafine may reduce the metabolism and clearance of Procainamide. Consider alternate therapy or monitor for therapeutic/adverse effects of Procainamide if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01069	Terbinafine may reduce the metabolism and clearance of Promethazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Promethazine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01182	Terbinafine may reduce the metabolism and clearance of Propafenone. Consider alternate therapy or monitor for therapeutic/adverse effects of Propafenone if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00571	Terbinafine may reduce the metabolism and clearance of Propranolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Propranolol if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00344	Terbinafine may reduce the metabolism and clearance of Protriptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Protriptyline if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00615	Rifabutin may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided.
DB00857	DB01045	Rifampin may increase the metabolism and clearance of Terbinafine. Co-administration may result in Terbinafine treatment failure.
DB00857	DB01201	Rifapentine may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided.
DB00857	DB00734	Terbinafine may reduce the metabolism and clearance of Risperidone. Consider alternate therapy or monitor for therapeutic/adverse effects of Risperidone if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB01104	Terbinafine may reduce the metabolism and clearance of Sertraline. Consider alternate therapy or monitor for therapeutic/adverse effects of Sertraline if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00675	Terbinafine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00857	DB00706	Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Terbinafine is initiated, discontinued, or dose changed.
DB00857	DB04844	Terbinafine may reduce the metabolism and clearance of Tetrabenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tetrabenazine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00277	Terbinafine increases the effect and toxicity of theophylline
DB00857	DB00679	Terbinafine may increase serum concentrations of Thioridazine. Concomitant therapy is contraindicated.
DB00857	DB00373	Terbinafine may reduce the metabolism and clearance of Timolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Timolol is initiated, discontinued or dose changed.
DB00857	DB01036	Terbinafine may reduce the metabolism and clearance of Tolterodine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tolterodine if Terbinafine is initiated, discontinued or dose changed.
DB00857	DB00193	Terbinafine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00857	DB00726	Terbinafine may decrease the metabolism and clearance of Trimipramine. Consider alternate therapy or monitor for changes in Trimipramine efficacy and toxicity if Terbinafine is initiated, discontinued or dose changed. Alteration in Trimipramine dose may be required.
DB00857	DB00285	Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Terbinafine is initiated, discontinued, or dose changed.
DB00857	DB01624	Terbinafine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if terbinafine is initiated, discontinued or dose changed.
DB00859	DB00390	Penicillamine decreases the effect of digoxin
DB00859	DB00893	The multivalent agent decreases the effect of penicillamine
DB00860	DB01418	The corticosteroid, prednisolone, alters the anticoagulant effect, acenocoumarol.
DB00860	DB00945	The corticosteroid, prednisolone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00860	DB01122	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, ambenonium.
DB00860	DB01351	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01125	The corticosteroid, prednisolone, alters the anticoagulant effect of anisindione.
DB00860	DB01352	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01294	The corticosteroid, prednisolone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB00860	DB00237	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00241	The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01353	The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00269	The estrogenic agent, chlorotrianisene, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB00882	The estrogenic agent, clomifene, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB00286	The estrogenic agent may increase the effect of the corticosteroid, prednisolone.
DB00860	DB00266	The corticosteroid, prednisolone, alters the anticoagulant effect of dicumarol.
DB00860	DB00255	The estrogenic agent, diethylstilbestrol, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB01341	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01010	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, edrophonium.
DB00860	DB00783	The estrogenic agent, estradiol, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB04573	The estrogenic agent, estriol, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB00655	The estrogenic agent, estrone, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB04574	The estrogenic agent, estropipate, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB00977	The estrogenic agent, ethinyl estradiol, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB00754	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01354	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01355	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01167	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
DB00860	DB01026	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
DB00860	DB01397	The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate.
DB00860	DB00532	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01357	The estrogenic agent, mestranol, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB00474	The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00849	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00211	Increased arterial pressure
DB00860	DB01400	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, neostigmine.
DB00860	DB00312	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00545	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00860	DB04575	The estrogenic agent, quinestrol, may increase the effect of the corticosteroid, prednisolone.
DB00860	DB01346	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB01398	The corticosteroid, prednisolone, may decrease the effect of the salicylate, salicylate-sodium.
DB00860	DB01399	The corticosteroid, prednisolone, may decrease the effect of the salicylate, salsalate.
DB00860	DB00418	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00382	Tacrine and Prednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00860	DB00306	The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisolone.
DB00860	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00860	DB01401	The corticosteroid, prednisolone, may decrease the effect of the salicylate, trisalicylate-choline.
DB00860	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB00860	DB00682	The corticosteroid, prednisolone, alters the anticoagulant effect of warfarin.
DB00861	DB01418	The NSAID, diflunisal, may increase the anticoagulant effect of acenocoumarol.
DB00861	DB00630	Increased risk of gastric toxicity
DB00861	DB01125	The NSAID, diflunisal, may increase the anticoagulant effect of anisindione.
DB00861	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00861	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00861	DB00266	The NSAID, diflunisal, may increase the anticoagulant effect of dicumarol.
DB00861	DB06210	Eltrombopag increases levels of Diflunisal via metabolism decrease.
DB00861	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00861	DB00328	Concomitant therapy with the two NSAIDs, indomethacin and diflunisal, increases the risk of NSAID-related adverse effects (e.g. GI ulcers, bleeds, increased blood pressure).
DB00861	DB01356	The NSAID, diflunisal, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB00861	DB00563	The NSAID, diflunisal, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00861	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00861	DB01032	Probenecid increases toxicity of diflunisal
DB00861	DB00966	Concomitant use of Telmisartan and Diflunisal may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00861	DB00373	The NSAID, Diflunisal, may antagonize the antihypertensive effect of Timolol.
DB00861	DB00519	The NSAID, Diflunisal, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diflunisal is initiated, discontinued or dose changed.
DB00861	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diflunisal. Monitor for increased bleeding during concomitant thearpy.
DB00861	DB00682	The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00862	DB00346	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Alfuzosin, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00862	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB01211	Clarithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB01264	Darunavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00590	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Doxazosin, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB00199	Erythromycin, a moderate CYP3A4 inhibitor, may reduce the metabolism and clearance of vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of vardenafil if erythromycin is initiated, discontinued or dose changed.
DB00862	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00619	Imatinib, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00224	Indinavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB00862	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00883	The vasodilatory effects of Isosorbide dinitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00862	DB01020	The vasodilatory effects of Isosorbide mononitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00862	DB01167	Itraconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB00862	DB01026	Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB00862	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB01110	Miconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00727	The vasodilatory effects of Nitroglycerin may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00862	DB06154	Possible significant hypotension with this combination
DB00862	DB00925	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phenoxybenzamine, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB00692	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phentolamine, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00457	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Prazosin, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB01035	Increased risk of cardiotoxicity and arrhythmias
DB00862	DB00908	Quinidine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB00503	Ritonavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB00862	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB06207	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Silodosin, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB00706	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Tamsulosin, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB00976	Telithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00862	DB01162	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Terazosin, may occur. Monitor for hypotension during concomitant therapy.
DB00862	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Vardenafil. Concomitant therapy is contraindicated.
DB00864	DB00679	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00862	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of vardenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of vardenafil if voriconazole is initiated, discontinued or dose changed.
DB00863	DB01418	Ranitidine may increase the anticoagulant effect of acenocoumarol. (Conflicting evidence)
DB00863	DB01125	Ranitidine may increase the anticoagulant effect of anisindione. (Conflicting evidence)
DB00863	DB01072	Ranitidine may decrease the levels/effects of atazanavir.
DB00863	DB01066	H2-Antagonists such as ranitidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB00863	DB08912	H2-receptor antagonists may alter the solubility of dabrafenib and reduce its bioavailability.
DB00863	DB01254	Ranitidine may decrease the serum level of dasatinib.
DB00863	DB00266	Ranitidine may increase the anticoagulant effect of dicumarol. (Conflicting evidence)
DB00863	DB01167	The H2-receptor antagonist, ranitidine, may decrease the absorption of itraconazole.
DB00863	DB01026	The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole.
DB00863	DB01035	The histamine H2-receptor antagonist, ranitidine, may increase the effect of procainamide.
DB00863	DB08864	Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB00863	DB00797	Anticipated loss of efficacy of tolazoline
DB00863	DB08828	Vismodegib serum concentrations may be decreased by histamine 2 receptor antagonists such as ranitidine.
DB00863	DB00682	Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence)
DB00864	DB00106	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01281	Avoid combination due to enhanced toxic effects of immunosuppressants.
DB00864	DB05773	Avoid combination due to the increase in immunosuppressant side effects.
DB00864	DB00479	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Amikacin. Use caution during concomitant therapy.
DB00864	DB01118	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00321	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00543	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00681	Additive renal impairment may occur during concomitant therapy with Amphotericin B. Use caution during concomitant therapy.
DB00864	DB00701	The protease inhibitor, Amprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Amprenavir therapy is initiated, discontinued or altered.
DB00864	DB00098	Avoid combination due to increased immunosuppressive effects
DB00864	DB00714	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB04626	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Apramycin. Use caution during concomitant therapy.
DB00864	DB01169	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00864	DB01072	The protease inhibitor, Atazanavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Atazanavir therapy is initiated, discontinued or altered.
DB00864	DB06681	Avoid combination due to enhanced immunosuppressive effect.
DB00864	DB08879	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB00864	DB00290	Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00864	DB08873	Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
DB00864	DB08870	Avoid combination due to the potential enhancement of toxic effects of immunosuppressants.
DB00864	DB01200	Bromocriptine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Bromocriptine therapy is initiated, discontinued or altered.
DB00864	DB00564	Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.
DB00864	DB00958	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00864	DB00262	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00864	DB00520	Caspofungin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Caspofungin therapy is initiated, discontinued or altered.
DB00864	DB00291	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants sucb as chlorambucil. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00864	DB00446	Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered.
DB00864	DB00477	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00501	Cimetidine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Cimetidine therapy is initiated, discontinued or altered.
DB00893	DB01017	Formation of non-absorbable complexes
DB00864	DB00604	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Cisapride may also increase the concentration of Tacrolimus in the blood.
DB00864	DB00515	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Cisplatin. Use caution during concomitant therapy.
DB00864	DB00242	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as tacrolimus. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00864	DB01211	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, Clarithromycin, may also increase the blood concentration of Tacrolimus.
DB00864	DB00631	Tacrolimus (topical) may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00864	DB01242	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00257	The antifungal, Clotrimazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Clotrimazole therapy is initiated, discontinued or altered.
DB00864	DB00872	The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Conivaptan is initiated, discontinued or dose changed.
DB00864	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB00864	DB00091	Additive renal impairment may occur during concomitant therapy with cyclosporine. Combination therapy should be avoided.
DB00864	DB01406	Danazol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Danazol therapy is initiated, discontinued or altered.
DB00864	DB01264	The protease inhibitor, Darunavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Darunavir therapy is initiated, discontinued or altered.
DB00864	DB01254	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00705	The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Delavirdine is initiated, discontinued or dose changed.
DB00864	DB01151	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00343	Diltiazem may increase the serum concentration of tacrolimus by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tacrolimus if diltiazem therapy is initiated, discontinued or dose changed.
DB00864	DB00280	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00204	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00757	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01184	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01142	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB04855	Tacrolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of tacrolimus. Monitor plasma concentrations and adjust dose accordingly.
DB00864	DB00450	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00199	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, erythromycin, may also increase the blood concentration of tacrolimus.
DB00864	DB00005	Avoid combination due to enhanced immunosuppressive effects
DB00864	DB00977	Ethinyl estradiol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ethinyl estradiol therapy is initiated, discontinued or altered.
DB00864	DB01023	Felodipine increases tacrolimus levels
DB00864	DB01195	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00196	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The antifungal, fluconazole, may also increase serum concentrations of tacrolimus.
DB00864	DB00472	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00875	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01319	The protease inhibitor, Fosamprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Fosamprenavir therapy is initiated, discontinued or altered.
DB00864	DB00529	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01320	The hydantoin decreases the effect of tacrolimus
DB00864	DB01044	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00056	Avoid combination of adverse effects of immunosuppressants.
DB00864	DB00798	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Gentamicin. Use caution during concomitant therapy.
DB00864	DB05259	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB00864	DB06674	Avoid combination due to the enhancement of side effects from immunosuppressants.
DB00893	DB00218	Formation of non-absorbable complexes
DB00864	DB01218	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00502	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB04865	Avoid combination as there is potential to increase immunosuppressant adverse effects.
DB00864	DB00078	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB00864	DB00308	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00619	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Imatinib is initiated, discontinued or dose changed.
DB00864	DB00458	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00808	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00224	The protease inhibitor, Indinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Indinavir therapy is initiated, discontinued or altered.
DB00864	DB00065	Avoid combination because of risk of enhance adverse effects of immunosuppressants
DB00864	DB00951	The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Isoniazid is initiated, discontinued or dose changed.
DB00864	DB00270	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01167	The antifungal, Itraconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Itraconazole therapy is initiated, discontinued or altered.
DB00864	DB01026	The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered.
DB00864	DB01259	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01137	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01601	The protease inhibitor, Lopinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Lopinavir therapy is initiated, discontinued or altered.
DB00864	DB00408	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00864	DB00934	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00358	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00933	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00333	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00959	Methylprednisone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Methylprednisone therapy is initiated, discontinued or altered.
DB00864	DB01233	Metoclopramide may increase the concentration of Tacrolimus in the blood. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Metoclopramide therapy is initiated, discontinued or altered.
DB00864	DB00916	Metronidazole increases the levels/toxicity of tacrolimus
DB00864	DB01388	The calcium channel blocker, Mibefradil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Mibefradil therapy is initiated, discontinued or altered.
DB00864	DB01110	The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Miconazole is initiated, discontinued or dose changed.
DB00864	DB00218	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00688	Tacrolimus may increase the plasma concentration of Mycophenolic acid. Monitor and adjust the dose of Mycophenolate mofetil to the therapeutic range.
DB00864	DB00108	Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.
DB00864	DB01149	Nefazodone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nefazodone therapy is initiated, discontinued or altered.
DB00864	DB00220	The protease inhibitor, Nelfinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nelfinavir therapy is initiated, discontinued or altered.
DB00864	DB00994	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Neomycin. Use caution during concomitant therapy.
DB00864	DB00955	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Netilmicin. Use caution during concomitant therapy.
DB00864	DB00622	The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered.
DB00864	DB01115	The calcium channel blocker, Nifedipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nifedipine therapy is initiated, discontinued or altered.
DB00864	DB04868	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB00893	DB01165	Formation of non-absorbable complexes
DB00864	DB01059	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00540	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB08935	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB00864	DB00104	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00043	Avoid combination due to enhanced adverse toxic effects.
DB00864	DB00338	Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered.
DB00864	DB01229	Avoid combination of topical tacrolimus due to the potential enhancement of adverse effects of immunosuppressants.
DB00864	DB00059	Tacrolimus enhances adverse effects of pegaspargase therefore the combination should be avoided.
DB00864	DB00738	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00556	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01174	Phenobarbital may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenobarbital therapy is initiated, discontinued or altered.
DB00864	DB00252	Phenytoin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenytoin therapy is initiated, discontinued or altered.
DB00864	DB01100	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01263	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Posaconazole is initiated, discontinued or dose changed.
DB00864	DB01599	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01035	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01182	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00344	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01224	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00908	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Quinidine, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance.
DB00864	DB01369	This combination presents an increased risk of toxicity
DB00864	DB00243	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00615	Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.
DB00864	DB01045	Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered.
DB00864	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00864	DB00734	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00503	The protease inhibitor, Ritonavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ritonavir therapy is initiated, discontinued or altered.
DB00864	DB01232	The protease inhibitor, Saquinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Saquinavir therapy is initiated, discontinued or altered.
DB00864	DB06207	The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of Silodosin. Increased Silodosin exposure may result in Silodosin toxicity. Concurrent use if not recommended.
DB00864	DB00877	Sirolimus may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Sirolimus therapy is initiated, discontinued or altered.
DB00864	DB00489	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01208	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01323	St. John's Wort may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if St. John's Wort therapy is initiated, discontinued or altered.
DB00864	DB01082	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Streptomycin. Use caution during concomitant therapy.
DB00864	DB01268	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy.
DB00864	DB00976	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Telithromycin, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance.
DB00864	DB06287	Temsirolimus may decrease the blood concentration of Tacrolimus. Concomitant therapy may increase the adverse/toxic effects of both agents. Concomitant therapy should be avoided.
DB00864	DB08880	Avoid combination due to the increased toxic effects of immunosuppressants.
DB00864	DB04844	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB00864	DB01623	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB00932	Tipranavir may decrease the metabolism and clearance of Tacrolimus. Dose adjustments may be required. Monitor for Tacrolimus efficacy and toxicity during concomitant therapy.
DB00864	DB00684	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Tobramycin. Use caution during concomitant therapy.
DB00864	DB08895	Avoid combination due to the potential increase in immunosuppressant associated adverse effects.
DB00864	DB01030	The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00864	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00864	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00864	DB00726	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00864	DB01361	The macrolide antibiotic, Troleandomycin, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Troleandomycin therapy is initiated, discontinued or altered.
DB00864	DB00661	The calcium channel blocker, Verapamil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Verapamil therapy is initiated, discontinued or altered.
DB00864	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tacrolimus by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of tacrolimus if voriconazole is initiated, discontinued or dose changed.
DB00864	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00864	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00864	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00865	DB00477	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB00472	Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.
DB00865	DB00623	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB00176	Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.
DB00865	DB01170	Benzphetamine may decrease the effect of guanethidine.
DB00865	DB01247	MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents.
DB00865	DB00933	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB01403	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB00715	Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.
DB00865	DB00850	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB00780	MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents.
DB00865	DB00433	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB01069	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB01608	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB01367	MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents.
DB00865	DB01390	Alkalinizing agents such as sodium bicarbonate may decrease the excretion of amphetamines like benzphetamine. Increased clinical effects and/or toxicity may occur. Therapy modification should be considered.
DB00865	DB00976	Telithromycin may reduce clearance of Benzphetamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Benzphetamine if Telithromycin is initiated, discontinued or dose changed.
DB00865	DB00679	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00865	DB00519	Benzphetamine may reduce the efficacy of Trandolapril.
DB00865	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Benzphetamine. Concomitant therapy should be avoided.
DB00865	DB00831	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00865	DB00427	Triprolidine may reduce the sedative effect of the antihistamine, Benzphetamine.
DB00865	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of benzphetamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of benzphetamine if voriconazole is initiated, discontinued or dose changed.
DB00869	DB01194	As both brinzolamide and dorzolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB00871	DB01193	Antagonism
DB00871	DB00386	Increased arterial pressure
DB00871	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of terbutaline.
DB00871	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of terbutaline.
DB00871	DB00335	Antagonism
DB00871	DB00195	Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like terbutaline. Therapy should be monitored.
DB00871	DB01295	Antagonism
DB00871	DB00612	Antagonism
DB00871	DB00521	Antagonism
DB00871	DB01136	Antagonism
DB00871	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of terbutaline.
DB00871	DB01089	Increased arterial pressure
DB00871	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of terbutaline.
DB00871	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of terbutaline.
DB00871	DB00187	Antagonism
DB00871	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of terbutaline.
DB00871	DB01247	Increased arterial pressure
DB00871	DB00598	Antagonism
DB00871	DB00601	Possible increase of arterial pressure
DB00871	DB00968	Increased arterial pressure
DB00871	DB00264	Antagonism
DB00871	DB00211	Increased arterial pressure
DB00871	DB01171	Moclobemide increases the sympathomimetic effect of terbutaline.
DB00871	DB01203	Antagonism
DB00871	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of terbutaline.
DB00871	DB01580	Antagonism
DB00871	DB01626	Increased arterial pressure
DB00871	DB01359	Antagonism
DB00871	DB00780	Increased arterial pressure
DB00871	DB00960	Antagonism
DB00871	DB01297	Antagonism
DB00871	DB00571	Antagonism
DB00871	DB00344	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of terbutaline.
DB00871	DB01367	Increased arterial pressure
DB00871	DB00206	Increased arterial pressure
DB00871	DB00489	Antagonism
DB00871	DB00373	Antagonism
DB00871	DB00752	Increased arterial pressure
DB00871	DB00726	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of terbutaline.
DB00872	DB00346	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. Concomitant use of alfuzosin with a strong CYP3A4 inhibitor is a listed contraindication according to alfuzosin prescribing information.
DB00872	DB00918	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Use an initial almotriptan dose of 6.25mg when using almotriptan with a strong CYP3A4 inhibitor, and do not exceed 12.5mg of almotriptan in any 24-hour period. Avoid concurrent use of almotriptan with a strong CYP3A4 inhibitor in patients with impaired hepatic or renal function.
DB00872	DB06697	Conivaptan, a strong CYP3A inhibitor, may increase the toxicity of artemether by inhibiting its metabolism. Consider alternate therapy or allow at least 7 days to elapse between conivaptan and artemether therapy.
DB00872	DB00307	Conivaptan may increase the serum concentration of CYP3A4 substrates such as bexarotene. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Consider therapy modification.
DB00872	DB01393	Conivaptan may increase the serum concentration of CYP3A4 substrates like bezafibrates. Consider therapy modification. Conivaptan may increase the serum concentration of CYP3A4 substrates.
DB00872	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00872	DB01558	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if conivaptan is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00872	DB01222	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). onsider reducing the oral budesonide dose when used together with a strong CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a strong CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess.
DB00893	DB00688	Oral iron decreases the absorption of mycophenolate-mofetil
DB00872	DB00297	Conivaptan may increase the serum concentration of CYP3A4 Substrates such as bupivacaine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00872	DB00921	Conivaptan may increase the serum concentration of CYP3A4 Substrates like buprenorphine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00872	DB00201	Conivaptan may increase the serum concentration of CYP3A4 substrates such as caffeine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00872	DB00185	Conivaptan may increase the serum concentration of CYP3A4 substrates such as cevimeline. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00872	DB01394	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor.
DB00872	DB01219	Conivaptan may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if conivaptan is initiated, discontinued or dose changed.
DB00872	DB04855	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. Concurrent use of strong CYP3A4 inhibitors with dronedarone is contraindicated according to dronedarone prescribing information.
DB00872	DB00700	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. The combination of eplerenone with any strong CYP3A4 inhibitor is contraindicated.
DB00872	DB01590	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus. Everolimus prescribing information recommends avoiding concurrent use with strong CYP3A4 inhbitors.
DB00872	DB00813	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.
DB00872	DB06702	CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. Avoid fesoterodine doses greater than 4mg daily in patients who are also receiving strong CYP3A4 inhibitors.
DB00872	DB00196	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB00872	DB00588	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended.
DB00872	DB01218	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended.
DB00872	DB04946	CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.
DB00872	DB01167	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB00872	DB04845	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. The dose of ixabepilone must be reduced when used with strong inhibitors of CYP3A.1 In one published abstract, ixabepilone 20mg/m2 was the maximum tolerated dose in patients who were also receiving the CYP3A-inhibitor ketoconazole (400mg).
DB00872	DB01026	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB00872	DB08815	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. Avoid use of lurasidone in patients receiving strong CYP3A4 inhibitors.
DB00872	DB04835	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  When used with a strong CYP3A4 inhibitor, the adult dose of maraviroc should be decreased to 150 mg twice daily. Maraviroc is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) receiving a strong CYP3A4 inhibitor. Maraviroc may be administered at a dose of 300 mg twice daily with concomitant tipranavir/ritonavir but not with other ritonavir combinations.
DB00872	DB00959	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Methylprednisolone. Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for increased steroid related adverse effects.
DB00872	DB04868	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. Nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong inhibitors of CYP3A4.
DB00872	DB00401	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. Avoid concurrent use of nisoldipine with strong inhibitors of CYP3A4, as the combination may lead to substantial increases in nisoldipine concentrations.
DB00872	DB01229	Avoid combination because it will likely increase the serum concentration of CYP3A4 substrates.
DB00872	DB06589	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib. Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not possible to avoid such a combination, reduce pazopanib dose to 400 mg. Further dose reductions may also be required.
DB00872	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB00893	DB01059	Formation of non-absorbable complexes
DB00872	DB01263	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB00872	DB00243	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. The manufacturer contraindicates the use of ranolazine and strong CYP3A4 inhibitors (such as the azole antifungals).1 Monitor for increased effects/toxicity of ranolazine during concomitant use.
DB00872	DB06228	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. Consider avoiding use of rivaroxaban with any strong CYP3A4 inhibitors as many such agents are inhibitors of both CYP3A4 and P-glycoprotein. Use of rivaroxaban concomitantly with drugs that are strong inhibitors of both CYP3A4 and P-glycoprotein is specifically contraindicated.
DB00872	DB06176	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Romidepsin. Avoid concurrent use of strong CYP3A4 inhibitors with romidepsin when possible.
DB00872	DB00938	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. Concurrent use of salmeterol with strong inhibitors of CYP3A4 is not recommended according to salmeterol prescribing information.
DB00872	DB06335	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor.
DB00872	DB00203	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Sildenafil. When sildenanfil is used for treatment of pulmonary arterial hypertension, concurrent use with strong CYP3A4 inhibitors is not recommended. When sildenafil is used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking a strong CYP3A4 inhibitor. Due to the particularly strong effects of ritonavir, sildenafil (for erectile dysfunction) doses greater than 25 mg per 48 hours are not recommended. Of note, the interaction between CYP3A4 inhibitors and sildenafil is predicted to be greater with orally administered than with injected sildenafil.
DB00872	DB06207	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Silodosin. Use of silodosin concomitantly with a strong CYP3A4 inhibitor is contraindicated.
DB00872	DB00864	The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Conivaptan is initiated, discontinued or dose changed.
DB00872	DB00820	Conivaptan may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00872	DB00675	Conivaptan may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB00872	DB00706	Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Conivaptan is initiated, discontinued, or dose changed.
DB00872	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00872	DB00976	Co-administration may result in altered plasma concentrations of Conivaptan and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00872	DB06287	Conivaptan may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00872	DB00444	The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Conivaptan is initiated, discontinued or dose changed.
DB00872	DB00906	The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Conivaptan is initiated, discontinued or dose changed.
DB00872	DB08816	CYP3A4 Inhibitors (Strong) such as conivaptan may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. Avoid use of ticagrelor in combination with strong CYP3A4 inhibitors.
DB00872	DB01036	Conivaptan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00872	DB06212	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated.
DB00872	DB00539	CYP3A4 Inhibitors (Strong) such as conivaptan may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. Concurrent use of toremifene with strong CYP3A4 inhibitors should be avoided.
DB00872	DB00193	Conivaptan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00872	DB00656	The CYP3A4 inhibitor, Conivaptan, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Conivaptan is initiated, discontinued or dose changed.
DB00872	DB00862	Conivaptan, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00872	DB00285	Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Conivaptan is initiated, discontinued, or dose changed.
DB00872	DB00661	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed.
DB00872	DB06684	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Vilazodone. Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB00872	DB00570	Conivaptan, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Conivaptan is initiated, discontinued or dose changed.
DB00882	DB00849	The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, clomifene.
DB00872	DB00541	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Conivaptan is initiated, discontinued or dose changed.
DB00872	DB00361	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Conivaptan is initiated, discontinued or dose changed.
DB00872	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of conivaptan by inhibiting its metabolism. Concomitant therapy is contraindicated.
DB00872	DB00425	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if conivaptan is initiated, discontinued or dose changed.
DB00872	DB00909	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if conivaptan is initiated, discontinued or dose changed.
DB00872	DB01198	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if conivaptan is initiated, discontinued or dose changed.
DB00875	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00875	DB00843	Possible antagonism of action
DB00875	DB00674	Possible antagonism of action
DB00875	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00875	DB00989	Possible antagonism of action
DB00875	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Flupenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00875	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00875	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB00875	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00875	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00875	DB00662	Trimethobenzamide and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00875	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00875	DB00427	Triprolidine and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00875	DB00209	Trospium and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00875	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00875	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00875	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00875	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00876	DB00594	Increased risk of hyperkalemia
DB00876	DB01395	Increased risk of hyperkalemia
DB00876	DB01356	The ARB increases serum levels of lithium
DB00876	DB01345	Increased risk of hyperkalemia
DB00876	DB00421	Increased risk of hyperkalemia
DB00876	DB00519	The angiotensin II receptor blocker, Eprosartan, may increase the adverse effects of Trandolapril.
DB00876	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00876	DB00384	Increased risk of hyperkalemia
DB00877	DB01072	Increases the effect and toxicity of immunosuppressant
DB00877	DB08873	Boceprevir increases levels of sirolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
DB00877	DB01211	The macrolide, clarithromycin, may increase the serum concentration of sirolimus.
DB00877	DB00091	Increases the effect and toxicity of sirolimus
DB00877	DB00343	Increases the effect and toxicity of sirolimus
DB00877	DB04855	Sirolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of sirolimus. Monitor plasma concentrations and adjust dose accordingly.
DB00877	DB00199	The macrolide, erythromycin, may increase the serum concentration of sirolimus.
DB00877	DB01320	The hydantoin decreases sirolimus levels
DB00877	DB01167	Itraconazole may increase the effect and toxicity of sirolimus.
DB00877	DB01026	Ketoconazole may increase the effect and toxicity of sirolimus.
DB00877	DB00252	The hydantoin decreases sirolimus levels
DB00877	DB00615	The rifamycin decreases the effect of sirolimus
DB00877	DB01045	The rifamycin decreases the effect of sirolimus
DB00877	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00882	DB00312	The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, clomifene.
DB00877	DB00864	Sirolimus may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Sirolimus therapy is initiated, discontinued or altered.
DB00877	DB00976	Telithromycin may reduce clearance of Sirolimus. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sirolimus if Telithromycin is initiated, discontinued or dose changed.
DB00877	DB00932	Tipranavir may affect the efficacy/toxicity of Sirolimus.
DB00877	DB00519	Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema.
DB00877	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00877	DB00582	Voriconazole may increase the serum concentration of sirolimus likely by inhibition of CYP3A4-mediated metabolism or p-glyprotein transport of sirolimus. Consider alternate therapy or reduce the dose of sirolimus and monitor serum levels during concomitant therapy.
DB00879	DB01610	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Emtricitabine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB00880	DB01143	Antihypertensives may enhance the hypotensive effect of amifostine. When amifostine is used at doses recommended for chemotherapy, antihypertensive medications should be withheld for 24 hours prior to amifostine administration to avoid excessive hypotension during or immediately after infusion. If antihypertensive therapy can not be withheld, then that patient should not receive amifostine. Caution is recommended when using amifostine at the lower doses recommended for radiotherapy, but routine interruption of antihypertensive therapy is not recommended in these patients.
DB00880	DB01432	Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction.
DB00880	DB00375	Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction.
DB00880	DB00390	Possible electrolyte variations and arrhythmias
DB00880	DB00204	Thiazide diuretics such as chlorothiazide may enhance the QTc-prolonging effect of dofetilide. Thiazide diuretics may increase the serum concentration of dofetilide. The concomitant use of hydrochlorothiazide and dofetilide is contraindicated by the manufacturer of dofetilide. Monitor for increased risk of QTc-prolongation and associated ventricular arrythmias during concomitant use of dofetilide and thiazide diuretics.
DB00880	DB01356	The thiazide diuretic, chlorothiazide, may increase serum levels of lithium.
DB00880	DB00073	Antihypertensives such as chlorothiazide may enhance the hypotensive effect of Rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion.
DB00880	DB00273	Thiazide diuretics such as chlorothiazide may enhance the hypokalemic effect of topiramate. Thiazide diuretics may increase the serum concentration of topiramate. Monitor for increased topiramate concentrations/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.
DB00880	DB00519	The thiazide diuretic, Chlorothiazide, may increase the hypotensive effect of Trandolapril. Chlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00880	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00881	DB00594	Increased risk of hyperkalemia
DB00881	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB00881	DB01395	Increased risk of hyperkalemia
DB00881	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB00881	DB01356	The ACE inhibitor increases serum levels of lithium
DB00881	DB01345	Increased risk of hyperkalemia
DB00881	DB00421	Increased risk of hyperkalemia
DB00881	DB00759	Quinapril may decrease the absorption of tetracycline.
DB00881	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB00881	DB00684	Increased risk of nephrotoxicity
DB00881	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00881	DB00384	Increased risk of hyperkalemia
DB00881	DB00685	Quinapril may decrease the absorption of orally administered Trovafloxacin. The Quinapril formulation contains magnesium ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Quinapril dose to minimize the interaction.
DB00882	DB01351	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB01352	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB00237	The enzyme inducer, butabarbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB00241	The enzyme inducer, butalbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB01353	The enzyme inducer, butethal, decreases the effect of the hormone agent, clomifene.
DB00882	DB00754	The enzyme inducer, ethotoin, decreases the effect of the hormone agent, clomifene.
DB00882	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, clomifene.
DB00882	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, clomifene.
DB00882	DB01354	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB01355	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB00532	The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, clomifene.
DB00882	DB00474	The enzyme inducer, methohexital, decreases the effect of the hormone agent, clomifene.
DB00882	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, clomifene.
DB00882	DB00860	The estrogenic agent, clomifene, may increase the effect of the corticosteroid, prednisolone.
DB00882	DB00635	The estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone.
DB00882	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, clomifene.
DB00882	DB00481	Association not recommended
DB00882	DB00418	The enzyme inducer, secobarbital, decreases the effect of the hormone agent, clomifene.
DB00882	DB00306	The enzyme inducer, talbutal, decreases the effect of the hormone agent, clomifene.
DB00882	DB01586	Estrogens decreases the effect of ursodiol
DB00883	DB06237	Additive vasodilation. Concomitant therapy is contraindicated.
DB00883	DB00320	Possible antagonism of action
DB00883	DB01253	Possible antagonism of action
DB00883	DB00696	Possible antagonism of action
DB00883	DB00353	Possible antagonism of action
DB00883	DB00247	Possible antagonism of action
DB00883	DB00203	Possible significant hypotension with this combination
DB00883	DB00820	The vasodilatory effects of Isosorbide dinitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00883	DB00976	Telithromycin may reduce clearance of Isosorbide Dinitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Dinitrate if Telithromycin is initiated, discontinued or dose changed.
DB00883	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00883	DB06267	The vasodilatory effects of Isosobide dinitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00883	DB00862	The vasodilatory effects of Isosorbide dinitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB00883	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide dinitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide dinitrate if voriconazole is initiated, discontinued or dose changed.
DB00884	DB01373	Formation of non-absorbable complexes
DB00884	DB00258	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate.
DB00884	DB01164	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate.
DB00884	DB00893	Formation of non-absorbable complexes
DB00884	DB01378	Formation of non-absorbable complexes
DB00887	DB00479	Increased ototoxicity
DB00887	DB00515	Increased ototoxicity
DB00887	DB00930	Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as bumetanide. Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00887	DB01078	Possible electrolyte variations and arrhythmias
DB00887	DB01396	Possible electrolyte variations and arrhythmias
DB00887	DB00390	Possible electrolyte variations and arrhythmias
DB00887	DB00798	Increased ototoxicity
DB00887	DB01404	Ginseng may decrease the therapeutic effect of diuretic, bumetanide.
DB00887	DB01050	The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, bumetanide.
DB00887	DB00328	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, bumetanide.
DB00887	DB01172	Increased ototoxicity
DB00887	DB00955	Increased ototoxicity
DB00887	DB01082	Increased ototoxicity
DB00887	DB00605	The NSAID, sulindac, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide.
DB00887	DB00684	Increased ototoxicity
DB00887	DB00519	The loop diuretic, Bumetanide, may increase the hypotensive effect of Trandolapril. Bumetanide may also increase the nephrotoxicity of Trandolapril.
DB00887	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00888	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00888	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00891	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB00891	DB00563	The sulfamide increases the toxicity of methotrexate
DB00893	DB00630	Formation of non-absorbable complexes
DB00893	DB00537	Formation of non-absorbable complexes
DB00893	DB00720	Formation of non-absorbable complexes
DB00893	DB08826	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DB00893	DB00618	Formation of non-absorbable complexes
DB00893	DB00254	Formation of non-absorbable complexes
DB00893	DB06210	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB00893	DB00467	Formation of non-absorbable complexes
DB00893	DB01077	Formation of non-absorbable complexes
DB00893	DB01044	Formation of non-absorbable complexes
DB00893	DB01155	Formation of non-absorbable complexes
DB00893	DB00365	Formation of non-absorbable complexes
DB00893	DB00710	Formation of non-absorbable complexes
DB00893	DB01235	Iron decreases the absorption of dopa derivatives
DB00893	DB01137	Formation of non-absorbable complexes
DB00893	DB00451	Iron decreases the absorption of levothyroxine
DB00893	DB00978	Formation of non-absorbable complexes
DB00893	DB00931	Formation of non-absorbable complexes
DB00893	DB00595	Formation of non-absorbable complexes
DB00893	DB00487	Formation of non-absorbable complexes
DB00893	DB00859	The multivalent agent decreases the effect of penicillamine
DB00893	DB00884	Formation of non-absorbable complexes
DB00893	DB01405	Formation of non-absorbable complexes
DB00893	DB00759	Formation of non-absorbable complexes
DB00893	DB00685	Formation of non-absorbable complexes
DB00894	DB01418	The androgen, Testolactone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testolactone is initiated, discontinued or dose changed.
DB00894	DB00091	The androgen, Testolactone, may increase the hepatotoxicity of Cyclosporine. Testolatone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB00894	DB00682	Testolactone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testolactone is initiated, discontinued or dose changed.
DB00895	DB00748	Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects.
DB00897	DB00701	Amprenavir may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB00673	Aprepitant may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB01072	Atazanavir may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB00501	Cimetidine may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of triazolam if cimetidine is initiated, discontinued or dose changed.
DB00897	DB01211	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, triazolam.
DB00897	DB00363	Increased risk of toxicity
DB00897	DB00705	The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB00343	The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB00625	The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB00199	The macrolide, erythromycin, may increase the effect of the benzodiazepine, triazolam.
DB00897	DB00754	Ethotoin may increase the metabolism of triazolam via CYP3A4.
DB00897	DB00196	Fluconazole may increase the effect of the benzodiazepine, triazolam.
DB00897	DB01319	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB01320	Fosphenytoin may increase the metabolism of triazolam via CYP3A4.
DB00897	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, triazolam.
DB00897	DB01167	Itraconazole may increase the effect of the benzodiazepine, triazolam.
DB00897	DB01321	The macrolide, josamycin, may increase the effect of the benzodiazepine, triazolam.
DB00897	DB01322	Kava may increase the effect of the benzodiazepine, triazolam.
DB00897	DB01026	Ketoconazole may increase the effect of the benzodiazepine, triazolam.
DB00897	DB00532	Mephenytoin may increase the metabolism of triazolam via CYP3A4.
DB00897	DB00745	Modafinil decreases the effect of triazolam
DB00897	DB01149	Nefazodone increases the effect of triazolam
DB00897	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, triazolam.
DB00897	DB00338	Omeprazole may increase the effect of the benzodiazepine, triazolam.
DB00897	DB00252	Phenytoin may increase the metabolism of triazolam via CYP3A4.
DB00897	DB01045	Rifampin may decrease the effect of the benzodiazepine, triazolam.
DB00897	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, triazolam.
DB00897	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, triazolam.
DB00897	DB01323	St. John's Wort may decrease the effect of the benzodiazepine, triazolam.
DB00897	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB00897	DB00976	Telithromycin may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00897	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Triazolam. Concomitant therapy is contraindicated.
DB00897	DB00427	The CNS depressants, Triprolidine and Triazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00897	DB00661	Verapamil may increase the serum concentration of Triazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Triazolam.
DB00897	DB00582	Voriconazole may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for triazolam toxicity if voriconazole is initiated or dose increased.
DB00898	DB01048	Abacavir is partly metabolized through the alcohol dehydrogenase enzyme system. Alcohol increases the area under the curve (about 41%) of Abacavir. Interaction does not appear to be clinically significant.
DB00898	DB08872	Avoid combination due to ethanol induced increased absorption of gabapentin enacarbil and increased CNS depression.
DB00898	DB05528	The combination of these drugs will likely enhance mipomersen related hepatotoxicity. Therefore patients using both these drugs, should limit their alcohol to a daily maximum of 1 drink (or equivalent).
DB00898	DB08883	Avoid combination due to the enhanced central nervous system depression, and likely worse behavioral and psychiatric adverse reactions.
DB00898	DB00697	Ethanol increases the adverse effects of Tizanidine. The CNS depressant effects of these agents are additive.
DB00898	DB00427	Triprolidine may enhance the CNS depressant effects of Ethanol.
DB00899	DB00752	Possible increased risk of serotonin syndrome.
DB00931	DB00301	Possible antagonism of action
DB00899	DB00427	The CNS depressants, Triprolidine and Remifentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00900	DB01004	The antiviral agent, ganciclovir, may increase the effect and toxicity of didanosine.
DB00900	DB00300	Tenofovir may decrease the therapeutic effects and increase the adverse effects of Didanosine. Monitor for changes in virologic response and Didanosine toxicity during concomitant therapy.
DB00900	DB00932	Tipranavir may decrease the concentration of Didanosine.
DB00900	DB00684	Increased risk of nephrotoxicity
DB00900	DB00685	Didanosine may decrease the absorption of orally administered Trovafloxacin. The Didanosine formulation contains magnesium and aluminum ions that intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Didanosine dose to minimize the interaction. This interaction is not observed with enteric coated Didanosine.
DB00900	DB01610	The adverse/toxic effects of Didanosine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided.
DB00900	DB00582	Didanosine may interfere with the absorption of orally administered voriconazole. Enteric coated didanosine does not exert this effect. Didanosine buffered formulations should be administered at least 2 hours from oral voriconazole administration.
DB00900	DB00943	Additive toxicities (peripheral neuropathy)
DB00901	DB00494	Entacapone may increase the effect and toxicity of bitolterol.
DB00902	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00902	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00902	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00902	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00902	DB00843	Possible antagonism of action
DB00902	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00902	DB00674	Possible antagonism of action
DB00902	DB01170	Methdilazine may decrease the effect of guanethidine.
DB00902	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00902	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00902	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00902	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00903	DB00479	Increased ototoxicity
DB00903	DB00515	Increased ototoxicity
DB00903	DB00930	Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as ethacrynic acid.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00903	DB01078	Possible electrolyte variations and arrhythmias
DB00903	DB01396	Possible electrolyte variations and arrhythmias
DB00903	DB00390	Possible electrolyte variations and arrhythmias
DB00903	DB00798	Increased ototoxicity
DB00903	DB01404	Ginseng may decrease the therapeutic effect of diuretic, ethacrynic acid.
DB00903	DB01050	The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid.
DB00903	DB05039	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB00903	DB00328	The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid.
DB00903	DB01172	Increased ototoxicity
DB00903	DB00955	Increased ototoxicity
DB00903	DB01082	Increased ototoxicity
DB00903	DB00605	The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacryninc acid.
DB00903	DB00684	Increased ototoxicity
DB00903	DB00519	The loop diuretic, Ethacrynic acid, may increase the hypotensive effect of Trandolapril. Ethacrynic acid may also increase the nephrotoxicity of Trandolapril.
DB00903	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00904	DB06216	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00904	DB08865	Concurrent use with crizotinib may decrease QTc interval. Consider alternative therapy.
DB00904	DB04953	Concurrent use of ezogabine and ondansetron can increase QTc interval. Consider alternate therapy.
DB00904	DB05039	Both indacaterol and ondansetron prolong the QT interval. Consider alternate therapy.
DB00904	DB06589	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00904	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00905	DB00654	The concomitant use of bimatoprost and latanoprost may result in increased intraocular pressure. Consider avoiding this combination of therapy. Monitor for paradoxical increases in intraocular pressure during concomitant use.
DB00906	DB00701	The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Amprenavir is initiated, discontinued or dose changed.
DB00906	DB01072	The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Atazanavir is initiated, discontinued or dose changed.
DB00906	DB01211	The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Clarithromycin is initiated, discontinued or dose changed.
DB00906	DB00872	The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Conivaptan is initiated, discontinued or dose changed.
DB00931	DB00893	Formation of non-absorbable complexes
DB00906	DB01264	The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Darunavir is initiated, discontinued or dose changed.
DB00906	DB00705	The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Delavirdine is initiated, discontinued or dose changed.
DB00906	DB01319	The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Fosamprenavir is initiated, discontinued or dose changed.
DB00906	DB00619	The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Imatinib is initiated, discontinued or dose changed.
DB00906	DB00224	The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Indinavir is initiated, discontinued or dose changed.
DB00906	DB00951	The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Isoniazid is initiated, discontinued or dose changed.
DB00906	DB01167	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Itraconazole is initiated, discontinued or dose changed.
DB00906	DB01026	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed.
DB00906	DB01601	The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Lopinavir is initiated, discontinued or dose changed.
DB00906	DB00358	Mefloquine increases the risk of seizure and is contraindicated in persons with a history of convulsions. Possible reduction in the therapeutic effect of Tiagabine when used for other indications may also occur.
DB00906	DB01110	The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Miconazole is initiated, discontinued or dose changed.
DB00906	DB01149	The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nefazodone is initiated, discontinued or dose changed.
DB00906	DB00220	The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nelfinavir is initiated, discontinued or dose changed.
DB00906	DB00622	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nicardipine is initiated, discontinued or dose changed.
DB00906	DB01263	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Posaconazole is initiated, discontinued or dose changed.
DB00906	DB00908	The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Quinidine is initiated, discontinued or dose changed.
DB00906	DB00503	The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ritonavir is initiated, discontinued or dose changed.
DB00906	DB01232	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Saquinavir is initiated, discontinued or dose changed.
DB00906	DB00976	The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Telithromycin is initiated, discontinued or dose changed.
DB00906	DB00427	The CNS depressants, Triprolidine and Tiagabine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00906	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tiagabine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tiagabine if voriconazole is initiated, discontinued or dose changed.
DB00907	DB00289	CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor.
DB00907	DB00822	Increases the cardiac toxicity of cocaine
DB00907	DB04946	CYP2D6 Inhibitors (Strong) such as cocaine may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.
DB00907	DB06704	Sympathomimetic that increase chances of producing a false negative imaging result
DB00916	DB01341	The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole.
DB00907	DB00675	Cocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00907	DB00706	Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cocaine is initiated, discontinued, or dose changed.
DB00907	DB00976	Telithromycin may reduce clearance of Cocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cocaine if Telithromycin is initiated, discontinued or dose changed.
DB00907	DB04844	CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Patients receiving a strong inhibitor of CYP2D6 together with tetrabenazine should not exceed 50mg of tetrabenazine. Also, patients already taking tetrabenazine prior to starting a strong CYP2D6 inhibitor should have their tetrabenazine dose reduced by 50% upon initiation of the strong CYP2D6 inhibitor.
DB00907	DB01036	Cocaine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB00907	DB00193	Cocaine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00907	DB00726	The strong CYP2D6 inhibitor, Cocaine, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate.
DB00907	DB00285	Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cocaine is initiated, discontinued, or dose changed.
DB00907	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cocaine if voriconazole is initiated, discontinued or dose changed.
DB00907	DB01624	Cocaine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cocaine is initiated, discontinued or dose changed.
DB00908	DB01418	Quinidine may increase the anticoagulant effect of acenocoumarol.
DB00908	DB06274	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB00908	DB00594	Amiloride may decrease the therapeutic effect of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if amiloride if initiated, discontinued or dose changed.
DB00908	DB01118	Amiodarone may increase the effect of quinidine.
DB00908	DB00321	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00908	DB01351	The anticonvulsant, amobarbital, decreases the effect of quinidine.
DB00908	DB01125	Quinidine may increase the anticoagulant effect of anisindione.
DB00908	DB01352	The anticonvulsant, aprobarbital, decreases the effect of quinidine.
DB00908	DB01238	Quinidine increases the effect and toxicity of aripiprazole
DB00908	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00908	DB01072	Increased risk of cardiotoxicity and arrhythmias.
DB00908	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB00908	DB00732	The quinine derivative increases the effect of the muscle relaxant
DB00908	DB01558	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if quinidine is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00908	DB00237	The anticonvulsant, butabarbital, decreases the effect of quinidine.
DB00908	DB00241	The anticonvulsant, butalbital, decreases the effect of quinidine.
DB00908	DB01353	The anticonvulsant, butethal, decreases the effect of quinidine.
DB00908	DB00501	Cimetidine may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if cimetidine is initiated, discontinued or dose changed.
DB00908	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB01242	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00908	DB00318	Quinidine decreases the analgesic effect of codeine
DB00908	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB00908	DB06695	Quinidine may increase the serum concentration of dabigatran etexilate, resulting in increased bleeding. Consider modification of therapy.
DB00908	DB01219	Quinidine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if quinidine is initiated, discontinued or dose changed.
DB00908	DB01151	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00908	DB00514	Quinidine increases the toxicity of dextromethorphan
DB00908	DB00266	Quinidine may increase the anticoagulant effect of dicumarol.
DB00908	DB01396	Quinine/quinidine increases the effect of digoxin
DB00908	DB00390	Quinine/quinidine increases the effect of digoxin
DB00908	DB01551	Use of quinidine may reduce dihydrocodeine's analgesic effect.
DB00908	DB01341	The anticonvulsant, dihydroquinidine. barbiturate, decreases the effect of quinidine.
DB00916	DB00822	Possible acute psychosis and confusion
DB00908	DB00343	Diltiazem may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if diltiazem is initiated, discontinued or dose changed.
DB00908	DB00843	Possible antagonism of action
DB00908	DB01142	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00908	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB06414	Quinidine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor quinidine therapy.
DB00908	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB00908	DB01320	The anticonvulsant, fosphenytoin, decreases the effect of quinidine.
DB00908	DB00674	Possible antagonism of action
DB00908	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB01354	The anticonvulsant, heptabarbital, decreases the effect of quinidine.
DB00908	DB01355	The anticonvulsant, hexobarbital, decreases the effect of quinidine.
DB00908	DB00458	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00908	DB01167	Itraconazole may increase the effect and toxicity of quinidine.
DB00908	DB01026	Ketoconazole may increase the effect and toxicity of quinidine.
DB00908	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00908	DB01378	Magnesium antacids may decrease the absorption of quindine.
DB00908	DB01397	The antacid increases the effect of quinidine
DB00908	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB00474	The anticonvulsant, methohexital, decreases the effect of quinidine.
DB00908	DB00849	The anticonvulsant, methylphenobarbital, decreases the effect of quinidine.
DB00908	DB01336	The quinine derivative increases the effect of the muscle relaxant
DB00908	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB00220	Nelfinavir increases the effect and toxicity of quinidine
DB00908	DB01115	Decreased quinidine effect, increased nifedipine effect
DB00908	DB00540	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00908	DB01165	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB01337	The quinine derivative increases the effect of the muscle relaxant
DB00908	DB00312	The anticonvulsant, pentobarbital, decreases the effect of quinidine.
DB00908	DB01174	The anticonvulsant, phenobarbital, decreases the effect of quinidine.
DB00908	DB00252	The anticonvulsant, phenytoin, decreases the effect of quinidine.
DB00908	DB01263	Contraindicated co-administration
DB00908	DB00794	The anticonvulsant, primidone, decreases the effect of quinidine.
DB00908	DB01035	Quinidine increases the effect of procainamide
DB00908	DB01182	Quinidine increases the effect of propafenone
DB00908	DB00344	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB00908	DB01346	The anticonvulsant, quinidine. barbiturate, decreases the effect of quinidine.
DB00908	DB01369	This combination presents an increased risk of toxicity
DB00908	DB00243	Possible additive effect on QT prolongation
DB00908	DB01045	Rifampin decreases the effect of quinidine
DB00908	DB00503	Ritonavir increases the effect and toxicity of quinidine
DB00908	DB00989	Possible antagonism of action
DB00908	DB00418	The anticonvulsant, secobarbital, decreases the effect of quinidine.
DB00908	DB01390	The antacid increases the effect of quinidine
DB00908	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB00202	The quinine derivative increases the effect of the muscle relaxant
DB00908	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Quinidine, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance.
DB00908	DB00820	Quinidine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00908	DB00306	The anticonvulsant, talbutal, decreases the effect of quinidine.
DB00908	DB00675	Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB00908	DB00706	Quinidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinidine is initiated, discontinued, or dose changed.
DB00908	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00908	DB00976	Co-administration may result in altered plasma concentrations of Quinidine and/or Telithromycin. Consider alternate therapy or monitor for changes in the the therapeutic/adverse effects of both agents during concomitant therapy.
DB00916	DB00544	Risk of 5-FU toxicity when associated with metronidazole
DB00908	DB06287	Quinidine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00908	DB00444	The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Quinidine is initiated, discontinued or dose changed.
DB00908	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB04844	Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose.
DB00908	DB00599	Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated.
DB00908	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00908	DB00906	The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Quinidine is initiated, discontinued or dose changed.
DB00908	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Quinidine. Concomitant therapy is contraindicated.
DB00908	DB01036	Quinidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00908	DB01030	The p-glycoprotein inhibitor, Quinidine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00908	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00908	DB00193	Quinidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Quinidine may decrease the effect of Tramadol by decreasing active metabolite production.
DB00908	DB00656	The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed.
DB00908	DB00726	Additive QTc-prolonging effects may occur, increasing the risk of serious cardiac arrhythmias. Quinidine, a CYP2D6/CYP3A4 inhibitor, may also inhibit the metabolism of Trimipramine, a CYP2D6/CYP3A4 substrate. Monitor for signs of cardiac arrhythmias and for changes in Trimipramine efficacy and toxicity if Quinidine is initiated, discontinued or dose changed.
DB00908	DB00862	Quinidine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00908	DB01339	The quinine derivative increases the effect of the muscle relaxant
DB00908	DB00285	Quinidine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Quinidine is initiated, discontinued, or dose changed.
DB00908	DB00661	Concurrent therapy may result in increased serum levels of both agents. Both agents are CYP3A4 inhibitors and substrates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of the agent if the other is initiated, discontinued or dose changed.
DB00908	DB06684	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB00908	DB00570	Quinidine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Quinidine is initiated, discontinued or dose changed.
DB00908	DB00541	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Quinidine is initiated, discontinued or dose changed.
DB00908	DB00361	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Quinidine is initiated, discontinued or dose changed.
DB00908	DB00582	Voriconazole may increase the serum concentration of quinidine likely by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the serum concentration and toxic effects of quinidine if voriconazole is initiated, discontinued or dose changed.
DB00908	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00908	DB00682	Quinidine may increase the anticoagulant effect of warfarin.
DB00908	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00908	DB00425	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if quinidine is initiated, discontinued or dose changed.
DB00908	DB00909	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if quinidine is initiated, discontinued or dose changed.
DB00908	DB01198	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if quinidine is initiated, discontinued or dose changed.
DB00908	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Quinidine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if quinidine is initiated, discontinued or dose changed.
DB00909	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if amprenavir is initiated, discontinued or dose changed.
DB00909	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if atazanavir is initiated, discontinued or dose changed.
DB00909	DB01194	As both brinzolamide and zonisamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB00909	DB01211	Clarithromcyin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if clarithromycin is initiated, discontinued or dose changed.
DB00909	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if conivaptan is initiated, discontinued or dose changed.
DB00909	DB01264	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if darunavir is initiated, discontinued or dose changed.
DB00909	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if delavirdine is initiated, discontinued or dose changed.
DB00909	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if fosamprenavir is initiated, discontinued or dose changed.
DB00909	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if imatinib is initiated, discontinued or dose changed.
DB00909	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if indinavir is initiated, discontinued or dose changed.
DB00909	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed.
DB00909	DB01167	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed.
DB00909	DB01026	Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed.
DB00909	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if lopinavir is initiated, discontinued or dose changed.
DB00909	DB00358	Mefloquine may decrease the serum concentration and therapeutic effect of zonisamide. Concomitant therapy is contraindicated in patients with history of convulsions.
DB00909	DB01403	Additive CNS depressant effects. Reduce zonisamide dose by half upon initiation of methotrimeprazine. Zonisamide dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.
DB00909	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nefazodone is initiated, discontinued or dose changed.
DB00909	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nelfinavir is initiated, discontinued or dose changed.
DB00909	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed.
DB00909	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if posaconazole is initiated, discontinued or dose changed.
DB00909	DB00908	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if quinidine is initiated, discontinued or dose changed.
DB00909	DB00503	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ritonavir is initiated, discontinued or dose changed.
DB00909	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if saquinavir is initiated, discontinued or dose changed.
DB00909	DB00976	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if telithromycin is initiated, discontinued or dose changed.
DB00909	DB00427	The CNS depressants, Triprolidine and Zonisamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00909	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if voriconazole is initiated, discontinued or dose changed.
DB00910	DB00169	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB00910	DB00930	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00912	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB00912	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB00912	DB00195	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB00912	DB01295	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB00912	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB00912	DB00521	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB00912	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB00912	DB01211	Clarithromycin may increase the effect of repaglinide.
DB00912	DB00091	Cyclosporine may increase the therapeutic and adverse effects of repaglinide.
DB00912	DB00199	The macrolide, erythromycin, may increase the effect of repaglinide.
DB00912	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB00912	DB01095	Inhibitors of CYP3A4 and P-glycoprotein may increase serum concentrations of repaglinide. Monitor concomitant therapy closely.
DB00912	DB01241	Gemfibrozil may increase the effect and toxicity of repaglinide.
DB00912	DB01296	Possible hyperglycemia
DB00912	DB01321	The macrolide, josamycin, may increase the effect of repaglinide.
DB00912	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB00912	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB00912	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB00912	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB00912	DB01359	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB00912	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00912	DB01297	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB00912	DB00175	Substrates of organic anion transporters may increase levels of repaglinide. Monitor concomitant therapy closely.
DB00912	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB00912	DB01045	Rifampin decreases the effect of repaglinide
DB00912	DB00489	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB00912	DB00976	Telithromycin may reduce clearance of Repaglinide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Repaglinide if Telithromycin is initiated, discontinued or dose changed.
DB00912	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB00912	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of repaglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of repaglinide if voriconazole is initiated, discontinued or dose changed.
DB00915	DB00843	Possible antagonism of action
DB00915	DB00674	Possible antagonism of action
DB00915	DB01043	Increased risk of CNS adverse effects with this association
DB00915	DB01267	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, amantadine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB00915	DB00989	Possible antagonism of action
DB00915	DB01623	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Amantadine. Consider alternate therapy or monitor for decreased effects of both agents.
DB00915	DB00246	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, amantadine. Consider alternate therapy or monitor for worsening of movement disorder.
DB00915	DB01624	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB00916	DB01418	Metronidazole may increase the anticoagulant effect of acenocoumarol.
DB00916	DB01351	The barbiturate, amobarbital, decreases the effect of metronidazole.
DB00916	DB00701	Increased risk of side effects (oral solution)
DB00916	DB01125	Metronidazole may increase the anticoagulant effect of anisindione.
DB00916	DB01352	The barbiturate, aprobarbital, decreases the effect of metronidazole.
DB00916	DB01008	Metronidazole increases the effect/toxicity of busulfan
DB00916	DB00237	The barbiturate, butabarbital, decreases the effect of metronidazole.
DB00916	DB00241	The barbiturate, butalbital, decreases the effect of metronidazole.
DB00916	DB01353	The barbiturate, butethal, decreases the effect of metronidazole.
DB00916	DB00564	Metronidazole increases the effect of carbamazepine
DB00916	DB00266	Metronidazole may increase the anticoagulant effect of dicumarol.
DB00931	DB00415	Possible antagonism of action
DB00916	DB01354	The barbiturate, heptabarbital, decreases the effect of metronidazole.
DB00916	DB01355	The barbiturate, hexobarbital, decreases the effect of metronidazole.
DB00916	DB01356	Metronidazole increases the effect and toxicity of lithium
DB00916	DB00474	The barbiturate, methohexital, decreases the effect of metronidazole.
DB00916	DB00849	The barbiturate, methylphenobarbital, decreases the effect of metronidazole.
DB00916	DB00312	The barbiturate, pentobarbital, decreases the effect of metronidazole.
DB00916	DB01174	The barbiturate, phenobarbital, decreases the effect of metronidazole.
DB00916	DB00794	The barbiturate, primidone, decreases the effect of metronidazole.
DB00916	DB01346	The barbiturate, quinidine barbiturate, decreases the effect of metronidazole.
DB00916	DB00418	The barbiturate, secobarbital, decreases the effect of metronidazole.
DB00916	DB00864	Metronidazole increases the levels/toxicity of tacrolimus
DB00916	DB00306	The barbiturate, talbutal, decreases the effect of metronidazole.
DB00916	DB00706	Metronidazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Metronidazole is initiated, discontinued, or dose changed.
DB00916	DB01036	Metronidazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00916	DB00193	Metronidazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB00916	DB00656	The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed.
DB00916	DB00682	Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed.
DB00917	DB01282	Dinoprostone may enhance the therapeutic effect of carbetocin. Avoid concomitant use of carbetocin with dinoprostone. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use.
DB00917	DB00107	Therapy modification should be considered because of enhanced oxytocic effects
DB00918	DB00215	Increased risk of CNS adverse effects
DB00918	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Use an initial almotriptan dose of 6.25mg when using almotriptan with a strong CYP3A4 inhibitor, and do not exceed 12.5mg of almotriptan in any 24-hour period. Avoid concurrent use of almotriptan with a strong CYP3A4 inhibitor in patients with impaired hepatic or renal function.
DB00918	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00918	DB00320	Possible severe and prolonged vasoconstriction
DB00918	DB01253	Possible severe and prolonged vasoconstriction
DB00918	DB00696	Possible severe and prolonged vasoconstriction
DB00918	DB01175	Increased risk of CNS adverse effects
DB00918	DB00472	Increased risk of CNS adverse effects
DB00918	DB00176	Increased risk of CNS adverse effects
DB00918	DB01247	The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.
DB00918	DB01167	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB00918	DB01026	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB00918	DB00353	Possible severe and prolonged vasoconstriction
DB00918	DB00247	Possible severe and prolonged vasoconstriction
DB00918	DB01149	Increased risk of CNS adverse effects
DB00918	DB00715	Increased risk of CNS adverse effects
DB00918	DB00780	The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.
DB00918	DB01104	Increased risk of CNS adverse effects
DB00918	DB01105	Increased risk of CNS adverse effects
DB00918	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00918	DB00752	The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Almotriptan. Risk of serotonin syndrome and Almotriptan toxicity. Concomitant therapy should be avoided.
DB00918	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00918	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00918	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00918	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of almotriptan by decreasing its metabolism. The initial and maximum doses should not exceed 6.25 mg and 12.5 mg, respectively during concomitant therapy. Concomitant therapy should be avoided in patients with impaired hepatic or renal function.
DB00918	DB00315	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and almotriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00920	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ketotifen, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00920	DB00662	Trimethobenzamide and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00920	DB00427	Triprolidine and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00931	DB01053	Possible antagonism of action
DB00931	DB01373	Formation of non-absorbable complexes
DB00920	DB00209	Trospium and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00921	DB06274	Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification.
DB00921	DB01072	Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Avoid use of buprenorphine in patients receiving atazanavir without ritonavir boosting due to possible decreases in atazanavir exposure. In patients receiving buprenorphine with atazanavir/ritonavir, monitor for increased buprenorphine effects and consider dose reductions if patients experience adverse effects.
DB00921	DB00872	Conivaptan may increase the serum concentration of CYP3A4 Substrates like buprenorphine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
DB00921	DB00450	Droperidol may enhance the CNS depressant effect of CNS Depressants like buprenorphine. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
DB00921	DB06414	Buprenorphine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for a decrease in buprenorphine levels (ie. reduced analgesia, and signs of opioid withdrawal).
DB00921	DB01247	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB00601	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB01171	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB00780	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like phenelzine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB01168	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB01367	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like rasagiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB01037	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB00976	Telithromycin may reduce clearance of Buprenorphine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buprenorphine if Telithromycin is initiated, discontinued or dose changed.
DB00921	DB00752	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like tranylcypromine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB00921	DB00427	The CNS depressants, Triprolidine and Buprenorphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00921	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of buprenorphine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of buprenorphine if voriconazole is initiated, discontinued or dose changed.
DB00923	DB00479	Increased risk of nephrotoxicity
DB00923	DB00798	Increased risk of nephrotoxicity
DB00923	DB00955	Increased risk of nephrotoxicity
DB00923	DB00684	Increased risk of nephrotoxicity
DB00924	DB00843	Possible antagonism of action
DB00924	DB00674	Possible antagonism of action
DB00924	DB05039	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB00924	DB01367	Increased risk of toxicity with this association
DB00924	DB00989	Possible antagonism of action
DB00924	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclobenzaprine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00924	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Cyclobenzaprine by decreasing Cyclobenzaprine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Cyclobenzaprine if Thiabendazole is initiated, discontinued or dose changed.
DB00924	DB00193	Increases risk of seizure.
DB00924	DB00752	Increased risk of serotonin syndrome. Concomitant use should be avoided. These agents should not be administered within 14 days of each other.
DB00924	DB00427	Triprolidine and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00924	DB00209	Trospium and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00925	DB00820	Tadalafil may enhance the hypotensive effect of Phenoxybenzamine. Monitor for hypotension during concomitant therapy.
DB00925	DB00706	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phenoxybenzamine, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB00925	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00931	DB00578	Possible antagonism of action
DB00931	DB00766	Possible antagonism of action
DB00925	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phenoxybenzamine, may occur. Monitor for hypotension during concomitant therapy.
DB00926	DB00618	Increased risk of intracranial hypertension
DB00926	DB00254	Increased risk of intracranial hypertension
DB00926	DB00931	Increased risk of intracranial hypertension
DB00926	DB00563	Acitretin/etretinate increases the effect and toxicity of methotrexate
DB00926	DB01017	Increased risk of intracranial hypertension
DB00926	DB00595	Increased risk of intracranial hypertension
DB00926	DB01301	Increased risk of intracranial hypertension
DB00926	DB00759	Increased risk of intracranial hypertension
DB00927	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB00927	DB01066	H2-Antagonists such as famotidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB00927	DB00467	Famotidine may decrease the absorption of enoxacin.
DB00927	DB01167	The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole.
DB00927	DB01026	The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole.
DB00927	DB08864	Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB00928	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00929	DB01282	Misoprostol may enhance the therapeutic effect of Carbetocin. Avoid the concomitant use of carbetocin and misoprostol. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use.
DB00929	DB00107	Avoid combination. Manufacturer advises not to administer concomitantly due to enhanced adverse effects of oxytocin, especially when given within 4 hours of oxytocin initiation.
DB00930	DB01436	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00930	DB01118	Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. Consider alternative antilipemic agent. The risk of subtherapeutic amiodarone serum concentrations when such is being used for the treatment of malignant arrhythmias can be very large. The effect (ie, reduced risk) of separating doses of these agents is unknown. Amiodarone should be administered at least 1 hour before or 4 hours after colesevelam.1 Similar dosing with other agents seems warranted.
DB00930	DB00887	Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as bumetanide. Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00136	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00930	DB00482	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB06777	Bile Acid Sequestrants may decrease the serum concentration of Chenodiol. Consider administration of chenodiol 5 hours or more after bile acid sequestrants to reduce chenodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.
DB00930	DB00169	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00931	DB01147	Possible antagonism of action
DB00931	DB00485	Possible antagonism of action
DB00930	DB00618	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00304	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00586	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00861	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB06410	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00930	DB00254	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB01395	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00153	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00930	DB00903	Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as ethacrynic acid.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00977	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain.
DB00930	DB00823	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00749	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00294	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00573	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00931	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00931	DB00926	Increased risk of intracranial hypertension
DB00930	DB00712	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00695	Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as furosemide.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB01016	Colesevelam may decrease the serum concentration of Glyburide. Glyburide should be administered at least 4 hours before colesevelam to minimize the risk of an interaction.
DB00930	DB01050	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00328	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB01009	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00465	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB01097	Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide. Unless using cholestyramine (or another bile acid sequestrant) together with leflunomide to intentionally enhance the removal/elimination of leflunomide, consider using an alternative to the bile acid sequestrants whenever possible. Separating the administration of these agents is unlikely to be an effective means of avoiding the interaction.
DB00930	DB00367	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00939	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00603	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00784	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00814	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB01357	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain.
DB00930	DB01017	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00461	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00788	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00627	Bile Acid Sequestrants may decrease the absorption of Niacin. It may be prudent to separate the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for reduced efficacy of these agents. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB06713	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00717	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00957	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00930	DB00991	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00910	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB00930	DB00252	Colesevelam may decrease the serum concentration of Phenytoin. Phenytoin should be administered at least 4 hours prior to colesevelam.
DB00930	DB01132	Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents.
DB00930	DB00554	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00175	Bile Acid Sequestrants may decrease the serum concentration of Pravastatin. Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.
DB00930	DB00481	Bile Acid Sequestrants may decrease the absorption of Raloxifene. It would seem prudent to separate the doses of raloxifene and bile acid sequestrants by at least 2 hours. The manufacturer of raloxifene recommends against coadministration of these agents.1 The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB00412	Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents.
DB00930	DB00605	The bile acid sequestrant, colesevelam, may decrease the absorption of the NSAID, sulindac. Sulindac should be administered at least 1 hour before or 4 hours after colesevelam. Monitor for changes in the therapeutic and adverse effects of sulindac if colesevelam is initiated, discontinued or dose changed.
DB00930	DB00759	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00930	DB01600	The bile acid sequestrant, Colesevelam, may reduce Tiaprofenic acid absorption and therapeutic effect.
DB00930	DB00500	Colesevelam may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00930	DB00214	Colesevelam may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB00930	DB01021	The bile acid sequestrant, Colesevelam, may inhibit the absorption of Trichlormethiazide.
DB00930	DB01586	Bile Acid Sequestrants may decrease the serum concentration of Ursodiol. Consider administration of ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.
DB00931	DB00459	Increased risk of intracranial hypertension
DB00931	DB01060	Possible antagonism of action
DB00931	DB00982	Increased risk of intracranial hypertension
DB00931	DB01378	Formation of non-absorbable complexes
DB00931	DB00417	Possible antagonism of action
DB00931	DB00319	Possible antagonism of action
DB00931	DB01604	Possible antagonism of action
DB00931	DB01605	Possible antagonism of action
DB00932	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Tipranavir. The antiviral response should be closely monitored.
DB00932	DB00404	Tipranavir may decrease the metabolism and clearance of Alprazolam. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB01118	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated.
DB00932	DB00381	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Amlopidine. Monitor for changes in Amlopidine therapeutic and toxic effects if Tipranavir is initiated, discontinued or dose changed.
DB00932	DB00637	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated.
DB00932	DB01072	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Atazanavir. Consider alternate therapy.
DB00932	DB01076	Tipranavir, co-administered with Ritonavir, increases the adverse/toxic effects of Atorvastatin. Concomitant therapy should be avoided.
DB00932	DB01244	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Bepridil. Concomitant therapy is contraindicated.
DB00932	DB01558	Tipranavir may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if tipranavir is initiated, discontinued or dose changed.
DB00932	DB01200	Tipranavir may increase the plasma concentration of Bromocriptine. Concomitant therapy should be avoided.
DB00932	DB01222	Tipranavir may increase the plasma concentration of Budesonide. Monitor for toxic Budesonide effects during concomitant administration.
DB00932	DB00564	Concomitant use may result in decreased Tipranavir and increased Carbamazepine concentrations.
DB00932	DB00475	Tipranavir may decrease the metabolism and clearance of Chlordiazepoxide. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB00604	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Cisapride. Concomitant therapy is contraindicated.
DB00932	DB01211	The concentrations of Tipranavir and Clarithromycin increase during concomitant therapy. Dose adjustments are required for patients with renal impairment.
DB00932	DB00349	Tipranavir may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for Clobazam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB01068	Tipranavir may decrease the metabolism and clearance of Clonazepam. Consider alternate therapy or monitor for Clonazepam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB00628	Tipranavir may decrease the metabolism and clearance of Clorazepate. Consider alternate therapy or monitor for Clorazepate toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB00286	Conjugated estrogens may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Conjugated estrogens. Monitor for estrogen deficiency during concomitant therapy.
DB00932	DB00091	Tipranavir may affect the efficacy/toxicity of Cyclosporine.
DB00932	DB06695	P-Glycoprotein inducers such as tipranavir may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB00932	DB00705	Concomitant use may result in increased Tipranavir and decreased Delavirdine concentrations. Monitor for altered therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.
DB00932	DB01151	Tipranavir, co-administered with Ritonavir, may increase the concentration of Desipramine. Monitor Desipramine concentration and efficacy/toxicity and adjust dose as required.
DB00932	DB00829	Tipranavir may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for Diazepam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB00900	Tipranavir may decrease the concentration of Didanosine.
DB00932	DB00255	Diethylstilbestrol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Diethylstilbestrol. Monitor estrogen levels during concomitant therapy.
DB00932	DB00320	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Dihydroergotamine. Concomitant therapy is contraindicated.
DB00932	DB00343	Tipranavir, co-administered with Ritonavir, may alter the concentration of Diltiazem. Monitor for efficacy and adverse/toxic effects of Diltiazem.
DB00932	DB00822	Disulfiram may cause Tipranavir (Aptivus brand) toxicity by inhibiting alcohol metabolism. Aptivus capsules contain alcohol.
DB00932	DB00625	Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed.
DB00932	DB00063	Monitor therapy due to increased antiplatelet effect.
DB00932	DB01049	Tipranavir may increase the plasma concentration of Ergoloid mesylates. Concomitant therapy should be avoided.
DB00932	DB01253	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergonovine. Concomitant therapy is contraindicated.
DB00932	DB00696	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergotamine. Concomitant therapy is contraindicated.
DB00932	DB00736	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Esomeprazole. Consider alternate therapy or increase the dose of Esomeprazole based on the therapeutic response.
DB00932	DB01215	Tipranavir may decrease the metabolism and clearance of Estazolam. Consider alternate therapy or monitor for Estazolam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB00783	Estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estradiol. Use an alternate form of contraception or monitor for estrogen deficiency if Estradiol is used for hormone replacement therapy.
DB00932	DB00655	Estropipate may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estropipate. Monitor for estrogen deficiency during concomitant therapy.
DB00932	DB00977	Tipranavir, co-administered with Ritonavir, decreases Ethinyl estradiol concentrations. Ethinyl estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Use an alternate form of contraception or monitor for estrogen deficiency if Ethinyl estradiol is used for hormone replacement therapy.
DB00932	DB06414	Tipranavir, co-administered with Ritonavir, may decrease the effect of Etravirene by decreasing Etravirene serum concentration. Concomitant therapy should be avoided.
DB00932	DB01023	Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine.
DB00932	DB01195	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Flecainide. Concomitant therapy is contraindicated.
DB00932	DB00196	Fluconazole may increase the serum concentration of Tipranavir. Dose adjustments are not required.
DB00932	DB00472	Tipranavir increases the concentration of Fluoxetine. The Fluoxetine dose may require an adjustment.
DB00932	DB00690	Tipranavir may decrease the metabolism and clearance of Flurazepam. Consider alternate therapy or monitor for Flurazepam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB00588	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Fluticasone propionate. Concomitant therapy should be avoided if possible.
DB00932	DB01319	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Fosamprenavir. Consider alternate therapy.
DB00932	DB02703	Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents.
DB00932	DB00270	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Isradipine. Monitor for changes in Isradipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB00932	DB01167	Tipranavir may increase the serum concentration of Itraconazole.
DB00932	DB01026	Tipranavir may increase the serum concentration of Ketoconazole.
DB00932	DB01601	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Lopinavir. Consider alternate therapy.
DB00932	DB00227	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Lovastatin. Concomitant therapy is contraindicated.
DB00932	DB01357	Mestranol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Mestranol. Use an alternate form of contraception or monitor for estrogen deficiency if Mestranol is used for hormone replacement therapy.
DB00932	DB00333	Tipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal.
DB00932	DB00353	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Methylergonovine. Concomitant therapy is contraindicated.
DB00932	DB00683	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Midazolam. Concomitant therapy is contraindicated.
DB00932	DB00238	Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed.
DB00932	DB00622	Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine.
DB00932	DB01115	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nifedipine. Monitor for changes in Nifedipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB00932	DB00393	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nimodipine. Monitor for changes in Nimodipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB00932	DB00401	Tipranavir, co-administered with Ritonavir, may alter the concentration of Nisoldipine. Monitor for efficacy and adverse/toxic effects of Nisoldipine.
DB00932	DB01054	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nitrendipine. Monitor for changes in Nitrendipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB00932	DB00338	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response.
DB00932	DB00715	Tipranavir increases the concentration of Paroxetine. The Paroxetine dose may require an adjustment.
DB00932	DB01186	Tipranavir may increase the plasma concentration of Pergolide. Concomitant therapy should be avoided.
DB00932	DB00454	Tipranavir may increase the adverse/toxic effects of Meperidine. Consider alternate therapy or monitor for Meperidine toxicity during concomitant use.
DB00932	DB01174	Phenobarbial decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy.
DB00932	DB00252	Phenytoin decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy.
DB00932	DB01100	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Pimozide. Concomitant therapy is contraindicated.
DB00932	DB01263	Tipranavir may increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Tipranavir.
DB00932	DB00175	Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy.
DB00932	DB01588	Tipranavir may decrease the metabolism and clearance of Prazepam. Consider alternate therapy or monitor for Prazepam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB01182	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Propafenone. Concomitant therapy is contraindicated.
DB00932	DB01589	Tipranavir may decrease the metabolism and clearance of Quazepam. Consider alternate therapy or monitor for Quazepam toxic effects if Tipranavir is initiated or dose increased.
DB00932	DB00908	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Quinidine. Concomitant therapy is contraindicated.
DB00932	DB00243	Increased levels of ranolazine - risk of toxicity
DB00932	DB00615	Tipranavir increases the concentration of Rifabutin. Adjust Rifabutin dose and monitor for adverse/toxic effects.
DB00932	DB01045	Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended.
DB00932	DB01201	Concomitant therapy may cause decreased Tipranavir and increased Rifapentine plasma concentrations.
DB00932	DB01098	Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may increase Rosuvastatin and Tipranavir concentrations. Consider alternate therapy.
DB00932	DB01232	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Saquinavir. Consider alternate therapy.
DB00932	DB01104	Tipranavir increases the concentration of Sertraline. The Sertraline dose may require an adjustment.
DB00932	DB00203	Tipranavir, co-administered with Ritonavir, may increase the concentration of Sildenafil. Alternate therapy should be considered.
DB00932	DB00641	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Simvastatin. Concomitant therapy is contraindicated.
DB00932	DB00877	Tipranavir may affect the efficacy/toxicity of Sirolimus.
DB00932	DB01390	Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir.
DB00932	DB01323	St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided.
DB00932	DB00864	Tipranavir may decrease the metabolism and clearance of Tacrolimus. Dose adjustments may be required. Monitor for Tacrolimus efficacy and toxicity during concomitant therapy.
DB00932	DB00820	Tipranavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00932	DB06287	Tipranavir may affect the efficacy/toxicity of Temsirolimus.
DB00932	DB00342	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Terfenadine. Concomitant therapy is contraindicated.
DB00932	DB00277	Tipranavir, co-administered with Ritonavir, may decrease the concentration of Theophylline.
DB00932	DB00656	The protease inhibitor, Tipranavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tipranavir is initiated, discontinued or dose changed.
DB00932	DB00897	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Triazolam. Concomitant therapy is contraindicated.
DB00932	DB00313	Tipranavir decreases the concentration of Valproic acid. Monitor Valproid acid efficacy.
DB00932	DB00862	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Vardenafil. Concomitant therapy is contraindicated.
DB00932	DB00661	Tipranavir, co-administered with Ritonavir, may alter the concentration of Verapamil. Monitor for efficacy and adverse/toxic effects of Verapamil.
DB00932	DB00582	Voriconazole may increase the serum concentration of tipranavir by decreasing its metabolism. Tipranavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB00932	DB00495	Tipranavir decreases the concentration of Zidovudine.
DB00933	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00321	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00182	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00933	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB00933	DB01053	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01200	The phenothiazine decreases the effect of bromocriptine
DB00933	DB00608	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB01576	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB00343	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01075	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00843	Possible antagonism of action
DB00933	DB01142	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB01195	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00472	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00176	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00674	Possible antagonism of action
DB00933	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01170	Mesoridazine may decrease the effect of guanethidine.
DB00933	DB01218	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00502	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00458	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00933	DB00934	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB01577	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB01578	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00715	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00738	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01579	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB00830	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB00933	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00960	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01035	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01182	Increased risk of cardiotoxicity and arrhythmias.
DB00933	DB00571	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00468	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00989	Possible antagonism of action
DB00933	DB06144	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB06145	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Mesoridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB00933	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00933	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00933	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB00933	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00933	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00933	DB00662	Trimethobenzamide and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00933	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00933	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Mesoridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00933	DB00209	Trospium and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00933	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00933	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00933	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00933	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00934	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00934	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00934	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00934	DB00843	Possible antagonism of action
DB00934	DB00674	Possible antagonism of action
DB00934	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00934	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00934	DB00571	Propranolol increases the serum levels of cisapride
DB00934	DB00989	Possible antagonism of action
DB00934	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Maprotiline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00934	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00934	DB00857	Terbinafine may reduce the metabolism and clearance of Maprotiline. Consider alternate therapy or monitor for therapeutic/adverse effects of Maprotiline if Terbinafine is initiated, discontinued or dose changed.
DB00934	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00934	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00934	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00934	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00934	DB00752	Maprotiline may increase the adverse effects of the MAO inhibitor, Tranylcypromine. These agents should not be administered within 14 days of each other.
DB00934	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00945	DB00860	The corticosteroid, prednisolone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00934	DB00662	Trimethobenzamide and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00934	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00934	DB00427	Triprolidine and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00934	DB00209	Trospium and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00934	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00934	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00934	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00934	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB00934	DB00315	Use of two serotonin modulators, such as zolmitriptan and maprotiline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB00934	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00935	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Oxymetazoline. Concomitant therapy should be avoided.
DB00937	DB01063	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB01246	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00477	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00392	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00472	Risk of serotoninergic syndrome
DB00937	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00176	Risk of serotoninergic syndrome
DB00937	DB01170	Diethylpropion may decrease the effect of guanethidine.
DB00937	DB01247	Possible hypertensive crisis
DB00937	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00902	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00715	Risk of serotoninergic syndrome
DB00937	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00780	Possible hypertensive crisis
DB00937	DB00433	Decreased anorexic effect, may increase psychotic symptoms.
DB00937	DB00420	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB01069	Decreased anorexic effect, may increase psychotic symptoms.
DB00937	DB01608	Decreased anorexic effect, may increase psychotic symptoms.
DB00937	DB00777	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB01367	Possible hypertensive crisis
DB00937	DB00372	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00752	Possible hypertensive crisis
DB00937	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00508	Decreased anorexic effect, may increase psychotic symptoms
DB00937	DB00285	Risk of serotoninergic syndrome
DB00938	DB01193	Antagonism
DB00938	DB00335	Antagonism
DB00938	DB00612	Antagonism
DB00938	DB01136	Antagonism
DB00938	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. Concurrent use of salmeterol with strong inhibitors of CYP3A4 is not recommended according to salmeterol prescribing information.
DB00938	DB00187	Antagonism
DB00938	DB05039	Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs.
DB00938	DB00598	Antagonism
DB00938	DB00264	Antagonism
DB00938	DB01203	Antagonism
DB00938	DB01580	Antagonism
DB00938	DB00960	Antagonism
DB00938	DB00571	Antagonism
DB00938	DB01369	This combination presents an increased risk of toxicity
DB00938	DB00976	Telithromycin may reduce clearance of Salmeterol. Concomitant therapy is contraindicated.
DB00938	DB00373	Antagonism
DB00938	DB00582	Voriconazole, a strong CYP3A4 inhibitor may increase the serum concentration of salmeterol by decreasing its metabolism. Consider alternate therapy.
DB00939	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00939	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00939	DB00091	Monitor for nephrotoxicity
DB00939	DB06210	Increases levels of Meclofenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00939	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00939	DB00563	The NSAID, meclofenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00951	DB00822	Increased risk of CNS adverse effects
DB00939	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00939	DB00966	Concomitant use of Telmisartan and Meclofenamic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00939	DB00373	The NSAID, Meclofenamate, may antagonize the antihypertensive effect of Timolol.
DB00939	DB00519	The NSAID, Meclofenamate, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meclofenamate is initiated, discontinued or dose changed.
DB00939	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meclofenamate. Monitor for increased bleeding during concomitant thearpy.
DB00939	DB00682	The antiplatelet effects of meclofenamic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00940	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00940	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00940	DB00662	Trimethobenzamide and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00940	DB00427	Triprolidine and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00940	DB00209	Trospium and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00943	DB00900	Additive toxicities (peripheral neuropathy)
DB00943	DB00709	Lamivudine may reduce the efficacy of zalcitabine. Combination therapy is not recommended.
DB00943	DB00738	Additive risk of pancreatitis. Concomitant therapy should be avoided.
DB00943	DB00811	Ribavirin may increase the hepatotoxicity of zalcitabine. May cause lactic acidosis. MOnitor for lactic acidosis during concomitant therapy.
DB00944	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Demcarium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB00945	DB01418	Acetylsalicylic acid increases the effect of the anticoagulant, acenocoumarol.
DB00945	DB00819	Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide.
DB00945	DB00414	Acetylsalicylic acid increases the effect of sulfonylurea, acetohexamide.
DB00945	DB01125	Acetylsalicylic acid increases effect of the anticoagulant, anisindione.
DB00945	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00945	DB00443	The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB00672	Acetylsalicylic acid may increase the effect of the sulfonylurea, chlorpropamide.
DB00945	DB01380	The corticosteroid, cortisone acetate, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB01234	The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB01144	Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, dichlorphenamide.
DB00945	DB00266	Acetylsalicylic acid increases effect of the anticoagulant, dicumarol.
DB00945	DB06210	Decreases metabolism, will increase effect/level of eltrombopag.
DB00945	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00945	DB01120	Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide.
DB00945	DB01067	Acetylsalicylic acid increases the effect of the sulfonylurea, glipizide.
DB00945	DB01289	Acetylsalicylic acid increases the effect of the sulfonylurea, glisoxepide.
DB00945	DB01016	Acetylsalicylic acid increases the effect of the sulfonylurea, glibenclamide.
DB00945	DB01382	Acetylsalicylic acid increases the effect of sulfonylurea, glycodiazine.
DB00945	DB00400	Griseofulvin may decrease the efficacy of acetylsalicylic acid.
DB00945	DB01109	Increased risk of bleeding.
DB00945	DB04865	Avoid combination with acetylsalicylic acid due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
DB00945	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB01050	Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended.
DB00945	DB01009	Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended.
DB00945	DB00465	Acetylsalicylic acid may increase the adverse GI effects ketorolac.
DB00945	DB00703	Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB00945	DB00563	Acetylsalicylic acid increases the effect and toxicity of methotrexate.
DB00945	DB00959	The corticosteroid, methylprednisolone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB01384	The corticosteroid, paramethasone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00951	DB00266	Isoniazid may increase the anticoagulant effect of dicumarol.
DB00945	DB00635	The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB01032	Acetylsalicylic acid decreases the uricosuric effect of probenecid.
DB00945	DB00605	Risk of additive toxicity (e.g. bleed risk). Acetylsalicylic acid may decrease the serum concentration of sulindac. Sulindac may counteract the cardioprotective effects of acetylsalicylic acid. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB00945	DB00966	Concomitant use of Telmisartan and Acetylsalicylic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00945	DB01600	Increased risk of gastrointestinal bleeding.
DB00945	DB00208	Increased effect of ticlopidine
DB00945	DB00839	Acetylsalicylic acid increases the effect of the sulfonylurea, tolazamide.
DB00945	DB01124	Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide.
DB00945	DB00500	Additive adverse effects increase the risk of gastrointestinal bleeding. Possible decrease in the cardioprotective effect of acetylsalicylic acid. Monitor for increased bleeding risk during concomitant therapy.
DB00945	DB00519	Acetylsalicylic acid may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Acetylsalicylic acid is initiated, discontinued or dose changed.
DB00945	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Acetylsalicylic acid. Monitor for increased bleeding during concomitant thearpy.
DB00945	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00945	DB00313	Acetylsalicylic acid increases the effect of valproic acid.
DB00945	DB00682	The antiplatelet effects of acetylsalicylic acid may increase the bleed risk associated with warfarin.
DB00948	DB00618	Possible antagonism of action
DB00948	DB00254	Possible antagonism of action
DB00948	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00948	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB00948	DB01017	Possible antagonism of action
DB00948	DB00759	Possible antagonism of action
DB00949	DB00564	Decreased effect of both products
DB00949	DB00754	Increased phenytoin levels and decreased felbamate levels
DB00949	DB01320	Increased phenytoin levels and decreased felbamate levels
DB00949	DB00532	Increased phenytoin levels and decreased felbamate levels
DB00949	DB01174	Felbamate increases the effect and toxicity of phenobarbital/primidone
DB00949	DB00252	Increased phenytoin levels and decreased felbamate levels
DB00949	DB00794	Felbamate may increase the effect and toxicity of primidone.
DB00949	DB01369	This combination presents an increased risk of toxicity
DB00949	DB00976	Telithromycin may reduce clearance of Felbamate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felbamate if Telithromycin is initiated, discontinued or dose changed.
DB00949	DB00427	The CNS depressants, Triprolidine and Felbamate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00949	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB00949	DB00313	Felbamate, a CYP2C19 inhibitor, may decrease the metabolism of Valproic acid, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Felbamate is initiated, discontinued or dose changed.
DB00949	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felbamate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felbamate if voriconazole is initiated, discontinued or dose changed.
DB00950	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB00950	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Fexofenadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00950	DB00662	Trimethobenzamide and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00950	DB00427	Triprolidine and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00950	DB00209	Trospium and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00951	DB01418	Isoniazid may increase the anticoagulant effect of acenocoumarol.
DB00951	DB00316	Risk of hepatotoxicity
DB00951	DB01223	Isoniazid may increase the effect and toxicity of oxtriphylline.
DB00951	DB01125	Isoniazid may increase the anticoagulant effect of anisindione.
DB00951	DB01558	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if isoniazid is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00951	DB00564	Carbamazepine effect is increased as is isoniazid toxicity
DB00951	DB00395	Strong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB00951	DB01219	Isoniazid may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if isoniazid is initiated, discontinued or dose changed.
DB00951	DB00651	Increases the effect and toxicity of theophylline
DB00951	DB06210	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB00951	DB00754	Isoniazid increases the effect of phenytoin in 20% of patients
DB00951	DB01320	Isoniazid may increase the effect of phenytoin in 20% of patients.
DB00951	DB01026	Isoniazid decreases the effect of ketoconazole
DB00951	DB00532	Isoniazid increases the effect of phenytoin in 20% of patients
DB00951	DB01303	Isoniazid may increase the effect and toxicity of oxtriphylline.
DB00951	DB00454	Possible episodes of hypotension
DB00951	DB00252	Isoniazid increases the effect of phenytoin in 20% of patients
DB00951	DB00864	The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00820	Isoniazid may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00951	DB00675	Isoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00706	Isoniazid, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Isoniazid is initiated, discontinued, or dose changed.
DB00951	DB00976	Isoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00951	DB06287	Isoniazid may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00951	DB00444	The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00277	Isoniazid may increase the therapeutic and adverse effects of theophylline.
DB00951	DB00906	The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB01036	Isoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00951	DB00193	Isoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production.
DB00951	DB00656	The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00726	The strong CYP3A4/CYP2C19 inhibitor, Isoniazide, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00862	Isoniazid, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00951	DB00285	Isoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed.
DB00951	DB00661	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00570	Isoniazid, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00541	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00361	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Isoniazid is initiated, discontinued or dose changed.
DB00951	DB00682	Isoniazid may increase the anticoagulant effect of warfarin.
DB00951	DB00425	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if isoniazid is initiated, discontinued or dose changed.
DB00951	DB00909	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed.
DB00951	DB01198	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if isoniazid is initiated, discontinued or dose changed.
DB00952	DB00215	Increased risk of CNS adverse effects
DB00952	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00952	DB00320	Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated.
DB00952	DB01253	Possible severe and prolonged vasocontriction
DB00952	DB00696	Possible severe and prolonged vasoconstriction.
DB00952	DB01175	Increased risk of CNS adverse effects
DB00952	DB00472	Increased risk of CNS adverse effects
DB00952	DB00176	Increased risk of CNS adverse effects
DB00952	DB01247	The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.
DB00952	DB00353	Possible severe and prolonged vasocontriction
DB00952	DB00247	Possible severe and prolonged vasoconstriction.
DB00952	DB01149	Increased risk of CNS adverse effects
DB00952	DB00715	Increased risk of CNS adverse effects
DB00952	DB00780	The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.
DB00952	DB01104	Increased risk of CNS adverse effects
DB00952	DB01105	Increased risk of CNS adverse effects
DB00952	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00952	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00952	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00952	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00952	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00952	DB06684	Increased risk of serotonin syndrome
DB00952	DB00315	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and naratriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00953	DB00215	Increased risk of CNS adverse effects
DB00953	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00953	DB00320	Possible severe and prolonged vasoconstriction
DB00953	DB00696	Possible severe and prolonged vasoconstriction
DB00953	DB01175	Increased risk of CNS adverse effects
DB00953	DB00472	Increased risk of CNS adverse effects
DB00953	DB00176	Increased risk of CNS adverse effects
DB00953	DB01247	The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
DB00953	DB00247	Possible severe and prolonged vasoconstriction
DB00953	DB01171	The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
DB00953	DB01149	Increased risk of CNS adverse effects
DB00953	DB00715	Increased risk of CNS adverse effects
DB00953	DB00780	The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
DB00953	DB00571	Propranolol increases the effect and toxicity of rizatriptan
DB00953	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00953	DB00752	The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Rizatriptan. Risk of serotonin syndrome and Rizatriptan toxicity. Concomitant therapy should be avoided.
DB00953	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00953	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00953	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00953	DB00315	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and rizatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00954	DB00243	Increased levels of ranolazine - risk of toxicity
DB00954	DB00570	Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Dirithromycin is initiated, discontinued or dose changed.
DB00954	DB00541	Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Dirithromycin is initiated, discontinued or dose changed.
DB00954	DB00361	Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Dirithromycin is initiated, discontinued or dose changed.
DB00955	DB00732	The agent increases the effect of muscle relaxant
DB00955	DB00887	Increased ototoxicity
DB00955	DB01326	Increased risk of nephrotoxicity
DB00955	DB01139	Increased risk of nephrotoxicity
DB00955	DB01327	Increased risk of nephrotoxicity
DB00955	DB01328	Increased risk of nephrotoxicity
DB00955	DB01329	Increased risk of nephrotoxicity
DB00955	DB00923	Increased risk of nephrotoxicity
DB00955	DB00493	Increased risk of nephrotoxicity
DB00955	DB01330	Increased risk of nephrotoxicity
DB00955	DB01331	Increased risk of nephrotoxicity
DB00955	DB01333	Increased risk of nephrotoxicity
DB00955	DB00438	Increased risk of nephrotoxicity
DB00955	DB01332	Increased risk of nephrotoxicity
DB00955	DB01212	Increased risk of nephrotoxicity
DB00955	DB01112	Increased risk of nephrotoxicity
DB00955	DB03450	Increased risk of nephrotoxicity
DB00955	DB00515	Increased risk of nephrotoxicity
DB00955	DB01135	The agent increases the effect of muscle relaxant
DB00955	DB00903	Increased ototoxicity
DB00955	DB00695	Increased ototoxicity
DB00955	DB01336	The agent increases the effect of muscle relaxant
DB00955	DB01226	The agent increases the effect of muscle relaxant
DB00955	DB01337	The agent increases the effect of muscle relaxant
DB00955	DB01338	The agent increases the effect of muscle relaxant
DB00955	DB00728	The agent increases the effect of muscle relaxant
DB00955	DB00202	The agent increases the effect of muscle relaxant
DB00955	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Netilmicin. Use caution during concomitant therapy.
DB00955	DB01041	Thalidomide increases the renal toxicity of the aminoglycoside
DB00955	DB00214	Increased ototoxicity
DB00955	DB01199	The agent increases the effect of muscle relaxant
DB00955	DB01339	The agent increases the effect of muscle relaxant
DB00956	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB00956	DB06210	Increases levels of Hydrocodone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB00956	DB00427	The CNS depressants, Triprolidine and Hydrocodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00957	DB06697	Artemether may decrease the effectiveness of norgestimate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00957	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norgestimate, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB00957	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB00957	DB00599	Thiopental may decrease the effect of Norgestimate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00957	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Norgestimate. An alternate form of contraception should be used during concomitant therapy.
DB00957	DB00682	Norgestimate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestimate is initiated, discontinued or dose changed.
DB00958	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB00958	DB01248	Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent.
DB00958	DB01320	The antineoplasic agent decreases the effect of hydantoin
DB00958	DB01097	Immunosuppressants such as carboplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB00958	DB00108	Immunosuppressants such as natalizumab may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
DB00958	DB01229	Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as paclitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent.
DB00958	DB00252	The antineoplasic agent decreases the effect of hydantoin
DB00958	DB00337	Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.
DB00958	DB01656	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carboplatin. he Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB00958	DB00398	Sorafenib may enhance the adverse/toxic effect of carboplatin. Concurrent use of sorafenib with carboplatin and placlitaxel in patients with squamous cell lung cancer is contraindicated. The use of this combination in other settings is not specifically contraindicated, but any such use should be approached with added caution.
DB00958	DB00864	Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
DB00958	DB01030	Administration of Topotecan after Carboplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed.
DB00958	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00959	DB00945	The corticosteroid, methylprednisolone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB00959	DB00673	Increases the effect and toxicity of methylprednisolone
DB00959	DB01211	The macrolide, clarithromycin, may increase the effect of corticosteroid, methylprednisolone.
DB00959	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Methylprednisolone. Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for increased steroid related adverse effects.
DB00959	DB00199	The macrolide, erythromycin, may increase the effect of corticosteroid, methylprednisolone.
DB01017	DB01593	Formation of non-absorbable complexes
DB00959	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, methylprednisolone.
DB00959	DB01167	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.
DB00959	DB01026	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.
DB00959	DB00211	Increased arterial pressure
DB00959	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, methylprednisolone.
DB00959	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, methylprednisolone.
DB00959	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, methylprednisolone.
DB00959	DB00545	The corticosteroid, methylprednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB00959	DB01369	This combination presents an increased risk of toxicity
DB00959	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone.
DB00959	DB00382	Tacrine and Methylprednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB00959	DB00864	Methylprednisone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Methylprednisone therapy is initiated, discontinued or altered.
DB00959	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00959	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB00960	DB00414	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01223	Antagonism of action and increased effect of theophylline
DB00960	DB00477	Increased effect of both drugs
DB00960	DB00672	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB00575	Increased hypertension when clonidine stopped
DB00960	DB00320	Ischemia with risk of gangrene
DB00960	DB00343	Increased risk of bradycardia
DB00960	DB00280	The beta-blocker, pindolol, may increase the toxicity of disopyramide.
DB00960	DB00651	Antagonism of action and increased effect of theophylline
DB00960	DB00668	Hypertension, then bradycardia
DB00960	DB01253	Ischemia with risk of gangrene
DB00960	DB00696	Ischemia with risk of gangrene
DB00960	DB01288	Antagonism
DB00960	DB00983	Antagonism
DB00960	DB01120	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01067	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01289	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01016	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01382	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01050	Risk of inhibition of renal prostaglandins
DB00960	DB00328	Risk of inhibition of renal prostaglandins
DB00960	DB00047	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01064	Antagonism
DB00960	DB00281	The beta-blocker increases the effect and toxicity of lidocaine
DB00960	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB00960	DB00968	Possible hypertensive crisis
DB00960	DB00247	Ischemia with risk of gangrene
DB00960	DB00816	Antagonism
DB00960	DB01303	Antagonism of action and increased effect of theophylline
DB00960	DB00236	Antagonism
DB00960	DB01291	Antagonism
DB00960	DB00554	Risk of inhibition of renal prostaglandins
DB00960	DB00457	Risk of hypotension at the beginning of therapy
DB00960	DB01366	Antagonism
DB00960	DB00912	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01001	Antagonism
DB00960	DB00938	Antagonism
DB00960	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB00960	DB00871	Antagonism
DB00960	DB00277	Antagonism of action and increased effect of theophylline
DB00960	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB00960	DB00839	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB01124	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB00960	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00960	DB00661	Increased effect of both drugs
DB00962	DB00501	Cimetidine may increase the serum concentration of zaleplon by decreasing its metabolism. Reduce the initial dose of zaleplon to 5 mg in patients receiving cimetidine.
DB00962	DB01403	Additive CNS depressant effects may occur. A dose reduction of zaleplon may be required. Monitor for increased CNS depression during concomitant therapy.
DB00962	DB01045	Rifampin decreases the effect of zaleplon
DB00962	DB00427	The CNS depressants, Triprolidine and Zaleplon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00963	DB06781	NSAIDs may slow healing.
DB00963	DB06210	Eltrombopag increases levels of Bromfenac via metabolism decrease.
DB00964	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Apraclonidine. Concomitant therapy is contraindicated.
DB00964	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00966	DB00945	Concomitant use of Telmisartan and Acetylsalicylic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB01143	Telmisartan may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Telmisartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB00966	DB00594	Telmisartan may increase the hyperkalemic effect of Amiloride. Monitor for increased serum potassium concentrations during concomitant therapy.
DB00966	DB00482	Concomitant use of Telmisartan and Celecoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00586	Concomitant use of Telmisartan and Diclofenac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00861	Concomitant use of Telmisartan and Diflunisal may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00390	Telmisartan may increase plasma Digoxin concentrations. Monitor Digoxin levels and adjust dose as required if Telmisartan is initiated, discontinued or dose changed.
DB00966	DB01395	Telmisartan may increase the hyperkalemic effect of Drospirenone. Monitor for increased serum potassium concentrations during concomitant therapy.
DB00966	DB00573	Concomitant use of Telmisartan and Fenoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00712	Concomitant use of Telmisartan and Flurbiprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00328	Concomitant use of Telmisartan and Indomethacin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB01009	Concomitant use of Telmisartan and Ketoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00465	Concomitant use of Telmisartan and Ketorolac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB01356	Telmisartan may increase serum Lithium concentrations. Monitor serum Lithium levels during concomitant therapy to avoid Lithium toxicity.
DB00966	DB01283	Concomitant use of Telmisartan and Lumiracoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00939	Concomitant use of Telmisartan and Meclofenamic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00814	Concomitant use of Telmisartan and Meloxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00461	Concomitant use of Telmisartan and Nabumetone may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00788	Concomitant use of Telmisartan and Naproxen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00991	Concomitant use of Telmisartan and Oxaprozin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00554	Concomitant use of Telmisartan and Piroxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB01345	Potassium may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use.
DB00966	DB00761	Potassium Chloride may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use.
DB00966	DB00073	Telmisartan may increase the hypotensive effect of Rituximab. Telmisartan should be withheld prior to and throughout Rituximab administration.
DB00966	DB00421	Telmisartan may increase the hyperkalemic effect of Spironolactone. Monitor for increased serum potassium concentrations during concomitant therapy.
DB00966	DB00605	Concomitant use of Telmisartan and Sulindac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB01600	Concomitant use of Telmisartan and Tiaprofenic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00684	Increased risk of nephrotoxicity
DB00966	DB00500	Concomitant use of Telmisartan and Tolmetin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00966	DB00519	The angiotensin II receptor blocker, Telmisartan, may increase the adverse effects of Trandolapril.
DB00966	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00966	DB00384	Telmisartan may increase the hyperkalemic effect of Triamterene. Monitor for increased serum potassium concentrations during concomitant therapy.
DB00967	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desloratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00967	DB00427	Triprolidine and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00967	DB00209	Trospium and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00968	DB00521	Possible hypertensive crisis
DB00968	DB00841	Increased arterial pressure
DB00968	DB00988	Increased arterial pressure
DB00968	DB00494	Entacapone may increase the effect and toxicity of the sympathomimetic, methyldopa.
DB00968	DB01363	Increased arterial pressure
DB00968	DB01364	Increased arterial pressure
DB00968	DB00668	Increased arterial pressure
DB00968	DB01288	Increased arterial pressure
DB00968	DB00502	Methyldopa increases haloperidol effect or risk of psychosis
DB00968	DB01592	Iron decreases the absorption of dopa derivatives
DB00968	DB00893	Iron decreases the absorption of dopa derivatives
DB00968	DB01064	Increased arterial pressure
DB00968	DB01235	Methyldopa increases the effect and toxicity of levodopa
DB00968	DB01356	Methyldopa may increase the adverse effects of lithium without affecting lithium serum levels. Monitor for signs and symptoms of lithium toxicity during concomitant therapy.
DB00968	DB01365	Increased arterial pressure
DB00968	DB00610	Increased arterial pressure
DB00968	DB00723	Increased arterial pressure
DB00968	DB01203	Possible hypertensive crisis
DB00968	DB00368	Increased arterial pressure
DB00968	DB00816	Increased arterial pressure
DB00968	DB01580	Possible hypertensive crisis
DB00968	DB01359	Possible hypertensive crisis
DB00968	DB00388	Increased arterial pressure
DB00968	DB00397	Increased arterial pressure
DB00968	DB00960	Possible hypertensive crisis
DB00968	DB01291	Increased arterial pressure
DB00968	DB01366	Increased arterial pressure
DB00968	DB00571	Possible hypertensive crisis
DB00968	DB00852	Increased arterial pressure
DB00968	DB01001	Increased arterial pressure
DB00968	DB00489	Possible hypertensive crisis
DB00968	DB00871	Increased arterial pressure
DB00968	DB00373	Possible hypertensive crisis
DB00968	DB00752	The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Methyldopa. Concomitant therapy is contraindicated.
DB00969	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed.
DB00970	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00971	DB06210	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB00972	DB01551	Enhanced CNS depressant effects contraindicates concurrent use.
DB00972	DB08872	Avoid combination due to increased CNS depression.
DB00972	DB08883	Avoid combination with azelastine or other CNS depressants due to the combined increase of CNS depression.
DB00972	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Azelastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00972	DB00662	Trimethobenzamide and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00972	DB00427	Concomitant therapy with triprolidine and azelastine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy.
DB00972	DB00209	Trospium and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00973	DB01432	Cholestyramine may decrease the levels of ezetimibe.
DB00973	DB00091	Cyclosporine may increase the therapeutic and adverse effects of ezetimibe.
DB00973	DB00682	If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.
DB00974	DB01306	Monitor therapy due to enhanced hypoglycemic effect.
DB00975	DB00640	Dipyridamole may increase the effect/toxicity of adenosine.
DB00975	DB01073	Dipyridamole may decrease the effect of fludarabine.
DB00975	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00975	DB06213	Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration.
DB00975	DB01030	The p-glycoprotein inhibitor, Dipyridamole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB00975	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB00976	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB00976	DB01418	Telithromycin may increase the anticoagulant effect of acenocoumarol.
DB00976	DB00802	Telithromycin may reduce clearance of Alfentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Alfentanil if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00346	Telithromycin may reduce clearance of Alfuzosin. Consider alternate therapy.
DB00976	DB00404	Telithromycin may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB00976	DB06403	Telithromycin may reduce clearance of Ambrisentan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ambrisentan if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00357	Aminoglutethimide may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB01118	Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00381	Telithromycin may reduce clearance of Amlopidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amlopidine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00701	Co-administration may result in altered plasma concentrations of Amprenavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB01125	Telithromycin may increase the anticoagulant effect of anisindione.
DB00976	DB00673	Telithromycin may reduce clearance of Aprepitant. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aprepitant if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01238	Telithromycin may reduce clearance of Aripiprazole. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aripiprazole if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB06413	Telithromycin may reduce clearance of Armodafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Armodafinil if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00976	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB00976	DB01072	Co-administration may result in altered plasma concentrations of Atazanavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB01076	The macrolide antibiotic, telithromycin, may increase the serum concentration of atorvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if telithromycin is initiated, discontinued or dose changed.
DB00976	DB00865	Telithromycin may reduce clearance of Benzphetamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Benzphetamine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00612	Telithromycin may reduce clearance of Bisoprolol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bisoprolol if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00188	Telithromycin may reduce clearance of Bortezomib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bortezomib if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00559	Co-administration may cause decreased Telithromycin and increased Bosentan plasma concentrations. Consider alternate therapy.
DB00976	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB00976	DB01558	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if telithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB00976	DB01200	Telithromycin may reduce clearance of Bromocriptine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bromocriptine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01222	Telithromycin may reduce clearance of Budesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Budesonide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00921	Telithromycin may reduce clearance of Buprenorphine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buprenorphine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00490	Telithromycin may reduce clearance of Buspirone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buspirone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01008	Telithromycin may reduce clearance of Busulfan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Busulfan if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB00976	DB00136	Telithromycin may reduce clearance of Calcitriol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Calcitriol if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00564	Co-administration may cause decreased Telithromycin and increased Carbemazepine plasma concentrations. Consider alternate therapy.
DB00976	DB00475	Telithromycin may reduce clearance of Chlordiazepoxide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlordiazepoxide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00608	Telithromycin may reduce clearance of Chloroquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chloroquine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01114	Telithromycin may reduce clearance of Chlorpheniramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlorpheniramine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01410	Telithromycin may reduce clearance of Ciclesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ciclesonide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01166	Telithromycin may reduce clearance of Cilostazol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cilostazol if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01012	Telithromycin may reduce clearance of Cinacalcet. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cinacalcet if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00604	Telithromycin may reduce clearance of Cisapride. Concomitant therapy is contraindicated.
DB00976	DB00215	Telithromycin may reduce clearance of Citalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Citalopram if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01211	Co-administration may result in altered plasma concentrations of Clarithromycin and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB00349	Telithromycin may reduce clearance of Clobazam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clobazam if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01068	Telithromycin may reduce clearance of Clonazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clonazepam if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00628	Telithromycin may reduce clearance of Clorazepate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clorazepate if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00907	Telithromycin may reduce clearance of Cocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cocaine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01394	Telithromycin may reduce clearance of Colchicine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Colchicine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00683	Telithromycin may increase the effect and toxicity of the benzodiazepine, midazolam.
DB00976	DB00872	Co-administration may result in altered plasma concentrations of Conivaptan and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB00091	Telithromycin may reduce clearance of cyclosporine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of cyclosporine if telithromycin is initiated, discontinued or dose changed.
DB00976	DB01219	Telithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if telithromycin is initiated, discontinued or dose changed.
DB00976	DB00250	Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00496	Telithromycin may reduce clearance of Darifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Darifenacin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01264	Co-administration may result in altered plasma concentrations of Darunavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB01254	Telithromycin may reduce clearance of Dasatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dasatinib if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00705	Delavirdine may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB01234	Co-administration may cause decreased Telithromycin and increased Dexamethasone plasma concentrations. Consider alternate therapy.
DB00976	DB00829	Telithromycin may reduce clearance of Diazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diazepam if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00266	Telithromycin may increase the anticoagulant effect of dicumarol.
DB00976	DB01396	Telithromycin may reduce clearance of Digitoxin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Digitoxin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00390	Telithromycin may increase the plasma concentration of Digoxin. Monitor for changes in Digoxin efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00320	Telithromycin may reduce clearance of Dihydroergotamine. Concomitant therapy is contraindicated.
DB00976	DB00343	Telithromycin may reduce clearance of Diltiazem. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diltiazem if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00280	Telithromycin may reduce clearance of Disopyramide. Concomitant therapy should be avoided.
DB00976	DB01248	Telithromycin may reduce clearance of Docetaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Docetaxel if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00976	DB01142	Telithromycin may reduce clearance of Doxepin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxepin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00997	Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB05331	Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB04855	Telithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB00976	DB00625	Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB00216	Telithromycin may reduce clearance of Eletriptan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eletriptan if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00700	Telithromycin may reduce clearance of Eplerenone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eplerenone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01049	Telithromycin may reduce clearance of Ergoloid mesylates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergoloid mesylates if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01253	Telithromycin may reduce clearance of Ergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergonivine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00696	Telithromycin may reduce clearance of Ergotamine. Concomitant therapy is contraindicated.
DB00976	DB00530	Telithromycin may reduce clearance of Erlotinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erlotinib if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00199	Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01175	Telithromycin may reduce clearance of Escitalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Escitalopram if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00402	Telithromycin may reduce clearance of Eszopiclone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eszopiclone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00593	Telithromycin may reduce clearance of Ethosuximide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ethosuximide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00773	Telithromycin may reduce clearance of Etoposide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Etoposide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00949	Telithromycin may reduce clearance of Felbamate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felbamate if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01023	Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00813	Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00180	Telithromycin may reduce clearance of Flunisolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flunisolide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00690	Telithromycin may reduce clearance of Flurazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flurazepam if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00499	Telithromycin may reduce clearance of Flutamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flutamide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00588	Telithromycin may reduce clearance of Fluticasone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fluticasone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01319	Fosamprevavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB01320	Fosphenytoin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB00317	Telithromycin may reduce clearance of Gefitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Gefitinib if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01218	Telithromycin may reduce clearance of Halofantrine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Halofantrine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00502	Telithromycin may reduce clearance of Haloperidol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Haloperidol if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01181	Telithromycin may reduce clearance of Ifosfamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ifosfamide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00619	Co-administration may result in altered plasma concentrations of Imatinib and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB00224	Indinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB00762	Telithromycin may reduce clearance of Irinotecan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Irinotecan if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00951	Isoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB00883	Telithromycin may reduce clearance of Isosorbide Dinitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Dinitrate if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01020	Telithromycin may reduce clearance of Isosorbide Mononitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Mononitrate if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00270	Telithromycin may reduce clearance of Isradipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isradipine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01167	Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB08820	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB00976	DB04845	Telithromycin may reduce clearance of Ixabepilone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ixabepilone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01221	Telithromycin may reduce clearance of Ketamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ketamine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01026	Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB01259	Telithromycin may reduce clearance of Lapatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lapatinib if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00281	Telithromycin may reduce clearance of Lidocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lidocaine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01601	Lopinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB00227	Telithromycin may increase the adverse effects of lovastatin by decreasing its metabolism. Concomitant therapy should be avoided.
DB00976	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB00976	DB04835	Telithromycin may reduce clearance of Maraviroc. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Maraviroc if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00358	Telithromycin may reduce clearance of Mefloquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mefloquine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00333	Telithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00353	Telithromycin may reduce clearance of Methylergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methylergonovine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00247	Risk of ergotism and severe ischemia with this association
DB00976	DB00264	Telithromycin may possibly increase metoprolol effect
DB00976	DB01110	Miconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB00370	Telithromycin may reduce clearance of Mirtazapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mirtazapine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00745	Telithromycin may reduce clearance of Modafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Modafinil if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00680	Telithromycin may reduce clearance of Moricizine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Moricizine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00607	Nafcillin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB00731	Telithromycin may reduce clearance of Nateglenide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nateglenide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01149	Co-administration may result in altered plasma concentrations of Nefazodone and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB00220	Nelfinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB00238	Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB00622	Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB00976	DB01115	Telithromycin may reduce clearance of Nifedipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nifedipine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB04868	Telithromycin may reduce clearance of Nilotinib. Concomitant therapy should be avoided.
DB00976	DB00393	Telithromycin may reduce clearance of Nimodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nimodipine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00401	Telithromycin may reduce clearance of Nisoldipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nisoldipine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01054	Telithromycin may reduce clearance of Nitrendipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nitrendipine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00776	Oxcarbazepine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB01229	Telithromycin may reduce clearance of Paclitaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Paclitaxel if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00312	Pentobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB01186	Telithromycin may reduce clearance of Pergolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pergolide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB03575	Telithromycin may reduce clearance of Phencyclidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Phencyclidine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01174	Phenobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB00252	Phenytoin may decrease the plasma concentration of Telithromycin by increasing its metabolism. Consider alternate therapy.
DB00976	DB01100	Telithromycin may reduce clearance of Pimozide. Concomitant therapy is contraindicated.
DB00976	DB01621	Telithromycin may reduce clearance of Pipotiazine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pipotiazine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB00976	DB01263	Posaconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB01058	Telithromycin may reduce clearance of Praziquantel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Praziquantel if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00794	Primidone may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB01224	Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00908	Co-administration may result in altered plasma concentrations of Quinidine and/or Telithromycin. Consider alternate therapy or monitor for changes in the the therapeutic/adverse effects of both agents during concomitant therapy.
DB00976	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB00976	DB00468	Telithromycin may reduce clearance of Quinine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quinine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00243	Telithromycin may reduce clearance of Ranolazine. Concomitant therapy should be avoided.
DB00976	DB08896	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB00976	DB00912	Telithromycin may reduce clearance of Repaglinide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Repaglinide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00615	Rifabutin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB01045	Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided.
DB00976	DB01201	Rifapentine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB00976	DB00503	Ritonavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB06228	Telithromycin may reduce clearance of Rivaroxaban. Concomitant therapy is contraindicated.
DB00976	DB00938	Telithromycin may reduce clearance of Salmeterol. Concomitant therapy is contraindicated.
DB00976	DB01232	Saquinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB00976	DB01105	Telithromycin may reduce clearance of Sibutramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sibutramine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00203	Telithromycin may reduce clearance of Sildenafil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sildenafil if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00641	Telithromycin may increase the adverse effects of simvastatin by decreasing its metabolism. Concomitant therapy should be avoided.
DB00976	DB00877	Telithromycin may reduce clearance of Sirolimus. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sirolimus if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01591	Telithromycin may reduce clearance of Solifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Solifenacin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00489	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB00976	DB06145	Telithromycin may reduce clearance of Spiramycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Spiramycin if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00708	Telithromycin may reduce clearance of Sufentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sufentanil if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01268	Telithromycin may reduce clearance of Sunitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sunitinib if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Telithromycin, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance.
DB00976	DB00820	Telithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB00976	DB00675	Telithromycin may reduce clearance of Tamoxifen. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tamoxifen if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00706	Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Telithromycin is initiated, discontinued, or dose changed.
DB00976	DB06287	Telithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB00976	DB00444	The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB00976	DB04844	Telithromycin may increase the QTc-prolonging effect of Tetrabenazine. Concomitant therapy should be avoided.
DB00976	DB00277	Telithromycin may reduce clearance of Theophylline. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Theophylline if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00679	Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided.
DB00976	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB00976	DB00906	The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB01036	Telithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB00976	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB00976	DB00193	Telithromycin may decrease the metabolism and clearance of tramadol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of tramadol if telithromycin is initiated, discontinued or dose changed.
DB00976	DB00656	The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00897	Telithromycin may increase the effect and toxicity of the benzodiazepine, triazolam.
DB00976	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Telithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution.
DB00976	DB00313	The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00862	Telithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB00976	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB00976	DB00285	Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Telithromycin is initiated, discontinued, or dose changed.
DB00976	DB00661	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed.
DB00977	DB01320	This product may cause a slight decrease of contraceptive effect
DB00977	DB00400	This product may cause a slight decrease of contraceptive effect
DB00976	DB00570	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00541	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00361	Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Telithromycin is initiated, discontinued or dose changed.
DB00976	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of telithromycin by decreasing its metabolism. Telithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. QTc interval prolongation may also occur.
DB00976	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00976	DB00682	Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy.
DB00976	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB00976	DB00425	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if telithromycin is initiated, discontinued or dose changed.
DB00976	DB00909	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if telithromycin is initiated, discontinued or dose changed.
DB00976	DB01198	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if telithromycin is initiated, discontinued or dose changed.
DB00976	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB00977	DB01418	Increased thrombotic risk due to estrogen
DB00977	DB01223	The contraceptive increases the effect and toxicity of theophylline
DB00977	DB01351	This product may cause a slight decrease of contraceptive effect
DB00977	DB01060	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00415	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00701	Ritonavir could decrease the contraceptive efficacy
DB00977	DB01125	Increased thrombotic risk due to estrogen
DB00977	DB00673	Aprepitant could decrease the effect of the oral contraceptive
DB00977	DB01352	This product may cause a slight decrease of contraceptive effect
DB00977	DB06697	Artemether may decrease the effectiveness of ethinyl estradiol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB00977	DB01061	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00355	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB01602	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB06769	Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine.
DB00977	DB00559	Bosentan may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
DB00977	DB00237	This product may cause a slight decrease of contraceptive effect
DB00977	DB00241	This product may cause a slight decrease of contraceptive effect
DB00977	DB01353	This product may cause a slight decrease of contraceptive effect
DB00977	DB00564	Carbamazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with carbamazepine.
DB00977	DB00766	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB01147	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain.
DB00977	DB01000	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00091	The contraceptive increases the effect and toxicity of cyclosporine
DB00977	DB00618	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00485	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00266	Increased thrombotic risk due to estrogen
DB00977	DB00254	Doxycycline may decrease the contraceptive effect of ethinyl estradiol.
DB00977	DB00651	The contraceptive increases the effect and toxicity of theophylline
DB00977	DB06210	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB00977	DB00754	This product may cause a slight decrease of contraceptive effect
DB00977	DB01628	Etoricoxib may increase the levels of ethinyl estradiol.
DB00977	DB00301	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB01354	This product may cause a slight decrease of contraceptive effect
DB00977	DB00739	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB01355	This product may cause a slight decrease of contraceptive effect
DB00977	DB01026	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00555	The oral contraceptive decreases the effect of lamotrigine
DB00977	DB00532	This product may cause a slight decrease of contraceptive effect
DB00977	DB00931	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00474	This product may cause a slight decrease of contraceptive effect
DB00977	DB00849	This product may cause a slight decrease of contraceptive effect
DB00977	DB01603	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00948	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB01017	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00745	Modafinil may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on during concomitant therapy with modafinil.
DB00977	DB00607	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00220	Ritonavir could decrease the contraceptive efficacy
DB00977	DB00713	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00776	Oxcarbazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied upon during concomitant therapy with oxcarbazepine.
DB00977	DB01303	The contraceptive increases the effect and toxicity of theophylline
DB00977	DB00595	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00312	This product may cause a slight decrease of contraceptive effect
DB00977	DB01174	This product may cause a slight decrease of contraceptive effect
DB00977	DB00252	This product may cause a slight decrease of contraceptive effect
DB00977	DB00319	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB01604	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00860	The estrogenic agent, ethinyl estradiol, may increase the effect of the corticosteroid, prednisolone.
DB00977	DB00635	The estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone.
DB00977	DB00794	This product may cause a slight decrease of contraceptive effect
DB00977	DB00481	Association not recommended
DB00977	DB00615	Rifabutin may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.
DB00977	DB01045	This product may cause a slight decrease of contraceptive effect
DB00977	DB01201	This product may cause a slight decrease of contraceptive effect
DB00977	DB00503	Ritonavir could decrease the contraceptive efficacy
DB00977	DB01301	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB06201	Rufinamide decreases plasma concentrations of ethinyl estradiol, thus consider therapy modification
DB00977	DB00418	This product may cause a slight decrease of contraceptive effect
DB00977	DB01323	St. John's Wort could reduce the contraceptive effect
DB00977	DB00864	Ethinyl estradiol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ethinyl estradiol therapy is initiated, discontinued or altered.
DB00977	DB00306	This product may cause a slight decrease of contraceptive effect
DB00977	DB01606	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00759	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00277	The contraceptive increases the effect and toxicity of theophylline
DB00977	DB00599	Thiopental may decrease the effect of Ethinyl estradiol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB00977	DB01607	This anti-infectious agent could decrease the effect of the oral contraceptive
DB00977	DB00932	Tipranavir, co-administered with Ritonavir, decreases Ethinyl estradiol concentrations. Ethinyl estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Use an alternate form of contraception or monitor for estrogen deficiency if Ethinyl estradiol is used for hormone replacement therapy.
DB00977	DB00697	Ethinyl estradiol may increase the serum concentration of tizanidine. Monitor for changes in the therapeutic and adverse effects of tizanidine if ethinyl estradiol is initiated, discontinued or dose changed.
DB00977	DB00273	Topiramate may decrease the effect of the oral contraceptive, Ethinyl estradiol. An alternate form of contraception should be used during concomitant therapy.
DB00977	DB00755	Oral Tretinoin may decrease the effect of the oral contraceptive, Ethinyl Estradiol. An alternate form of contraception should be used during concomitant therapy.
DB00977	DB00197	Possible loss of contracepitve effect
DB00977	DB01586	Estrogens decreases the effect of ursodiol
DB00977	DB00682	Ethinyl estradiol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethinyl estradiol is initiated, discontinued or dose changed.
DB00978	DB01373	Formation of non-absorbable complexes
DB00978	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as lomefloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB00978	DB00893	Formation of non-absorbable complexes
DB00978	DB01378	Formation of non-absorbable complexes
DB00988	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dopamine.
DB00988	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dopamine.
DB00979	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclopentolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00979	DB00427	Triprolidine and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00979	DB00209	Trospium and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00980	DB01072	Atazanavir increases levels/toxicity of ramelteon
DB00980	DB00537	Ciprofloxacin increases levels/toxicity of ramelteon
DB00980	DB00467	Enoxacin increases levels/toxicity of ramelteon
DB00980	DB00196	Fluconazole may increase the serum levels and toxcity of ramelteon.
DB00980	DB00176	Fluvoxamine may increase the serum level and toxicity of ramelteon.
DB00980	DB01026	Ketoconazole may increase the serum levels and toxicity of ramelteon.
DB00980	DB00379	Mexiletine increases levels/toxicity of ramelteon
DB00980	DB01045	Rifampin reduces the levels/effect of ramelteon
DB00980	DB00382	Tacrine increases levels/toxicity of ramelteon
DB00980	DB00730	Thiabendazole increases levels/toxicity of ramelteon
DB00980	DB00427	The CNS depressants, Triprolidine and Ramelteon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00980	DB00744	Zileuton increases levels/toxicity of ramelteon
DB00982	DB00564	Isotretinoine decreases the effect of carbamazepine
DB00982	DB00618	Increased risk of intracranial hypertension
DB00982	DB00254	Increased risk of intracranial hypertension
DB00982	DB00931	Increased risk of intracranial hypertension
DB00982	DB01017	Increased risk of intracranial hypertension
DB00982	DB00595	Increased risk of intracranial hypertension
DB00982	DB01301	Increased risk of intracranial hypertension
DB00982	DB00759	Increased risk of intracranial hypertension
DB00982	DB00162	Isotretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking isotretinoin.
DB00983	DB01193	Antagonism
DB00983	DB00335	Antagonism
DB00983	DB00195	Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like formoterol. Therapy should be monitored.
DB00983	DB01295	Antagonism
DB00983	DB00612	Antagonism
DB00983	DB00521	Antagonism
DB00983	DB01136	Antagonism
DB00983	DB00187	Antagonism
DB00983	DB05039	Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs.
DB00983	DB00598	Antagonism
DB00983	DB00264	Antagonism
DB00983	DB01203	Antagonism
DB00983	DB01580	Antagonism
DB00983	DB01359	Antagonism
DB00983	DB00960	Antagonism
DB00983	DB01297	Antagonism
DB00983	DB00571	Antagonism
DB00983	DB00489	Antagonism
DB00983	DB00373	Antagonism
DB00984	DB00682	Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.
DB00985	DB00843	Possible antagonism of action
DB00985	DB00674	Possible antagonism of action
DB00985	DB00989	Possible antagonism of action
DB00985	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dimenhydrinate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00985	DB00662	Trimethobenzamide and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00985	DB00427	Triprolidine and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB00985	DB00209	Trospium and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00986	DB00843	Possible antagonism of action
DB00986	DB00674	Possible antagonism of action
DB00986	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB00986	DB00989	Possible antagonism of action
DB00986	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Glycopyrrolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB00986	DB00662	Trimethobenzamide and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00986	DB00427	Triprolidine and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00986	DB00209	Trospium and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB00987	DB00390	The antineoplasic agent decreases the effect of digoxin
DB00987	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00988	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dopamine.
DB00988	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dopamine.
DB00988	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dopamine.
DB00988	DB00494	Entacapone increases the effect and toxicity of the sympathomimetic, dopamine.
DB00988	DB01320	Risk of severe hypotension
DB00988	DB01170	Dopamine may decrease the effect of guanethidine.
DB00988	DB00070	Consider modifying therapy due to enhanced adverse effects of dopamine.
DB00988	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dopamine.
DB00988	DB01247	Increased arterial pressure
DB00988	DB00601	Possible increase of arterial pressure
DB00988	DB08815	Dopamine increases toxicity (enhanced hypotensive effects) of lurasidone.
DB00988	DB00968	Increased arterial pressure
DB00988	DB00211	Increased arterial pressure
DB00988	DB01171	Moclobemide increases the sympathomimetic effect of dopamine.
DB00988	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dopamine.
DB00988	DB00780	Increased arterial pressure
DB00988	DB00252	Risk of severe hypotension
DB00988	DB01367	Increased arterial pressure
DB00988	DB00206	Increased arterial pressure
DB00989	DB00915	Possible antagonism of action
DB00989	DB00321	Possible antagonism of action
DB00989	DB00543	Possible antagonism of action
DB00989	DB00719	Possible antagonism of action
DB00989	DB00245	Possible antagonism of action
DB00989	DB00810	Possible antagonism of action
DB00989	DB00835	Possible antagonism of action
DB00989	DB01114	Possible antagonism of action
DB00989	DB00477	Possible antagonism of action
DB00989	DB01239	Possible antagonism of action
DB00989	DB00501	Possible antagonism of action
DB00989	DB00283	Possible antagonism of action
DB00989	DB01242	Possible antagonism of action
DB00989	DB00363	Possible antagonism of action
DB00989	DB01176	Possible antagonism of action
DB00989	DB00924	Possible antagonism of action
DB00989	DB00434	Possible antagonism of action
DB00989	DB00496	Possible antagonism of action
DB00989	DB01151	Possible antagonism of action
DB00989	DB00804	Possible antagonism of action
DB00989	DB00985	Possible antagonism of action
DB00989	DB01075	Possible antagonism of action
DB00989	DB00280	Possible antagonism of action
DB00989	DB01142	Possible antagonism of action
DB00989	DB01148	Possible antagonism of action
DB00989	DB00875	Possible antagonism of action
DB00989	DB01437	Possible antagonism of action
DB00989	DB00986	Possible antagonism of action
DB00989	DB00557	Possible antagonism of action
DB00989	DB00424	Possible antagonism of action
DB00989	DB00458	Possible antagonism of action
DB00989	DB01247	Possible antagonism of action
DB00989	DB00408	Possible antagonism of action
DB00989	DB00934	Possible antagonism of action
DB00989	DB00737	Possible antagonism of action
DB00989	DB00933	Possible antagonism of action
DB00989	DB01403	Possible antagonism of action
DB00989	DB00370	Possible antagonism of action
DB00989	DB01171	Possible antagonism of action
DB00989	DB00540	Possible antagonism of action
DB00989	DB00334	Possible antagonism of action
DB00989	DB01173	Possible antagonism of action
DB00989	DB01062	Possible antagonism of action
DB00989	DB00850	Possible antagonism of action
DB00989	DB00454	Possible antagonism of action
DB00989	DB00780	Possible antagonism of action
DB00989	DB01100	Possible antagonism of action
DB00989	DB01035	Possible antagonism of action
DB00989	DB00433	Possible antagonism of action
DB00989	DB01069	Possible antagonism of action
DB00989	DB01608	Possible antagonism of action
DB00989	DB01224	Possible antagonism of action
DB00989	DB00908	Possible antagonism of action
DB00989	DB01622	Possible antagonism of action
DB00989	DB00679	Possible antagonism of action
DB00989	DB00697	Possible antagonism of action
DB00989	DB00656	Possible antagonism of action
DB00989	DB00831	Possible antagonism of action
DB00989	DB00376	Possible antagonism of action
DB00989	DB00662	The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00989	DB00209	The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.
DB00990	DB06414	Exemestane, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dosage of exemestane and to closely monitor therapy for efficacy and toxicity.
DB00991	DB01418	The NSAID, oxaprozin, may increase the anticoagulant effect of acenocoumarol.
DB00991	DB00630	Increased risk of gastric toxicity
DB00991	DB01125	The NSAID, oxaprozin, may increase the anticoagulant effect of anisinodione.
DB00991	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB00991	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB00991	DB00091	Monitor for nephrotoxicity
DB00991	DB00266	The NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol.
DB00991	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB00991	DB00563	The NSAID, oxaprozin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB00991	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB00991	DB00966	Concomitant use of Telmisartan and Oxaprozin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB00991	DB00373	The NSAID, Oxaprozin, may antagonize the antihypertensive effect of Timolol.
DB00991	DB00519	The NSAID, Oxaprozin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Oxaprozin is initiated, discontinued or dose changed.
DB00991	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy.
DB00991	DB00682	The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB00993	DB01418	Azathioprine may decrease the anticoagulant effect of acenocoumarol.
DB00993	DB00437	Allopurinol may increase the effect of thiopurine, azathioprine.
DB00993	DB00233	Aminosalicylic acid may increase the toxicity of thiopurine, azathioprine.
DB00993	DB01125	Azathioprine may decrease the anticoagulant effect of anisindione.
DB00993	DB00732	The agent decreases the effect of the muscle relaxant
DB00993	DB06168	results in increased immunosuppressive effects; increases the risk of infection.
DB00993	DB00266	Azathioprine may decrease the anticoagulant effect of dicumarol.
DB00993	DB01135	The agent decreases the effect of the muscle relaxant
DB00993	DB04854	Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes.
DB00993	DB00244	Mesalazine may increase the toxicity of thiopurine, azathioprine.
DB00993	DB01336	The agent decreases the effect of the muscle relaxant
DB00993	DB01226	The agent decreases the effect of the muscle relaxant
DB00993	DB01250	Olsalazine may increase the toxicity of thiopurine, azathioprine.
DB00993	DB01337	The agent decreases the effect of the muscle relaxant
DB00993	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB00993	DB00795	Sulfasalazine may increase the toxicity of thiopurine, azathioprine.
DB00993	DB00519	Trandolapril may increase the risk of neutropenia. Monitor for increased toxic effects of Azathioprine if Trandolapril is initiated or dose increased.
DB00993	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00993	DB01199	The agent decreases the effect of the muscle relaxant
DB00993	DB01339	The agent decreases the effect of the muscle relaxant
DB00993	DB00682	Azathioprine may decrease the anticoagulant effect of warfarin.
DB00994	DB00493	Increased risk of nephrotoxicity
DB00994	DB01330	Increased risk of nephrotoxicity
DB00994	DB01331	Increased risk of nephrotoxicity
DB00994	DB00438	Increased risk of nephrotoxicity
DB00994	DB01212	Increased risk of nephrotoxicity
DB00994	DB01111	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB00994	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Neomycin. Use caution during concomitant therapy.
DB00994	DB01607	Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB00996	DB00754	Increases the effect of hydantoin
DB00996	DB01320	Gabapentin may increase the effect of fosphenytoin.
DB00996	DB00532	Increases the effect of hydantoin
DB00996	DB00252	Gabapentin may increase the therapeutic and adverse effects of phenytoin.
DB00996	DB00427	The CNS depressants, Triprolidine and Gabapentin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB00997	DB06695	P-Glycoprotein inducers such as doxorubicin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB00997	DB00390	The antineoplasic agent decreases the effect of digoxin
DB00997	DB00976	Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed.
DB00997	DB00857	Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed.
DB00997	DB00072	Trastuzumab may increase the cardiotoxicity of Doxorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB00997	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of doxorubicin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxorubicin if voriconazole is initiated, discontinued or dose changed.
DB00997	DB00495	Additive myelosuppression may occur. Doxorubicin may decrease the efficacy of zidovudine. Concomitant therapy should be avoided.
DB00998	DB00215	Increased risk of CNS adverse effects
DB00998	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00998	DB00320	Possible severe and prolonged vasoconstriction
DB00998	DB01253	Possible severe and prolonged vasoconstriction
DB00998	DB00696	Possible severe and prolonged vasoconstriction
DB00998	DB01175	Increased risk of CNS adverse effects
DB00998	DB00472	Increased risk of CNS adverse effects
DB00998	DB00176	Increased risk of CNS adverse effects
DB00998	DB00353	Possible severe and prolonged vasoconstriction
DB00998	DB00247	Possible severe and prolonged vasoconstriction
DB00998	DB01149	Increased risk of CNS adverse effects
DB00998	DB00715	Increased risk of CNS adverse effects
DB00998	DB01104	Increased risk of CNS adverse effects
DB00998	DB01105	Increased risk of CNS adverse effects
DB00998	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00998	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB00998	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00998	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00998	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB00998	DB00315	Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and frovatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB00999	DB01078	Possible electrolyte variations and arrhythmias
DB00999	DB01119	Significant hyperglycemic effect
DB00999	DB01396	Possible electrolyte variations and arrhythmias
DB00999	DB00390	Possible electrolyte variations and arrhythmias
DB00999	DB01551	Dihydrocodeine may enhance the hypotensive effects of thiazide diuretics. \r\nIt is recommended to monitor therapy.
DB00999	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB00999	DB05039	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB00999	DB00046	Concomitant therapy with diuretics may reduce the blood-glucose-lowering effect of insulin lispro.
DB00999	DB01356	The thiazide diuretic, hydrochlorothiazide, may increase serum levels of lithium.
DB00999	DB00469	Tenoxicam may antagonize the blood pressure lowering effect of Hydrochlorothiazide. Monitor for changes in the therapeutic effect of Hydrochlorothiazide if Tenoxicam is initiated, discontinued or dose changed.
DB00999	DB00519	The thiazide diuretic, Hydrochlorothiazide, may increase the hypotensive effect of Trandolapril. Hydrochlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB00999	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01000	DB00618	Possible antagonism of action
DB01000	DB00254	Possible antagonism of action
DB01000	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01000	DB01017	Possible antagonism of action
DB01000	DB00759	Possible antagonism of action
DB01001	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of salbutamol.
DB01001	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of salbutamol.
DB01001	DB00335	Antagonism
DB01001	DB00612	Antagonism
DB01001	DB01136	Antagonism
DB01001	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of salbutamol.
DB01001	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of salbutamol.
DB01001	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of salbutamol.
DB01001	DB00187	Antagonism
DB01001	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of salbutamol.
DB01001	DB01247	Increased arterial pressure
DB01001	DB00598	Antagonism
DB01001	DB00601	Possible increase of arterial pressure
DB01001	DB00968	Increased arterial pressure
DB01001	DB00264	Antagonism
DB01001	DB00211	Increased arterial pressure
DB01001	DB01171	Moclobemide increases the sympathomimetic effect of salbutamol.
DB01001	DB01203	Antagonism
DB01001	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of salbutamol.
DB01001	DB01580	Antagonism
DB01001	DB00780	Increased arterial pressure
DB01001	DB00960	Antagonism
DB01001	DB00571	Antagonism
DB01001	DB01367	Increased arterial pressure
DB01001	DB00206	Increased arterial pressure
DB01001	DB00373	Antagonism
DB01004	DB01048	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Ganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is required.
DB01004	DB00900	The antiviral agent, ganciclovir, may increase the effect and toxicity of didanosine.
DB01004	DB01032	Probenecid increases the effect and toxicity of ganciclovir/valganciclovir
DB01004	DB00495	Increased risk of hematologic toxicity. Concomitant therapy should be avoided.
DB01005	DB08879	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB01005	DB06769	May increase risk of myelosuppression.
DB01005	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01008	DB06769	Increases toxicity through pharmacodynamic synergism.
DB01008	DB01167	Itraconazole reduced busulfan clearance by up to 25% in patients receiving itraconazole compared to those that did not receive it. Concomitant therapy may lead to toxic plasma levels of busulfan.
DB01008	DB00916	Metronidazole increases the effect/toxicity of busulfan
DB01008	DB00976	Telithromycin may reduce clearance of Busulfan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Busulfan if Telithromycin is initiated, discontinued or dose changed.
DB01008	DB00352	Busulfan increases the hepatoxicity of Thioguanine during long-term concomitant therapy.
DB01008	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01008	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of busulfan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of busulfan if voriconazole is initiated, discontinued or dose changed.
DB01009	DB01418	The NSAID, ketoprofen, may increase the anticoagulant effect of acenocoumarol.
DB01009	DB00945	Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended.
DB01009	DB01125	The NSAID, ketoprofen, may increase the anticoagulant effect of anisindione.
DB01009	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB01009	DB00215	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01009	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB01009	DB00091	The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine.
DB01009	DB00266	The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol.
DB01009	DB00055	The antiplatelet effect of ketoprofen may increase the bleed risk associated with drotrecogin alfa. Consider spacing use of the two agents by at least 7 days. Increase monitoring for signs and symptoms of bleeding during concomitant therapy.
DB01009	DB06210	Increases levels of Ketoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB01009	DB01175	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01009	DB00472	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01009	DB00176	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01009	DB01381	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01009	DB01404	Increased risk of bleeding due to additive anticoagulant properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01009	DB00465	Concomitant use of ketoprofen and ketorolac, two NSAIDs, is contraindicated due to the risk of additive or synergistic NSAID toxicities (e.g. GI bleeding, ulceration, renal dysfunction, etc).
DB01009	DB01356	The NSAID, ketoprofen, may increase the serum concentration of lithium by decreasing its renal clearance. Consider a dose reduction in lithium upon initiation of ketoprofen therapy. Monitor for changes in the therapeutic and adverse effects of lithium if ketoprofen is initiated, discontinued or does changed.
DB01009	DB00563	The NSAID, ketoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB01009	DB00715	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01009	DB00642	The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy.
DB01009	DB00118	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01009	DB01104	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01009	DB00966	Concomitant use of Telmisartan and Ketoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB01009	DB00373	The NSAID, Ketoprofen, may antagonize the antihypertensive effect of Timolol.
DB01009	DB00519	The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed.
DB01009	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy.
DB01009	DB00682	The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB01010	DB00443	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, edrophonium.
DB01010	DB01234	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, edrophonium.
DB01010	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, edrophonium.
DB01010	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, edrophonium.
DB01010	DB00860	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, edrophonium.
DB01010	DB00635	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium.
DB01010	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Edrophonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB01010	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium.
DB01011	DB00434	This combination renders test invalid
DB01011	DB01320	The combination renders the test invalid
DB01011	DB00252	The combination renders the test invalid
DB01012	DB00199	The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet.
DB01012	DB01167	Itraconazole may increase the effect and toxicity of cinacalcet.
DB01012	DB01026	Ketoconazole may increase the effect and toxicity of cinacalcet.
DB01012	DB00675	Cinacalcet may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB01012	DB00706	Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cinacalcet is initiated, discontinued, or dose changed.
DB01012	DB00976	Telithromycin may reduce clearance of Cinacalcet. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cinacalcet if Telithromycin is initiated, discontinued or dose changed.
DB01012	DB01036	Cinacalcet may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01012	DB00193	Cinacalcet may decrease the effect of Tramadol by decreasing active metabolite production.
DB01012	DB00726	The strong CYP2D6 inhibitor, Cinacalcet, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Cinacalcet is initiated, discontinued or dose changed.
DB01012	DB00285	Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cinacalcet is initiated, discontinued, or dose changed.
DB01012	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cinacalcet by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cinacalcet if voriconazole is initiated, discontinued or dose changed.
DB01012	DB01624	Cinacalcet, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cinacalcet is initiated, discontinued or dose changed.
DB01013	DB00041	Corticosteroids such as clobetasol may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
DB01013	DB05521	Corticosteroids such as clobetasol may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects.
DB01015	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB01015	DB00091	The sulfonamide decreases the effect of cyclosporine
DB01015	DB00563	The sulfamide increases the toxicity of methotrexate
DB01015	DB06813	Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects.
DB01015	DB00684	Increased risk of nephrotoxicity
DB01015	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01015	DB00682	Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed.
DB01016	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01016	DB00945	Acetylsalicylic acid increases the effect of the sulfonylurea, glibenclamide.
DB01016	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01016	DB00195	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB01016	DB01295	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB01016	DB01294	The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, glibenclamide.
DB01016	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01016	DB00559	Increased risk of hepatic toxicity
DB01016	DB00521	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB01016	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01016	DB00446	Chloramphenicol may increase the effect of sulfonylurea, glibenclamide.
DB01016	DB00636	Clofibrate may increase the effect of sulfonylurea, glibenclamide.
DB01016	DB00930	Colesevelam may decrease the serum concentration of Glyburide. Glyburide should be administered at least 4 hours before colesevelam to minimize the risk of an interaction.
DB01016	DB00091	The sulfonylurea, glibenclamide, may increase the effect of cyclosporine.
DB01016	DB01119	Antagonism.
DB01016	DB00266	Dicumarol may increase the effect of sulfonylurea, glibenclamide.
DB01016	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01016	DB01296	Possible hyperglycemia
DB01016	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB01016	DB01397	The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, glibenclamide.
DB01016	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB01016	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01016	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01016	DB01359	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB01016	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB01016	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB01016	DB01297	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01016	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB01016	DB01045	Rifampin may decrease the effect of sulfonylurea, glibenclamide.
DB01016	DB01398	The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, glibenclamide.
DB01016	DB01399	The salicylate, salsalate, increases the effect of the sulfonylurea, glibenclamide.
DB01016	DB00052	Somatropin may antagonize the hypoglycemic effect of glibenclamide. Monitor for changes in fasting and postprandial blood sugars.
DB01016	DB00489	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB01016	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB01016	DB01401	The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, glibenclamide.
DB01017	DB01418	The tetracycline, minocycline, may increase the anticoagulant effect of acenocoumarol.
DB01017	DB00459	Increased risk of intracranial hypertension.
DB01017	DB01370	Formation of non-absorbable complexes
DB01017	DB01060	Possible antagonism of action
DB01017	DB00415	Possible antagonism of action
DB01017	DB01125	The tetracycline, minocycline, may increase the anticoagulant effect of anisindione.
DB01017	DB01574	Formation of non-absorbable complexes
DB01017	DB01061	Possible antagonism of action
DB01017	DB00355	Possible antagonism of action
DB01017	DB01602	Possible antagonism of action
DB01017	DB01053	Possible antagonism of action
DB01017	DB00307	Tetracycline derivatives like minocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).
DB01017	DB01294	Formation of non-absorbable complexes
DB01017	DB01373	Formation of non-absorbable complexes
DB01017	DB00258	Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB01017	DB01164	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB01017	DB00578	Possible antagonism of action
DB01017	DB00766	Possible antagonism of action
DB01017	DB01147	Possible antagonism of action
DB01017	DB00930	Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB01017	DB01000	Possible antagonism of action
DB01017	DB00485	Possible antagonism of action
DB01017	DB00266	The tetracycline, minocycline, may increase the anticoagulant effect of dicumarol.
DB01017	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01017	DB00926	Increased risk of intracranial hypertension
DB01017	DB00301	Possible antagonism of action
DB01017	DB00739	Possible antagonism of action
DB01017	DB01592	Formation of non-absorbable complexes
DB01017	DB00893	Formation of non-absorbable complexes
DB01017	DB00982	Increased risk of intracranial hypertension
DB01017	DB01378	Formation of non-absorbable complexes
DB01017	DB01377	Formation of non-absorbable complexes
DB01017	DB01397	Formation of non-absorbable complexes
DB01017	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01017	DB02443	Possible antagonism of action
DB01017	DB01028	The tetracycline, minocycline, may increase the renal toxicity of methoxyflurane.
DB01017	DB00948	Possible antagonism of action
DB01017	DB00607	Possible antagonism of action
DB01017	DB00713	Possible antagonism of action
DB01017	DB00417	Possible antagonism of action
DB01017	DB00319	Possible antagonism of action
DB01017	DB01604	Possible antagonism of action
DB01017	DB01605	Possible antagonism of action
DB01017	DB01606	Possible antagonism of action
DB01017	DB01607	Minocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Minocycline.
DB01017	DB00755	Minocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.
DB01017	DB01401	Formation of non-absorbable complexes
DB01017	DB00682	The tetracycline, minocycline, may increase the anticoagulant effect of warfarin.
DB01018	DB06414	Guanfacine, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase guanfacine dosage up to 8mg/day, as tolerated, and to monitor gefitinib therapy.
DB01018	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01018	DB00726	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanfacine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanfacine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
DB01019	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Bethanecol, a cholinergic agonist. Monitor for increased cholinergic effects.
DB01020	DB06237	Additive vasodilation. Concomitant therapy is contraindicated.
DB01020	DB00320	Possible antagonism of action
DB01020	DB01253	Possible antagonism of action
DB01020	DB00696	Possible antagonism of action
DB01020	DB00353	Possible antagonism of action
DB01020	DB00247	Possible antagonism of action
DB01020	DB00203	Possible significant hypotension with this combination
DB01020	DB00820	The vasodilatory effects of Isosobide mononitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB01020	DB00976	Telithromycin may reduce clearance of Isosorbide Mononitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Mononitrate if Telithromycin is initiated, discontinued or dose changed.
DB01020	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01020	DB06267	The vasodilatory effects of Isosobide mononitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB01020	DB00862	The vasodilatory effects of Isosorbide mononitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB01020	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide mononitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide mononitrate if voriconazole is initiated, discontinued or dose changed.
DB01021	DB01143	Trichlormethiazide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trichlomethiazide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01021	DB01432	The bile acid sequestrant, Cholestyramine resin, may inhibit the absorption of Trichlormethiazide.
DB01021	DB00930	The bile acid sequestrant, Colesevelam, may inhibit the absorption of Trichlormethiazide.
DB01021	DB00375	The bile acid sequestrant, Colestipol, may inhibit the absorption of Trichlormethiazide.
DB01021	DB00390	Possible electrolyte variations and arrhythmias
DB01021	DB00204	Trichlormethiazide may increase Dofetilide serum concentrations and increase the QTc-prolonging effect of Dofetilide. Increased risk of ventricular arrhythmias.
DB01021	DB01356	Trichlormethiazide may increase the serum concentration of Lithium by decreasing Lithium excretion. Monitor for changes in the therapeutic/adverse effects of Lithium if Trichlorthiazide is initiated, discontinued or dose changed.
DB01021	DB00073	Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Trichlormethiazide for 12 hours prior to administration of Rituximab.
DB01021	DB00519	The thiazide diuretic, Trichlormethiazide, may increase the hypotensive effect of Trandolapril. Trichlormethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB01021	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01022	DB00682	Phytonadione (vitamin K) may antagonize the anticoagulant effects of warfarin. Monitor for changes in prothrombin time if phytonadione intake (either via supplements or vitamin K-rich foods) is increased or decreased.
DB01023	DB01351	The barbiturate, amobarbital, decreases the effect of felodipine.
DB01023	DB01352	The barbiturate, aprobarbital, decreases the effect of felodipine.
DB01023	DB00237	The barbiturate, butabarbital, decreases the effect of felodipine.
DB01023	DB00241	The barbiturate, butalbital, decreases the effect of felodipine.
DB01023	DB01353	The barbiturate, butethal, decreases the effect of felodipine.
DB01023	DB00564	Carbamazepine may increase the metabolism of felodipine. Monitor for changes in the therapeutic and adverse effects of felodipine if carbamazepine is initiated, discontinued or dose changed.
DB01023	DB01341	The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine.
DB01023	DB00199	Erythromycin increases the effect of felodipine
DB01023	DB00754	The hydantoin decreases the effect of felodipine
DB01023	DB01320	The hydantoin decreases the effect of felodipine
DB01023	DB01354	The barbiturate, heptabarbital, decreases the effect of felodipine.
DB01023	DB01355	The barbiturate, hexobarbital, decreases the effect of felodipine.
DB01023	DB01167	Itraconazole may increase the therapeutic and adverse effects of felodipine.
DB01023	DB01321	Erythromycin increases the effect of felodipine
DB01023	DB00532	The hydantoin decreases the effect of felodipine
DB01023	DB00474	The barbiturate, methohexital, decreases the effect of felodipine.
DB01023	DB00849	The barbiturate, methylphenobarbital, decreases the effect of felodipine.
DB01023	DB00220	Nelfinavir increases the effect and toxicity of felodipine
DB01023	DB00776	Oxcarbazepine decreases the levels of felodipine
DB01023	DB00312	The barbiturate, pentobarbital, decreases the effect of felodipine.
DB01023	DB01174	The barbiturate, phenobarbital, decreases the effect of felodipine.
DB01023	DB00252	The hydantoin decreases the effect of felodipine
DB01023	DB00794	The barbiturate, primidone, decreases the effect of felodipine.
DB01023	DB01346	The barbiturate, quinidine barbiturate, decreases the effect of felodipine.
DB01023	DB01369	This combination presents an increased risk of toxicity
DB01023	DB00418	The barbiturate, secobarbital, decreases the effect of felodipine.
DB01023	DB00864	Felodipine increases tacrolimus levels
DB01023	DB00306	The barbiturate, talbutal, decreases the effect of felodipine.
DB01023	DB00976	Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed.
DB01023	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed.
DB01023	DB00932	Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine.
DB01023	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01023	DB00755	The moderate CYP2C8 inhibitor, Felopidine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Felopidine is initiated, discontinued to dose changed.
DB01023	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felodipine if voriconazole is initiated, discontinued or dose changed.
DB01024	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01024	DB01610	The excretion rates of Valganciclovir and/or Mycophenolic acid may decrease. Monitor for increased serum concentrations and toxicity of both agents.
DB01026	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB01026	DB01418	Ketoconazole may increase the anticoagulant effect of acenocoumarol.
DB01026	DB00802	Ketoconazole may increase the effect and toxicity of alfentanil.
DB01026	DB00346	The antifungal increases the effect of alfuzosin
DB01026	DB09026	Monitor therapy due to increased serum concentration of aliskiren.
DB01026	DB00918	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB01026	DB00404	Ketoconazole may increase the effect of the benzodiazepine, alprazolam.
DB01026	DB01370	Aluminum-containing antacids may decrease the effect of ketoconazole.
DB01026	DB00321	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB01125	Ketoconazole may increase the anticoagulant effect of anisindione.
DB01026	DB06605	Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration.
DB01026	DB00673	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB01026	DB01238	Ketoconazole may increase the effect of aripiprazole.
DB01026	DB06697	Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects.
DB01026	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01026	DB01076	Increased risk of myopathy/rhabdomyolysis
DB01026	DB06237	Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax.
DB01026	DB08903	Strong CYP3A4 inhibitors may increase exposure of bedaquiline. Monitor concomitant therapy closely.
DB01026	DB00559	Ketoconazole may increase the effect and toxicity of bosentan.
DB01026	DB06616	Strong CYP3A4 inhibitors may increase levels of bosutinib. Monitor concomitant therapy closely.
DB01026	DB01558	Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB01222	Ketoconazole may increase levels/effect of budesonide.
DB01026	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB01026	DB01373	Calcium-containing antacids may decrease the absorption of ketoconazole.
DB01026	DB00564	Ketoconazole may increase the effect of carbamazepine.
DB01026	DB00439	Increased risk of myopathy/rhabdomyolysis
DB01026	DB00475	Ketoconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB01026	DB01410	Increased effects/toxicity of ciclesonide
DB01026	DB01166	Ketoconazole may increase the effect of cilostazol.
DB01026	DB00501	The H2-receptor antagonist, cimetidine, may decrease the absorption of ketoconazole.
DB01026	DB01012	Ketoconazole may increase the effect and toxicity of cinacalcet.
DB01026	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01026	DB00349	Clobazam may increase levels by affecting CYP2C19 metabolism. Interaction is significant so monitor closely. Dose adjustment may be necessary.
DB01026	DB01068	Ketoconazole may increase the effect of the benzodiazepine, clonazepam.
DB01026	DB00628	Ketoconazole may increase the effect of the benzodiazepine, clorazepate.
DB01026	DB00872	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB01026	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
DB01026	DB00091	Ketoconazole may increase the effect of cyclosporine.
DB01026	DB06695	Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects.
DB01026	DB08912	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB01026	DB01219	Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00496	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01026	DB00829	Ketoconazole may increase the effect of the benzodiazepine, diazepam.
DB01026	DB00266	Ketoconazole may increase the anticoagulant effect of dicumarol.
DB01026	DB00320	Possible ergotism and severe ischemia with this combination
DB01026	DB01248	Ketoconazole may increase the serum levels and toxicity of docetaxel.
DB01026	DB00204	This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide
DB01026	DB04855	Ketoconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB01026	DB00216	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB01026	DB00700	Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone.
DB01026	DB00696	Possible ergotism and severe ischemia with this combination.
DB01026	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB01026	DB00736	The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole.
DB01026	DB01215	Ketoconazole may increase the effect of the benzodiazepine, estazolam.
DB01026	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01026	DB06414	Etravirine, when used concomitantly with Ketoconazole (and other azole derivatives), may experience an increase in serum concentration.\r\n\r\nKetoconazole (and other azole derivatives), when used concomitantly with etravirine, may experience a decrease in serum concentration.\r\n\r\nIt is recommended to monitor etravirine therapy for toxicity.
DB01026	DB01590	Ketoconazole may increase everolimus levels/toxicity.
DB01026	DB00927	The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole.
DB01026	DB00813	Ketoconazole may increase levels/toxicity of fentanyl.
DB01026	DB06702	Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine.
DB01026	DB08868	Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater.
DB01026	DB00690	Ketoconazole may increase the effect of the benzodiazepine, flurazepam.
DB01026	DB08906	Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely.
DB01026	DB00674	Ketoconazole increases the effect and toxicity of galantamine
DB01026	DB00317	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB01026	DB00222	Ketoconazole increases the effect of rosiglitazone
DB01026	DB00801	Ketoconazole may increase the effect of the benzodiazepine, halazepam.
DB01026	DB00502	Ketoconazole may increase the effect and toxicity of haloperidol.
DB01026	DB04946	Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50%
DB01026	DB00619	Ketoconazole may increase the levels of imatinib.
DB01026	DB00458	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB05039	Strong CYP3A4 inhibitors increase levels of indacaterol. Consider alternate therapy.
DB01026	DB00224	Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.
DB01026	DB00762	Ketoconazole increases the effect and toxicity of irinotecan
DB01026	DB00951	Isoniazid decreases the effect of ketoconazole
DB01026	DB08820	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB01026	DB00448	The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.
DB01026	DB08918	Strong CYP3A4 inhibitors may increase exposure levomilnacipran.
DB01026	DB00227	Increased risk of myopathy/rhabdomyolysis
DB01026	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB01026	DB01377	The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption.
DB01026	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01026	DB00959	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.
DB01026	DB00683	Ketoconazole may increase the effect of the benzodiazepine, midazolam.
DB01026	DB08893	Concomitant therapy with p-glycoprotein and strong CYP3A4 inhibitors may increase levels of mirabegron. Monitor concomitant therapy closely.
DB01026	DB00238	Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed.
DB01026	DB00585	The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole.
DB01026	DB00540	Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00338	The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.
DB01026	DB04938	Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1.4-fold. Administration of ketoconazole chronically with ospemifene may increase the risk of OSPHENA-related adverse reactions.
DB01026	DB00213	The proton pump inhibitor, pantoprazole, may decrease the absorption of ketoconazole.
DB01026	DB06589	Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects.
DB01026	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB01026	DB01132	Ketoconazole increases the effect of pioglitazone
DB01026	DB08910	Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided.
DB01026	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB01026	DB06209	Ketoconazole is a potent inhibitor of CYP3A4 which decreases the Cmax of prasugrel due to a reduction of prasugrel bioactivation. However, there was no reduction of inhibition of platelet aggregation.
DB01026	DB00860	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
DB01026	DB00635	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
DB01026	DB01589	Ketoconazole may increase the effect of the benzodiazepine, quazepam.
DB01026	DB01224	Ketoconazole may increase the therapeutic and adverse effects of quetiapine.
DB01026	DB00908	Ketoconazole may increase the effect and toxicity of quinidine.
DB01026	DB01346	Ketoconazole may increase the effect and toxicity of quinidine barbiturate.
DB01026	DB01129	The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole.
DB01026	DB00980	Ketoconazole may increase the serum levels and toxicity of ramelteon.
DB01026	DB00863	The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole.
DB01026	DB00243	Increased levels of ranolazine - risk of toxicity
DB01026	DB08896	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB01026	DB01045	Rifampin may decrease the effect of ketoconazole.
DB01026	DB00503	Ketoconazole may increase the effect and toxicity of ritonavir.
DB01026	DB06228	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
DB01026	DB01656	Increases roflumilast levels.
DB01026	DB00412	Ketoconazole increases the effect of rosiglitazone
DB01026	DB08877	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
DB01026	DB01232	Ketoconazole may increase the effect and toxicity of saquinavir.
DB01026	DB06335	Ketoconazole is a strong inhibitor of CYP3A4/5 which increases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also decreases. Decrease dose of saxagliptin to 2.5 mg per day.
DB01026	DB01105	Ketoconazole increases the levels and toxicity of sibutramine
DB01026	DB00203	Ketoconazole may increase the effect and toxicity of sildenafil.
DB01026	DB06207	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects
DB01026	DB00641	Increased risk of myopathy/rhabdomyolysis
DB01026	DB00877	Ketoconazole may increase the effect and toxicity of sirolimus.
DB01026	DB01591	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01026	DB00364	Sucralfate may decrease the absorption of ketoconazole.
DB01026	DB01268	Possible increase in sunitinib levels
DB01026	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed.
DB01026	DB00864	The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered.
DB01026	DB00820	Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01026	DB00675	Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00706	Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed.
DB01026	DB05521	Strong CYP3A4 inhibitors increase exposure of telaprevir.
DB01026	DB00976	Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB01026	DB06287	Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01026	DB00444	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01026	DB01623	The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00906	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00932	Tipranavir may increase the serum concentration of Ketoconazole.
DB01026	DB00697	Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01026	DB01124	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB01036	Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01026	DB06212	Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%.
DB01026	DB01030	The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01042	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB01026	DB00214	Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00193	Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production.
DB01026	DB00656	The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00897	Ketoconazole may increase the effect of the benzodiazepine, triazolam.
DB01026	DB00440	The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00726	The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB08867	Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy.
DB01026	DB00580	Ketoconazole may increase the effect and toxicity of valdecoxib.
DB01026	DB00862	Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB01026	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB01026	DB00285	Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed.
DB01026	DB00661	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB06684	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB01026	DB00570	Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00541	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00361	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00582	Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00682	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00549	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00246	Ketoconazole increases the effect and toxicity of ziprasidone
DB01026	DB00425	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB00909	Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed.
DB01026	DB01198	Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed.
DB01028	DB00618	The tetracycline, demeclocycline, may increase the renal toxicity of methoxyflurane.
DB01028	DB01017	The tetracycline, minocycline, may increase the renal toxicity of methoxyflurane.
DB01028	DB01174	The barbiturate, phenobarbital, increases the renal toxicity of methoxyflurane.
DB01028	DB00794	The barbiturate, primidone, increases the renal toxicity of methoxyflurane.
DB01028	DB00759	Tetracycline may increase the renal toxicity of methoxyflurane.
DB01029	DB00594	Increased risk of hyperkalemia
DB01029	DB01395	Increased risk of hyperkalemia
DB01029	DB01356	The ARB increases serum levels of lithium
DB01029	DB01345	Increased risk of hyperkalemia
DB01029	DB00421	Increased risk of hyperkalemia
DB01029	DB00684	Increased risk of nephrotoxicity
DB01029	DB00519	The angiotensin II receptor blocker, Irbesartan, may increase the adverse effects of Trandolapril.
DB01029	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01029	DB00755	The moderate CYP2C8 inhibitor, Irbesartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Irbesartan is initiated, discontinued to dose changed.
DB01029	DB00384	Increased risk of hyperkalemia
DB01042	DB00091	Melphalan increases toxicity of cyclosporine
DB01030	DB01118	The p-glycoprotein inhibitor, Amiodarone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB01076	The p-glycoprotein inhibitor, Atorvastatin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00958	Administration of Topotecan after Carboplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed.
DB01030	DB01136	The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00515	Administration of Topotecan after Cisplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed.
DB01030	DB01211	The p-glycoprotein inhibitor, Clarithromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00091	The p-glycoprotein inhibitor, Cyclosporine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB01264	The p-glycoprotein inhibitor, Darunavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00975	The p-glycoprotein inhibitor, Dipyridamole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00199	The p-glycoprotein inhibitor, Erythromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00099	Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia.
DB01030	DB00317	The BCRP/ABCG2 inhibitor, Gefitnib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Gefitinib is initiated, discontinued or dose changed.
DB01030	DB00619	The BCRP/ABCG2 inhibitor, Imatinib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Imatinib is initiated, discontinued or dose changed.
DB01030	DB01167	The p-glycoprotein inhibitor, Itraconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB01026	The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB01259	The p-glycoprotein inhibitor, Lapatinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB01601	The p-glycoprotein inhibitor, Lopinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00358	The p-glycoprotein inhibitor, Mefloquine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00108	The immunosuppressant, Topotecan, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB01030	DB00220	The p-glycoprotein inhibitor, Nelfinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00622	The p-glycoprotein inhibitor, Nicardipine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB04868	The p-glycoprotein inhibitor, Nilotinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00526	Administration of Topotecan after Oxaliplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed.
DB01030	DB00213	The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed.
DB01030	DB00396	The p-glycoprotein inhibitor, Progesterone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00571	The p-glycoprotein inhibitor, Propranolol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00908	The p-glycoprotein inhibitor, Quinidine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00243	The p-glycoprotein inhibitor, Ranolazine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00206	The p-glycoprotein inhibitor, Reserpine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00503	The p-glycoprotein inhibitor, Ritonavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB01232	The p-glycoprotein inhibitor, Saquinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01101	DB00532	Capecitabine increases the effect of hydantoin
DB01030	DB01268	The p-glycoprotein inhibitor, Sunitinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00864	The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00675	The p-glycoprotein inhibitor, Tamoxifen, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01030	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01030	DB00661	The p-glycoprotein inhibitor, Verapamil, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01032	DB00945	Acetylsalicylic acid decreases the uricosuric effect of probenecid.
DB01032	DB01294	The salicylate, bismuth subsalicylate, decreases the uricosuric effect of probenecid.
DB01032	DB00833	Probenecid may increase the serum level of cefaclor.
DB01032	DB01140	Probenecid may increase the serum level of cefadroxil.
DB01032	DB01326	Probenecid may increase the serum level of cefamandole.
DB01032	DB01327	Probenecid may increase the serum level of cefazolin.
DB01032	DB01413	Probenecid may increase the serum level of cefepime.
DB01032	DB00671	Probenecid may increase the serum level of cefixime.
DB01032	DB00274	Probenecid may increase the serum level of cefmatzole.
DB01032	DB01328	Probenecid may increase the serum level of cefonicib.
DB01032	DB00493	Probenecid may increase the serum level of cefotaxime.
DB01032	DB01330	Probenecid may increase the serum level of cefotetan.
DB01032	DB01331	Probenecid may increase the serum level of cefoxitin.
DB01032	DB01150	Probenecid may increase the serum level of cefprozil.
DB01032	DB01333	Probenecid may increase the serum level of cefradine.
DB01032	DB01332	Probenecid may increase the serum level of ceftizoxime.
DB01032	DB01112	Probenecid may increase the serum level of cefuroxime.
DB01032	DB00567	Probenecid may increase the serum level of cephalexin.
DB01032	DB00689	Probenecid may increase the serum level of cephaloglycin.
DB01032	DB03450	Probenecid may increase the serum level of cephalothin.
DB01032	DB00861	Probenecid increases toxicity of diflunisal
DB01032	DB01004	Probenecid increases the effect and toxicity of ganciclovir/valganciclovir
DB01032	DB08909	Probenecid may inhibit the renal excretion of metabolites of glycerol phenylbutyrate including PAGN and PAA.
DB01032	DB00328	Probenecid increases the effect/toxicity of indomethacin
DB01032	DB00465	Probenecid increases toxicity of ketorolac
DB01032	DB00447	Probenecid may increase the serum level of loracarbef.
DB01032	DB01397	The salicylate, magnesium salicylate, decreases the uricosuric effect of probenecid.
DB01032	DB00563	Probenecid increases the effect and toxicity of methotrexate
DB01032	DB02588	Probenecid may increase the serum level of the moxalactam derivative.
DB01032	DB06813	Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects.
DB01032	DB01398	The salicylate, salicylate-sodium, decreases the uricosuric effect of probenecid.
DB01032	DB01399	The salicylate, salsalate, decreases the uricosuric effect of probenecid.
DB01032	DB06207	Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely.
DB01032	DB06204	Increases the AUC of tapentadol by 57%. These changes are not considered clinically relevant and no change in dose is required.
DB01032	DB01401	The salicylate, trisalicylate-choline, decreases the uricosuric effect of probenecid.
DB01032	DB01610	Probenecid may decrease excretion of Valganciclovir. Monitor for increased serum concentration and toxicity of Valganciclovir.
DB01032	DB00495	Rash, malaise, myalgia
DB01033	DB01418	Mercaptopurine may decrease the anticoagulant effect of acenocoumarol.
DB01033	DB00437	Allopurinol may increase the effect of thiopurine, mercaptopurine.
DB01033	DB00233	Aminosalicylic acid may increase the toxicity of thiopurine, mercaptopurine.
DB01033	DB01125	Mercaptopurine may decrease the anticoagulant effect of anisindione.
DB01033	DB00732	The agent dereases the effect of the muscle relaxant
DB01033	DB00266	Mercaptopurine may decrease the anticoagulant effect of dicumarol.
DB01033	DB01135	The agent dereases the effect of the muscle relaxant
DB01033	DB04854	Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes.
DB01033	DB00244	Mesalazine may increase the toxicity of thiopurine, mercaptopurine.
DB01033	DB01336	The agent dereases the effect of the muscle relaxant
DB01033	DB01226	The agent dereases the effect of the muscle relaxant
DB01033	DB01250	Olsalazine may increase the toxicity of thiopurine, mercaptopurine.
DB01033	DB01337	The agent dereases the effect of the muscle relaxant
DB01033	DB00795	Sulfasalazine may increase the toxicity of thiopurine, mercaptopurine.
DB01033	DB00352	Complete cross resistance may occur.
DB01033	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01033	DB01199	The agent dereases the effect of the muscle relaxant
DB01033	DB01339	The agent dereases the effect of the muscle relaxant
DB01033	DB00682	Mercaptopurine may decrease the anticoagulant effect of warfarin.
DB01035	DB01118	Amiodarone may increase serum levels and toxicity of procainamide.
DB01035	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01035	DB00501	The histamine H2-receptor antagonist, cimetidine, may increase the effect of procainamide.
DB01035	DB00537	Ciprofloxacin may increase the effect of procainamide.
DB01035	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01035	DB01341	Quinidine increases the effect of procainamide
DB01035	DB00843	Possible antagonism of action
DB01035	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB01035	DB00674	Possible antagonism of action
DB01035	DB01137	Levofloxacin may increase the effect of procainamide.
DB01035	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01035	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01035	DB01165	Ofloxacin may increase the effect of procainamide.
DB01035	DB00908	Quinidine increases the effect of procainamide
DB01035	DB01346	Quinidine increases the effect of procainamide
DB01035	DB00863	The histamine H2-receptor antagonist, ranitidine, may increase the effect of procainamide.
DB01035	DB00243	Possible additive effect on QT prolongation
DB01035	DB00989	Possible antagonism of action
DB01035	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01035	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01035	DB00857	Terbinafine may reduce the metabolism and clearance of Procainamide. Consider alternate therapy or monitor for therapeutic/adverse effects of Procainamide if Terbinafine is initiated, discontinued or dose changed.
DB01035	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01035	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01035	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01035	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01035	DB00440	Trimethoprim may reduce the clearance of Procainamide. Alternative treatments should be considered. If Trimethoprim is initiated or the dose is increased, monitor for increased toxicity of Procainamide (e.g. QTc intervals, EKG, serum drug concentrations). If Trimethoprim is discontinued or the dose decreased, monitor for reduced effects of Procainamide.
DB01035	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01035	DB00862	Increased risk of cardiotoxicity and arrhythmias
DB01035	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01035	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01035	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB01035	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01036	DB01118	Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00701	Amprenavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00673	Aprepitant may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01072	Atazanavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00201	Caffeine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00477	Chlorpromazine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01036	DB00501	Cimetidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01012	Cinacalcet may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01036	DB01211	Clarithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00257	Clotrimazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00907	Cocaine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01036	DB00872	Conivaptan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00091	Cyclosporine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01264	Darunavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00705	Delavirdine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01151	Desipramine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00343	Diltiazem may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00843	Possible antagonism of action
DB01036	DB00254	Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00625	Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB06414	Etravirene may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01101	DB00252	Capecitabine increases the effect of hydantoin
DB01036	DB00196	Fluconazole may decrease the metabolism and clearance of tolterodine. Adjust tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00472	Fluoxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01036	DB01319	Fosamprenavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00674	Possible antagonism of action
DB01036	DB00502	Haloperidol may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00619	Imatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00224	Indinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00951	Isoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01167	Itraconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01026	Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01259	Lapatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00281	Lidocaine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01601	Lopinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00916	Metronidazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01110	Miconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01149	Nefazodone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00220	Nelfinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00622	Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01059	Norfloxacin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00715	Paroxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01036	DB01186	Peroglide may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01036	DB01263	Posaconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00761	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB01036	DB01278	Additive reduction in gut motility may occur. Consider alternate therapy or use caution during concomitant therapy.
DB01036	DB00908	Quinidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00243	Ranolazine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00503	Ritonavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB01232	Saquinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00021	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB01036	DB01104	Sertraline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB06268	Sitaxsentan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tolterodine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01036	DB00976	Telithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00857	Terbinafine may reduce the metabolism and clearance of Tolterodine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tolterodine if Terbinafine is initiated, discontinued or dose changed.
DB01036	DB00759	Tetracycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00662	Trimethobenzamide and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01036	DB00427	Triprolidine and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01036	DB00209	Trospium and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01036	DB00661	Verapamil may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01036	DB00570	Vinblastine, a CYP3A4 inhibitor, may increase the serum concentration of Tolterodine by decreasing its metabolism. Poor CYP2D6 metabolizers metabolize Tolterodine via CYP3A4. A dose adjustment of Tolterodine may be required. Monitor for changes in the therapeutic/adverse effects of Tolterodine if Vinblastine is initiated, discontinued or dose changed.
DB01036	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tolterodine by decreasing its metabolism. Tolterodine is mainly metabolized via the CYP2D6 pathway. This interaction is likely only a concern in patients who are poor CYP2D6 metabolizers. Monitor for changes in the therapeutic and adverse effects of tolterodine if voriconazole is initiated, discontinued or dose changed.
DB01037	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like selegiline.
DB01037	DB00484	MAO Inhibitors like selegiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB01037	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB01037	DB00215	Possible severe adverse reaction with this combination
DB01037	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01037	DB00514	Combination associated with possible serotoninergic syndrome
DB01037	DB01175	Possible severe adverse reaction with this combination
DB01037	DB00472	Possible severe adverse reaction with this combination
DB01037	DB00176	Possible severe adverse reaction with this combination
DB01037	DB01171	Decrease in selectivity
DB01037	DB00715	Possible severe adverse reaction with this combination
DB01037	DB00454	Potentially fatal adverse effects
DB01037	DB06204	Increases the toxicity of tapentadol by unknown mechanism. Discontinue selegiline at least 14 days prior to tapentadol administration.
DB01037	DB04844	Tetrabenazine may increase the adverse/toxic effects of Selegiline. Concomitant therapy is contraindicated.
DB01037	DB04572	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Selegiline, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Selegiline if Thiotepa is initiated, discontinued or dose changed.
DB01037	DB00323	Tolcapone and Selegiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB01037	DB00193	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Selegiline.
DB01037	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01037	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01037	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB01037	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01037	DB06684	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
DB01037	DB00315	The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated.
DB01039	DB01418	Fenofibrate may increase the anticoagulant effect of acenocoumarol.
DB01039	DB01125	Fenofibrate may increase the anticoagulant effect of anisindione.
DB01039	DB01076	Increased risk of myopathy/rhabdomyolysis
DB01039	DB00439	Increased risk of myopathy/rhabdomyolysis
DB01039	DB00266	Fenofibrate may increase the anticoagulant effect of dicumarol.
DB01039	DB01095	Increased risk of myopathy/rhabdomyolysis
DB01039	DB00046	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB01039	DB00227	Increased risk of myopathy/rhabdomyolysis
DB01039	DB08860	Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both fenofibrate and pitavastatin via pharmacodynamic synergism. Use alternative therapy.
DB01039	DB00175	Increased risk of myopathy/rhabdomyolysis
DB01039	DB01098	May cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy.
DB01039	DB00641	Increased risk of myopathy/rhabdomyolysis
DB01039	DB01586	The fibric acid derivative decreases the effect of ursodiol
DB01039	DB00682	Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed.
DB01041	DB01281	Thalidomide may increase the adverse effects of Abatacept. Increased risk of serious infection. Concomitant therapy should be avoided.
DB01041	DB00479	Thalidomide increases the renal toxicity of the aminoglycoside
DB01041	DB00026	Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided.
DB01041	DB01234	Increased risk of dermatologic adverse effects and venous thromboembolic events (VTE). Consider VTE prophylaxis during concomitant therapy and monitor for adverse dematologic effects.
DB01041	DB00798	Thalidomide increases the renal toxicity of the aminoglycoside
DB01041	DB00108	Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.
DB01041	DB00955	Thalidomide increases the renal toxicity of the aminoglycoside
DB01041	DB06372	Thalidomide may increase the adverse effects of Rilonacept. Increased risk of serious infection. Concomitant therapy should be avoided.
DB01041	DB00684	Thalidomide increases the renal toxicity of the aminoglycoside
DB01041	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01041	DB00427	The CNS depressants, Triprolidine and Thalidomide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01042	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01043	DB00819	Possible increased levels of memantine
DB01043	DB00915	Increased risk of CNS adverse effects with this association
DB01043	DB01144	Possible increased levels of memantine
DB01043	DB01221	Increased risk of CNS adverse effects with this association
DB01043	DB00703	Possible increased levels of memantine
DB01043	DB01390	Possible increased levels of memantine
DB01044	DB01370	Formation of non-absorbable complexes
DB01044	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00390	Gatifloxacin increases the effect of digoxin
DB01044	DB01341	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00623	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01592	Formation of non-absorbable complexes
DB01044	DB00893	Formation of non-absorbable complexes
DB01044	DB01378	Formation of non-absorbable complexes
DB01044	DB01377	Formation of non-absorbable complexes
DB01044	DB01397	Formation of non-absorbable complexes
DB01044	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01403	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00850	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00433	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00420	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01069	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00777	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01369	This combination presents an increased risk of toxicity
DB01044	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00364	Formation of non-absorbable complexes
DB01044	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01044	DB00372	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01044	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01044	DB00831	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00508	Increased risk of cardiotoxicity and arrhythmias
DB01044	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01044	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01044	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01044	DB01593	Formation of non-absorbable complexes
DB01044	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01045	DB05812	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB01045	DB01418	Rifampin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.
DB01045	DB00414	Rifampin may decrease the effect of sulfonylurea, acetohexamide.
DB01045	DB00802	Rifampin reduces levels and efficacy of alfentanil
DB01045	DB01223	Rifampin decreases the effect of theophylline
DB01045	DB01118	Rifampin decreases the effect of amiodarone
DB01045	DB00321	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed.
DB01045	DB00543	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed.
DB01045	DB00701	In presence of rifampin anticipate decrease of amprenavir efficiency
DB01045	DB01125	Rifampin may decrease the anticoagulant effect of anisindione.
DB01045	DB00673	The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant.
DB01045	DB06697	Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. Johns wort is contraindicated with Coartem Tablets.
DB01045	DB01072	Rifampin reduces levels and efficacy of atazanavir
DB01045	DB01076	Rifampin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifampin is initiated, discontinued or dose changed.
DB01045	DB01117	Rifampin may decrease the effect of atovaquone.
DB01045	DB08903	Strong CYP3A4 inducers may decrease exposure of bedaquiline. Co-administration should be avoided.
DB01045	DB06769	CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine.
DB01045	DB00443	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone.
DB01045	DB00612	Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism.
DB01045	DB08873	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB01045	DB06616	Strong CYP3A4 inducers may decrease levels of bosutinib. Monitor concomitant therapy closely.
DB01045	DB01558	Rifampin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifampin is initiated, discontinued or dose changed.
DB01045	DB01156	Rifampin reduces bupropion levels
DB01045	DB00490	Rifampin decreases the effect of buspirone
DB01045	DB06772	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB01045	DB08907	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB01045	DB00520	Decreased levels/effects of caspofungin
DB01045	DB00482	Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed.
DB01045	DB00439	Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed.
DB01045	DB00446	Rifampin decreases the effect of chloramphenicol
DB01045	DB00672	Rifampin may decrease the effect of sulfonylurea, chlorpropamide.
DB01045	DB01211	The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin.
DB01045	DB01242	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed.
DB01045	DB00363	Rifampin decreases the effect of clozapine
DB01045	DB01380	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, cortisone acetate.
DB01045	DB08865	Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely.
DB01045	DB08865	Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely.
DB01045	DB00091	The rifamycin decreases the effect of cyclosporine
DB01045	DB06695	P-Glycoprotein inducers such as rifampin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB01045	DB08912	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB01045	DB00250	Decreased levels of dapsone
DB01045	DB01254	Rifampin may decrease the serum level and efficacy of dasatinib.
DB01045	DB00705	Rifampin decreases the effect of delavirdine
DB01045	DB01151	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed.
DB01045	DB01234	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone.
DB01045	DB00829	Rifampin may decrease the effect of the benzodiazepine, diazepam.
DB01045	DB00586	Rifampin, a CYP2C9 inducer, may increase the metabolism of diclofenac.
DB01045	DB00266	Rifampin may decrease the anticoagulant effect of dicumarol.
DB01045	DB00343	Rifampin decreases levels of diltiazem
DB01045	DB00280	Rifampin decreases the effect of disopyramide
DB01045	DB01142	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed.
DB01045	DB00254	The rifamycin decreases the effect of doxycycline
DB01045	DB00651	Rifampin decreases the effect of theophylline
DB01045	DB00584	Rifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed.
DB01045	DB00530	Decreased levels/effect of erlotinib
DB01045	DB00199	The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.
DB01045	DB00977	This product may cause a slight decrease of contraceptive effect
DB01045	DB00754	Rifampin decreases the effect of the hydantoin
DB01045	DB01628	Rifampin reduces levels and efficacy of etoricoxib
DB01045	DB00813	Rifampin may decrease the serum level and therapeutic effect of fentanyl.
DB01045	DB00196	Rifampin may decrease the effect of fluconazole.
DB01045	DB00687	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone.
DB01045	DB01095	Rifampin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifampin is initiated, discontinued or dose changed.
DB01045	DB01319	Rifampin may decrease the effectiveness of fosamprenavir.
DB01045	DB01320	Rifampin may decrease the effect of fosphenytoin.
DB01045	DB08884	Substrates of OATP1B1 and OATP1B3 may limit uptake of gadoxetate disodium into heptatocytes. This may alter the intensity of the signal.
DB01045	DB00317	Rifampin reduces levels and efficacy of gefitinib
DB01045	DB01120	Rifampin may decrease the effect of sulfonylurea, gliclazide.
DB01045	DB00222	Rifampin may decrease the effect of sulfonylurea, glimepiride.
DB01045	DB01067	Rifampin may decrease the effect of sulfonylurea, glipizide.
DB01045	DB01289	Rifampin may decrease the effect of sulfonylurea, glisoxepide.
DB01045	DB01016	Rifampin may decrease the effect of sulfonylurea, glibenclamide.
DB01045	DB01382	Rifampin may decrease the effect of sulfonylurea, glycodiazine.
DB01045	DB00502	The rifamycin decreases the effect of haloperidol
DB01045	DB00741	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone.
DB01045	DB00619	Rifampin decreases levels of imatinib
DB01045	DB00458	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed.
DB01045	DB00224	Rifampin decreases the effect of indinavir
DB01045	DB01167	Rifampin may decrease the effect of itraconazole.
DB01045	DB08820	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB01045	DB01321	The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin.
DB01045	DB01026	Rifampin may decrease the effect of ketoconazole.
DB01045	DB00555	Rifampin decreases levels of lamotrigine
DB01045	DB01097	Rifampin increases the effect of leflunomide
DB01045	DB08882	CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely.
DB01045	DB00678	Rifampin decreases the effect of losartan
DB01045	DB00227	Rifampin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifampin is initiated, discontinued or dose changed.
DB01045	DB00358	Rifampin lowers mefloquine levels
DB01045	DB00532	Rifampin decreases the effect of the hydantoin
DB01045	DB01357	This product may cause a slight decrease of contraceptive effect
DB01045	DB00333	The rifamycin decreases the effect of methadone
DB01045	DB00959	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone.
DB01045	DB00264	Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism.
DB01045	DB00379	Rifampin decreases the effect of mexiletine
DB01045	DB00683	Rifampin may increase the metabolism of midazolam. Monitor for changes in the therapeutic and adverse effects of midazolam if rifampin is initiated, discontinued or dose changed.
DB01045	DB08893	Strong CYP3A4 inducers may decrease levels of mirabegron. Monitor concomitant therapy closely.
DB01045	DB00295	Rifampin decreases the effect of morphine/codeine
DB01045	DB00688	Rifampin may decrease the serum concentration of mycophenolate. Concomitant therapy should be avoided.
DB01045	DB00220	Rifampin decreases the effect of nelfinavir
DB01045	DB01115	Rifampin decreases the effect of the calcium channel blocker, nifedipine.
DB01045	DB00717	This product may cause a slight decrease of contraceptive effect
DB01045	DB00540	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed.
DB01045	DB04938	Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect.
DB01045	DB01303	Rifampin may decrease the effect and toxicity of oxtriphylline.
DB01045	DB01384	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, paramethasone.
DB01045	DB06589	Concomitant therapy with a CYP3A4 inducer may decrease exposure of pazopanib.
DB01045	DB00252	Rifampin may decrease the therapeutic and adverse effects of phenytoin.
DB01045	DB08860	Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded.
DB01045	DB08860	Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded.
DB01045	DB08910	Strong CYP3A4 inducers may decrease levels of pomalidomide. Concomitant therapy should be avoided.
DB01045	DB08901	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB01045	DB08901	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB01045	DB01058	Significant decrease in praziquantel level
DB01045	DB00860	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone.
DB01045	DB00635	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone.
DB01045	DB01182	Rifampin decreases the effect of propafenone
DB01045	DB00571	Rifampin may decrease the serum concentration of propranolol by increasing its metabolism.
DB01045	DB00344	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifampin is initiated, discontinued or dose changed.
DB01045	DB00908	Rifampin decreases the effect of quinidine
DB01045	DB01346	Rifampin decreases the effect of quinidine
DB01045	DB00980	Rifampin reduces the levels/effect of ramelteon
DB01045	DB08896	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB01045	DB00912	Rifampin decreases the effect of repaglinide
DB01045	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB01045	DB00503	Rifampin decreases the effect of ritonavir
DB01045	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB01045	DB00412	Rifampin reduces levels and efficacy of rosiglitazone
DB01045	DB08877	Strong CYP3A4 inducers may decrease levels of ruxolitinib. Closely monitor patient.
DB01045	DB01232	Rifampin decreases the effect of saquinavir
DB01045	DB06335	Rifampin is a strong inducer of CYP3A4 which decreases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also increases.
DB01045	DB00641	Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed.
DB01045	DB00877	The rifamycin decreases the effect of sirolimus
DB01045	DB01268	Possible decrease in sunitinib levels
DB01045	DB00864	Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered.
DB01045	DB00820	Rifampin may reduce Tadalafil plasma concentrations and efficacy.
DB01045	DB00675	The rifamycin decreases the effect of anti-estrogen
DB01045	DB05521	Strong CYP3A4 inducers will decrease levels of telaprevir. Concomitant therapy is contraindicated.
DB01045	DB00976	Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided.
DB01045	DB06287	Rifampin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB01045	DB00857	Rifampin may increase the metabolism and clearance of Terbinafine. Co-administration may result in Terbinafine treatment failure.
DB01045	DB00277	Rifampin decreases the effect of theophylline
DB01045	DB00932	Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended.
DB01045	DB01056	Rifampin lowers tocainide levels/effects
DB01045	DB08895	Rifampin (and other potent CYP3A4 inducers), when used in combination with tofacitinib, may decrease tofacitinib toxicity.
DB01045	DB00839	Rifampin may decrease the effect of sulfonylurea, tolazamide.
DB01045	DB01124	Rifampin may decrease the effect of sulfonylurea, tolbutamide.
DB01045	DB06212	Rifampin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB01045	DB00539	The rifamycin decreases the effect of anti-estrogen
DB01045	DB00193	Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB01045	DB00656	The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed.
DB01045	DB00755	The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed.
DB01045	DB00620	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone.
DB01045	DB00897	Rifampin may decrease the effect of the benzodiazepine, triazolam.
DB01045	DB00440	Rifampin decreases the effect of trimethoprim
DB01045	DB00726	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifampin is initiated, discontinued or dose changed.
DB01045	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB01045	DB00313	Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed.
DB01045	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB01045	DB08881	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB01045	DB00661	Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed.
DB01045	DB00582	Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.
DB01045	DB00682	Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism.
DB01045	DB00962	Rifampin decreases the effect of zaleplon
DB01045	DB00495	Rifampin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifampin is initiated, discontinued or dose changed.
DB01048	DB00701	The serum concentration of Abacavir may be decreased by protease inhibitors such as Amprenavir. The antiviral response should be closely monitored.
DB01048	DB01072	The serum concentration of Abacavir may be decreased by protease inhibitors such as Atazanavir. The antiviral response should be closely monitored.
DB01048	DB01264	The serum concentration of Abacavir may be decreased by protease inhibitors such as Darunavir. The antiviral response should be closely monitored.
DB01048	DB00898	Abacavir is partly metabolized through the alcohol dehydrogenase enzyme system. Alcohol increases the area under the curve (about 41%) of Abacavir. Interaction does not appear to be clinically significant.
DB01048	DB01319	The serum concentration of Abacavir may be decreased by protease inhibitors such as Fosamprenavir. The antiviral response should be closely monitored.
DB01048	DB01004	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Ganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is required.
DB01048	DB00224	The serum concentration of Abacavir may be decreased by protease inhibitors such as Indinavir. The antiviral response should be closely monitored.
DB01048	DB01601	The serum concentration of Abacavir may be decreased by protease inhibitors such as Lopinavir. The antiviral response should be closely monitored.
DB01048	DB00220	The serum concentration of Abacavir may be decreased by protease inhibitors such as Nelfinavir. The antiviral response should be closely monitored.
DB01048	DB00811	Ribavirin may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.
DB01048	DB01693	Ribavirin Monophosphate may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.
DB01048	DB00503	The serum concentration of Abacavir may be decreased by protease inhibitors such as Ritonavir. The antiviral response should be closely monitored.
DB01136	DB00457	Risk of hypotension at the beginning of therapy
DB01048	DB01232	The serum concentration of Abacavir may be decreased by protease inhibitors such as Saquinavir. The antiviral response should be closely monitored.
DB01048	DB00932	The serum concentration of Abacavir may be decreased by protease inhibitors such as Tipranavir. The antiviral response should be closely monitored.
DB01048	DB01610	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB01049	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01049	DB00976	Telithromycin may reduce clearance of Ergoloid mesylates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergoloid mesylates if Telithromycin is initiated, discontinued or dose changed.
DB01049	DB00932	Tipranavir may increase the plasma concentration of Ergoloid mesylates. Concomitant therapy should be avoided.
DB01049	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01049	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01049	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01049	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01049	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01049	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergoloid mesylates by decreasing their metabolism. Concomitant therapy is contraindicated.
DB01049	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergoloid mesylate, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB01050	DB01193	Risk of inhibition of renal prostaglandins
DB01050	DB01418	The NSAID, ibuprofen, may increase the anticoagulant effect of acenocoumarol.
DB01050	DB00945	Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended.
DB01050	DB00630	Increased risk of gastric toxicity
DB01050	DB01125	The NSAID, ibuprofen, may increase the anticoagulant effect of anisindione.
DB01050	DB00335	Risk of inhibition of renal prostaglandins
DB01050	DB08822	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB01050	DB00195	Nonsteroidal Anti-Inflammatory Agents such as ibuprofen may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.
DB01050	DB01295	Risk of inhibition of renal prostaglandins
DB01050	DB00612	Risk of inhibition of renal prostaglandins
DB01050	DB00887	The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, bumetanide.
DB01050	DB00521	Risk of inhibition of renal prostaglandins
DB01050	DB01136	Risk of inhibition of renal prostaglandins
DB01050	DB00930	Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
DB01050	DB00091	Monitor for nephrotoxicity
DB01050	DB00266	The NSAID, ibuprofen, may increase the anticoagulant effect of dicumarol.
DB01050	DB06210	Increases levels of Ibuprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB01050	DB00187	Risk of inhibition of renal prostaglandins
DB01050	DB00903	The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid.
DB01050	DB00695	The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, furosemide.
DB01050	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01050	DB04865	Avoid combination with ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
DB01050	DB00598	Risk of inhibition of renal prostaglandins
DB01050	DB01356	The NSAID, ibuprofen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01050	DB00563	The NSAID, ibuprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
DB01050	DB00264	Risk of inhibition of renal prostaglandins
DB01050	DB01203	Risk of inhibition of renal prostaglandins
DB01050	DB01580	Risk of inhibition of renal prostaglandins
DB01050	DB01359	Risk of inhibition of renal prostaglandins
DB01050	DB00960	Risk of inhibition of renal prostaglandins
DB01050	DB01297	Risk of inhibition of renal prostaglandins
DB01050	DB06813	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB01050	DB06209	Coadministration with NSAIDS used chronically may increase the risk of bleeding.
DB01050	DB00571	Risk of inhibition of renal prostaglandins
DB01050	DB00489	Risk of inhibition of renal prostaglandins
DB01059	DB00091	Norfloxacin may increase the effect and toxicity of cyclosporine.
DB01136	DB01366	Antagonism
DB01050	DB00675	Ibuprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Ibuprofen is initiated, discontinued or dose changed.
DB01050	DB01124	Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ibuprofen is initiated, discontinued or dose changed.
DB01050	DB00214	The NSAID, ibuprofen, may decrease the diuretic and antihypertensive effect of the loop diuretic, torasemide.
DB01050	DB00519	The NSAID, Ibuprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ibuprofen is initiated, discontinued or dose changed.
DB01050	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ibuprofen. Monitor for increased bleeding during concomitant thearpy.
DB01050	DB08814	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of ibuprofen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB01050	DB00440	The strong CYP2C9 inhibitor, Ibuprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ibuprofen is initiated, discontinued or dose changed.
DB01050	DB06684	Increased risk of bleeding with concomitant use of non-steroidal anti-inflammatory drugs with vilazodone.
DB01050	DB00582	Ibuprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ibuprofen is initiated, discontinued or dose changed.
DB01050	DB00682	Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed.
DB01053	DB00618	Possible antagonism of action
DB01053	DB00254	Possible antagonism of action
DB01053	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01053	DB01357	This anti-infectious agent could decreases the effect of the oral contraceptive
DB01053	DB00931	Possible antagonism of action
DB01053	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB01053	DB01017	Possible antagonism of action
DB01053	DB00595	Possible antagonism of action
DB01053	DB01301	Possible antagonism of action
DB01053	DB00759	Possible antagonism of action
DB01053	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01054	DB00501	Cimetidine increases the effect of the calcium channel blocker, nitrendipine.
DB01054	DB00976	Telithromycin may reduce clearance of Nitrendipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nitrendipine if Telithromycin is initiated, discontinued or dose changed.
DB01054	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nitrendipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nitrendipine if Thiopental is initiated, discontinued or dose changed.
DB01054	DB00932	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nitrendipine. Monitor for changes in Nitrendipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB01054	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01054	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nitrendipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nitrendipine if voriconazole is initiated, discontinued or dose changed.
DB01056	DB01045	Rifampin lowers tocainide levels/effects
DB01056	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01057	DB00202	Echothiophate iodide may increase the effect of succinylcholine.
DB01058	DB00564	Markedly lower praziquantel levels
DB01058	DB00608	Markedly lower praziquantel levels
DB01058	DB06414	Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB01058	DB06414	Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB01058	DB00252	Markedly lower praziquantel levels
DB01058	DB01045	Significant decrease in praziquantel level
DB01058	DB00976	Telithromycin may reduce clearance of Praziquantel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Praziquantel if Telithromycin is initiated, discontinued or dose changed.
DB01058	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of praziquantel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of praziquantel if voriconazole is initiated, discontinued or dose changed.
DB01059	DB01418	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01059	DB01370	Formation of non-absorbable complexes
DB01059	DB01223	Norfloxacin may increase the effect of aminophylline.
DB01059	DB01125	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of anisindione.
DB01059	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01059	DB00201	Norfloxacin may increase the effect and toxicity of caffeine.
DB01059	DB01373	Formation of non-absorbable complexes
DB01059	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB01059	DB00363	Ciprofloxacin may increase clozapine serum levels
DB01059	DB00266	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of dicumarol.
DB01059	DB00651	Norfloxacin may increase the effect of dyphylline.
DB01059	DB00529	Increased risk of convulsions
DB01059	DB01592	Formation of non-absorbable complexes
DB01059	DB00893	Formation of non-absorbable complexes
DB01059	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01059	DB01378	Formation of non-absorbable complexes
DB01059	DB01377	Formation of non-absorbable complexes
DB01059	DB01303	Norfloxacin may increase the effect of oxtriphylline.
DB01059	DB00364	Formation of non-absorbable complexes
DB01059	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Norfloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Norfloxacin is initiated, discontinued or if the dose is changed.
DB01059	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01059	DB00706	Norfloxacin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Norfloxacin is initiated, discontinued, or dose changed.
DB01059	DB00277	Norfloxacin may increase the effect of theophylline.
DB01059	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. The strong CYP1A2 inhibitor, Norfloxacin, may also decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. Thorough risk:benefit assessment is required prior to co-administration.
DB01059	DB00697	Norfloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01059	DB01036	Norfloxacin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01059	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01059	DB00193	Norfloxacin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01059	DB00656	The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed.
DB01059	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01059	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01059	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01059	DB00682	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin.
DB01059	DB01593	Formation of non-absorbable complexes
DB01059	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01059	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01060	DB00618	Possible antagonism of action
DB01060	DB00254	Possible antagonism of action
DB01060	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01060	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01060	DB00931	Possible antagonism of action
DB01060	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB01060	DB01017	Possible antagonism of action
DB01060	DB00595	Possible antagonism of action
DB01060	DB01301	Possible antagonism of action
DB01060	DB00759	Possible antagonism of action
DB01061	DB00618	Possible antagonism of action
DB01061	DB00254	Possible antagonism of action
DB01061	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01061	DB01017	Possible antagonism of action
DB01061	DB00759	Possible antagonism of action
DB01062	DB00564	Oxybutynin may cause carbamazepine toxicity
DB01062	DB00843	Possible antagonism of action
DB01062	DB00674	Possible antagonism of action
DB01062	DB00989	Possible antagonism of action
DB01062	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Oxybutynin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01062	DB00662	Trimethobenzamide and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01062	DB00427	Triprolidine and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01062	DB00209	Trospium and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01063	DB01200	The phenothiazine decreases the effect of bromocriptine
DB01063	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01063	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB01063	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB01063	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB01063	DB01170	Acetophenazine may decrease the effect of guanethidine.
DB01063	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB01063	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB01063	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB01063	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Acetophenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB01063	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01063	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB01063	DB00662	Trimethobenzamide and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01063	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Acetophenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01063	DB00209	Trospium and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01064	DB01193	Antagonism
DB01064	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of isoproterenol.
DB01064	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of isoproterenol.
DB01064	DB00335	Antagonism
DB01064	DB00612	Antagonism
DB01064	DB01136	Antagonism
DB01064	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of isoproterenol.
DB01064	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of isoproterenol.
DB01064	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of isoproterenol.
DB01064	DB00494	Entacapone increases the effect and toxicity of the sympathomimetic, isoproterenol.
DB01064	DB00187	Antagonism
DB01064	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of isoproterenol.
DB01064	DB01247	Increased arterial pressure
DB01064	DB00598	Antagonism
DB01064	DB00601	Possible increase of arterial pressure
DB01064	DB00968	Increased arterial pressure
DB01064	DB00264	Antagonism
DB01064	DB00211	Increased arterial pressure
DB01064	DB01171	Moclobemide increases the sympathomimetic effect of isoproterenol.
DB01064	DB01203	Antagonism
DB01064	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of isoproterenol.
DB01064	DB01580	Antagonism
DB01064	DB00780	Increased arterial pressure
DB01064	DB00960	Antagonism
DB01064	DB00571	Antagonism
DB01064	DB01367	Increased arterial pressure
DB01064	DB00206	Increased arterial pressure
DB01064	DB00373	Antagonism
DB01065	DB01115	Melatonin can possibly decrease the effect of nifedipine
DB01066	DB00501	H2-Antagonists such as cimetidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB01066	DB00736	Proton pump inhibitors such as esomeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB01066	DB00927	H2-Antagonists such as famotidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB01066	DB00448	Proton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB01066	DB00585	H2-Antagonists such as nizatidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB01066	DB00338	Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB01066	DB00213	Proton pump inhibitors such as pantoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB01066	DB01129	Proton pump inhibitors such as rabeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB01066	DB00863	H2-Antagonists such as ranitidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
DB01083	DB00091	Orlistat decreases the effect of cyclosporine
DB01067	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01067	DB00945	Acetylsalicylic acid increases the effect of the sulfonylurea, glipizide.
DB01067	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01067	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01067	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01067	DB00446	Chloramphenicol may increase the effect of sulfonylurea, glipizide.
DB01067	DB00636	Clofibrate may increase the effect of sulfonylurea, glipizide.
DB01067	DB00091	The sulfonylurea, glipizide, may increase the effect of cyclosporine.
DB01067	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01067	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB01067	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB01067	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01067	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01067	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB01067	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB01067	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB01067	DB01045	Rifampin may decrease the effect of sulfonylurea, glipizide.
DB01067	DB00052	Somatropin may antagonize the hypoglycemic effect of glipizide. Monitor for changes in fasting and postprandial blood sugars.
DB01067	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB01067	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glipizide. Consider alternate therapy or monitor for changes in Glipizide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01068	DB00501	Cimetidine may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB00363	Increased risk of toxicity
DB01068	DB00196	Fluconazole may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB01167	Itraconazole may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB01322	Kava may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB01026	Ketoconazole may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB00338	Omeprazole may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clonazepam.
DB01068	DB01323	St. John's Wort may decrease the effect of the benzodiazepine, clonazepam.
DB01068	DB00976	Telithromycin may reduce clearance of Clonazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clonazepam if Telithromycin is initiated, discontinued or dose changed.
DB01068	DB00932	Tipranavir may decrease the metabolism and clearance of Clonazepam. Consider alternate therapy or monitor for Clonazepam toxic effects if Tipranavir is initiated or dose increased.
DB01068	DB00427	The CNS depressants, Triprolidine and Clonazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01068	DB01080	Vigabatrin increases Cmax of clonazepam by 30% and decreases Tmax by 45%
DB01068	DB00582	Voriconazole may increase the serum concentration of clonazepam by decreasing its metabolism. Monitor for clonazepam toxicity if voriconazole is initiated or dose increased.
DB01069	DB00182	Decreased anorexic effect, may increase pyschotic symptoms
DB01069	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB01069	DB01200	The phenothiazine decreases the effect of bromocriptine
DB01069	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01069	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01069	DB01191	Decreased anorexic effect, may increase pyschotic symptoms.
DB01069	DB01576	Decreased anorexic effect, may increase pyschotic symptoms
DB01069	DB00937	Decreased anorexic effect, may increase psychotic symptoms.
DB01069	DB00843	Possible antagonism of action
DB01069	DB00574	Decreased anorexic effect, may increase psychotic symptoms.
DB01069	DB00674	Possible antagonism of action
DB01069	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB01069	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01069	DB01170	Promethazine may decrease the effect of guanethidine.
DB01069	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01069	DB00579	Decreased anorexic effect, may increase psychotic symptoms.
DB01069	DB01577	Decreased anorexic effect, may increase pyschotic symptoms
DB01069	DB01578	Increased risk of convulsions
DB01069	DB01579	Decreased anorexic effect, may increase pyschotic symptoms
DB01069	DB00830	Decreased anorexic effect, may increase pyschotic symptoms
DB01069	DB00191	Decreased anorexic effect, may increase psychotic symptoms.
DB01069	DB00397	Decreased anorexic effect, may increase psychotic symptoms.
DB01069	DB00989	Possible antagonism of action
DB01069	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB01069	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Promethazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01139	DB00479	Increased risk of nephrotoxicity
DB01069	DB00857	Terbinafine may reduce the metabolism and clearance of Promethazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Promethazine if Terbinafine is initiated, discontinued or dose changed.
DB01069	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01069	DB04572	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Promethazine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Promethazine if Thiotepa is initiated, discontinued or dose changed.
DB01069	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01069	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01069	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01069	DB00662	Trimethobenzamide and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01069	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01069	DB00427	Triprolidine and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01069	DB00209	Trospium and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01069	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01069	DB00315	Use of two serotonin modulators, such as zolmitriptan and promethazine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01072	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Atazanavir. The antiviral response should be closely monitored.
DB01072	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB01072	DB01418	The protease inhibitor, atazanavir, may increase the anticoagulant effect of acenocoumarol.
DB01072	DB01370	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB01118	Increased risk of cardiotoxicity and arrhythmias.
DB01072	DB00321	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if atazanavir if initiated, discontinued or dose changed.
DB01072	DB00543	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if atazanavir if initiated, discontinued or dose changed.
DB01072	DB01125	The protease inhibitor, atazanavir, may increase the anticoagulant effect of anisindione.
DB01072	DB01076	Atazanavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01072	DB01244	Atazanavir may increase the effect and toxicity of bepridil.
DB01072	DB01294	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB01558	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if atazanavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01072	DB00921	Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Avoid use of buprenorphine in patients receiving atazanavir without ritonavir boosting due to possible decreases in atazanavir exposure. In patients receiving buprenorphine with atazanavir/ritonavir, monitor for increased buprenorphine effects and consider dose reductions if patients experience adverse effects.
DB01072	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB01072	DB01373	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00501	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01072	DB01211	Atazanavir may increase serum level of clarithromycin.
DB01072	DB01242	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if atazanavir is initiated, discontinued or dose changed.
DB01072	DB00091	Atazanavir may increase the therapeutic and adverse effects of cyclosporine.
DB01072	DB01219	Atazanavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if atazanavir is initiated, discontinued or dose changed.
DB01072	DB01151	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if atazanavir is initiated, discontinued or dose changed.
DB01072	DB00266	The protease inhibitor, atazanavir, may increase the anticoagulant effect of dicumarol.
DB01072	DB00320	Atazanavir may increase the therapeutic and adverse effects of dihydroergotamine.
DB01072	DB01341	Increased risk of cardiotoxicity and arrhythmias
DB01072	DB01375	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00343	Atazanavir may increase the therapeutic and adverse effects of diltiazem resulting in increased risk of AV block. Consider alternate therapy, a 50% dose reduction of diltiazem and monitor for changes in the therapeutic and adverse effects of diltiazem if atazanavir is initiated, discontinued or dose changed.
DB01072	DB01142	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if atazanavir if initiated, discontinued or dose changed.
DB01072	DB00625	Efavirenz decreases the levels/effects of atazanavir
DB01072	DB06210	Decreases metabolism, will increase effect/level of eltrombopag. UDP-glucuronosyltransferase inhibition.
DB01072	DB00696	Atazanavir may increase the effect and toxicity of ergotamine.
DB01072	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB01072	DB00736	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB06414	Atazanavir, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. \r\n\r\nEtravirine, when administered concomitantly with Atazanavir, may expereince an increase in serum concentrations. \r\n\r\nRecommended to avoid use of this combination.
DB01072	DB00927	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00458	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if atazanavir if initiated, discontinued or dose changed.
DB01072	DB00224	Increased risk of hyperbilirubinemia with this association
DB01072	DB00762	Increases levels/effect of irinotecan
DB01072	DB00448	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00281	Increased risk of cardiotoxicity and arrhythmias
DB01072	DB00227	Atazanavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB01072	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB01072	DB01378	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB01377	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00653	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00353	Increases the effect and toxicity of ergot derivative
DB01072	DB00683	Atazanavir may increase the effect and toxicity of the benzodiazepine, midazolam.
DB01072	DB00238	Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed.
DB01072	DB00585	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00540	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if atazanavir if initiated, discontinued or dose changed.
DB01072	DB00338	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB00213	This gastric pH modifier decreases the levels/effects of atazanavir
DB01072	DB01100	The protease inhibitor, atazanavir, may increase the effect and toxicity of pimozide.
DB01072	DB08860	Increases serum concentration of pitavastatin and the potential for adverse drug reactions. Avoid concomitant drug therapy.
DB01072	DB00344	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if atazanavir if initiated, discontinued or dose changed.
DB01072	DB00908	Increased risk of cardiotoxicity and arrhythmias.
DB01072	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB01072	DB01129	Rabeprazole may decrease the serum levels and therapeutic effects of atazanavir.
DB01072	DB00980	Atazanavir increases levels/toxicity of ramelteon
DB01072	DB00863	Ranitidine may decrease the levels/effects of atazanavir.
DB01072	DB00243	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated.
DB01072	DB00615	Atazanavir may increase levels/toxicity of rifabutin.
DB01072	DB01045	Rifampin reduces levels and efficacy of atazanavir
DB01072	DB00503	Association with dose adjustment
DB01072	DB00203	Increases the effect and toxicity of sildenafil
DB01072	DB00641	Increased risk of myopathy/rhabdomyolysis
DB01072	DB00877	Increases the effect and toxicity of immunosuppressant
DB01072	DB01390	This gastric pH modifier decreases the levels/effect of atazanavir
DB01072	DB01323	St. John's Wort decreases the levels/effects of atazanavir
DB01072	DB01268	Possible increase in sunitinib levels
DB01072	DB00864	The protease inhibitor, Atazanavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Atazanavir therapy is initiated, discontinued or altered.
DB01072	DB00820	Atazanavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01072	DB00675	Atazanavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01072	DB00706	Atazanvir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Atazanavir is initiated, discontinued, or dose changed.
DB01072	DB00976	Co-administration may result in altered plasma concentrations of Atazanavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB01072	DB06287	Atazanavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01072	DB00444	The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB00300	Concomitant therapy may result in decreased serum levels of Atazanavir and increased levels of Tenofovir. Concomitant therapy should only be used with the inclusion of Ritonavir.
DB01072	DB00906	The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Atazanavir. Consider alternate therapy.
DB01083	DB00266	Orlistat may increase the anticoagulant effect of dicumarol.
DB01072	DB01036	Atazanavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity.
DB01072	DB00193	Atazanavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01072	DB00656	The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB00755	The strong CYP2C8 inhibitor, Atazanavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Atazanavir is initiated, discontinued to dose changed.
DB01072	DB00897	Atazanavir may increase the effect and toxicity of the benzodiazepine, triazolam.
DB01072	DB00726	The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB00862	Atazanavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01072	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB01072	DB00285	Atazanavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Atazanavir is initiated, discontinued, or dose changed.
DB01072	DB00661	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB06684	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB01072	DB00570	Atazanavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB00541	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB00361	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Atazanavir is initiated, discontinued or dose changed.
DB01072	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB01072	DB00682	The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin.
DB01072	DB00425	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if atazanavir is initiated, discontinued or dose changed.
DB01072	DB00909	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if atazanavir is initiated, discontinued or dose changed.
DB01072	DB01198	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if atazanavir is initiated, discontinued or dose changed.
DB01073	DB00975	Dipyridamole may decrease the effect of fludarabine.
DB01073	DB00552	Unacceptable pulmonary toxicity
DB01073	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01075	DB00289	Diphenhydramine, a moderate CYP2D6 inhibitor, may increase the therapeutic and adverse effects of atomoxetine by decreasing its metabolism.
DB01075	DB00843	Possible antagonism of action
DB01075	DB00674	Possible antagonism of action
DB01075	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01075	DB00989	Possible antagonism of action
DB01075	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Diphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01075	DB00675	Diphenhydramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB01075	DB00706	Diphenhydramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diphenhydramine is initiated, discontinued, or dose changed.
DB01075	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01075	DB00193	Diphenhydramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB01075	DB00662	Trimethobenzamide and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01075	DB00427	Triprolidine and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01075	DB00209	Trospium and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01076	DB09026	Therapy modification should be considered because atorvastatin increases aliskiren serum concentration.
DB01076	DB06274	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB01076	DB00701	Amprenavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01076	DB01072	Atazanavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01076	DB01393	Increased risk of myopathy/rhabdomyolysis
DB01076	DB08873	Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored.
DB01076	DB00559	Bosentan may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if bosentan is initiated, discontinued or dose changed.
DB01076	DB00564	Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of atorvastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if carbamazepine is initiated, discontinued or dose changed.
DB01076	DB01211	The macrolide, clarithromycin, may increase the toxicity of the statin, atorvastatin.
DB01076	DB01394	Increased risk of rhadbomyolysis with this combination.
DB01076	DB00091	Possible myopathy and rhabdomyolysis
DB01076	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if delavirdine is initiated, discontinued or dose changed.
DB01076	DB00343	Diltiazem may increase the serum concentration of atorvastatin. Atorvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB01076	DB04855	Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of atorvastatin. Lower doses of atorvastatin or consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone.
DB01076	DB00625	Efavirenz may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if efavirenz is initiated, discontinued or dose changed.
DB01076	DB06210	Eltrombopag increases levels of Atorvastatin via metabolism decrease.
DB01076	DB00199	The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin.
DB01076	DB06414	Atorvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of atorvastatin therapy.
DB01076	DB01039	Increased risk of myopathy/rhabdomyolysis
DB01076	DB00196	Increased risk of myopathy/rhabdomyolysis
DB01076	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if fosamprenavir is initiated, discontinued or dose changed.
DB01076	DB02703	Increased risk of myopathy/rhabdomyolysis
DB01076	DB01241	Increased risk of myopathy/rhabdomyolysis
DB01076	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if imatinib is initiated, discontinued or dose changed.
DB01076	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01076	DB01167	Increased risk of myopathy/rhabdomyolysis
DB01076	DB01321	The macrolide, josamycin, may increase the toxicity of the statin, atorvastatin.
DB01076	DB01026	Increased risk of myopathy/rhabdomyolysis
DB01076	DB06655	These agents may have decreased C max and a delayed T max during coadministration.
DB01076	DB08827	Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4.
DB01076	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nefazodone is initiated, discontinued or dose changed.
DB01076	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nelfinavir is initiated, discontinued or dose changed.
DB01076	DB00238	Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nevirapine is initiated, discontinued or dose changed.
DB01076	DB01369	This combination presents an increased risk of toxicity
DB01076	DB00615	Rifabutin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifabutin is initiated, discontinued or dose changed.
DB01076	DB01045	Rifampin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifampin is initiated, discontinued or dose changed.
DB01076	DB00503	Ritonavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if ritonavir is initiated, discontinued or dose changed.
DB01076	DB01232	Saquinavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if saquinavir is initiated, discontinued or dose changed.
DB01076	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB01083	DB00162	Orlistat may impair the absorption of vitamin A, a fat soluble vitamin. Oral vitamin A should be administered 2 hours prior to or post orlistat administration.
DB01076	DB00976	The macrolide antibiotic, telithromycin, may increase the serum concentration of atorvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if telithromycin is initiated, discontinued or dose changed.
DB01076	DB00932	Tipranavir, co-administered with Ritonavir, increases the adverse/toxic effects of Atorvastatin. Concomitant therapy should be avoided.
DB01076	DB01030	The p-glycoprotein inhibitor, Atorvastatin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01076	DB00661	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed.
DB01076	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if voriconazole is initiated, discontinued or dose changed.
DB01077	DB01370	Formation of non-absorbable complexes
DB01077	DB01373	Formation of non-absorbable complexes
DB01077	DB00258	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB01077	DB01164	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB01077	DB01592	Formation of non-absorbable complexes
DB01077	DB00893	Formation of non-absorbable complexes
DB01077	DB01378	Formation of non-absorbable complexes
DB01077	DB01377	Formation of non-absorbable complexes
DB01077	DB00364	Formation of non-absorbable complexes
DB01078	DB00436	Possible electrolyte variations and arrhythmias
DB01078	DB00887	Possible electrolyte variations and arrhythmias
DB01078	DB00310	Possible electrolyte variations and arrhythmias
DB01078	DB00903	Possible electrolyte variations and arrhythmias
DB01078	DB00695	Possible electrolyte variations and arrhythmias
DB01078	DB00999	Possible electrolyte variations and arrhythmias
DB01078	DB00808	Possible electrolyte variations and arrhythmias
DB01078	DB00524	Possible electrolyte variations and arrhythmias
DB01080	DB01068	Vigabatrin increases Cmax of clonazepam by 30% and decreases Tmax by 45%
DB01080	DB01320	Vigabatrin decreases the effect of hydantoin
DB01080	DB00358	Mefloquine may decrease the serum concentration of Vigabatrin. This may increase the risk of seizure in patients receiving Vigabatrin to prevent seizures. Consider alternate therapy or monitor for changes in Vigabatrin serum concentration, therapeutic or adverse effects if Mefloquin is initiated, discontinued or dose changed.
DB01080	DB01403	Additive CNS depression may occur. Dose adjustments may be required if one agent is added to existing therapy with the other agent. Monitor for increased CNS depression during concomitant therapy.
DB01080	DB01174	Vigabatrin reduces serum concentrations of phenobarbital by 8-16%.
DB01080	DB00252	Vigabatrin reduces plasma levels of phenytoin by 16-20% which may be due to induction of CYP2C. Consider dosage adjustment.
DB01080	DB00203	Increased anticonvulsant effects of vigabatrin due to pharmacodynamic synergism. Monitor for adverse effects during concomitant therapy.
DB01080	DB00427	The CNS depressants, Triprolidine and Vigabatrin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01080	DB00313	Vigabatrin reduces serum concentrations of valproic acid by 8%.
DB01081	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01081	DB00843	Possible antagonism of action
DB01081	DB00674	Possible antagonism of action
DB01082	DB00887	Increased ototoxicity
DB01082	DB00493	Increased risk of nephrotoxicity
DB01082	DB01330	Increased risk of nephrotoxicity
DB01082	DB01331	Increased risk of nephrotoxicity
DB01082	DB00438	Increased risk of nephrotoxicity
DB01082	DB01212	Increased risk of nephrotoxicity
DB01082	DB01111	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB01082	DB00903	Increased ototoxicity
DB01082	DB00695	Increased ototoxicity
DB01082	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Streptomycin. Use caution during concomitant therapy.
DB01082	DB01607	Ticarcillin may reduce the serum concentration of Streptomycin. Ticarcillin may inactivate Streptomycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB01083	DB01418	Orlistat may increase the anticoagulant effect of acenocoumarol.
DB01083	DB01125	Orlistat may increase the anticoagulant effect of anisindione.
DB01083	DB02300	Orlistat may decrease the serum concentration of fat soluble vitamins like vitamin D. Hence, this applies to calcipotriol, a synthetic derivative of vitamin D. Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Similar precautions do not apply to parenterally administered fat soluble vitamins.
DB01083	DB00169	Orlistat may decrease the serum concentration of Vitamin D analogs. More specifically, orlistat may impair absorption of Vitamin D analogs such as cholecalciferol. Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat.
DB01083	DB00163	Orlistat may impair the absorption of vitamin E, a fat soluble vitamin. Oral vitamin E should be administered 2 hours prior to or post orlistat administration.
DB01083	DB00682	Orlistat may increase the anticoagulant effect of warfarin.
DB01085	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Pilocarpine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB01087	DB06697	Primaquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB01087	DB06708	Primaquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB01087	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Primaquine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Primaquine is initiated, discontinued or if the dose is changed.
DB01087	DB01623	The strong CYP1A2 inhibitor, Primaquine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Primaquine is initiated, discontinued or dose changed.
DB01087	DB00697	Primaquine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01088	DB00519	The prostacyclin analogue, Iloprost, may increase the hypotensive effect of Trandolapril.
DB01089	DB00668	Increased arterial pressure
DB01089	DB01288	Increased arterial pressure
DB01089	DB00816	Increased arterial pressure
DB01089	DB00388	Increased arterial pressure
DB01089	DB00397	Increased arterial pressure
DB01089	DB00852	Increased arterial pressure
DB01089	DB00871	Increased arterial pressure
DB01095	DB01418	Fluvastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if fluvastatin is initiated, discontinued or dose changed.
DB01095	DB01125	Fluvastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if fluvastatin if initiated, discontinued or dose changed.
DB01095	DB01393	Increased risk of myopathy/rhabdomyolysis
DB01095	DB01432	Increased/decreased effect according to spacing
DB01095	DB01394	Increased risk of rhabdomyolysis with this combination
DB01095	DB00375	Increased/decreased effect according to spacing
DB01095	DB00091	Possible myopathy and rhabdomyolysis
DB01095	DB00266	Fluvastatin may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if fluvastatin if initiated, discontinued or dose changed.
DB01095	DB06210	Increases levels of Fluvastatin via metabolism decrease. OATP transporter protein inhibition.
DB01095	DB06414	Fluvastatin, when administered concomitantly with etravirin, may experience an increase in serum concentration. It is recommended to monitor for signs of toxicity from fluvastatin, such as myopathy and hepatic enzyme elevations.
DB01095	DB01039	Increased risk of myopathy/rhabdomyolysis
DB01095	DB00196	Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed.
DB01095	DB01241	Increased risk of myopathy/rhabdomyolysis
DB01095	DB00912	Inhibitors of CYP3A4 and P-glycoprotein may increase serum concentrations of repaglinide. Monitor concomitant therapy closely.
DB01095	DB00615	Rifabutin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifabutin is initiated, discontinued or dose changed.
DB01095	DB01045	Rifampin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifampin is initiated, discontinued or dose changed.
DB01095	DB00682	Fluvastatin may increase the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if fluvastatin is initiated, discontinued or dose changed.
DB01097	DB01281	Therapy modification should be considered due to enhanced adverse effects of leflunomide, specifically hematologic toxicity.
DB01097	DB01418	Leflunomide may increase the anticoagulant effect of acenocoumarol.
DB01097	DB01125	Leflunomide may increase the anticoagulant effect of anisindione.
DB01097	DB00098	Therapy modification may be required because the combination enhances toxic effects of leflunomide.
DB01097	DB06681	Consider therapy modification due to enhanced adverse effects of leflunomide, especially hematologic toxicities.
DB01097	DB08879	Consider modifying therapy as belimumab may enhance the adverse effects of leflunomide, such as hematologic toxicities.
DB01097	DB00290	Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity.
DB01097	DB00958	Immunosuppressants such as carboplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01098	DB00091	Cyclosporine may increase the serum concentration of rosuvastatin. Limit rosuvastatin dosing to 5 mg/day and monitor for changes in the therapeutic and adverse effects of rosuvastatin if cyclosporine is initiated, discontinued or dose changed.
DB01098	DB01039	May cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy.
DB01110	DB00820	Miconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01097	DB00262	Immunosuppressants such as carmustine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01097	DB00291	Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01097	DB00515	Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01097	DB00242	Immunosuppressants such as cladribine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01097	DB00631	Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01097	DB00930	Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide. Unless using cholestyramine (or another bile acid sequestrant) together with leflunomide to intentionally enhance the removal/elimination of leflunomide, consider using an alternative to the bile acid sequestrants whenever possible. Separating the administration of these agents is unlikely to be an effective means of avoiding the interaction.
DB01097	DB01285	Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01097	DB00266	Leflunomide may increase the anticoagulant effect of dicumarol.
DB01097	DB06210	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB01097	DB00005	Consider modifying therapy due to enhanced adverse effects of leflunomide including hematologic toxicity.
DB01097	DB00056	Consider modifying therapy due to adverse effects of leflunomide including the risk of hematologic toxicity.
DB01097	DB05259	Consider therapy modification due to enhanced adverse effects of leflunomide including hematologic toxicity.
DB01097	DB00078	May need to modify therapy to avoid adverse effects of leflunomide such as hematologic toxicity.
DB01097	DB00065	Therapy modification should be considered in order to reduce the risk of hematologic toxicities.
DB01097	DB08935	Consider modifying therapy. Risk of hematologic toxicity of leflunomide may be increased due to enhanced adverse effects.
DB01097	DB00043	Consider modifying therapy due to increased adverse effects of leflunomide including hematological toxicity.
DB01097	DB00059	Immunosuppressants can increase toxic effects of leflunomide such as hematologic toxicity.
DB01097	DB01045	Rifampin increases the effect of leflunomide
DB01097	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB01097	DB08880	Avoid combination due to increased adverse effects of teriflunomide.
DB01097	DB08895	Leflunomide may experience an increase in toxicity and adverse effects (ie. pancytopenia, agranulocytosis, thrombocytopenia). It is recommended to adjust therapy by forgoing a leflunomide loading dose, and to monitor for bone marrow suppression monthly.
DB01097	DB00570	Vinblastine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinblastine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.
DB01097	DB00541	Vincristine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vincristine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.
DB01097	DB00361	Vinorelbine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinorelbine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.
DB01097	DB00682	Leflunomide may increase the anticoagulant effect of warfarin.
DB01098	DB01394	Increased risk of rhabdomyolysis with this combination
DB01101	DB01320	Capecitabine increases the effect of hydantoin
DB01098	DB01241	Gemfibrozil may increase the therapeutic and toxic effects of rosuvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of rosuvastatin if gemfibrozil is initiated, discontinued or dose changed.
DB01098	DB01378	Magnesium-containing antacids may decrease the absorption of rosuvastatin.
DB01098	DB00932	Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may increase Rosuvastatin and Tipranavir concentrations. Consider alternate therapy.
DB01100	DB00701	Amprenavir may increase the effect and toxicity of pimozide.
DB01100	DB00673	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB06697	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB01100	DB01072	The protease inhibitor, atazanavir, may increase the effect and toxicity of pimozide.
DB01100	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB01100	DB00215	The SSRI, citalopram, may increase the effect and toxicity of pimozide.
DB01100	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB00843	Possible antagonism of action
DB01100	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB01175	The SSRI, escitalopram, increases the effect and toxicity of pimozide.
DB01100	DB00196	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB01319	Amprenavir increases the effect and toxicity of pimozide
DB01100	DB00674	Possible antagonism of action
DB01100	DB00619	Imatinib may increase the effect and toxicity of pimozide.
DB01100	DB00224	The protease inhibitor, indinavir, may increase the effect and toxicity of pimozide.
DB01100	DB01167	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB01026	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB06708	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB01100	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB01149	Nefazodone may increase the effect and toxicity of pimozide.
DB01100	DB00220	Nelfinavir increases the effect and toxicity of pimozide
DB01100	DB00715	Increased risk of cardiotoxicity and arrhythmias.
DB01100	DB01263	Contraindicated co-administration
DB01100	DB00503	The protease inhibitor, ritonavir, may increase the effect and toxicity of pimozide.
DB01100	DB00989	Possible antagonism of action
DB01100	DB01232	The protease inhibitor, saquinavir, may increase the effect and toxicity of pimozide.
DB01100	DB01104	The SSRI, sertraline, increases the effect and toxicity of pimozide.
DB01100	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Pimozide, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB01100	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01100	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB01100	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01100	DB00976	Telithromycin may reduce clearance of Pimozide. Concomitant therapy is contraindicated.
DB01100	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB01100	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01100	DB00208	Avoid combination with pimozide and other major CYP3A4 substrates due to the potential increase of pimozide concentration.
DB01100	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Pimozide. Concomitant therapy is contraindicated.
DB01100	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01100	DB00662	Trimethobenzamide and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01100	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01100	DB00427	Triprolidine and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01100	DB01361	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB00209	Trospium and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01100	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pimozide by decreasing its metabolism. Increased risk of QTc prolongation and development arrhythmias. Concomitant use is contraindicated.
DB01100	DB02546	Additive QTc prolongation may occur. Concomitant therapy is contraindicated.
DB01100	DB00744	Increased risk of cardiotoxicity and arrhythmias
DB01100	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB01100	DB01624	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
DB01101	DB01418	Capecitabine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB01101	DB01125	Capecitabine may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB01101	DB00266	Capecitabine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
DB01101	DB00754	Capecitabine increases the effect of hydantoin
DB01101	DB00675	Capecitabine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Capecitabine is initiated, discontinued or dose changed.
DB01101	DB01124	Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Capecitabine is initiated, discontinued or dose changed.
DB01101	DB00214	Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed.
DB01101	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01101	DB00440	The strong CYP2C9 inhibitor, Capecitabine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Capecitabine is initiated, discontinued or dose changed.
DB01101	DB00582	Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if capecitabine is initiated, discontinued or dose changed.
DB01101	DB00682	Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect.
DB01101	DB00549	Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if capecitabine is initiated, discontinued or dose changed.
DB01103	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB01104	DB00918	Increased risk of CNS adverse effects
DB01104	DB00564	Sertraline increases the effect of carbamazepine
DB01104	DB01136	The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB01104	DB01166	Sertraline increases the effect of cilostazol
DB01104	DB01211	Possible serotoninergic syndrome with this combination
DB01104	DB00363	The antidepressant increases the effect of clozapine
DB01104	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01104	DB00843	Possible antagonism of action
DB01104	DB00216	Increased risk of CNS adverse effects
DB01104	DB00199	Possible serotoninergic syndrome with this combination
DB01104	DB01320	Sertraline increases the effect of hydantoin
DB01104	DB00998	Increased risk of CNS adverse effects
DB01104	DB00674	Possible antagonism of action
DB01104	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01104	DB01247	Possible severe adverse reaction with this combination
DB01104	DB01009	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01104	DB00601	Combination associated with possible serotoninergic syndrome
DB01104	DB00264	The SSRI increases the effect of the beta-blocker
DB01104	DB01171	Possible severe adverse reaction with this combination
DB01104	DB00952	Increased risk of CNS adverse effects
DB01104	DB00497	Increased risk of serotonin syndrome
DB01104	DB00780	Possible severe adverse reaction with this combination
DB01104	DB00252	Sertraline increases the effect of hydantoin
DB01104	DB01100	The SSRI, sertraline, increases the effect and toxicity of pimozide.
DB01104	DB01182	Fluoxetine increases the effect and toxicity of propafenone
DB01104	DB00571	The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, propranolol.
DB01104	DB01367	Possible severe adverse reaction with this combination
DB01104	DB00675	Sertraline may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB01104	DB00706	Sertraline, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sertraline is initiated, discontinued, or dose changed.
DB01104	DB00857	Terbinafine may reduce the metabolism and clearance of Sertraline. Consider alternate therapy or monitor for therapeutic/adverse effects of Sertraline if Terbinafine is initiated, discontinued or dose changed.
DB01104	DB01600	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01104	DB00932	Tipranavir increases the concentration of Sertraline. The Sertraline dose may require an adjustment.
DB01104	DB00500	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB01104	DB01036	Sertraline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01104	DB00193	Tramadol increases the risk of serotonin syndrome and seizures. Sertraline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Sertraline may decrease the effect of Tramadol by decreasing active metabolite production.
DB01104	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB01104	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01104	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Sertraline. Monitor for increased bleeding during concomitant thearpy.
DB01104	DB00726	The SSRI, Sertraline, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Sertraline is initiated, discontinued or dose changed.
DB01115	DB01354	The barbiturate, heptabarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01104	DB00427	The CNS depressants, Triprolidine and Sertraline, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01104	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01104	DB00315	Use of two serotonin modulators, such as zolmitriptan and sertraline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01105	DB00918	Increased risk of CNS adverse effects
DB01105	DB00321	Increased risk of CNS adverse effects
DB01105	DB00543	Increased risk of CNS adverse effects
DB01105	DB00215	Risk of serotoninergic syndrome
DB01105	DB01242	Increased risk of CNS adverse effects
DB01105	DB00091	Sibutramine increases the effect and toxicity of cyclosporine
DB01105	DB01151	Increased risk of CNS adverse effects
DB01105	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01105	DB00514	Combination associated with possible serotoninergic syndrome
DB01105	DB00320	Possible serotoninergic syndrome with this combination
DB01105	DB01142	Increased risk of CNS adverse effects
DB01105	DB00696	Possible serotoninergic syndrome with this combination
DB01105	DB00199	Erythromycin increases the effect and toxicity of sibutramine
DB01105	DB01175	Risk of serotoninergic syndrome
DB01105	DB00472	Risk of serotoninergic syndrome
DB01105	DB00176	Risk of serotoninergic syndrome
DB01105	DB00998	Increased risk of CNS adverse effects
DB01105	DB00458	Increased risk of CNS adverse effects
DB01105	DB01247	Possible serotoninergic syndrome with this combination
DB01105	DB01026	Ketoconazole increases the levels and toxicity of sibutramine
DB01105	DB01356	Possible serotoninergic syndrome with this combination
DB01105	DB00247	Possible serotoninergic syndrome
DB01105	DB01171	Possible serotoninergic syndrome with this combination
DB01105	DB00952	Increased risk of CNS adverse effects
DB01105	DB01149	Risk of serotoninergic syndrome
DB01105	DB00540	Increased risk of CNS adverse effects
DB01105	DB00715	Risk of serotoninergic syndrome
DB01105	DB00454	Possible serotoninergic syndrome
DB01105	DB00780	Possible serotoninergic syndrome with this combination
DB01105	DB01367	Possible serotoninergic syndrome with this combination
DB01105	DB00976	Telithromycin may reduce clearance of Sibutramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sibutramine if Telithromycin is initiated, discontinued or dose changed.
DB01105	DB00193	Sibutramine may incrase the serotonergic effect of the Tramadol. Concomitant therapy should be avoided.
DB01105	DB00752	Increased risk of serotonin syndrome. Avoid concomitant therapy.
DB01105	DB00656	Increased risk of serotonin syndrome. Avoid concomitant therapy.
DB01105	DB00726	Increased risk of serotonin syndrome. Concomitant therapy is contraindicated.
DB01105	DB00285	Increased risk of serotonin syndrome. Concurrent therapy should be avoided.
DB01105	DB06684	Sibutramine may enhance the serotonergic effect of Serotonin Modulators. This may cause serotonin syndrome. Avoid combination.
DB01105	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sibutramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sibutramine if voriconazole is initiated, discontinued or dose changed.
DB01105	DB00315	Use of sibutramine, which inhibits serotonin reuptake, and zolmitriptan, a serotonin 5-HT1D receptor agonist, may cause serotonin syndrome. Concomitant therapy is contraindicated.
DB01109	DB00945	Increased risk of bleeding.
DB01109	DB09026	Monitor therapy due to enhanced hyperkalemic effect of aliskiren.
DB01109	DB06692	Aprotinin, in the presence of heparin, has been found to prolong the activated clotting time (ACT) as measured by a celite surface activation method. The kaolin activated clotting time appears to be much less affected.
DB01109	DB05394	Contraindication: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. Corticorelin prescribing information describes a case in which a patient experienced a substantial fall in blood pressure and heart rate, resulting in asystole and requiring resuscitation.
DB01109	DB01395	Heparin can increase risk of hyperkalemia for patients on drospirenone
DB01109	DB00055	The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin.
DB01109	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01109	DB00208	Increased bleeding risk. Monitor aPTT.
DB01109	DB00684	Increased risk of nephrotoxicity
DB01109	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Heparin. Monitor for increased bleeding during concomitant thearpy.
DB01110	DB01418	Miconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism.
DB01110	DB01125	Miconazole may increase the serum concentration of anisindione by decreasing its metabolism.
DB01110	DB00266	Miconazole may increase the serum concentration of dicumarol by decreasing its metabolism.
DB01110	DB06210	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB01110	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Miconazole, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Miconazole is initiated, discontinued or if the dose is changed.
DB01110	DB00864	The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00675	Miconazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB01110	DB00706	Miconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Miconazole is initiated, discontinued, or dose changed.
DB01110	DB00976	Miconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB01110	DB06287	Miconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01110	DB00444	The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00906	The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00697	Miconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01110	DB01124	Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Miconazole is initiated, discontinued or dose changed.
DB01110	DB01036	Miconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01110	DB00214	Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00193	Miconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Miconazole may decrease the effect of Tramadol by decreasing active metabolite production.
DB01110	DB00656	The CYP3A4 inhibitor, Miconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00440	The strong CYP2C9 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00726	The strong CYP3A4/2D6/2C19 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/2D6/2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00862	Miconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01110	DB00285	Miconazole, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Miconazole is initiated, discontinued, or dose changed.
DB01110	DB00661	Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00570	Miconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00541	Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00361	Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Miconazole is initiated, discontinued or dose changed.
DB01110	DB00582	Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if miconazole is initiated, discontinued or dose changed.
DB01110	DB00682	Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if miconazole is initiated, discontinued or dose changed.
DB01111	DB00479	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB01111	DB00681	Amphotericin B may enhance the nephrotoxic effect of Colistimethate. Due to the potential for additive or synergistic nephrotoxicity between colistimethate and other nephrotoxic drugs, such as amphotericin B, this combination should be avoided whenever possible. If these agents must be used together, patients' renal function should be monitored closely.
DB01111	DB00732	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB01111	DB00565	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB01111	DB00798	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB01111	DB01172	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB01111	DB00994	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB01111	DB01337	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB01111	DB00728	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB01111	DB01082	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB01111	DB00684	Increased risk of nephrotoxicity
DB01111	DB00512	Additive nephrotoxic effects may occur. Consider alternate therapy or monitor for renal function during concomitant therapy.
DB01111	DB01339	Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
DB01112	DB00479	Increased risk of nephrotoxicity
DB01112	DB00798	Increased risk of nephrotoxicity
DB01112	DB00955	Increased risk of nephrotoxicity
DB01112	DB01032	Probenecid may increase the serum level of cefuroxime.
DB01112	DB00684	Increased risk of nephrotoxicity
DB01113	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01113	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01114	DB00843	Possible antagonism of action
DB01114	DB00754	The antihistamine increases the effect of hydantoin
DB01114	DB01320	The antihistamine increases the effect of hydantoin
DB01114	DB00674	Possible antagonism of action
DB01114	DB00532	The antihistamine increases the effect of hydantoin
DB01114	DB00252	The antihistamine increases the effect of hydantoin
DB01114	DB00989	Possible antagonism of action
DB01114	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Chlorpheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01114	DB00976	Telithromycin may reduce clearance of Chlorpheniramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlorpheniramine if Telithromycin is initiated, discontinued or dose changed.
DB01114	DB00662	Trimethobenzamide and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01114	DB00427	Triprolidine and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01114	DB00209	Trospium and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01114	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chlorpheniramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorpheniramine if voriconazole is initiated, discontinued or dose changed.
DB01115	DB01351	The barbiturate, amobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB01352	The barbiturate, aprobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00237	The barbiturate, butabarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00241	The barbiturate, butalbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB01353	The barbiturate, butethal, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00501	Cimetidine may increase the effect of the calcium channel blocker, nifedipine.
DB01115	DB00604	Cisapride may increase the effect and toxicity of nifedipine.
DB01115	DB00091	Increased risk of gingivitis
DB01115	DB01341	Decreased quinidine effect, increased nifedipine effect
DB01115	DB06414	Nifedipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor nifedipine therapy for reduced effectiveness.
DB01115	DB01404	Ginseng increases the effect and toxicity of nifedipine
DB01115	DB01355	The barbiturate, hexobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00619	Imatinib increases the effect and toxicity of nifedipine
DB01115	DB01065	Melatonin can possibly decrease the effect of nifedipine
DB01115	DB00474	The barbiturate, methohexital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00849	The barbiturate, methylphenobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00312	The barbiturate, pentobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB01174	The barbiturate, phenobarbital, may decrease the effect of the calcium channel blocker, nifedipine.
DB01115	DB00794	The barbiturate, primidone, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00908	Decreased quinidine effect, increased nifedipine effect
DB01115	DB01346	Decreased quinidine effect, increased nifedipine effect
DB01115	DB01369	Synercid increases the effect of ziprasidone
DB01115	DB01045	Rifampin decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00418	The barbiturate, secobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB01323	St. John's Wort decreases the effect of nifedipine
DB01115	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Nifedipine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Nifedipine is initiated, discontinued or if the dose is changed.
DB01115	DB00864	The calcium channel blocker, Nifedipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nifedipine therapy is initiated, discontinued or altered.
DB01115	DB00306	The barbiturate, talbutal, decreases the effect of the calcium channel blocker, nifedipine.
DB01115	DB00976	Telithromycin may reduce clearance of Nifedipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nifedipine if Telithromycin is initiated, discontinued or dose changed.
DB01115	DB00599	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nifedipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nifedipine if Thiopental is initiated, discontinued or dose changed.
DB01115	DB00932	Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nifedipine. Monitor for changes in Nifedipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed.
DB01115	DB00697	Nifedipine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01115	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01115	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nifedipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nifedipine if voriconazole is initiated, discontinued or dose changed.
DB01117	DB00615	Rifabutin decreases the effect of atovaquone
DB01117	DB01045	Rifampin may decrease the effect of atovaquone.
DB01117	DB00759	Tetracycline may decrease the effect of atovaquone.
DB01117	DB00495	Atovaquone increases the effect and toxicity of zidovudine
DB01118	DB01418	Amiodarone may increase the anticoagulant effect of acenocoumarol.
DB01118	DB06274	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB01118	DB00701	The protease inhibitor, amprenavir, may increase the effect and toxicity of amiodarone.
DB01118	DB01125	Amiodarone may increase the anticoagulant effect of anisindione.
DB01118	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01118	DB01072	Increased risk of cardiotoxicity and arrhythmias.
DB01118	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB01118	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00930	Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. Consider alternative antilipemic agent. The risk of subtherapeutic amiodarone serum concentrations when such is being used for the treatment of malignant arrhythmias can be very large. The effect (ie, reduced risk) of separating doses of these agents is unknown. Amiodarone should be administered at least 1 hour before or 4 hours after colesevelam.1 Similar dosing with other agents seems warranted.
DB01118	DB00091	Amiodarone may increase the therapeutic and adverse effects of cyclosporine.
DB01118	DB06695	Amiodarone may increase the serum concentration of dabigatran etexilate, resulting in increased risk of bleeding. Consider modifying therapy.
DB01118	DB00266	Amiodarone may increase the anticoagulant effect of dicumarol.
DB01118	DB00390	Amiodarone may increase the effect of digoxin.
DB01118	DB01341	Increases the effect of quinidine
DB01118	DB00343	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB06210	Affects hepatic enzyme CYP2C9/10 metabolism, increases effect/level of eltrombopag.
DB01118	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00754	Increases the effect of hydantoin
DB01118	DB06414	Amiodarone, when used concomitantly with etravirine, may decrease in serum concentration. If possible, monitoring for decreased amiodarone levels is recommended.
DB01118	DB06414	Amiodarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. If possible, monitoring of amiodarone levels is recommended.
DB01118	DB00813	Possible bradycardia, hypotension
DB01118	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB01118	DB01195	Amiodarone may increase the effect and toxicity of flecainide
DB01118	DB01319	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of amiodarone.
DB01118	DB01320	Amiodarone may increase the effect of fosphenytoin.
DB01118	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB05039	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB01118	DB00224	Indinavir increases the effect and toxicity of amiodarone
DB01118	DB01362	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01118	DB00532	Increases the effect of hydantoin
DB01118	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00220	Nelfinavir may increase the effect and toxicity of amiodarone.
DB01118	DB00252	Amiodarone may increase the therapeutic and adverse effects of phenytoin.
DB01118	DB01035	Amiodarone may increase serum levels and toxicity of procainamide.
DB01118	DB00908	Amiodarone may increase the effect of quinidine.
DB01118	DB01346	Increases the effect of qiunidine
DB01118	DB00243	Possible additive effect on QT prolongation
DB01118	DB01045	Rifampin decreases the effect of amiodarone
DB01118	DB00503	Ritonavir increases the effect and toxicity of amiodarone
DB01118	DB01656	Increases roflumilast levels.
DB01118	DB01232	The protease inhibitor, saquinavir, may increase the effect and toxicity of amiodarone.
DB01118	DB00641	Increased risk of rhabdomyolysis
DB01118	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01118	DB00675	Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB01118	DB00706	Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed.
DB01118	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01118	DB00976	Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed.
DB01118	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01118	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated.
DB01118	DB00697	Amiodarone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01118	DB01036	Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01118	DB01030	The p-glycoprotein inhibitor, Amiodarone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01118	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01118	DB00193	Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production.
DB01118	DB00656	The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed.
DB01118	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01118	DB00862	Increased risk of cardiotoxicity and arrhythmias
DB01118	DB00661	Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed.
DB01118	DB00582	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amiodarone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of amiodarone if voriconazole is initiated, discontinued or dose changed.
DB01118	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01118	DB00682	Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed.
DB01118	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB01118	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01119	DB09026	Monitor therapy due to enhanced hypotensive effect of aliskiren.
DB01119	DB00436	Significant hyperglycemic effect
DB01119	DB00672	Antagonism.
DB01119	DB00310	Significant hyperglycemic effect
DB01119	DB01320	Diazoxide decreases the hydantoin effect
DB01119	DB01016	Antagonism.
DB01119	DB00999	Significant hyperglycemic effect
DB01119	DB00808	Significant hyperglycemic effect
DB01119	DB00252	Diazoxide decreases the efficacy of phenytoin.
DB01119	DB00519	Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure.
DB01120	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01120	DB00945	Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide.
DB01120	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01120	DB00195	The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.
DB01120	DB01295	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB01120	DB01294	The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, gliclazide.
DB01120	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01120	DB00521	The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.
DB01120	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01120	DB00446	Chloramphenicol may increase the effect of sulfonylurea, gliclazide.
DB01120	DB00636	Clofibrate may increase the effect of sulfonylurea, gliclazide.
DB01120	DB00266	Dicumarol may increase the effect of sulfonylurea, gliclazide.
DB01120	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01120	DB01296	Possible hyperglycemia
DB01120	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB01120	DB01397	The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, gliclazide.
DB01120	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB01120	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01120	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01120	DB01359	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB01120	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB01120	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB01120	DB01297	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01120	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB01120	DB01045	Rifampin may decrease the effect of sulfonylurea, gliclazide.
DB01120	DB01398	The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, gliclazide.
DB01120	DB01399	The salicylate, salsalate, increases the effect of the sulfonylurea, gliclazide.
DB01120	DB00052	Somatropin may antagonize the hypoglycemic effect of gliclazide. Monitor for changes in fasting and postprandial blood sugars.
DB01120	DB00489	The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.
DB01120	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB01120	DB01401	The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, gliclazide.
DB01122	DB00443	The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, ambenonium.
DB01122	DB01234	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, ambenonium.
DB01122	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, ambenonium.
DB01122	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, ambenonium.
DB01122	DB00860	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, ambenonium.
DB01122	DB00635	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, ambenonium.
DB01122	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Ambenonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB01122	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, ambenonium.
DB01124	DB01193	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01124	DB01418	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Acenocoumarol. Consider alternate therapy or monitor for changes in Acenocoumarol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00945	Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide.
DB01124	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01124	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01124	DB00559	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Bosentan. Consider alternate therapy or monitor for changes in Bosentan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01101	Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Capecitabine is initiated, discontinued or dose changed.
DB01124	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01124	DB00482	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00446	Chloramphenicol may increase the effect of sulfonylurea, tolbutamide.
DB01124	DB00636	Clofibrate may increase the effect of sulfonylurea, tolbutamide.
DB01124	DB00250	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00705	Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
DB01124	DB00390	Tolbutamide increases the effect of digoxin
DB01124	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01124	DB00322	Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Floxuridine is initiated, discontinued or dose changed.
DB01136	DB00236	Antagonism
DB01124	DB00196	Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed.
DB01124	DB00544	Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Fluorouracil is initiated, discontinued or dose changed.
DB01124	DB00472	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for changes in Fluoxetine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00712	Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Flurbiprofen is initiated, discontinued or dose changed.
DB01124	DB01320	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for changes in Fosphenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01241	Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Gemfibrozil is initiated, discontinued or dose changed.
DB01124	DB00222	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glimepiride. Consider alternate therapy or monitor for changes in Glimepiride therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01067	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glipizide. Consider alternate therapy or monitor for changes in Glipizide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01050	Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ibuprofen is initiated, discontinued or dose changed.
DB01124	DB00328	Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed.
DB01124	DB01221	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Ketamine. Consider alternate therapy or monitor for changes in Ketamine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01026	Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
DB01124	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB01124	DB00678	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Losartan. Consider alternate therapy or monitor for changes in Losartan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01283	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Lumiracoxib. Consider alternate therapy or monitor for changes in Lumiracoxib therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00784	Mefanamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Mefanamic acid is initiated, discontinued or dose changed.
DB01124	DB01357	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Mestranol. Consider alternate therapy or monitor for changes in Mestranol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB01124	DB01110	Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Miconazole is initiated, discontinued or dose changed.
DB01124	DB00471	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Montelukast. Consider alternate therapy or monitor for changes in Montelukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01124	DB00731	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Nateglinide. Consider alternate therapy or monitor for changes in Nateglinide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00622	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed.
DB01124	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01124	DB01229	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Paclitaxel. Consider alternate therapy or monitor for changes in Paclitaxel therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB01124	DB00252	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB01124	DB00554	Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Piroxicam is initiated, discontinued or dose changed.
DB01124	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB01124	DB01045	Rifampin may decrease the effect of sulfonylurea, tolbutamide.
DB01124	DB06268	Sitaxsentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Sitaxsentan is initiated, discontinued or dose changed.
DB01124	DB00052	Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required.
DB01124	DB00359	Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
DB01124	DB01015	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01138	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfinpyrazone. Consider alternate therapy or monitor for changes in Sulfinpyrazone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00263	Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
DB01124	DB00675	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tamoxifen. Consider alternate therapy or monitor for changes in Tamoxifen therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB01124	DB00214	Tolbutamide, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00440	The strong CYP2C9 inhibitor, Tolbutamide, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00582	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00682	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed.
DB01124	DB00549	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if tolbutamide is initiated, discontinued or dose changed.
DB01124	DB01198	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zopiclone. Consider alternate therapy or monitor for changes in Zopiclone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01125	DB00316	Acetaminophen increases the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if acetaminophen is initiated, discontinued or dose changed.
DB01125	DB00945	Acetylsalicylic acid increases effect of the anticoagulant, anisindione.
DB01125	DB00437	Allopurinol may increase the anticoagulant effect of anisindione.
DB01125	DB00357	Aminoglutethimide may decrease the anticoagulant effect of anisindione.
DB01125	DB01118	Amiodarone may increase the anticoagulant effect of anisindione.
DB01125	DB00701	Amprenavir may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB01125	DB00673	Aprepitant may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.
DB01125	DB01072	The protease inhibitor, atazanavir, may increase the anticoagulant effect of anisindione.
DB01125	DB00993	Azathioprine may decrease the anticoagulant effect of anisindione.
DB01125	DB00207	Azithromycin may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB01125	DB00443	The corticosteroid, betamethasone, alters the anticoagulant effect of anisindione.
DB01125	DB00559	Bosentan may decrease the anticoagulant effect of anisindione by increasing its metabolism.
DB01125	DB01101	Capecitabine may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB01125	DB00564	Carbamazepine may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.
DB01125	DB01330	The cephalosporin, cefotetan, may increase the anticoagulant effect of anisindione.
DB01125	DB01331	The cephalosporin, cefoxitin, may increase the anticoagulant effect of anisindione.
DB01125	DB01212	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of anisindione.
DB01125	DB00482	Celecoxib may increase the anticoagulant effect of anisindione.
DB01125	DB01432	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of anisindione by decreasing its absorption.
DB01125	DB00501	Cimetidine may increase the anticoagulant effect of anisindione.
DB01125	DB00537	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of anisindione.
DB01125	DB00604	Cisapride may increase the anticoagulant effect of anisindione.
DB01125	DB00215	The SSRI, citalopram, increases the effect of anticoagulant, anisindione.
DB01125	DB01211	The macrolide, clarithromycin, may increase the anticoagulant effect of anisindione.
DB01125	DB00636	The fibrate increases the anticoagulant effect
DB01125	DB00375	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of anisindione by decreasing its absorption.
DB01125	DB00531	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of anisindione.
DB01125	DB01406	The androgen, danazol, may increase the anticoagulant effect of anisindione.
DB01136	DB01291	Antagonism
DB01125	DB00618	The tetracycline, demeclocycline, may increase the anticoagulant effect of anisindione.
DB01125	DB01234	The corticosteroid, dexamethasone, alters the anticoagulant effect of anisindione.
DB01125	DB00647	Propoxyphene may increase the anticoagulant effect of anisindione.
DB01125	DB00509	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of anisindione.
DB01125	DB00586	The NSAID, diclofenac, may increase the anticoagulant effect of anisindione.
DB01125	DB00485	Dicloxacillin may decrease the anticoagulant effect of anisindione.
DB01125	DB00861	The NSAID, diflunisal, may increase the anticoagulant effect of anisindione.
DB01125	DB00822	Disulfiram may increase the anticoagulant effect of anisindione.
DB01125	DB00254	The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione.
DB01125	DB00199	The macrolide, erythromycin, may increase the anticoagulant effect of anisindione.
DB01125	DB00189	Ethchlorvynol may decrease the anticoagulant effect of anisindione.
DB01125	DB00977	Increased thrombotic risk due to estrogen
DB01125	DB00749	The NSAID, etodolac, may increase the anticoagulant effect of anisindione.
DB01125	DB01628	Etoricoxib may increase the anticoagulant effect of anisindione.
DB01125	DB01039	Fenofibrate may increase the anticoagulant effect of anisindione.
DB01125	DB00573	The NSAID, fenoprofen, may increase the anticoagulant effect of anisindione.
DB01125	DB00196	Fluconazole may increase the serum concentration of anisindione by decreasing its metabolism.
DB01125	DB00687	The corticosteroid, fludrocortisone, alters the anticoagulant effect of anisindione.
DB01125	DB00544	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of anisindione.
DB01125	DB00472	The SSRI, fluoxetine, increases the effect of anticoagulant, anisindione.
DB01125	DB01185	The androgen, fluoxymesterone, may increase the anticoagulant effect of anisindione.
DB01125	DB00712	The NSAID, flurbiprofen, may increase the anticoagulant effect anisindione.
DB01125	DB01095	Fluvastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if fluvastatin if initiated, discontinued or dose changed.
DB01125	DB00176	Fluvoxamine may increase the anticoagulant effect of anisindione by increasing its serum concentration.
DB01125	DB01319	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of anisindione.
DB01125	DB01320	Increased hydantoin levels and risk of bleeding
DB01125	DB00317	Gefitinib may increase the anticoagulant effect of anisindione.
DB01125	DB00441	Gemcitabine may increase the anticoagulant effect of anisindione.
DB01125	DB01241	Gemfibrozil may increase the anticoagulant effect of anisindione.
DB01125	DB01437	Glutethimide may decrease the anticoagulant effect of anisindione.
DB01125	DB00400	Griseofulvin may decrease the anticoagulant effect of anisindione.
DB01125	DB00741	The corticosteroid, hydrocortisone, alters the anticoagulant effect of anisindione.
DB01125	DB01050	The NSAID, ibuprofen, may increase the anticoagulant effect of anisindione.
DB01125	DB00619	Imatinib may increase the anticoagulant effect of anisindione.
DB01125	DB00224	The protease inhibitor, indinavir, may increase the anticoagulant effect of anisindione.
DB01125	DB00328	The NSAID, indomethacin, may increase the anticoagulant effect of anisindione.
DB01125	DB00951	Isoniazid may increase the anticoagulant effect of anisindione.
DB01125	DB01167	Itraconazole may increase the anticoagulant effect of anisindione.
DB01125	DB01026	Ketoconazole may increase the anticoagulant effect of anisindione.
DB01125	DB01009	The NSAID, ketoprofen, may increase the anticoagulant effect of anisindione.
DB01125	DB00465	The NSAID, ketorolac, may increase the anticoagulant effect of anisindione.
DB01125	DB01097	Leflunomide may increase the anticoagulant effect of anisindione.
DB01125	DB00848	Levamisole may increase the anticoagulant effect of anisindione.
DB01125	DB01137	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of anisindione.
DB01125	DB00451	The thyroid hormone, levothyroxine, increase the anticoagulant effect of anisindione.
DB01125	DB00227	Lovastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if lovastatin if initiated, discontinued or dose changed.
DB01125	DB01283	Lumiracoxib may increase the anticoagulant effect of anisindione.
DB01125	DB00603	Medroxyprogesterone may increase the anticoagulant effect of anisindione.
DB01125	DB00784	The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione.
DB01125	DB00358	Mefloquine may increase the anticoagulant effect of anisindione.
DB01125	DB00814	Meloxicam may increase the anticoagulant effect of anisindione.
DB01125	DB01033	Mercaptopurine may decrease the anticoagulant effect of anisindione.
DB01125	DB00763	The antithyroid agent, methimazole, may decrease the anticoagulant effect of anisindione.
DB01125	DB00916	Metronidazole may increase the anticoagulant effect of anisindione.
DB01125	DB01110	Miconazole may increase the serum concentration of anisindione by decreasing its metabolism.
DB01125	DB01017	The tetracycline, minocycline, may increase the anticoagulant effect of anisindione.
DB01125	DB00648	Mitotane may decrease the anticoagulant effect of anisindione.
DB01125	DB00218	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of anisindione.
DB01125	DB00461	The NSAID, nabumetone, may increase the anticoagulant effect anisindione.
DB01125	DB00779	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of anisindione.
DB01125	DB00788	The NSAID, naproxen, may increase the anticoagulant effect of anisindione.
DB01125	DB00220	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of anisindione.
DB01125	DB00238	Nevirapine may decrease the anticoagulant effect of anisindione.
DB01136	DB00554	Risk of inhibition of renal prostaglandins
DB01125	DB01059	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of anisindione.
DB01125	DB01165	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of anisindione.
DB01125	DB01083	Orlistat may increase the anticoagulant effect of anisindione.
DB01125	DB00991	The NSAID, oxaprozin, may increase the anticoagulant effect of anisinodione.
DB01125	DB03585	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of anisindione.
DB01125	DB00715	The SSRI, paroxetine, increases the effect of the anticoagulant, anisindione.
DB01125	DB00806	Pentoxifylline may increase the anticoagulant effect of anisindione.
DB01125	DB01174	The barbiturate, phenobarbital, decreases the anticoagulant effect of anisindione.
DB01125	DB00812	The NSAID, phenylbutazone, may increase the anticoagulant effect of anisindione.
DB01125	DB00252	Increased hydantoin levels and risk of bleeding
DB01125	DB00554	The NSAID, piroxicam, may increase the anticoagulant effect of anisindione.
DB01125	DB00860	The corticosteroid, prednisolone, alters the anticoagulant effect of anisindione.
DB01125	DB00635	The corticosteroid, prednisone, alters the anticoagulant effect of anisindione.
DB01125	DB00794	The barbiturate, primidone, decreases the anticoagulant effect of anisindione.
DB01125	DB01182	Propafenone may increase the anticoagulant effect of anisindione.
DB01125	DB00550	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of anisindione.
DB01125	DB00908	Quinidine may increase the anticoagulant effect of anisindione.
DB01125	DB00468	Quinine may increase the anticoagulant effect of anisindione.
DB01125	DB00863	Ranitidine may increase the anticoagulant effect of anisindione. (Conflicting evidence)
DB01125	DB00615	Rifabutin, may decrease the anticoagulant effect of anisindione.
DB01125	DB01045	Rifampin may decrease the anticoagulant effect of anisindione.
DB01125	DB00976	Telithromycin may increase the anticoagulant effect of anisindione.
DB01125	DB00469	The NSAID, tenoxicam, may increase the anticoagulant effect of anisindione.
DB01125	DB00624	The androgen may increase the anticoagulant effect of anisindione.
DB01125	DB00759	Tetracycline may increase the anticoagulant effect of anisindione.
DB01125	DB00560	Tigecycline may increase the anticoagulant effect of anisindione.
DB01125	DB00620	The corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione.
DB01128	DB01222	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of budesonide. The clinical significance of this interaction is greater for oral budesonide than for orally inhaled budesonide. Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.
DB01128	DB01394	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of colchicine. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function.
DB01128	DB00700	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of eplerenone. A lower starting dose of eplerenone (25 mg once daily) is recommended in patients with hypertension who are also taking drugs that are moderate inhibitors of CYP3A4.
DB01128	DB01590	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of everolimus. Consider therapy modification. Recommendations regarding optimal management of this interaction vary according to specific indication and product used.
DB01128	DB00813	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of fentanyl. The risk of prolonged adverse effects, including potentially fatal respiratory depression is increased. Consider therapy modification.
DB01128	DB01218	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).
DB01128	DB08815	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor.
DB01128	DB00243	CYP3A4 inhibitors like ranolazine may increase the serum concentration of ranolazine. Consider therapy modification.
DB01128	DB06212	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of tolvaptan. This combination is contraindicated.
DB01129	DB01072	Rabeprazole may decrease the serum levels and therapeutic effects of atazanavir.
DB01129	DB01066	Proton pump inhibitors such as rabeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
DB01129	DB00758	Rabeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent rabeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with rabeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
DB01129	DB01254	Rabeprazole may decrease the serum level of dasatinib.
DB01129	DB00390	Rabeprazole increases the effect of digoxin
DB01129	DB00467	Rabeprazole may decrease the absorption of enoxacin.
DB01129	DB00224	Omeprazole decreases the absorption of indinavir
DB01129	DB01167	The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole.
DB01129	DB01026	The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole.
DB01129	DB08864	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB01129	DB00755	The moderate CYP2C8 inhibitor, Rabaprazole, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rabaprazole is initiated, discontinued to dose changed.
DB01131	DB06697	Proguanil may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB01131	DB06708	Proguanil may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB01132	DB00930	Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents.
DB01132	DB01241	Gemfibrozil may increase the effect and toxicity of pioglitazone.
DB01132	DB01296	Possibly hyperglycemia
DB01132	DB01026	Ketoconazole increases the effect of pioglitazone
DB01132	DB01357	Possible loss of contraceptive effect
DB01132	DB00717	Possible loss of contraceptive effect
DB01132	DB00052	Somatropin may antagonize the hypoglycemic effect of pioglitazone. Monitor for changes in fasting and postprandial blood sugars.
DB01132	DB00675	Pioglitazone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB01132	DB00706	Pioglitazone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pioglitazone is initiated, discontinued, or dose changed.
DB01132	DB00193	Pioglitazone may decrease the effect of Tramadol by decreasing active metabolite production.
DB01132	DB00755	The moderate CYP2C8 inhibitor, Pioglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Pioglitazone is initiated, discontinued to dose changed.
DB01133	DB00258	The divalent cation of oral Calcium Acetate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
DB01133	DB01164	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB01133	DB01377	The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
DB01133	DB00653	The divalent cation of oral Magnesium sulfate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
DB01135	DB00479	The agent increases the effect of muscle relaxant
DB01135	DB01223	Theophylline decreases the effect of muscle relaxant
DB01135	DB00993	The agent decreases the effect of the muscle relaxant
DB01135	DB00564	Decreases the effect of muscle relaxant
DB01135	DB01190	The agent increases the effect of muscle relaxant
DB01135	DB01320	Phenytoin decreases the effect of muscle relaxant
DB01135	DB00798	The agent increases the effect of muscle relaxant
DB01135	DB01627	The agent increases the effect of muscle relaxant
DB01135	DB01033	The agent dereases the effect of the muscle relaxant
DB01135	DB00955	The agent increases the effect of muscle relaxant
DB01135	DB01303	Theophylline decreases the effect of muscle relaxant
DB01135	DB00252	Phenytoin decreases the effect of the muscle relaxant
DB01135	DB00319	The agent increases the effect of the muscle relaxant
DB01135	DB00277	Theophylline decreases the effect of the muscle relaxant
DB01135	DB00684	The agent increases the effect of the muscle relaxant
DB01136	DB00414	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB00672	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB00215	The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB01136	DB00575	Increased hypertension when clonidine stopped
DB01136	DB00091	Carvedilol may increase the therapeutic and adverse effects of cyclosporine.
DB01136	DB00390	Carvedilol may increase the serum levels and effect of digoxin.
DB01136	DB00320	Ischemia with risk of gangrene
DB01136	DB00280	The beta-blocker, carvedilol, may increase the toxicity of disopyramide.
DB01136	DB00668	Hypertension, then bradycardia
DB01136	DB01253	Ischemia with risk of gangrene
DB01136	DB00696	Ischemia with risk of gangrene
DB01136	DB01175	The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB01136	DB06414	Carvedilol, when used concomitantly with etravirine (a CYP2C9 inhibitor), may experience an increase in serum concentration. \r\n\r\nIt is recommended to monitor for signs and symptoms of an increased response to carvedilol, such as orthostatic hypotension and bradycardia.
DB01136	DB01288	Antagonism
DB01136	DB00472	The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB01136	DB00983	Antagonism
DB01136	DB01120	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01067	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01289	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01016	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01382	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01050	Risk of inhibition of renal prostaglandins
DB01136	DB00328	Risk of inhibition of renal prostaglandins
DB01136	DB01306	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01307	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB00047	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01309	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB00046	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01064	Antagonism
DB01136	DB00281	The beta-blocker, carvedilol, may increase the effect and toxicity of lidocaine.
DB01136	DB00247	Ischemia with risk of gangrene
DB01136	DB00816	Antagonism
DB01136	DB00715	The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB01136	DB00912	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01001	Antagonism
DB01136	DB00938	Antagonism
DB01136	DB01104	The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB01136	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01136	DB00857	Terbinafine may reduce the metabolism and clearance of Carvedilol. Consider alternate therapy or monitor for therapeutic/adverse effects of Carvedilol if Terbinafine is initiated, discontinued or dose changed.
DB01136	DB00871	Antagonism
DB01136	DB00839	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01124	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01136	DB01030	The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01136	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01136	DB00661	Increased effect of both drugs
DB01137	DB01418	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01137	DB01370	Formation of non-absorbable complexes
DB01137	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01125	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of anisindione.
DB01137	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01137	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01373	Formation of non-absorbable complexes
DB01137	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB01137	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00266	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of dicumarol.
DB01137	DB01341	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00623	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01592	Formation of non-absorbable complexes
DB01137	DB00893	Formation of non-absorbable complexes
DB01137	DB01321	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01137	DB01378	Formation of non-absorbable complexes
DB01137	DB01377	Formation of non-absorbable complexes
DB01137	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01403	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00850	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01035	Levofloxacin may increase the effect of procainamide.
DB01137	DB00433	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00420	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01069	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00777	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01369	This combination presents an increased risk of toxicity
DB01137	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00364	Formation of non-absorbable complexes
DB01137	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01137	DB00372	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01137	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01137	DB00831	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00508	Increased risk of cardiotoxicity and arrhythmias
DB01137	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01137	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01137	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01137	DB00682	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin.
DB01137	DB01593	Formation of non-absorbable complexes
DB01137	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01137	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01138	DB00091	Sulfinpyrazone decreases the effect of cyclosporine
DB01138	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfinpyrazone. Consider alternate therapy or monitor for changes in Sulfinpyrazone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01138	DB00682	Sulfinpyrazone may increase the anticoagulant effect of warfarin by decreasing its metabolism and protein binding.
DB01139	DB00798	Increased risk of nephrotoxicity
DB01139	DB00955	Increased risk of nephrotoxicity
DB01139	DB00684	Increased risk of nephrotoxicity
DB01140	DB01032	Probenecid may increase the serum level of cefadroxil.
DB01142	DB00488	Risk of severe hypotension
DB01142	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01142	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if atazanavir if initiated, discontinued or dose changed.
DB01142	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB01142	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB01142	DB00564	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed.
DB01142	DB00501	Cimetidine may increase the effect of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if cimetidine is initiated, discontinued or dose changed.
DB01142	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01142	DB00575	The tricyclic antidepressant, doxepin, decreases the effect of clonidine.
DB01142	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01142	DB01341	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, doxepin.
DB01142	DB00841	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dobutamine.
DB01142	DB00843	Possible antagonism of action
DB01142	DB00988	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dopamine.
DB01142	DB01363	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedra.
DB01142	DB01364	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedrine.
DB01142	DB00668	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of epinephrine.
DB01142	DB01288	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of fenoterol.
DB01142	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluoxetine is initiated, discontinued or dose changed.
DB01142	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed.
DB01142	DB00674	Possible antagonism of action
DB01142	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01142	DB01170	The tricyclic antidepressant, doxepin, decreases the effect of guanethidine.
DB01142	DB01247	Possibility of severe adverse effects
DB01142	DB01064	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of isoproterenol.
DB01142	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01142	DB01365	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of mephentermine.
DB01142	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01142	DB00610	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol.
DB01142	DB00723	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of methoxamine.
DB01142	DB01171	Possible severe adverse reaction with this combination
DB01142	DB00368	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of norepinephrine.
DB01142	DB00816	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of orciprenaline.
DB01142	DB00780	Possibility of severe adverse effects
DB01142	DB00388	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylephrine.
DB01142	DB00397	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylpropanolamine.
DB01142	DB01291	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pirbuterol.
DB01142	DB01366	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of procaterol.
DB01142	DB00852	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pseudoephedrine.
DB01142	DB00908	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB01142	DB01346	Quinidine barbiturate increases the effect of tricyclic antidepressant, doxepin.
DB01142	DB01367	Possibility of severe adverse effects
DB01142	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifabutin is initiated, discontinued or dose changed.
DB01149	DB01247	Possible severe adverse reaction with this combination
DB01142	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed.
DB01142	DB00503	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if ritonavir if initiated, discontinued or dose changed.
DB01142	DB00989	Possible antagonism of action
DB01142	DB01001	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of salbutamol.
DB01142	DB01105	Increased risk of CNS adverse effects
DB01142	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB01142	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxepin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01142	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01142	DB00976	Telithromycin may reduce clearance of Doxepin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxepin if Telithromycin is initiated, discontinued or dose changed.
DB01142	DB00857	Terbinafine may reduce the metabolism and clearance of Doxepin. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Doxepin is initiated, discontinued or dose changed.
DB01142	DB00871	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of terbutaline.
DB01142	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01142	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Doxepin if Thiabendazole is initiated, discontinued or dose changed.
DB01142	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01142	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01142	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01142	DB00193	Tramadol increases the risk of serotonin syndrome and seizures.
DB01142	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB01142	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01142	DB00662	Trimethobenzamide and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01142	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01142	DB00427	Triprolidine and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01142	DB00209	Trospium and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01142	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01142	DB00582	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed.
DB01142	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01142	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01142	DB00315	Use of two serotonin modulators, such as zolmitriptan and doxepin, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01142	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01143	DB09026	Amifostine hypotensive effect can be exacerbated with administration of antihypertensives. If amifostine is administered, no antihypertensives should be administered within 24 hours. If the antihypertensives can't be withheld, amifostine should not be administered.
DB01143	DB08822	Azilsartan medoxomil used in combintation with amifostine may lead to hypotension.
DB01143	DB00880	Antihypertensives may enhance the hypotensive effect of amifostine. When amifostine is used at doses recommended for chemotherapy, antihypertensive medications should be withheld for 24 hours prior to amifostine administration to avoid excessive hypotension during or immediately after infusion. If antihypertensive therapy can not be withheld, then that patient should not receive amifostine. Caution is recommended when using amifostine at the lower doses recommended for radiotherapy, but routine interruption of antihypertensive therapy is not recommended in these patients.
DB01143	DB00966	Telmisartan may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Telmisartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01143	DB01162	Terazosin may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Terazosin should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01143	DB00839	Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Tolazamide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01149	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB01149	DB00998	Increased risk of CNS adverse effects
DB01143	DB00214	Torasemide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Torasemide should be withheld for  24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01143	DB00519	Trandolapril may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trandolapril should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01143	DB01021	Trichlormethiazide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trichlomethiazide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01143	DB00177	Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Valsartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01143	DB00661	Verapamil may enhance the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Verapamil should be withheld for 24 hours prior to Amifostine administration. Caution should be used at lower Amifostine doses used during radiotherapy, but routine interruption of Verapamil therapy is not recommended.
DB01144	DB00945	Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, dichlorphenamide.
DB01144	DB01194	As both brinzolamide and dichlorphenamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB01144	DB01043	Possible increased levels of memantine
DB01144	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01146	DB00843	Possible antagonism of action
DB01146	DB00674	Possible antagonism of action
DB01147	DB00618	Possible antagonism of action
DB01147	DB00254	Possible antagonism of action
DB01147	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01147	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01147	DB00931	Possible antagonism of action
DB01147	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB01147	DB01017	Possible antagonism of action
DB01147	DB00595	Possible antagonism of action
DB01147	DB01301	Possible antagonism of action
DB01147	DB00759	Possible antagonism of action
DB01148	DB00843	Possible antagonism of action
DB01148	DB00674	Possible antagonism of action
DB01148	DB00989	Possible antagonism of action
DB01148	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Flavoxate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01148	DB00662	Trimethobenzamide and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01148	DB00427	Triprolidine and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01148	DB00209	Trospium and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01149	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB01149	DB00918	Increased risk of CNS adverse effects
DB01149	DB00673	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB01149	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01149	DB01076	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nefazodone is initiated, discontinued or dose changed.
DB01149	DB01558	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nefazodone is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01149	DB00490	Nefazodone increases the effect of buspirone
DB01149	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB01149	DB00564	Nefazodone increases the effect of carbamazepine
DB01149	DB00439	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if nefazodone is initiated, discontinued or dose changed.
DB01149	DB01166	Nefazodone increases the effect of cilostazol
DB01149	DB00604	Nefazodone increases serum levels of cisapride
DB01149	DB00091	The antidepressant increases the effect and toxicity of cyclosporine
DB01149	DB06695	P-Glycoprotein inducers such as nefazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB01149	DB08912	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB01149	DB01219	Nefazodone may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nefazodone is initiated, discontinued or dose changed.
DB01149	DB00496	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01149	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01149	DB00320	Possible ergotism and severe ischemia with this combination
DB01149	DB04855	Nefazodone is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB01149	DB00216	Increased risk of CNS adverse effects
DB01149	DB00700	Nefazodone increases the effect and toxicity of eplerenone
DB01149	DB00696	Possible ergotism and severe ischemia with this combination
DB01149	DB00601	Combination associated with possible serotoninergic syndrome
DB01149	DB00455	Increased risk of cardiotoxicity
DB01149	DB00227	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if nefazodone is initiated, discontinued or dose changed.
DB01149	DB00952	Increased risk of CNS adverse effects
DB01149	DB06589	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB01149	DB00780	Possible severe adverse reaction with this combination
DB01149	DB01100	Nefazodone may increase the effect and toxicity of pimozide.
DB01149	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB01149	DB01367	Possible severe adverse reaction with this combination
DB01149	DB00953	Increased risk of CNS adverse effects
DB01149	DB06335	Nefazodone is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB01149	DB01105	Risk of serotoninergic syndrome
DB01149	DB00641	Nefazodone may increase the effect and toxicity of simvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nefazodone is initiated, discontinued or dose changed.
DB01149	DB01591	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01149	DB01323	St. John's Wort increases the effect and toxicity of the SSRI, nefazodone.
DB01149	DB00669	Increased risk of CNS adverse effects
DB01149	DB01268	Possible increase in sunitinib levels
DB01149	DB00864	Nefazodone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nefazodone therapy is initiated, discontinued or altered.
DB01149	DB00820	Nefazodone may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01149	DB00675	Nefazodone may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01149	DB00706	Nefazodone, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nefazodone is initiated, discontinued, or dose changed.
DB01149	DB00976	Co-administration may result in altered plasma concentrations of Nefazodone and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB01149	DB06287	Nefazodone may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01149	DB00444	The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nefazodone is initiated, discontinued or dose changed.
DB01149	DB00857	Terbinafine may reduce the metabolism and clearance of Nefazodone. Consider alternate therapy or monitor for therapeutic/adverse effects of Nefazodone if Terbinafine is initiated, discontinued or dose changed.
DB01149	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01149	DB00906	The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nefazodone is initiated, discontinued or dose changed.
DB01149	DB01036	Nefazodone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01149	DB06212	Nefazodone is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB01149	DB00193	Nefazodone may increase tramadol toxicity by decreasing tramadol metabolism and clearance. Increased risk of serotonin syndrome. Monitor for tramadol toxicity and symptoms of serotonin syndrome.
DB01149	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01149	DB00656	Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Nefazodone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for symtpoms of sertonin syndrome and changes in Trazodone efficacy/toxicity if Nefazodone is initiated, discontinued or dose changed.
DB01149	DB00897	Nefazodone increases the effect of triazolam
DB01149	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Nefazodone, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nefazodone is initiated, discontinued or dose changed.
DB01149	DB00427	The CNS depressants, Triprolidine and Nefazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01149	DB00862	Nefazodone, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01149	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB01149	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01149	DB00661	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed.
DB01149	DB00570	Nefazodone, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nefazodone is initiated, discontinued or dose changed.
DB01149	DB00541	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nefazodone is initiated, discontinued or dose changed.
DB01151	DB00723	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of methoxamine.
DB01149	DB00361	Nafazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nefazodone is initiated, discontinued or dose changed.
DB01149	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nefazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nefazodone if voriconazole is initiated, discontinued or dose changed.
DB01149	DB00315	Use of two serotonin modulators, such as zolmitriptan and nafazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01149	DB00425	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nefazodone is initiated, discontinued or dose changed.
DB01149	DB00909	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nefazodone is initiated, discontinued or dose changed.
DB01149	DB01198	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nefazodone is initiated, discontinued or dose changed.
DB01150	DB01032	Probenecid may increase the serum level of cefprozil.
DB01151	DB00488	Risk of severe hypotension
DB01151	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01151	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if atazanavir is initiated, discontinued or dose changed.
DB01151	DB06237	Co-administration with avanafil resulted in an approximate 5.7% increase in AUC0-inf and 5.2% decrease in Cmax of rosiglitazone.
DB01151	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB01151	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB01151	DB00564	Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if carbamazepine is initiated, discontinued or dose changed.
DB01151	DB00501	Cimetidine may increase the effect of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if cimetidine is initiated, discontinued or dose changed.
DB01151	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01151	DB00575	The tricyclic antidepressant, desipramine, decreases the effect of clonidine.
DB01151	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01151	DB01341	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, desipramine.
DB01151	DB00841	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dobutamine.
DB01151	DB00843	Possible antagonism of action
DB01151	DB00988	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dopamine.
DB01151	DB00476	Possible increase in the levels of this agent when used with duloxetine
DB01151	DB01363	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedra.
DB01151	DB01364	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedrine.
DB01151	DB00668	Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB01151	DB01288	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of fenoterol.
DB01151	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluoxetine is initiated, discontinued or dose changed.
DB01151	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed.
DB01151	DB00674	Possible antagonism of action
DB01151	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01151	DB01170	The tricyclic antidepressant, desipramine, decreases the effect of guanethidine.
DB01151	DB05039	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB01151	DB01247	Possibility of severe adverse effects
DB01151	DB01064	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of isoproterenol.
DB01151	DB01365	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of mephentermine.
DB01151	DB00610	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of metaraminol.
DB01167	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01151	DB08893	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB01151	DB01171	Possible severe adverse reaction with this combination
DB01151	DB00368	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of norepinephrine.
DB01151	DB00816	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of orciprenaline.
DB01151	DB00780	Possibility of severe adverse effects
DB01151	DB00388	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylephrine.
DB01151	DB00397	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB01151	DB01291	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pirbuterol.
DB01151	DB01366	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of procaterol.
DB01151	DB00852	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pseudoephedrine.
DB01151	DB00908	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB01151	DB01346	Quinidine barbiturate increases the effect of tricyclic antidepressant, desipramine.
DB01151	DB01367	Possibility of severe adverse effects
DB01151	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifabutin is initiated, discontinued or dose changed.
DB01151	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed.
DB01151	DB00503	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if ritonavir if initiated, discontinued or dose changed.
DB01151	DB00989	Possible antagonism of action
DB01151	DB01001	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of salbutamol.
DB01151	DB01105	Increased risk of CNS adverse effects
DB01151	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB01151	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01151	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01151	DB00675	Desipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB01151	DB00706	Desipramine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Desipramine is initiated, discontinued, or dose changed.
DB01151	DB00857	Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of desipramine if terbinafine is initiated, discontinued or dose changed.
DB01151	DB00871	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of terbutaline.
DB01151	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01151	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01151	DB00932	Tipranavir, co-administered with Ritonavir, may increase the concentration of Desipramine. Monitor Desipramine concentration and efficacy/toxicity and adjust dose as required.
DB01151	DB01036	Desipramine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01151	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01151	DB00193	Tramadol increases the risk of serotonin syndrome and seizures. Desipramine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Desipramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB01151	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB01151	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01151	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01151	DB00427	Triprolidine and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01151	DB00209	Trospium and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01151	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01151	DB06684	Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved.
DB01151	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01151	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01151	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01151	DB00315	Use of two serotonin modulators, such as zolmitriptan and desipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01151	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01155	DB01370	Formation of non-absorbable complexes
DB01155	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as gemifloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB01155	DB01592	Formation of non-absorbable complexes
DB01155	DB00893	Formation of non-absorbable complexes
DB01155	DB01378	Formation of non-absorbable complexes
DB01155	DB01377	Formation of non-absorbable complexes
DB01155	DB01397	Formation of non-absorbable complexes
DB01155	DB00364	Formation of non-absorbable complexes
DB01155	DB01593	Formation of non-absorbable complexes
DB01156	DB00564	Carbamazepine, a strong CYP2B6 inducer, may increase the metabolism of bupropion. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bupropion if carbamazepine is initiated, discontinued or dose changed.
DB01156	DB00091	Bupropion may decrease the therapeutic effect of cyclosporine.
DB01156	DB01247	Possible severe adverse reaction with this combination
DB01156	DB00780	Possible severe adverse reaction with this combination
DB01156	DB01367	Possible severe adverse reaction with this combination
DB01156	DB00615	Rifampin reduces bupropion levels
DB01156	DB01045	Rifampin reduces bupropion levels
DB01156	DB00503	Ritonavir increases the effect and toxicity of bupropion
DB01156	DB00679	Bupropion may increase the effect and toxicity of thioridazine.
DB01156	DB04572	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Bupropion, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Bupropion if Thiotepa is initiated, discontinued or dose changed.
DB01156	DB00752	The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Bupropion. These agents should not be administered within 14 days of each other.
DB01156	DB00427	The CNS depressants, Triprolidine and Bupropion, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01156	DB01624	Bupropion, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if bupropion is initiated, discontinued or dose changed.
DB01157	DB01418	The anticoagulant effect of Acenocoumarol, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use.
DB01157	DB00390	The absorption of Digoxin, a cardiac glycoside, may be decreased by antineoplastic agents such as Trimetrexate. Liquid forms of Digoxin do not appear to be significantly affected. Monitor Digoxin tablet efficacy if Trimetrexate therapy is initiated, discontinued or if the dose is altered.
DB01157	DB00682	The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use.
DB01158	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB00199	Increased risk of cardiotoxicity and arryhthmias
DB01158	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB00243	Possible additive effect on QT prolongation
DB01158	DB00976	Increased risk of cardiotoxicity and arrhythmias
DB01158	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01159	DB01223	Increased risk of cardiac arrhythmia
DB01159	DB00598	Monitor arterial pressure closely
DB01159	DB01303	Increased risk of cardiac arrhythmia
DB01159	DB00277	Increased risk of cardiac arrhythmia
DB01162	DB01193	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00346	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.
DB01162	DB01143	Terazosin may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Terazosin should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.
DB01162	DB00335	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00195	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00612	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00521	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB01136	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB04846	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00187	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00598	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00264	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB01203	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01167	DB01076	Increased risk of myopathy/rhabdomyolysis
DB01162	DB04861	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB01580	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB01359	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00960	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00571	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00073	Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab.
DB01162	DB00203	Increased risk of hypotension.
DB01162	DB06207	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.
DB01162	DB00489	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00820	Tadalafil may enhance the hypotensive effect of Terazosin. Monitor for hypotension during concomitant therapy.
DB01162	DB00706	Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Terazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
DB01162	DB00373	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01162	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01162	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Terazosin, may occur. Monitor for hypotension during concomitant therapy.
DB01164	DB00630	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate.
DB01164	DB00258	Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
DB01164	DB06724	Calcium salts may enhance the adverse/toxic effect of calcium chloride. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
DB01164	DB01212	Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
DB01164	DB00720	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB01164	DB00618	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as demeclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB01164	DB00254	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB01164	DB06210	Calcium salts such as calcium chloride may decrease the serum concentration of eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.
DB01164	DB01077	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB01164	DB00710	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate.
DB01164	DB00451	Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB01164	DB00279	Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB01164	DB01017	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB01164	DB00884	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate.
DB01164	DB00759	Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DB01167	DB00559	Itraconazole may increase the effect and toxicity of bosentan.
DB01171	DB00458	Possible severe adverse reaction with this combination
DB01164	DB01133	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DB01164	DB06824	Calcium salts such as calcium chloride may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk.
DB01164	DB00685	Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction.
DB01165	DB01418	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01165	DB01370	Formation of non-absorbable complexes
DB01165	DB01125	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of anisindione.
DB01165	DB01373	Formation of non-absorbable complexes
DB01165	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB01165	DB00266	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol.
DB01165	DB01341	Increased risk of cardiotoxicity and arrhythmias
DB01165	DB00529	Increased risk of convulsions
DB01165	DB01592	Formation of non-absorbable complexes
DB01165	DB00893	Formation of non-absorbable complexes
DB01165	DB01378	Formation of non-absorbable complexes
DB01165	DB01377	Formation of non-absorbable complexes
DB01165	DB01035	Ofloxacin may increase the effect of procainamide.
DB01165	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB01165	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB01165	DB00364	Formation of non-absorbable complexes
DB01165	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ofloxacin is initiated, discontinued or if the dose is changed.
DB01165	DB01623	The strong CYP1A2 inhibitor, Ofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ofloxacin is initiated, discontinued or dose changed.
DB01165	DB00697	Ofloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01165	DB00682	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin.
DB01165	DB01593	Formation of non-absorbable complexes
DB01166	DB00343	Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cilostazol if diltiazem is initiated, discontinued or dose changed.
DB01166	DB00199	Erythromycin increases the effect of cilostazol
DB01166	DB00196	Fluconazole may decrease the effect of cilostazol.
DB01166	DB00472	Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed.
DB01166	DB00176	Fluvoxamine increases the effect of cilostazol
DB01166	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01166	DB01167	Itraconazole may increase the effect of cilostazol.
DB01166	DB01321	Erythromycin increases the effect of cilostazol
DB01166	DB01026	Ketoconazole may increase the effect of cilostazol.
DB01166	DB01149	Nefazodone increases the effect of cilostazol
DB01166	DB00338	Omeprazole increases the effect of cilostazol
DB01166	DB01104	Sertraline increases the effect of cilostazol
DB01166	DB00976	Telithromycin may reduce clearance of Cilostazol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cilostazol if Telithromycin is initiated, discontinued or dose changed.
DB01166	DB00208	Ticlopidine may decrease the metabolism and clearance of Cilostazol. Consider alternate therapy or monitor for adverse/toxic effects of Cilostazol if Ticlopidine is initiated, discontinued or dose changed.
DB01166	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Cilostazol. Monitor for increased bleeding during concomitant thearpy.
DB01166	DB00582	Voriconzole may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for increased therapeutic/adverse effects of cilostazol and consider reducing the dose during concomitant therapy.
DB01167	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB01167	DB01418	Itraconazole may increase the anticoagulant effect of acenocoumarol.
DB01167	DB00802	Itraconazole may increase the effect and toxicity of alfentanil.
DB01167	DB00346	The antifungal increases the effect of alfuzosin
DB01167	DB09026	Avoid combination due to increased serum concentration of aliskiren.
DB01167	DB00918	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB01167	DB00404	Itraconazole may increase the effect of the benzodiazepine, alprazolam.
DB01167	DB01370	Aluminum-containing antacids may decrease the effect of itraconazole.
DB01167	DB01125	Itraconazole may increase the anticoagulant effect of anisindione.
DB01167	DB06605	Avoid combination. Otherwise, itraconazole will likely increase apixaban serum concentration.
DB01167	DB00673	This CYP3A4 inhibitor, itraconazole, may increase the effect and toxicity of aprepitant.
DB01167	DB01238	Itraconazole may increase the effect of aripiprazole.
DB01167	DB01558	Itraconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if itraconazole is initiated, discontinued or dose changed.
DB01167	DB01222	Itraconazole may increase levels/effect of budesonide.
DB01167	DB01008	Itraconazole reduced busulfan clearance by up to 25% in patients receiving itraconazole compared to those that did not receive it. Concomitant therapy may lead to toxic plasma levels of busulfan.
DB01167	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB01167	DB01373	Calcium-containing antacids may decrease the effect of itraconazole.
DB01167	DB06724	The antacid, calcium carbonate, may decrease the effect of itraconazole by decreasing its absorption.
DB01167	DB00564	Itraconazole may increase the effect of carbamazepine.
DB01167	DB04846	Itaconazole increases levels/effect of celiprolol
DB01167	DB00439	Increased risk of myopathy/rhabdomyolysis
DB01167	DB00475	Itraconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
DB01167	DB01410	Increased effects/toxicity of ciclesonide
DB01167	DB01166	Itraconazole may increase the effect of cilostazol.
DB01167	DB00501	The H2-receptor antagonist, cimetidine, may decrease the absorption of itraconazole.
DB01167	DB01012	Itraconazole may increase the effect and toxicity of cinacalcet.
DB01167	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01167	DB01211	The macrolide, clarithromycin, may increase the effect and toxicity of itraconazole.
DB01167	DB01068	Itraconazole may increase the effect of the benzodiazepine, clonazepam.
DB01167	DB00628	Itraconazole may increase the effect of the benzodiazepine, clorazepate.
DB01167	DB00872	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB01167	DB00091	Itraconazole may increase the effect of cyclosporine.
DB01167	DB01219	Itraconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if itraconazole is initiated, discontinued or dose changed.
DB01167	DB00496	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01167	DB00829	Itraconazole may increase the effect of the benzodiazepine, diazepam.
DB01167	DB00266	Itraconazole may increase the anticoagulant effect of dicumarol.
DB01167	DB00390	Itraconazole increases the effect of digoxin
DB01167	DB00320	Possible ergotism and severe ischemia with this combination
DB01167	DB00204	This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide
DB01167	DB04855	Itraconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB01167	DB00216	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
DB01167	DB00700	Itraconazole may increase the effect and toxicity of eplerenone.
DB01167	DB00696	Possible ergotism and severe ischemia with this combination
DB01167	DB00530	Itraconazole may decrease the metabolism of erlotinib. Monitor for changes in the therapeutic and adverse effects of erlotinib if itraconazole is initiated, discontinued or dose changed.
DB01167	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.
DB01167	DB00736	The proton pump inhibitor, esomeprazole, may decrease the absorption of itraconazole.
DB01167	DB01215	Itraconazole may increase the effect of the benzodiazepine, estazolam.
DB01167	DB00754	Phenytoin decreases the effect of itraconazole
DB01167	DB01590	Itraconazole may increase everolimus levels/toxicity.
DB01167	DB00927	The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole.
DB01167	DB01023	Itraconazole may increase the therapeutic and adverse effects of felodipine.
DB01167	DB00813	Itraconazole may increase levels/toxicity of fentanyl.
DB01167	DB00690	Itraconazole may increase the effect of the benzodiazepine, flurazepam.
DB01167	DB01320	Phenytoin decreases the effect of itraconazole
DB01167	DB00317	Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of gefitinib. Monitor for changes in the therapeutic and adverse effects of gefitinib if itraconazole is initiated, discontinued or dose changed.
DB01167	DB00801	Itraconazole may increase the effect of the benzodiazepine, halazepam.
DB01167	DB00502	Itraconazole may increase the effect and toxicity of haloperidol.
DB01167	DB00619	Itraconazole may increase the levels of imatinib.
DB01167	DB08820	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB01167	DB01321	The macrolide, josamycin, may increase the effect and toxicity of itraconazole.
DB01167	DB00448	The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole.
DB01167	DB01227	Itraconazole increases the effect/toxicity of levomethadyl
DB01167	DB00227	Increased risk of myopathy/rhabdomyolysis
DB01167	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB01167	DB01377	The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption.
DB01167	DB00532	Phenytoin decreases the effect of itraconazole
DB01167	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01167	DB00959	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.
DB01167	DB00683	Itraconazole may increase the effect of the benzodiazepine, midazolam.
DB01167	DB00585	The H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole.
DB01167	DB00338	The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole.
DB01167	DB00213	The proton pump inhibitor, pantoprazole, may decrease the absorption of itraconazole.
DB01170	DB00477	Chlorpromazine may decrease the effect of guanethidine.
DB01167	DB06589	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB01167	DB01174	The barbiturate, phenobarbital, decreases the effect of itraconazole.
DB01167	DB00252	Phenytoin decreases the effect of itraconazole
DB01167	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB01167	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB01167	DB00860	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
DB01167	DB00635	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
DB01167	DB01589	Itraconazole may increase the effect of the benzodiazepine, quazepam.
DB01167	DB00908	Itraconazole may increase the effect and toxicity of quinidine.
DB01167	DB01346	Itraconazole may increase the effect and toxicity of quinidine barbiturate.
DB01167	DB01129	The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole.
DB01167	DB00863	The H2-receptor antagonist, ranitidine, may decrease the absorption of itraconazole.
DB01167	DB00243	Increased levels of ranolazine - risk of toxicity
DB01167	DB08896	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB01167	DB00615	Rifabutin decreases the effect of itraconazole
DB01167	DB01045	Rifampin may decrease the effect of itraconazole.
DB01167	DB00734	Increases the level of risperidone
DB01167	DB00503	Itraconazole may increase the effect and toxicity of ritonavir.
DB01167	DB06228	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
DB01167	DB08877	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
DB01167	DB00203	Itraconazole may increase the effect and toxicity of sildenafil.
DB01167	DB06207	Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated.
DB01167	DB00641	Increased risk of myopathy/rhabdomyolysis
DB01167	DB00877	Itraconazole may increase the effect and toxicity of sirolimus.
DB01167	DB01591	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01167	DB00364	Sucralfate may decrease the absorption of itraconazole.
DB01167	DB01268	Possible increase in sunitinib levels
DB01167	DB00864	The antifungal, Itraconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Itraconazole therapy is initiated, discontinued or altered.
DB01167	DB00820	Itraconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01167	DB00675	Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01167	DB00706	Itraconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Itraconazole is initiated, discontinued, or dose changed.
DB01167	DB00976	Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB01167	DB06287	Itraconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01167	DB00444	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Itraconazole is initiated, discontinued or dose changed.
DB01167	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01167	DB00906	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Itraconazole is initiated, discontinued or dose changed.
DB01167	DB00932	Tipranavir may increase the serum concentration of Itraconazole.
DB01167	DB01036	Itraconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01167	DB06212	Itraconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB01167	DB01030	The p-glycoprotein inhibitor, Itraconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01167	DB00193	Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01167	DB00656	The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed.
DB01167	DB00897	Itraconazole may increase the effect of the benzodiazepine, triazolam.
DB01167	DB00726	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Itraconazole is initiated, discontinued or dose changed.
DB01167	DB08867	Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy.
DB01167	DB00862	Itraconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
DB01167	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB01167	DB00285	Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed.
DB01167	DB00661	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed.
DB01170	DB01239	Chlorprothixene may decrease the effect of guanethidine.
DB01167	DB00570	Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Itraconazole is initiated, discontinued or dose changed.
DB01167	DB00541	Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Itraconazole is initiated, discontinued or dose changed.
DB01167	DB00361	Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Itraconazole is initiated, discontinued or dose changed.
DB01167	DB00682	Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism.
DB01167	DB00425	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if itraconazole is initiated, discontinued or dose changed.
DB01167	DB00909	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed.
DB01167	DB01198	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if itraconzole is initiated, discontinued or dose changed.
DB01168	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like procarbazine.
DB01168	DB00484	MAO Inhibitors like procarbazine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB01168	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB01168	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01168	DB00390	The antineoplasic agent decreases the effect of digoxin
DB01168	DB00563	Increased nephrotoxicity with this combination
DB01168	DB04896	Increase serotonin levels. Combination therapy is contraindicated.
DB01168	DB04844	Tetrabenazine may increase the adverse/toxic effects of Procarbazine. Concomitant therapy is contraindicated.
DB01168	DB00323	Tolcapone and Procarbazine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB01168	DB00193	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Procarbazine.
DB01168	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01168	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01168	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01168	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB01168	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01168	DB00315	The MAO inhibitor, procarbazine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing procarbazine are contraindicated.
DB01169	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01169	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01169	DB01369	This combination presents an increased risk of toxicity
DB01169	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01169	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01169	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01169	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01169	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01169	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01169	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01169	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01169	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01170	DB01063	Acetophenazine may decrease the effect of guanethidine.
DB01170	DB01246	Trimeprazine may decrease the effect of guanethidine.
DB01170	DB00321	The tricyclic antidepressant, amitriptyline, decreases the effect of guanethidine.
DB01170	DB00543	The tricyclic antidepressant, amoxapine, decreases the effect of guanethidine.
DB01170	DB00182	Amphetamine may decrease the effect of guanethidine.
DB01170	DB00865	Benzphetamine may decrease the effect of guanethidine.
DB01170	DB01242	The tricyclic antidepressant, clomipramine, decreases the effect of guanethidine.
DB01170	DB01151	The tricyclic antidepressant, desipramine, decreases the effect of guanethidine.
DB01170	DB01191	Dexfenfluramine may decrease the effect of guanethidine.
DB01170	DB01576	Dextroamphetamine may decrease the effect of guanethidine.
DB01170	DB00937	Diethylpropion may decrease the effect of guanethidine.
DB01170	DB00841	Dobutamine may decrease the effect of guanethidine.
DB01170	DB00988	Dopamine may decrease the effect of guanethidine.
DB01170	DB01142	The tricyclic antidepressant, doxepin, decreases the effect of guanethidine.
DB01170	DB01363	Ephedra may decrease the effect of guanethidine.
DB01170	DB01364	Ephedrine may decrease the effect of guanethidine.
DB01170	DB00668	Epinephrine may decrease the effect of guanethidine.
DB01170	DB00392	Ethopropazine may decrease the effect of guanethidine.
DB01170	DB00574	Fenfluramine may decrease the effect of guanethidine.
DB01170	DB00623	Fluphenazine may decrease the effect of guanethidine.
DB01170	DB00502	Haloperidol may decrease the effect of guanethidine.
DB01170	DB00458	The tricyclic antidepressant, imipramine, may increase the sympathomimetic effect of guanethidine.
DB01170	DB01247	Isocarboxazid may decrease the effect of guanethidine.
DB01170	DB00579	Mazindol may decrease the effect of guanethidine.
DB01170	DB00933	Mesoridazine may decrease the effect of guanethidine.
DB01170	DB00610	Metaraminol may decrease the effect of guanethidine.
DB01170	DB01577	Methamphetamine may decrease the effect of guanethidine.
DB01170	DB00902	Methdilazine may decrease the effect of guanethidine.
DB01170	DB01403	Methotrimeprazine may decrease the effect of guanethidine.
DB01170	DB00723	Methoxamine may decrease the effect of guanethidine.
DB01170	DB00422	Methylphenidate may decrease the effect of guanethidine.
DB01170	DB00368	Norepinephrine may decrease the effect of guanethidine.
DB01170	DB00540	The tricyclic antidepressant, nortriptyline, decreases the effect of guanethidine.
DB01170	DB01626	Pargyline may decrease the effect of guanethidine.
DB01170	DB00850	Perphenazine may decrease the effect of guanethidine.
DB01170	DB01579	Phendimetrazine may decrease the effect of guanethidine.
DB01170	DB00780	Phenelzine may decrease the effect of guanethidine.
DB01170	DB00830	Phenmetrazine may decrease the effect of guanethidine.
DB01170	DB00191	Phentermine may decrease the effect of guanethidine.
DB01170	DB00388	Phenylephrine may decrease the effect of guanethidine.
DB01170	DB00397	Phenylpropanolamine may decrease the effect of guanethidine.
DB01170	DB00433	Prochlorperazine may decrease the effect of guanethidine.
DB01170	DB00420	Promazine may decrease the effect of guanethidine.
DB01170	DB01069	Promethazine may decrease the effect of guanethidine.
DB01170	DB01608	Propericiazine may decrease the effect of guanethidine.
DB01170	DB00777	Propiomazine may decrease the effect of guanethidine.
DB01170	DB00344	The tricyclic antidepressant, protriptyline, decreases the effect of guanethidine.
DB01170	DB00852	Pseudoephedrine may decrease the effect of guanethidine.
DB01170	DB00372	Thiethylperazine may decrease the effect of guanethidine.
DB01170	DB00679	Thioridazine may decrease the effect of guanethidine.
DB01170	DB01623	Thiothixene may decrease the effect of guanethidine.
DB01170	DB00752	Tranylcypromine may decrease the effect of guanethidine.
DB01170	DB00831	Trifluoperazine may decrease the effect of guanethidine.
DB01170	DB00508	Triflupromazine may decrease the effect of guanethidine.
DB01170	DB00726	The tricyclic antidepressant, trimipramine, decreases the effect of guanethidine.
DB01171	DB00321	Possible severe adverse reaction with this combination
DB01171	DB00543	Possible severe adverse reaction with this combination
DB01171	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like moclobemide.
DB01171	DB00484	MAO Inhibitors like moclobemide may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB01171	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB01171	DB00501	Cimetidine may increase the serum concentration of moclobemide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moclobemide if cimetidine is initiated, discontinued or dose changed.
DB01171	DB00215	Possible serotoninergic syndrome
DB01171	DB01242	Possible severe adverse reaction with this combination
DB01171	DB01151	Possible severe adverse reaction with this combination
DB01171	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01171	DB00514	Increased CNS toxicity
DB01171	DB00841	Moclobemide increases the sympathomimetic effect of dobutamine.
DB01171	DB00843	Possible antagonism of action
DB01171	DB00988	Moclobemide increases the sympathomimetic effect of dopamine.
DB01171	DB01142	Possible severe adverse reaction with this combination
DB01171	DB01363	Moclobemide increases the sympathomimetic effect of ephedra.
DB01171	DB01364	Moclobemide increases the sympathomimetic effect of ephedrine.
DB01171	DB00668	Moclobemide increases the sympathomimetic effect of epinephrine.
DB01171	DB01288	Moclobemide increases the sympathomimetic effect of fenoterol.
DB01171	DB00472	Risk of serotoninergic syndrome
DB01171	DB00176	Increased incidence of adverse effects with this association
DB01171	DB00674	Possible antagonism of action
DB01171	DB01064	Moclobemide increases the sympathomimetic effect of isoproterenol.
DB01171	DB01365	Moclobemide increases the sympathomimetic effect of mephentermine.
DB01171	DB00610	Moclobemide increases the sympathomimetic effect of metaraminol.
DB01171	DB00723	Moclobemide increases the sympathomimetic effect of methoxamine.
DB01171	DB04896	Increase serotonin levels. Combination therapy is contraindicated.
DB01171	DB00368	Moclobemide increases the sympathomimetic effect of norepinephrine.
DB01171	DB00540	Possible severe adverse reaction with this combination
DB01171	DB00816	Moclobemide increases the sympathomimetic effect of orciprenaline.
DB01171	DB00715	Possible severe adverse reaction with this combination
DB01171	DB00454	Increased CNS toxicity (can cause death)
DB01171	DB00388	Moclobemide increases the sympathomimetic effect of phenylephrine.
DB01171	DB00397	Moclobemide increases the sympathomimetic effect of phenylpropanolamine.
DB01171	DB01291	Moclobemide increases the sympathomimetic effect of pirbuterol.
DB01171	DB01366	Moclobemide increases the sympathomimetic effect of procaterol.
DB01171	DB00344	Possible severe adverse reaction with this combination
DB01171	DB00852	Moclobemide increases the sympathomimetic effect of pseudoephedrine.
DB01171	DB00989	Possible antagonism of action
DB01171	DB00953	The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
DB01171	DB01001	Moclobemide increases the sympathomimetic effect of salbutamol.
DB01171	DB01037	Decrease in selectivity
DB01171	DB01104	Possible severe adverse reaction with this combination
DB01171	DB01105	Possible serotoninergic syndrome with this combination
DB01171	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Moclobemide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01171	DB00857	Terbinafine may reduce the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for therapeutic/adverse effects of Moclobemide if Terbinafine is initiated, discontinued or dose changed.
DB01171	DB00871	Moclobemide increases the sympathomimetic effect of terbutaline.
DB01171	DB04844	Tetrabenazine may increase the adverse/toxic effects of Moclobemide. Concomitant therapy is contraindicated.
DB01171	DB00208	Ticlopidine may decrease the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for adverse/toxic effects of Moclobemide if Ticlopidine is initiated, discontinued or dose changed.
DB01171	DB00323	Tolcapone and Moclobemide decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB01171	DB00193	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide.
DB01171	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01171	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01171	DB00662	Trimethobenzamide and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01171	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB01171	DB00427	Triprolidine and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01171	DB00209	Trospium and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01171	DB01831	Possible severe adverse reaction with this combination
DB01171	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01171	DB00315	The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated.
DB01172	DB00887	Increased ototoxicity
DB01172	DB00493	Increased risk of nephrotoxicity
DB01172	DB01330	Increased risk of nephrotoxicity
DB01172	DB01331	Increased risk of nephrotoxicity
DB01172	DB00438	Increased risk of nephrotoxicity
DB01172	DB01212	Increased risk of nephrotoxicity
DB01172	DB01111	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
DB01172	DB00903	Increased ototoxicity
DB01172	DB00695	Increased ototoxicity
DB01172	DB01607	Ticarcillin may reduce the serum concentration of Kanamycin. Ticarcillin may inactivate Kanamycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB01173	DB01248	Orphenadrine may increase the serum levels and toxicity of docetaxel.
DB01173	DB00843	Possible antagonism of action
DB01173	DB00674	Possible antagonism of action
DB01173	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB01173	DB00989	Possible antagonism of action
DB01173	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Orphenadrine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01173	DB00662	Trimethobenzamide and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01173	DB00427	Triprolidine and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01173	DB00209	Trospium and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01174	DB05812	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB01174	DB01418	The barbiturate, phenobarbital, decreases the anticoagulant effect of acenocoumarol.
DB01174	DB01223	The barbiturate, phenobarbital, decreases the effect of aminophylline.
DB01174	DB01125	The barbiturate, phenobarbital, decreases the anticoagulant effect of anisindione.
DB01174	DB06216	Phenobarbital is a CYP1A2 inducer and may increase metabolism of asenapine.
DB01174	DB06769	Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine.
DB01174	DB00443	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB01174	DB08873	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB01174	DB06772	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB01174	DB08907	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB01174	DB00269	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, chlorotrianisene.
DB01174	DB00882	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, clomifene.
DB01174	DB00286	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB01174	DB01380	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, cortisone acetate.
DB01174	DB00091	The barbiturate, phenobarbital, may decrease the therapeutic effect of cyclosporine by increasing its metabolism.
DB01174	DB08912	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB01174	DB01254	Phenobarbital may decrease the serum level and efficacy of dasatinib.
DB01174	DB00705	The anticonvulsant, phenobarbital, decreases the effect of delavirdine.
DB01174	DB01234	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01174	DB00266	The barbiturate, phenobarbital, decreases the anticoagulant effect, dicumarol.
DB01174	DB00255	The enzyme inducer, phenobarbital, may decrease the therapeutic effect of diethylstilbestrol.
DB01174	DB00280	Phenobarbital decreases levels of disopyramide
DB01174	DB00254	The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline.
DB01174	DB00651	The barbiturate, phenobarbital, decreases the effect of dyphylline.
DB01174	DB00783	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estradiol.
DB01174	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB01174	DB04573	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estriol.
DB01174	DB00655	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estrone.
DB01174	DB04574	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estropipate.
DB01174	DB00977	This product may cause a slight decrease of contraceptive effect
DB01174	DB06414	Etravirine, when used concomitantly with phenobarbital, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB01174	DB00949	Felbamate increases the effect and toxicity of phenobarbital/primidone
DB01174	DB01023	The barbiturate, phenobarbital, decreases the effect of felodipine.
DB01174	DB00687	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB01174	DB00158	Folic acid decreases the effect of anticonvulsant, phenobarbital.
DB01174	DB00317	The CYP3A4 inducer, phenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01174	DB00400	The barbiturate, phenobarbital, decreases the effect of griseofulvin.
DB01174	DB00741	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB01174	DB00619	Phenobarbital decreases levels of imatinib
DB01174	DB01167	The barbiturate, phenobarbital, decreases the effect of itraconazole.
DB01174	DB08820	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB01174	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01174	DB00603	The enzyme inducer, phenobarbital, may decrease the effect of the hormone, medroxyprogesterone.
DB01174	DB00351	The enzyme inducer, phenobarbital, may decrease the effect of the hormone, megestrol.
DB01174	DB01357	This product may cause a slight decrease of contraceptive effect
DB01174	DB00333	The barbiturate, phenobarbital, decreases the effect of methadone.
DB01174	DB01028	The barbiturate, phenobarbital, increases the renal toxicity of methoxyflurane.
DB01174	DB00959	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, methylprednisolone.
DB01174	DB00264	The barbiturate decreases the effect of the metabolized beta-blocker
DB01174	DB00916	The barbiturate, phenobarbital, decreases the effect of metronidazole.
DB01174	DB01115	The barbiturate, phenobarbital, may decrease the effect of the calcium channel blocker, nifedipine.
DB01174	DB00717	This product may cause a slight decrease of contraceptive effect
DB01174	DB01303	The barbiturate, phenobarbital, decreases the effect of oxtriphylline.
DB01174	DB01384	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, paramethasone.
DB01174	DB00860	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB01174	DB00635	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone.
DB01174	DB00571	The barbiturate decreases the effect of the metabolized beta-blocker
DB01174	DB04575	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, quinestrol.
DB01174	DB00908	The anticonvulsant, phenobarbital, decreases the effect of quinidine.
DB01174	DB08896	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB01174	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB01174	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB01174	DB06201	Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.
DB01174	DB01268	Possible decrease in sunitinib levels
DB01174	DB00864	Phenobarbital may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenobarbital therapy is initiated, discontinued or altered.
DB01174	DB00976	Phenobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB01174	DB06287	Phenobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB01174	DB00277	The barbiturate, phenobarbital, decreases the effect of theophylline.
DB01174	DB00208	Ticlopidine may decrease the metabolism and clearance of Phenobarbital. Consider alternate therapy or monitor for adverse/toxic effects of Phenobarbital if Ticlopidine is initiated, discontinued or dose changed.
DB01174	DB00932	Phenobarbial decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy.
DB01174	DB00193	Phenobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB01174	DB00656	The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed.
DB01174	DB00755	The strong CYP2C8 inducer, Phenobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenobarbital is initiated, discontinued or dose changed.
DB01174	DB00620	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB01174	DB00726	The barbiturate, Phenobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Phenobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB01174	DB00427	The CNS depressants, Triprolidine and Phenobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01174	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB01174	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB01174	DB08881	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB01174	DB00661	Phenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Phenobarbital is initiated, discontinued or dose changed.
DB01174	DB01080	Vigabatrin reduces serum concentrations of phenobarbital by 8-16%.
DB01174	DB00582	Phenobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB01174	DB00682	Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed.
DB01175	DB00918	Increased risk of CNS adverse effects
DB01175	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01175	DB01136	The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, carvedilol.
DB01175	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01175	DB00216	Increased risk of CNS adverse effects
DB01175	DB00998	Increased risk of CNS adverse effects
DB01175	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01175	DB01247	Possible severe adverse reaction with this combination
DB01175	DB01009	Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
DB01175	DB00601	Combination associated with possible serotoninergic syndrome
DB01175	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01175	DB00264	The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, metoprolol.
DB01175	DB00952	Increased risk of CNS adverse effects
DB01175	DB00497	Increased risk of serotonin syndrome
DB01175	DB00780	Possible severe adverse reaction with this combination
DB01175	DB01100	The SSRI, escitalopram, increases the effect and toxicity of pimozide.
DB01175	DB00571	The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, propranolol.
DB01175	DB01367	Possible severe adverse reaction with this combination
DB01175	DB00953	Increased risk of CNS adverse effects
DB01175	DB01037	Possible severe adverse reaction with this combination
DB01175	DB01105	Risk of serotoninergic syndrome
DB01175	DB01323	St. John's Wort increases the effect and toxicity of the SSRI, escitalopram.
DB01175	DB00669	Increased risk of CNS adverse effects
DB01175	DB05521	Telaprevir decreases Cmax, Cmin, and AUC of escitalopram however the mechanism of this interaction is unknown. Concomitant therapy may call for dose adjustment.
DB01186	DB01036	Peroglide may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine.
DB01175	DB00976	Telithromycin may reduce clearance of Escitalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Escitalopram if Telithromycin is initiated, discontinued or dose changed.
DB01175	DB01600	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01175	DB00208	Ticlopidine may decrease the metabolism and clearance of Escitalopram. Consider alternate therapy or monitor for adverse/toxic effects of Ambrisentan if Escitalopram is initiated, discontinued or dose changed.
DB01175	DB00500	Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy.
DB01175	DB00193	Tramadol may increase the risk of serotonin syndrome and seizures.
DB01175	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB01175	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01175	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Escitalopram. Monitor for increased bleeding during concomitant thearpy.
DB01175	DB00726	The SSRI, Escitalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Escitalopram is initiated, discontinued or dose changed.
DB01175	DB00427	The CNS depressants, Triprolidine and Escitalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01175	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01175	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of escitalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of escitalopram if voriconazole is initiated, discontinued or dose changed.
DB01175	DB00246	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB01175	DB00315	Use of two serotonin modulators, such as zolmitriptan and escitalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01175	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01176	DB00843	Possible antagonism of action
DB01176	DB00674	Possible antagonism of action
DB01176	DB00989	Possible antagonism of action
DB01176	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01176	DB00662	Trimethobenzamide and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01176	DB00427	Triprolidine and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01176	DB00209	Trospium and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01177	DB00072	Trastuzumab may increase the cardiotoxicity of Idarubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01181	DB00673	Aprepitant may change levels of the chemotherapy agent, ifosfamide.
DB01181	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB01181	DB06414	Ifosfamide, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience an increase in the serum concentrations of its active metabolites. It is recommended to monitor for toxicity of ifosfamide therapy.
DB01181	DB06589	Ifosfamide decreases plasma levels of pazopanib.
DB01181	DB00976	Telithromycin may reduce clearance of Ifosfamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ifosfamide if Telithromycin is initiated, discontinued or dose changed.
DB01181	DB00208	Ticlopidine may decrease the metabolism and clearance of Ifosfamide. Consider alternate therapy or monitor for adverse/toxic effects of Ifosfamide if Ticlopidine is initiated, discontinued or dose changed.
DB01181	DB00752	Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Ifosmadine.
DB01181	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01181	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ifosfamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ifosfamide if voriconazole is initiated, discontinued or dose changed.
DB01182	DB01418	Propafenone may increase the anticoagulant effect of acenocoumarol.
DB01182	DB01223	Propafenone increases the effect of theophylline
DB01182	DB01125	Propafenone may increase the anticoagulant effect of anisindione.
DB01182	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01182	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01182	DB00091	Propafenone increases the effect and toxicity of cyclosporine
DB01182	DB00266	Propafenone may increase the anticoagulant effect of dicumarol.
DB01182	DB00390	Propafenone increases the effect of digoxin
DB01182	DB01341	Quinidine increases the effect of propafenone
DB01182	DB00476	Possible increase in the levels of this agent when used with duloxetine
DB01182	DB00651	Propafenone increases the effect of theophylline
DB01182	DB06414	Propafenone, when used concomitantly with Etravirine, may experience a decrease in serum concentration. It is recommended to monitor for continued efficacy of propafenone therapy.
DB01182	DB00472	Additive QTc-prolongation may occur increasing the risk of serious life-threatening arrhythmias. Fluoxetine may also increase the serum concentration of propafenone. Use caution during concomitant therapy and monitor for QTc-prolongation.
DB01182	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01182	DB00933	Increased risk of cardiotoxicity and arrhythmias.
DB01182	DB00264	Propafenone may increase the effect of beta-blocker, metoprolol.
DB01182	DB00379	Propafenone may increase the effect and toxicity of mexilitine.
DB01182	DB08893	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB01182	DB01303	Propafenone increases the effect of theophylline
DB01182	DB00715	Paroxetine may increase the effect and toxicity of propafenone.
DB01182	DB00571	Propafenone may increase the effect of the beta-blocker, propranolol.
DB01182	DB00908	Quinidine increases the effect of propafenone
DB01182	DB01346	Quinidine increases the effect of propafenone
DB01182	DB00615	Rifampin decreases the effect of propafenone
DB01182	DB01045	Rifampin decreases the effect of propafenone
DB01182	DB00503	Ritonavir increases the effect and toxicity of propafenone
DB01182	DB01104	Fluoxetine increases the effect and toxicity of propafenone
DB01182	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01182	DB00857	Terbinafine may reduce the metabolism and clearance of Propafenone. Consider alternate therapy or monitor for therapeutic/adverse effects of Propafenone if Terbinafine is initiated, discontinued or dose changed.
DB01182	DB00342	Increased risk of cardiotoxicity and arrhythmias.
DB01182	DB00277	Propafenone increases the effect of theophylline
DB01182	DB00599	Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated.
DB01182	DB00679	Increased risk of cardiotoxicity and arrhythmias.
DB01182	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01182	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Propafenone. Concomitant therapy is contraindicated.
DB01182	DB00697	Propafenone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01182	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01182	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01182	DB00285	Propafenone increases the effect and toxicity of venlafaxine
DB01182	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01182	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01182	DB00682	Propafenone may increase the anticoagulant effect of warfarin.
DB01182	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01182	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01184	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01184	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01184	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01184	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01184	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01184	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01184	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01184	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01185	DB01418	The androgen, fluoxymesterone, may increase the anticoagulant effect of acenocoumarol.
DB01185	DB01125	The androgen, fluoxymesterone, may increase the anticoagulant effect of anisindione.
DB01185	DB00266	The androgen, fluoxymesterone, may increase the anticoagulant effect of dicumarol.
DB01185	DB00682	Fluoxymesterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if fluoxymesterone is initiated, discontinued or dose changed.
DB01186	DB00675	Pergolide may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB01186	DB00706	Pergolide, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pergolide is initiated, discontinued, or dose changed.
DB01186	DB00976	Telithromycin may reduce clearance of Pergolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pergolide if Telithromycin is initiated, discontinued or dose changed.
DB01186	DB01623	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pergolide. Consider alternate therapy or monitor for decreased effects of both agents.
DB01186	DB00932	Tipranavir may increase the plasma concentration of Pergolide. Concomitant therapy should be avoided.
DB01186	DB00193	Pergolide may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.
DB01186	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01186	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01186	DB00726	Increased risk of serotonin syndrome. Pergolide, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Monitor for symptoms of serotonin syndrome and changes in Trimipramine therapeutic and adverse effects if Pergolide is initiated, discontinued or dose changed.
DB01186	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01186	DB00582	Voriconazole may increase the serum concentration of pergolide likely by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01186	DB00246	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pergolide. Consider alternate therapy or monitor for worsening of movement disorder.
DB01186	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, pergolide, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB01186	DB01624	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pergolide, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. Pergolide, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if pergolide is initiated, discontinued or dose changed.
DB01190	DB01370	The aluminium salt decreases the absorption of lincosamides
DB01190	DB00732	The agent increases the effect of muscle relaxant
DB01190	DB01574	The aluminium salt decreases the absorption of lincosamides
DB01190	DB00091	Clindamycin may decrease the therapeutic effect of cyclosporine.
DB01190	DB01375	The aluminium salt decreases the absorption of lincosamides
DB01190	DB01135	The agent increases the effect of muscle relaxant
DB01190	DB01575	The aluminium salt decreases the absorption of lincosamides
DB01190	DB01336	The agent increases the effect of muscle relaxant
DB01190	DB01226	The agent increases the effect of muscle relaxant
DB01190	DB01337	The agent increases the effect of muscle relaxant
DB01190	DB01338	The agent increases the effect of muscle relaxant
DB01190	DB00728	The agent increases the effect of muscle relaxant
DB01190	DB00202	The agent increases the effect of muscle relaxant
DB01190	DB01199	The agent increases the effect of muscle relaxant
DB01190	DB01339	The agent increases the effect of muscle relaxant
DB01191	DB01063	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB01246	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00477	Decreased anorexic effect, may increase psychotic symptoms.
DB01191	DB00392	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00472	Risk of serotoninergic syndrome
DB01191	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00176	Risk of serotoninergic syndrome
DB01191	DB01170	Dexfenfluramine may decrease the effect of guanethidine.
DB01191	DB01306	Fenfluramine increases the effect of insulin
DB01191	DB01307	Fenfluramine increases the effect of insulin
DB01191	DB01309	Fenfluramine increases the effect of insulin
DB01191	DB01247	Risk of hypertensive crisis.
DB01191	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00902	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00715	Risk of serotoninergic syndrome
DB01191	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00780	Possible hypertensive crisis
DB01191	DB00433	Decreased anorexic effect, may increase psychotic symptoms.
DB01191	DB00420	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB01069	Decreased anorexic effect, may increase pyschotic symptoms.
DB01191	DB01608	Decreased anorexic effect, may increase psychotic symptoms.
DB01191	DB00777	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB01367	Possible hypertensive crisis
DB01191	DB00372	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00752	Possible hypertensive crisis
DB01191	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00508	Decreased anorexic effect, may increase psychotic symptoms
DB01191	DB00285	Risk of serotoninergic syndrome
DB01192	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01192	DB00501	Increases the effect of the narcotic
DB01192	DB00427	The CNS depressants, Triprolidine and Oxymorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01193	DB00414	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB00672	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB00575	Increased hypertension when clonidine stopped
DB01193	DB00320	Ischemia with risk of gangrene
DB01193	DB00280	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB00668	Hypertension, then bradycardia
DB01193	DB01253	Ischemia with risk of gangrene
DB01193	DB00696	Ischemia with risk of gangrene
DB01193	DB01288	Antagonism
DB01193	DB00983	Antagonism
DB01193	DB01120	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB01067	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB01289	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01193	DB01016	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB01050	Risk of inhibition of renal prostaglandins
DB01193	DB05039	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB01193	DB00328	Risk of inhibition of renal prostaglandins
DB01193	DB01306	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01193	DB01307	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01193	DB00047	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01193	DB01309	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01193	DB00046	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01193	DB01064	Antagonism
DB01193	DB00281	The beta-blocker, acebutolol, may increase the effect and toxicity of lidocaine.
DB01193	DB00247	Ischemia with risk of gangrene
DB01193	DB00816	Antagonism
DB01193	DB00236	Antagonism
DB01193	DB01291	Antagonism
DB01193	DB00554	Risk of inhibition of renal prostaglandins
DB01193	DB00457	Risk of hypotension at the beginning of therapy
DB01193	DB00912	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB00938	Antagonism
DB01193	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01193	DB00871	Antagonism
DB01193	DB00839	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB01124	Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia.
DB01193	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01193	DB00661	Increased effect of both drugs
DB01194	DB00819	As both brinzolamide and acetazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB01194	DB01144	As both brinzolamide and dichlorphenamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB01194	DB00869	As both brinzolamide and dorzolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB01194	DB00703	As both brinzolamide and methazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB01194	DB00273	As both brinzolamide and topiramate are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB01194	DB00909	As both brinzolamide and zonisamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
DB01195	DB01118	Amiodarone may increase the effect and toxicity of flecainide
DB01195	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01195	DB00501	Cimetidine, a moderate CYP2D6 inhibitor, may decrease the metabolism of flecainide.
DB01195	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01195	DB00476	Possible increase in the levels of this agent when used with duloxetine
DB01195	DB06414	Flecainide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor flecainide therapy.
DB01195	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01195	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01195	DB08893	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB01195	DB01369	This combination presents an increased risk of toxicity
DB01195	DB00503	Ritonavir increases the toxicity of the anti-arrhythmic
DB01195	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01195	DB00857	Terbinafine may reduce the metabolism and clearance of Flecainide. Consider alternate therapy or monitor for therapeutic/adverse effects of Flecainide if Terbinafine is initiated, discontinued or dose changed.
DB01195	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01195	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01195	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01195	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Flecainide. Concomitant therapy is contraindicated.
DB01195	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01195	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01195	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01195	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01195	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01195	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01196	DB00258	Calcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk.
DB01196	DB00720	Clodronate may increase the levels of estramustine.
DB01196	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01197	DB00594	Increased risk of hyperkalemia
DB01197	DB06692	In study of nine patients with untreated hypertension, aprotinin infused intravenously in a dose of 2 million KIU over two hours blocked the acute hypotensive effect of 100mg of captopril.
DB01197	DB08822	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB01197	DB01395	Increased risk of hyperkalemia
DB01197	DB06196	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB01197	DB01356	The ACE inhibitor increases serum levels of lithium
DB01197	DB01345	Increased risk of hyperkalemia
DB01197	DB00421	Increased risk of hyperkalemia
DB01197	DB00857	Terbinafine may reduce the metabolism and clearance of Captopril. Consider alternate therapy or monitor for therapeutic/adverse effects of Captopril if Terbinafine is initiated, discontinued or dose changed.
DB01197	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB01197	DB00684	Increased risk of nephrotoxicity
DB01197	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01197	DB00384	Increased risk of hyperkalemia
DB01198	DB00701	Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if amprenavir is initiated, discontinued or dose changed.
DB01198	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if atazanavir is initiated, discontinued or dose changed.
DB01198	DB01211	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if clarithromycin is initiated, discontinued or dose changed.
DB01198	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if conivaptan is initiated, discontinued or dose changed.
DB01198	DB01264	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if darunavir is initiated, discontinued or dose changed.
DB01198	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if delavirdine is initiated, discontinued or dose changed.
DB01198	DB00199	The macrolide antibiotic, erythromycin, may increase the serum concentration of zopiclone. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if erythromycin is initiated, discontinued or dose changed.
DB01198	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if fosamprenavir is initiated, discontinued or dose changed.
DB01198	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if imatinib is initiated, discontinued or dose changed.
DB01198	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if indinavir is initiated, discontinued or dose changed.
DB01198	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if isoniazid is initiated, discontinued or dose changed.
DB01198	DB01167	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if itraconzole is initiated, discontinued or dose changed.
DB01198	DB01026	Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed.
DB01198	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if lopinavir is initiated, discontinued or dose changed.
DB01198	DB01403	Additive CNS depressant effects. Reduce zopiclone dose by half upon initiation of methotrimeprazine. Zopiclone dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.
DB01198	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nefazodone is initiated, discontinued or dose changed.
DB01198	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nelfinavir is initiated, discontinued or dose changed.
DB01198	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nicardipine is initiated, discontinued or dose changed.
DB01198	DB01263	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if posaconazole is initiated, discontinued or dose changed.
DB01198	DB00908	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if quinidine is initiated, discontinued or dose changed.
DB01198	DB00503	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ritonavir is initiated, discontinued or dose changed.
DB01198	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if saquinavir is initiated, discontinued or dose changed.
DB01198	DB00976	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if telithromycin is initiated, discontinued or dose changed.
DB01198	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zopiclone. Consider alternate therapy or monitor for changes in Zopiclone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01198	DB00427	The CNS depressants, Triprolidine and Zopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01198	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if voriconazole is initiated, discontinued or dose changed.
DB01199	DB00479	The agent increases the effect of muscle relaxant
DB01199	DB01223	Theophylline decreases the effect of muscle relaxant
DB01199	DB00993	The agent decreases the effect of the muscle relaxant
DB01199	DB00564	Decreases the effect of muscle relaxant
DB01199	DB01190	The agent increases the effect of muscle relaxant
DB01199	DB01320	Phenytoin decreases the effect of muscle relaxant
DB01199	DB00798	The agent increases the effect of muscle relaxant
DB01199	DB01627	The agent increases the effect of muscle relaxant
DB01199	DB01033	The agent dereases the effect of the muscle relaxant
DB01199	DB00955	The agent increases the effect of muscle relaxant
DB01199	DB01303	Theophylline decreases the effect of muscle relaxant
DB01199	DB00252	Phenytoin decreases the effect of the muscle relaxant
DB01199	DB00319	The agent increases the effect of the muscle relaxant
DB01199	DB00277	Theophylline decreases the effect of the muscle relaxant
DB01199	DB00684	The agent increases the effect of the muscle relaxant
DB01200	DB01063	The phenothiazine decreases the effect of bromocriptine
DB01200	DB01246	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00477	The phenothiazine decreases the effect of bromocriptine
DB01200	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01200	DB00199	Erythromycin increases serum levels of bromocriptine
DB01200	DB00392	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00623	The phenothiazine decreases the effect of bromocriptine
DB01200	DB01321	Erythromycin increases serum levels of bromocriptine
DB01200	DB00933	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00902	The phenothiazine decreases the effect of bromocriptine
DB01200	DB01403	The phenothiazine decreases the effect of bromocriptine
DB01200	DB01267	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, bromocriptine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01200	DB00850	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00397	The sympathomimetic, phenylpropanolamine, increases the toxicity of bromocriptine.
DB01200	DB00433	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00420	The phenothiazine decreases the effect of bromocriptine
DB01200	DB01069	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00777	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00852	The sympathomimetic, pseudoephedrine, increases the toxicity of bromocriptine.
DB01200	DB00864	Bromocriptine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Bromocriptine therapy is initiated, discontinued or altered.
DB01200	DB00976	Telithromycin may reduce clearance of Bromocriptine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bromocriptine if Telithromycin is initiated, discontinued or dose changed.
DB01200	DB00372	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00679	The phenothiazine decreases the effect of bromocriptine
DB01200	DB01623	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Bromocriptine. Consider alternate therapy or monitor for decreased effects of both agents.
DB01200	DB00932	Tipranavir may increase the plasma concentration of Bromocriptine. Concomitant therapy should be avoided.
DB01200	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01200	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01200	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01200	DB00831	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00508	The phenothiazine decreases the effect of bromocriptine
DB01200	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01200	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01200	DB00582	Voriconazole may increase the serum concentration of bromocriptine likely by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01200	DB00246	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, bromocriptine. Consider alternate therapy or monitor for worsening of movement disorder.
DB01200	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \r\nUse of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01200	DB01624	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01201	DB05812	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB01201	DB01558	Rifapentine may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifapentine is initiated, discontinued or dose changed.
DB01201	DB06772	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB01201	DB00530	Decreased levels/effect of erlotinib
DB01201	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB01201	DB00977	This product may cause a slight decrease of contraceptive effect
DB01201	DB00333	The rifamycin decreases the effect of methadone
DB01201	DB00717	This product may cause a slight decrease of contraceptive effect
DB01201	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB01201	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01201	DB00976	Rifapentine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB01201	DB06287	Rifapentine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB01201	DB00857	Rifapentine may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided.
DB01201	DB00932	Concomitant therapy may cause decreased Tipranavir and increased Rifapentine plasma concentrations.
DB01201	DB00193	Rifapentine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB01201	DB00656	The CYP3A4 inducer, Rifapentine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifapentine is initiated, discontinued or dose changed.
DB01201	DB00755	The strong CYP2C8 inducer, Rifapentine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifapentine is initiated, discontinued or dose changed.
DB01201	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB01201	DB08881	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB01201	DB00661	Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed.
DB01201	DB00582	Rifapentine may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifapentin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.
DB01201	DB00495	Rifapentin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifapentin is initiated, discontinued or dose changed.
DB01202	DB00564	Concomitant therapy may results in additive adverse CNS effects.
DB01202	DB00427	The CNS depressants, Triprolidine and Levetiracetam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01203	DB00414	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01223	Antagonism of action and increased effect of theophylline
DB01203	DB00672	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB00575	Increased hypertension when clonidine stopped
DB01203	DB00320	Ischemia with risk of gangrene.
DB01203	DB00280	The beta-blocker, nadolol, may increase the toxicity of disopyramide.
DB01203	DB00651	Antagonism of action and increased effect of theophylline
DB01203	DB00668	Hypertension, then bradycardia
DB01203	DB01253	Ischemia with risk of gangrene
DB01203	DB00696	Ischemia with risk of gangrene
DB01203	DB01288	Antagonism
DB01203	DB00983	Antagonism
DB01203	DB01120	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01067	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01289	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01016	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01382	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01050	Risk of inhibition of renal prostaglandins
DB01203	DB00328	Risk of inhibition of renal prostaglandins
DB01203	DB00047	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01064	Antagonism
DB01203	DB00281	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB00968	Possible hypertensive crisis
DB01203	DB00247	Ischemia with risk of gangrene
DB01203	DB00816	Antagonism
DB01203	DB01303	Antagonism of action and increased effect of theophylline
DB01203	DB00236	Antagonism
DB01203	DB01291	Antagonism
DB01203	DB00554	Risk of inhibition of renal prostaglandins
DB01203	DB00457	Risk of hypotension at the beginning of therapy
DB01203	DB01366	Antagonism
DB01203	DB00912	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01001	Antagonism
DB01203	DB00938	Antagonism
DB01203	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01203	DB00871	Antagonism
DB01203	DB00277	Antagonism of action and increased effect of theophylline
DB01203	DB00839	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB01124	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01203	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01203	DB00661	Increased effect of both drugs
DB01204	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01206	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB01206	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB01206	DB00857	Terbinafine may reduce the metabolism and clearance of Lomustine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lomustine if Terbinafine is initiated, discontinued or dose changed.
DB01206	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01208	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00321	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00543	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01208	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB01244	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00258	Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as sparfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
DB01208	DB00477	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB01242	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB01151	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB01142	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00623	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00458	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01208	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB01403	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00540	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00850	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00433	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB01069	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01208	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01208	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01208	DB00831	Increased risk of cardiotoxicity and arrhythmias
DB01208	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01208	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01208	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01208	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01208	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01209	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01209	DB00427	The CNS depressants, Triprolidine and Dezocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01210	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01211	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB01211	DB01418	The macrolide, clarithromycin, may increase the anticoagulant effect of acenocoumarol.
DB01211	DB00404	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, alprazolam.
DB01211	DB06274	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB01211	DB01223	Clarithromycin may increase the effect amd toxicity of aminophylline.
DB01211	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB01125	The macrolide, clarithromycin, may increase the anticoagulant effect of anisindione.
DB01211	DB00673	The CYP3A4 inhibitor, clarithromycin, may increase the effect and toxicity of aprepitant.
DB01211	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01211	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB01072	Atazanavir may increase serum level of clarithromycin.
DB01211	DB01076	The macrolide, clarithromycin, may increase the toxicity of the statin, atorvastatin.
DB01211	DB01158	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB01558	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if clarithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01211	DB00490	Clarithromycin may increase the effect and toxicity of buspirone.
DB01211	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB01211	DB00564	Clarithromycin may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic or adverse effects of carbamazepine if clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00439	The macrolide, clarithromycin, may increase the toxicity of the statin, cerivastatin.
DB01211	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB00215	Possible serotoninergic syndrome with this combination
DB01211	DB01394	Severe colchicine toxicity can occur
DB01211	DB00091	The macrolide, clarithromycin, may increase the effect of cyclosporine.
DB01211	DB08912	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB01211	DB01219	Clarithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00496	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01211	DB01264	Increased levels of clarithromycin
DB01211	DB00829	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, diazepam.
DB01211	DB00266	The macrolide, clarithromycin, may increase the anticoagulant effect of dicumarol.
DB01211	DB00390	The macrolide, clarithromycin, may increase the effect of digoxin in 10% of patients.
DB01211	DB00320	Risk of ergotism and severe ischemia with this association
DB01211	DB00280	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB00204	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB04855	Clarithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB01211	DB00651	Increases the effect and toxicity of theophylline
DB01211	DB00625	Efavirenz decreases levels of clarithromycin
DB01211	DB00216	The macrolide, clarithromycin, may increase the effect and toxicity of eletriptan.
DB01211	DB00700	The macrolide, clarithromycin, may increase the effect and toxicity of eplerenone.
DB01211	DB00696	Risk of ergotism and severe ischemia with this association
DB01211	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB01211	DB06414	Clarithromycin (and other macrolide antibiotics), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to use alternative antibiotic agents if available. If concurrent therapy cannot be avoided, monitor for reduced effectiveness of clarithromycin.
DB01211	DB01590	The macrolide, clarithromycin, may increase the serum concentration and toxicity of everolimus.
DB01211	DB00472	Possible serotoninergic syndrome with this combination
DB01211	DB01320	Clarithromycin may increase the therapeutic and adverse effects of fosphenytoin.
DB01211	DB00317	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
DB01211	DB04946	Clarithromycin is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50%
DB01211	DB00619	The macrolide, clarithromycin, may increase the serum concentration of imatinib.
DB01211	DB00224	Indinavir may decrease the effectiveness of clarithromycin by decreasing the formatin of the active metabolite, 14-hydroxy-clarithromycin. Clarithromycin may increase the serum concentration of indinavir. Indinavir may increase the serum concentration of clarithromycin. Consider alternate therapy or monitor the efficacy and adverse effects of both agents more closely during concomitant therapy.
DB01211	DB01167	The macrolide, clarithromycin, may increase the effect and toxicity of itraconazole.
DB01211	DB08820	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB01211	DB00227	The macrolide, clarithromycin, may increase the toxicity of the statin, lovastatin.
DB01211	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB01211	DB00959	The macrolide, clarithromycin, may increase the effect of corticosteroid, methylprednisolone.
DB01211	DB00247	Risk of ergotism and severe ischemia with this association
DB01211	DB00683	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, midazolam.
DB01211	DB01303	Clarithromycin may increase the effect and toxicity of oxtriphylline.
DB01211	DB06589	Clarithromycin is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib.
DB01211	DB00252	Clarithromycin may increase the therapeutic and adverse effects of phenytoin.
DB01211	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB01211	DB01224	The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine.
DB01211	DB00908	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB01346	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB01369	This combination presents an increased risk of toxicity
DB01211	DB00243	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated.
DB01211	DB08896	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB01211	DB00912	Clarithromycin may increase the effect of repaglinide.
DB01211	DB00615	The rifamycin, rifabutin, may decrease the effect of the macrolide, clarithromycin.
DB01211	DB01045	The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin.
DB01211	DB06335	Clarithromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB01211	DB01104	Possible serotoninergic syndrome with this combination
DB01211	DB00203	Increases the effect and toxicity of sildenafil
DB01211	DB00641	The macrolide, clarithromycin, may increase the toxicity of the statin, simvastatin.
DB01211	DB00877	The macrolide, clarithromycin, may increase the serum concentration of sirolimus.
DB01211	DB01591	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01211	DB00489	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB01268	Possible increase in sunitinib levels
DB01211	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, Clarithromycin, may also increase the blood concentration of Tacrolimus.
DB01211	DB00820	Clarithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01211	DB00675	Clarithromycin may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01211	DB00706	Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clarithromycin is initiated, discontinued, or dose changed.
DB01211	DB00976	Co-administration may result in altered plasma concentrations of Clarithromycin and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB01211	DB06287	Clarithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01211	DB00444	The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01211	DB00277	Clarithromycin may increase the therapeutic and adverse effects of theophylline.
DB01211	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01211	DB00906	The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00932	The concentrations of Tipranavir and Clarithromycin increase during concomitant therapy. Dose adjustments are required for patients with renal impairment.
DB01211	DB01036	Clarithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01211	DB06212	Clarithromycin is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB01211	DB01030	The p-glycoprotein inhibitor, Clarithromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01211	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01211	DB00193	Clarithromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01211	DB00656	The CYP3A4 inhibitor, Clarithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00897	The macrolide, clarithromycin, may increase the effect of the benzodiazepine, triazolam.
DB01211	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Clarithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution.
DB01211	DB00313	The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00862	Clarithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01211	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB01211	DB00285	Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Clarithromycin is initiated, discontinued, or dose changed.
DB01211	DB00661	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB06684	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB01211	DB00570	Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00541	Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00361	Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Clarithromycin is initiated, discontinued or dose changed.
DB01211	DB08828	P-glycoprotein inhibitors may increase the chance of adverse drug reactions.
DB01211	DB00582	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of clarithromycin by decreasing its metabolism. Clarithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB01211	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01211	DB00682	The macrolide, clarithromycin, may increase the anticoagulant effect of warfarin.
DB01211	DB00495	Clarithromycin may decrease the serum concentration of zidovudine. Increased myelosuppression in mice has been observed. Consider staggering doses during concomitant therapy and closely monitor response to zidovudine therapy.
DB01211	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01211	DB00425	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if clarithromycin is initiated, discontinued or dose changed.
DB01211	DB00909	Clarithromcyin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if clarithromycin is initiated, discontinued or dose changed.
DB01211	DB01198	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if clarithromycin is initiated, discontinued or dose changed.
DB01211	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01212	DB01418	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of acenocoumarol.
DB01212	DB00479	Increased risk of nephrotoxicity
DB01212	DB01125	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of anisindione.
DB01212	DB00258	Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
DB01212	DB01164	Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
DB01212	DB00266	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of dicumarol.
DB01212	DB00798	Increased risk of nephrotoxicity
DB01212	DB01172	Increased risk of nephrotoxicity
DB01212	DB00994	Increased risk of nephrotoxicity
DB01212	DB00955	Increased risk of nephrotoxicity
DB01212	DB01082	Increased risk of nephrotoxicity
DB01212	DB00684	Increased risk of nephrotoxicity
DB01212	DB00682	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of warfarin.
DB01214	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01215	DB00501	Cimetidine may increase the effect of the benzodiazepine, estazolam.
DB01215	DB00363	Increased risk of toxicity
DB01215	DB00196	Fluconazole may increase the effect of the benzodiazepine, estazolam.
DB01215	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, estazolam.
DB01215	DB01167	Itraconazole may increase the effect of the benzodiazepine, estazolam.
DB01215	DB01322	Kava may increase the effect of the benzodiazepine, estazolam.
DB01215	DB01026	Ketoconazole may increase the effect of the benzodiazepine, estazolam.
DB01215	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, estazolam.
DB01215	DB00338	Omeprazole may increase the effect of the benzodiazepine, estazolam.
DB01215	DB00503	The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, estazolam.
DB01215	DB01232	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, estazolam.
DB01215	DB00932	Tipranavir may decrease the metabolism and clearance of Estazolam. Consider alternate therapy or monitor for Estazolam toxic effects if Tipranavir is initiated or dose increased.
DB01215	DB00427	The CNS depressants, Triprolidine and Estazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01215	DB00582	Voriconazole may increase the serum concentration of estazolam by decreasing its metabolism. Monitor for estazolam toxicity if voriconazole is initiated or dose increased.
DB01218	DB06697	Halofantrine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB01218	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).
DB01218	DB00257	CYP3A4 Inhibitors (Moderate) such as clotrmazole may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).
DB01218	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended.
DB01218	DB06708	Halofantrine may increase the adverse effects of lumefantrine. Additive QTc-prolongation may occur. Combination therapy is contraindicated and therapies should not be administered within one month of each other due to the long half-life of lumefantrine.
DB01218	DB00358	Increased risk of cardiac toxicity
DB01218	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01218	DB01263	Contraindicated co-administration
DB01218	DB01369	This combination presents an increased risk of toxicity
DB01218	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01218	DB00976	Telithromycin may reduce clearance of Halofantrine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Halofantrine if Telithromycin is initiated, discontinued or dose changed.
DB01218	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01218	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01218	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01218	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01218	DB00661	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Halofantrine by decreasing its metabolism. Extreme caution with increased cardiac status monitoring should be used during concomitant therapy.
DB01218	DB00582	Voriconazole may increase the serum concentration of halofantrine by decreasing its metabolism by CYP3A4.  Concomitant therapy should be avoided due to the concentration-dependent risk of QTc prolongation related to halofantrine.
DB01218	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01218	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB01218	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01219	DB01072	Atazanavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if atazanavir is initiated, discontinued or dose changed.
DB01219	DB01211	Clarithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if clarithromycin is initiated, discontinued or dose changed.
DB01219	DB00872	Conivaptan may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if conivaptan is initiated, discontinued or dose changed.
DB01219	DB01264	Darunavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if darunavir is initiated, discontinued or dose changed.
DB01219	DB00705	Delavirdine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if delavirdine is initiated, discontinued or dose changed.
DB01219	DB01319	Fosamprenavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if fosamprenavir is initiated, discontinued or dose changed.
DB01219	DB00619	Imatinib may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if imatinib is initiated, discontinued or dose changed.
DB01219	DB00224	Indinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if indinavir is initiated, discontinued or dose changed.
DB01219	DB00951	Isoniazid may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if isoniazid is initiated, discontinued or dose changed.
DB01223	DB00732	Theophylline decreases the effect of muscle relaxant
DB01219	DB01167	Itraconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if itraconazole is initiated, discontinued or dose changed.
DB01219	DB01026	Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed.
DB01219	DB01601	Lopinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if lopinavir is initiated, discontinued or dose changed.
DB01219	DB01403	Concomitant therapy may result in additive CNS depressant effects. The dosage of dantrolene should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression.
DB01219	DB01149	Nefazodone may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nefazodone is initiated, discontinued or dose changed.
DB01219	DB00220	Nelfinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nelfinavir is initiated, discontinued or dose changed.
DB01219	DB00622	Nicardipine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nicardipine is initiated, discontinued or dose changed.
DB01219	DB01263	Posaconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if posaconazole is initiated, discontinued or dose changed.
DB01219	DB00908	Quinidine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if quinidine is initiated, discontinued or dose changed.
DB01219	DB00503	Ritonavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ritonavir is initiated, discontinued or dose changed.
DB01219	DB01232	Saquinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if saquinavir is initiated, discontinued or dose changed.
DB01219	DB00976	Telithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if telithromycin is initiated, discontinued or dose changed.
DB01219	DB00427	The CNS depressants, Triprolidine and Dantrolene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01219	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if voriconazole is initiated, discontinued or dose changed.
DB01221	DB01043	Increased risk of CNS adverse effects with this association
DB01221	DB00976	Telithromycin may reduce clearance of Ketamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ketamine if Telithromycin is initiated, discontinued or dose changed.
DB01221	DB04572	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Ketamine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Ketamine if Thiotepa is initiated, discontinued or dose changed.
DB01221	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Ketamine. Consider alternate therapy or monitor for changes in Ketamine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01221	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ketamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ketamine if voriconazole is initiated, discontinued or dose changed.
DB01222	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of budesonide. The clinical significance of this interaction is greater for oral budesonide than for orally inhaled budesonide. Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.
DB01222	DB00257	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a moderate CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess.
DB01222	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). onsider reducing the oral budesonide dose when used together with a strong CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a strong CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess.
DB01222	DB01167	Itraconazole may increase levels/effect of budesonide.
DB01222	DB01026	Ketoconazole may increase levels/effect of budesonide.
DB01222	DB00976	Telithromycin may reduce clearance of Budesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Budesonide if Telithromycin is initiated, discontinued or dose changed.
DB01222	DB00932	Tipranavir may increase the plasma concentration of Budesonide. Monitor for toxic Budesonide effects during concomitant administration.
DB01222	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of budesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of budesonide if voriconazole is initiated, discontinued or dose changed.
DB01223	DB00787	Acyclovir increases the effect and toxicity of theophylline
DB01223	DB00640	This xanthine decreases the effect of adenosine
DB01223	DB01351	The barbiturate, amobarbital, decreases the effect of aminophylline.
DB01223	DB01352	The barbiturate, aprobarbital, decreases the effect of aminophylline.
DB01223	DB01558	Aminophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if aminophylline is initiated, discontinued or dose changed.
DB01223	DB00237	The barbiturate, butabarbital, decreases the effect of aminophylline.
DB01223	DB00241	The barbiturate, butalbital, decreases the effect of aminophylline.
DB01223	DB01353	The barbiturate, butethal, decreases the effect of aminophylline.
DB01223	DB00564	Carbamazepine may decrease the serum concentration of aminophylline. Aminophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB01223	DB00521	Antagonism of action and increased effect of theophylline
DB01223	DB00501	Cimetidine may increase the serum concentration of aminophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aminophylline if cimetidine is initiated, discontinued or dose changed.
DB01223	DB00537	Ciprofloxacin may increase the effect of aminophylline.
DB01223	DB01211	Clarithromycin may increase the effect amd toxicity of aminophylline.
DB01223	DB01341	The barbiturate, dihydroquinidine barbiturate, decreases the effect of aminophylline.
DB01223	DB00822	Disulfiram may increase the effect and toxicity of aminophylline.
DB01223	DB01135	Theophylline decreases the effect of muscle relaxant
DB01223	DB00467	Enoxacin may increase the effect of aminophylline.
DB01223	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
DB01223	DB00977	The contraceptive increases the effect and toxicity of theophylline
DB01223	DB00754	Decreased effect of both products
DB01223	DB00176	Fluvoxamine may increase the effect and toxicity of aminophylline.
DB01223	DB01320	Decreased effect of both products
DB01223	DB00365	Grepafloxacin may increase the effect of aminophylline.
DB01223	DB01159	Increased risk of cardiac arrhythmia
DB01223	DB01354	The barbiturate, heptabarbital, decreases the effect of aminophylline.
DB01223	DB01355	The barbiturate, hexobarbital, decreases the effect of aminophylline.
DB01223	DB00034	Interferon increases the effect and toxicity of theophylline
DB01223	DB00105	Interferon increases the effect and toxicity of theophylline
DB01223	DB00011	Interferon increases the effect and toxicity of theophylline
DB01223	DB00951	Isoniazid may increase the effect and toxicity of oxtriphylline.
DB01223	DB01321	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
DB01223	DB01356	Theophylline decreases serum levels of lithium
DB01223	DB00532	Decreased effect of both products
DB01223	DB01357	The contraceptive increases the effect and toxicity of theophylline
DB01223	DB00474	The barbiturate, methohexital, decreases the effect of aminophylline.
DB01223	DB00849	The barbiturate, methylphenobarbital, decreases the effect of aminophylline.
DB01223	DB01336	Theophylline decreases the effect of muscle relaxant
DB01223	DB00379	Mexiletine increases the effect and toxicity of theophylline
DB01223	DB01226	Theophylline decreases the effect of muscle relaxant
DB01223	DB01203	Antagonism of action and increased effect of theophylline
DB01223	DB01059	Norfloxacin may increase the effect of aminophylline.
DB01223	DB01337	Theophylline decreases the effect of muscle relaxant
DB01223	DB00487	Pefloxacin may increase the effect of aminophylline.
DB01223	DB00008	Interferon increases the effect and toxicity of theophylline
DB01223	DB00022	Interferon increases the effect and toxicity of theophylline
DB01223	DB01359	Antagonism of action and increased effect of theophylline
DB01223	DB00312	The barbiturate, pentobarbital, decreases the effect of aminophylline.
DB01223	DB00806	Pentoxifylline may increase the effect and toxicity of aminophylline.
DB01223	DB01174	The barbiturate, phenobarbital, decreases the effect of aminophylline.
DB01223	DB00252	Decreased effect of both products
DB01223	DB00960	Antagonism of action and increased effect of theophylline
DB01223	DB00794	The barbiturate, primidone, decreases the effect of aminophylline.
DB01223	DB01182	Propafenone increases the effect of theophylline
DB01223	DB00571	Antagonism of action and increased effect of theophylline
DB01223	DB01346	The barbiturate, quinidine barbiturate, decreases the effect of aminophylline.
DB01223	DB06213	Reduces duration of >2-fold increase in peak flow velocity. No effect on heart rate increase.
DB01223	DB01045	Rifampin decreases the effect of theophylline
DB01223	DB00503	Ritonavir decreases the effect of theophylline
DB01223	DB00533	Rofecoxib increases the effect and toxicity of theophylline
DB01223	DB00418	The barbiturate, secobarbital, decreases the effect of aminophylline.
DB01223	DB00489	Antagonism of action and increased effect of theophylline
DB01223	DB01323	St. John's Wort decreases the effect of theophylline
DB01223	DB00382	Tacrine may reduce the elimination rate of Aminophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed.
DB01223	DB00306	The barbiturate, talbutal, decreases the effect of aminophylline.
DB01223	DB00231	Aminophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Aminophylline is initiated, discontinued or dose changed.
DB01223	DB00857	Terbinafine increases the effect and toxicity of theophylline
DB01223	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Aminophylline by decreasing Aminophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Aminophylline if Thiabendazole is initiated, discontinued or dose changed.
DB01223	DB00208	Ticlopidine increases the effect and toxicity of theophylline
DB01223	DB00373	Antagonism of action and increased effect of theophylline
DB01223	DB01361	The macrolide, troleandomycin, may increase the effect and toxicity of theophylline derivative, aminophylline.
DB01223	DB01199	Theophylline decreases the effect of muscle relaxant
DB01223	DB01339	Theophylline decreases the effect of muscle relaxant
DB01223	DB00661	Verapamil increases the effect of theophylline
DB01223	DB00549	Zafirlukast serum concentrations may be decreased by the theophylline derivative Aminophylline.
DB01223	DB00744	Zileuton increases the effect and toxicity of theophylline
DB01224	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01224	DB01211	The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine.
DB01224	DB00843	Possible antagonism of action
DB01224	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.
DB01224	DB00754	Phenytoin decreases the effect of quetiapine
DB01224	DB06414	Quetiapine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase quetiapine dosage if concurrent therapy is required.
DB01224	DB01320	Phenytoin decreases the effect of quetiapine
DB01224	DB00674	Possible antagonism of action
DB01224	DB01026	Ketoconazole may increase the therapeutic and adverse effects of quetiapine.
DB01224	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01224	DB00532	Phenytoin decreases the effect of quetiapine
DB01224	DB00252	Phenytoin decreases the effect of quetiapine
DB01224	DB01369	This combination presents an increased risk of toxicity
DB01224	DB00989	Possible antagonism of action
DB01224	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Quetiapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB01224	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01224	DB00976	Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed.
DB01224	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB01224	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01224	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01224	DB00662	Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01224	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01224	DB00427	Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01224	DB00209	Trospium and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01224	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed.
DB01224	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01224	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01224	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01225	DB06605	Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy.
DB01225	DB00055	Combination should be used with caution after weighing advantages and disadvantages. Low molecular weight heparins such as enoxaparin may increase the adverse effects of drotrecogin. Monitor for bleeding if used concomitantly.
DB01225	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01225	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Exoxaparin. Monitor for increased bleeding during concomitant thearpy.
DB01226	DB00479	The agent increases the effect of muscle relaxant
DB01226	DB01223	Theophylline decreases the effect of muscle relaxant
DB01226	DB00993	The agent decreases the effect of the muscle relaxant
DB01226	DB00564	Decrease the effect of muscle relaxant
DB01226	DB01190	The agent increases the effect of muscle relaxant
DB01226	DB01320	Phenytoin decreases the effect of muscle relaxant
DB01226	DB00798	The agent increases the effect of muscle relaxant
DB01226	DB01627	The agent increases the effect of muscle relaxant
DB01226	DB01033	The agent dereases the effect of the muscle relaxant
DB01226	DB00955	The agent increases the effect of muscle relaxant
DB01226	DB01303	Theophylline decreases the effect of muscle relaxant
DB01226	DB00252	Phenytoin decreases the effect of the muscle relaxant
DB01226	DB00319	The agent increases the effect of the muscle relaxant
DB01226	DB00277	Theophylline decreases the effect of the muscle relaxant
DB01226	DB00684	The agent increases the effect of the muscle relaxant
DB01253	DB00998	Possible severe and prolonged vasoconstriction
DB01227	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01227	DB01167	Itraconazole increases the effect/toxicity of levomethadyl
DB01227	DB01369	This combination presents an increased risk of toxicity
DB01228	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01229	DB00673	Aprepitant may change levels of the chemotherapy agent, paclitaxel.
DB01229	DB06626	Avoid combination due to potential for decrease in serum concentration of axitinib.
DB01229	DB00958	Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as paclitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent.
DB01229	DB00515	Cisplatin increases the effect and toxicity of paclitaxel
DB01229	DB00363	Avoid combination due to the potential enhancement of agranulocytosis by clozapine.
DB01229	DB00872	Avoid combination because it will likely increase the serum concentration of CYP3A4 substrates.
DB01229	DB06414	Paclitaxel, when used concomitantly with NNRTIs, may experience an increase in serum concentration. It is recommended to monitor for paclitaxel toxicity.
DB01229	DB00441	Paclitaxel increases the effect/toxicity of gemcitabine
DB01229	DB00108	Avoid combination due to the increased risk of infection.
DB01229	DB06589	Pazopanib increases exposure of paclitaxel
DB01229	DB00337	Avoid combination due to the enhancement of adverse effects of immunosuppressants.
DB01229	DB01369	This combination presents an increased risk of toxicity
DB01229	DB01323	Avoid combination due to potential decrease in serum concentration of paclitaxel.
DB01229	DB00864	Avoid combination of topical tacrolimus due to the potential enhancement of adverse effects of immunosuppressants.
DB01229	DB00976	Telithromycin may reduce clearance of Paclitaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Paclitaxel if Telithromycin is initiated, discontinued or dose changed.
DB01229	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Paclitaxel. Consider alternate therapy or monitor for changes in Paclitaxel therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01229	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Concomitant therapy may also increase Trastuzumab serum concentration and decrease Paclitaxel serum concentrations. Monitor closely for adverse events and therapeutic response.
DB01229	DB00385	The taxane derivative, Paclitaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
DB01229	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of paclitaxel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of paclitaxel if voriconazole is initiated, discontinued or dose changed.
DB01232	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Saquinavir. The antiviral response should be closely monitored.
DB01232	DB05812	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB01232	DB00404	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, alprazolam.
DB01232	DB01118	The protease inhibitor, saquinavir, may increase the effect and toxicity of amiodarone.
DB01232	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01232	DB06216	Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided.
DB01232	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01232	DB01076	Saquinavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if saquinavir is initiated, discontinued or dose changed.
DB01232	DB01558	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if saquinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01232	DB06772	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB01232	DB00475	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
DB01232	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01232	DB01068	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clonazepam.
DB01232	DB00628	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clorazepate.
DB01232	DB00091	The protease inhibitor, saquinavir, may increase the effect of cyclosporine.
DB01232	DB01219	Saquinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if saquinavir is initiated, discontinued or dose changed.
DB01232	DB01264	Decreased levels of darunavir
DB01232	DB00705	Increases the effect of saquinavir and hepatic toxicity
DB01232	DB00829	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, diazepam.
DB01232	DB00320	The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.
DB01232	DB00625	Efavirenz decreases the effect of saquinavir
DB01232	DB00700	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
DB01232	DB00696	The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, ergotamine.
DB01232	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB01232	DB01215	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, estazolam.
DB01232	DB00582	Voriconazole may increase the serum concentration of saquinavir by decreasing its metabolism. Saquinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB01253	DB00883	Possible antagonism of action
DB01232	DB06414	Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \r\n\r\nProtease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \r\n\r\nRitonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.
DB01232	DB00813	The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl.
DB01232	DB00690	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, flurazepam.
DB01232	DB02703	The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid.
DB01232	DB00224	Possible antagonism of action
DB01232	DB01026	Ketoconazole may increase the effect and toxicity of saquinavir.
DB01232	DB00227	Saquinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB01232	DB00683	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, midazolam.
DB01232	DB00238	Decreases the effect of saquinavir
DB01232	DB06589	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB01232	DB01100	The protease inhibitor, saquinavir, may increase the effect and toxicity of pimozide.
DB01232	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB01232	DB00243	Increased levels of ranolazine - risk of toxicity
DB01232	DB00615	Rifabutin decreases the effect of saquinavir
DB01232	DB01045	Rifampin decreases the effect of saquinavir
DB01232	DB00864	The protease inhibitor, Saquinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Saquinavir therapy is initiated, discontinued or altered.
DB01232	DB00820	Saquinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01232	DB00675	Saquinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01232	DB00706	Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Saquinavir is initiated, discontinued, or dose changed.
DB01232	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01232	DB00976	Saquinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB01232	DB06287	Saquinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01232	DB00444	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01232	DB00906	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Saquinavir. Consider alternate therapy.
DB01232	DB01036	Saquinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01232	DB06212	Saquinavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB01232	DB01030	The p-glycoprotein inhibitor, Saquinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01232	DB00193	Saquinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01232	DB00656	The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00897	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, triazolam.
DB01232	DB00726	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00862	Saquinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01232	DB08881	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB01232	DB00285	Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Saquinavir is initiated, discontinued, or dose changed.
DB01232	DB00661	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00570	Saquinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00541	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00361	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Saquinavir is initiated, discontinued or dose changed.
DB01232	DB00425	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if saquinavir is initiated, discontinued or dose changed.
DB01232	DB00909	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if saquinavir is initiated, discontinued or dose changed.
DB01232	DB01198	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if saquinavir is initiated, discontinued or dose changed.
DB01233	DB00091	Metoclopramide increases serum levels of cyclosporine
DB01233	DB01235	Levodopa decreases the effect of metoclopramide
DB01233	DB08815	Increases toxicity and risk of extrapyramidal effects of lurasidone by antidopaminergic effects. Concomitant therapy should be avoided.
DB01233	DB01267	Metoclopramide may increase the risk of extrapyramidal side effects of paliperidone. Concomitant therapy should be avoided.
DB01233	DB00864	Metoclopramide may increase the concentration of Tacrolimus in the blood. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Metoclopramide therapy is initiated, discontinued or altered.
DB01233	DB04844	Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB01233	DB00285	Possible serotoninergic syndrome with this combination
DB01233	DB06684	Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.
DB01233	DB01624	Additive dopamine D2 receptor antagonism may cause dopaminergic imbalance in the nigrostriatal (dopamine D1 receptors) and striatopallidal (dopamine D2 receptors). Increased risk of extrapyramidal reactions and neuroleptic malignant syndrome. Concomitant therapy should be avoided.
DB01234	DB01418	The corticosteroid, dexamethasone, alters the anticoagulant effect, acenocoumarol.
DB01234	DB00945	The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB01234	DB01122	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, ambenonium.
DB01234	DB00357	Aminoglutethimide may decrease the effect of dexamethasone.
DB01234	DB01351	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01125	The corticosteroid, dexamethasone, alters the anticoagulant effect of anisindione.
DB01234	DB00673	Aprepitant may increase the effect and toxicity of dexamethasone.
DB01234	DB01352	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB08886	Monitor therapy as asparaginase erwinia chrysanthemi may increase the serum concentration of dexamethasone due to a decrease of hepatic proteins necessary for dexamethasone metabolism.
DB01234	DB00237	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00241	The barbiturate, butalbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01353	The barbiturate, butethal, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB06695	P-Glycoprotein inducers such as dexamethasone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB01234	DB00266	The corticosteroid, dexamethasone, alters the anticoagulant effect of dicumarol.
DB01234	DB01341	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01010	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, edrophonium.
DB01234	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB01234	DB00754	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01354	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01355	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00619	Dexamethasone may decrease levels of imatinib.
DB01234	DB08815	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. Will decrease Cmax of lurasidone by 85%.
DB01234	DB01397	The corticosteroid, dexamethasone, may decrease the effect of magnesium salicylate.
DB01234	DB00532	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00474	The barbiturate, methohexital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00849	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00211	Increased arterial pressure
DB01234	DB01400	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, neostigmine.
DB01234	DB00312	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00545	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB01234	DB01346	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB08864	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB01234	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01234	DB01399	The corticosteroid, dexamethasone, may decrease the effect of the salicylate, salsalate.
DB01234	DB00418	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB01268	Possible decrease in sunitinib levels
DB01234	DB00382	Tacrine and Dexamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB01234	DB00306	The barbiturate, talbutal, may decrease the effect of the corticosteroid, dexamethasone.
DB01234	DB00976	Co-administration may cause decreased Telithromycin and increased Dexamethasone plasma concentrations. Consider alternate therapy.
DB01234	DB06287	Dexamethasone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB01234	DB01041	Increased risk of dermatologic adverse effects and venous thromboembolic events (VTE). Consider VTE prophylaxis during concomitant therapy and monitor for adverse dematologic effects.
DB01234	DB00193	Dexamethasone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB01234	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01234	DB00656	The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed.
DB01234	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB01234	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Dexamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01234	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dexamethasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dexamethasone if voriconazole is initiated, discontinued or dose changed.
DB01234	DB00682	The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin.
DB01235	DB01320	The hydantoin decreases the effect of levodopa
DB01235	DB00893	Iron decreases the absorption of dopa derivatives
DB01235	DB01247	Possible hypertensive crisis
DB01235	DB00968	Methyldopa increases the effect and toxicity of levodopa
DB01235	DB01233	Levodopa decreases the effect of metoclopramide
DB01235	DB01267	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, levodopa. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01235	DB00780	Possible hypertensive crisis
DB01235	DB00252	The hydantoin decreases the effect of levodopa
DB01235	DB04844	Tetrabenazine may cause Parkinsonian symptoms and neutralize the effect of Levodopa.
DB01235	DB01623	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Levodopa. Consider alternate therapy or monitor for decreased effects of both agents.
DB01235	DB00752	Levodopa may increase the adverse effects of Tranylcypromine. Risk of severe hypertension. Concomitant therapy should be avoided or monitored closely for adverse effects of Tranylcypromine.
DB01235	DB00246	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, levodopa. Consider alternate therapy or monitor for worsening of movement disorder.
DB01235	DB01624	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01237	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Bromodiphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01237	DB00662	Trimethobenzamide and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01237	DB00427	Triprolidine and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01237	DB00209	Trospium and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01238	DB00564	Carbamazepine, a strong CYP3A4 inducer, may decrease the serum concentration of aripiprazole by increasing its metabolism.
DB01238	DB01341	Quinidine increases the effect and toxicity of aripiprazole
DB01238	DB06414	Ariprazole, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dose of oral aripiprazole to maintain therapeutic efficacy, and to adjust the dose of aripiprazole appropriately when the dose of etravirine is altered.
DB01238	DB01167	Itraconazole may increase the effect of aripiprazole.
DB01238	DB01026	Ketoconazole may increase the effect of aripiprazole.
DB01238	DB00908	Quinidine increases the effect and toxicity of aripiprazole
DB01238	DB01346	Quinidine increases the effect and toxicity of aripiprazole
DB01238	DB00382	Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Aripiprazole. Monitor for extrapyramidal symptoms.
DB01238	DB00976	Telithromycin may reduce clearance of Aripiprazole. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aripiprazole if Telithromycin is initiated, discontinued or dose changed.
DB01238	DB00857	Terbinafine may reduce the metabolism and clearance of Aripiprazole. Consider alternate therapy or monitor for therapeutic/adverse effects of Aripiprazole if Terbinafine is initiated, discontinued or dose changed.
DB01238	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB01247	DB01291	Increased arterial pressure
DB01247	DB01366	Increased arterial pressure
DB01238	DB00427	The CNS depressants, Triprolidine and Aripiprazole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01238	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aripiprazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aripiprazole if voriconazole is initiated, discontinued or dose changed.
DB01239	DB00843	Possible antagonism of action
DB01239	DB00674	Possible antagonism of action
DB01239	DB01170	Chlorprothixene may decrease the effect of guanethidine.
DB01239	DB00989	Possible antagonism of action
DB01240	DB00519	The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect of Trandolapril.
DB01241	DB01418	Gemfibrozil may increase the anticoagulant effect of acenocoumarol.
DB01241	DB01125	Gemfibrozil may increase the anticoagulant effect of anisindione.
DB01241	DB01076	Increased risk of myopathy/rhabdomyolysis
DB01241	DB00307	Gemfibrozil may increase the serum concentration of bexarotene. This combination should be avoided.
DB01241	DB00395	Strong CYP2C19 inhibitors such as gemfibrozil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB01241	DB00439	Increased risk of myopathy/rhabdomyolysis
DB01241	DB08912	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB01241	DB00266	Gemfibrozil may increase the anticoagulant effect of dicumarol.
DB01241	DB01095	Increased risk of myopathy/rhabdomyolysis
DB01241	DB00222	Gemfibrozil increases the effect and toxicity of rosiglitazone/pioglitazone
DB01241	DB00227	Increased risk of myopathy/rhabdomyolysis
DB01241	DB01132	Gemfibrozil may increase the effect and toxicity of pioglitazone.
DB01241	DB08860	Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both gemfibrozil and pitavastatin via pharmacodynamic synergism. Use alternative therapy.
DB01241	DB00175	Increased risk of myopathy/rhabdomyolysis
DB01241	DB00912	Gemfibrozil may increase the effect and toxicity of repaglinide.
DB01241	DB00412	Increases the effect and toxicity of rosiglitazone/pioglitazone
DB01241	DB01098	Gemfibrozil may increase the therapeutic and toxic effects of rosuvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of rosuvastatin if gemfibrozil is initiated, discontinued or dose changed.
DB01241	DB00641	Increased risk of myopathy/rhabdomyolysis
DB01241	DB00382	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Gemfibrozil, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Gemfibrozil is initiated, discontinued or if the dose is changed.
DB01241	DB00675	Gemfibrozil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Gemfibrozil  is initiated, discontinued or dose changed.
DB01241	DB00697	Gemfibrozil may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
DB01241	DB01124	Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Gemfibrozil is initiated, discontinued or dose changed.
DB01241	DB00214	Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Gemfibrozil is initiated, discontinued or dose changed.
DB01241	DB00755	The strong CYP2C8 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Gemfibrozil is initiated, discontinued to dose changed.
DB01241	DB00440	The strong CYP2C9 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Gemfibrozil is initiated, discontinued or dose changed.
DB01241	DB00726	The strong CYP2C19 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Gemfibrozil is initiated, discontinued or dose changed.
DB01241	DB01586	The fibric acid derivative decreases the effect of ursodiol
DB01241	DB00582	Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if gemfibrozil is initiated, discontinued or dose changed.
DB01241	DB00682	Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if gemfibrozil is initiated, discontinued or dose changed.
DB01241	DB00549	Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if gemfibrozil is initiated, discontinued or dose changed.
DB01242	DB00488	Risk of severe hypotension
DB01242	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01242	DB01072	Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if atazanavir is initiated, discontinued or dose changed.
DB01242	DB00237	Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB01242	DB00241	Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.
DB01242	DB00501	Cimetidine may increase the effect of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if cimetidine is initiated, discontinued or dose changed.
DB01242	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01242	DB00575	The tricyclic antidepressant, clomipramine, may decrease the effect of clonidine.
DB01242	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01242	DB01341	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, clomipramine.
DB01242	DB00841	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dobutamine.
DB01242	DB00843	Possible antagonism of action
DB01242	DB00988	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dopamine.
DB01242	DB01363	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedra.
DB01242	DB01364	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedrine.
DB01242	DB00668	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of epinephrine.
DB01242	DB01288	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of fenoterol.
DB01242	DB00472	The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluoxetine is initiated, discontinued or dose changed.
DB01242	DB00176	The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluvoxamine is initiated, discontinued or dose changed.
DB01242	DB00674	Possible antagonism of action
DB01242	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01242	DB01170	The tricyclic antidepressant, clomipramine, decreases the effect of guanethidine.
DB01242	DB01247	Possibility of severe adverse effects
DB01242	DB01064	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of isoproterenol.
DB01242	DB01365	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of mephentermine.
DB01242	DB00610	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of metaraminol.
DB01242	DB00723	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of methoxamine.
DB01242	DB01171	Possible severe adverse reaction with this combination
DB01242	DB00368	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of norepinephrine.
DB01242	DB00816	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of orciprenaline.
DB01242	DB00780	Possibility of severe adverse effects
DB01242	DB00388	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylephrine.
DB01242	DB00397	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylpropanolamine.
DB01242	DB01291	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pirbuterol.
DB01242	DB01366	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of procaterol.
DB01242	DB00852	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pseudoephedrine.
DB01242	DB00908	Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.
DB01242	DB01346	Quinidine barbiturate increases the effect of tricyclic antidepressant, clomipramine.
DB01242	DB01367	Possibility of severe adverse effects
DB01242	DB00615	The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifabutin is initiated, discontinued or dose changed.
DB01242	DB01045	The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed.
DB01242	DB00503	Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if ritonavir if initiated, discontinued or dose changed.
DB01242	DB00989	Possible antagonism of action
DB01242	DB01001	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of salbutamol.
DB01242	DB01105	Increased risk of CNS adverse effects
DB01242	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB01242	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clomipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01242	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01242	DB00675	Clomipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB01242	DB00706	Clomipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clomipramine is initiated, discontinued, or dose changed.
DB01242	DB00857	Terbinafine may reduce the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for therapeutic/adverse effects of Clomipramine if Terbinafine is initiated, discontinued or dose changed.
DB01242	DB00871	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of terbutaline.
DB01242	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01242	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clomipramine by decreasing Clomipramine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clomipramine if Thiabendazole is initiated, discontinued or dose changed.
DB01242	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01242	DB00208	Ticlopidine may decrease the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for adverse/toxic effects of Clomipramine if Ticlopidine is initiated, discontinued or dose changed.
DB01242	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01242	DB00193	Tramadol increases the risk of serotonin syndrome and seizures. Clomipramine may decrease the effect of Tramadol by decreasing active metabolite production.
DB01242	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB01242	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01242	DB00662	Trimethobenzamide and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01242	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01242	DB00427	Triprolidine and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01242	DB00209	Trospium and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01242	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01242	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01242	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01242	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01242	DB00315	Use of two serotonin modulators, such as zolmitriptan and clomipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01242	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01244	DB00701	Amprenavir may increase the effect and toxicity of bepridil.
DB01244	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01244	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB01072	Atazanavir may increase the effect and toxicity of bepridil.
DB01244	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB06414	Bepridil (withdrawn from US. market), when used concomitantly with etravirine, may experience a decrease in serum concentration. If possible, it is recommended to monitor for decreased bepridil concentrations and therapeutic efficacy.
DB01244	DB01319	Amprenavir increases the effect and toxicity of bepridil
DB01244	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01244	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB00503	Ritonavir increases the effect and toxicity of bepridil
DB01244	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01244	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01244	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Bepridil. Concomitant therapy is contraindicated.
DB01246	DB01200	The phenothiazine decreases the effect of bromocriptine
DB01246	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01246	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB01246	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB01246	DB00843	Possible antagonism of action
DB01246	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB01246	DB00674	Possible antagonism of action
DB01246	DB01170	Trimeprazine may decrease the effect of guanethidine.
DB01246	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB01246	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB01246	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB01247	DB00344	Possibility of severe adverse effects
DB01247	DB00852	Increased arterial pressure
DB01247	DB00989	Possible antagonism of action
DB01253	DB01020	Possible antagonism of action
DB01246	DB01278	The anticholinergic effects of Trimeprazine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01246	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimeprazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01246	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01246	DB00662	Trimethobenzamide and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01246	DB00427	Triprolidine and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01246	DB00209	Trospium and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01247	DB00918	The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated.
DB01247	DB00488	Risk of severe hypotension
DB01247	DB00321	Possibility of severe adverse effects
DB01247	DB00543	Possibility of severe adverse effects
DB01247	DB00182	Possible hypertensive crisis
DB01247	DB00289	Possible severe adverse reaction with this combination
DB01247	DB00865	MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents.
DB01247	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like isocarboxazid.
DB01247	DB00484	MAO Inhibitors like isocarboxazid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB01247	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB01247	DB01156	Possible severe adverse reaction with this combination
DB01247	DB00490	Possible blood pressure elevation
DB01247	DB00215	Possible severe adverse reaction with this combination
DB01247	DB01242	Possibility of severe adverse effects
DB01247	DB01151	Possibility of severe adverse effects
DB01247	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01247	DB01191	Risk of hypertensive crisis.
DB01247	DB01576	Possible hypertensive crisis
DB01247	DB00514	Possible severe adverse reaction
DB01247	DB00937	Possible hypertensive crisis
DB01247	DB00841	Increased arterial pressure
DB01247	DB00843	Possible antagonism of action
DB01247	DB00988	Increased arterial pressure
DB01247	DB01142	Possibility of severe adverse effects
DB01247	DB00476	Possible severe adverse reaction with this combination
DB01247	DB00494	Possible hypertensive crisis with this combination
DB01247	DB01363	Increased arterial pressure
DB01247	DB01364	Increased arterial pressure
DB01247	DB00668	Increased arterial pressure
DB01247	DB01175	Possible severe adverse reaction with this combination
DB01247	DB00574	Possible hypertensive crisis
DB01247	DB01288	Increased arterial pressure
DB01247	DB00472	Possible severe adverse reaction with this combination
DB01247	DB00176	Possible severe adverse reaction with this combination
DB01247	DB00674	Possible antagonism of action
DB01247	DB01170	Isocarboxazid may decrease the effect of guanethidine.
DB01247	DB00458	Possibility of severe adverse effects
DB01247	DB01064	Increased arterial pressure
DB01247	DB01235	Possible hypertensive crisis
DB01247	DB00150	Possible severe adverse reaction with this combination
DB01247	DB00579	Possible hypertensive crisis
DB01247	DB01365	Increased arterial pressure
DB01247	DB00610	Increased arterial pressure
DB01247	DB01577	Possible hypertensive crisis
DB01247	DB01403	Possible severe adverse reaction with this combination
DB01247	DB00723	Increased arterial pressure
DB01247	DB00422	Possible hypertensive crisis with this combination
DB01247	DB00211	Possible hypertensive crisis with this combination
DB01247	DB04896	Increase serotonin levels. Combination therapy is contraindicated.
DB01247	DB00370	Possible severe adverse reaction with this combination
DB01247	DB00952	The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome.
DB01247	DB01149	Possible severe adverse reaction with this combination
DB01247	DB00368	Increased arterial pressure
DB01247	DB00540	Possibility of severe adverse effects
DB01247	DB00816	Increased arterial pressure
DB01247	DB00715	Possible severe adverse reaction with this combination
DB01247	DB00454	Potentially fatal adverse effects
DB01247	DB01579	Possible hypertensive crisis
DB01247	DB00830	Possible hypertensive crisis
DB01247	DB00191	Possible hypertensive crisis
DB01247	DB00388	Increased arterial pressure
DB01247	DB00397	Increased arterial pressure
DB01247	DB00953	The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
DB01247	DB01001	Increased arterial pressure
DB01247	DB01104	Possible severe adverse reaction with this combination
DB01247	DB01105	Possible serotoninergic syndrome with this combination
DB01247	DB00669	The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated.
DB01247	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01247	DB00871	Increased arterial pressure
DB01247	DB04844	Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated.
DB01247	DB00323	Tolcapone and Isocarboxazid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB01247	DB00193	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid.
DB01247	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01247	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01247	DB00662	Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01247	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB01247	DB00427	Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01247	DB00209	Trospium and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01247	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01247	DB06684	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
DB01247	DB00315	The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated.
DB01248	DB00673	Aprepitant may change levels of the chemotherapy agent, docetaxel.
DB01248	DB00958	Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent.
DB01248	DB00515	Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent.
DB01248	DB00199	Erythromycin may increase the serum levels and toxicity of docetaxel.
DB01248	DB01321	Josamycin may increase the serum levels and toxicity of docetaxel.
DB01248	DB01026	Ketoconazole may increase the serum levels and toxicity of docetaxel.
DB01248	DB00683	Midazolam may increase the serum levels and toxicity of docetaxel.
DB01248	DB01173	Orphenadrine may increase the serum levels and toxicity of docetaxel.
DB01248	DB01369	This combination presents an increased risk of toxicity.
DB01248	DB00976	Telithromycin may reduce clearance of Docetaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Docetaxel if Telithromycin is initiated, discontinued or dose changed.
DB01248	DB00624	Testosterone may increase the serum levels and toxicity of docetaxel.
DB01248	DB01420	Testosterone propionate may increase the serum levels and toxicity of docetaxel.
DB01248	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01248	DB00385	The taxane derivative, Docetaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
DB01248	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of docetaxel by decreasing its metabolism. Consider using a non-interacting antifungal or monitor for changes in the therapeutic and adverse effects of docetaxel if voriconazole is initiated, discontinued or dose changed.
DB01250	DB00993	Olsalazine may increase the toxicity of thiopurine, azathioprine.
DB01250	DB01033	Olsalazine may increase the toxicity of thiopurine, mercaptopurine.
DB01250	DB00352	Olsalazine may increase the toxicity of thiopurine, thioguanine.
DB01253	DB01193	Ischemia with risk of gangrene
DB01253	DB00918	Possible severe and prolonged vasoconstriction
DB01253	DB00335	Ischmeia with risk of gangrene
DB01253	DB00612	Ischemia with risk of gangrene
DB01253	DB01136	Ischemia with risk of gangrene
DB01253	DB00705	The antiretroviral agent may increase the ergot derivative toxicity
DB01253	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01253	DB00095	The antiretroviral agent may increase the ergot derivative
DB01253	DB00216	Possible severe and prolonged vasoconstriction
DB01253	DB00668	Possible marked increase of arterial pressure
DB01253	DB00199	Possible ergotism and severe ischemia with this combination
DB01253	DB00187	Ischemia with risk of gangrene
DB01253	DB00598	Ischemia with risk of gangrene
DB01253	DB00264	Ischemia with risk of gangrene
DB01253	DB01203	Ischemia with risk of gangrene
DB01253	DB00952	Possible severe and prolonged vasocontriction
DB01253	DB00727	Possible antagonism of action
DB01253	DB01580	Ischemia with risk of gangrene
DB01253	DB06154	Possible antagonism of action
DB01253	DB00388	Possible marked increase of arterial pressure
DB01253	DB00960	Ischemia with risk of gangrene
DB01253	DB00571	Ischemia with risk of gangrene
DB01253	DB00976	Telithromycin may reduce clearance of Ergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergonivine if Telithromycin is initiated, discontinued or dose changed.
DB01253	DB00373	Ischemia with risk of gangrene
DB01253	DB00932	Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergonovine. Concomitant therapy is contraindicated.
DB01253	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01253	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01253	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01253	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01253	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01253	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergonovine by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01253	DB00315	Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
DB01254	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01254	DB00063	Monitor therapy due to enhanced anticoagulant effect.
DB01254	DB06414	Dasatinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. \r\n\r\nIt is recommended to avoid this combination if possible. If concurrent therapy cannot be avoided it is recommended to increase the dose of dasitinib and monitor for efficacy and toxicity.
DB01254	DB00338	Omeprazole may decrease the serum level of dasatinib.
DB01254	DB00213	Pantoprazole may decrease the serum level of dasatinib.
DB01254	DB01174	Phenobarbital may decrease the serum level and efficacy of dasatinib.
DB01254	DB00252	Phenytoin may decrease the serum level and efficacy of dasatinib.
DB01254	DB01129	Rabeprazole may decrease the serum level of dasatinib.
DB01254	DB00863	Ranitidine may decrease the serum level of dasatinib.
DB01254	DB01045	Rifampin may decrease the serum level and efficacy of dasatinib.
DB01254	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01254	DB00976	Telithromycin may reduce clearance of Dasatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dasatinib if Telithromycin is initiated, discontinued or dose changed.
DB01254	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01254	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01254	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01254	DB00582	Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed.
DB01254	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01254	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01254	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01255	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01255	DB00519	Lisdexamfetamine may reduce the efficacy of Trandolapril.
DB01255	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Lisdexamfetamine. Concomitant therapy should be avoided.
DB01255	DB00427	Triprolidine may reduce the sedative effect of the antihistamine, Lisdexamfetamine.
DB01259	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01259	DB06414	Lapatinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB01259	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01259	DB06589	Lapatinib is a weak inhibitor of CYP3A4, BCRP, and p-glycoprotein and may increase exposure of pazopanib. AUC and Cmax increase by 50-60%.
DB01259	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01259	DB00706	Lapatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lapatinib is initiated, discontinued, or dose changed.
DB01259	DB00976	Telithromycin may reduce clearance of Lapatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lapatinib if Telithromycin is initiated, discontinued or dose changed.
DB01259	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01259	DB01036	Lapatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01259	DB01030	The p-glycoprotein inhibitor, Lapatinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01259	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01259	DB00193	Lapatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01259	DB00656	The CYP3A4 inhibitor, Lapatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lapatinib is initiated, discontinued or dose changed.
DB01259	DB00755	The moderate CYP2C8 inhibitor, Lapatinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Lapatinib is initiated, discontinued to dose changed.
DB01259	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01259	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lapatinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lapatinib if voriconazole is initiated, discontinued or dose changed.
DB01259	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01259	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01259	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01261	DB00052	Somatropin may antagonize the hypoglycemic effect of sitagliptin. Monitor for changes in fasting and postprandial blood sugars.
DB01263	DB06605	Avoid combination. Otherwise, posaconazole will likely increase apixaban serum concentration.
DB01263	DB00637	Contraindicated co-administration
DB01263	DB01558	Posaconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if posaconazole is initiated, discontinued or dose changed.
DB01263	DB00501	Significant decrease of posaconazole levels
DB01263	DB00604	Contraindicated co-administration
DB01263	DB00872	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
DB01263	DB00091	Increased level of cyclosporine
DB01263	DB01219	Posaconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if posaconazole is initiated, discontinued or dose changed.
DB01263	DB00320	Contraindicated co-administration
DB01263	DB00696	Contraindicated co-administration
DB01263	DB01320	Modifications of drug levels for both agents
DB01263	DB01218	Contraindicated co-administration
DB01263	DB08820	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB01263	DB00247	Contraindicated co-administration
DB01263	DB00252	Modifications of drug levels for both agents
DB01263	DB01100	Contraindicated co-administration
DB01263	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB01263	DB00908	Contraindicated co-administration
DB01263	DB08896	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB01263	DB00615	Modification of drug levels for both agents
DB01263	DB06228	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
DB01263	DB00864	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00820	Posaconzole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01263	DB00675	Posaconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01263	DB00706	Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Posaconazole is initiated, discontinued, or dose changed.
DB01263	DB00976	Posaconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB01263	DB06287	Posaconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01263	DB00444	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00342	Contraindicated co-administration
DB01263	DB00906	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00932	Tipranavir may increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Tipranavir.
DB01263	DB01036	Posaconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01263	DB00193	Posaconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01264	DB00193	Darunavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01297	DB00554	Risk of inhibition of renal prostaglandins
DB01263	DB00656	The CYP3A4 inhibitor, Posaconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00726	The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00862	Posaconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01263	DB00285	Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Posaconazole is initiated, discontinued, or dose changed.
DB01263	DB00661	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00570	Posaconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00541	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00361	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Posaconazole is initiated, discontinued or dose changed.
DB01263	DB00425	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if posaconazole is initiated, discontinued or dose changed.
DB01263	DB00909	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if posaconazole is initiated, discontinued or dose changed.
DB01263	DB01198	Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if posaconazole is initiated, discontinued or dose changed.
DB01264	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Darunavir. The antiviral response should be closely monitored.
DB01264	DB01558	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if darunavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01264	DB01211	Increased levels of clarithromycin
DB01264	DB01219	Darunavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if darunavir is initiated, discontinued or dose changed.
DB01264	DB06414	Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \r\n\r\nProtease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \r\n\r\nRitonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.
DB01264	DB00281	Possible increase in lidocaine levels
DB01264	DB01601	Decreased levels of darunavir
DB01264	DB00227	Darunavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
DB01264	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB01264	DB01232	Decreased levels of darunavir
DB01264	DB00864	The protease inhibitor, Darunavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Darunavir therapy is initiated, discontinued or altered.
DB01264	DB00820	Darunavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01264	DB00675	Darunavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01264	DB00706	Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darunavir is initiated, discontinued, or dose changed.
DB01264	DB00976	Co-administration may result in altered plasma concentrations of Darunavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
DB01264	DB06287	Darunavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01264	DB00444	The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Darunavir is initiated, discontinued or dose changed.
DB01264	DB00906	The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Darunavir is initiated, discontinued or dose changed.
DB01264	DB01036	Darunavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01264	DB01030	The p-glycoprotein inhibitor, Darunavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01291	DB00335	Antagonism
DB01291	DB00612	Antagonism
DB01264	DB00656	The protease inhibitor, Darunavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Darunavir is initiated, discontinued or dose changed.
DB01264	DB00726	The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Darunavir is initiated, discontinued or dose changed.
DB01264	DB00862	Darunavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01264	DB00285	Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Darunavir is initiated, discontinued, or dose changed.
DB01264	DB00661	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Darunavir is initiated, discontinued or dose changed.
DB01264	DB00570	Darunavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Darunavir is initiated, discontinued or dose changed.
DB01264	DB00541	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Darunavir is initiated, discontinued or dose changed.
DB01264	DB00361	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Darunavir is initiated, discontinued or dose changed.
DB01264	DB00582	Darunavir may reduce serum concentrations and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy.
DB01264	DB00425	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if darunavir is initiated, discontinued or dose changed.
DB01264	DB00909	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if darunavir is initiated, discontinued or dose changed.
DB01264	DB01198	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if darunavir is initiated, discontinued or dose changed.
DB01265	DB00008	Co-administration of Peginterferon alpha-2a and Telbivudine may increase the risk of serious peripheral neuropathy.
DB01267	DB00915	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, amantadine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01267	DB00714	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, apomorphine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01267	DB01200	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, bromocriptine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01267	DB01235	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, levodopa. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01267	DB01403	The CNS depressant agents, paliperidone and methotrimeprazine, may cause additive CNS depressant effects. Monitor for increased CNS depressant effects during concomitant therapy.
DB01267	DB01233	Metoclopramide may increase the risk of extrapyramidal side effects of paliperidone. Concomitant therapy should be avoided.
DB01267	DB00413	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, pramipexole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01267	DB00734	Paliperidone is the active metabolite of risperidone, 9-OH-risperidone. Concomitant therapy may increase the adverse effects of paliperidone due to additive paliperidone exposure. Consider alternate therapy.
DB01267	DB00268	The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, ropinirole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
DB01267	DB00382	Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Paliperidone. Monitor for extrapyramidal symptoms.
DB01267	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB01267	DB00427	The CNS depressants, Triprolidine and Paliperidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01268	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01268	DB01072	Possible increase in sunitinib levels
DB01291	DB01136	Antagonism
DB01297	DB00457	Risk of hypotension at the beginning of therapy
DB01268	DB00112	Sunitinib may enhance the adverse/toxic effect of bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of sunitinib. This combination is contraindicated.
DB01268	DB00564	Possible decrease in sunitinib levels
DB01268	DB01211	Possible increase in sunitinib levels
DB01268	DB01234	Possible decrease in sunitinib levels
DB01268	DB00224	Possible increase in sunitinib levels
DB01268	DB01167	Possible increase in sunitinib levels
DB01268	DB01026	Possible increase in sunitinib levels
DB01268	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01268	DB01149	Possible increase in sunitinib levels
DB01268	DB00220	Possible increase in sunitinib levels
DB01268	DB01174	Possible decrease in sunitinib levels
DB01268	DB00252	Possible decrease in sunitinib levels
DB01268	DB00615	Possible decrease in sunitinib levels
DB01268	DB01045	Possible decrease in sunitinib levels
DB01268	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01268	DB00976	Telithromycin may reduce clearance of Sunitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sunitinib if Telithromycin is initiated, discontinued or dose changed.
DB01268	DB06287	Co-administration of Temsirolimus and Sunitinib may result in serious adverse drug reactions.
DB01268	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01268	DB01030	The p-glycoprotein inhibitor, Sunitinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01268	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01268	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01268	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01268	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sunitinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of sunitinib if voriconazole is initiated, discontinued or dose changed.
DB01268	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01268	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01268	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01275	DB00264	Increased effect of both drugs
DB01275	DB00571	Increased effect of both drugs
DB01275	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01276	DB08822	Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity.
DB01276	DB01406	Monitor therapy due to reduced hypoglycemic effect of exenatide.
DB01276	DB00082	Monitor therapy due to enhanced hypoglycemic effect.
DB01276	DB00052	Somatropin may antagonize the hypoglycemic effect of exenatide. Monitor for changes in fasting and postprandial blood sugars.
DB01278	DB08897	May increase the risk of inhibition of GI motility via pharmacodynamic synergism. Consider alternate therapy.
DB01278	DB01246	The anticholinergic effects of Trimeprazine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB00748	Pramlintide may enhance the anticholinergic effect of Anticholinergics such as carbinoxamine. These effects are specific to the gastrointestinal tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced gastrointestinal motility may occur.
DB01278	DB00771	Pramlintide may enhance the anticholinergic effect of anticholinergics such as clidinium. These effects are specific to the GI tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur.
DB01278	DB00366	May cause additive slowing of GI motility.
DB01278	DB00046	Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
DB01278	DB01623	The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB01409	The anticholinergic effects of Tiotropium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB01036	Additive reduction in gut motility may occur. Consider alternate therapy or use caution during concomitant therapy.
DB01278	DB00752	The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB00376	The anticholinergic effects of Trihexyphenidyl may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01297	DB00236	Antagonism
DB01278	DB00662	The anticholinergic effects of Trimethobenzamide may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB00726	The anticholinergic effects of Trimipramine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB00427	The anticholinergic effects of Triprolidine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB00209	The anticholinergic effects of Trospium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01278	DB01624	May cause additive reduction in GI motility. Use caution or consider alternate therapy.
DB01280	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01281	DB00026	Avoid combination due to enhanced adverse effects of abatacept
DB01281	DB08879	Avoid combination due to enhanced adverse effects of belimumab.
DB01281	DB08904	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB01281	DB06643	Monitor therapy due to enhanced effects of immunosuppressants and the risk of serious infections.
DB01281	DB00005	Avoid combination because of increased adverse effects of Abatacept.
DB01281	DB06674	Avoid combination with abatacept due to the increased chance of serious infection.
DB01281	DB00065	The combination shoould be avoided as there have been reports of increased risk of serious infections.
DB01281	DB01097	Therapy modification should be considered due to enhanced adverse effects of leflunomide, specifically hematologic toxicity.
DB01281	DB00108	Avoid combination due to enhanced adverse effects of natalizumab and the risk of infections.
DB01281	DB00337	Avoid combination due to enhanced adverse effects of immunosuppressive agents.
DB01281	DB00073	Avoid combination due to enhanced adverse effects of abatacept.
DB01281	DB01656	Consider therapy modification due to enhanced immunosuppressive action.
DB01281	DB06688	Monitor therapy due to reduced therapeutic effect of sipuleucel-t.
DB01281	DB00864	Avoid combination due to enhanced toxic effects of immunosuppressants.
DB01281	DB01041	Thalidomide may increase the adverse effects of Abatacept. Increased risk of serious infection. Concomitant therapy should be avoided.
DB01281	DB06273	Avoid combination due to enhanced adverse effects of abatacept.
DB01281	DB08895	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB01281	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01282	DB00917	Dinoprostone may enhance the therapeutic effect of carbetocin. Avoid concomitant use of carbetocin with dinoprostone. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use.
DB01282	DB00929	Misoprostol may enhance the therapeutic effect of Carbetocin. Avoid the concomitant use of carbetocin and misoprostol. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use.
DB01283	DB01418	Lumiracoxib may increase the anticoagulant effect of acenocoumarol.
DB01283	DB01125	Lumiracoxib may increase the anticoagulant effect of anisindione.
DB01283	DB00266	Lumiracoxib may increase the anticoagulant effect of dicumarol.
DB01283	DB01356	The COX-2 inhibitor increases serum levels of lithium
DB01283	DB00966	Concomitant use of Telmisartan and Lumiracoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB01283	DB00373	The NSAID, Lumiracoxib, may antagonize the antihypertensive effect of Timolol.
DB01283	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Lumiracoxib. Consider alternate therapy or monitor for changes in Lumiracoxib therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01283	DB00519	The NSAID, Lumiracoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Lumiracoxib is initiated, discontinued or dose changed.
DB01283	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Lumiracoxib. Monitor for increased bleeding during concomitant thearpy.
DB01283	DB00682	Lumiracoxib may increase the anticoagulant effect of warfarin.
DB01285	DB00041	Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
DB01285	DB00673	Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen.
DB01285	DB06717	Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant.
DB01285	DB01097	Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.
DB01285	DB00545	The corticosteroid, corticotropin, may decrease the effect of the anticholinesterase, pyridostigmine.
DB01285	DB00382	Tacrine and Corticotropin may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB01285	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01285	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Corticotropin. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01288	DB01193	Antagonism
DB01288	DB00386	Increased arterial pressure
DB01288	DB00321	The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of fenoterol.
DB01288	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of fenoterol.
DB01288	DB00335	Antagonism
DB01288	DB00195	Beta-Blockers (Beta-1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like fenoterol.  Therapy should be monitored.
DB01288	DB01295	Antagonism
DB01288	DB00612	Antagonism
DB01288	DB00521	Antagonism
DB01288	DB01136	Antagonism
DB01288	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of fenoterol.
DB01288	DB01089	Increased arterial pressure
DB01288	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of fenoterol.
DB01288	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of fenoterol.
DB01288	DB00187	Antagonism
DB01288	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of fenoterol.
DB01288	DB01247	Increased arterial pressure
DB01288	DB00598	Antagonism
DB01288	DB00601	Possible increase of arterial pressure
DB01288	DB00968	Increased arterial pressure
DB01288	DB00264	Antagonism
DB01288	DB00211	Increased arterial pressure
DB01288	DB01171	Moclobemide increases the sympathomimetic effect of fenoterol.
DB01288	DB01203	Antagonism
DB01288	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of fenoterol.
DB01288	DB01580	Antagonism
DB01288	DB01626	Increased arterial pressure
DB01288	DB01359	Antagonism
DB01288	DB00780	Increased arterial pressure
DB01288	DB00960	Antagonism
DB01288	DB01297	Antagonism
DB01288	DB00571	Antagonism
DB01288	DB00344	The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of fenoterol.
DB01288	DB01367	Increased arterial pressure
DB01288	DB00206	Increased arterial pressure
DB01288	DB00489	Antagonism
DB01288	DB00373	Antagonism
DB01288	DB00752	Increased arterial pressure
DB01288	DB00726	The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of fenoterol.
DB01289	DB01193	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01289	DB00945	Acetylsalicylic acid increases the effect of the sulfonylurea, glisoxepide.
DB01289	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01289	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01289	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01289	DB00446	Chloramphenicol may increase the effect of sulfonylurea, glisoxepide.
DB01289	DB00636	Clofibrate may increase the effect of sulfonylurea, glisoxepide.
DB01289	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01289	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB01289	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB01289	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01289	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01289	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB01289	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB01289	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB01289	DB01045	Rifampin may decrease the effect of sulfonylurea, glisoxepide.
DB01289	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB01291	DB01193	Antagonism
DB01291	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pirbuterol.
DB01291	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pirbuterol.
DB01291	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pirbuterol.
DB01291	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pirbuterol.
DB01291	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pirbuterol.
DB01291	DB00187	Antagonism
DB01291	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pirbuterol.
DB01291	DB01247	Increased arterial pressure
DB01291	DB00598	Antagonism
DB01291	DB00601	Possible increase of arterial pressure
DB01291	DB00968	Increased arterial pressure
DB01291	DB00264	Antagonism
DB01291	DB00211	Increased arterial pressure
DB01291	DB01171	Moclobemide increases the sympathomimetic effect of pirbuterol.
DB01291	DB01203	Antagonism
DB01291	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pirbuterol.
DB01291	DB01580	Antagonism
DB01291	DB00780	Increased arterial pressure
DB01291	DB00960	Antagonism
DB01291	DB00571	Antagonism
DB01291	DB01367	Increased arterial pressure
DB01291	DB00206	Increased arterial pressure
DB01291	DB00373	Antagonism
DB01294	DB00819	The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide.
DB01294	DB00701	The antiacid decreases the absorption of amprenavir
DB01294	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB01294	DB00443	The corticosteroid, betamethasone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB01294	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB01294	DB01120	The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, gliclazide.
DB01294	DB01016	The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, glibenclamide.
DB01294	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB01294	DB00703	The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB01294	DB00563	The salicylate, bismuth subsalicylate, increases the effect and toxicity of methotrexate.
DB01294	DB01017	Formation of non-absorbable complexes
DB01294	DB00860	The corticosteroid, prednisolone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB01294	DB00635	The corticosteroid, prednisone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB01294	DB01032	The salicylate, bismuth subsalicylate, decreases the uricosuric effect of probenecid.
DB01294	DB00759	Formation of non-absorbable complexes
DB01294	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, bismuth subsalicylate.
DB01295	DB00672	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB01295	DB00575	Increased hypertension when clonidine stopped
DB01295	DB00320	Ischemia with risk of gangrene
DB01295	DB00280	The beta-blocker, bevantolol, may increase the toxicity of disopyramide.
DB01295	DB00668	Hypertension, then bradycardia
DB01295	DB00696	Ischemia with risk of gangrene
DB01295	DB01288	Antagonism
DB01295	DB00983	Antagonism
DB01295	DB01120	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB01295	DB01016	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB01295	DB01050	Risk of inhibition of renal prostaglandins
DB01295	DB00328	Risk of inhibition of renal prostaglandins
DB01295	DB00047	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB01295	DB00247	Ischemia with risk of gangrene
DB01295	DB00816	Antagonism
DB01295	DB00236	Antagonism
DB01295	DB00554	Risk of inhibition of renal prostaglandins
DB01295	DB00457	Risk of hypotension at the beginning of therapy
DB01295	DB00912	The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
DB01295	DB00871	Antagonism
DB01296	DB00672	Possible hyperglycemia
DB01296	DB00063	Monitor therapy due to enhanced antiplatelet effect.
DB01296	DB01120	Possible hyperglycemia
DB01296	DB00222	Possible hyperglycemia
DB01296	DB01016	Possible hyperglycemia
DB01296	DB00331	Possible hyperglycemia
DB01296	DB00491	Possible hyperglycemia
DB01296	DB00731	Possible hyperglycemia
DB01296	DB01132	Possibly hyperglycemia
DB01296	DB00912	Possible hyperglycemia
DB01296	DB00682	Possible interaction and enhanced antiplatelet activity of warfarin
DB01297	DB00414	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01297	DB00672	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01297	DB00575	Increased hypertension when clonidine stopped
DB01297	DB00320	Ischemia with risk of gangrene
DB01297	DB00280	The beta-blocker, practolol, may increase the toxicity of disopyramide.
DB01297	DB00668	Hypertension, then bradycardia
DB01297	DB00696	Ischemia with risk of gangrene
DB01297	DB01288	Antagonism
DB01297	DB00983	Antagonism
DB01297	DB01120	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01297	DB01016	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01297	DB01050	Risk of inhibition of renal prostaglandins
DB01297	DB00328	Risk of inhibition of renal prostaglandins
DB01297	DB00047	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01297	DB00247	Ischemia with risk of gangrene
DB01297	DB00816	Antagonism
DB01297	DB01580	Antagonism
DB01297	DB00912	The beta-blocker, practolol, may decrease symptoms of hypoglycemia.
DB01297	DB00871	Antagonism
DB01298	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB01298	DB00563	The sulfamide increases the toxicity of methotrexate
DB01299	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB01299	DB00563	The sulfamide increases the toxicity of methotrexate
DB01301	DB00459	Increased risk of intracranial hypertension
DB01301	DB01060	Possible antagonism of action
DB01301	DB00415	Possible antagonism of action
DB01301	DB01053	Possible antagonism of action
DB01301	DB00578	Possible antagonism of action
DB01301	DB00766	Possible antagonism of action
DB01301	DB01147	Possible antagonism of action
DB01301	DB00485	Possible antagonism of action
DB01301	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01301	DB00926	Increased risk of intracranial hypertension
DB01301	DB00301	Possible antagonism of action
DB01301	DB00982	Increased risk of intracranial hypertension
DB01301	DB00417	Possible antagonism of action
DB01301	DB00319	Possible antagonism of action
DB01301	DB01604	Possible antagonism of action
DB01301	DB01605	Possible antagonism of action
DB01303	DB00787	Aciclovir may increase the effect and toxicity of oxtriphylline.
DB01303	DB00640	This xanthine decreases the effect of adenosine
DB01303	DB01351	The barbiturate, amobarbital, decreases the effect of oxtriphylline.
DB01303	DB01352	The barbiturate, aprobarbital, decreases the effect of oxtriphylline.
DB01303	DB00732	Theophylline decreases the effect of muscle relaxant
DB01303	DB00237	The barbiturate, butabarbital, decreases the effect of oxtriphylline.
DB01303	DB00241	The barbiturate, butalbital, decreases the effect of oxtriphylline.
DB01303	DB01353	The barbiturate, butethal, decreases the effect of oxtriphylline.
DB01303	DB00564	Carbamazepine may decrease the serum concentration of oxtriphylline. Oxtriphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed.
DB01303	DB00521	Antagonism of action and increased effect of theophylline
DB01303	DB00501	Cimetidine may increase the serum concentration of oxtriphylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of oxtriphylline if cimetidine is initiated, discontinued or dose changed.
DB01303	DB00537	Ciprofloxacin may increase the effect of oxtriphylline.
DB01303	DB01211	Clarithromycin may increase the effect and toxicity of oxtriphylline.
DB01303	DB01341	The barbiturate, dihydroquinidine barbiturate, decreases the effect of oxtriphylline.
DB01303	DB00822	Disulfiram may increase the effect and toxicity of oxtriphylline.
DB01303	DB01135	Theophylline decreases the effect of muscle relaxant
DB01303	DB00467	Enoxacin may increase the effect of oxtriphylline.
DB01303	DB00199	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
DB01303	DB00977	The contraceptive increases the effect and toxicity of theophylline
DB01303	DB00754	Decreased effect of both products
DB01303	DB00176	Fluvoxamine may increase the therapeutic and adverse effects of oxtriphylline.
DB01303	DB01320	Decreased effect of both products
DB01303	DB00365	Grepafloxacin may increase the effect of oxtriphylline.
DB01303	DB01159	Increased risk of cardiac arrhythmia
DB01303	DB01354	The barbiturate, heptabarbital, decreases the effect of oxtriphylline.
DB01303	DB01355	The barbiturate, hexobarbital, decreases the effect of oxtriphylline.
DB01303	DB00034	Interferon increases the effect and toxicity of theophylline
DB01303	DB00105	Interferon increases the effect and toxicity of theophylline
DB01303	DB00011	Interferon increases the effect and toxicity of theophylline
DB01303	DB00951	Isoniazid may increase the effect and toxicity of oxtriphylline.
DB01303	DB01321	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
DB01303	DB01356	Theophylline decreases serum levels of lithium
DB01303	DB00532	Decreased effect of both products
DB01303	DB01357	The contraceptive increases the effect and toxicity of theophylline
DB01303	DB00474	The barbiturate, methohexital, decreases the effect of oxtriphylline.
DB01303	DB00849	The barbiturate, methylphenobarbital, decreases the effect of oxtriphylline.
DB01303	DB01336	Theophylline decreases the effect of muscle relaxant
DB01303	DB00379	Mexiletine increases the effect and toxicity of theophylline
DB01303	DB01226	Theophylline decreases the effect of muscle relaxant
DB01303	DB01203	Antagonism of action and increased effect of theophylline
DB01303	DB01059	Norfloxacin may increase the effect of oxtriphylline.
DB01303	DB01337	Theophylline decreases the effect of muscle relaxant
DB01303	DB00487	Pefloxacin may increase the effect of oxtriphylline.
DB01303	DB00008	Interferon increases the effect and toxicity of theophylline
DB01303	DB00022	Interferon increases the effect and toxicity of theophylline
DB01303	DB01359	Antagonism of action and increased effect of theophylline
DB01303	DB00312	The barbiturate, pentobarbital, decreases the effect of oxtriphylline.
DB01303	DB00806	Pentoxifylline increases the effect and toxicity of theophylline
DB01303	DB01174	The barbiturate, phenobarbital, decreases the effect of oxtriphylline.
DB01303	DB00252	Decreased effect of both products
DB01303	DB00960	Antagonism of action and increased effect of theophylline
DB01303	DB00794	The barbiturate, primidone, decreases the effect of oxtriphylline.
DB01303	DB01182	Propafenone increases the effect of theophylline
DB01303	DB00571	Antagonism of action and increased effect of theophylline
DB01303	DB01346	The barbiturate, quinidine barbiturate, decreases the effect of oxtriphylline.
DB01303	DB01045	Rifampin may decrease the effect and toxicity of oxtriphylline.
DB01303	DB00503	Ritonavir decreases the effect of theophylline
DB01303	DB00533	Rofecoxib increases the effect and toxicity of theophylline
DB01303	DB00418	The barbiturate, secobarbital, decreases the effect of oxtriphylline.
DB01303	DB00489	Antagonism of action and increased effect of theophylline
DB01303	DB01323	St. John's Wort decreases the effect of theophylline
DB01303	DB00382	Tacrine increases the effect and toxicity of theophylline
DB01303	DB00306	The barbiturate, talbutal, decreases the effect of oxtriphylline.
DB01303	DB00857	Terbinafine increases the effect and toxicity of theophylline
DB01303	DB00730	Thiabendazole increases the effect and toxicity of theophylline
DB01303	DB00208	Ticlopidine increases the effect and toxicity of theophylline
DB01303	DB00373	Antagonism of action and increased effect of theophylline
DB01303	DB01361	The macrolide, troleandomycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
DB01303	DB01199	Theophylline decreases the effect of muscle relaxant
DB01303	DB01339	Theophylline decreases the effect of muscle relaxant
DB01303	DB00661	Verapamil increases the effect of theophylline
DB01303	DB00744	Zileuton increases the effect and toxicity of theophylline
DB01306	DB01193	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01306	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01306	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01306	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01306	DB00636	Increases the effect of insulin
DB01306	DB01406	Monitor therapy due to decreased hypoglycemic effect of insulin aspart.
DB01306	DB01191	Fenfluramine increases the effect of insulin
DB01306	DB00974	Monitor therapy due to enhanced hypoglycemic effect.
DB01306	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01306	DB00574	Fenfluramine increases the effect of insulin
DB01306	DB00082	Monitor therapy due to enhanced hypoglycemic effect.
DB01306	DB00052	Somatropin may antagonize the hypoglycemic effect of insulin aspart. Monitor for changes in fasting and postprandial blood sugars.
DB01307	DB01193	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01307	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01307	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01307	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01307	DB00636	Increases the effect of insulin
DB01307	DB01191	Fenfluramine increases the effect of insulin
DB01307	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01307	DB00574	Fenfluramine increases the effect of insulin
DB01307	DB00052	Somatropin may antagonize the hypoglycemic effect of insulin detemir. Monitor for changes in fasting and postprandial blood sugars.
DB01309	DB01193	The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
DB01309	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01309	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01309	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01309	DB00636	Increases the effect of insulin
DB01309	DB01191	Fenfluramine increases the effect of insulin
DB01309	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01309	DB00574	Fenfluramine increases the effect of insulin
DB01309	DB00052	Somatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars.
DB01319	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Fosamprenavir. The antiviral response should be closely monitored.
DB01319	DB01418	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of acenocoumarol.
DB01319	DB00404	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam.
DB01319	DB01370	The antiacid decreases the absorption of amprenavir
DB01319	DB01118	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of amiodarone.
DB01319	DB01125	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of anisindione.
DB01319	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01319	DB01076	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB01244	Amprenavir increases the effect and toxicity of bepridil
DB01319	DB01558	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if fosamprenavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01319	DB01373	The antiacid decreases the absorption of amprenavir
DB01319	DB00604	Amprenavir increases the effect and toxicity of cisapride
DB01319	DB00628	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate.
DB01319	DB00091	The protease inhibitor, fosamprenavir, may increase the effect of cyclosporine.
DB01319	DB01219	Fosamprenavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00705	Decreased levels of delavirdine with increased levels of amprenavir
DB01319	DB00829	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, diazepam.
DB01319	DB00266	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of dicumarol.
DB01319	DB00320	Amprenavir increases the effect and toxicity of ergot derivative
DB01319	DB00696	Amprenavir increases the effect and toxicity of ergot derivative
DB01319	DB06414	Fosamprenavir, when administered concomitantly with etravirine, may experience an increase in the serum concentration of its active metabolits. It is recommended to avoid this combination.
DB01319	DB00813	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fentanyl.
DB01319	DB00690	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam.
DB01319	DB02703	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid.
DB01319	DB00227	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB01319	DB08815	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB01319	DB01378	The antiacid decreases the absorption of amprenavir
DB01319	DB01377	The antiacid decreases the absorption of amprenavir
DB01319	DB00333	The protease inhibitor, fosamprenavir, may decrease the effect of methadone.
DB01319	DB00683	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, midazolam.
DB01319	DB01100	Amprenavir increases the effect and toxicity of pimozide
DB01319	DB00243	Increased levels of ranolazine - risk of toxicity
DB01319	DB00615	Amprenavir increases the effect and toxicity of rifabutin
DB01319	DB01045	Rifampin may decrease the effectiveness of fosamprenavir.
DB01319	DB00203	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of sildenafil.
DB01319	DB00641	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB01323	St. John's Wort decreases the effect of indinavir
DB01319	DB00864	The protease inhibitor, Fosamprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Fosamprenavir therapy is initiated, discontinued or altered.
DB01319	DB00820	Fosamprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01319	DB00675	Fosmprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
DB01319	DB00706	Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fosamprenavir is initiated, discontinued, or dose changed.
DB01319	DB00976	Fosamprevavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB01319	DB06287	Fosamprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01319	DB00444	The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01319	DB00906	The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Fosamprenavir. Consider alternate therapy.
DB01319	DB01036	Fosamprenavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01319	DB00193	Fosamprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB01319	DB00656	The protease inhibitor, Fosamprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00897	Fosamprenavir may increase the effect and toxicity of the benzodiazepine, triazolam.
DB01319	DB00726	The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00862	Fosamprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01319	DB00285	Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Fosamprenavir is initiated, discontinued, or dose changed.
DB01319	DB00661	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00570	Fosamprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00541	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00361	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00582	Voriconazole may increase the serum concentration of fosamprenavir by decreasing its metabolism. Fosamprenavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
DB01319	DB00682	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of warfarin.
DB01319	DB00425	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB00909	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if fosamprenavir is initiated, discontinued or dose changed.
DB01319	DB01198	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if fosamprenavir is initiated, discontinued or dose changed.
DB01320	DB01418	Increased hydantoin levels and risk of bleeding
DB01320	DB00404	Fosphenytoin may increase the metabolism of alprazolam via CYP3A4.
DB01320	DB01223	Decreased effect of both products
DB01320	DB01118	Amiodarone may increase the effect of fosphenytoin.
DB01320	DB01125	Increased hydantoin levels and risk of bleeding
DB01320	DB00673	The CYP3A4 inducer, fosphenytoin, may decrease the effect of aprepitant.
DB01320	DB00732	Phenytoin decreases the effect of muscle relaxant
DB01320	DB00443	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, betamethasone.
DB01320	DB00290	The antineoplasic agent decreases the effect of hydantoin
DB01320	DB08873	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB01320	DB01101	Capecitabine increases the effect of hydantoin
DB01320	DB00958	The antineoplasic agent decreases the effect of hydantoin
DB01320	DB00262	The antineoplasic agent decreases the effect of hydantoin
DB01320	DB00446	Increases phenytoin, modifies chloramphenicol
DB01320	DB00475	Fosphenytoin may increase the metabolism of chlordiazepoxide via CYP3A4.
DB01320	DB00269	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, chlorotrianisene.
DB01320	DB01114	The antihistamine increases the effect of hydantoin
DB01320	DB00501	Cimetidine may increase the serum concentration of fosphenytoin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fosphenytoin if cimetidine is initiated, discontinued or dose changed.
DB01320	DB00515	The antineoplasic agent decreases the effect of hydantoin
DB01320	DB01211	Clarithromycin may increase the therapeutic and adverse effects of fosphenytoin.
DB01320	DB00882	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, clomifene.
DB01320	DB00628	Fosphenytoin may increase the metabolism of clorazepate via CYP3A4.
DB01320	DB00363	Hydantoin decreases the effect of clozapine
DB01320	DB00286	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, conjugated estrogens.
DB01320	DB01380	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, cortisone acetate.
DB01320	DB00091	The hydantoin decreases the effect of cyclosporine
DB01320	DB00705	The anticonvulsant, fosphenytoin, decreases the effect of delavirdine.
DB01320	DB01234	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, dexamethasone.
DB01320	DB00829	Fosphenytoin may increase the metabolism of diazepam via CYP3A4.
DB01320	DB01119	Diazoxide decreases the hydantoin effect
DB01320	DB00266	Increased hydantoin levels and risk of bleeding
DB01320	DB00255	The enzyme inducer, fosphenytoin, may decrease the therapeutic effect of diethylstilbestrol.
DB01320	DB00280	The hydantoin decreases the effect of disopyramide
DB01320	DB00822	Disulfiram may increase the effect of fosphenytoin.
DB01320	DB00988	Risk of severe hypotension
DB01320	DB01135	Phenytoin decreases the effect of muscle relaxant
DB01320	DB00254	The anticonvulsant, fosphenytoin, decreases the effect of doxycycline.
DB01320	DB00651	Decreased effect of both products
DB01320	DB00783	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estradiol.
DB01320	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB01320	DB04573	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estriol.
DB01320	DB00655	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estrone.
DB01320	DB04574	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estropipate.
DB01320	DB00977	This product may cause a slight decrease of contraceptive effect
DB01320	DB06414	Etravirine, when administered concomitantly with fosphenytoin, may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB01320	DB00949	Increased phenytoin levels and decreased felbamate levels
DB01320	DB01023	The hydantoin decreases the effect of felodipine
DB01320	DB00196	Fluconazole may increase the effect of hydantoin.
DB01320	DB00687	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, fludrocortisone.
DB01320	DB00544	Fluorouracil increases the effect of hydantoin
DB01320	DB00472	Fluoxetine increases the effect of phenytoin
DB01320	DB00690	Fosphenytoin may increase the metabolism of flurazepam via CYP3A4.
DB01320	DB00176	Fluvoxamine may increase the therapeutic and adverse effects of fosphenytoin.
DB01320	DB00158	Folic acid decreases the levels of hydantoin
DB01320	DB00695	The hydantoin decreases the effect of furosemide
DB01320	DB00996	Gabapentin may increase the effect of fosphenytoin.
DB01320	DB00317	The CYP3A4 inducer, fosphenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01320	DB00741	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
DB01320	DB00619	The hydantoin decreases the levels of imatinib
DB01320	DB00762	The hydantoin decreases the effect of irinotecan
DB01320	DB00951	Isoniazid may increase the effect of phenytoin in 20% of patients.
DB01320	DB01167	Phenytoin decreases the effect of itraconazole
DB01320	DB01235	The hydantoin decreases the effect of levodopa
DB01320	DB00555	Phenytoin may reduce levels of lamotrigine
DB01320	DB00367	Phenytoin decreases the contraceptive effect
DB01320	DB01601	Levels of both drugs are affected
DB01320	DB08815	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB01320	DB00643	The hydantoin decreases the efficiency of mebendazole
DB01320	DB00603	The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, medroxyprogesterone.
DB01320	DB00351	The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, megestrol.
DB01320	DB01357	This product may cause a slight decrease of contraceptive effect
DB01320	DB00333	The hydantoin decreases the effect of methadone
DB01320	DB00563	The antineoplasic agent decreases the effect of hydantoin
DB01320	DB00553	The hydantoin decreases the effect of psoralene
DB01320	DB00959	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, methylprednisolone.
DB01320	DB01336	Phenytoin decreases the effect of muscle relaxant
DB01320	DB01011	The combination renders the test invalid
DB01320	DB00379	The hydantoin decreases the effect of mexiletine
DB01320	DB00683	Fosphenytoin may increase the metabolism of midazolam via CYP3A4.
DB01320	DB00370	The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects
DB01320	DB01226	Phenytoin decreases the effect of muscle relaxant
DB01320	DB00401	Phenytoin decreases the efficiency of nisoldipine
DB01320	DB00717	This product may cause a slight decrease of contraceptive effect
DB01320	DB00338	Omeprazole increases the effect of hydantoin
DB01320	DB00776	Oxcarbazepine increases the effect of hydantoin
DB01320	DB01303	Decreased effect of both products
DB01320	DB03585	The NSAID, oxphenbutazone, may increase the hydantoin effect of fosphenytoin.
DB01320	DB01337	Phenytoin decreases the effect of muscle relaxant
DB01320	DB01384	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, paramethasone.
DB01320	DB00812	The NSAID, phenylbutazone, may increase the hydantoin effect of fosphenytoin.
DB01320	DB01263	Modifications of drug levels for both agents
DB01320	DB00860	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisolone.
DB01320	DB00635	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone.
DB01320	DB01224	Phenytoin decreases the effect of quetiapine
DB01320	DB04575	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, quinestrol.
DB01320	DB00908	The anticonvulsant, fosphenytoin, decreases the effect of quinidine.
DB01320	DB01369	This combination presents an increased risk of toxicity
DB01320	DB01045	Rifampin may decrease the effect of fosphenytoin.
DB01320	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01320	DB01104	Sertraline increases the effect of hydantoin
DB01320	DB00877	The hydantoin decreases sirolimus levels
DB01320	DB00364	Sucralfate decreases the effect of hydantoin
DB01320	DB00359	The sulfonamide increases the effect of hydantoin
DB01320	DB00576	The sulfonamide increases the effect of hydantoin
DB01320	DB00864	The hydantoin decreases the effect of tacrolimus
DB01320	DB00976	Fosphenytoin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
DB01320	DB06287	Fosphenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB01320	DB00277	Decreased effect of both products
DB01320	DB04572	Possible increase in thiotepa levels
DB01320	DB00208	Ticlopidine may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for adverse/toxic effects of Fosphenytoin if Ticlopidine is initiated, discontinued or dose changed.
DB01320	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for changes in Fosphenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01320	DB00273	Increased phenytoin/decreased topiramate
DB01320	DB00193	Fosphenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
DB01320	DB00656	The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed.
DB01320	DB00755	The strong CYP2C8 inducer, Fosphenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Fosphenytoin is initiated, discontinued or dose changed.
DB01320	DB00620	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone.
DB01320	DB00897	Fosphenytoin may increase the metabolism of triazolam via CYP3A4.
DB01320	DB00440	Trimethoprim increases the effect of hydantoin
DB01320	DB04571	The hydantoin decreases the effect of psoralene
DB01320	DB00427	The CNS depressants, Triprolidine and Fosphenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01320	DB01199	Phenytoin decreases the effect of muscle relaxant
DB01320	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB01320	DB01339	Phenytoin decreases the effect of muscle relaxant
DB01320	DB01080	Vigabatrin decreases the effect of hydantoin
DB01320	DB00570	The antineoplasic agent decreases the effect of hydantoin
DB01320	DB00582	The hydantoin decreases the effect of voriconazole
DB01320	DB00682	Increased hydantoin levels and risk of bleeding
DB01321	DB00404	The macrolide, josamycin, may increase the effect of the benzodiazepine, alprazolam.
DB01321	DB01223	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
DB01321	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB01076	The macrolide, josamycin, may increase the toxicity of the statin, atorvastatin.
DB01321	DB01200	Erythromycin increases serum levels of bromocriptine
DB01321	DB00490	The macrolide, josamycin, may increase the effect and toxicity of buspirone.
DB01321	DB00564	The macrolide, josamycin, may increase the effect of carbamazepine.
DB01321	DB00439	The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin.
DB01321	DB01166	Erythromycin increases the effect of cilostazol
DB01321	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB00215	Possible serotoninergic sydrome with this combination
DB01321	DB00363	Erythromycin increases the effect of clozapine
DB01321	DB00091	The macrolide, josamycin, may increase the effect of cyclosporine.
DB01321	DB00829	The macrolide, josamycin, may increase the effect of the benzodiazepine, diazepam.
DB01321	DB00390	The macrolide, josamycin, may increase the effect of digoxin in 10% of patients.
DB01321	DB00320	Possible ergotism and severe ischemia with this combination
DB01321	DB01248	Josamycin may increase the serum levels and toxicity of docetaxel.
DB01321	DB00696	Possible ergotism and severe ischemia with this combination
DB01321	DB01023	Erythromycin increases the effect of felodipine
DB01321	DB00472	Possible serotoninergic syndrome with this combination
DB01321	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB00619	The macrolide, josamycin, may increase the serum concentration of imatinib.
DB01321	DB01167	The macrolide, josamycin, may increase the effect and toxicity of itraconazole.
DB01321	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB00227	The macrolide, josamycin, may increase the toxicity of the statin, lovastatin.
DB01321	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB00247	Possible ergotism and severe ischemia with this combination
DB01321	DB00683	The macrolide, josamycin, may increase the effect of the benzodiazepine, midazolam.
DB01321	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB01303	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
DB01321	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB00912	The macrolide, josamycin, may increase the effect of repaglinide.
DB01321	DB00615	The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin.
DB01321	DB01045	The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin.
DB01321	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB00277	The macrolide, josamycin, may increase the effect and toxicity of theophylline.
DB01321	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01321	DB00897	The macrolide, josamycin, may increase the effect of the benzodiazepine, triazolam.
DB01322	DB00404	Kava may increase the effect of the benzodiazepine, alprazolam.
DB01322	DB00475	Kava may increase the effect of the benzodiazepine, chlordiazepoxide.
DB01322	DB00349	Kava may increase the effect of the benzodiazepine, clobazam.
DB01322	DB01068	Kava may increase the effect of the benzodiazepine, clonazepam.
DB01322	DB00628	Kava may increase the effect of the benzodiazepine, clorazepate.
DB01322	DB00829	Kava may increase the effect of the benzodiazepine, diazepam.
DB01322	DB01215	Kava may increase the effect of the benzodiazepine, estazolam.
DB01322	DB00690	Kava may increase the effect of the benzodiazepine, flurazepam.
DB01322	DB00186	Kava may increase the effect of the benzodiazepine, lorazepam.
DB01322	DB00683	Kava may increase the effect of the benzodiazepine, midazolam.
DB01322	DB00842	Kava may increase the effect of the benzodiazepine, oxazepam.
DB01322	DB00231	Kava may increase the effect of the benzodiazepine, temazepam.
DB01322	DB00897	Kava may increase the effect of the benzodiazepine, triazolam.
DB01323	DB00404	St. John's Wort may decrease the effect of the benzodiazepine, alprazolam.
DB01323	DB01223	St. John's Wort decreases the effect of theophylline
DB01323	DB00701	St. John's Wort decreases the effect of indinavir
DB01323	DB01072	St. John's Wort decreases the levels/effects of atazanavir
DB01323	DB06626	Avoid combination due to the likely decreased levels of axitinib.
DB01323	DB08873	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB01323	DB06772	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB01323	DB08875	Avoid combination. May decrease concentration of cabozantinib. Also avoid all other strong CYP3A4 inducers.
DB01323	DB00215	St. John's Wort increases the effect and toxicity of the SSRI, citalopram.
DB01323	DB01068	St. John's Wort may decrease the effect of the benzodiazepine, clonazepam.
DB01323	DB00091	St. John's Wort decreases the effect of cyclosporine
DB01323	DB00705	St. John's Wort decreases the antiretroviral effect
DB01323	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01323	DB00829	St. John's Wort may decrease the effect of the benzodiazepine, diazepam.
DB01323	DB00390	St. John's Wort decreases the effect of digoxin
DB01323	DB00625	St. John's Wort decreases the antiretroviral effect
DB01323	DB00530	Decreased levels/effect of erlotinib
DB01323	DB01175	St. John's Wort increases the effect and toxicity of the SSRI, escitalopram.
DB01323	DB08866	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB01323	DB00977	St. John's Wort could reduce the contraceptive effect
DB01323	DB06414	Etravirine may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB01323	DB00472	St. John's Wort increases the effect and toxicity of the SSRI, fluoxetine.
DB01323	DB00176	St. John's Wort increases the effect and toxicity of the SSRI, fluvoxamine.
DB01323	DB01319	St. John's Wort decreases the effect of indinavir
DB01323	DB00317	The CYP3A4 inducer, St. John's Wort, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01323	DB00619	St. John's Wort decreases levels of imatinib
DB01323	DB00224	St. John's Wort decreases the effect of indinavir
DB01323	DB08820	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB01323	DB00333	St. John's Wort decreases levels/effect of methadone
DB01323	DB00683	St. John's Wort may decrease the effect of the benzodiazepine, midazolam.
DB01323	DB01149	St. John's Wort increases the effect and toxicity of the SSRI, nefazodone.
DB01323	DB00220	St. John's Wort decreases the effect of indinavir
DB01323	DB00238	St. John's Wort decreases nevirapine effect
DB01323	DB01115	St. John's Wort decreases the effect of nifedipine
DB01323	DB00717	St. John's Wort could reduce the contraceptive effect
DB01323	DB00338	St. John's Wort decreases the levels/effects of omeprazole
DB01323	DB01303	St. John's Wort decreases the effect of theophylline
DB01323	DB01229	Avoid combination due to potential decrease in serum concentration of paclitaxel.
DB01323	DB00715	St. John's Wort increases the effect and toxicity of the SSRI, paroxetine.
DB01323	DB08883	Avoid combination due to the potential decrease in perampanel concentration.
DB01323	DB01367	Increased risk of toxicity with this association
DB01323	DB08896	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB01323	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01323	DB00864	St. John's Wort may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if St. John's Wort therapy is initiated, discontinued or altered.
DB01323	DB06287	St. John's Wort may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB01323	DB00277	St. John's Wort decreases the effect of theophylline
DB01323	DB00932	St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided.
DB01323	DB06212	St. John's Wort is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB01323	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01323	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01323	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01323	DB00897	St. John's Wort may decrease the effect of the benzodiazepine, triazolam.
DB01323	DB00726	St. John's Wort may decrease serum concentrations of Trimipramine. Possible increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if St. John's Wort is initiated, discontinued or dose changed.
DB01323	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB01323	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB01323	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01323	DB00582	St. John's Wort may decrease the serum concentration of voriconazole by increasing its elimination. Concomitant therapy is contraindicated.
DB01323	DB00682	St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed.
DB01323	DB00315	Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01324	DB00390	Possible electrolyte variations and arrhythmias
DB01324	DB01356	The thiazide diuretic, polythiazide, may increase serum levels of lithium.
DB01324	DB00519	The thiazide diuretic, Polythiazide, may increase the hypotensive effect of Trandolapril. Polythiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy.
DB01324	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01325	DB00390	Possible electrolyte variations and arrhythmias
DB01325	DB01356	The thiazide diuretic, quinethazone, may increase serum levels of lithium.
DB01326	DB00479	Increased risk of nephrotoxicity
DB01326	DB00798	Increased risk of nephrotoxicity
DB01326	DB00955	Increased risk of nephrotoxicity
DB01326	DB01032	Probenecid may increase the serum level of cefamandole.
DB01326	DB00684	Increased risk of nephrotoxicity
DB01327	DB00479	Increased risk of nephrotoxicity
DB01327	DB00798	Increased risk of nephrotoxicity
DB01327	DB00955	Increased risk of nephrotoxicity
DB01327	DB01032	Probenecid may increase the serum level of cefazolin.
DB01327	DB00684	Increased risk of nephrotoxicity
DB01328	DB00479	Increased risk of nephrotoxicity
DB01328	DB00798	Increased risk of nephrotoxicity
DB01328	DB00955	Increased risk of nephrotoxicity
DB01328	DB01032	Probenecid may increase the serum level of cefonicib.
DB01328	DB00684	Increased risk of nephrotoxicity
DB01329	DB00479	Increased risk of nephrotoxicity
DB01329	DB00798	Increased risk of nephrotoxicity
DB01329	DB00955	Increased risk of nephrotoxicity
DB01329	DB00684	Increased risk of nephrotoxicity
DB01330	DB01418	The cephalosporin, cefotetan, may increase the anticoagulant effect of acenocoumarol.
DB01330	DB00479	Increased risk of nephrotoxicity
DB01330	DB01125	The cephalosporin, cefotetan, may increase the anticoagulant effect of anisindione.
DB01330	DB00266	The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol.
DB01330	DB00798	Increased risk of nephrotoxicity
DB01330	DB01172	Increased risk of nephrotoxicity
DB01330	DB00994	Increased risk of nephrotoxicity
DB01330	DB00955	Increased risk of nephrotoxicity
DB01330	DB01032	Probenecid may increase the serum level of cefotetan.
DB01330	DB01082	Increased risk of nephrotoxicity
DB01330	DB00684	Increased risk of nephrotoxicity
DB01330	DB00682	The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin.
DB01331	DB01418	The cephalosporin, cefoxitin, may increase the anticoagulant effect of acenocoumarol.
DB01331	DB00479	Increased risk of nephrotoxicity
DB01331	DB01125	The cephalosporin, cefoxitin, may increase the anticoagulant effect of anisindione.
DB01331	DB00266	The cephalosporin, cefoxitin, may increase the anticoagulant effect of dicumarol.
DB01331	DB00798	Increased risk of nephrotoxicity
DB01331	DB01172	Increased risk of nephrotoxicity
DB01331	DB00994	Increased risk of nephrotoxicity
DB01331	DB00955	Increased risk of nephrotoxicity
DB01331	DB01032	Probenecid may increase the serum level of cefoxitin.
DB01331	DB01082	Increased risk of nephrotoxicity
DB01331	DB00684	Increased risk of nephrotoxicity
DB01331	DB00682	The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin.
DB01332	DB00479	Increased risk of nephrotoxicity
DB01332	DB00798	Increased risk of nephrotoxicity
DB01332	DB00955	Increased risk of nephrotoxicity
DB01332	DB01032	Probenecid may increase the serum level of ceftizoxime.
DB01332	DB00684	Increased risk of nephrotoxicity
DB01333	DB00479	Increased risk of nephrotoxicity
DB01333	DB00798	Increased risk of nephrotoxicity
DB01333	DB00955	Increased risk of nephrotoxicity
DB01333	DB01032	Probenecid may increase the serum level of cefradine.
DB01333	DB00684	Increased risk of nephrotoxicity
DB01336	DB00479	The agent increases the effect of muscle relaxant
DB01336	DB01223	Theophylline decreases the effect of muscle relaxant
DB01336	DB00993	The agent decreases the effect of the muscle relaxant
DB01336	DB00564	Decreases the effect of muscle relaxant
DB01336	DB01190	The agent increases the effect of muscle relaxant
DB01336	DB01320	Phenytoin decreases the effect of muscle relaxant
DB01336	DB00798	The agent increases the effect of muscle relaxant
DB01336	DB01627	The agent increases the effect of muscle relaxant
DB01336	DB01033	The agent dereases the effect of the muscle relaxant
DB01336	DB00955	The agent increases the effect of muscle relaxant
DB01336	DB01303	Theophylline decreases the effect of muscle relaxant
DB01336	DB00252	Phenytoin decreases the effect of the muscle relaxant
DB01336	DB00319	The agent increases the effect of the muscle relaxant
DB01336	DB00908	The quinine derivative increases the effect of the muscle relaxant
DB01336	DB00468	The quinine derivative increases the effect of the muscle relaxant
DB01336	DB00277	Theophylline decreases the effect of the muscle relaxant
DB01336	DB00684	The agent increases the effect of the muscle relaxant
DB01337	DB00479	The agent increases the effect of muscle relaxant
DB01337	DB01223	Theophylline decreases the effect of muscle relaxant
DB01337	DB00993	The agent decreases the effect of the muscle relaxant
DB01337	DB00564	Decreases the effect of muscle relaxant
DB01337	DB01190	The agent increases the effect of muscle relaxant
DB01337	DB01111	Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).
DB01337	DB01320	Phenytoin decreases the effect of muscle relaxant
DB01337	DB00798	The agent increases the effect of muscle relaxant
DB01337	DB01627	The agent increases the effect of muscle relaxant
DB01337	DB01033	The agent dereases the effect of the muscle relaxant
DB01337	DB00955	The agent increases the effect of muscle relaxant
DB01337	DB01303	Theophylline decreases the effect of muscle relaxant
DB01337	DB00252	Phenytoin decreases the effect of the muscle relaxant
DB01337	DB00319	The agent increases the effect of the muscle relaxant
DB01337	DB00908	The quinine derivative increases the effect of the muscle relaxant
DB01337	DB00468	The quinine derivative increases the effect of the muscle relaxant
DB01337	DB00277	Theophylline decreases the effect of the muscle relaxant
DB01337	DB00684	The agent increases the effect of the muscle relaxant
DB01338	DB00479	The agent increases the effect of muscle relaxant
DB01338	DB01190	The agent increases the effect of muscle relaxant
DB01338	DB00798	The agent increases the effect of muscle relaxant
DB01338	DB01627	The agent increases the effect of muscle relaxant
DB01338	DB00955	The agent increases the effect of muscle relaxant
DB01338	DB00319	The agent increases the effect of the muscle relaxant
DB01338	DB00684	The agent increases the effect of the muscle relaxant
DB01339	DB00479	The agent increases the effect of muscle relaxant
DB01339	DB01223	Theophylline decreases the effect of muscle relaxant
DB01339	DB00993	The agent decreases the effect of the muscle relaxant
DB01339	DB00443	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB00564	Decreases the effect of muscle relaxant
DB01339	DB01190	The agent increases the effect of muscle relaxant
DB01339	DB01111	Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
DB01339	DB01285	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Corticotropin. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB01380	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB01234	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Dexamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB00687	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB01320	Phenytoin decreases the effect of muscle relaxant
DB01339	DB00798	The agent increases the effect of muscle relaxant
DB01339	DB00741	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB01627	The agent increases the effect of muscle relaxant
DB01339	DB01033	The agent dereases the effect of the muscle relaxant
DB01339	DB00959	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB00955	The agent increases the effect of muscle relaxant
DB01339	DB01303	Theophylline decreases the effect of muscle relaxant
DB01339	DB00252	Phenytoin decreases the effect of the muscle relaxant
DB01339	DB00319	The agent increases the effect of the muscle relaxant
DB01339	DB00781	Polymyxin B may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
DB01339	DB00860	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB00635	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01339	DB00908	The quinine derivative increases the effect of the muscle relaxant
DB01339	DB00468	Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided.
DB01339	DB00277	Theophylline decreases the effect of the muscle relaxant
DB01339	DB00684	The agent increases the effect of the muscle relaxant
DB01339	DB00620	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01340	DB00594	Increased risk of hyperkalemia
DB01340	DB01395	Increased risk of hyperkalemia
DB01340	DB01356	The ACE inhibitor increases serum levels of lithium
DB01340	DB01345	Increased risk of hyperkalemia
DB01340	DB00421	Increased risk of hyperkalemia
DB01340	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB01340	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01340	DB00384	Increased risk of hyperkalemia
DB01341	DB00594	Decreases the antiarrhythmic effect of quinidine
DB01341	DB01223	The barbiturate, dihydroquinidine barbiturate, decreases the effect of aminophylline.
DB01341	DB01118	Increases the effect of quinidine
DB01341	DB00321	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, amitriptyline.
DB01341	DB01238	Quinidine increases the effect and toxicity of aripiprazole
DB01341	DB01072	Increased risk of cardiotoxicity and arrhythmias
DB01341	DB00443	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
DB01341	DB00501	Increases the effect of quinidine
DB01341	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01341	DB01242	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, clomipramine.
DB01341	DB00318	Quinidine decreases the analgesic effect of codeine
DB01341	DB00091	The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine.
DB01341	DB01151	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, desipramine.
DB01341	DB01234	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone.
DB01341	DB00514	Quinidine increases the toxicity of dextromethorphan
DB01341	DB00390	Quinine/quinidine increases the effect of digoxin
DB01341	DB00343	Increases the effect and toxicity of quinidine
DB01341	DB01142	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, doxepin.
DB01341	DB00254	The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline.
DB01341	DB01023	The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine.
DB01341	DB00687	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.
DB01341	DB00158	Folic acid decreases the effect of anticonvulsant, dihydroquinidine barbiturate.
DB01341	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB01341	DB00317	The CYP3A4 inducer, dihydroquinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01341	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01341	DB00400	The barbiturate, dihydroquinidine barbiturate, decreases the effect of griseofulvin.
DB01341	DB00741	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
DB01341	DB00458	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, imipramine.
DB01341	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01341	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01341	DB01378	The antiacid decreases the absorption of quinidine
DB01341	DB00333	The barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone.
DB01341	DB00916	The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole.
DB01341	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB01341	DB00220	Nelfinavir increases the effect and toxicity of quindine
DB01341	DB01115	Decreased quinidine effect, increased nifedipine effect
DB01341	DB00540	Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline.
DB01341	DB01165	Increased risk of cardiotoxicity and arrhythmias
DB01341	DB01303	The barbiturate, dihydroquinidine barbiturate, decreases the effect of oxtriphylline.
DB01341	DB00860	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
DB01341	DB00635	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
DB01341	DB01035	Quinidine increases the effect of procainamide
DB01341	DB01182	Quinidine increases the effect of propafenone
DB01341	DB00908	The anticonvulsant, dihydroquinidine. barbiturate, decreases the effect of quinidine.
DB01341	DB01369	This combination presents an increased risk of toxicity
DB01341	DB00277	The barbiturate, dihydroquinidine barbiturate, decreases the effect of theophylline.
DB01341	DB00620	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
DB01342	DB00594	Increased risk of hyperkalemia
DB01342	DB01356	The ARB increases serum levels of lithium
DB01342	DB01345	Increased risk of hyperkalemia
DB01342	DB00384	Increased risk of hyperkalemia
DB01344	DB01370	Risk of alkalosis in renal impairment
DB01344	DB00594	Risk of alkalosis in renal impairment
DB01344	DB01373	Formation of non-absorbable complexes
DB01344	DB00700	Risk of alkalosis in renal impairment
DB01344	DB01378	Risk of alkalosis in renal impairment
DB01344	DB01345	Risk of alkalosis in renal impairment
DB01344	DB00421	Risk of alkalosis in renal impairment
DB01344	DB00384	Antagonism of action
DB01345	DB00594	Increased risk of hyperkalemia
DB01345	DB00542	Increased risk of hyperkalemia
DB01345	DB00796	Increased risk of hyperkalemia
DB01345	DB01197	Increased risk of hyperkalemia
DB01345	DB01340	Increased risk of hyperkalemia
DB01345	DB01395	Increased risk of hyperkalemia
DB01345	DB00584	Increased risk of hyperkalemia
DB01345	DB00700	This association presents an increased risk of hyperkalemia
DB01345	DB00876	Increased risk of hyperkalemia
DB01345	DB01342	Increased risk of hyperkalemia
DB01345	DB00492	Increased risk of hyperkalemia
DB01345	DB01029	Increased risk of hyperkalemia
DB01345	DB00722	Increased risk of hyperkalemia
DB01345	DB01356	The urine alkalizer decreases the effect of lithium
DB01345	DB00678	Increased risk of hyperkalemia
DB01345	DB00691	Increased risk of hyperkalemia
DB01345	DB00790	Increased risk of hyperkalemia
DB01345	DB01344	Risk of alkalosis in renal impairment
DB01345	DB00881	Increased risk of hyperkalemia
DB01345	DB00178	Increased risk of hyperkalemia
DB01345	DB01347	Increased risk of hyperkalemia
DB01345	DB01348	Increased risk of hyperkalemia
DB01345	DB00421	Increased risk of hyperkalemia
DB01345	DB01349	Increased risk of hyperkalemia
DB01345	DB00966	Potassium may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use.
DB01345	DB00519	Increased risk of hyperkalemia
DB01345	DB00384	Increased risk of hyperkalemia
DB01345	DB00177	Increased risk of hyperkalemia
DB01346	DB00594	Decreases the antiarrhythmic effect of quinidine
DB01346	DB01223	The barbiturate, quinidine barbiturate, decreases the effect of aminophylline.
DB01346	DB01118	Increases the effect of qiunidine
DB01346	DB00321	Quinidine barbiturate increases the effect of tricyclic antidepressant, amitriptyline.
DB01346	DB01238	Quinidine increases the effect and toxicity of aripiprazole
DB01346	DB01072	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB01346	DB00443	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
DB01346	DB00501	Increases the effect of quinidine
DB01346	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB01211	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB01242	Quinidine barbiturate increases the effect of tricyclic antidepressant, clomipramine.
DB01346	DB00318	Quinidine decreases the analgesic effect of codeine
DB01346	DB00091	The barbiturate, quinidine barbiturate, increases the effect of cyclosporine.
DB01346	DB01151	Quinidine barbiturate increases the effect of tricyclic antidepressant, desipramine.
DB01346	DB01234	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone.
DB01346	DB00514	Quinidine increases the toxicity of dextromethorphan
DB01346	DB00390	Quinine/quinidine increases the effect of digoxin
DB01346	DB00343	Increases the effect and toxicity of quinidine
DB01346	DB00843	Possible antagonism of action
DB01346	DB01142	Quinidine barbiturate increases the effect of tricyclic antidepressant, doxepin.
DB01346	DB00254	The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline.
DB01346	DB00199	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB01023	The barbiturate, quinidine barbiturate, decreases the effect of felodipine.
DB01346	DB00687	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.
DB01346	DB00158	Folic acid decreases the effect of anticonvulsant, quinidine barbiturate.
DB01346	DB00674	Possible antagonism of action
DB01346	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00317	The CYP3A4 inducer, quinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01346	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00400	The barbiturate, quinidine barbiturate, decreases the effect of griseofulvin.
DB01346	DB00741	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
DB01346	DB00458	Quinidine barbiturate increases the effect of tricyclic antidepressant, imipramine.
DB01346	DB01167	Itraconazole may increase the effect and toxicity of quinidine barbiturate.
DB01346	DB01026	Ketoconazole may increase the effect and toxicity of quinidine barbiturate.
DB01346	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01346	DB01378	The antiacid decreases the absorption of quinidine
DB01346	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00333	The barbiturate, quinidine barbiturate, decreases the effect of methadone.
DB01346	DB00916	The barbiturate, quinidine barbiturate, decreases the effect of metronidazole.
DB01346	DB00218	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00220	Nelfinavir increases the effect and toxicity of quinidine
DB01346	DB01115	Decreased quinidine effect, increased nifedipine effect
DB01346	DB00540	Quinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline.
DB01346	DB01165	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB01303	The barbiturate, quinidine barbiturate, decreases the effect of oxtriphylline.
DB01346	DB00860	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
DB01346	DB00635	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
DB01346	DB01035	Quinidine increases the effect of procainamide
DB01346	DB01182	Quinidine increases the effect of propafenone
DB01346	DB00908	The anticonvulsant, quinidine. barbiturate, decreases the effect of quinidine.
DB01346	DB01369	This combination presents an increased risk of toxicity
DB01346	DB01045	Rifampin decreases the effect of quinidine
DB01346	DB00976	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00277	The barbiturate, quinidine barbiturate, decreases the effect of theophylline.
DB01346	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB01346	DB00620	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
DB01347	DB00594	Increased risk of hyperkalemia
DB01347	DB01356	The ARB increases serum levels of lithium
DB01347	DB01345	Increased risk of hyperkalemia
DB01347	DB00384	Increased risk of hyperkalemia
DB01348	DB00594	Increased risk of hyperkalemia
DB01348	DB01356	The ACE inhibitor increases serum levels of lithium
DB01348	DB01345	Increased risk of hyperkalemia
DB01348	DB00697	Tizanidine increases the risk of hypotension with the ACE inhibitor
DB01348	DB00384	Increased risk of hyperkalemia
DB01349	DB00594	Increased risk of hyperkalemia
DB01349	DB01356	The ARB increases serum levels of lithium
DB01349	DB01345	Increased risk of hyperkalemia
DB01349	DB00384	Increased risk of hyperkalemia
DB01351	DB01223	The barbiturate, amobarbital, decreases the effect of aminophylline.
DB01351	DB00443	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB01351	DB00882	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, clomifene.
DB01351	DB00286	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB01351	DB00091	The barbiturate, amobarbital, increases the effect of cyclosporine.
DB01351	DB01234	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01351	DB00255	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB01351	DB00254	The anticonvulsant, amobarbital, decreases the effect of doxycycline.
DB01351	DB06210	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB01351	DB00783	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, estradiol.
DB01351	DB00977	This product may cause a slight decrease of contraceptive effect
DB01351	DB01023	The barbiturate, amobarbital, decreases the effect of felodipine.
DB01351	DB00687	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB01351	DB00158	Folic acid decreases the effect of anticonvulsant, amobarbital.
DB01351	DB00317	The CYP3A4 inducer, amobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01351	DB00400	The barbiturate, amobarbital, decreases the effect of griseofulvin.
DB01351	DB00741	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB01351	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01351	DB00603	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB01351	DB00351	The enzyme inducer, amobarbital, decreases the effect of the hormone agent, megestrol.
DB01351	DB00333	The barbiturate, amobarbital, decreases the effect of methadone.
DB01351	DB00916	The barbiturate, amobarbital, decreases the effect of metronidazole.
DB01351	DB01115	The barbiturate, amobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01351	DB00717	This product may cause a slight decrease of contraceptive effect
DB01351	DB01303	The barbiturate, amobarbital, decreases the effect of oxtriphylline.
DB01351	DB00860	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB01351	DB00635	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisone.
DB01351	DB00908	The anticonvulsant, amobarbital, decreases the effect of quinidine.
DB01351	DB00277	The barbiturate, amobarbital, decreases the effect of theophylline.
DB01351	DB00620	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB01351	DB00726	The barbiturate, Amobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Amobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
DB01351	DB00427	The CNS depressants, Triprolidine and Amobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01351	DB00661	Amobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Amobarbital is initiated, discontinued or dose changed.
DB01351	DB00582	Amobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.
DB01351	DB00682	Amobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if amobarbital is initiated, discontinued or dose changed.
DB01352	DB01223	The barbiturate, aprobarbital, decreases the effect of aminophylline.
DB01352	DB00443	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB01352	DB00882	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, clomifene.
DB01352	DB00286	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB01352	DB00091	The barbiturate, aprobarbital, increases the effect of cyclosporine.
DB01352	DB01234	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01352	DB00255	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB01352	DB00254	The anticonvulsant, aprobarbital, decreases the effect of doxycycline.
DB01352	DB00783	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, estradiol.
DB01352	DB00977	This product may cause a slight decrease of contraceptive effect
DB01352	DB01023	The barbiturate, aprobarbital, decreases the effect of felodipine.
DB01352	DB00687	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB01352	DB00158	Folic acid decreases the effect of anticonvulsant, aprobarbital.
DB01352	DB00317	The CYP3A4 inducer, aprobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01352	DB00400	The barbiturate, aprobarbital, decreases the effect of griseofulvin.
DB01352	DB00741	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB01352	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01352	DB00603	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB01352	DB00351	The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, megestrol.
DB01352	DB00333	The barbiturate, aprobarbital, decreases the effect of methadone.
DB01352	DB00916	The barbiturate, aprobarbital, decreases the effect of metronidazole.
DB01352	DB01115	The barbiturate, aprobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01352	DB00717	This product may cause a slight decrease of contraceptive effect
DB01352	DB01303	The barbiturate, aprobarbital, decreases the effect of oxtriphylline.
DB01352	DB00860	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB01352	DB00635	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisone.
DB01352	DB00908	The anticonvulsant, aprobarbital, decreases the effect of quinidine.
DB01352	DB00277	The barbiturate, aprobarbital, decreases the effect of theophylline.
DB01352	DB00620	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB01353	DB01223	The barbiturate, butethal, decreases the effect of aminophylline.
DB01353	DB00443	The barbiturate, butethal, may decrease the effect of the corticosteroid, betamethasone.
DB01353	DB00882	The enzyme inducer, butethal, decreases the effect of the hormone agent, clomifene.
DB01353	DB00286	The enzyme inducer, butethal, decreases the effect of the hormone agent, conjugated estrogens.
DB01353	DB00091	The barbiturate, butethal, increases the effect of cyclosporine.
DB01353	DB01234	The barbiturate, butethal, may decrease the effect of the corticosteroid, dexamethasone.
DB01353	DB00255	The enzyme inducer, butethal, decreases the effect of the hormone agent, diethylstilbestrol.
DB01353	DB00254	The anticonvulsant, butethal, decreases the effect of doxycycline.
DB01353	DB00783	The enzyme inducer, butethal, decreases the effect of the hormone agent, estradiol.
DB01353	DB00977	This product may cause a slight decrease of contraceptive effect
DB01353	DB01023	The barbiturate, butethal, decreases the effect of felodipine.
DB01353	DB00687	The barbiturate, butethal, may decrease the effect of the corticosteroid, fludrocortisone.
DB01353	DB00158	Folic acid decreases the effect of anticonvulsant, butethal.
DB01353	DB00317	The CYP3A4 inducer, butethal, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01353	DB00400	The barbiturate, butethal, decreases the effect of griseofulvin.
DB01353	DB00741	The barbiturate, butethal, may decrease the effect of the corticosteroid, hydrocortisone.
DB01353	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01353	DB00603	The enzyme inducer, butethal, decreases the effect of the hormone agent, medroxyprogesterone.
DB01353	DB00351	The enzyme inducer, butethal, decreases the effect of the hormone agent, megestrol.
DB01353	DB00333	The barbiturate, butethal, decreases the effect of methadone.
DB01353	DB00916	The barbiturate, butethal, decreases the effect of metronidazole.
DB01353	DB01115	The barbiturate, butethal, decreases the effect of the calcium channel blocker, nifedipine.
DB01353	DB00717	This product may cause a slight decrease of contraceptive effect
DB01353	DB01303	The barbiturate, butethal, decreases the effect of oxtriphylline.
DB01353	DB00860	The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisolone.
DB01353	DB00635	The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisone.
DB01353	DB00908	The anticonvulsant, butethal, decreases the effect of quinidine.
DB01353	DB00277	The barbiturate, butethal, decreases the effect of theophylline.
DB01353	DB00620	The barbiturate, butethal, may decrease the effect of the corticosteroid, triamcinolone.
DB01354	DB01223	The barbiturate, heptabarbital, decreases the effect of aminophylline.
DB01354	DB00443	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, betamethasone.
DB01354	DB00882	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, clomifene.
DB01354	DB00286	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB01354	DB00091	The barbiturate, heptabarbital, increases the effect of cyclosporine.
DB01354	DB01234	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01354	DB00255	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB01354	DB00254	The anticonvulsant, heptabarbital, decreases the effect of doxycycline.
DB01354	DB00783	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, estradiol.
DB01354	DB00977	This product may cause a slight decrease of contraceptive effect
DB01354	DB01023	The barbiturate, heptabarbital, decreases the effect of felodipine.
DB01354	DB00687	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB01354	DB00158	Folic acid decreases the effect of anticonvulsant, heptabarbital.
DB01354	DB00317	The CYP3A4 inducer, heptabarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01354	DB00400	The barbiturate, heptabarbital, decreases the effect of griseofulvin.
DB01354	DB00741	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB01354	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01354	DB00603	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB01354	DB00351	The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, megestrol.
DB01354	DB00333	The barbiturate, heptabarbital, decreases the effect of methadone.
DB01354	DB00916	The barbiturate, heptabarbital, decreases the effect of metronidazole.
DB01354	DB01115	The barbiturate, heptabarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01354	DB00717	This product may cause a slight decrease of contraceptive effect
DB01354	DB01303	The barbiturate, heptabarbital, decreases the effect of oxtriphylline.
DB01354	DB00860	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisolone.
DB01354	DB00635	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisone.
DB01354	DB00908	The anticonvulsant, heptabarbital, decreases the effect of quinidine.
DB01354	DB00277	The barbiturate, heptabarbital, decreases the effect of theophylline.
DB01354	DB00620	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB01355	DB01223	The barbiturate, hexobarbital, decreases the effect of aminophylline.
DB01355	DB00443	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, betamethasone.
DB01355	DB00882	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, clomifene.
DB01355	DB00286	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, conjugated estrogens.
DB01355	DB00091	The barbiturate, hexobarbital, increases the effect of cyclosporine.
DB01355	DB01234	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, dexamethasone.
DB01355	DB00255	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, diethylstilbestrol.
DB01355	DB00254	The anticonvulsant, hexobarbital, decreases the effect of doxycycline.
DB01355	DB00783	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, estradiol.
DB01355	DB00977	This product may cause a slight decrease of contraceptive effect
DB01355	DB01023	The barbiturate, hexobarbital, decreases the effect of felodipine.
DB01355	DB00687	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, fludrocortisone.
DB01355	DB00158	Folic acid decreases the effect of anticonvulsant, hexobarbital.
DB01355	DB00317	The CYP3A4 inducer, hexobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.
DB01355	DB00400	The barbiturate, hexobarbital, decreases the effect of griseofulvin.
DB01355	DB00741	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
DB01355	DB00367	Phenobarbital decreases the effect of levonorgestrel
DB01355	DB00603	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, medroxyprogesterone.
DB01355	DB00351	The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, megestrol.
DB01355	DB00333	The barbiturate, hexobarbital, decreases the effect of methadone.
DB01355	DB00916	The barbiturate, hexobarbital, decreases the effect of metronidazole.
DB01355	DB01115	The barbiturate, hexobarbital, decreases the effect of the calcium channel blocker, nifedipine.
DB01355	DB00717	This product may cause a slight decrease of contraceptive effect
DB01355	DB01303	The barbiturate, hexobarbital, decreases the effect of oxtriphylline.
DB01355	DB00860	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisolone.
DB01355	DB00635	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisone.
DB01355	DB00908	The anticonvulsant, hexobarbital, decreases the effect of quinidine.
DB01355	DB00277	The barbiturate, hexobarbital, decreases the effect of theophylline.
DB01355	DB00620	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, triamcinolone.
DB01356	DB01223	Theophylline decreases serum levels of lithium
DB01356	DB08822	Azilsartan medoxomil may increase lithium serum concentrations.
DB01356	DB00542	The ACE inhibitor increases serum levels of lithium
DB01356	DB00436	The thiazide diuretic, bendroflumethiazide, may increase serum levels of lithium.
DB01356	DB00562	The thiazide diuretic, benzthiazide, may increase serum levels of lithium.
DB01356	DB00201	Caffeine decreases serum levels of lithium
DB01356	DB00796	The ARB increases serum levels of lithium
DB01356	DB01197	The ACE inhibitor increases serum levels of lithium
DB01356	DB00482	The COX-2 inhibitor increases serum levels of lithium
DB01356	DB00880	The thiazide diuretic, chlorothiazide, may increase serum levels of lithium.
DB01356	DB00310	The thiazide diuretic, chlorthalidone, may increase serum levels of lithium.
DB01356	DB01340	The ACE inhibitor increases serum levels of lithium
DB01356	DB04272	The urine alkalizer decreases the effect of lithium
DB01356	DB00606	The thiazide diuretic, cyclothiazide, may increase serum levels of lithium.
DB01356	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01356	DB00586	The NSAID, diclofenac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB00861	The NSAID, diflunisal, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB00651	Theophylline decreases serum levels of lithium
DB01356	DB00584	The ACE inhibitor increases serum levels of lithium
DB01356	DB00700	Eplerenone increases serum levels of lithium
DB01356	DB00876	The ARB increases serum levels of lithium
DB01356	DB01628	Etoricoxib increases serum levels of lithium
DB01356	DB00472	The SSRI, fluoxetine, increases serum levels of lithium.
DB01356	DB00176	The SSRI, fluvoxamine, increases serum levels of lithium.
DB01356	DB01342	The ARB increases serum levels of lithium
DB01356	DB00492	The ACE inhibitor increases serum levels of lithium
DB01356	DB00502	Possible extrapyramidal effects and neurotoxicity with this combination
DB01356	DB00999	The thiazide diuretic, hydrochlorothiazide, may increase serum levels of lithium.
DB01356	DB00774	The thiazide diuretic, hydroflumethiazide, may increase serum levels of lithium.
DB01356	DB01050	The NSAID, ibuprofen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB00808	The thiazide diuretic, indapamide, may increase serum levels of lithium.
DB01356	DB00328	The NSAID, indomethacin, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB05247	Possible hypothyroidism with this combination
DB01356	DB01029	The ARB increases serum levels of lithium
DB01356	DB01009	The NSAID, ketoprofen, may increase the serum concentration of lithium by decreasing its renal clearance. Consider a dose reduction in lithium upon initiation of ketoprofen therapy. Monitor for changes in the therapeutic and adverse effects of lithium if ketoprofen is initiated, discontinued or does changed.
DB01356	DB00465	The NSAID, ketorolac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB00722	The ACE inhibitor increases serum levels of lithium
DB01356	DB00678	Losartan increases serum levels of lithium
DB01356	DB01283	The COX-2 inhibitor increases serum levels of lithium
DB01356	DB00784	The NSAID, mefenamic acid, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB00814	Meloxicam increases serum levels of lithium
DB01356	DB00232	The thiazide diuretic, methyclothiazide, may increase serum levels of lithium.
DB01356	DB00968	Methyldopa may increase the adverse effects of lithium without affecting lithium serum levels. Monitor for signs and symptoms of lithium toxicity during concomitant therapy.
DB01356	DB00524	The thiazide diuretic, metolazone, may increase serum levels of lithium.
DB01356	DB00916	Metronidazole increases the effect and toxicity of lithium
DB01356	DB00691	The ACE inhibitor increases serum levels of lithium
DB01356	DB00788	The NSAID, naproxen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB01303	Theophylline decreases serum levels of lithium
DB01356	DB00790	The ACE inhibitor increases serum levels of lithium
DB01356	DB00812	The NSAID, phenylbutazone, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB00554	The NSAID, piroxicam, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
DB01356	DB01324	The thiazide diuretic, polythiazide, may increase serum levels of lithium.
DB01356	DB01345	The urine alkalizer decreases the effect of lithium
DB01356	DB00881	The ACE inhibitor increases serum levels of lithium
DB01356	DB01325	The thiazide diuretic, quinethazone, may increase serum levels of lithium.
DB01356	DB00178	The ACE inhibitor increases serum levels of lithium
DB01356	DB00533	The COX-2 inhibitor increases serum levels of lithium
DB01356	DB00017	Monitor therapy because calcitonin may reduce the serum concentration of lithium.
DB01356	DB01347	The ARB increases serum levels of lithium
DB01356	DB01105	Possible serotoninergic syndrome with this combination
DB01356	DB01390	The urine alkalizer decreases the effect of lithium
DB01356	DB01348	The ACE inhibitor increases serum levels of lithium
DB01356	DB00669	Possible serotoninergic syndrome with this combination
DB01356	DB01349	The ARB increases serum levels of lithium
DB01356	DB00966	Telmisartan may increase serum Lithium concentrations. Monitor serum Lithium levels during concomitant therapy to avoid Lithium toxicity.
DB01356	DB00469	Tenoxicam may increase the serum concentration of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed.
DB01356	DB04844	Inhibit biochemical and behavioural effects of tetrabenazine. Heed caution when using agents in combination.
DB01356	DB00277	Theophylline decreases serum levels of lithium
DB01356	DB01600	Tiaprofenic acid may increase the therapeutic/adverse effects of Lithium by increasing Lithium serum concentrations. Monitor for changes in the therapeutic/adverse effects of Lithium if Tiaprofenic acid is initiated, discontinued or dose changed.
DB01356	DB00684	Increased risk of nephrotoxicity
DB01356	DB00500	Tolmetin may increase the risk of Lithium toxicity by decreasing the renal elminiation of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tolmetin is initiated, discontinued or dose changed.
DB01356	DB00273	Topiramate could modify lithium levels
DB01356	DB00519	Trandolapril may increase the serum concentration of Lithium increasing the risk of Lithium toxicity. Monitor for changes in Lithium serum concentrations, toxicity and efficacy if Trandolapril is initiated, discontinued or dose changed.
DB01356	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01356	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01356	DB01021	Trichlormethiazide may increase the serum concentration of Lithium by decreasing Lithium excretion. Monitor for changes in the therapeutic/adverse effects of Lithium if Trichlorthiazide is initiated, discontinued or dose changed.
DB01356	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01356	DB00580	The COX-2 inhibitor increases serum levels of lithium
DB01356	DB00177	Valsartan may increase serum lithium concentrations. Monitor serum lithium levels during concomitant therapy to avoid lithium toxicity.
DB01356	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01356	DB00661	Signs of lithium toxicity
DB01356	DB00315	Use of two serotonin modulators, such as zolmitriptan and lithium, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB01357	DB01223	The contraceptive increases the effect and toxicity of theophylline
DB01357	DB01060	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00415	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00701	Ritonavir could decrease the contraceptive efficacy
DB01357	DB00673	Aprepitant could decrease the effect of the oral contraceptive
DB01357	DB06697	Artemether may decrease the effectiveness of mestranol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB01357	DB01053	This anti-infectious agent could decreases the effect of the oral contraceptive
DB01357	DB00559	Decreases the effect of contraceptive
DB01357	DB00564	This product may cause a slight decrease of contraceptive effect
DB01357	DB00578	This anti-infectious agent could decreases the effect of the oral contraceptive
DB01357	DB00766	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB01147	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain.
DB01357	DB00091	The contraceptive increases the effect and toxicity of cyclosporine
DB01357	DB00618	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00485	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00254	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00301	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB01320	This product may cause a slight decrease of contraceptive effect
DB01357	DB00400	This product may cause a slight decrease of contraceptive effect
DB01357	DB01167	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB01026	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00555	The oral contraceptive decreases the effect of lamotrigine
DB01357	DB01017	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00745	Modafinil decreases the effect of the contraceptive
DB01357	DB00220	Ritonavir could decrease the contraceptive efficacy
DB01357	DB00776	Oxcarbazepine decreases the effect of the contraceptive
DB01357	DB01303	The contraceptive increases the effect and toxicity of theophylline
DB01357	DB00417	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB01174	This product may cause a slight decrease of contraceptive effect
DB01357	DB00252	This product may cause a slight decrease of contraceptive effect
DB01357	DB01132	Possible loss of contraceptive effect
DB01357	DB00319	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB01604	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00860	The estrogenic agent, mestranol, may increase the effect of the corticosteroid, prednisolone.
DB01357	DB00635	The estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone.
DB01357	DB00794	This product may cause a slight decrease of contraceptive effect
DB01357	DB00481	Association not recommended
DB01357	DB00615	This product may cause a slight decrease of the contraceptive effect
DB01357	DB01045	This product may cause a slight decrease of contraceptive effect
DB01357	DB00759	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01357	DB00277	The contraceptive increases the effect and toxicity of theophylline
DB01357	DB00599	Thiopental may decrease the effect of Mestranol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB01357	DB00932	Mestranol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Mestranol. Use an alternate form of contraception or monitor for estrogen deficiency if Mestranol is used for hormone replacement therapy.
DB01357	DB00697	Oral contraceptives decrease the clearance of Tizanidine.
DB01357	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Mestranol. Consider alternate therapy or monitor for changes in Mestranol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01357	DB00273	Topiramate may decrease the effect of the oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy.
DB01357	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy.
DB01357	DB00682	Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed.
DB01359	DB01223	Antagonism of action and increased effect of theophylline
DB01359	DB00672	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB01359	DB00575	Increased hypertension when clonidine stopped
DB01359	DB00390	Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.
DB01359	DB00320	Ischemia with risk of gangrene
DB01359	DB00280	The beta-blocker, penbutolol,  may increase the toxicity of disopyramide.
DB01359	DB00668	Hypertension, then bradycardia
DB01359	DB00696	Ischemia with risk of gangrene
DB01359	DB01288	Antagonism
DB01359	DB00983	Antagonism
DB01359	DB01120	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB01359	DB01016	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB01359	DB01050	Risk of inhibition of renal prostaglandins
DB01359	DB00328	Risk of inhibition of renal prostaglandins
DB01359	DB00047	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB01359	DB00281	Penbutolol increases the volume of distribution of lidocaine in normal subjects. This could result in a requirement for higher loading doses of lidocaine.
DB01359	DB00968	Possible hypertensive crisis
DB01359	DB00247	Ischemia with risk of gangrene
DB01359	DB00816	Antagonism
DB01359	DB01303	Antagonism of action and increased effect of theophylline
DB01359	DB00236	Antagonism
DB01359	DB00554	Risk of inhibition of renal prostaglandins
DB01359	DB00457	Risk of hypotension at the beginning of therapy
DB01359	DB00912	The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.
DB01359	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01359	DB00871	Antagonism
DB01359	DB00277	Antagonism of action and increased effect of theophylline
DB01359	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01361	DB01223	The macrolide, troleandomycin, may increase the effect and toxicity of theophylline derivative, aminophylline.
DB01361	DB00673	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
DB01361	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01361	DB00564	The macrolide, troleandomycin, may increase the effect of carbamazepine.
DB01361	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01361	DB00215	Possible serotoninergic syndrome with this combination
DB01361	DB01394	Severe colchicine toxicity can occur
DB01361	DB00091	The macrolide, troleandomycin, may increase the effect of cyclosporine.
DB01361	DB00320	Possible ergotism and severe ischemia with this combination
DB01361	DB00216	The macrolide, troleandomycin, may increase the effect and toxicity of eletriptan.
DB01361	DB00700	The macrolide, troleandomycin, may increase the effect and toxicity of eplerenone.
DB01361	DB00696	Possible ergotism and severe ischemia with this combination
DB01361	DB00530	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
DB01361	DB00472	Possible serotoninergic syndrome with this combination
DB01361	DB00247	Possible ergotism and severe ischemia with this combination
DB01361	DB01303	The macrolide, troleandomycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
DB01361	DB01100	Increased risk of cardiotoxicity and arrhythmias
DB01361	DB00864	The macrolide antibiotic, Troleandomycin, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Troleandomycin therapy is initiated, discontinued or altered.
DB01361	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01361	DB00277	The macrolide, troleandomycin, may increase the effect and toxicity of theophylline.
DB01362	DB01118	Increased risk of cardiotoxicity and arrhythmias
DB01363	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedra.
DB01363	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedra.
DB01363	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedra.
DB01363	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedra.
DB01363	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedra.
DB01363	DB01170	Ephedra may decrease the effect of guanethidine.
DB01363	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedra.
DB01363	DB01247	Increased arterial pressure
DB01363	DB00601	Possible increase of arterial pressure
DB01363	DB00968	Increased arterial pressure
DB01363	DB00211	Increased arterial pressure
DB01363	DB01171	Moclobemide increases the sympathomimetic effect of ephedra.
DB01363	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedra.
DB01363	DB00780	Increased arterial pressure
DB01363	DB01367	Increased arterial pressure
DB01363	DB00206	Increased arterial pressure
DB01363	DB00519	Ephedra may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy.
DB01364	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedrine.
DB01364	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedrine.
DB01364	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedrine.
DB01364	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedrine.
DB01364	DB06700	Desvenlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB01364	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedrine.
DB01364	DB01170	Ephedrine may decrease the effect of guanethidine.
DB01364	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedrine.
DB01364	DB06704	Sympathomimetic that increase chances of producing a false negative imaging result
DB01364	DB01247	Increased arterial pressure
DB01364	DB00601	Possible increase of arterial pressure
DB01364	DB00968	Increased arterial pressure
DB01364	DB00211	Increased arterial pressure
DB01364	DB01171	Moclobemide increases the sympathomimetic effect of ephedrine.
DB01364	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedrine.
DB01364	DB00780	Increased arterial pressure
DB01364	DB01367	Increased arterial pressure
DB01364	DB00206	Increased arterial pressure
DB01364	DB05271	Risk of sedation may decrease with concomitant therapy. Monitor therapy closely.
DB01364	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Ephedrine. Concomitant therapy should be avoided.
DB01364	DB00285	Venlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB01365	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of mephentermine.
DB01365	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of mephentermine.
DB01365	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of mephentermine.
DB01365	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of mephentermine.
DB01365	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of mephentermine.
DB01365	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of mephentermine.
DB01365	DB01247	Increased arterial pressure
DB01365	DB00601	Possible increase of arterial pressure
DB01365	DB00968	Increased arterial pressure
DB01365	DB00211	Increased arterial pressure
DB01365	DB01171	Moclobemide increases the sympathomimetic effect of mephentermine.
DB01365	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of mephentermine.
DB01365	DB00780	Increased arterial pressure
DB01365	DB01367	Increased arterial pressure
DB01365	DB00206	Increased arterial pressure
DB01365	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Concomitant therapy should be avoided.
DB01365	DB00726	Trimipramine may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly.
DB01366	DB00321	The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of procaterol.
DB01366	DB00543	The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of procaterol.
DB01366	DB00335	Antagonism
DB01366	DB00612	Antagonism
DB01366	DB01136	Antagonism
DB01366	DB01242	The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of procaterol.
DB01366	DB01151	The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of procaterol.
DB01366	DB01142	The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of procaterol.
DB01366	DB00187	Antagonism
DB01366	DB00458	The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of procaterol.
DB01366	DB01247	Increased arterial pressure
DB01366	DB00598	Antagonism
DB01366	DB00601	Possible increase of arterial pressure
DB01366	DB00968	Increased arterial pressure
DB01366	DB00264	Antagonism
DB01366	DB00211	Increased arterial pressure
DB01366	DB01171	Moclobemide increases the sympathomimetic effect of procaterol.
DB01366	DB01203	Antagonism
DB01366	DB00540	The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of procaterol.
DB01366	DB00780	Increased arterial pressure
DB01366	DB00960	Antagonism
DB01366	DB00571	Antagonism
DB01366	DB01367	Increased arterial pressure
DB01366	DB00206	Increased arterial pressure
DB01366	DB00373	Antagonism
DB01367	DB00488	Risk of severe hypotension
DB01367	DB00321	Possibility of severe adverse effects
DB01367	DB00543	Possibility of severe adverse effects
DB01367	DB00182	Possible hypertensive crisis
DB01367	DB00289	Possible severe adverse reaction with this combination
DB01367	DB00865	MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents.
DB01367	DB01393	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) rasagiline.
DB01367	DB00484	MAO Inhibitors like rasagiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
DB01367	DB00921	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like rasagiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
DB01367	DB01156	Possible severe adverse reaction with this combination
DB01367	DB00490	Possible blood pressure elevation
DB01367	DB00537	Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of rasagiline. Monitor for changes in the therapeutic and adverse effects of rasagiline if ciprofloxacin is initiated or discontinued.
DB01367	DB00215	Possible severe adverse reaction with this combination
DB01367	DB01242	Possibility of severe adverse effects
DB01367	DB00924	Increased risk of toxicity with this association
DB01367	DB01151	Possibility of severe adverse effects
DB01367	DB06700	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01367	DB01191	Possible hypertensive crisis
DB01367	DB01576	Possible hypertensive crisis
DB01367	DB00514	Possible severe adverse reaction
DB01367	DB00937	Possible hypertensive crisis
DB01367	DB00841	Increased arterial pressure
DB01367	DB00988	Increased arterial pressure
DB01367	DB01142	Possibility of severe adverse effects
DB01367	DB00476	Possible severe adverse reaction with this combination
DB01367	DB01363	Increased arterial pressure
DB01367	DB01364	Increased arterial pressure
DB01367	DB00668	Increased arterial pressure
DB01367	DB01175	Possible severe adverse reaction with this combination
DB01367	DB00574	Possible hypertensive crisis
DB01367	DB01288	Increased arterial pressure
DB01367	DB00472	Possible severe adverse reaction with this combination
DB01367	DB00176	Possible severe adverse reaction with this combination
DB01367	DB00458	Possibility of severe adverse effects
DB01367	DB01064	Increased arterial pressure
DB01367	DB00579	Possible hypertensive crisis
DB01367	DB01365	Increased arterial pressure
DB01367	DB00610	Increased arterial pressure
DB01367	DB01577	Possible hypertensive crisis
DB01367	DB00723	Increased arterial pressure
DB01367	DB00422	Possible hypertensive crisis with this combination.
DB01367	DB00211	Risk of hypertensive crisis.
DB01367	DB04896	Increase serotonin levels. Combination therapy is contraindicated.
DB01367	DB00370	Possible severe adverse reaction with this combination
DB01367	DB01149	Possible severe adverse reaction with this combination
DB01367	DB00368	Increased arterial pressure
DB01367	DB00540	Possibility of severe adverse effects
DB01367	DB00816	Increased arterial pressure
DB01367	DB00715	Possible severe adverse reaction with this combination
DB01367	DB00454	Increased risk of serotonin syndrome. Concomitant use should be avoided.
DB01367	DB01579	Possible hypertensive crisis
DB01367	DB00830	Possible hypertensive crisis
DB01367	DB00191	Possible hypertensive crisis
DB01367	DB00388	Increased arterial pressure
DB01367	DB00397	Increased arterial pressure
DB01367	DB01291	Increased arterial pressure
DB01367	DB01366	Increased arterial pressure
DB01367	DB00344	Possibility of severe adverse effects
DB01367	DB00852	Increased arterial pressure
DB01367	DB01001	Increased arterial pressure
DB01367	DB01104	Possible severe adverse reaction with this combination
DB01367	DB01105	Possible serotoninergic syndrome with this combination
DB01367	DB01323	Increased risk of toxicity with this association
DB01367	DB06204	Increases the toxicity of tapentadol by unknown mechanism. Discontinue rasagiline at least 14 days prior to tapentadol administration.
DB01367	DB00871	Increased arterial pressure
DB01367	DB04844	Tetrabenazine may increase the adverse/toxic effects of Rasagiline. Concomitant therapy is contraindicated.
DB01367	DB00323	Tolcapone and Rasagiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
DB01367	DB00193	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, rasagiline.
DB01367	DB00752	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
DB01367	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01367	DB00726	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
DB01367	DB00285	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB01367	DB00315	The MAO inhibitor, rasagiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing rasagiline are contraindicated.
DB01369	DB00381	This combination presents an increased risk of toxicity
DB01369	DB01169	This combination presents an increased risk of toxicity
DB01369	DB00637	This combination presents an increased risk of toxicity
DB01369	DB01076	This combination presents an increased risk of toxicity
DB01369	DB00564	This combination presents an increased risk of toxicity
DB01369	DB00439	This combination presents an increased risk of toxicity
DB01369	DB00604	This combination presents an increased risk of toxicity
DB01369	DB01211	This combination presents an increased risk of toxicity
DB01369	DB00091	Synercid increases the effect of cyclosporine
DB01369	DB00705	This combination presents an increased risk of toxicity
DB01369	DB00829	This combination presents an increased risk of toxicity
DB01369	DB01341	This combination presents an increased risk of toxicity
DB01369	DB00343	This combination presents an increased risk of toxicity
DB01369	DB00280	This combination presents an increased risk of toxicity
DB01369	DB01248	This combination presents an increased risk of toxicity.
DB01369	DB00204	This combination presents an increased risk of toxicity
DB01369	DB00450	This combination presents an increased risk of toxicity
DB01369	DB00199	This combination presents an increased risk of toxicity
DB01369	DB00773	This combination presents an increased risk of toxicity
DB01369	DB00949	This combination presents an increased risk of toxicity
DB01369	DB01023	This combination presents an increased risk of toxicity
DB01369	DB01195	This combination presents an increased risk of toxicity
DB01369	DB00529	This combination presents an increased risk of toxicity
DB01369	DB01320	This combination presents an increased risk of toxicity
DB01369	DB01044	This combination presents an increased risk of toxicity
DB01369	DB00365	This combination presents an increased risk of toxicity
DB01369	DB01218	This combination presents an increased risk of toxicity
DB01369	DB00224	This combination presents an increased risk of toxicity
DB01369	DB00270	This combination presents an increased risk of toxicity
DB01369	DB00528	This combination presents an increased risk of toxicity
DB01369	DB01137	This combination presents an increased risk of toxicity
DB01369	DB01227	This combination presents an increased risk of toxicity
DB01369	DB00281	This combination presents an increased risk of toxicity
DB01369	DB00678	This combination presents an increased risk of toxicity
DB01369	DB00227	This combination presents an increased risk of toxicity
DB01369	DB00959	This combination presents an increased risk of toxicity
DB01369	DB00683	This combination presents an increased risk of toxicity
DB01369	DB00691	This combination presents an increased risk of toxicity
DB01369	DB00218	This combination presents an increased risk of toxicity
DB01369	DB00238	This combination presents an increased risk of toxicity
DB01369	DB00622	This combination presents an increased risk of toxicity
DB01369	DB01115	Synercid increases the effect of ziprasidone
DB01369	DB00393	This combination presents an increased risk of toxicity
DB01369	DB00401	This combination presents an increased risk of toxicity
DB01369	DB00104	This combination presents an increased risk of toxicity
DB01369	DB01229	This combination presents an increased risk of toxicity
DB01369	DB00738	This combination presents an increased risk of toxicity
DB01369	DB01224	This combination presents an increased risk of toxicity
DB01369	DB00908	This combination presents an increased risk of toxicity
DB01369	DB01346	This combination presents an increased risk of toxicity
DB01369	DB00503	This combination presents an increased risk of toxicity
DB01369	DB00938	This combination presents an increased risk of toxicity
DB01369	DB00641	This combination presents an increased risk of toxicity
DB01369	DB00864	This combination presents an increased risk of toxicity
DB01369	DB00675	This combination presents an increased risk of toxicity
DB01369	DB00444	This combination presents an increased risk of toxicity
DB01369	DB00342	This combination presents an increased risk of toxicity
DB01369	DB00697	This combination presents an increased risk of toxicity
DB01369	DB00285	This combination presents an increased risk of toxicity
DB01369	DB00661	This combination presents an increased risk of toxicity
DB01369	DB00570	This combination presents an increased risk of toxicity
DB01369	DB00541	This combination presents an increased risk of toxicity
DB01369	DB00309	This combination presents an increased risk of toxicity
DB01369	DB00361	This combination presents an increased risk of toxicity
DB01370	DB00701	The antiacid decreases the absorption of amprenavir
DB01370	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB01370	DB00608	The antiacid decreases the absorption of chloroquine
DB01370	DB00537	Formation of non-absorbable complexes
DB01370	DB01190	The aluminium salt decreases the absorption of lincosamides
DB01370	DB00720	Formation of non-absorbable complexes
DB01370	DB00250	Formation of non-absorbable complexes
DB01370	DB01609	Possible physicochemical interaction
DB01370	DB00705	The antiacid decreases the effect of delavirdine
DB01370	DB00618	Formation of non-absorbable complexes
DB01370	DB00254	Formation of non-absorbable complexes
DB01370	DB01077	Formation of non-absorbable complexes
DB01370	DB01319	The antiacid decreases the absorption of amprenavir
DB01370	DB01044	Formation of non-absorbable complexes
DB01370	DB01155	Formation of non-absorbable complexes
DB01370	DB00365	Formation of non-absorbable complexes
DB01370	DB00710	Formation of non absorbable complexes
DB01370	DB00224	The antacid decreases the absorption of indinavir
DB01370	DB01167	Aluminum-containing antacids may decrease the effect of itraconazole.
DB01370	DB01026	Aluminum-containing antacids may decrease the effect of ketoconazole.
DB01370	DB01137	Formation of non-absorbable complexes
DB01370	DB01627	The aluminium salt decreases the absorption of lincosamides
DB01370	DB01017	Formation of non-absorbable complexes
DB01370	DB00218	Formation of non-absorbable complexes
DB01370	DB01059	Formation of non-absorbable complexes
DB01370	DB01165	Formation of non-absorbable complexes
DB01370	DB00299	The multivalent agent decreases the effect of penicillamine
DB01370	DB01344	Risk of alkalosis in renal impairment
DB01370	DB00759	Formation of non-absorbable complexes
DB01370	DB00685	Aluminum may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the aluminum containing agent to minimize the interaction.
DB01373	DB00630	Formation of non-absorbable complexes
DB01373	DB00701	The antiacid decreases the absorption of amprenavir
DB01373	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB01373	DB00608	The antiacid decreases the absorption of chloroquine
DB01373	DB00537	Formation of non-absorbable complexes
DB01373	DB00720	Formation of non-absorbable complexes
DB01373	DB00250	Formation of non-absorbable complexes
DB01373	DB08826	Deferiprone serum concentrations may be decreased by calcium salts.
DB01373	DB00705	The antiacid decreases the effect of delavirdine
DB01373	DB00618	Formation of non-absorbable complexes
DB01373	DB00254	Formation of non-absorbable complexes
DB01373	DB00467	Formation of non-absorbable complexes
DB01373	DB01077	Formation of non-absorbable complexes
DB01373	DB01319	The antiacid decreases the absorption of amprenavir
DB01373	DB00365	Calcium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours.
DB01373	DB00710	Formation of non-absorbable complexes
DB01373	DB00224	Calcium may decrease the absorption of indinavir.
DB01373	DB01167	Calcium-containing antacids may decrease the effect of itraconazole.
DB01373	DB01026	Calcium-containing antacids may decrease the absorption of ketoconazole.
DB01373	DB01137	Formation of non-absorbable complexes
DB01373	DB00451	Calcium decreases absorption of levothyroxine
DB01373	DB00978	Formation of non-absorbable complexes
DB01373	DB00931	Formation of non-absorbable complexes
DB01373	DB01017	Formation of non-absorbable complexes
DB01373	DB00218	Formation of non-absorbable complexes
DB01373	DB00688	Formation of non-absorbable complexes
DB01373	DB01059	Formation of non-absorbable complexes
DB01373	DB01165	Formation of non-absorbable complexes
DB01373	DB00595	Formation of non-absorbable complexes
DB01373	DB00487	Formation of non-absorbable complexes
DB01373	DB01344	Formation of non-absorbable complexes
DB01373	DB00884	Formation of non-absorbable complexes
DB01373	DB01405	Formation of non-absorbable complexes
DB01373	DB00759	Formation of non-absorbable complexes
DB01373	DB00685	Formation of non-absorbable complexes
DB01375	DB00701	The antiacid decreases the absorption of amprenavir
DB01375	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB01375	DB00608	The antiacid decreases the absorption of chloroquine
DB01375	DB00537	Formation of non-absorbable complexes
DB01375	DB01190	The aluminium salt decreases the absorption of lincosamides
DB01375	DB00720	Formation of non-absorbable complexes
DB01375	DB00759	Formation of non-absorbable complexes
DB01377	DB00701	The antiacid decreases the absorption of amprenavir
DB01377	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB01377	DB00608	The antiacid decreases the absorption of chloroquine
DB01377	DB00537	Formation of non-absorbable complexes
DB01377	DB00720	Formation of non-absorbable complexes
DB01377	DB00250	Formation of non-absorbable complexes
DB01377	DB00705	The antiacid decreases the effect of delavirdine
DB01377	DB00618	Formation of non-absorbable complexes
DB01377	DB00254	Formation of non-absorbable complexes
DB01377	DB01077	Formation of non-absorbable complexes
DB01377	DB01319	The antiacid decreases the absorption of amprenavir
DB01377	DB01044	Formation of non-absorbable complexes
DB01377	DB01155	Formation of non-absorbable complexes
DB01377	DB00365	Formation of non-absorbable complexes
DB01377	DB00710	Formation of non absorbable complexes
DB01377	DB00224	The antacid decreases the absorption of indinavir
DB01377	DB01167	The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption.
DB01377	DB01026	The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption.
DB01377	DB01137	Formation of non-absorbable complexes
DB01377	DB01017	Formation of non-absorbable complexes
DB01377	DB00218	Formation of non-absorbable complexes
DB01377	DB01059	Formation of non-absorbable complexes
DB01377	DB01165	Formation of non-absorbable complexes
DB01377	DB01133	The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
DB01377	DB00685	Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.
DB01378	DB00630	Formation of non-absorbable complexes
DB01378	DB00701	The antiacid decreases the absorption of amprenavir
DB01378	DB01072	This gastric pH modifier decreases the levels/effects of atazanavir
DB01378	DB00608	The antiacid decreases the absorption of chloroquine
DB01378	DB00537	Formation of non-absorbable complexes
DB01378	DB00720	Formation of non-absorbable complexes
DB01378	DB00250	Formation of non-absorbable complexes
DB01378	DB08826	Deferiprone serum concentrations may be decreased by magnesium salts.
DB01378	DB00705	Magnesium antacids may decrease the absorption of delavirdine.
DB01378	DB00618	Formation of non-absorbable complexes
DB01378	DB01341	The antiacid decreases the absorption of quinidine
DB01378	DB00254	Formation of non-absorbable complexes
DB01378	DB00467	Formation of non-absorbable complexes
DB01378	DB01077	Formation of non-absorbable complexes
DB01378	DB01319	The antiacid decreases the absorption of amprenavir
DB01378	DB01044	Formation of non-absorbable complexes
DB01378	DB01155	Formation of non-absorbable complexes
DB01378	DB00365	Magnesium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours.
DB01378	DB00710	Formation of non-absorbable complexes
DB01378	DB00224	Magnesium may decrease the absorption of indinavir.
DB01378	DB01137	Formation of non-absorbable complexes
DB01378	DB00978	Formation of non-absorbable complexes
DB01378	DB00931	Formation of non-absorbable complexes
DB01378	DB01017	Formation of non-absorbable complexes
DB01378	DB00218	Formation of non-absorbable complexes
DB01378	DB01059	Formation of non-absorbable complexes
DB01378	DB01165	Formation of non-absorbable complexes
DB01378	DB00595	Formation of non-absorbable complexes
DB01378	DB00487	Formation of non-absorbable complexes
DB01378	DB01344	Risk of alkalosis in renal impairment
DB01378	DB00908	Magnesium antacids may decrease the absorption of quindine.
DB01378	DB01346	The antiacid decreases the absorption of quinidine
DB01378	DB00884	Formation of non-absorbable complexes
DB01378	DB01098	Magnesium-containing antacids may decrease the absorption of rosuvastatin.
DB01378	DB01405	Formation of non-absorbable complexes
DB01378	DB00759	Formation of non-absorbable complexes
DB01378	DB00685	Formation of non-absorbable complexes
DB01380	DB00945	The corticosteroid, cortisone acetate, may decrease the effect of the salicylate, acetylsalicylic acid.
DB01380	DB06223	decreases the effect of cortisone by metabolism alteration.
DB01380	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, cortisone acetate.
DB01380	DB00211	Increased arterial pressure
DB01380	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, cortisone acetate.
DB01380	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, cortisone acetate.
DB01380	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, cortisone acetate.
DB01380	DB00545	The corticosteroid, cortisone acetate, may decrease the effect of the anticholinesterase, pyridostigmine.
DB01380	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, cortisone acetate.
DB01380	DB00382	Tacrine and Cortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
DB01380	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB01380	DB01339	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
DB01381	DB00054	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01418	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00945	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00009	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00261	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00278	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00006	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01166	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01396	DB00903	Possible electrolyte variations and arrhythmias
DB01381	DB00215	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00758	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB06695	Additive anticoagulant/antiplatelet effects of gingko may increase bleed risk for patients on dabigatran. Concomitant therapy should be avoided.
DB01381	DB00586	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00861	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00975	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01225	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00063	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01175	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00749	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00573	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00472	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00712	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00176	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00569	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01404	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01109	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01050	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00328	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01009	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01381	DB00465	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00001	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00939	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00814	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00461	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00788	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00991	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00715	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00554	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB06209	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00015	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB06228	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00118	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01104	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00605	Ginkgo biloba may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
DB01381	DB00382	Ginkgo biloba may cause additive/toxic cholinergic effects when administered with Tacrine. Monitor for cholinergic toxicity.
DB01381	DB00031	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB01600	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01381	DB00208	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00775	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01381	DB00500	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01381	DB00656	Increased effect and toxicity of both agents
DB01381	DB00013	Increased risk of bleeding.
DB01381	DB00682	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01382	DB00945	Acetylsalicylic acid increases the effect of sulfonylurea, glycodiazine.
DB01382	DB00335	The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.
DB01382	DB00612	The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
DB01382	DB01136	The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.
DB01382	DB00446	Chloramphenicol may increase the effect of sulfonylurea, glycodiazine.
DB01382	DB00636	Clofibrate may increase the effect of sulfonylurea, glycodiazine.
DB01382	DB00187	The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
DB01396	DB00695	Possible electrolyte variations and arrhythmias
DB01382	DB00598	The beta-blocker, labetalol, may decrease symptoms of hypoglycemia.
DB01382	DB00264	The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.
DB01382	DB01203	The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.
DB01382	DB01580	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01382	DB00812	Phenylbutazone increases the effect of the hypoglycemic agent
DB01382	DB00960	The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
DB01382	DB00571	The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.
DB01382	DB01045	Rifampin may decrease the effect of sulfonylurea, glycodiazine.
DB01382	DB00373	The beta-blocker, timolol, may decrease symptoms of hypoglycemia.
DB01384	DB00945	The corticosteroid, paramethasone, may decrease the effect of the salicylate, acetylsalicylic acid.
DB01384	DB01320	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, paramethasone.
DB01384	DB00211	Increased arterial pressure
DB01384	DB01174	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, paramethasone.
DB01384	DB00252	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, paramethasone.
DB01384	DB00794	The barbiturate, primidone, may decrease the effect of the corticosteroid, paramethasone.
DB01384	DB00545	The corticosteroid, paramethasone, may decrease the effect of the anticholinesterase, pyridostigmine.
DB01384	DB01045	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, paramethasone.
DB01388	DB00637	Increased risk of cardiotoxicity and arrhythmias
DB01388	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB01388	DB00604	Mibefradil increases levels of cisapride
DB01388	DB00864	The calcium channel blocker, Mibefradil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Mibefradil therapy is initiated, discontinued or altered.
DB01388	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01390	DB01072	This gastric pH modifier decreases the levels/effect of atazanavir
DB01390	DB00865	Alkalinizing agents such as sodium bicarbonate may decrease the excretion of amphetamines like benzphetamine. Increased clinical effects and/or toxicity may occur. Therapy modification should be considered.
DB01390	DB08826	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DB01390	DB06210	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB01390	DB01356	The urine alkalizer decreases the effect of lithium
DB01390	DB01043	Possible increased levels of memantine
DB01390	DB06146	Urine alkalizer decreases the effect of methenamine
DB01390	DB00908	The antacid increases the effect of quinidine
DB01390	DB00208	Sodium bicarbonate may decrease Ticlopidine levels. Administer agents 1 to 2 hours apart.
DB01390	DB00932	Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir.
DB01390	DB00519	Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced.
DB01392	DB09026	Monitor therapy due to decreased antihypertensive effects of aliskiren.
DB01392	DB06216	Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided.
DB01392	DB00289	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
DB01393	DB01076	Increased risk of myopathy/rhabdomyolysis
DB01393	DB00439	Increased risk of myopathy/rhabdomyolysis
DB01393	DB01432	Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.
DB01393	DB00872	Conivaptan may increase the serum concentration of CYP3A4 substrates like bezafibrates. Consider therapy modification. Conivaptan may increase the serum concentration of CYP3A4 substrates.
DB01393	DB00091	Cyclosporine may enhance the nephrotoxic effect of fibric acid derivatives like bezafibrate. Fibric acid derivatives may decrease the serum concentration of cyclosporine. Extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary.
DB01393	DB01095	Increased risk of myopathy/rhabdomyolysis
DB01393	DB01247	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like isocarboxazid.
DB01393	DB00601	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like linezolid.
DB01393	DB00227	Increased risk of myopathy/rhabdomyolysis
DB01393	DB01171	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like moclobemide.
DB01393	DB00780	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like phenelzine.
DB01393	DB00175	Increased risk of myopathy/rhabdomyolysis
DB01393	DB01168	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like procarbazine.
DB01393	DB01367	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) rasagiline.
DB01393	DB01037	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like selegiline.
DB01393	DB00752	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like tranylcypromine.
DB01396	DB00999	Possible electrolyte variations and arrhythmias
DB01396	DB00808	Possible electrolyte variations and arrhythmias
DB01393	DB00682	Bezafibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if bezafibrate is initiated, discontinued or dose changed.
DB01394	DB01076	Increased risk of rhadbomyolysis with this combination.
DB01394	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of colchicine. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function.
DB01394	DB00439	Increased risk of rhabdomyolysis with this combination
DB01394	DB01211	Severe colchicine toxicity can occur
DB01394	DB00257	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function.
DB01394	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor.
DB01394	DB00091	Increased toxicity of both drugs
DB01394	DB00199	Severe colchicine toxicity can occur
DB01394	DB01095	Increased risk of rhabdomyolysis with this combination
DB01394	DB00227	Increased risk of rhabdomyolysis with this combination
DB01394	DB08860	Increased incidence of myotoxicity including rhabdomyolysis during concomitant therapy. The mechanism of this interaction is unclear, it may arise from pharmacodynamic and/or pharmacokinetic interactions.
DB01394	DB00175	Increased risk of rhabdomyolysis with this combination
DB01394	DB01098	Increased risk of rhabdomyolysis with this combination
DB01394	DB00641	Increased risk of rhabdomyolysis with this combination
DB01394	DB00976	Telithromycin may reduce clearance of Colchicine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Colchicine if Telithromycin is initiated, discontinued or dose changed.
DB01394	DB01361	Severe colchicine toxicity can occur
DB01394	DB00661	Verapamil may increase the serum concentration of Colchicine. This likely occurs via Verapamil-mediated inhibition of CYP3A4 and p-glycoprotein-mediated transport. Monitor for changes in the therapeutic/adverse effects of Colchicine if Verapamil is initiated, discontinued or dose changed.
DB01394	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of colchicine by decreasing its metabolism. A dose reduction of colchicine is recommended along with increased monitoring for colchicine toxicity. Concomitant therapy is contraindicated in patients with renal and/or hepatic impairment.
DB01395	DB06697	Artemether may decrease the effectiveness of drospirinone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB01395	DB00542	Increased risk of hyperkalemia
DB01395	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of drospirenone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB01395	DB08873	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB01395	DB00796	Increased risk of hyperkalemia
DB01395	DB01197	Increased risk of hyperkalemia
DB01395	DB01340	Increased risk of hyperkalemia
DB01395	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB01395	DB00584	Increased risk of hyperkalemia
DB01395	DB00876	Increased risk of hyperkalemia
DB01395	DB00492	Increased risk of hyperkalemia
DB01395	DB01109	Heparin can increase risk of hyperkalemia for patients on drospirenone
DB01395	DB01029	Increased risk of hyperkalemia
DB01395	DB00722	Increased risk of hyperkalemia
DB01395	DB00678	Increased risk of hyperkalemia
DB01395	DB00275	Increased risk of hyperkalemia
DB01395	DB00790	Increased risk of hyperkalemia
DB01395	DB01345	Increased risk of hyperkalemia
DB01395	DB00881	Increased risk of hyperkalemia
DB01395	DB00178	Increased risk of hyperkalemia
DB01395	DB00966	Telmisartan may increase the hyperkalemic effect of Drospirenone. Monitor for increased serum potassium concentrations during concomitant therapy.
DB01395	DB00599	Thiopental may decrease the effect of Drospirenone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
DB01395	DB00519	Increased risk of hyperkalemia. Monitor serum potassium levels.
DB01395	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01395	DB00755	Oral Tretinoin may decrease the effect of oral contraceptive, Drospirenone. An alternate form of contraception should be used during concomitant therapy.
DB01395	DB00384	Increased risk of hyperkalemia
DB01395	DB00682	Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed.
DB01396	DB00436	Possible electrolyte variations and arrhythmias
DB01396	DB00887	Possible electrolyte variations and arrhythmias
DB01396	DB00310	Possible electrolyte variations and arrhythmias
DB01396	DB00524	Possible electrolyte variations and arrhythmias
DB01396	DB00908	Quinine/quinidine increases the effect of digoxin
DB01396	DB00468	Quinine/quinidine increases the effect of digoxin
DB01396	DB00976	Telithromycin may reduce clearance of Digitoxin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Digitoxin if Telithromycin is initiated, discontinued or dose changed.
DB01396	DB00661	Verapamil may increase the serum concentration of Digitoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digitoxin if Verpamail is initiated, discontinued or dose changed.
DB01396	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of digitoxin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of digitoxin if voriconazole is initiated, discontinued or dose changed.
DB01397	DB00443	The corticosteroid, betamethasone, may decrease the effect of magnesium salicylate.
DB01397	DB01234	The corticosteroid, dexamethasone, may decrease the effect of magnesium salicylate.
DB01397	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of magnesium salicylate.
DB01397	DB01044	Formation of non-absorbable complexes
DB01397	DB01155	Formation of non-absorbable complexes
DB01397	DB01120	The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, gliclazide.
DB01397	DB01016	The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, glibenclamide.
DB01397	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of magnesium salicylate.
DB01397	DB00703	The salicylate, magnesium salicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB01397	DB00563	The salicylate, magnesium salicylate, increases the effect and toxicity of methotrexate.
DB01397	DB01017	Formation of non-absorbable complexes
DB01397	DB00860	The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate.
DB01397	DB00635	The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate.
DB01397	DB01032	The salicylate, magnesium salicylate, decreases the uricosuric effect of probenecid.
DB01397	DB00908	The antacid increases the effect of quinidine
DB01397	DB00759	Formation of non-absorbable complexes
DB01397	DB00620	The corticosteroid, triamcinolone, may decrease the effect of magnesium salicylate.
DB01398	DB00443	The corticosteroid, betamethasone, may decrease the effect of the salicylate, salicylate-sodium.
DB01398	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salicylate-sodium.
DB01398	DB01120	The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, gliclazide.
DB01398	DB01016	The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, glibenclamide.
DB01398	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salicylate-sodium.
DB01398	DB00703	The salicylate, salicylate-sodium, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB01398	DB00563	The salicylate, salicylate-sodium, increases the effect and toxicity of methotrexate.
DB01398	DB00860	The corticosteroid, prednisolone, may decrease the effect of the salicylate, salicylate-sodium.
DB01398	DB00635	The corticosteroid, prednisone, may decrease the effect of the salicylate, salicylate-sodium.
DB01398	DB01032	The salicylate, salicylate-sodium, decreases the uricosuric effect of probenecid.
DB01398	DB00605	Risk of additive toxicity (e.g. bleed risk). Salicylate-sodium may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB01398	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salicylate-sodium.
DB01398	DB00682	The antiplatelet effects of sodium salicylate may increase the bleed risk associated with warfarin.
DB01399	DB00443	The corticosteroid, betamethasone, may decrease the effect of the salicylate, salsalate.
DB01399	DB00672	The salicylate, salsalate, increases the effect of the sulfonylurea, chlorpropamide.
DB01399	DB01234	The corticosteroid, dexamethasone, may decrease the effect of the salicylate, salsalate.
DB01399	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salsalate.
DB01399	DB01120	The salicylate, salsalate, increases the effect of the sulfonylurea, gliclazide.
DB01399	DB01016	The salicylate, salsalate, increases the effect of the sulfonylurea, glibenclamide.
DB01399	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salsalate.
DB01399	DB00703	The salicylate, salsalate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB01399	DB00563	The salicylate, salsalate, increases the effect and toxicity of methotrexate.
DB01399	DB00860	The corticosteroid, prednisolone, may decrease the effect of the salicylate, salsalate.
DB01399	DB00635	The corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate.
DB01399	DB01032	The salicylate, salsalate, decreases the uricosuric effect of probenecid.
DB01399	DB00605	Risk of additive toxicity (e.g. bleed risk). Salsalate may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed.
DB01399	DB01600	Increased risk of gastrointestinal bleeding.
DB01399	DB00500	Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy.
DB01399	DB00519	The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Salsalate is initiated, discontinued or dose changed.
DB01399	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Salsalate. Monitor for increased bleeding during concomitant thearpy.
DB01399	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate.
DB01400	DB01234	The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, neostigmine.
DB01400	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, neostigmine.
DB01400	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine.
DB01400	DB00860	The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, neostigmine.
DB01400	DB00635	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine.
DB01400	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine.
DB01401	DB00443	The corticosteroid, betamethasone, may decrease the effect of the salicylate, trisalicylate-choline.
DB01401	DB00672	The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, chlorpropamide.
DB01401	DB00687	The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, trisalicylate-choline.
DB01401	DB01120	The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, gliclazide.
DB01401	DB01016	The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, glibenclamide.
DB01401	DB00741	The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, trisalicylate-choline.
DB01401	DB00703	The salicylate, trisalicylate-choline, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.
DB01401	DB00563	The salicylate, trisalicylate-choline, increases the effect and toxicity of methotrexate.
DB01401	DB01017	Formation of non-absorbable complexes
DB01401	DB00860	The corticosteroid, prednisolone, may decrease the effect of the salicylate, trisalicylate-choline.
DB01401	DB00635	The corticosteroid, prednisone, may decrease the effect of the salicylate, trisalicylate-choline.
DB01401	DB01032	The salicylate, trisalicylate-choline, decreases the uricosuric effect of probenecid.
DB01401	DB00759	Formation of non-absorbable complexes
DB01401	DB00620	The corticosteroid, triamcinolone, may decrease the effect of the salicylate, trisalicylate-choline.
DB01401	DB00682	The antiplatelet effects of trisalicylate-choline may increase the bleed risk associated with warfarin.
DB01403	DB00182	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01403	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB01403	DB00484	Brimonidine may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of brimonidine. Consider therapy modification.
DB01403	DB01558	Concomitant therapy may result in additive CNS depressant effects. The dosage of bromazepam should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression.
DB01403	DB01200	The phenothiazine decreases the effect of bromocriptine
DB01403	DB00395	Carisoprodol, a CNS depressant, may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants like carisoprodol. Reduce the dosage of CNS depressants by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose has been established. Monitor for increased CNS depression with concomitant therapy.
DB01403	DB00604	Increased risk of cardiotoxicity and arrhythmias
DB01403	DB01219	Concomitant therapy may result in additive CNS depressant effects. The dosage of dantrolene should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression.
DB01403	DB01191	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB01576	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB00937	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB00843	Possible antagonism of action
DB01403	DB00574	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB00674	Possible antagonism of action
DB01403	DB01044	Increased risk of cardiotoxicity and arrhythmias
DB01403	DB00365	Increased risk of cardiotoxicity and arrhythmias
DB01403	DB01170	Methotrimeprazine may decrease the effect of guanethidine.
DB01403	DB01247	Possible severe adverse reaction with this combination
DB01403	DB01137	Increased risk of cardiotoxicity and arrhythmias
DB01403	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01403	DB00579	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB01577	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB01578	Increased risk of convulsions
DB01403	DB01267	The CNS depressant agents, paliperidone and methotrimeprazine, may cause additive CNS depressant effects. Monitor for increased CNS depressant effects during concomitant therapy.
DB01403	DB01626	Possible severe adverse reaction with this combination
DB01403	DB01579	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB00780	Possible severe adverse reaction with this combination
DB01403	DB00830	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB00191	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB00397	Decreased anorexic effect, may increase psychotic symptoms
DB01403	DB00989	Possible antagonism of action
DB01403	DB01208	Increased risk of cardiotoxicity and arrhythmias
DB01403	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01403	DB00193	Additive CNS depressant effects. Decrease dose of tramadol by 50% if initiating methotrimeprazine therapy. Monitor for increased CNS depression and apply further dosage adjustments as required.
DB01403	DB00752	Possible severe adverse reaction with this combination
DB01418	DB00199	The macrolide, erythromycin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00977	Increased thrombotic risk due to estrogen
DB01403	DB01080	Additive CNS depression may occur. Dose adjustments may be required if one agent is added to existing therapy with the other agent. Monitor for increased CNS depression during concomitant therapy.
DB01403	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01403	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01403	DB00962	Additive CNS depressant effects may occur. A dose reduction of zaleplon may be required. Monitor for increased CNS depression during concomitant therapy.
DB01403	DB06283	Additive CNS depressant effects may occur. A dose reduction of ziconotide may be required. Monitor for increased CNS depression during concomitant therapy.
DB01403	DB00246	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB01403	DB00425	Additive CNS depressant effects. Reduce zolpidem dose by half upon initiation of methotrimeprazine. Zolpidem dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.
DB01403	DB00909	Additive CNS depressant effects. Reduce zonisamide dose by half upon initiation of methotrimeprazine. Zonisamide dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.
DB01403	DB01198	Additive CNS depressant effects. Reduce zopiclone dose by half upon initiation of methotrimeprazine. Zopiclone dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.
DB01403	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed.
DB01404	DB00887	Ginseng may decrease the therapeutic effect of diuretic, bumetanide.
DB01404	DB00390	Changes in digoxin serum levels
DB01404	DB00903	Ginseng may decrease the therapeutic effect of diuretic, ethacrynic acid.
DB01404	DB00695	Ginseng decreases the therapeutic effect
DB01404	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01404	DB01009	Increased risk of bleeding due to additive anticoagulant properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01404	DB01115	Ginseng increases the effect and toxicity of nifedipine
DB01404	DB00605	Ginseng may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
DB01404	DB00031	Increased risk of bleeding.
DB01404	DB01600	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01404	DB00500	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01404	DB00519	Ginseng may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy.
DB01404	DB00013	Increased risk of bleeding.
DB01404	DB00682	Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
DB01405	DB01373	Formation of non-absorbable complexes
DB01405	DB00893	Formation of non-absorbable complexes
DB01405	DB01378	Formation of non-absorbable complexes
DB01406	DB01418	The androgen, danazol, may increase the anticoagulant effect of acenocoumarol.
DB01406	DB01125	The androgen, danazol, may increase the anticoagulant effect of anisindione.
DB01406	DB00564	Danazol may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of carbamazepine if danazol is initiated, discontinued or dose changed.
DB01406	DB00091	The androgen, danazol, may increase the effect and toxicity of cyclosporine.
DB01406	DB00266	The androgen, danazol, may increase the anticoagulant effect of dicumarol.
DB01406	DB01276	Monitor therapy due to reduced hypoglycemic effect of exenatide.
DB01406	DB01306	Monitor therapy due to decreased hypoglycemic effect of insulin aspart.
DB01406	DB00227	Risk of severe myopathy/rhabdomyolysis with this combination
DB01406	DB00864	Danazol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Danazol therapy is initiated, discontinued or altered.
DB01406	DB00682	Danazol may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if danazol is initiated, discontinued or dose changed.
DB01408	DB05039	Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs.
DB01409	DB00761	The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Tiotropium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
DB01409	DB01278	The anticholinergic effects of Tiotropium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01409	DB00021	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
DB01418	DB00189	Ethchlorvynol may decrease the anticoagulant effect of acenocoumarol.
DB01409	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tiotropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01409	DB00662	Trimethobenzamide and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01409	DB00427	Triprolidine and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01409	DB00209	Trospium and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01410	DB01167	Increased effects/toxicity of ciclesonide
DB01410	DB01026	Increased effects/toxicity of ciclesonide
DB01410	DB00220	Increased effects/toxicity of ciclesonide
DB01410	DB00503	Increased effects/toxicity of ciclesonide
DB01410	DB00976	Telithromycin may reduce clearance of Ciclesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ciclesonide if Telithromycin is initiated, discontinued or dose changed.
DB01410	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ciclesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ciclesonide if voriconazole is initiated, discontinued or dose changed.
DB01413	DB01032	Probenecid may increase the serum level of cefepime.
DB01418	DB00316	Acetaminophen may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if acetaminophen is initiated, discontinued or dose changed.
DB01418	DB00945	Acetylsalicylic acid increases the effect of the anticoagulant, acenocoumarol.
DB01418	DB00437	Allopurinol may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00357	Aminoglutethimide may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB01118	Amiodarone may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00701	Amprenavir may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB01418	DB00673	Aprepitant may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration.
DB01418	DB01072	The protease inhibitor, atazanavir, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00993	Azathioprine may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00207	Azithromycin may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB01418	DB00443	The corticosteroid, betamethasone, alters the anticoagulant effect, acenocoumarol.
DB01418	DB00559	Bosentan may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.
DB01418	DB00237	Barbiturates like butabarbital may increase the metabolism of Vitamin K Antagonists like acenocoumarol. onitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes.
DB01418	DB00241	Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes.
DB01418	DB01101	Capecitabine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB01418	DB00564	Carbamazepine may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration.
DB01418	DB01330	The cephalosporin, cefotetan, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01331	The cephalosporin, cefoxitin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01212	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00482	Celecoxib may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01432	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption.
DB01418	DB00501	Cimetidine may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00537	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00604	Cisapride may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00215	The SSRI, citalopram, increases the effect of anticoagulant, acenocoumarol.
DB01418	DB01211	The macrolide, clarithromycin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00636	The fibrate increases the anticoagulant effect
DB01418	DB00375	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption.
DB01418	DB00531	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of acenocoumarol.
DB01418	DB01406	The androgen, danazol, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00618	The tetracycline, demeclocycline, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01234	The corticosteroid, dexamethasone, alters the anticoagulant effect, acenocoumarol.
DB01418	DB00647	Propoxyphene may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00509	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of acenocoumarol.
DB01418	DB00485	Dicloxacillin may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00861	The NSAID, diflunisal, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00822	Disulfiram may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00254	The tetracycline, doxycycline, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00749	The NSAID, etodolac, may increase the anticoagulant effect or acenocoumarol.
DB01418	DB01628	Etoricoxib may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01039	Fenofibrate may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00573	The NSAID, fenoprofen, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00196	Fluconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism.
DB01418	DB00687	The corticosteroid, fludrocortisone, alters the anticoagulant effect, acenocoumarol.
DB01418	DB00544	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00472	The SSRI, fluoxetine, increases the effect of anticoagulant, acenocoumarol.
DB01418	DB01185	The androgen, fluoxymesterone, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00712	The NSAID, flurbiprofen, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01095	Fluvastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if fluvastatin is initiated, discontinued or dose changed.
DB01418	DB00176	Fluvoxamine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.
DB01418	DB01319	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01320	Increased hydantoin levels and risk of bleeding
DB01418	DB00317	Gefitinib may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00441	Gemcitabine may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01241	Gemfibrozil may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB01418	DB01437	Glutethimide may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00400	Griseofulvin may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00741	The corticosteroid, hydrocortisone, alters the anticoagulant effect, acenocoumarol.
DB01418	DB01050	The NSAID, ibuprofen, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00619	Imatinib may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00224	The protease inhibitor, indinavir, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00328	The NSAID, indomethacin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00951	Isoniazid may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01167	Itraconazole may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01026	Ketoconazole may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01009	The NSAID, ketoprofen, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00465	The NSAID, ketorolac, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01097	Leflunomide may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00848	Levamisole may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01137	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00451	The thyroid hormone, levothyroxine, increase the anticoagulant effect of acenocoumarol.
DB01418	DB00227	Lovastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if lovastatin is initiated, discontinued or dose changed.
DB01418	DB01283	Lumiracoxib may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00603	Medroxyprogesterone may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00784	The NSAID, mefanamic acid, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00358	Mefloquine may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00814	Meloxicam may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01033	Mercaptopurine may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00763	The antithyroid agent, methimazole, may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00916	Metronidazole may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01110	Miconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism.
DB01418	DB01017	The tetracycline, minocycline, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00648	Mitotane may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00218	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00461	The NSAID, nabumetone, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00779	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00788	The NSAID, naproxen, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00220	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00238	Nevirapine may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB01059	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01165	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01083	Orlistat may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00991	The NSAID, oxaprozin, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB03585	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00715	The SSRI, paroxetine, increases the effect of the anticoagulant, acenocoumarol.
DB01418	DB00806	Pentoxifylline may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01174	The barbiturate, phenobarbital, decreases the anticoagulant effect of acenocoumarol.
DB01418	DB00812	The NSAID, phenylbutazone, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00252	Increased hydantoin levels and risk of bleeding
DB01544	DB00363	Increased risk of toxicity
DB01418	DB00554	The NSAID, piroxicam, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00860	The corticosteroid, prednisolone, alters the anticoagulant effect, acenocoumarol.
DB01418	DB00635	The corticosteroid, prednisone, alters the anticoagulant effect, acenocoumarol.
DB01418	DB00794	The barbiturate, primidone, decreases the anticoagulant effect of acenocoumarol.
DB01418	DB01182	Propafenone may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00550	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of acenocoumarol.
DB01418	DB00908	Quinidine may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00468	Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of acenocoumarol by decreasing its metabolism via CYP2C9.
DB01418	DB00863	Ranitidine may increase the anticoagulant effect of acenocoumarol. (Conflicting evidence)
DB01418	DB00615	Rifabutin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.
DB01418	DB01045	Rifampin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.
DB01418	DB00605	The NSAID, sulindac, may increase the anticoagulant effect of acenocoumarol. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB01418	DB00675	Tamoxifen may increase the serum concentration of Acenocoumarol increasing the risk of bleeding. Concomitant therapy should be avoided.
DB01418	DB00976	Telithromycin may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00469	The NSAID, tenoxicam, may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00894	The androgen, Testolactone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testolactone is initiated, discontinued or dose changed.
DB01418	DB00624	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed.
DB01418	DB01420	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed.
DB01418	DB00759	Tetracycline may increase the anticoagulant effect of acenocoumarol.
DB01418	DB00730	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Acenocoumarol by decreasing Acenocoumarol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Acenocoumarol if Thiabendazole is initiated, discontinued or dose changed.
DB01418	DB00599	Thiopental may increase the metabolism of the Vitamin K antagonist, Acenocoumarol. Acenocoumarol dose adjustment may be required.
DB01418	DB01600	Increased risk of bleeding.
DB01418	DB00560	Tigecycline may increase the anticoagulant effect of acenocoumarol.
DB01418	DB01124	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Acenocoumarol. Consider alternate therapy or monitor for changes in Acenocoumarol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
DB01418	DB00500	Increased risk of bleeding. Monitor for signs and symptoms of bleeding.
DB01418	DB05275	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed.
DB01418	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Acenocoumarol. Monitor for increased bleeding during concomitant thearpy.
DB01418	DB00620	The corticosteroid, triamcinolone, alters the anticoagulant effect, acenocoumarol.
DB01418	DB01157	The anticoagulant effect of Acenocoumarol, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use.
DB01418	DB00549	Zafirlukast may inhibit the metabolism of the vitamin K antagonist Acenocoumarol and increase INR and risk of bleeding.
DB01420	DB01418	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed.
DB01420	DB00091	The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB01420	DB01248	Testosterone propionate may increase the serum levels and toxicity of docetaxel.
DB01420	DB00682	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.
DB01432	DB01418	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption.
DB01432	DB01125	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of anisindione by decreasing its absorption.
DB01432	DB01393	Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.
DB01432	DB00880	Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction.
DB01483	DB08867	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
DB01501	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01529	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01432	DB00169	Bile acid sequestrants such as cholestyramine may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB01432	DB00266	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of dicumarol by decreasing its absorption.
DB01432	DB00390	The resin decreases the effect of digoxin
DB01432	DB00973	Cholestyramine may decrease the levels of ezetimibe.
DB01432	DB01095	Increased/decreased effect according to spacing
DB01432	DB00741	Cholestyramine may decrease the effect of hydrocortisone.
DB01432	DB00451	The resin, cholestyramine, decreases the absorption of the thyroid hormone, levothyroxine.
DB01432	DB00279	The resin, cholestyramine, decreases the absorption of the thyroid hormones, liothyronine.
DB01432	DB01583	The resin, cholestyramine, decreases the absorption of the thyroid hormone, liotrix.
DB01432	DB08827	Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours.
DB01432	DB00563	Decreased levels of methotrexate
DB01432	DB00481	The resin decreases the effect of raloxifene
DB01432	DB00421	Increased risk of acidosis and hyperkalemia
DB01432	DB00605	The bile acid sequestrant, cholestyramine, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if cholestyramine is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions.
DB01432	DB00469	Cholestyramine may decrease the serum concentration of Tenoxicam by increasing clearance. Monitor for changes in Tenoxicam therapeutic and adverse effects if Cholestyramine is initiated, discontinued or dose changed.
DB01432	DB01584	The resin, cholestyramine, decreases the absorption of the thyroid hormone, thyroglobulin.
DB01432	DB01600	The bile acid sequestrant, Cholestyramine resin, may reduce Tiaprofenic acid absorption and therapeutic effect.
DB01432	DB00500	Cholestyramine may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB01432	DB00214	Cholestyramine may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.
DB01432	DB01021	The bile acid sequestrant, Cholestyramine resin, may inhibit the absorption of Trichlormethiazide.
DB01432	DB00197	Decreases the effect of troglitazone
DB01432	DB01586	The resin decreases the effect of ursodiol
DB01432	DB00682	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of warfarin by decreasing its absorption.
DB01436	DB02300	Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use.
DB01436	DB00169	Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB01436	DB00930	Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs.
DB01437	DB01418	Glutethimide may decrease the anticoagulant effect of acenocoumarol.
DB01437	DB01125	Glutethimide may decrease the anticoagulant effect of anisindione.
DB01437	DB00266	Glutethimide may decrease the anticoagulant effect of dicumarol.
DB01437	DB00843	Possible antagonism of action
DB01437	DB00674	Possible antagonism of action
DB01437	DB00989	Possible antagonism of action
DB01437	DB00427	The CNS depressants, Triprolidine and Glutethimide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01437	DB00682	Glutethimide may decrease the serum concentration of warfarin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if glutethimide is initiated, discontinued or dose changed.
DB01452	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01452	DB00501	Cimetidine increases the effect of the narcotic
DB01483	DB06212	Barbital is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB01491	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB01551	DB06274	Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days.
DB01551	DB06767	May enhance excretion of dihydrocodeine. Recommended to monitor for reduced therapeutic effect.
DB01551	DB00182	Amphetamines may enhance analgesic effects of dihydrocodeine. Monitor for enhanced analgesia. Dose reductions of dihydrocodeine may be appropriate.
DB01551	DB00972	Enhanced CNS depressant effects contraindicates concurrent use.
DB01551	DB00477	Phenothiazines may enhance hypotensive effects of opioid analgesics. It is recommended to monitor patients for hypotension.
DB01551	DB00363	CNS depressants may enhance the adverse effects and toxicity of other CNS depressants. It is recommended to monitor therapy.
DB01551	DB00035	Opioids may enhance the adverse effects and toxicity of desmopressin. It is recommended to monitor therapy.
DB01551	DB00450	Enhanced CNS depressant effects are possible. Consider dose reduction of a CNS agent, if concurrent use is not avoidable.
DB01551	DB00999	Dihydrocodeine may enhance the hypotensive effects of thiazide diuretics. \r\nIt is recommended to monitor therapy.
DB01551	DB00557	May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy.
DB01551	DB00653	May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy.
DB01551	DB00765	Concurrent use may enhance the sedative effect of Metyrosine.  It is recommended to monitor therapy.
DB01551	DB00104	Concurrent use may enhance the analgesic effect of dihydrocodeine. It is recommended to monitor therapy, and reduce the dose of dihydrocodeine as appropriate.
DB01551	DB00038	May increase the serum levels of opioid analgesics. It is recommended to monitor therapy for the signs and symptoms of respiratory depression and enhanced sedation.
DB01551	DB00715	Opioid analgesics may enhance the 5HT effects of SSRIs to cause serotonin syndrome. It is recommended to monitor therapy.
DB01551	DB00082	Opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy.
DB01551	DB08883	Enhanced CNS depressant effects. Consider therapy modification, and avoid performing complex and high risk activities like driving until side effects are known.
DB01551	DB00413	Dihydrocodeine may enhance the sedative effect of pramipexole. It is recommended to monitor therapy
DB01551	DB00908	Use of quinidine may reduce dihydrocodeine's analgesic effect.
DB01551	DB00268	Dihydrocodeine may enhance the sedative effect of ropinirole. It is recommended to monitor therapy
DB01551	DB05271	Dihydrocodeine may enhance the sedative effect of rotigotine. It is recommended to monitor therapy.
DB01551	DB00202	May enhance the bradycardic effect of opioid analgesics. It is recommended to monitor therapy.
DB01551	DB00427	The CNS depressants, Triprolidine and Dihydrocodeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01551	DB00425	Enhanced CNS depressant effects contraindicates concurrent use for certain brand name formulations of zolpidem.
DB01558	DB01223	Aminophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if aminophylline is initiated, discontinued or dose changed.
DB01558	DB01072	Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if atazanavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00501	Co-administration with cimetidine will cause a reduction in bromazepam clearance and increases half-life.
DB01558	DB01211	Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if clarithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00363	Bromazepam may increase the adverse effects of clozapine. Consider alternate therapy or a reduction in the bromazepam dose. Monitor for respiratory depression and hypotension if concomitant therapy is initiated.
DB01558	DB00872	Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if conivaptan is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB01264	Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if darunavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00705	Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if delavirdine is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00343	Diltiazem may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if diltiazem is initiated, discontinued or dose changed.
DB01558	DB00651	Dyphylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if dyphylline is initiated, discontinued or dose changed.
DB01558	DB00199	Erythromcyin may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if erythromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00196	Fluconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if fluconazole is initiated, discontinued or dose changed.
DB01558	DB01319	Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if fosamprenavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00619	Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if imatinib is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00224	Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if indinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00951	Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if isoniazid is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB01167	Itraconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if itraconazole is initiated, discontinued or dose changed.
DB01558	DB01026	Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed.
DB01558	DB01601	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if lopinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB01403	Concomitant therapy may result in additive CNS depressant effects. The dosage of bromazepam should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression.
DB01558	DB01149	Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nefazodone is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00220	Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nelfinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00622	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nicardipine is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB01263	Posaconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if posaconazole is initiated, discontinued or dose changed.
DB01558	DB00571	Co-administration with propranolol will cause a reduction in bromazepam clearance and increases half-life.
DB01558	DB00908	Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if quinidine is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00615	Rifabutin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifabutin is initiated, discontinued or dose changed.
DB01558	DB01045	Rifampin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifampin is initiated, discontinued or dose changed.
DB01558	DB01201	Rifapentine may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifapentine is initiated, discontinued or dose changed.
DB01558	DB00503	Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if ritonavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB01232	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if saquinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00976	Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if telithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01558	DB00277	Theophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if theophylline is initiated, discontinued or dose changed.
DB01558	DB00932	Tipranavir may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if tipranavir is initiated, discontinued or dose changed.
DB01558	DB00427	The CNS depressants, Triprolidine and Bromazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01558	DB00661	Verapamil may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if verapamil is initiated, discontinued or dose changed.
DB01558	DB00582	Voriconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if voriconazole is initiated, discontinued or dose changed.
DB01563	DB00427	The CNS depressants, Triprolidine and Chloral hydrate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01574	DB00608	The antiacid decreases the absorption of chloroquine
DB01574	DB01190	The aluminium salt decreases the absorption of lincosamides
DB01574	DB00618	Formation of non-absorbable complexes
DB01574	DB00254	Formation of non-absorbable complexes
DB01574	DB01627	The aluminium salt decreases the absorption of lincosamides
DB01574	DB01017	Formation of non-absorbable complexes
DB01574	DB00299	The multivalent agent decreases the effect of penicillamine
DB01574	DB00759	Formation of non-absorbable complexes
DB01575	DB00608	The antiacid decreases the absorption of chloroquine
DB01575	DB01190	The aluminium salt decreases the absorption of lincosamides
DB01575	DB01627	The aluminium salt decreases the absorption of lincosamides
DB01575	DB00299	The multivalent agent decreases the effect of penicillamine
DB01576	DB00477	Decreased anorexic effect, may increases psychotic symptoms
DB01576	DB00472	Risk of serotoninergic syndrome
DB01576	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB01576	DB00176	Risk of serotoninergic syndrome
DB01576	DB01170	Dextroamphetamine may decrease the effect of guanethidine.
DB01576	DB01247	Possible hypertensive crisis
DB01576	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB01576	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB01576	DB00715	Risk of serotoninergic syndrome
DB01576	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB01576	DB00780	Possible hypertensive crisis
DB01576	DB00433	Decreased anorexic effect, may increase pyschotic symptoms
DB01576	DB01069	Decreased anorexic effect, may increase pyschotic symptoms
DB01576	DB01608	Decreased anorexic effect, may increase pyschotic symptoms
DB01576	DB01367	Possible hypertensive crisis
DB01576	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB01576	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01576	DB00519	Dextroamphetamine may reduce the efficacy of Trandolapril.
DB01576	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Dextroamphetamine. Concomitant therapy should be avoided.
DB01576	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB01576	DB00427	Triprolidine may reduce the sedative effect of the antihistamine, Dextroamphetamine.
DB01577	DB00477	Decreased anorexic effect, may increases psychotic symptoms
DB01577	DB00472	Risk of serotoninergic syndrome
DB01577	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB01577	DB00176	Risk of serotoninergic syndrome
DB01577	DB01170	Methamphetamine may decrease the effect of guanethidine.
DB01577	DB01247	Possible hypertensive crisis
DB01577	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB01577	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB01577	DB00715	Risk of serotoninergic syndrome
DB01577	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB01577	DB00780	Possible hypertensive crisis
DB01577	DB00433	Decreased anorexic effect, may increase pyschotic symptoms
DB01577	DB01069	Decreased anorexic effect, may increase pyschotic symptoms
DB01577	DB01608	Decreased anorexic effect, may increase pyschotic symptoms
DB01577	DB01367	Possible hypertensive crisis
DB01577	DB00857	Terbinafine may reduce the metabolism and clearance of Methamphetamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Methamphetamine if Terbinafine is initiated, discontinued or dose changed.
DB01577	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB01577	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01577	DB00519	Methamphetamine may reduce the efficacy of Trandolapril.
DB01577	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Methamphetamine. Concomitant therapy should be avoided.
DB01577	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB01577	DB00427	Triprolidine may reduce the sedative effect of the antihistamine, Methamphetamine.
DB01578	DB00477	Increased risk of convulsions
DB01578	DB00623	Increased risk of convulsions
DB01578	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB01578	DB01403	Increased risk of convulsions
DB01578	DB00850	Increased risk of convulsions
DB01578	DB00433	Increased risk of convulsions
DB01578	DB01069	Increased risk of convulsions
DB01578	DB01608	Increased risk of convulsions
DB01578	DB00679	Increased risk of convulsions
DB01578	DB00831	Increased risk of convulsions
DB01579	DB00477	Decreased anorexic effect, may increases psychotic symptoms
DB01579	DB00472	Risk of serotoninergic syndrome
DB01579	DB00623	Decreased anorexic effect, may increase psychotic symptoms
DB01579	DB00176	Risk of serotoninergic syndrome
DB01579	DB01170	Phendimetrazine may decrease the effect of guanethidine.
DB01579	DB01247	Possible hypertensive crisis
DB01579	DB00933	Decreased anorexic effect, may increase psychotic symptoms
DB01579	DB01403	Decreased anorexic effect, may increase psychotic symptoms
DB01579	DB00715	Risk of serotoninergic syndrome
DB01579	DB00850	Decreased anorexic effect, may increase psychotic symptoms
DB01579	DB00780	Possible hypertensive crisis
DB01579	DB00433	Decreased anorexic effect, may increase pyschotic symptoms
DB01579	DB01069	Decreased anorexic effect, may increase pyschotic symptoms
DB01579	DB01608	Decreased anorexic effect, may increase pyschotic symptoms
DB01579	DB01367	Possible hypertensive crisis
DB01579	DB00679	Decreased anorexic effect, may increase psychotic symptoms
DB01579	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB01579	DB00519	Phendimetrazine may reduce the efficacy of Trandolapril.
DB01579	DB00752	The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Phendimetrazine. Concomitant therapy should be avoided.
DB01579	DB00831	Decreased anorexic effect, may increase psychotic symptoms
DB01579	DB00427	Triprolidine may reduce the sedative effect of the antihistamine, Phendimetrazine.
DB01580	DB00414	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB00672	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB00575	Increased hypertension when clonidine stopped
DB01580	DB00320	Ischemia with risk of gangrene
DB01580	DB00280	The beta-blocker, oxprenolol, may increase the toxicity of disopyramide.
DB01580	DB00668	Hypertension, then bradycardia
DB01580	DB01253	Ischemia with risk of gangrene
DB01580	DB00696	Ischemia with risk of gangrene
DB01580	DB01288	Antagonism
DB01580	DB00983	Antagonism
DB01580	DB01120	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01067	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01289	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01016	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01382	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01050	Risk of inhibition of renal prostaglandins
DB01580	DB00328	Risk of inhibition of renal prostaglandins
DB01580	DB00047	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01064	Antagonism
DB01580	DB00281	The beta-blocker increases the effect and toxicity of lidocaine
DB01580	DB00968	Possible hypertensive crisis
DB01580	DB00247	Ischemia with risk of gangrene
DB01580	DB00816	Antagonism
DB01580	DB00236	Antagonism
DB01580	DB01291	Antagonism
DB01580	DB00554	Risk of inhibition of renal prostaglandins
DB01580	DB01297	Antagonism
DB01580	DB00457	Risk of hypotension at the beginning of therapy
DB01580	DB00912	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01001	Antagonism
DB01580	DB00938	Antagonism
DB01580	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB01580	DB00871	Antagonism
DB01580	DB00839	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB01124	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
DB01580	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01580	DB00661	Increased effect of both drugs
DB01581	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB01581	DB00563	The sulfamide increases the toxicity of methotrexate
DB01582	DB00672	Sulfonamide/sulfonylurea: possible hypoglycemia
DB01582	DB00091	The sulfonamide decreases the effect of cyclosporine
DB01582	DB00563	The sulfamide increases the toxicity of methotrexate
DB01583	DB00258	Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
DB01583	DB01432	The resin, cholestyramine, decreases the absorption of the thyroid hormone, liotrix.
DB01583	DB00375	The resin, colestipol, decreases the absorption of the thyroid hormone, liotrix.
DB01583	DB00390	The thyroid hormone, liotrix, decreases the effect of digoxin.
DB01583	DB00682	Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed.
DB01584	DB01432	The resin, cholestyramine, decreases the absorption of the thyroid hormone, thyroglobulin.
DB01584	DB00375	The resin, colestipol, decreases the absorption of the thyroid hormone, thyroglobulin.
DB01584	DB00390	The thyroid hormone, thyroglobulin, decreases the effect of digoxin.
DB01586	DB01432	The resin decreases the effect of ursodiol
DB01586	DB00636	The fibric acid derivative decreases the effect of ursodiol
DB01586	DB00882	Estrogens decreases the effect of ursodiol
DB01586	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Ursodiol. Consider administration of ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.
DB01586	DB00375	The resin decreases the effect of ursodiol
DB01586	DB00286	Estrogens decreases the effect of ursodiol
DB01586	DB00091	Ursodiol increases the levels of cyclosporine
DB01586	DB00255	Estrogens decreases the effect of ursodiol
DB01586	DB00783	Estrogens decreases the effect of ursodiol
DB01586	DB00977	Estrogens decreases the effect of ursodiol
DB01586	DB01039	The fibric acid derivative decreases the effect of ursodiol
DB01586	DB01241	The fibric acid derivative decreases the effect of ursodiol
DB01587	DB00501	Cimetidine may increase the effect of the benzodiazepine, ketazolam.
DB01587	DB00363	Increased risk of toxicity
DB01587	DB00338	Omeprazole may increase the effect of the benzodiazepine, ketazolam.
DB01588	DB00501	Cimetidine may increase the effect of the benzodiazepine, prazepam.
DB01588	DB00363	Increased risk of toxicity
DB01588	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, prazepam.
DB01588	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, prazepam.
DB01588	DB00338	Omeprazole may increase the effect of the benzodiazepine, prazepam.
DB01588	DB00932	Tipranavir may decrease the metabolism and clearance of Prazepam. Consider alternate therapy or monitor for Prazepam toxic effects if Tipranavir is initiated or dose increased.
DB01588	DB00427	The CNS depressants, Triprolidine and Prazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01588	DB00582	Voriconazole may increase the serum concentration of prazepam by decreasing its metabolism. Monitor for prazepam toxicity if voriconazole is initiated or dose increased.
DB01589	DB00501	Cimetidine may increase the effect of the benzodiazepine, quazepam.
DB01589	DB00363	Increased risk of toxicity
DB01589	DB00196	Fluconazole may increase the effect of the benzodiazepine, quazepam.
DB01589	DB00224	The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, quazepam.
DB01589	DB01167	Itraconazole may increase the effect of the benzodiazepine, quazepam.
DB01589	DB01026	Ketoconazole may increase the effect of the benzodiazepine, quazepam.
DB01589	DB00220	The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, quazepam.
DB01589	DB00338	Omeprazole may increase the effect of the benzodiazepine, quazepam.
DB01589	DB00932	Tipranavir may decrease the metabolism and clearance of Quazepam. Consider alternate therapy or monitor for Quazepam toxic effects if Tipranavir is initiated or dose increased.
DB01589	DB00427	The CNS depressants, Triprolidine and Quazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB01590	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of everolimus. Consider therapy modification. Recommendations regarding optimal management of this interaction vary according to specific indication and product used.
DB01590	DB01211	The macrolide, clarithromycin, may increase the serum concentration and toxicity of everolimus.
DB01590	DB00257	CYP3A4 Inhibitors (Moderate)such as clotrimazole may increase the serum concentration of everolimus. The prescribing information for the Afinitor branded everolimus product lists indication-specific recommendations for managing this interaction.
DB01590	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus. Everolimus prescribing information recommends avoiding concurrent use with strong CYP3A4 inhbitors.
DB01590	DB00199	The macrolide, erythromycin, may increase the serum concentration and toxicity of everolimus.
DB01590	DB06414	Everolimus, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. If concurrent therapy cannot be avoided, a gradual dosage increase of everolimus is recommended.
DB01590	DB00196	Fluconazole may increase everolimus levels/toxicity.
DB01590	DB01167	Itraconazole may increase everolimus levels/toxicity.
DB01590	DB01026	Ketoconazole may increase everolimus levels/toxicity.
DB01590	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB01590	DB00661	Concomitant administration may increase the serum concentrations of both agents. Concurrent use should be avoided.
DB01590	DB00582	Voriconzole, a strong CYP3A4 inhibitor, may increase the serum concentration of everolimus by decreasing its metabolism. Concurrent therapy should be avoided.
DB01591	DB01211	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01591	DB00843	Possible antagonism of action
DB01591	DB00674	Possible antagonism of action
DB01591	DB01167	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01591	DB01026	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01591	DB01149	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
DB01591	DB00220	This potent CYP3A4 inhibitor slows darifenacin / solifenacin metabolism
DB01591	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Solifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01591	DB00976	Telithromycin may reduce clearance of Solifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Solifenacin if Telithromycin is initiated, discontinued or dose changed.
DB01591	DB00662	Trimethobenzamide and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01591	DB00427	Triprolidine and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01591	DB00209	Trospium and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01591	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of solifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of solifenacin if voriconazole is initiated, discontinued or dose changed.
DB01592	DB00537	Formation of non-absorbable complexes
DB01592	DB00720	Formation of non-absorbable complexes
DB01592	DB08826	Deferiprone serum concentrations may be decreased by iron salts except for ferric gluconate, ferumoxytol, iron dextran complex, and iron sucrose.
DB01592	DB00618	Formation of non-absorbable complexes
DB01592	DB00254	Formation of non-absorbable complexes
DB01592	DB01077	Formation of non-absorbable complexes
DB01592	DB01044	Formation of non-absorbable complexes
DB01592	DB01155	Formation of non-absorbable complexes
DB01592	DB00365	Formation of non-absorbable complexes
DB01592	DB00710	Formation of non absorbable complexes
DB01592	DB01137	Formation of non-absorbable complexes
DB01592	DB00451	Iron decreases absorption of levothyroxine
DB01592	DB00968	Iron decreases the absorption of dopa derivatives
DB01592	DB01017	Formation of non-absorbable complexes
DB01592	DB00218	Formation of non-absorbable complexes
DB01592	DB00688	Oral iron decreases the absorption of mycophenolate-mofetil
DB01592	DB01059	Formation of non-absorbable complexes
DB01592	DB01165	Formation of non-absorbable complexes
DB01592	DB00085	If pancrelipase and iron salts are used in combination then monitor therapy. Pancrelipase may decrease the absorption of iron salts except for ferumoxytol, iron dextran complex, and iron sucrose.
DB01592	DB00299	The multivalent agent decreases the effect of penicillamine
DB01592	DB00759	Formation of non-absorbable complexes
DB01592	DB00685	Iron may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the iron containing agent to minimize the interaction.
DB01593	DB00537	Formation of non-absorbable complexes
DB01593	DB08826	Deferiprone serum concentrations may be decreased by zinc salts except for zinc chloride.
DB01593	DB00618	Formation of non-absorbable complexes
DB01593	DB00254	Formation of non-absorbable complexes
DB01593	DB01044	Formation of non-absorbable complexes
DB01593	DB01155	Formation of non-absorbable complexes
DB01593	DB00365	Formation of non-absorbable complexes
DB01593	DB01137	Formation of non-absorbable complexes
DB01593	DB01017	Formation of non-absorbable complexes
DB01593	DB00218	Formation of non-absorbable complexes
DB01593	DB01059	Formation of non-absorbable complexes
DB01593	DB01165	Formation of non-absorbable complexes
DB01593	DB00759	Formation of non-absorbable complexes
DB01593	DB00685	Zinc may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the zinc containing agent to minimize the interaction.
DB01594	DB00363	Increased risk of toxicity
DB01595	DB00363	Increased risk of toxicity
DB01597	DB00091	Imipenem increases the effect and toxicity of cyclosporine
DB01597	DB01610	Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)
DB01598	DB00091	Imipenem increases the effect and toxicity of cyclosporine
DB01598	DB01610	Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)
DB01599	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01599	DB00091	Probucol decreases the effect of cyclosporine
DB01599	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01599	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01599	DB01623	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01599	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01599	DB00726	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01599	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01599	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01599	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB01599	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01600	DB01418	Increased risk of bleeding.
DB01600	DB00945	Increased risk of gastrointestinal bleeding.
DB01600	DB00233	Increased risk of gastrointestinal bleeding.
DB01600	DB01432	The bile acid sequestrant, Cholestyramine resin, may reduce Tiaprofenic acid absorption and therapeutic effect.
DB01600	DB00215	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01600	DB00930	The bile acid sequestrant, Colesevelam, may reduce Tiaprofenic acid absorption and therapeutic effect.
DB01600	DB00375	The bile acid sequestrant, Colestipol, may reduce Tiaprofenic acid absorption and therapeutic effect.
DB01600	DB00091	Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy.
DB01600	DB01175	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01600	DB00472	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01600	DB00176	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01600	DB01381	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01600	DB01404	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
DB01600	DB00465	Concomitant therapy is contraindicated due to the risk of synergistic NSAID toxicity.
DB01600	DB01356	Tiaprofenic acid may increase the therapeutic/adverse effects of Lithium by increasing Lithium serum concentrations. Monitor for changes in the therapeutic/adverse effects of Lithium if Tiaprofenic acid is initiated, discontinued or dose changed.
DB01600	DB00563	Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity.
DB01600	DB00715	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01600	DB00642	Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered.
DB01600	DB01399	Increased risk of gastrointestinal bleeding.
DB01600	DB01104	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
DB01600	DB00966	Concomitant use of Telmisartan and Tiaprofenic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
DB01600	DB00373	The NSAID, Tiaprofenic acid, may antagonize the antihypertensive effect of Timolol.
DB01600	DB00519	The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed.
DB01600	DB00374	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy.
DB01600	DB00682	The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
DB01601	DB01048	The serum concentration of Abacavir may be decreased by protease inhibitors such as Lopinavir. The antiviral response should be closely monitored.
DB01601	DB01558	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if lopinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
DB01601	DB01219	Lopinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if lopinavir is initiated, discontinued or dose changed.
DB01601	DB01264	Decreased levels of darunavir
DB01601	DB06414	Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \r\n\r\nProtease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \r\n\r\nRitonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.
DB01601	DB01320	Levels of both drugs are affected
DB01601	DB00252	Levels of both drugs are affected
DB01601	DB08860	Lopinavir decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy.
DB01601	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB01601	DB01656	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB01601	DB00864	The protease inhibitor, Lopinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Lopinavir therapy is initiated, discontinued or altered.
DB01601	DB00820	Lopinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
DB01601	DB00675	Lopinavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.
DB01601	DB00706	Lopinavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lopinavir is initiated, discontinued, or dose changed.
DB01601	DB00976	Lopinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
DB01601	DB06287	Lopinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB01601	DB00444	The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Lopinavir is initiated, discontinued or dose changed.
DB01601	DB00906	The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Lopinavir is initiated, discontinued or dose changed.
DB01601	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Lopinavir. Consider alternate therapy.
DB01601	DB01036	Lopinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB01601	DB01030	The p-glycoprotein inhibitor, Lopinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB01601	DB00193	Lopinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lopinavir may decrease the effect of Tramadol by decreasing active metabolite production.
DB01601	DB00656	The protease inhibitor, Lopinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lopinavir is initiated, discontinued or dose changed.
DB01601	DB00726	The strong CYP3A4/CYP2D6 inhibitor, Lopinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Lopinavir is initiated, discontinued or dose changed.
DB01601	DB00862	Lopinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
DB01601	DB00285	Lopinavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Lopinavir is initiated, discontinued, or dose changed.
DB01601	DB00661	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Lopinavir is initiated, discontinued or dose changed.
DB01601	DB00570	Lopinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Lopinavir is initiated, discontinued or dose changed.
DB01618	DB00674	Possible antagonism of action
DB01601	DB00541	Lopinavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Lopinavir is initiated, discontinued or dose changed.
DB01601	DB00361	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Lopinavir is initiated, discontinued or dose changed.
DB01601	DB00582	Lopinavir may reduce serum concentration and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy.
DB01601	DB00425	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if lopinavir is initiated, discontinued or dose changed.
DB01601	DB00909	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if lopinavir is initiated, discontinued or dose changed.
DB01601	DB01198	Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if lopinavir is initiated, discontinued or dose changed.
DB01601	DB01624	Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed.
DB01602	DB00618	Possible antagonism of action
DB01602	DB00254	Possible antagonism of action
DB01602	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01602	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB01602	DB01017	Possible antagonism of action
DB01602	DB00759	Possible antagonism of action
DB01603	DB00618	Possible antagonism of action
DB01603	DB00254	Possible antagonism of action
DB01603	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01604	DB00618	Possible antagonism of action
DB01604	DB00254	Possible antagonism of action
DB01604	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01604	DB01357	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01604	DB00931	Possible antagonism of action
DB01604	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB01604	DB01017	Possible antagonism of action
DB01604	DB00595	Possible antagonism of action
DB01604	DB01301	Possible antagonism of action
DB01604	DB00759	Possible antagonism of action
DB01605	DB00618	Possible antagonism of action
DB01605	DB00254	Possible antagonism of action
DB01605	DB00931	Possible antagonism of action
DB01605	DB01017	Possible antagonism of action
DB01605	DB00595	Possible antagonism of action
DB01605	DB01301	Possible antagonism of action
DB01605	DB00759	Possible antagonism of action
DB01606	DB00618	Possible antagonism of action
DB01606	DB00254	Possible antagonism of action
DB01606	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01606	DB01017	Possible antagonism of action
DB01606	DB00759	Possible antagonism of action
DB01607	DB00479	Ticarcillin may reduce the serum concentration of Amikacin. Ticarcillin may inactivate Amikacin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB01607	DB00618	Demeclocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Demeclocycline.
DB01607	DB00254	Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline.
DB01607	DB00977	This anti-infectious agent could decrease the effect of the oral contraceptive
DB01607	DB02703	Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid.
DB01607	DB00798	Ticarcillin may reduce the serum concentration of Gentamicin. Ticarcillin may inactivate Gentamicin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB01607	DB01172	Ticarcillin may reduce the serum concentration of Kanamycin. Ticarcillin may inactivate Kanamycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB01607	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB01607	DB01017	Minocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Minocycline.
DB01607	DB00994	Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB01607	DB00595	Oxytetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Oxytetracycline.
DB01607	DB01082	Ticarcillin may reduce the serum concentration of Streptomycin. Ticarcillin may inactivate Streptomycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB02546	DB01218	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01607	DB00759	Tetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Tetracycline.
DB01607	DB00684	Ticarcillin may reduce the serum concentration of Tobramycin. Ticarcillin may inactivate Tobramycin in vitro and the two agents should not be administered simultaneously through the same IV line.
DB01608	DB00182	Decreased anorexic effect, may increase pyschotic symptoms
DB01608	DB00865	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
DB01608	DB01191	Decreased anorexic effect, may increase psychotic symptoms.
DB01608	DB01576	Decreased anorexic effect, may increase pyschotic symptoms
DB01608	DB00937	Decreased anorexic effect, may increase psychotic symptoms.
DB01608	DB00843	Possible antagonism of action
DB01608	DB00574	Decreased anorexic effect, may increase psychotic symptoms.
DB01608	DB00674	Possible antagonism of action
DB01608	DB01170	Propericiazine may decrease the effect of guanethidine.
DB01608	DB00579	Decreased anorexic effect, may increase psychotic symptoms.
DB01608	DB01577	Decreased anorexic effect, may increase pyschotic symptoms
DB01608	DB01578	Increased risk of convulsions
DB01608	DB01579	Decreased anorexic effect, may increase pyschotic symptoms
DB01608	DB00830	Decreased anorexic effect, may increase pyschotic symptoms
DB01608	DB00191	Decreased anorexic effect, may increase psychotic symptoms.
DB01608	DB00397	Decreased anorexic effect, may increase psychotic symptoms.
DB01608	DB00989	Possible antagonism of action
DB01608	DB00342	Increased risk of cardiotoxicity and arrhythmias
DB01609	DB01370	Possible physicochemical interaction
DB01609	DB00006	Anticoagulants increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity.
DB01609	DB06414	Etravirine, when administered concomitantly with deferasirox, may experience a decrease in serum concentration. It is recommended to monitor therapy.
DB01609	DB08895	Tofacitinib (and other CYP3A4 substrates), when used in combination with deferasirox, may experience a decrease in concentration. It is recommended to monitor therapy.
DB01610	DB01048	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB01610	DB00718	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Adefovir Dipivoxil, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB01610	DB01597	Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)
DB01610	DB00900	The adverse/toxic effects of Didanosine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided.
DB01610	DB00879	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Emtricitabine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB01610	DB01598	Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)
DB01610	DB00709	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.
DB01610	DB00688	The excretion rates of Valganciclovir and/or Mycophenolate mofetil may decrease. Monitor for increased serum concentrations and toxicity of both agents.
DB01610	DB01024	The excretion rates of Valganciclovir and/or Mycophenolic acid may decrease. Monitor for increased serum concentrations and toxicity of both agents.
DB01610	DB01032	Probenecid may decrease excretion of Valganciclovir. Monitor for increased serum concentration and toxicity of Valganciclovir.
DB01610	DB00300	The excretion rates of Valganciclovir and/or Tenofovir may decrease as both drugs are eliminated by active tubular secretion. Monitor for increased serum concentrations and toxicity of both agents.
DB01610	DB00495	The adverse/toxic effects of Zidovudine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided.
DB01611	DB06697	Hydroxychloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB01611	DB00390	Hydroxychloroquine increases the effect of digoxin
DB01611	DB06708	Hydroxychloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB01611	DB00563	Hydroxychloroquine increases the effect and toxicity of methotrexate
DB01611	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB01612	DB00320	Possible antagonism of action
DB01612	DB00696	Possible antagonism of action
DB01612	DB00247	Possible antagonism of action
DB01612	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB01613	DB00320	Possible antagonism of action
DB01613	DB00696	Possible antagonism of action
DB01613	DB00247	Possible antagonism of action
DB01614	DB00843	Possible antagonism of action
DB01614	DB00674	Possible antagonism of action
DB01615	DB00843	Possible antagonism of action
DB01615	DB00674	Possible antagonism of action
DB01616	DB00843	Possible antagonism of action
DB01616	DB00674	Possible antagonism of action
DB01618	DB00843	Possible antagonism of action
DB01618	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Molindone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB01618	DB04844	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB01618	DB00662	Trimethobenzamide and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01618	DB00427	Triprolidine and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01618	DB00209	Trospium and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01619	DB00843	Possible antagonism of action
DB01619	DB00674	Possible antagonism of action
DB01619	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenindamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB01619	DB00662	Trimethobenzamide and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01619	DB00427	Triprolidine and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01619	DB00209	Trospium and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01621	DB00843	Possible antagonism of action
DB01621	DB00674	Possible antagonism of action
DB01621	DB00976	Telithromycin may reduce clearance of Pipotiazine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pipotiazine if Telithromycin is initiated, discontinued or dose changed.
DB01621	DB00857	Terbinafine may reduce the metabolism and clearance of Pipotiazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Pipotiazine if Terbinafine is initiated, discontinued or dose changed.
DB01621	DB00427	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Pipotiazine. Monitor for symptoms of ventricular arrhythmias.
DB01621	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pipotiazine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of pipotiazine if voriconazole is initiated, discontinued or dose changed.
DB01622	DB00843	Possible antagonism of action
DB01622	DB00674	Possible antagonism of action
DB01622	DB00989	Possible antagonism of action
DB01623	DB00106	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00915	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Amantadine. Consider alternate therapy or monitor for decreased effects of both agents.
DB01623	DB01118	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00321	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00543	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00714	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Thiothixene may also antagonize the effects of the anti-Parkinsonian agent, Apomorphine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses changed.
DB01623	DB01169	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01623	DB01200	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Bromocriptine. Consider alternate therapy or monitor for decreased effects of both agents.
DB01623	DB00477	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00537	The strong CYP1A2 inhibitor, Ciprofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ciprofloxacin is initiated, discontinued or dose changed.
DB01623	DB00604	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01211	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01242	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01254	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01151	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00280	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00204	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00757	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01184	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00843	Possible antagonism of action
DB01623	DB01142	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00450	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00199	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01195	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00196	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00472	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00875	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00176	The strong CYP1A2 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Fluvoxamine is initiated, discontinued or dose changed.
DB01623	DB00529	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00674	Possible antagonism of action
DB01623	DB01044	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01170	Thiothixene may decrease the effect of guanethidine.
DB01623	DB01218	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00502	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00308	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00458	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00808	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00270	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01026	The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.
DB01623	DB01235	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Levodopa. Consider alternate therapy or monitor for decreased effects of both agents.
DB01623	DB01259	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01137	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00281	The strong CYP1A2 inhibitor, Lidocaine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Lidocaine is initiated, discontinued or dose changed.
DB01623	DB00408	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01623	DB00934	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00358	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00933	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00333	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00553	The strong CYP1A2 inhibitor, Methoxsalen, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Methoxsalen is initiated, discontinued or dose changed.
DB01623	DB00379	The strong CYP1A2 inhibitor, Mexiletine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Mexiletine is initiated, discontinued or dose changed.
DB01623	DB00218	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB04868	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB01623	DB01059	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. The strong CYP1A2 inhibitor, Norfloxacin, may also decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00540	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00104	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01165	The strong CYP1A2 inhibitor, Ofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ofloxacin is initiated, discontinued or dose changed.
DB01623	DB00738	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00556	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01186	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pergolide. Consider alternate therapy or monitor for decreased effects of both agents.
DB01623	DB01100	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00413	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pramipexole. Consider alternate therapy or monitor for decreased effects of both agents.
DB01623	DB01278	The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy.
DB01623	DB01087	The strong CYP1A2 inhibitor, Primaquine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Primaquine is initiated, discontinued or dose changed.
DB01623	DB01599	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01035	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01182	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00344	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01224	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00468	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB01623	DB00243	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00734	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00268	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Ropinirole. Consider alternate therapy or monitor for decreased effects of both agents.
DB01623	DB05271	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Rotigotine. Consider alternate therapy or monitor for decreased effects of both agents.
DB01623	DB00489	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01208	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB01268	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thiothixene, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB01623	DB00864	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
DB01623	DB00976	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB04844	Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.
DB01623	DB00730	The strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed.
DB01623	DB00679	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB01624	DB00204	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01623	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01623	DB00662	Trimethobenzamide and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01623	DB00726	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01623	DB00427	Triprolidine and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01623	DB00209	Trospium and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01623	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01623	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01623	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB01623	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00106	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00915	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01624	DB01118	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00321	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00543	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00714	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Antagonism may also occur between zuclopenthixol, a dopamine D2 receptor antagonist, and apomorphine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01624	DB01169	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB06216	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00207	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01200	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01624	DB01156	Bupropion, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if bupropion is initiated, discontinued or dose changed.
DB01624	DB00477	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed.
DB01624	DB01012	Cinacalcet, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cinacalcet is initiated, discontinued or dose changed.
DB01624	DB00604	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00215	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01211	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01242	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00907	Cocaine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cocaine is initiated, discontinued or dose changed.
DB01624	DB01254	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00705	Delavirdine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if delavirdine is initiated, discontinued or dose changed.
DB01624	DB01151	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00280	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01831	DB01171	Possible severe adverse reaction with this combination
DB01624	DB00757	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01184	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00843	Possible antagonism of action
DB01624	DB01142	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB04855	Additive or synergistic QTc-prolonging effects may occur. Concomitant therapy is contraindicated.
DB01624	DB00450	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00199	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01175	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB06414	Zuclopenthixol (especially oral dosage form) may experience a decrease in serum concentration when used concomitantly with etravirine. It is recommended to monitor zuclopenthixol therapy for efficacy.
DB01624	DB01195	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00196	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00472	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Fluoxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if fluoxetine is initiated, discontinued or dose changed.
DB01624	DB00875	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00529	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00674	Possible antagonism of action
DB01624	DB01218	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00502	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00308	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB04946	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00458	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00808	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00270	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01235	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01624	DB01259	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01137	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01601	Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed.
DB01624	DB00408	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB01624	DB00934	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00358	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00933	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00333	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01403	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed.
DB01624	DB01233	Additive dopamine D2 receptor antagonism may cause dopaminergic imbalance in the nigrostriatal (dopamine D1 receptors) and striatopallidal (dopamine D2 receptors). Increased risk of extrapyramidal reactions and neuroleptic malignant syndrome. Concomitant therapy should be avoided.
DB01624	DB00218	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB04868	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.
DB01624	DB01059	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00540	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00104	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00715	Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed.
DB01624	DB06589	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00738	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00556	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01186	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pergolide, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. Pergolide, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if pergolide is initiated, discontinued or dose changed.
DB01624	DB01100	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
DB01624	DB00413	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pramipexole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01624	DB01278	May cause additive reduction in GI motility. Use caution or consider alternate therapy.
DB01624	DB01599	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01035	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01182	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00344	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01224	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00908	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Quinidine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if quinidine is initiated, discontinued or dose changed.
DB01624	DB00468	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.
DB01624	DB00243	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00734	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00503	Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed.
DB01624	DB06176	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00268	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01624	DB05271	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and rotigotine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB01624	DB00489	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01208	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB01268	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Zuclopenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
DB01624	DB00864	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB06402	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00976	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01831	DB00780	Possible severe adverse reaction with this combination
DB06802	DB06781	NSAIDs may slow healing.
DB01624	DB00857	Terbinafine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if terbinafine is initiated, discontinued or dose changed.
DB01624	DB04844	Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.
DB01624	DB00679	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
DB01624	DB01623	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB01624	DB00662	Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01624	DB00726	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00427	Triprolidine and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
DB01624	DB00209	Trospium and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB01624	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB01624	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB01625	DB00843	Possible antagonism of action
DB01625	DB00674	Possible antagonism of action
DB01625	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB01626	DB00668	Increased arterial pressure
DB01626	DB01288	Increased arterial pressure
DB01626	DB01170	Pargyline may decrease the effect of guanethidine.
DB01626	DB01403	Possible severe adverse reaction with this combination
DB01626	DB04896	Increase serotonin levels. Combination therapy is contraindicated.
DB01626	DB00816	Increased arterial pressure
DB01626	DB00388	Increased arterial pressure
DB01626	DB00397	Increased arterial pressure
DB01626	DB00852	Increased arterial pressure
DB01626	DB00871	Increased arterial pressure
DB01627	DB01370	The aluminium salt decreases the absorption of lincosamides
DB01627	DB00732	The agent increases the effect of muscle relaxant
DB01627	DB01574	The aluminium salt decreases the absorption of lincosamides
DB01627	DB01135	The agent increases the effect of muscle relaxant
DB01627	DB00199	Possible antagonism of action with this combination.
DB01627	DB01575	The aluminium salt decreases the absorption of lincosamides
DB01627	DB01336	The agent increases the effect of muscle relaxant
DB01627	DB01226	The agent increases the effect of muscle relaxant
DB01627	DB01337	The agent increases the effect of muscle relaxant
DB01627	DB01338	The agent increases the effect of muscle relaxant
DB01627	DB00728	The agent increases the effect of muscle relaxant
DB01627	DB00202	The agent increases the effect of muscle relaxant
DB01627	DB01199	The agent increases the effect of muscle relaxant
DB01627	DB01339	The agent increases the effect of muscle relaxant
DB01628	DB01418	Etoricoxib may increase the anticoagulant effect of acenocoumarol.
DB01628	DB01125	Etoricoxib may increase the anticoagulant effect of anisindione.
DB01628	DB00266	Etoricoxib may increase the anticoagulant effect of dicumarol.
DB01628	DB00977	Etoricoxib may increase the levels of ethinyl estradiol.
DB01628	DB01356	Etoricoxib increases serum levels of lithium
DB01628	DB01045	Rifampin reduces levels and efficacy of etoricoxib
DB01628	DB00682	Etoricoxib may increase the anticoagulant effect of warfarin.
DB01656	DB01281	Consider therapy modification due to enhanced immunosuppressive action.
DB01656	DB01118	Increases roflumilast levels.
DB01656	DB00098	Therapy may need to be modified due to enhanced immunosuppressive effects.
DB01656	DB06413	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB01656	DB06681	Consider modifying therapy due to enhanced immunosuppressive effect.
DB01656	DB08879	Consider therapy modification due to enhanced immunosuppressive effect.
DB01656	DB00290	Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning.
DB01656	DB00559	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB00564	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB01656	DB00958	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carboplatin. he Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB04573	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estriol.
DB01656	DB00262	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB01656	DB00291	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as chlorambucil. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB01656	DB00501	Increases roflumilast levels.
DB01656	DB00515	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cisplatin. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB01656	DB00242	Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB01656	DB00631	Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.
DB01656	DB01234	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB00625	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB00199	Increases roflumilast levels.
DB01656	DB00005	Due to enhanced immunosuppressive effects, therapy modification should be considered.
DB01656	DB06414	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB06414	Roflumilast, when used concomitantly with etravirine, may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy.
DB01656	DB00176	Increases roflumilast levels.
DB01656	DB01320	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB00056	Consider therapy modification due to enhanced immunosuppressive effect.
DB01656	DB05259	Consider therapy modification due to enhanced immunosuppressive effects.
DB01656	DB00078	Consider modifying therapy due to enhanced immunosuppressive effect.
DB01656	DB00065	Roflumilast enhances the adverse effects of immune suppressants thus a therapy modification should be considered.
DB01656	DB01026	Increases roflumilast levels.
DB01656	DB01601	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB01656	DB00745	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB01656	DB00607	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB00238	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB08935	Consider therapy modification due to enhanced immunosuppressive effect.
DB01656	DB00043	Consider therapy modification due to enhanced immunosuppressive effects.
DB01656	DB00338	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB01656	DB00776	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB00059	Consider therapy modification because pegaspargase enhances the immunosuppressive effect of roflumilast.
DB01656	DB00312	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB01174	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB01656	DB00794	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB01656	DB00615	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB01045	Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
DB01656	DB01201	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB00503	Affects CYP1A2 metabolism; decreases level or effect of roflumilast.
DB01656	DB01323	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB01656	DB08895	Roflumilast, when used in combination with tofacitinib, may increase the immunosuppressive effect of tofaciitinib and other immunosuppressive agents.   It is recommended to modify therapy.
DB01656	DB00549	Increases roflumilast levels.
DB01693	DB01048	Ribavirin Monophosphate may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.
DB02300	DB01436	Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use.
DB02300	DB06723	Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB02300	DB00169	Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). hough not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity.
DB02300	DB01083	Orlistat may decrease the serum concentration of fat soluble vitamins like vitamin D. Hence, this applies to calcipotriol, a synthetic derivative of vitamin D. Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Similar precautions do not apply to parenterally administered fat soluble vitamins.
DB02300	DB00364	Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB02443	DB00563	The penicillin increases the effect and toxicity of methotrexate
DB02443	DB01017	Possible antagonism of action
DB02443	DB00759	Possible antagonism of action
DB02546	DB00106	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01118	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00321	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00543	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00714	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01169	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB02546	DB06216	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00207	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00477	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00604	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01211	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01242	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01254	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01151	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00280	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00204	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00757	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01184	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01142	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB04855	Additive QTc prolongation may occur. Concomitant therapy is contraindicated.
DB02546	DB00450	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00199	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01195	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00196	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00472	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00875	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00529	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01044	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00502	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00308	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00458	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00808	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00270	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01259	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01137	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00408	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB02546	DB00934	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00358	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00933	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00333	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01403	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00218	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB04868	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB02546	DB01059	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00540	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00104	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00738	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00556	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01100	Additive QTc prolongation may occur. Concomitant therapy is contraindicated.
DB02546	DB01599	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01035	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01182	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00344	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01224	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00908	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00468	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB02546	DB00243	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00734	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00489	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01208	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01268	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00864	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00976	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB04844	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB02546	DB00679	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB01623	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00539	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
DB02546	DB00726	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02546	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB02546	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB02588	DB01032	Probenecid may increase the serum level of the moxalactam derivative.
DB02703	DB00701	The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid.
DB02703	DB01076	Increased risk of myopathy/rhabdomyolysis
DB02703	DB01319	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid.
DB02703	DB00224	Indinavir may increase the effect and toxicity of fusidic acid.
DB02703	DB00220	The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid.
DB02703	DB00417	Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid.
DB02703	DB00503	The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid.
DB02703	DB01232	The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid.
DB02703	DB00641	Increased risk of myopathy/rhabdomyolysis
DB02703	DB01607	Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid.
DB02703	DB00932	Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents.
DB03128	DB00382	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Acetylcholine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.
DB03225	DB00315	Use of two serotonin modulators, such as zolmitriptan and D-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB03450	DB00798	Increased risk of nephrotoxicity
DB03450	DB00955	Increased risk of nephrotoxicity
DB03450	DB01032	Probenecid may increase the serum level of cephalothin.
DB03450	DB00684	Increased risk of nephrotoxicity
DB03575	DB00976	Telithromycin may reduce clearance of Phencyclidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Phencyclidine if Telithromycin is initiated, discontinued or dose changed.
DB03575	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of phencyclidine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of phencyclidine if voriconazole is initiated, discontinued or dose changed.
DB03585	DB01418	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of acenocoumarol.
DB03585	DB00630	Increased risk of gastric toxicity
DB03585	DB01125	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of anisindione.
DB03585	DB00266	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of dicumarol.
DB03585	DB00754	The NSAID, oxyphenbutazone, may increase the hydantoin effect of ethotoin.
DB03585	DB01320	The NSAID, oxphenbutazone, may increase the hydantoin effect of fosphenytoin.
DB03585	DB00532	The NSAID, oxyphenbutazone, may increase the hydantoin effect of mephenytoin.
DB03585	DB00252	The NSAID, oxphenbutazone, may increase the therapeutic and adverse effects of phenytoin.
DB03585	DB00682	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin.
DB03904	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB04220	DB06414	Etravirine, when used concomitantly with rifamycin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB04272	DB08822	Increases serum potassium.
DB04272	DB06210	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB04272	DB01356	The urine alkalizer decreases the effect of lithium
DB04571	DB01320	The hydantoin decreases the effect of psoralene
DB04571	DB00252	The hydantoin decreases the effect of psoralene
DB04572	DB06769	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
DB04572	DB01156	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Bupropion, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Bupropion if Thiotepa is initiated, discontinued or dose changed.
DB04572	DB00531	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Cyclophosphamide, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Cyclophosphamide if Thiotepa is initiated, discontinued or dose changed.
DB04572	DB01320	Possible increase in thiotepa levels
DB04572	DB00762	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Irinotecan, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Irinotecan if Thiotepa is initiated, discontinued or dose changed.
DB04572	DB01221	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Ketamine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Ketamine if Thiotepa is initiated, discontinued or dose changed.
DB04572	DB00108	The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
DB04572	DB00252	Possible increase in thiotepa levels
DB04572	DB01069	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Promethazine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Promethazine if Thiotepa is initiated, discontinued or dose changed.
DB04572	DB01037	Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Selegiline, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Selegiline if Thiotepa is initiated, discontinued or dose changed.
DB04572	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB04573	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estriol.
DB04573	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estriol.
DB04573	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estriol.
DB04573	DB00860	The estrogenic agent, estriol, may increase the effect of the corticosteroid, prednisolone.
DB04573	DB00635	The estrogenic agent, estriol, may increase the effect of corticosteroid, prednisone.
DB04573	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, estriol.
DB04573	DB00481	Association not recommended
DB04574	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estropipate.
DB04574	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estropipate.
DB04574	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estropipate.
DB04574	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estropipate.
DB04574	DB00860	The estrogenic agent, estropipate, may increase the effect of the corticosteroid, prednisolone.
DB04574	DB00635	The estrogenic agent, estropipate, may increase the effect of corticosteroid, prednisone.
DB04574	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, estropipate.
DB04574	DB00481	Association not recommended
DB04575	DB01320	The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, quinestrol.
DB04575	DB00400	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, quinestrol.
DB04575	DB01174	The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, quinestrol.
DB04575	DB00252	The enzyme inducer, phenytoin, decreases the effect of the hormone agent, quinestrol.
DB04575	DB00860	The estrogenic agent, quinestrol, may increase the effect of the corticosteroid, prednisolone.
DB04575	DB00635	The estrogenic agent, quinestrol, may increase the effect of corticosteroid, prednisone.
DB04575	DB00794	The enzyme inducer, primidone, decreases the effect of the hormone agent, quinestrol.
DB04626	DB00864	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Apramycin. Use caution during concomitant therapy.
DB04835	DB08822	Pharmacodynamic synergist- increases effects.
DB04835	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  When used with a strong CYP3A4 inhibitor, the adult dose of maraviroc should be decreased to 150 mg twice daily. Maraviroc is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) receiving a strong CYP3A4 inhibitor. Maraviroc may be administered at a dose of 300 mg twice daily with concomitant tipranavir/ritonavir but not with other ritonavir combinations.
DB04835	DB06414	Maraviroc, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB04835	DB00976	Telithromycin may reduce clearance of Maraviroc. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Maraviroc if Telithromycin is initiated, discontinued or dose changed.
DB04835	DB00273	Topiramate, a CYP3A4 inducer, may decrease the serum concentration of Maraviroc by increasing Maraviroc metabolism and clearance. A dose adjustment of Maraviroc may be required. Monitor for changes in Maraviroc therapeutic and adverse effects if Topiramate is initiated, discontinued or dose changed.
DB04835	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of maraviroc by decreasing its metabolism. A dose reduction in maraviroc is warranted. Monitor for changes in the therapeutic and adverse effects of maraviroc if voriconazole is initiated, discontinued or dose changed.
DB04838	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB04841	DB00427	The CNS depressants, Triprolidine and Flunarizine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB04843	DB00502	The anticholinergic increases the risk of psychosis and tardive dyskinesia
DB04843	DB00382	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Mepenzolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
DB04843	DB00662	Trimethobenzamide and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB04843	DB00427	Triprolidine and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB04843	DB00209	Trospium and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DB04844	DB01063	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB01238	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB04844	DB00477	May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB00363	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB00907	CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Patients receiving a strong inhibitor of CYP2D6 together with tetrabenazine should not exceed 50mg of tetrabenazine. Also, patients already taking tetrabenazine prior to starting a strong CYP2D6 inhibitor should have their tetrabenazine dose reduced by 50% upon initiation of the strong CYP2D6 inhibitor.
DB04868	DB06769	P-glycoprotein (MDR-1) efflux transporter increases bendamustine levels.
DB04844	DB00450	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB00472	Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose.
DB04844	DB00875	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB00623	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB00614	Tetrabenazine may increase the adverse/toxic effects of Furazolidine. Concomitant therapy is contraindicated.
DB04844	DB00502	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB01247	Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated.
DB04844	DB01235	Tetrabenazine may cause Parkinsonian symptoms and neutralize the effect of Levodopa.
DB04844	DB00601	Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated.
DB04844	DB01356	Inhibit biochemical and behavioural effects of tetrabenazine. Heed caution when using agents in combination.
DB04844	DB00408	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB04844	DB00933	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB01233	Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB01171	Tetrabenazine may increase the adverse/toxic effects of Moclobemide. Concomitant therapy is contraindicated.
DB04844	DB01618	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB00334	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB01267	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
DB04844	DB00715	Paroxetine is a strong CYP2D6 inhibitor thus increasing half life of dihydrotetrabenazine moieties. Dose of tetrabenazine should be reduced
DB04844	DB00850	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB00780	Tetrabenazine may increase the adverse/toxic effects of Phenelzine. Concomitant therapy is contraindicated.
DB04844	DB01100	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB01168	Tetrabenazine may increase the adverse/toxic effects of Procarbazine. Concomitant therapy is contraindicated.
DB04844	DB00433	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB01224	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB00908	Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose.
DB04844	DB01367	Tetrabenazine may increase the adverse/toxic effects of Rasagiline. Concomitant therapy is contraindicated.
DB04844	DB00206	Reserpine may increase the adverse/toxic effects of tetrabenazine as they have similar pharmacologic properties. Concomitant therapy is contraindicated.
DB04844	DB00734	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB01037	Tetrabenazine may increase the adverse/toxic effects of Selegiline. Concomitant therapy is contraindicated.
DB04844	DB00864	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB04844	DB00976	Telithromycin may increase the QTc-prolonging effect of Tetrabenazine. Concomitant therapy should be avoided.
DB04844	DB00857	Terbinafine may reduce the metabolism and clearance of Tetrabenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tetrabenazine if Terbinafine is initiated, discontinued or dose changed.
DB04844	DB00679	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB01623	Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.
DB04844	DB00539	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB04844	DB00752	Tetrabenazine may increase the adverse/toxic effects of Tranylcypromine. Concomitant therapy is contraindicated.
DB04844	DB00831	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
DB04844	DB00726	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB04844	DB00427	The CNS depressants, Triprolidine and Tetrabenazine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB04844	DB00582	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB04844	DB02546	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB04844	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
DB04844	DB01624	Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.
DB04845	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. The dose of ixabepilone must be reduced when used with strong inhibitors of CYP3A.1 In one published abstract, ixabepilone 20mg/m2 was the maximum tolerated dose in patients who were also receiving the CYP3A-inhibitor ketoconazole (400mg).
DB04845	DB00976	Telithromycin may reduce clearance of Ixabepilone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ixabepilone if Telithromycin is initiated, discontinued or dose changed.
DB05521	DB00346	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB04845	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ixabepilone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ixabepilone if voriconazole is initiated, discontinued or dose changed.
DB04855	DB06697	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB04855	DB01076	Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of atorvastatin. Lower doses of atorvastatin or consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone.
DB04855	DB01211	Clarithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. Concurrent use of strong CYP3A4 inhibitors with dronedarone is contraindicated according to dronedarone prescribing information.
DB04855	DB08865	Concurrent use with drugs that prolong QTc interval is contraindicated.
DB04855	DB00091	Cyclosporine is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB06695	Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of dabigatran 1.1-1.9-fold.
DB04855	DB00390	Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of digoxin 2.5-fold.
DB04855	DB00343	Diltiazem is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker.
DB04855	DB06414	Dronedarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB04855	DB08868	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB04855	DB01167	Itraconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB01026	Ketoconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB06708	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB04855	DB00264	Metoprolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase metoprolol exposure 1.6-fold. Lower dose of metoprolol.
DB04855	DB01149	Nefazodone is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB00571	Propranolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase propranolol exposure 1.3-fold. Lower dose of metoprolol.
DB04855	DB00503	Ritonavir is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB00641	Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of simvastatin 4-fold. Lower doses of simvastatin and doses should not exceed 20 mg to avoid statin-induced toxicities like myopathy. Consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone.
DB04855	DB00877	Sirolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of sirolimus. Monitor plasma concentrations and adjust dose accordingly.
DB04855	DB00864	Tacrolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of tacrolimus. Monitor plasma concentrations and adjust dose accordingly.
DB04855	DB00976	Telithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB00661	Verapamil is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker.
DB04855	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated.
DB04855	DB00582	Voriconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
DB04855	DB02546	Additive QTc prolongation may occur. Concomitant therapy is contraindicated.
DB04855	DB00682	Dronedarone is a moderate inhibitor of CYP3A4 which is responsible for warfarin metabolism. Increases serum concentration of S-isomer warfarin by 1.2 fold
DB04855	DB00246	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB04855	DB01624	Additive or synergistic QTc-prolonging effects may occur. Concomitant therapy is contraindicated.
DB04861	DB01162	Increased risk of hypotension. Initiate concomitant therapy cautiously.
DB04861	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB04865	DB00945	Avoid combination with acetylsalicylic acid due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
DB04865	DB01050	Avoid combination with ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
DB04865	DB00108	Avoid combination due to the increased risk of infection.
DB04865	DB00337	Avoid combination as there is potential to increase immunosuppressant adverse effects.
DB04865	DB00864	Avoid combination as there is potential to increase immunosuppressant adverse effects.
DB04865	DB08895	Avoid combination with tofacitinib and other potent immunosuppressants as there is potential to increase the immunosuppressant effects. Other less potent immunosuppressants such as methotrexate, at antirheumatic doses, and other non-disease modifying antirheumatic drugs (non-DMARDs) can be combined.
DB04865	DB00682	Avoid combination with warfarin and other anticoagulants due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
DB04868	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB04868	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. Nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong inhibitors of CYP3A4.
DB04868	DB06414	Nilotinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB04868	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB04868	DB00864	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB04868	DB00675	Nilotinib may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
DB04868	DB00706	Nilotinib, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nilotinib is initiated, discontinued, or dose changed.
DB04868	DB00976	Telithromycin may reduce clearance of Nilotinib. Concomitant therapy should be avoided.
DB04868	DB01623	May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.
DB04868	DB01030	The p-glycoprotein inhibitor, Nilotinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
DB04868	DB00539	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB04868	DB00193	Nilotinib may decrease the effect of Tramadol by decreasing active metabolite production.
DB04868	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB04868	DB00755	The moderate CYP2C8 inhibitor, Nilotinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Nilotinib is initiated, discontinued to dose changed.
DB04868	DB00726	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
DB04868	DB00582	Voriconazole may increase the serum concentration of nilotinib by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Concomitant therapy should be avoided.
DB04868	DB02546	Additive QTc prolongation may occur. Concomitant therapy should be avoided.
DB04868	DB00246	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB04868	DB01624	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.
DB04871	DB00696	Avoid all combinations with any ergot derivative such as ergotamine. The combination can increase the risk of developing serotonin syndrome and/or valvular heart disease.
DB04871	DB00679	Avoid combination.The combination is likely to reduce the metabolism of Thioridazine.
DB04896	DB00575	Because Savella inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine's anti-hypertensive effect.
DB04896	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB04896	DB00390	Use of Savella concomitantly with digoxin may be associated with potentiation of adverse hemodynamic effects. Co-administration of Savella and intravenous digoxin should be avoided.
DB04896	DB00614	Increase serotonin levels. Combination therapy is contraindicated.
DB04896	DB06704	Milnacipran decreases the effects of Iobenguane thus increases the risk of producing a false-negative result. May discontinue milnacipran for at least 5 half-live.
DB04896	DB01247	Increase serotonin levels. Combination therapy is contraindicated.
DB04896	DB01171	Increase serotonin levels. Combination therapy is contraindicated.
DB04896	DB01626	Increase serotonin levels. Combination therapy is contraindicated.
DB04896	DB00780	Increase serotonin levels. Combination therapy is contraindicated.
DB04896	DB01168	Increase serotonin levels. Combination therapy is contraindicated.
DB04896	DB01367	Increase serotonin levels. Combination therapy is contraindicated.
DB04896	DB00752	Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.
DB04896	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB04896	DB00315	Use of two serotonin modulators, such as zolmitriptan and milnacipran, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB04899	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB04920	DB00374	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
DB04938	DB08866	Pharmacodynamic synergist; contraindicated.
DB04938	DB00196	Fluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with ospemifene. Fluconazole increases the systemic exposure of ospemifene by 2.7-fold. Administration of fluconazole with ospemifene may increase the risk of adverse events.
DB04938	DB01026	Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1.4-fold. Administration of ketoconazole chronically with ospemifene may increase the risk of OSPHENA-related adverse reactions.
DB04938	DB00338	Moderate CYP2C19 inhibitors may increase levels of ospemifene. Monitor concomitant therapy closely.
DB04938	DB01045	Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect.
DB04946	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB04946	DB01211	Clarithromycin is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50%
DB04946	DB00907	CYP2D6 Inhibitors (Strong) such as cocaine may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.
DB04946	DB00872	CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.
DB04946	DB00472	Fluoxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50%
DB04946	DB01026	Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50%
DB04946	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB04946	DB00715	Paroxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50%
DB04946	DB00246	Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.
DB04946	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB04953	DB00564	Ezogabine increases the clearance of carbamazepine (30%). The mechanism of this interaction is unknown.
DB04953	DB00555	In healthy adults, the AUCs of lamotrigine and ezogabine were both increased. The clinical significance of this is still unknown. Multiple doses of ezogabine also increase the clearance and decrease the terminal half-life of lamotrigine.
DB04953	DB00904	Concurrent use of ezogabine and ondansetron can increase QTc interval. Consider alternate therapy.
DB04953	DB00252	Ezogabine increases the clearance of phenytoin (30%). The mechanism of this interaction is unknown.
DB05039	DB01193	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB05039	DB01118	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB05039	DB00321	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB05039	DB06216	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB05039	DB00335	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB05039	DB01408	Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs.
DB05039	DB00443	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB05039	DB00612	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB05039	DB00310	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB05039	DB00924	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB05039	DB01151	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB05039	DB00199	Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events.
DB05039	DB00903	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB05039	DB00983	Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs.
DB05039	DB00695	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB05039	DB00502	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB05039	DB00999	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB05039	DB00741	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB05039	DB01026	Strong CYP3A4 inhibitors increase levels of indacaterol. Consider alternate therapy.
DB05039	DB00904	Both indacaterol and ondansetron prolong the QT interval. Consider alternate therapy.
DB05039	DB00635	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
DB05039	DB00571	Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
DB05039	DB00503	Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events.
DB05521	DB00404	Telaprevir inhibits systemic metabolism of alprazolam and dose adjustment may be necessary.
DB05039	DB00938	Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs.
DB05039	DB00661	Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events.
DB05246	DB00555	Methsuximide decreases the effect of lamotrigine
DB05246	DB00208	Ticlopidine may decrease the metabolism and clearance of Methsuximide. Consider alternate therapy or monitor for adverse/toxic effects of Methsuximide if Ticlopidine is initiated, discontinued or dose changed.
DB05246	DB00427	The CNS depressants, Triprolidine and Methsuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB05259	DB06643	Monitor therapy due to enhanced immunosuppressive effects and the risk of infections.
DB05259	DB01097	Consider therapy modification due to enhanced adverse effects of leflunomide including hematologic toxicity.
DB05259	DB00108	Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
DB05259	DB00337	Avoid combination due to enhanced immunosuppressive effects.
DB05259	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB05259	DB01656	Consider therapy modification due to enhanced immunosuppressive effects.
DB05259	DB06688	Monitor therapy due to decreased therapeutic effect of sipuleucel-T.
DB05259	DB00864	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB05259	DB08895	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB05259	DB00072	Monitor therapy due to enhanced neutropenic effects of immunosuppressants.
DB05260	DB00512	Additive nephrotoxic effects may occur. Avoid concomitant therapy.
DB05271	DB00349	Concomitant therapy may potentiate adverse CNS effects such as increased sedation or respiratory depression. Monitor therapy closely.
DB05271	DB01551	Dihydrocodeine may enhance the sedative effect of rotigotine. It is recommended to monitor therapy.
DB05271	DB00228	Risk of sedation may increase with concomitant therapy. Monitor therapy closely.
DB05271	DB01364	Risk of sedation may decrease with concomitant therapy. Monitor therapy closely.
DB05271	DB00813	Pharmacodynamic synergism may increase the effects of rotigotine. Monitor therapy closely.
DB05271	DB00408	Pharmacodynamic antagonism may decrease the effects of rotigotine. Consider alternate therapy.
DB05271	DB01623	Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Rotigotine. Consider alternate therapy or monitor for decreased effects of both agents.
DB05271	DB00427	The CNS depressants, Triprolidine and Rotigotine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
DB05271	DB00246	The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, rotigotine. Consider alternate therapy or monitor for worsening of movement disorder.
DB05271	DB01624	Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and rotigotine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
DB05275	DB01418	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed.
DB05275	DB00091	The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.
DB05275	DB00682	The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.
DB05294	DB00559	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00564	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB01234	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00625	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB06414	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB01320	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00607	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00238	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00312	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB01174	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00252	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00794	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB00615	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB01045	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB01201	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05294	DB01323	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB05331	DB00976	Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed.
DB05331	DB00857	Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed.
DB05394	DB01109	Contraindication: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. Corticorelin prescribing information describes a case in which a patient experienced a substantial fall in blood pressure and heart rate, resulting in asystole and requiring resuscitation.
DB05521	DB00381	Telaprevir inhibits the metabolism of amlodipine and concomitant therapy is contraindicated.
DB05521	DB01076	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00604	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB01013	Corticosteroids such as clobetasol may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects.
DB05521	DB00838	Corticosteroids such as clocortolone may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of Corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects.
DB05521	DB00872	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00091	Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy.
DB05521	DB00390	Telaprevir is a substrate of p-glycoprotein and thus increases the AUC and Cmax of digoxin. This indicates an increased absorption of digoxin. Lowest dose of digoxin should be used first and levels be closely monitored.
DB05521	DB00320	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00625	Inducers of CYP3A enzymes will decrease telaprevir levels.
DB05521	DB00696	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB01175	Telaprevir decreases Cmax, Cmin, and AUC of escitalopram however the mechanism of this interaction is unknown. Concomitant therapy may call for dose adjustment.
DB05521	DB06414	Telaprevir, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor telaprevir therapy closely.
DB05521	DB01026	Strong CYP3A4 inhibitors increase exposure of telaprevir.
DB05521	DB08827	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00227	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00333	Telaprevir decreases exposure of methane by 30% however opioid withdrawal was not observed in patients.
DB05521	DB00683	Telaprevir increases AUC and Cmax of oral midazolam by approximately 9-fold and 3-fold respectively.
DB05521	DB00220	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB01100	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB05521	DB06817	Telaprevir increases the exposure of raltegravir by up to 31%  but this interaction is considered as not clinically relevant.
DB05521	DB01045	Strong CYP3A4 inducers will decrease levels of telaprevir. Concomitant therapy is contraindicated.
DB05521	DB00503	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00641	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00864	Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy.
DB05521	DB00820	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05521	DB00897	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB05528	DB00898	The combination of these drugs will likely enhance mipomersen related hepatotoxicity. Therefore patients using both these drugs, should limit their alcohol to a daily maximum of 1 drink (or equivalent).
DB05773	DB08879	Avoid combination due to the increased risk of belimumab associated side effects.
DB05773	DB00363	Avoid combination due to the increased potential for agranulocytosis.
DB05773	DB00108	Avoid combination due to the increased risk of infection.
DB05773	DB00252	Avoid combination with phenytoin and other strong CYP3A4 inducers due to the likely increase in metabolism of ado-trastuzumab emtansine to its active component, DM1.
DB05773	DB00337	Avoid combination due to the increase in immunosuppressant side effects.
DB05773	DB00864	Avoid combination due to the increase in immunosuppressant side effects.
DB05773	DB08895	Avoid combination with tofacitinib and other potent immunosuppressants due to the likely enhancement of immunosuppression.
DB05812	DB01072	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB06616	Abiraterone increases levels by P-glycoprotein (MDR1) efflux transporter. Consider alternate therapy.
DB05812	DB00564	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01211	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB00514	Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely.
DB05812	DB00224	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01167	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01026	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01149	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB00220	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01174	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB00252	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB06402	DB01118	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB05812	DB00615	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01045	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01201	Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB00503	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB01232	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB00976	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB05812	DB00679	Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely.
DB05812	DB00582	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
DB06144	DB00933	Increased risk of cardiotoxicity and arrhythmias
DB06144	DB00679	Increased risk of cardiotoxicity and arrhythmias
DB06147	DB06146	Possible crystallization of urates with this combination
DB06147	DB00563	The sulfamide increases the toxicity of methotrexate
DB06150	DB00563	The sulfamide increases the toxicity of methotrexate
DB06168	DB00051	Increases immunosuppressive effects and risk of infection.
DB06168	DB00092	Increases immunosuppressive effects and risk of infection.
DB06168	DB00026	results in increased immunosuppressive effects; increases the risk of infection.
DB06168	DB00098	results in increased immunosuppressive effects; increases the risk of infection.
DB06168	DB00993	results in increased immunosuppressive effects; increases the risk of infection.
DB06168	DB00074	results in increased immunosuppressive effects; increases the risk of infection.
DB06168	DB00005	Combination should be avoided because Etanercept increase the toxic effects of canakinumab including neutropenia.
DB06168	DB06674	Avoid combination with canakinumab due to the increased chance of neutropenia and/or serious infection.
DB06168	DB00065	Avoid combination due to increased risk of infection as anti-TNF agents enhance adverse effects of Canakinumab.
DB06168	DB00108	Avoid combination due to the increased risk of infection.
DB06168	DB00337	Avoid combination due the potential increase in immunosuppressant adverse effects.
DB06168	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB06168	DB08895	Avoid combination with tofacitinib and other potent immunosuppressants due to potential enhancement of immunosuppressant effects.
DB06186	DB08881	Consider therapy modification due to enhanced hepatotoxicity of vemurafenib
DB06196	DB00542	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB01197	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB00584	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB00492	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB00691	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB00790	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB00881	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB00178	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06196	DB00519	Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
DB06201	DB00564	Decrease concentration of rufinamide thus monitor therapy
DB06201	DB00977	Rufinamide decreases plasma concentrations of ethinyl estradiol, thus consider therapy modification
DB06201	DB00717	Rufinamide decreases plasma concentrations of norethindrone, thus consider therapy modification
DB06201	DB01174	Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.
DB06201	DB00252	Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.
DB06201	DB00794	Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.
DB06201	DB00313	Valproic acid may increase the therapeutic/toxic effects of Rufinamide. Consider alternate therapy or monitor for changes in Rufinamide serum concentrations, therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. Decreases clearance of rufinamide and is a selective inhibitor of human carboxylesterase thus increasing serum concentrations.
DB06204	DB06274	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06204	DB06700	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06204	DB00788	Increases the AUC of tapentadol by 17%. These changes are not considered clinically relevant and no change in dose is required.
DB06204	DB01032	Increases the AUC of tapentadol by 57%. These changes are not considered clinically relevant and no change in dose is required.
DB06204	DB01367	Increases the toxicity of tapentadol by unknown mechanism. Discontinue rasagiline at least 14 days prior to tapentadol administration.
DB06204	DB01037	Increases the toxicity of tapentadol by unknown mechanism. Discontinue selegiline at least 14 days prior to tapentadol administration.
DB06204	DB00315	Use of two serotonin modulators, such as zolmitriptan and tapentadol, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
DB06207	DB00446	Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated.
DB06207	DB00872	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Silodosin. Use of silodosin concomitantly with a strong CYP3A4 inhibitor is contraindicated.
DB06207	DB00343	Moderate inhibitors of CYP3A4 may increase levels of silodosin. Monitor concomitant therapy closely.
DB06207	DB00199	Erythromycin is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects
DB06207	DB00196	Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely.
DB06207	DB00224	Indinavir is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated.
DB06207	DB01167	Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated.
DB06207	DB01026	Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects
DB06207	DB01032	Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely.
DB06207	DB00503	Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated.
DB06207	DB00864	The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of Silodosin. Increased Silodosin exposure may result in Silodosin toxicity. Concurrent use if not recommended.
DB06207	DB00706	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy is not recommended.
DB06207	DB01162	Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.
DB06207	DB00313	Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely.
DB06207	DB00862	Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Silodosin, may occur. Monitor for hypotension during concomitant therapy.
DB06207	DB00661	Verapamil is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects
DB06207	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism. Concomitant therapy is contraindicated.
DB06209	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB06209	DB01050	Coadministration with NSAIDS used chronically may increase the risk of bleeding.
DB06209	DB01026	Ketoconazole is a potent inhibitor of CYP3A4 which decreases the Cmax of prasugrel due to a reduction of prasugrel bioactivation. However, there was no reduction of inhibition of platelet aggregation.
DB06209	DB00448	Lansoprazole is a CYP2C19 substrate which decreases AUC and Cmax of prasugrel. Despite these decreases, there was no significant reduction of inhibition of platelet aggregation.
DB06209	DB00503	Ritonavir is a inhibitor of CYP3A4, thus blocking the bioactivation of prasugrel. As a result, a reduction in prasugrel efficiency may be observed in patients.
DB06209	DB00682	Coadministration with warfarin may increase the risk of bleeding.
DB06210	DB00316	Eltrombopag increases acetaminophen levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00945	Decreases metabolism, will increase effect/level of eltrombopag.
DB06210	DB06723	Decreases levels of eltrombopag by GI absorption inhibition.
DB06210	DB01118	Affects hepatic enzyme CYP2C9/10 metabolism, increases effect/level of eltrombopag.
DB06210	DB01351	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB06210	DB01072	Decreases metabolism, will increase effect/level of eltrombopag. UDP-glucuronosyltransferase inhibition.
DB06210	DB01076	Eltrombopag increases levels of Atorvastatin via metabolism decrease.
DB06210	DB00963	Eltrombopag increases levels of Bromfenac via metabolism decrease.
DB06210	DB00237	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB06210	DB00241	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB06210	DB00258	Calcium Salts such as calcium acetate may decrease the serum concentration of Eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.
DB06210	DB06724	Decreases levels of eltrombopag by GI absorption inhibition.
DB06210	DB01164	Calcium salts such as calcium chloride may decrease the serum concentration of eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.
DB06210	DB00564	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB06210	DB00482	Eltrombopag increases levels of Celecoxib via metabolism decrease.
DB06210	DB00501	Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.
DB06210	DB00537	Affects hepatic CYP1A2 metabolism, will increase effect/level of eltrombopag.
DB06210	DB04272	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB06210	DB00586	Eltrombopag increases levels of Diclofenac via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB06210	DB00861	Eltrombopag increases levels of Diflunisal via metabolism decrease.
DB06210	DB00343	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB06210	DB00625	Affects hepatic enzyme CYP2C9/10 metabolism and may increase the level of eltrombopag.
DB06210	DB00467	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB06210	DB00199	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB06210	DB00977	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB06210	DB00749	Increases levels of Etodolac via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB06210	DB00573	Increases levels of Fenoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB06210	DB00813	Increases levels of Fentanyl via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB06210	DB00712	Increases levels of Flurbiprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition.
DB06210	DB01095	Increases levels of Fluvastatin via metabolism decrease. OATP transporter protein inhibition.
DB06210	DB00176	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB06210	DB00176	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB06210	DB00365	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB06210	DB00956	Increases levels of Hydrocodone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00327	Increases levels of Hydromorphone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB01050	Increases levels of Ibuprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00328	Increases levels of Indomethacin via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00893	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB06210	DB06790	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB06210	DB00951	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB06210	DB01009	Increases levels of Ketoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00465	Increases levels of Ketorolac via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB01097	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB06210	DB00854	Increases levels of Levorphanol via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00653	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB06210	DB00939	Increases levels of Meclofenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00784	Increases levels of Mefenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00814	Increases levels of Meloxicam via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00333	Increases levels of Methadone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00563	Increases levels of Methotrexate via metabolism decrease. OATP transporter protein inhibition.
DB06210	DB00379	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
DB06210	DB01110	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB06210	DB00295	Eltrombopag increases Morphine levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00454	Increases levels of Meperidine via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
DB06210	DB00971	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB06210	DB01390	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
DB06210	DB00755	The moderate CYP2C8 inhibitor, Eltrombopag, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Eltrombopag is initiated, discontinued or dose changed.
DB06210	DB00313	Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.
DB06210	DB00177	Eltrombopag may increase the therapeutic and/or toxic effects of Valsartan. Increased Valsartan serum concentrations may be caused by inhibition of hepatic uptake and decreased metabolism. Consider dose modification, alternate therapy or monitor for changes in the therapeutic and toxic effects of Valsartan if Eltrombopag is initiated, discontinued or dose changed.
DB06210	DB00744	Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag.
DB06212	DB01483	Barbital is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB06212	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of tolvaptan. This combination is contraindicated.
DB06212	DB00564	Carbamazepine is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB06212	DB01211	Clarithromycin is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB06212	DB00257	CYP3A4 Inhibitors (Moderate) may increase the serum concentration of tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated.
DB06212	DB00872	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated.
DB06212	DB00390	Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects.
DB06212	DB00343	Diltiazem is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
DB06212	DB00199	Erythromycin is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
DB06212	DB06414	Tolvaptan may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06212	DB00196	Fluconazole is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
DB06212	DB01167	Itraconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB06212	DB01026	Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%.
DB06212	DB01149	Nefazodone is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB06212	DB00252	Phenytoin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB06212	DB00615	Rifabutin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB06212	DB01045	Rifampin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB06212	DB00503	Ritonavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB06212	DB01232	Saquinavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
DB06212	DB01323	St. John's Wort is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
DB06212	DB00661	Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan. Concomitant therapy is contraindicated.
DB06212	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan by decreasing its metabolism. Concomitant therapy is contraindicated.
DB06213	DB01223	Reduces duration of >2-fold increase in peak flow velocity. No effect on heart rate increase.
DB06213	DB00201	Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear.
DB06213	DB00975	Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration.
DB06213	DB00277	Non-specific adenosine receptor antagonist may interfere with the vasodilation activity of regadenoson. Avoid methylxanthines for at least 12 hours before administration of regadenoson.
DB06216	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06216	DB00564	Carbamazepine is a CYP1A2 inducer that decreases asenapine's exposure by 20%.
DB06216	DB00176	Fluvoxamine is a CYP1A2 inhibitor that increases exposure of asenapine by 30%.
DB06216	DB05039	Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
DB06216	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06216	DB00904	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06216	DB00715	Paroxetine is a substrate of CYP2D6 and concomitant therapy with asenapine (CYP2D6 inhibitor) increases concentrations of paroxetine 2-fold. May require dosing adjustments.
DB06216	DB01174	Phenobarbital is a CYP1A2 inducer and may increase metabolism of asenapine.
DB06216	DB00252	Phenytoin is a CYP1A2 inducer and may increase metabolism of asenapine.
DB06216	DB00794	Primidone is a CYP1A2 inducer and may increase metabolism of asenapine.
DB06216	DB01232	Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided.
DB06216	DB00203	Increased incidence of adverse effects (hypotension) due to pharmacodynamic synergism. Concomitant therapy should be avoided.
DB06216	DB00679	Thioridazine is a CYP2D6 substrate in which concomitant therapy with asenapine will increase serum levels of thioridazine. Consider alternative therapy.
DB06216	DB00539	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06216	DB00313	Valproate completely inhibits the glucuronidation of asenapine but does not effect its exposure. Dose adjustment is not necessary with concomitant therapy.
DB06216	DB00582	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB06216	DB02546	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB06216	DB01392	Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided.
DB06216	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB06216	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB06218	DB00313	Valproic acid toxicity may occur at any time during the treatment course and should be considered in patients with acute changes in mentation, especially if there has been a recent change in antiepileptic therapy.
DB06228	DB06605	Avoid combination. Otherwise, excessive anticoagulation will likely occur.
DB06228	DB00006	Anticoagulants may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding.
DB06228	DB00758	Antiplatelet agents such as clopidogrel may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding. Canadian rivaroxaban labeling recommends avoiding concurrent use with any antiplatelet agent, while the U.S. rivaroxaban labeling recommends caution and increased monitoring if used with any other antiplatelet agent. Any combined use should only be undertaken with increased monitoring for evidence of bleeding.
DB06228	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. Consider avoiding use of rivaroxaban with any strong CYP3A4 inhibitors as many such agents are inhibitors of both CYP3A4 and P-glycoprotein. Use of rivaroxaban concomitantly with drugs that are strong inhibitors of both CYP3A4 and P-glycoprotein is specifically contraindicated.
DB06228	DB06695	Using additional anticoagulants such as dabigatran can increase the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding.
DB06228	DB00063	Consider modifying therapy due to enhanced anticoagulant effect.
DB06228	DB06414	Rivaroxaban may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy.
DB06228	DB01381	Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
DB06402	DB01169	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06228	DB01167	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
DB06228	DB01026	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
DB06228	DB01263	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
DB06228	DB00503	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 like ritonavir and P-glycoproteins are contraindicated.
DB06228	DB00675	Tamoxifen may increase serum concentrations of Rivaroxaban increasing the risk of bleeding. Concomitant therapy should be avoided.
DB06228	DB00976	Telithromycin may reduce clearance of Rivaroxaban. Concomitant therapy is contraindicated.
DB06228	DB00374	The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Rivaroxaban. Monitor for increased bleeding during concomitant thearpy.
DB06228	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of rivaroxaban by decreasing its metabolism. Increased bleed risks may occur. Consider alternate therapy.
DB06237	DB08822	Pharmacodynamic synergist- increases effects.
DB06237	DB01151	Co-administration with avanafil resulted in an approximate 5.7% increase in AUC0-inf and 5.2% decrease in Cmax of rosiglitazone.
DB06237	DB00199	Co-administration with the moderate CYP3A4 inhibitor erythromycin resulted in an approximate 3.6-fold increase in AUC0-inf and 2.0-fold increase in Cmax of avanafil.
DB06237	DB00883	Additive vasodilation. Concomitant therapy is contraindicated.
DB06237	DB01020	Additive vasodilation. Concomitant therapy is contraindicated.
DB06237	DB01026	Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax.
DB06237	DB00727	Additive vasodilation. Concomitant therapy is contraindicated.
DB06237	DB00338	Nineteen healthy male volunteers received a single 40 omeprazole delayed-release capsule once daily for 8 days (Days 1-8), and a single 200 mg avanafil on Day 8. Twelve hour pharmacokinetics of omeprazole on Days 7 and 8 were compared. Co-administration with avanafil resulted in an approximate 5.9% increase in AUC0-inf and 8.6% increase in Cmax of omeprazole.
DB06237	DB00503	Co-administration with the strong CYP3A4 inhibitor ritonavir resulted in an approximate 13-fold increase in AUC0-inf and 2.4-fold increase in Cmax of avanafil.
DB06237	DB00412	Co-administration with avanafil resulted in an approximate 2.0% increase in AUC0-inf and 14% decrease in Cmax of rosiglitazone.
DB06237	DB00682	Co-administration with avanafil resulted in an approximate 1.6% increase in AUC(0-inf) and 5.2% decrease in Cmax of S-warfarin.
DB06267	DB00883	The vasodilatory effects of Isosobide dinitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB06267	DB01020	The vasodilatory effects of Isosobide mononitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB06267	DB00727	The vasodilatory effects of Nitroglycerin may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
DB06268	DB00395	Strong CYP2C19 inhibitors such as sitaxentan may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DB06268	DB00675	Sitaxsentan may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sitaxsentan is initiated, discontinued or dose changed.
DB06268	DB00706	Sitaxsentan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sitaxsentan is initiated, discontinued, or dose changed.
DB06268	DB08895	Sitaxentan (moderate CYP3A4 inhibitors, strong CYP2C19 inhbitors), when used in combination with tofacitinib, may increase tofaciitinib serum concentration toxicity and adverse effects. It is recommended to adjust therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5 mg daily.
DB06268	DB01124	Sitaxsentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Sitaxsentan is initiated, discontinued or dose changed.
DB06268	DB01036	Sitaxsentan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB06268	DB00214	Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sitaxsentan is initiated, discontinued or dose changed.
DB06268	DB00193	Sitaxsentan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
DB06268	DB00656	The CYP3A4 inhibitor, Sitaxsenten, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed.
DB06268	DB00440	The strong CYP2C9 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sitaxsentan is initiated, discontinued or dose changed.
DB06268	DB00726	The strong CYP2C19 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Sitaxsentan is initiated, discontinued or dose changed.
DB06268	DB00582	Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sitaxsentan is initiated, discontinued or dose changed.
DB06268	DB00682	Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Warfarin doses should be decreased by 80% upon initiated of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of warfarin if sitaxentan is initiated, discontinued or dose changed.
DB06268	DB00549	Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sitaxentan is initiated, discontinued or dose changed.
DB06273	DB01281	Avoid combination due to enhanced adverse effects of abatacept.
DB06273	DB00514	Dextromethorphan is a CYP2D6 and CYP3A4 substrate. Exposure of dextromethorphan decreases following administration of tocilizumab.
DB06273	DB00005	Avoid combination due to enhanced immunosuppressive effects.
DB06273	DB06674	Avoid combination due to the enhanced immunosuppression by TNF blockers.
DB06273	DB00065	Avoid combination because enhanced immunosuppression by anti-TNF agents.
DB06273	DB00338	Omeprazole is a CYP2C19 and CYP3A4 substrate. Exposure of omeprazole decreases following administration of tocilizumab..
DB06273	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB06273	DB00641	Simvastatin is a CYP3A4 and OATP1B1 substrate. Exposure of simvastatin decreases following administration of tocilizumab.
DB06273	DB08895	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB06274	DB00802	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01118	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB06274	DB01076	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB06274	DB00921	Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification.
DB06274	DB00611	Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan.
DB06274	DB01211	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB06274	DB00257	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB06274	DB00318	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01529	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00647	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01209	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01501	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01551	Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days.
DB06274	DB01081	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01491	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00813	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01452	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00956	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00327	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB08820	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB06274	DB01227	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00854	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00333	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00295	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00844	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00497	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01192	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB01113	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00652	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00454	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00908	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB06274	DB00708	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB06204	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06274	DB00193	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
DB06287	DB00357	Aminoglutethimide may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00701	Amprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01072	Atazanavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00559	Bosentan may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00564	Carbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB01211	Clarithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00872	Conivaptan may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01264	Darunavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00705	Delavirdine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01234	Dexamethasone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00625	Efavirenz may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00544	Co-administration of Temsirolimus and Fluorouracil may result in serious adverse drug reactions.
DB06287	DB01319	Fosamprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01320	Fosphenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00441	Co-administration of Temsirolimus and Gemcitabine may result in serious adverse drug reactions.
DB06287	DB00619	Imatinib may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00224	Indinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00951	Isoniazid may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01167	Itraconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01026	Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01601	Lopinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01110	Miconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00607	Nafcillin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00108	Temsirolimus may increase the toxicity of Natalizumab. Concomitant therapy should be avoided.
DB06287	DB01149	Nefazodone may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00220	Nelfinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00238	Nevirapine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00622	Nicardipine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00776	Oxcarbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00312	Pentobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB01174	Phenobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00252	Phenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB01263	Posaconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00794	Primidone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB00908	Quinidine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00615	Rifabutin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB01045	Rifampin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB01201	Rifapentine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB06287	DB00503	Ritonavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01232	Saquinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB01323	St. John's Wort may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
DB06287	DB01268	Co-administration of Temsirolimus and Sunitinib may result in serious adverse drug reactions.
DB06287	DB00864	Temsirolimus may decrease the blood concentration of Tacrolimus. Concomitant therapy may increase the adverse/toxic effects of both agents. Concomitant therapy should be avoided.
DB06287	DB00976	Telithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
DB06287	DB00932	Tipranavir may affect the efficacy/toxicity of Temsirolimus.
DB06287	DB00519	Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema.
DB06287	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB06402	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06287	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of temsirolimus and its active metabolite, sirolimus, by decreasing their metabolism. Concomitant therapy should be avoided.
DB06335	DB01211	Clarithromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB06335	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor.
DB06335	DB00343	Diltiazem is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 109%. Exposure of the active metabolite decreased by 34%. However, these changes in pharmacokinetics are not clinical significant.
DB06335	DB00199	Erythromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB06335	DB00224	Indinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB06335	DB01026	Ketoconazole is a strong inhibitor of CYP3A4/5 which increases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also decreases. Decrease dose of saxagliptin to 2.5 mg per day.
DB06335	DB01149	Nefazodone is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB06335	DB00220	Nelfinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB06335	DB01045	Rifampin is a strong inducer of CYP3A4 which decreases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also increases.
DB06335	DB00503	Ritonavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
DB06335	DB00641	Simvastatin is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 12%. Exposure of the active metabolite decreased by 2%. However, these changes in pharmacokinetics are not clinical significant.
DB06335	DB00052	Somatropin may antagonize the hypoglycemic effect of saxagliptin. Monitor for changes in fasting and postprandial blood sugars.
DB06335	DB00582	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of saxagliptin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of saxagliptin if voriconazole is initiated, discontinued or dose changed.
DB06372	DB00051	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00092	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00026	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00098	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00993	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00074	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB06681	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
DB06372	DB06681	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
DB06372	DB06681	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
DB06372	DB06168	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00091	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00111	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00004	decreases effects of toxoids by pharmacodynamic antagonism.
DB06372	DB06643	Use caution with patients on concomitant immunosuppressants or those with compromised immune systems; increased risk of serious infection.
DB06372	DB00095	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00005	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB01590	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB05259	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB06674	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB06674	Avoid combination due to the enhancement of rilonacept associated side effects.
DB06372	DB01611	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00065	Anti-TNF alfa agents enhance adverse effects of rilonacept thus combination should be avoided.
DB06372	DB01097	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00563	Rilonacept and methotrexate both increase immunosuppressive effects; combination may increase risk of myelosuppression.
DB06372	DB00075	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00688	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB06688	decreases effectiveness of APC8015 by pharmacodynamic antagonism.
DB06372	DB00877	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00864	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB06287	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB01041	Thalidomide may increase the adverse effects of Rilonacept. Increased risk of serious infection. Concomitant therapy should be avoided.
DB06372	DB06273	results in increased immunosuppressive effects; increases the risk of infection.
DB06372	DB00072	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
DB06402	DB00637	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB01244	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00604	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00280	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00308	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00808	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00904	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00738	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB01100	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB01035	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00908	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB01232	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00489	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00342	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06402	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB06402	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB06414	DB01118	Amiodarone, when used concomitantly with etravirine, may decrease in serum concentration. If possible, monitoring for decreased amiodarone levels is recommended.
DB06414	DB01118	Amiodarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. If possible, monitoring of amiodarone levels is recommended.
DB06414	DB06605	Apixaban, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. Concomitant use should be avoided.
DB06414	DB01238	Ariprazole, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dose of oral aripiprazole to maintain therapeutic efficacy, and to adjust the dose of aripiprazole appropriately when the dose of etravirine is altered.
DB06414	DB06697	Artemether, when administered concomitantly with etravirine, may experience a decrease in serum concentrations of active metabolites such as dihydroartemisinin; however, artemether may increase in serum concentration. \r\n\r\nEtravirine, when used with artemether, may increase in serum concentration.  \r\n\r\nCaution and monitoring of therapeuric efficacy of artemether is recommended.
DB06414	DB01072	Atazanavir, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. \r\n\r\nEtravirine, when administered concomitantly with Atazanavir, may expereince an increase in serum concentrations. \r\n\r\nRecommended to avoid use of this combination.
DB06414	DB01076	Atorvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of atorvastatin therapy.
DB06414	DB06626	Axitinib, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. Recommended to avoid use of this combination.
DB06414	DB01244	Bepridil (withdrawn from US. market), when used concomitantly with etravirine, may experience a decrease in serum concentration. If possible, it is recommended to monitor for decreased bepridil concentrations and therapeutic efficacy.
DB06414	DB08873	The exposure of etravirine decreases whereas boceprevir's exposure increased. Therapeutic implications of this observation is unknown.
DB06414	DB00188	Bortezombib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06414	DB06616	Bosutinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06414	DB08870	Brentuximab, when used concomitantly with etravirine, may experience a decrease in serum concentrations. The levels of an active metabolite of brentuximab, monomethyl auristatin E, may decrease. It is recommended to monitor efficacy of brentuximab therapy.
DB06414	DB00921	Buprenorphine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for a decrease in buprenorphine levels (ie. reduced analgesia, and signs of opioid withdrawal).
DB06414	DB08875	Cabozantinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by 40mg (without exceeding 180mg/day).
DB06414	DB00564	Carbamazepine, when used concomitantly with certain NNRTIs (ie. efavirenz), may experience a decrease in serum concentration. \r\n\r\nEtravirine, and other NNRTIs, when used concomitantly with carbamazepine, may experience an increase in serum concentration. \r\n\r\nIt is recommended to avoid this combination.
DB06414	DB01136	Carvedilol, when used concomitantly with etravirine (a CYP2C9 inhibitor), may experience an increase in serum concentration. \r\n\r\nIt is recommended to monitor for signs and symptoms of an increased response to carvedilol, such as orthostatic hypotension and bradycardia.
DB06414	DB00215	Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration. \r\n\r\nIt is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes).
DB06414	DB01211	Clarithromycin (and other macrolide antibiotics), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to use alternative antibiotic agents if available. If concurrent therapy cannot be avoided, monitor for reduced effectiveness of clarithromycin.
DB06697	DB00714	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06414	DB00758	Clopidogrel, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in the serum concentrations of it's active metabolites. \r\n\r\nCaution and close monitoring for decreased efficacy of clopidogrel is recommended.
DB06414	DB08865	Crizotinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06414	DB01264	Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \r\n\r\nProtease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \r\n\r\nRitonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.
DB06414	DB01254	Dasatinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. \r\n\r\nIt is recommended to avoid this combination if possible. If concurrent therapy cannot be avoided it is recommended to increase the dose of dasitinib and monitor for efficacy and toxicity.
DB06414	DB01609	Etravirine, when administered concomitantly with deferasirox, may experience a decrease in serum concentration. It is recommended to monitor therapy.
DB06414	DB00705	Etravirine, when used concomitantly with Delaviridine, may experience an increase in serum concentration.  \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination.
DB06414	DB00829	Diazepam (a CYP21C9 and CYP3A4 substrate), when administered concomitantly with etravirine, may experience an increase (via CYP21C9 inhibition) or a decrease(via CYP3A4 induction) in serum concentration. Overall clinical significance is unknown. It is recommended to monitor diazepam therapy.
DB06414	DB00390	Digoxin, when administered concomitantly with etravirine, may experience an increase in serum concentration. It is recommended to monitor serum levels of digoxin and titrate dosage to achieve desired therapeutic range. Pre-emptive dose adjustments are not required.
DB06414	DB00280	Disopyramide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for disopyramide therapy.
DB06414	DB04855	Dronedarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06414	DB00625	Etravirine, when used concomitantly with Efavirenz, may experience a  significant decrease in plasma levels and a loss of efficacy. \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination.
DB06414	DB01590	Everolimus, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. If concurrent therapy cannot be avoided, a gradual dosage increase of everolimus is recommended.
DB06414	DB00990	Exemestane, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dosage of exemestane and to closely monitor therapy for efficacy and toxicity.
DB06414	DB01195	Flecainide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor flecainide therapy.
DB06414	DB01095	Fluvastatin, when administered concomitantly with etravirin, may experience an increase in serum concentration. It is recommended to monitor for signs of toxicity from fluvastatin, such as myopathy and hepatic enzyme elevations.
DB06414	DB01319	Fosamprenavir, when administered concomitantly with etravirine, may experience an increase in the serum concentration of its active metabolits. It is recommended to avoid this combination.
DB06414	DB01320	Etravirine, when administered concomitantly with fosphenytoin, may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06414	DB00317	Gefitinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase gefitinib dosage, if clinically appropriate, and to monitor for gefitinib therapy for efficacy and toxicity.
DB06414	DB01018	Guanfacine, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase guanfacine dosage up to 8mg/day, as tolerated, and to monitor gefitinib therapy.
DB06414	DB01181	Ifosfamide, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience an increase in the serum concentrations of its active metabolites. It is recommended to monitor for toxicity of ifosfamide therapy.
DB06414	DB00619	Imatinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by a minimum of 50%, and to monitor therapy.
DB06414	DB08820	Ivacaftor, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06414	DB01026	Etravirine, when used concomitantly with Ketoconazole (and other azole derivatives), may experience an increase in serum concentration.\r\n\r\nKetoconazole (and other azole derivatives), when used concomitantly with etravirine, may experience a decrease in serum concentration.\r\n\r\nIt is recommended to monitor etravirine therapy for toxicity.
DB06414	DB01259	Lapatinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06414	DB00281	Lidocaine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor lidocaine therapy.
DB06414	DB08882	Linagliptin, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy if possible, and to monitor linagliptin therapy if concurrent use cannot be avoided.
DB06414	DB01601	Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \r\n\r\nProtease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \r\n\r\nRitonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.
DB06697	DB01169	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06414	DB00227	Lovastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of lovastatin therapy.
DB06414	DB08815	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB06414	DB08815	Lurasidone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB04835	Maraviroc, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00333	Methadone, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor methadone therapy for decrease effectiveness and symptoms of withdrawal.
DB06414	DB00379	Mexiletine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor mexiletine therapy for reduced effectiveness.
DB06414	DB00834	Mifepristone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00238	Nevirapine may cause a significant decrease in plasma levels of etravirine and a loss of efficacy. \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy.
DB06414	DB01115	Nifedipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor nifedipine therapy for reduced effectiveness.
DB06414	DB04868	Nilotinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00401	Nisoldipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB01229	Paclitaxel, when used concomitantly with NNRTIs, may experience an increase in serum concentration. It is recommended to monitor for paclitaxel toxicity.
DB06414	DB06589	Pazopanib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00008	Etravirine (a CYP2C9 substrate), when used concomitantly with peginterferon alfa-2a, may experience a decrease in serum concentration. It is recommended to monitor effectiveness of etravirine therapy.
DB06414	DB08883	Perampanel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB01174	Etravirine, when used concomitantly with phenobarbital, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00252	Etravirine, when used concomitantly with phenytoin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB01058	Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB01058	Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00794	Etravirine, when used concomitantly with Primidone (primarily metabolized to phenobarbital), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB01182	Propafenone, when used concomitantly with Etravirine, may experience a decrease in serum concentration. It is recommended to monitor for continued efficacy of propafenone therapy.
DB06414	DB01224	Quetiapine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase quetiapine dosage if concurrent therapy is required.
DB06414	DB00908	Quinidine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor quinidine therapy.
DB06414	DB00615	Etravirine may experience a decrease in serum concentration. It is recommended to monitor etravirine therapy for efficacy. The combination of rifabutin and etravirine therapy is contraindicated if a protease inhibitor which is ritonavir boosted is also being used.
DB06414	DB04220	Etravirine, when used concomitantly with rifamycin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB08864	Rilpivirine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. Use of rilpivirine and other NNRTIs is containdicated.
DB06414	DB06228	Rivaroxaban may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy.
DB06414	DB01656	Affects CYP3A4 metabolism, decreases level or effect of roflumilast.
DB06414	DB01656	Roflumilast, when used concomitantly with etravirine, may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy.
DB06414	DB06176	Romidepsin, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB01232	Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \r\n\r\nProtease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \r\n\r\nRitonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.
DB06414	DB00203	Sildenafil (and other phosphodiesterase 5 inhibitors), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor the efficacy of sildenafil therapy.
DB06414	DB00641	Simvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of simvastatin therapy.
DB06414	DB00398	Sorafebib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB01323	Etravirine may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00706	Etravirine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Etravirine is initiated, discontinued, or dose changed.
DB06414	DB05521	Telaprevir, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor telaprevir therapy closely.
DB06414	DB08816	Etravirine, when used concomitantly with ritonavir boosted ticagrelor, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00932	Tipranavir, co-administered with Ritonavir, may decrease the effect of Etravirene by decreasing Etravirene serum concentration. Concomitant therapy should be avoided.
DB06414	DB01036	Etravirene may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
DB06414	DB06212	Tolvaptan may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00539	Toremifene, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00193	Tramadol,when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration and efficacy due to increased tramadol metabolism and clearance.
DB06414	DB00656	The CYP3A4 inducer, Etravirene, may decrease Trazodone efficacy/toxicity by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Etravirine is initiated, discontinued or dose changed.
DB06414	DB05294	Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
DB06414	DB00541	Vincristine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06414	DB00582	Etravirine, when used concomitantly with variconazole, may experience an increase in serum concentration due to decreased metabolism of etravirine. \r\n\r\nVoriconazole, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in serum concentration. \r\n\r\nMonitor for changes in efficacy and toxicity of both agents if concomitant therapy is initiated, modified or discontinued.
DB06414	DB01624	Zuclopenthixol (especially oral dosage form) may experience a decrease in serum concentration when used concomitantly with etravirine. It is recommended to monitor zuclopenthixol therapy for efficacy.
DB06589	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06589	DB00564	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB06589	DB00501	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB06589	DB01211	Clarithromycin is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib.
DB06589	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib. Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not possible to avoid such a combination, reduce pazopanib dose to 400 mg. Further dose reductions may also be required.
DB06589	DB00199	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB06589	DB06414	Pazopanib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB06589	DB01181	Ifosfamide decreases plasma levels of pazopanib.
DB06589	DB00762	Irinotecan is an uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) substrate and serum concentrations may increase if administered concurrently with pazopanib, an UGT1A1 inhibitor.
DB06589	DB01167	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB06589	DB08820	Inhibits p-glycoprotein and affects heptatic metabolism via CYP3A4 therefore increases levels of pazopanib. Consider alternate therapy.
DB06589	DB01026	Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects.
DB06589	DB01259	Lapatinib is a weak inhibitor of CYP3A4, BCRP, and p-glycoprotein and may increase exposure of pazopanib. AUC and Cmax increase by 50-60%.
DB06589	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06589	DB01149	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB06589	DB00904	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB06589	DB01229	Pazopanib increases exposure of paclitaxel
DB06589	DB00615	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB06589	DB01045	Concomitant therapy with a CYP3A4 inducer may decrease exposure of pazopanib.
DB06589	DB00503	Ritonavir is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib.
DB06589	DB01232	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
DB06589	DB00641	Elevated liver enzyme levels may be observed with concomitant therapy with pazopanib. Monitor closely for adverse effects.
DB06589	DB00539	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB06589	DB00246	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
DB06589	DB01624	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
DB06605	DB06695	Concomitant therapy with another anticoagulant may increase bleed risk. Monitor closely for adverse effects.
DB06605	DB01225	Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy.
DB06605	DB00063	Monitor therapy due to potential risk of bleeding.
DB06605	DB06414	Apixaban, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. Concomitant use should be avoided.
DB06605	DB01167	Avoid combination. Otherwise, itraconazole will likely increase apixaban serum concentration.
DB06605	DB01026	Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration.
DB06605	DB00788	Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy.
DB06605	DB01263	Avoid combination. Otherwise, posaconazole will likely increase apixaban serum concentration.
DB06605	DB00503	Avoid combination. Otherwise, ritonavir will likely increase apixaban serum concentration.
DB06605	DB06228	Avoid combination. Otherwise, excessive anticoagulation will likely occur.
DB06605	DB00582	Avoid combination. Otherwise, voriconazole will likely increase apixaban serum concentration.
DB06616	DB05812	Abiraterone increases levels by P-glycoprotein (MDR1) efflux transporter. Consider alternate therapy.
DB06616	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB06616	DB00390	Bosutinib is a substrate and inhibitor of p-glycoprotein (p-gp) and may increase levels of other p-gp substrates.
DB06616	DB06414	Bosutinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB06616	DB01026	Strong CYP3A4 inhibitors may increase levels of bosutinib. Monitor concomitant therapy closely.
DB06616	DB00448	Concomitant lansoprazole (PPI) decreased bosutinib Cmax by 46% and AUC by 26% compared to bosutinib alone. Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours.
DB06616	DB01045	Strong CYP3A4 inducers may decrease levels of bosutinib. Monitor concomitant therapy closely.
DB06626	DB00349	Clobazam decreases levels by affecting CYP3A4 metabolism. Consider alternate therapy.
DB06626	DB06414	Axitinib, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. Recommended to avoid use of this combination.
DB06626	DB01229	Avoid combination due to potential for decrease in serum concentration of axitinib.
DB06626	DB08883	Avoid combination with axitinib or other major CYP3A4 drug susbtrates due to the potential decrease in the drug's  concentration by perampanel induction of CYP3A4.
DB06626	DB00252	Avoid combination with phenytoin and other strong, moderate, or weak CYP3A4 inducers due to the likely decreased levels of axitinib.
DB06626	DB01323	Avoid combination due to the likely decreased levels of axitinib.
DB06643	DB01281	Monitor therapy due to enhanced effects of immunosuppressants and the risk of serious infections.
DB06643	DB00098	Monitor therapy because of the enhanced immunosuppressive effect and increased risk of infections.
DB06643	DB06681	Montinor therapy due to enhanced adverse effects of immunosuppressants and the risk of infections.
DB06643	DB08879	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB06643	DB00005	Monitor therapy as there may be an enhanced immunosuppressive effect.
DB06643	DB00056	Monitor therapy due to enhanced adverse effects of immunosuppressants including the risk of infections.
DB06643	DB05259	Monitor therapy due to enhanced immunosuppressive effects and the risk of infections.
DB06643	DB00078	Monitor therapy for enhanced immunosuppressive effects and increased risk of infections.
DB06643	DB00065	Therapy should be monitored when combination is initiated as there may be an increase in serious infections.
DB06643	DB08935	Monitor therapy due to increased risk of infections due to adverse effects of immunosuppressants.
DB06643	DB00043	Monitor therapy due to increased risk of infections consequent to increased adverse effects of immunosuppressants.
DB06643	DB00059	Monitor therapy due to increased immunosuppressive effect and risk of infections.
DB06643	DB06813	Increased immunosuppresive effects and risk of infection. Monitor for adverse effects .
DB06643	DB06372	Use caution with patients on concomitant immunosuppressants or those with compromised immune systems; increased risk of serious infection.
DB06643	DB08895	Denosumab, when used in combination with tofacitinib, may increase tofaciitinib toxicity and worsen side effects. It may specifically increase the risk of serious infection. It is recommended to monitor therapy.
DB06655	DB00316	These agents may have decreased C max and a delayed T max during coadministration.
DB06655	DB01076	These agents may have decreased C max and a delayed T max during coadministration.
DB06655	DB08822	Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity.
DB06655	DB00390	These agents may have decreased C max and a delayed T max during coadministration.
DB06655	DB00400	Cmax may be increased.
DB06655	DB00030	Coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed.
DB06655	DB00052	Somatropin may antagonize the hypoglycemic effect of liraglutide. Monitor for changes in fasting and postprandial blood sugars.
DB06663	DB00834	Avoid combination with mifepristone and other moderate to high risk QTc prolonging agents. The combinaton may enhance the QTc-prolonging effect of these drugs.
DB06674	DB01281	Avoid combination with abatacept due to the increased chance of serious infection.
DB06674	DB00026	Avoid combination with anakinra due to the increased chance of serious infection.
DB06674	DB08879	Avoid combination with belimumab due to the increased chance of belimumab associated side effects.
DB06674	DB06168	Avoid combination with canakinumab due to the increased chance of neutropenia and/or serious infection.
DB06674	DB08904	Avoid combination due to the potential increased immunosuppression of Certolizumab Pegol.
DB06674	DB00065	Avoid combination with infliximab due to the potential increased immunosuppression of infliximab.
DB06674	DB00108	Avoid combination due to the increased chance of infection.
DB06674	DB00337	Avoid combination due to enhancement of side effects from immunosuppressants.
DB06674	DB06372	results in increased immunosuppressive effects; increases the risk of infection.
DB06674	DB06372	Avoid combination due to the enhancement of rilonacept associated side effects.
DB06674	DB00864	Avoid combination due to the enhancement of side effects from immunosuppressants.
DB06674	DB06273	Avoid combination due to the enhanced immunosuppression by TNF blockers.
DB06697	DB06216	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06674	DB08895	Golimumab, and other anti-TNF immunosuppressants, when used in combination with tofacitinib, may increase the serum concentration of tofacitinib, and increase tofacitinib associated side effects and immunosuppresion. It is recommended to avoid concurrent therapy.
DB06681	DB08879	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB06681	DB06643	Montinor therapy due to enhanced adverse effects of immunosuppressants and the risk of infections.
DB06681	DB01097	Consider therapy modification due to enhanced adverse effects of leflunomide, especially hematologic toxicities.
DB06681	DB00688	Belatacept increases the Cmax and AUC of mycophenolate mofetil.
DB06681	DB00108	Avoid infection due to enhanced adverse effects of natalizumab and the risk of infections.
DB06681	DB00337	Avoid combination due to enhanced effects of immunosuppressants.
DB06681	DB06813	Increased immunosuppresive effects and risk of infection. Monitor for adverse effects .
DB06681	DB06372	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
DB06681	DB06372	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
DB06681	DB06372	Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both.
DB06681	DB01656	Consider modifying therapy due to enhanced immunosuppressive effect.
DB06681	DB06688	Monitor therapy due to to potential decrease in therapeutic effect of sipuleucel-t.
DB06681	DB00864	Avoid combination due to enhanced immunosuppressive effect.
DB06681	DB08895	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB06681	DB00072	Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
DB06684	DB00321	Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved.
DB06684	DB01072	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB06684	DB00564	Carbamazepine may increase the metabolism of Selective Serotonin Reuptake Inhibitors (SSRI). Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Carbamazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
DB06684	DB00482	Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). To minimize the risk of bleeding associated with this combination, consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent, such as a proton pump inhibitor for the time that combined selective serotonin reuptake inhibitor (SSRIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) is necessary.
DB06684	DB00501	Cimetidine may decrease the metabolism of Selective Serotonin Reuptake Inhibitors. Consider using an alternative H2-antagonist to avoid the risk of selective serotonin reuptake inhibitor (SSRI) toxicity. Monitor for increased therapeutic or toxic effects of SSRI if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.
DB06684	DB01211	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB06684	DB00363	Selective Serotonin Reuptake Inhibitors may decrease the metabolism of clozapine. If concurrent use of these agents is employed, monitor for increased toxic effects of clozapine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased effects if a SSRI is discontinued/dose decreased.
DB06684	DB00872	CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Vilazodone. Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB06684	DB01151	Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved.
DB06684	DB00514	Consideration should be given to avoiding the concomitant use of dextromethorphan and selective serotonin reuptake inhibitors (SSRI). Monitor for toxic effects of dextromethorphan (eg, CNS, Cardiovascular) if an SSRI is initiated or the dose is increased. SSRIs, other than fluoxetine and paroxetine, may be safer alternatives due to lesser CYP2D6 inhibition; however, the mechanism for the interaction is not fully understood, and caution is still advised.
DB06684	DB00586	Increased risk of bleeding with concomitant use of NSAIDs with vilazodone.
DB06684	DB00055	Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.
DB06684	DB01050	Increased risk of bleeding with concomitant use of non-steroidal anti-inflammatory drugs with vilazodone.
DB06684	DB01247	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
DB06684	DB01026	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB06684	DB00465	Increased risk of bleeding with concomitant use of vilazodone and ketorolac
DB06684	DB00150	Due to risks of enhanced serotonin activity and/or adverse reactions (e.g., serotonin syndrome), concomitant use of selective serotonin reuptake inhibitors (SSRIs) and tryptophan is not recommended. Avoid combination.
DB06684	DB00601	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
DB06684	DB01233	Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.
DB06697	DB00207	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06684	DB00379	Monitor for increased serum concentrations/toxic effects of mexiletine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased concentrations/effects if an SSRI is discontinued/dose decreased.
DB06684	DB00788	Increased risk of bleeding with concomitant use of NSAIDs with vilazodone.
DB06684	DB00952	Increased risk of serotonin syndrome
DB06684	DB00540	Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved.
DB06684	DB00780	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.
DB06684	DB00554	Increased risk of bleeding with concomitant use of NSAIDs and vilazodone
DB06684	DB00908	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB06684	DB01037	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination.
DB06684	DB01105	Sibutramine may enhance the serotonergic effect of Serotonin Modulators. This may cause serotonin syndrome. Avoid combination.
DB06684	DB00669	Increased risk of serotonin syndrome
DB06684	DB00679	Thioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes.  Avoid combination.
DB06684	DB00752	MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.
DB06684	DB00582	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.
DB06684	DB00682	Increased risk of bleeding with concomitant use of warfarin and vilazodone.
DB06692	DB01197	In study of nine patients with untreated hypertension, aprotinin infused intravenously in a dose of 2 million KIU over two hours blocked the acute hypotensive effect of 100mg of captopril.
DB06692	DB01109	Aprotinin, in the presence of heparin, has been found to prolong the activated clotting time (ACT) as measured by a celite surface activation method. The kaolin activated clotting time appears to be much less affected.
DB06692	DB00031	Aprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase.
DB06692	DB00013	Aprotonin may antagonize the effect of Urokinase. Monitor for decreased effects of Urokinase.
DB06695	DB01118	Amiodarone may increase the serum concentration of dabigatran etexilate, resulting in increased risk of bleeding. Consider modifying therapy.
DB06695	DB06605	Concomitant therapy with another anticoagulant may increase bleed risk. Monitor closely for adverse effects.
DB06695	DB00564	P-Glycoprotein inducers such as carbamazepine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB01234	P-Glycoprotein inducers such as dexamethasone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB00997	P-Glycoprotein inducers such as doxorubicin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB04855	Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of dabigatran 1.1-1.9-fold.
DB06695	DB00063	Monitor therapy due to increased bleeding.
DB06695	DB01381	Additive anticoagulant/antiplatelet effects of gingko may increase bleed risk for patients on dabigatran. Concomitant therapy should be avoided.
DB06695	DB01026	Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects.
DB06695	DB08827	Dabigatran is a p-glycoprotien (P-gp) substrate. Levels of dabigatran may increase if coadministered with lomipatide, which is a P-gp inhibitor. Thus, it is recommended to dose reduce P-gp substrates (such as ambrisentan, aliskiren, colchicine, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) with the concomitant use of lomipatide.
DB06695	DB00834	May lead to excessive post-abortion bleeding in patients on anticoagulant therapy. Concomitant therapy is contraindicated.
DB06695	DB01149	P-Glycoprotein inducers such as nefazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB00213	Proton pump inhibitors may decrease the bioavailability of dabigatran by 28% and increase inter-patient pharmacokinetic variability, especially in females. However, dose adjustment is not required.
DB06695	DB00457	P-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB00908	Quinidine may increase the serum concentration of dabigatran etexilate, resulting in increased bleeding. Consider modification of therapy.
DB06695	DB01045	P-Glycoprotein inducers such as rifampin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB06228	Using additional anticoagulants such as dabigatran can increase the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding.
DB06695	DB00932	P-Glycoprotein inducers such as tipranavir may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB00656	P-Glycoprotein inducers such as trazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06695	DB00661	Verapamil may increase serum concentrations of the active metabolite(s) of dabigatran etexilate, resulting in an increased risk of bleeding. It is also a strong p-glycoprotein inhibitor. Therapy modification should be considered.
DB06695	DB00570	P-Glycoprotein inducers such as vinblastine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
DB06697	DB01118	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00321	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00543	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01244	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00608	Chloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB00477	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00604	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00215	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01211	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01242	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00872	Conivaptan, a strong CYP3A inhibitor, may increase the toxicity of artemether by inhibiting its metabolism. Consider alternate therapy or allow at least 7 days to elapse between conivaptan and artemether therapy.
DB06697	DB01254	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB06699	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01151	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00304	Artemether may decrease the effectiveness of desogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00280	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00204	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00757	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01184	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01142	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB04855	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB06697	DB00450	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01395	Artemether may decrease the effectiveness of drospirinone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00199	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01175	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00977	Artemether may decrease the effectiveness of ethinyl estradiol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00823	Artemether may decrease the effectiveness of ethynodiol diacetate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00294	Artemether may decrease the effectiveness of etonogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB06414	Artemether, when administered concomitantly with etravirine, may experience a decrease in serum concentrations of active metabolites such as dihydroartemisinin; however, artemether may increase in serum concentration. \r\n\r\nEtravirine, when used with artemether, may increase in serum concentration.  \r\n\r\nCaution and monitoring of therapeuric efficacy of artemether is recommended.
DB06697	DB01195	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00196	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00472	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00875	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00529	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB06703	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB06705	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01218	Halofantrine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB00502	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01611	Hydroxychloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB00308	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB04946	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00458	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00808	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00270	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01026	Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects.
DB06697	DB01259	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01137	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00367	Artemether may decrease the effectiveness of levonorgestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00408	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00934	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00603	Artemether may decrease the effectiveness of medroxyprogesterone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00358	Mefloquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB00933	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01357	Artemether may decrease the effectiveness of mestranol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00333	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01403	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00218	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB04868	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB06713	Artemether may decrease the effectiveness of norelgestromin by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00717	Artemether may decrease the effectiveness of norethindrone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB01059	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00957	Artemether may decrease the effectiveness of norgestimate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06697	DB00540	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00104	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB06589	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00738	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00556	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01100	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB06697	DB01087	Primaquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB01599	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01035	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01131	Proguanil may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB01182	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00344	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00205	Pyrimethamine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB01224	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00908	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00468	Quinine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.
DB06697	DB00243	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01045	Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. Johns wort is contraindicated with Coartem Tablets.
DB06697	DB00734	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB06176	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01232	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00489	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01208	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB01268	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00864	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00976	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB04844	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00679	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB06697	DB01623	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00539	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00726	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00582	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB02546	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06697	DB00246	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06699	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06699	DB00834	Enhance QTc-prolonging effect
DB06700	DB00918	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00321	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00543	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01200	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00490	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00215	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01242	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01151	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00514	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00320	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00449	Desvenlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06700	DB01142	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00476	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00216	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01364	Desvenlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06700	DB00668	Desvenlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06700	DB01049	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01253	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00696	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01175	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00472	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00176	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00998	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00458	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01247	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB06706	Desvenlafaxine may increase the tachycardic and vasopressor effects of isometheptene. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06700	DB00150	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB06707	Desvenlafaxine may increase the tachycardic and vasopressor effects of levonordefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06700	DB00601	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB01356	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00934	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00353	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB04896	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00370	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01171	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB00952	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01149	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00368	Desvenlafaxine may increase the tachycardic and vasopressor effects of norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06700	DB00540	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00715	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00454	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00780	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB01168	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB01069	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00344	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00852	Desvenlafaxine may increase the tachycardic and vasopressor effects of pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06700	DB01367	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB00953	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00118	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01037	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB01104	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB01105	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB01323	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00669	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB06204	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00193	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00752	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
DB06700	DB00656	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00726	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00285	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06700	DB00315	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
DB06708	DB00458	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06702	DB00872	CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. Avoid fesoterodine doses greater than 4mg daily in patients who are also receiving strong CYP3A4 inhibitors.
DB06702	DB00196	Fluconazole is a moderate CYP3A4 inhibitor thus reducing clearance. Monitor for adverse effects when using concomitant therapy with fesoterodine.
DB06702	DB01026	Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine.
DB06703	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06703	DB06708	Additive QTc-prolongation may occur. Consider alternate therapy or monitor closely for QTc-prolongation.
DB06704	DB00321	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function
DB06704	DB00907	Sympathomimetic that increase chances of producing a false negative imaging result
DB06704	DB01364	Sympathomimetic that increase chances of producing a false negative imaging result
DB06704	DB00458	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function
DB06704	DB00598	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores
DB06704	DB04896	Milnacipran decreases the effects of Iobenguane thus increases the risk of producing a false-negative result. May discontinue milnacipran for at least 5 half-live.
DB06704	DB00388	Sympathomimetic that increase chances of producing a false negative imaging result
DB06704	DB00397	Sympathomimetic that increase chances of producing a false negative imaging result
DB06704	DB00852	Sympathomimetic that increase chances of producing a false negative imaging result
DB06704	DB00206	May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores
DB06705	DB06697	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06705	DB06708	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06705	DB00682	In a clinical trial of 10 patients receiving a stable dose of warfarin, a single dose of ABLAVAR (0.05 mmol/kg) did not alter \r\nthe anticoagulant activity of warfarin as measured by the International Normalized Ratio (INR).
DB06706	DB06700	Desvenlafaxine may increase the tachycardic and vasopressor effects of isometheptene. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06707	DB06700	Desvenlafaxine may increase the tachycardic and vasopressor effects of levonordefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache.
DB06708	DB01118	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00321	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00543	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00714	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01169	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB06216	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00207	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01244	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00608	Chloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB06708	DB00477	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00604	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00215	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00250	Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions.
DB06708	DB01142	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB04855	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB06708	DB00450	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00199	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01175	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01195	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00196	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00472	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00875	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00529	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB06703	Additive QTc-prolongation may occur. Consider alternate therapy or monitor closely for QTc-prolongation.
DB06708	DB06705	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01218	Halofantrine may increase the adverse effects of lumefantrine. Additive QTc-prolongation may occur. Combination therapy is contraindicated and therapies should not be administered within one month of each other due to the long half-life of lumefantrine.
DB06708	DB00502	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01611	Hydroxychloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB06708	DB00308	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB04946	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00808	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00270	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01259	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01137	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00408	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00934	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00358	Mefloquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB06708	DB00933	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00333	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01403	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00218	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB04868	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01059	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00540	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00104	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB06589	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00738	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00556	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01100	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
DB06708	DB01087	Primaquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB06708	DB01599	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01035	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01131	Proguanil may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB06708	DB01182	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00344	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00205	Pyrimethamine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB06708	DB01224	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00908	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00468	Quinine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
DB06708	DB00243	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00734	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB06176	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00489	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01208	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01268	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00864	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00675	Lumefantrine, a moderate CYP2D6 inhibitor, may decrease the formation of highly potent tamoxifen metabolites. Concomitant therapy may decrease the effectiveness of tamoxifen. Consider alternate therapy.
DB06708	DB06402	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00976	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB04844	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00679	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01623	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00539	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00726	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00582	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB02546	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB00246	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06708	DB01624	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
DB06709	DB00195	Beta-Blockers like betaxolol may worsen brochoconstriction and decrease the effectiveness of agents used to treat the resulting bronchoconstriction. Use of betaxolol and methacholine concomitantly is contraindicated.
DB06713	DB06697	Artemether may decrease the effectiveness of norelgestromin by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
DB06713	DB00307	Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norelgestromin, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form).
DB06713	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.
DB06781	DB06802	NSAIDs may slow healing.
DB06813	DB06681	Increased immunosuppresive effects and risk of infection. Monitor for adverse effects .
DB06813	DB00482	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06717	DB01285	Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant.
DB06719	DB00089	Avoid combination because luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide.
DB06719	DB00834	Buserelin moderately contributes to Q-Tc prolongation. Combination must be avoided because mifepristone can further enhance that effect.
DB06723	DB02300	Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB06723	DB00169	Vitamin D analogs such as cholecalciferol may increase the serum concentration of aluminum hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities.
DB06723	DB08826	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DB06723	DB06210	Decreases levels of eltrombopag by GI absorption inhibition.
DB06724	DB00258	Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
DB06724	DB01164	Calcium salts may enhance the adverse/toxic effect of calcium chloride. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
DB06724	DB06210	Decreases levels of eltrombopag by GI absorption inhibition.
DB06724	DB01167	The antacid, calcium carbonate, may decrease the effect of itraconazole by decreasing its absorption.
DB06772	DB01072	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00564	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00515	Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as cabazitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity.Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent.
DB06772	DB01211	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00224	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01167	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01026	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01149	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00220	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01174	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00252	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00615	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01045	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01201	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00503	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01232	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB01323	Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00976	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06772	DB00582	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
DB06777	DB00930	Bile Acid Sequestrants may decrease the serum concentration of Chenodiol. Consider administration of chenodiol 5 hours or more after bile acid sequestrants to reduce chenodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.
DB06779	DB00055	Low molecular weight heparin (LMWH) such as dalteparin may enhance the adverse/toxic effect of drotrecogin alfa. Bleeding may occur.
DB06781	DB00963	NSAIDs may slow healing.
DB06781	DB00586	NSAIDs may slow healing.
DB06781	DB00712	NSAIDs may slow healing.
DB06781	DB00465	NSAIDs may slow healing.
DB06813	DB06643	Increased immunosuppresive effects and risk of infection. Monitor for adverse effects .
DB06813	DB00586	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00861	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00749	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00573	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00712	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB01050	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00328	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00939	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00814	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00461	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00788	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00991	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00039	Increases the toxicity of pralatrexate. Avoid concomitant therapy or do not use palifermin within 24 hours after administration of pralatrexate.
DB06813	DB00554	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB01032	Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects.
DB06813	DB01015	Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects.
DB06813	DB00605	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06813	DB00500	NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
DB06817	DB05521	Telaprevir increases the exposure of raltegravir by up to 31%  but this interaction is considered as not clinically relevant.
DB06822	DB00055	Low molecular weight heparins (LMWHs) such as tinzaparin may enhance the adverse/toxic effects of drotrecogin alfa. Bleeding may occur. The potential benefits of drotrecogin alfa should be weighed against the increased risk of bleeding in patients on therapeutic doses of LMWHs.
DB08804	DB00682	Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.
DB08810	DB00572	Anticholinergic agents like atropine may reduce the action of cinitapride.
DB08810	DB00390	Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.
DB08810	DB00076	Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.
DB08810	DB00462	Anticholinergic agents like methylscopolamine may reduce the action of cinitapride.
DB08810	DB00747	Anticholinergic agents like scopolamine may reduce the action of cinitapride.
DB08813	DB00055	The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin.
DB08814	DB01050	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of ibuprofen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB08814	DB00788	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of naproxen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB08814	DB00554	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of glisentide to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB08814	DB00682	The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of warfarin to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
DB08815	DB01072	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB01128	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor.
DB08815	DB00559	Concomitant therapy with a CYP3A4 substrate and inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB00564	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB08822	DB06237	Pharmacodynamic synergist- increases effects.
DB08815	DB00446	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB01211	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB00257	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor.
DB08815	DB00872	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. Avoid use of lurasidone in patients receiving strong CYP3A4 inhibitors.
DB08815	DB01264	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB00705	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB01234	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. Will decrease Cmax of lurasidone by 85%.
DB08815	DB00988	Dopamine increases toxicity (enhanced hypotensive effects) of lurasidone.
DB08815	DB00668	Epinephrine increases toxicity (enhance hypotensive effects) of lurasidone by pharmacodynamic synergism.
DB08815	DB06414	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB06414	Lurasidone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB08815	DB01319	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB01320	Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB00619	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB00224	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB01167	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB01026	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
DB08815	DB01233	Increases toxicity and risk of extrapyramidal effects of lurasidone by antidopaminergic effects. Concomitant therapy should be avoided.
DB08815	DB00607	Concomitant therapy will decrease levels of lurasidone via effects on CYP 3A4. Concomitant therapy is contraindicated.
DB08816	DB00872	CYP3A4 Inhibitors (Strong) such as conivaptan may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. Avoid use of ticagrelor in combination with strong CYP3A4 inhibitors.
DB08816	DB06414	Etravirine, when used concomitantly with ritonavir boosted ticagrelor, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB08816	DB08827	Ticagrelor increases levels of lomitapide by affecting CYP3A4 enzyme metabolism. Concomitant therapy is contraindicated.
DB08816	DB00227	Patients receiving more than 40 mg per day of lovastatin may be at increased risk of statin-related adverse effects.
DB08816	DB00641	Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects.
DB08820	DB06274	Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates.
DB08820	DB06769	Increases levels of bendamustine by P-glycoprotein (MDR-1) efflux transporter.
DB08820	DB00564	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB01211	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB00199	Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction.
DB08820	DB06414	Ivacaftor, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB08820	DB00196	Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction.
DB08820	DB01167	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB01026	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB06589	Inhibits p-glycoprotein and affects heptatic metabolism via CYP3A4 therefore increases levels of pazopanib. Consider alternate therapy.
DB08820	DB01174	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB00252	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB01263	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB00615	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB01045	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB01323	Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB00976	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB08820	DB08895	Ivacaftor, when used in combination with tofacitinib, may increase tofaciitinib concentrations, It is recommended to monitor therapy for signs of toxicity or worsened side effects.
DB08820	DB08828	P-glycoprotein inhibitors may increase the chance of adverse drug reactions. Consider using alternative therapy.
DB08820	DB00582	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
DB08822	DB00945	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB01143	Azilsartan medoxomil used in combintation with amifostine may lead to hypotension.
DB08822	DB00542	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB01197	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB00482	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB04272	Increases serum potassium.
DB08822	DB00586	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00861	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00584	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB00749	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB01276	Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity.
DB08822	DB00573	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00712	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00492	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB01050	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00328	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB01009	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00465	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB06655	Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity.
DB08822	DB00722	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB01356	Azilsartan medoxomil may increase lithium serum concentrations.
DB08822	DB04835	Pharmacodynamic synergist- increases effects.
DB08822	DB00939	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00784	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00814	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00691	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB00461	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00788	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00727	Pharmacodynamic synergist- increases effects.
DB08822	DB00991	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00790	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB00554	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00881	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB00178	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08822	DB00073	Azilsartan medoxomil used in combination with rituximab may lead to hypotension.
DB08822	DB00795	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00605	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00820	Pharmacodynamic synergist- increases effects.
DB08822	DB00500	Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
DB08822	DB00519	Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
DB08826	DB06723	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DB08826	DB01373	Deferiprone serum concentrations may be decreased by calcium salts.
DB08826	DB01592	Deferiprone serum concentrations may be decreased by iron salts except for ferric gluconate, ferumoxytol, iron dextran complex, and iron sucrose.
DB08826	DB00893	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DB08826	DB06790	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DB08826	DB01378	Deferiprone serum concentrations may be decreased by magnesium salts.
DB08872	DB00972	Avoid combination due to increased CNS depression.
DB08826	DB01390	Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DB08826	DB01593	Deferiprone serum concentrations may be decreased by zinc salts except for zinc chloride.
DB08827	DB01076	Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4.
DB08827	DB08873	Boceprevir increases levels of lomipatide by 27 folds by inhibiting CYP3A4 metabolism. Concomitant therapy of Boceprevir and strong CYP3A4 inhibitors (such as clarithromycin, conivaptan, indinavir, intraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, variconazole) with lomipatide is contraindicated.
DB08827	DB01432	Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours.
DB08827	DB00537	The effect of coadminstration of lomipatide with ciproflaxacin, and other moderate CYP3A4 inhibitors (such as aprepitant, amprenavir, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) is unknown. However, as coadministration is likely to increase serum concentrations of lomipatide, concomitant use is contraindicated.
DB08827	DB00375	Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours.
DB08827	DB08865	Strong CYP3A4 inhibitors may increase levels of crizotinib. Concomitant therapy is contraindicated.
DB08827	DB06695	Dabigatran is a p-glycoprotien (P-gp) substrate. Levels of dabigatran may increase if coadministered with lomipatide, which is a P-gp inhibitor. Thus, it is recommended to dose reduce P-gp substrates (such as ambrisentan, aliskiren, colchicine, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) with the concomitant use of lomipatide.
DB08827	DB00227	Lovastatin plasma concentrations may increase by lomitapide.
DB08827	DB00641	Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions.
DB08827	DB05521	Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08827	DB08816	Ticagrelor increases levels of lomitapide by affecting CYP3A4 enzyme metabolism. Concomitant therapy is contraindicated.
DB08827	DB00682	Warfarin plasma concentrations may increase by lomitapide by 30%..\r\nINR levels may increase by 22%. Regular INR monitoring is required.
DB08828	DB00207	P-glycoprotein inhibitors may increase the chance of adverse drug reactions.
DB08828	DB01211	P-glycoprotein inhibitors may increase the chance of adverse drug reactions.
DB08828	DB00199	P-glycoprotein inhibitors may increase the chance of adverse drug reactions.
DB08828	DB08820	P-glycoprotein inhibitors may increase the chance of adverse drug reactions. Consider using alternative therapy.
DB08828	DB00338	Vismodegib serum concentrations may be decreased by proton pump inhibitors such as omeprazole.
DB08828	DB00863	Vismodegib serum concentrations may be decreased by histamine 2 receptor antagonists such as ranitidine.
DB08860	DB01072	Increases serum concentration of pitavastatin and the potential for adverse drug reactions. Avoid concomitant drug therapy.
DB08860	DB01394	Increased incidence of myotoxicity including rhabdomyolysis during concomitant therapy. The mechanism of this interaction is unclear, it may arise from pharmacodynamic and/or pharmacokinetic interactions.
DB08860	DB00091	Cyclosporine decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy.
DB08860	DB00199	Erythromycin decreases metabolism of pitavastatin. Do not exceed 1 mg per day of pitavastatin or use alternative therapy.
DB08860	DB01039	Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both fenofibrate and pitavastatin via pharmacodynamic synergism. Use alternative therapy.
DB08860	DB01241	Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both gemfibrozil and pitavastatin via pharmacodynamic synergism. Use alternative therapy.
DB08860	DB01601	Lopinavir decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy.
DB08860	DB00627	Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both niacin and pitavastatin via pharmacodynamic synergism. Use alternative therapy.
DB08860	DB01045	Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded.
DB08860	DB01045	Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded.
DB08864	DB00564	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08864	DB00705	Concentration of rilpivirine increases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's.
DB08864	DB01234	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08864	DB00625	Concentration of rilpivirine decreases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's.
DB08864	DB00736	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB08864	DB06414	Rilpivirine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. Use of rilpivirine and other NNRTIs is containdicated.
DB08864	DB00927	Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB08864	DB00448	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB08864	DB00333	Dose adjustment and clinical monitoring of rilpivirine may be necessary if coadministered with methadone.
DB08864	DB00338	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB08864	DB00776	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08864	DB00213	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB08864	DB01174	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08864	DB00252	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08864	DB01129	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB08864	DB00863	Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
DB08864	DB00615	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08864	DB01045	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08864	DB01201	Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
DB08865	DB06616	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB08865	DB00604	Concurrent use with drugs that prolong QTc interval is contraindicated.
DB08865	DB00280	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB08865	DB04855	Concurrent use with drugs that prolong QTc interval is contraindicated.
DB08865	DB06414	Crizotinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.
DB08865	DB00588	Concurrent use with crizotinib may prolong QTc interval. Consider alternative therapy.
DB08865	DB01026	Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
DB08865	DB08827	Strong CYP3A4 inhibitors may increase levels of crizotinib. Concomitant therapy is contraindicated.
DB08865	DB00683	Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
DB08865	DB00683	Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely.
DB08865	DB00904	Concurrent use with crizotinib may decrease QTc interval. Consider alternative therapy.
DB08865	DB00908	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB08865	DB01045	Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely.
DB08865	DB01045	Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely.
DB08865	DB00864	Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy.
DB08865	DB00679	Concurrent use with drugs that prolong QTc interval is contraindicated.
DB08866	DB00559	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB00564	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB01234	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB00625	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB01320	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB00607	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB00238	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB04938	Pharmacodynamic synergist; contraindicated.
DB08866	DB00312	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB01174	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB00252	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB00794	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB00615	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB01201	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08866	DB01323	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
DB08868	DB01118	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08868	DB08879	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB08868	DB00280	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08868	DB00204	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08868	DB04855	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08868	DB00308	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08868	DB01026	Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater.
DB08868	DB01035	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08868	DB00908	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08868	DB00489	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
DB08870	DB00290	Pulmonary toxicity of bleomycin may be increased. Avoid combination.
DB08870	DB06414	Brentuximab, when used concomitantly with etravirine, may experience a decrease in serum concentrations. The levels of an active metabolite of brentuximab, monomethyl auristatin E, may decrease. It is recommended to monitor efficacy of brentuximab therapy.
DB08870	DB00108	Avoid combination due to the increased risk of concurrent infection.
DB08870	DB00337	Avoid combination due to the potential enhancement of toxic effects of immunosuppressants
DB08870	DB00864	Avoid combination due to the potential enhancement of toxic effects of immunosuppressants.
DB08872	DB00898	Avoid combination due to ethanol induced increased absorption of gabapentin enacarbil and increased CNS depression.
DB08873	DB00346	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08873	DB01076	Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored.
DB08873	DB00564	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB08873	DB00604	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08873	DB00872	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08873	DB00320	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08873	DB01395	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08873	DB06414	The exposure of etravirine decreases whereas boceprevir's exposure increased. Therapeutic implications of this observation is unknown.
DB08873	DB01320	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB08873	DB08827	Boceprevir increases levels of lomipatide by 27 folds by inhibiting CYP3A4 metabolism. Concomitant therapy of Boceprevir and strong CYP3A4 inhibitors (such as clarithromycin, conivaptan, indinavir, intraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, variconazole) with lomipatide is contraindicated.
DB08873	DB00683	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08873	DB01174	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB08873	DB00252	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB08873	DB01100	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08873	DB08901	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08873	DB00175	Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored.
DB08873	DB01045	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB08873	DB00877	Boceprevir increases levels of sirolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
DB08873	DB01323	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
DB08873	DB00864	Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
DB08873	DB00820	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
DB08874	DB00091	Cyclosporin is an inhibitor of p-glycoprotein and concomitant therapy will result in a increase in Cmax and AUC of fidaxomicin and its metabolite.
DB08875	DB06414	Cabozantinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by 40mg (without exceeding 180mg/day).
DB08875	DB01323	Avoid combination. May decrease concentration of cabozantinib. Also avoid all other strong CYP3A4 inducers.
DB08877	DB01167	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
DB08877	DB01026	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
DB08877	DB01045	Strong CYP3A4 inducers may decrease levels of ruxolitinib. Closely monitor patient.
DB08877	DB00582	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
DB08879	DB01281	Avoid combination due to enhanced adverse effects of belimumab.
DB08879	DB05773	Avoid combination due to the increased risk of belimumab associated side effects.
DB08879	DB06681	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB08879	DB00112	Avoid combination due to enhanced adverse effects of bevacizumab
DB08879	DB00531	Avoid combination due to enhanced toxic effects of cyclophosphamide.
DB08879	DB06643	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB08879	DB00005	Avoid combination because of enhanced adverse effects of belimumab.
DB08879	DB00005	Avoid combination due to enhanced toxic effects of belimumab.
DB08879	DB08868	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB08879	DB00056	Avoid combination due to enhanced adverse effects of belimumab.
DB08879	DB06674	Avoid combination with belimumab due to the increased chance of belimumab associated side effects.
DB08879	DB01005	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
DB08879	DB00078	Avoid combination due to enhanced adverse effects of belimumab.
DB08879	DB01097	Consider modifying therapy as belimumab may enhance the adverse effects of leflunomide, such as hematologic toxicities.
DB08879	DB00108	Avoid combination due to enhance adverse effects of natalizumab such as the risk of concurrent infections.
DB08879	DB08935	Avoid combination due to enhanced toxic effects of monoclonal antibody.
DB08879	DB00043	Avoid combination due to enhanced toxic effects of monoclonal antibodies.
DB08879	DB00337	Avoid combination due to enhanced toxic effects of immunosuppressants.
DB08879	DB01656	Consider therapy modification due to enhanced immunosuppressive effect.
DB08879	DB06688	Monitor therapy due to decreased therapeutic effect of sipuleucel-t.
DB08879	DB00864	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB08879	DB08895	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB08880	DB01097	Avoid combination due to increased adverse effects of teriflunomide.
DB08880	DB00108	Avoid combination due to the increased risk of infection.
DB08880	DB00337	Avoid combination due to the increased toxic effects of immunosuppressants.
DB08880	DB00864	Avoid combination due to the increased toxic effects of immunosuppressants.
DB08881	DB01072	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00201	Vemurafenib increases the AUC of caffeine (CYP1A2 substrate) 2.6-fold.
DB08881	DB00564	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB01211	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00514	Vemurafenib increases the AUC (CYP2D6 substrate) by 47% .
DB08881	DB00224	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB06186	Consider therapy modification due to enhanced hepatotoxicity of vemurafenib
DB08881	DB01167	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB01026	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00683	Vemurafenib decreases the AUC (CYP3A4 substrate) by 39%.
DB08881	DB01149	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00220	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB01174	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00252	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00615	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB01045	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB01201	Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00503	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB01232	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00976	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00582	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
DB08881	DB00682	Vemurafenib increases the AUC of S-warfarin (CYP2C9 substrate). Monitor concomitant therapy closely.
DB08882	DB00564	CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely.
DB08882	DB06414	Linagliptin, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy if possible, and to monitor linagliptin therapy if concurrent use cannot be avoided.
DB08882	DB00741	CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely.
DB08882	DB00635	CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely.
DB08882	DB01045	CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely.
DB08882	DB00503	CYP3A4 inhibitors may increase levels of linagliptin. Monitor concomitant therapy closely.
DB08883	DB06626	Avoid combination with axitinib or other major CYP3A4 drug susbtrates due to the potential decrease in the drug's  concentration by perampanel induction of CYP3A4.
DB08883	DB00972	Avoid combination with azelastine or other CNS depressants due to the combined increase of CNS depression.
DB08883	DB01551	Enhanced CNS depressant effects. Consider therapy modification, and avoid performing complex and high risk activities like driving until side effects are known.
DB08883	DB00898	Avoid combination due to the enhanced central nervous system depression, and likely worse behavioral and psychiatric adverse reactions.
DB08883	DB06414	Perampanel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
DB08883	DB00252	Avoid combination with phenytoin or other strong CYP3A4 inducers due to the likely decrease of perampanel concentration. If the combination must be used, an increase in perampanel dose is necessary.
DB08883	DB01323	Avoid combination due to the potential decrease in perampanel concentration.
DB08884	DB01045	Substrates of OATP1B1 and OATP1B3 may limit uptake of gadoxetate disodium into heptatocytes. This may alter the intensity of the signal.
DB08885	DB00363	Avoid combination with systemic aflibercept due to enhanced adverse effects of clozapine, including the risk of agranulocytosis
DB08886	DB01234	Monitor therapy as asparaginase erwinia chrysanthemi may increase the serum concentration of dexamethasone due to a decrease of hepatic proteins necessary for dexamethasone metabolism.
DB08893	DB01151	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB08893	DB00390	Mirabegron increased Cmax and AUC of digoxin. Initiate therapy with digoxin at lowest possible dose. Monitor concomitant therapy closely.
DB08893	DB01195	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB08893	DB01026	Concomitant therapy with p-glycoprotein and strong CYP3A4 inhibitors may increase levels of mirabegron. Monitor concomitant therapy closely.
DB08893	DB00264	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB08893	DB01182	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB08893	DB01045	Strong CYP3A4 inducers may decrease levels of mirabegron. Monitor concomitant therapy closely.
DB08893	DB00679	Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
DB08893	DB00682	Mirabegron increased Cmax and AUC of S- and R-warfarin. Monitor concomitant therapy closely.
DB08895	DB01281	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB08895	DB00051	Adalimumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy.
DB08895	DB05773	Avoid combination with tofacitinib and other potent immunosuppressants due to the likely enhancement of immunosuppression.
DB08895	DB00026	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB08895	DB00098	Avoid combination due to enhanced immunosuppressive effects.
DB08895	DB06681	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB08895	DB08879	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB08895	DB06168	Avoid combination with tofacitinib and other potent immunosuppressants due to potential enhancement of immunosuppressant effects.
DB08895	DB08904	Certolizumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy.
DB08895	DB00363	Avoid combination due to the increased risk of clozapine induced agranulocytosis.
DB08895	DB00091	Cyclosporin (and other strong immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression and infection. It is recommended to avoid concurrent therapy.
DB08895	DB01609	Tofacitinib (and other CYP3A4 substrates), when used in combination with deferasirox, may experience a decrease in concentration. It is recommended to monitor therapy.
DB08895	DB06643	Denosumab, when used in combination with tofacitinib, may increase tofaciitinib toxicity and worsen side effects. It may specifically increase the risk of serious infection. It is recommended to monitor therapy.
DB08895	DB00005	Etanercept increases the risk of added immunosuppression. It is recommended to avoid concurrent therapy.
DB08895	DB00196	Fluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily.
DB08895	DB00056	Avoid combination due to enhancement of immunosuppressants.
DB08895	DB05259	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB08895	DB06674	Golimumab, and other anti-TNF immunosuppressants, when used in combination with tofacitinib, may increase the serum concentration of tofacitinib, and increase tofacitinib associated side effects and immunosuppresion. It is recommended to avoid concurrent therapy.
DB08895	DB04865	Avoid combination with tofacitinib and other potent immunosuppressants as there is potential to increase the immunosuppressant effects. Other less potent immunosuppressants such as methotrexate, at antirheumatic doses, and other non-disease modifying antirheumatic drugs (non-DMARDs) can be combined.
DB08895	DB00078	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB08895	DB00065	Avoid combination with infliximab and other anti-TNF drugs due to the potential enhancement of tofacitinib related adverse effects.
DB08895	DB08820	Ivacaftor, when used in combination with tofacitinib, may increase tofaciitinib concentrations, It is recommended to monitor therapy for signs of toxicity or worsened side effects.
DB08895	DB01097	Leflunomide may experience an increase in toxicity and adverse effects (ie. pancytopenia, agranulocytosis, thrombocytopenia). It is recommended to adjust therapy by forgoing a leflunomide loading dose, and to monitor for bone marrow suppression monthly.
DB08895	DB00834	Mifepristone, when used in combination with tofacitinib, may increase tofacitinib concentrations. It is recommended to adjust therapy by using a minimized dose of tofacitinib, and monitoring for increased tofacitinib concentrations and signs of toxicity, during and 2 weeks after discontinuation of mifepristone therapy.
DB08895	DB00108	Avoid combination due to the increased risk of infection.
DB08895	DB08935	Avoid combination due to enhanced immunosuppressive effect.
DB08895	DB00043	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB08895	DB00059	Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
DB08895	DB00252	Avoid combination with phenytoin and other strong CYP3A4 inducers due to the potential decrease in tofacitinib serum levels.
DB08895	DB00337	Avoid combination due to the potential increase in immunosuppressant associated adverse effects.
DB08895	DB01045	Rifampin (and other potent CYP3A4 inducers), when used in combination with tofacitinib, may decrease tofacitinib toxicity.
DB08895	DB00073	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB08895	DB01656	Roflumilast, when used in combination with tofacitinib, may increase the immunosuppressive effect of tofaciitinib and other immunosuppressive agents.   It is recommended to modify therapy.
DB08895	DB06268	Sitaxentan (moderate CYP3A4 inhibitors, strong CYP2C19 inhbitors), when used in combination with tofacitinib, may increase tofaciitinib serum concentration toxicity and adverse effects. It is recommended to adjust therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5 mg daily.
DB08895	DB00864	Avoid combination due to the potential increase in immunosuppressant associated adverse effects.
DB08895	DB06273	Avoid combination due to the potential increase in tofacitinib related adverse effects.
DB08895	DB00072	Trastuzumab, when used in combination with tofacitinib, may increase tofacitinib adverse effects, ie. neutropenic effects. It is recommended to monitor therapy.
DB08896	DB00564	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB08896	DB01211	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB08896	DB00762	Regorafenib may increase levels of irinotecan, a UGT1A1 substrate.
DB08896	DB01167	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB08896	DB01026	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB08896	DB01174	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB08896	DB00252	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB08896	DB01263	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB08896	DB01045	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB08896	DB01323	Strong CYP3A4 inducers may decrease levels of regorafenib.
DB08896	DB00976	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB08896	DB00582	Strong CYP3A4 inhibitors may increase levels of regorafenib.
DB08897	DB01278	May increase the risk of inhibition of GI motility via pharmacodynamic synergism. Consider alternate therapy.
DB08898	DB00650	Do not administer leucovorin within 2 hours of glucarpidase due to the fact that leucovorin is degraded by glucarpidase.
DB08901	DB08873	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00564	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00564	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01211	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00872	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00224	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01167	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01026	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01601	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01149	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00220	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00252	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00252	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01263	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01045	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01045	Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00503	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00503	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB01232	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB05521	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00976	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08901	DB00582	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
DB08903	DB01026	Strong CYP3A4 inhibitors may increase exposure of bedaquiline. Monitor concomitant therapy closely.
DB08903	DB01045	Strong CYP3A4 inducers may decrease exposure of bedaquiline. Co-administration should be avoided.
DB08904	DB01281	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB08904	DB00026	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB08904	DB00005	Avoid combination as certolizumab pegol toxic effects would be enhanced.
DB08904	DB06674	Avoid combination due to the potential increased immunosuppression of Certolizumab Pegol.
DB08904	DB00065	Avoid combination because anti-TNF agents increase adverse effects of certolizumab pegol
DB08904	DB00108	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB08904	DB00073	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
DB08904	DB08895	Certolizumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy.
DB08906	DB01026	Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely.
DB08906	DB00503	Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Consider alternative therapy.
DB08907	DB09026	Monitor therapy because canagliflozin may enhance aliskiren antihypertensive and hyperkalemic effects.
DB08907	DB00390	When coadministered with 300 mg canagliflozin, the AUC and mean peak drug concentration of digoxin increased. Monitor concomitant therapy closely.
DB08907	DB01174	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB08907	DB00252	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB08907	DB01045	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB08907	DB00503	Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
DB08909	DB00502	Haloperidol may induce hyperammonemia. Monitor ammonia levels closely when use of haloperidol is necessary in UCD patients.
DB08909	DB00635	Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol pehnylbutyrate are used concomitantly.
DB08909	DB01032	Probenecid may inhibit the renal excretion of metabolites of glycerol phenylbutyrate including PAGN and PAA.
DB08909	DB00313	Valproic acid may induce hyperammonemia. Monitor ammonia levels closely when use of valproic acid is necessary in UCD patients.
DB08910	DB01026	Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided.
DB08910	DB01045	Strong CYP3A4 inducers may decrease levels of pomalidomide. Concomitant therapy should be avoided.
DB08912	DB00564	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB08912	DB01211	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB08912	DB01241	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB08912	DB01026	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB08912	DB00683	Dabrafenib decreased the maximum concentration (Cmax) and area under the curve (AUC) of midazolam (a substrate of CYP3A4) by 61% and 74%, respectively.
DB08912	DB01149	Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy.
DB08912	DB00213	Proton pump inhibitors may alter the solubility of dabrafenib and reduce its bioavailability.
DB08912	DB01174	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB08912	DB00252	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB08912	DB00863	H2-receptor antagonists may alter the solubility of dabrafenib and reduce its bioavailability.
DB08912	DB01045	Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
DB08918	DB01026	Strong CYP3A4 inhibitors may increase exposure levomilnacipran.
DB08935	DB09026	Obinutuzumab antihypertensive effect may be enhanced. Administration of antihypertensives should be withheld 12 hours before infusion of obinutuzumab and 1 hour after the end of infusion.
DB08935	DB08879	Avoid combination due to enhanced toxic effects of monoclonal antibody.
DB08935	DB00363	Risk of agranulocytosis may be increased due to enhanced adverse effects of clozapine by myelosuppressive agents. It is recommanded that combination may be avoided.
DB08935	DB06643	Monitor therapy due to increased risk of infections due to adverse effects of immunosuppressants.
DB08935	DB00063	Monitor therapy due to increased risk of bleeding events.
DB08935	DB01097	Consider modifying therapy. Risk of hematologic toxicity of leflunomide may be increased due to enhanced adverse effects.
DB08935	DB00108	Avoid combination due to enhanced adverse effects of natalizumab.
DB08935	DB00337	Avoid combination due to enhanced immunosuppressive effects.
DB08935	DB01656	Consider therapy modification due to enhanced immunosuppressive effect.
DB08935	DB06688	Monitor therapy due to diminished therapeutic effect of sipuleucel-t.
DB08935	DB00864	Avoid combination due to enhanced adverse effects of immunosuppressants.
DB08935	DB08895	Avoid combination due to enhanced immunosuppressive effect.
DB08935	DB00072	Monitor therapy due to enhanced neutropenic effect of immunosuppressants
DB09026	DB00346	Monitor therapy due to enhanced hypotensive effect of aliskiren.
DB09026	DB01143	Amifostine hypotensive effect can be exacerbated with administration of antihypertensives. If amifostine is administered, no antihypertensives should be administered within 24 hours. If the antihypertensives can't be withheld, amifostine should not be administered.
DB09026	DB01076	Therapy modification should be considered because atorvastatin increases aliskiren serum concentration.
DB09026	DB00484	Monitor therapy because of enhanced hypotensive effect.
DB09026	DB08907	Monitor therapy because canagliflozin may enhance aliskiren antihypertensive and hyperkalemic effects.
DB09026	DB00091	Avoid combination because cyclosporine increases aliskiren serum concentration.
DB09026	DB01119	Monitor therapy due to enhanced hypotensive effect of aliskiren.
DB09026	DB00476	Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
DB09026	DB00695	Monitor therapy due to potential decreased serum concentration of furosemide.
DB09026	DB01109	Monitor therapy due to enhanced hyperkalemic effect of aliskiren.
DB09026	DB01167	Avoid combination due to increased serum concentration of aliskiren.
DB09026	DB01026	Monitor therapy due to increased serum concentration of aliskiren.
DB09026	DB00422	Monitor therapy due to reduced antihypertensive effect of aliskiren.
DB09026	DB08935	Obinutuzumab antihypertensive effect may be enhanced. Administration of antihypertensives should be withheld 12 hours before infusion of obinutuzumab and 1 hour after the end of infusion.
DB09026	DB00806	Monitor therapy due to enhanced antihypertensive effects of aliskiren.
DB09026	DB00073	Consider therapy modification due to enhanced hypotensive effect of rituximab.
DB09026	DB00661	Monitor therapy due to increased concentration of aliskiren.
DB09026	DB01392	Monitor therapy due to decreased antihypertensive effects of aliskiren.
